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Abstract 
 
Background 
Moderate to severe chronic pain affects one in five of adults. The prevalence and impact 
of pain increase with age. Pain may increase the risk of mortality but the relationship is 
not clear.  
Aims 
To test the hypothesis that pain increases the risk of mortality, to test if the relationship 
was dependent on pain classification and identify mediators and moderators of the 
relationship. 
Methods 
A systematic review and meta-analysis evaluated existing evidence. Survival analyses 
(Cox’s proportional hazard modelling and a novel technique to assess mediation within 
survival models) were conducted on two large population studies of adults aged ≥50 
years; the English Longitudinal Study of Ageing (ELSA) (n=6324) and the North 
Staffordshire Osteoarthritis Project (NorStOP) (n=10985). Lifestyle, health, social and 
psychological factors were tested as potential mediators. Sex and comorbidity were 
tested as moderators.  
Results 
In the systematic review pooled analysis from 7 studies revealed a modest but non-
significant risk of mortality for people with chronic pain (Mortality Rate Ratio 1.14, 95%CI 
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(0.95, 1.37)). In survival analyses the relationship with mortality was influenced by pain 
classification: pain that was troubling (1.29 (1.12, 1.49)) or that interfered with daily 
activities (1.88 (1.54, 2.29)) was associated with an increased risk of mortality while 
reporting any pain was not (1.06 (0.95, 1.19)). 
The strongest mediators in ELSA that were replicated in NorStOP were functional 
limitation (Hazard Ratio 1.31; 95%CI (1.20, 1.39)), physical inactivity (1.14 (1.10, 1.20)) 
and poor self-rated health (1.32 (1.23, 1.41)). Sex and comorbidity moderated the extent 
of some mediating pathways (e.g. depression) but the findings were inconsistent between 
datasets.   
Conclusion 
Specific opportunities to reduce mortality risk for people with pain were identified. At a 
population level, mortality risk for people with pain could be reduced by the effective 
management of pain and its impact. 
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Chapter One. Background 
1.1 Introduction  
 
Pain has a major impact on the individual and society (Woolf, Erwin, & March, 2012) 
which is recognised by the World Health Organisation and the United Nations as a global 
problem that is expected to escalate as life expectancy increases and the world’s 
population ages (Woolf & Pfleger, 2003). The impact of pain is broad and includes 
reduced quality of life, disability, lost workdays and demands on healthcare (Soldato et 
al., 2007; Tüzün, 2007; Woolf, Erwin & March., 2012). Pain can be considered as a 
condition in its own right as it can persist even after a precipitating injury or condition has 
healed (Siddall & Cousins, 2004). Irrespective of cause, the high prevalence of pain and its 
subsequent impact warrant the recognition of pain as an important public health problem 
(Blyth, Van Der Windt, & Croft, 2015; Croft, Blyth, & Van Der Windt, 2010). 
1.2 What is pain? 
 
The definition of pain proposed by the International Association for the Study of Pain 
(IASP) (i.e. “pain is an unpleasant sensory and emotional experience associated with 
actual or potential tissue damage, or described in terms of such damage” (Merskey & 
Bogduk, 1994)) is highly cited but lacks the detail necessary to characterise what is a 
complex phenomenon. Pain is essential for survival; when the nervous system responds 
to the detection of potentially damaging stimuli behavioural responses are initiated to 
protect against further damage (Kopf & Patel, 2010). However pain is more than a 
sensation in response to an external stimulus. It is a complex interaction of physical and 
psychological factors (Serpell, 2005); the neurophysiological response to a painful 
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stimulus is influenced by a complex combination of genetic, environmental, cultural, 
socioeconomic and psychological factors (Brooks, 2005). This complexity and the 
uniqueness of the pain experience to the individual makes defining pain challenging. 
Meaningful theories of pain have evolved which provide the basis for pain phenotypes, an 
understanding of pain mechanisms and the resulting impact for the individual.  
1.3  Theories of pain 
1.3.1 Early theories of pain 
 
In 1664, Descartes’ theory of pain was the first time a link between mind and body had 
been proposed to explain the experience of pain. Prior to this, early theories attributed 
pain to religious influences (e.g. punishment or a test from god, or the entry of evil spirits 
into the body through an injury), an imbalance in vital fluids, or considered it to be an 
emotion or sensation experienced in the heart (Main, Sullivan, & Watson, 2007). 
Descartes’ theory proposed that pain was a perception that existed in the brain and was 
separate to the neural phenomenon of sensory transduction conducted through nerves 
which he described as hollow tubes that conveyed both sensory and motor information 
(Moayedi & Davis, 2013).  A sensory cue would ‘tug’ on a tube which would open a gate 
between the tube and the brain allowing “animal spirits” to flow through them and within 
the muscles to initiate movement (Moayedi & Davis, 2013).  A pervasive assumption from 
this theory was that the amount of pain was directly related to the amount of tissue 
damage. The theory also implied pain travelled in one direction only and that pain would 
cease if the stimulus was stopped (Main et al., 2007).  
Descartes’ concept of a pain pathway linking peripheral body parts to the brain provided 
the basis for the development of the Specificity Theory by Charles Bell in 1811 (Moayedi 
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& Davis, 2013).  Bell suggested that the brain was a heterogeneous structure and that 
nerves consisted of heterogeneous bundles of neurons which had specialized functions 
(Moayedi & Davis, 2013).  Both Descartes and Bell’s theories suggested a relatively simple 
relationship between tissue damage and pain however these could not explain 
phenomena such as phantom limb pain (where pain is experienced in a limb that has 
been amputated), dissociations between injuries and pain like those observed in soldiers 
in the Second World War (where severe wounds resulted in little reported pain) (Beecher, 
1946), pain in the absence of tissue damage or the persistence of pain beyond tissue-
healing time (Main et al., 2007).     
Other theories began to develop ideas on the mechanism between tissue damage and the 
perception of pain by the individual. Examples were the Intensity Theory (Erb, 1874), 
which proposed that pain occurs in any sensory system if the stimulus is of sufficient 
intensity (i.e. there are no distinct pathways), and the Pattern Theory (Nafe, 1929), where 
a specific and particular pattern of activity of different neurons determines the stimulus 
type and intensity of a sensation (Perl, 2007). Despite these alternative theories, the 
Specificity Theory of pain became dominant; posing different types of neurons for 
different types of stimuli and proposed a dedicated pain pathway (Moayedi & Davis, 
2013). This theory gained support from the work of von Frey between 1894 and 1896 
who proposed four somatosensory modalities: cold, heat, pain and touch. In 1947, 
Sherrington recognised that neurons responded to specific stimuli including von Frey’s 
four modalities and proposed the framework for nociception (described below) (Moayedi 
& Davis, 2013) which was incorporated into the ensuing dominant theory; the Gate 
Control Theory of pain (Melzack & Wall, 1965).    
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1.3.2 The Gate Control Theory 
 The Gate Control Theory (Melzack & Wall, 1965) (Figure 1.1) provided a framework to 
view pain as a psychophysiological phenomenon; a combination of mental and biological 
processes. The Gate Control Theory outlined mechanisms for the transmission and 
modulation of nociceptive (pain) signals which, for the first time, highlighted the potential 
role of psychological and social/environmental factors in the overall pain experience 
(Main et al., 2007). 
Nociception    
Nociception is the process of transduction and transmission of noxious stimuli via a pain 
pathway to the brain (Steeds, 2009). Noxious stimuli are detected by nociceptors which 
are receptors in tissues that respond to painful stimuli (Steeds, 2009). Nociceptors are the 
free nerve endings of nerve fibres of which there are two main types; fast conducting A-
delta fibres and slower conducting C fibres (Steeds, 2009). A-delta fibres are involved in 
the rapid localisation of pain and withdrawal from the stimulus thus having a protective 
effect. They are high threshold receptors which respond to thermal and mechanical 
stimuli and are thinly myelinated (Serpell, 2005). Myelination refers to the coating of the 
axons of nerve fibres with myelin which acts to increase the speed of conductivity of 
nerve impulses by reducing leakage of the electrical current and causing the signal to 
jump along sections of the nerve fibre between breaks in the myelin (Widmaier, Raff, & 
Strang, 2008). C fibres are involved in delayed pain sensation in response to tissue injury 
and elicit processes which act to protect and heal the damaged area. They are 
unmyelinated, slow conducting and respond to mechanical, thermal and chemical stimuli. 
About 15% of C fibres have ‘silent’ or ‘sleeping’ nociceptors present in the skin and 
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viscera which become active under inflammatory conditions only (Serpell, 2005). C fibres 
travel alongside larger myelinated A-beta fibres which are involved in the processing of 
non-painful stimuli like touch and vibration (Steeds, 2009).  
Pain modulation 
Pain modulation refers to the regulation of the intensity of pain perception by other 
factors (Ossipov, Dussor, & Porreca, 2010). Modulation occurs when a ‘gate’ located in 
the substantia gelatinosa in the dorsal horn of the spinal cord either ‘opens’ or ‘closes’ in 
response to collective inputs leading to increased or decreased pain perception (Melzack 
& Wall, 1965).  This gating mechanism is influenced by the relative amount of activity in 
the nerve fibres and by nerve impulses that descend from the brain. For example, activity 
of larger A-beta fibres (L in Figure 1.1) (associated with non-painful stimuli) act to close 
the gate whereas activity by the smaller A-delta and C-fibres (S in Figure 1.1) (associated 
with painful stimuli) open the gate (Melzack, 1993).  Selective cognitive processes are 
activated by the central control trigger; a system of large fast conducting fibres, which 
influence modulation via the gating system. This ‘central control’ refers to processes in 
the brain involved in the identification, evaluation and modulation of input before the 
activation of the action system (neural areas which control the experience of and 
behaviours associated with pain) by the transmission (T) cells. The action system is 
activated once the spinal cord transmission exceeds a certain level (Melzack, 1993) 
(Figure 1.1).  
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Figure 1.1 Circuit diagram of the Gate Control Theory of pain perception (Melzack and 
Wall, 1965) 
Large diameter fibres (L) and small diameter fibres (S) project to the substantia gelatinosa (SG) and the first 
central transmission (T) cells. The SG exerts an inhibitory effect on the afferent fibre terminals which is 
increased by activity of the L fibres and decreased by activity of the S fibres. The line running from the large 
fibres to the central control mechanisms represents the central control trigger. The central control 
mechanisms then project back to the gate control system. The T cells project to the action system (Melzack 
and Wall, 1965)  
 
The Gate Control Theory was further revised in 1999 to acknowledge that different neural 
systems were responsible for the motivational, affective and cognitive aspects of the pain 
experience (Main et al., 2007). This emphasised the dynamic role of the brain/central 
neural mechanisms in pain processes with psychological factors playing an integral part 
(Melzack, 1999). 
1.3.3 The Neuromatrix Theory 
The emphasis on central neural mechanisms posited by the Gate Control Theory and the 
integration of pain research and psychophysiological research culminated in the 
Neuromatrix Theory (Melzack, 1999). This coincided with increasing interest in chronic 
pain and disability, and introduced a theoretical framework for their development (Main 
-
 
 + 
 + 
 + 
+ 
SG
 
 Large 
Fibres (L) 
-
- +
+ 
Action 
system 
Central control 
Large 
fibres (L) 
Input from 
periphery 
Small 
fibres (S) 
T
Gate control 
 
7 
 
et al., 2007). The Neuromatrix theory proposed a characteristic pattern of nerve impulses 
or “neurosignature” which is generated by a widely distributed neural network and may 
be triggered by or occurs independently of sensory inputs (Melzack and Katz in 
Hadjistavropoulos & Craig, 2004). The neuromatrix is genetically determined but is 
modified by sensory experience and its output pattern is determined by multiple 
influences  (Melzack, 1999) (Figure 1.2). 
    
 
Figure 1.2 Factors that contribute to the pattern of activity gated by the body-self 
neuromatrix (Melzack and Katz, 2004) 
The neuromatrix is comprised of sensory (S), affective (A), and cognitive neuromodules (C). Combinations of 
input factors influence the patterns of activity of these neuromodules which results in output patterns 
representing the multidimensional experience of pain (Melzack and Katz, 2004).     
 
Different areas of the brain play a more or less active role depending on the interaction 
between factors (e.g. cognition, mood, injury) influencing pain perception. At present, 
there is no clear consensus over which areas of the brain make up the pain matrix (Tracey 
& Mantyh, 2007). Neuroimaging has enabled the identification of neural activity in pain 
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processing but pain experience is determined by the interaction of different brain regions. 
An individual neural ‘pain signature’ is a more useful way to describe the subjective 
experience of pain rather than trying to explain it in terms of a rigid neuroanatomical pain 
matrix (Tracey & Mantyh, 2007). The Neuromatrix Theory aligned with the 
biopsychosocial approach to health and illness and highlighted the multidimensional 
(biological, psychological and social/environmental) aspects of pain perception which also 
determine the extent and characteristics of its impact.  
The understanding of the experience of pain will continue to develop. The theories of 
pain, through identifying the multifactorial influences indicate that different approaches 
(e.g. analgesia, cognitive behavioural approaches) may be applied to reduce the 
experience of pain by individuals.  Pain should be considered to be a complex, subjective 
multifactorial experience similar to other chronic health conditions. Symptoms and 
illnesses may originate from a biological source but the chronicity of a condition and the 
development of incapacity can often be the result of psychosocial factors (Waddell, 
2006). Theories of pain have linked with disability frameworks to provide an 
understanding of how its impact occurs but perhaps more importantly to identify 
potential targets to reduce it. More recent models of disability embody a biopsychosocial 
approach to health and illness, first proposed by Engel in 1977. The biopsychosocial 
model posits illness and the impact of health conditions as a complex interaction of 
biological (e.g. injury), psychological (e.g. depression) and social factors (e.g. living alone) 
(Engel, 1977) (Figure 1.3). The distinction between disease; “an objective biological event 
involving the disruption of specific body structures or organ systems caused by 
anatomical, pathological or physiological changes” and illness; “a subjective experience or 
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self-attribution that a disease is present” can be likened to the distinction between 
nociception (objective processes) and pain (subjective experience) (Gatchel, Peng, Peters, 
Fuchs, & Turk, 2007). 
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Figure 1.3 The biopsychosocial model of health and illness  
The biopsychosocial model of health and illness reproduced from Waddell (2006) with corresponding 
International Classification of Functioning, Disability and Health (ICF) components (Waddell, 2006). 
 
The experience of pain is unique to the individual. A range of psychological and 
environmental factors interact with physical pathology to influence the experiences of 
pain and an individual’s responses to it. The emergence of the biopsychosocial model has 
driven an interdisciplinary approach to pain management (Gatchel et al., 2007) and 
provides the basis for the World Health Organisation International Classification of 
Functioning, Disability and Health (ICF). The ICF is widely accepted as the framework for 
disability and rehabilitation and considers functioning and disability as a dynamic 
interaction between an individual’s health condition, personal/psychological factors and 
social/contextual factors  (Waddell, 2006). Understanding how pain, lifestyle, health, 
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social and psychological factors link together can help to focus and direct what health and 
social care should target to reduce the burden of pain on individuals.  
The evolving theories, outlined above, have provided a platform for our understanding of 
pain and its impact and broad frameworks that drive the current approaches to 
management by multidisciplinary health teams. The current challenge of unpicking the 
‘pain signature’, identifying how biological, psychological and environmental factors 
interact and further refinement of the theories of pain would benefit from 
epidemiological studies which can identify exposures and potential mechanisms of the 
pain experience and its impact.  Focusing on specific phenotypes provides a basis for the 
epidemiology of pain; these are often how pain is characterised in clinical practice and 
research and provide a focus for identifying natural history (incidence and prognosis), 
predictors and pertinent treatment approaches.  
1.4  Pain phenotypes 
 
Phenotypes are the appearances, signs and symptoms of disease and are dynamic; 
influenced by the underlying genotype, the environment and interactions between them 
(Wojczynski & Tiwari, 2008).  Pain phenotypes overlap and can be viewed as a continuous 
spectrum, with common acute regional pain problems such as minor headaches at the 
lower end of the spectrum and chronic pain problems such as chronic widespread pain 
(CWP) including fibromyalgia at the other (Croft et al., 2010). Pain phenotypes are 
routinely characterised using duration and anatomical location.  
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1.4.1 Pain duration 
 
Pain defined by duration can be classed as acute (less than three months) or chronic 
(three months or more).  Acute pain typically occurs in response to a noxious stimulus 
which does not overwhelm the body’s responses and resolves in days or weeks (Loeser & 
Melzack, 1999). It has a protective function, either by initiating the withdrawal reflex 
from a noxious stimulus or by heightening sensory sensitivity following tissue damage 
which aids healing of the damaged area by discouraging movement or physical contact 
and reduces the risk of further damage (Woolf, 2010).  
Chronic pain is commonly defined as that which lasts beyond normal healing time, usually 
taken to be beyond three months (Merskey & Bogduk, 1994). Pain is often considered as 
a symptom of underlying disease or injury (Blyth et al., 2015). However chronic pain 
should be regarded as a health condition in its own right because, as the theories of pain 
indicate, it has its own pathology, symptoms and signs (e.g. altered receptor function, 
mood dysfunction, social disruption) (Siddall & Cousins, 2004). Pain can persist beyond its 
precipitating cause (i.e. beyond what we would regard as acute pain) and it may not be 
possible to address the underlying pathology (Siddall & Cousins, 2004). Pain can also 
occur without an obvious pathological reason, for example in fibromyalgia patients an 
underlying cause is often difficult to determine (Bergman, 2007). The pathological 
processes of chronic pain result in persistent noxious inputs and the influence of 
environmental factors may serve to maintain these inputs (Siddall & Cousins, 2004). The 
factors that predict chronicity of pain link to musculoskeletal conditions, the lifestyle of 
the individual and psychosocial factors (Bergman, 2007).  Once pain is established it is 
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likely to persist in older individuals and those with other somatic symptoms 
(Papageorgiou, Silman, & Macfarlane, 2002).  
In accordance with the theories of pain, one key biological factor for chronicity may be an 
underlying genetic vulnerability (Holliday & McBeth, 2011). Twin studies can help to 
establish the heritability of conditions through a better understanding of genetic and 
environmental influences. In 2004, Kato and colleagues studied 4,170 monozygotic, 5,881 
same-sex dizygotic and 5,755 opposite-sex dizygotic twins aged 42 and over in Sweden 
and found differences in susceptibility to chronic widespread pain reflecting modest 
genetic and negligible family environment influences (Kato, Sullivan, Evengård, & 
Pedersen, 2006). The role of underlying genetic vulnerability for chronicity was also 
highlighted in a systematic review of twin studies of pain; Nielsen and colleagues (2012) 
reported heritability (the estimated proportion of observed variation in pain phenotype 
attributable to genetic influences) of 45-50% for migraine, tension-type headache and 
chronic widespread pain and 35% for back pain in adult samples (Nielsen, Knudsen, & 
Steingrímsdóttir, 2012).  
In addition to genetic vulnerability, there are a number of lifestyle, health, social and 
psychological factors which reportedly predict pain chronicity. Examples include smoking, 
high BMI and poor diet (in women) (Vandenkerkhof, Macdonald, Jones, Power, & 
Macfarlane, 2011), female sex and lower socioeconomic status (Bergman, 2005; Davies et 
al., 2009; Fillingim, King, Ribeiro-Dasilva, Rahim-Williams, & Riley, 2009; Fuentes, Hart-
Johnson, & Green, 2007; Macfarlane, Norrie, Atherton, Power, & Jones, 2009), physical 
trauma, occupational characteristics and traumatic life events (Holliday & McBeth, 2011).  
Social networks and social support have also been identified as important factors 
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influencing the persistence of chronic pain (Bergman, 2005). Patient beliefs regarding the 
meaning of symptoms, the ability to control their pain, impact on life and worry about the 
future have an important role in the persistence of chronic pain as a result of their effect 
on physical and psychological functioning, coping efforts, behavioural responses and 
response to treatment (Turk & Okifuji, 2002).  
1.4.2 Location 
 
Pain phenotypes can also be defined by specific anatomical site (regional pain), number of 
pain sites (multi-site pain) or a combination of anatomical area and number of painful 
sites (widespread pain).  
Regional pain 
Regional pain refers to pain occurring in an individual anatomical site such as the foot or 
lower back (Bergman, 2007; Jordan et al., 2010; Macfarlane et al., 2009). Comparisons 
between prevalence estimates are difficult due to the use of different definitions of the 
pain phenotype and of the method of estimating prevalence (e.g. point prevalence, 
lifetime prevalence) (see section 1.5.1). However, although prevalence estimates for 
regional pains differ due to variation in definition, most indicate that regional pain is 
common.  A recent review reported the ranges for one month period prevalence in adults 
(18 and over) for neck pain was 15.4% to 45.3%, for low back pain was 24.0% to 49.5%, 
for shoulder pain was 18.6% to 31.0% and for knee pain was 13.0% to 28.0%. The pooled 
prevalence for foot pain was 28% (Table 1.1) (Henschke, Kamper, & Maher, 2015). Back 
pain is the most common regional pain; in the United Kingdom (UK), the range for point 
prevalence is 12% to 35% and for lifetime prevalence is 49% to 80% (Maniadakis & Gray, 
2000).   
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Table 1.1 Prevalence figures for common regional pain sites in adults (reproduced from 
Henschke et al., 2015) 
Reference Number of 
included studies 
Pain site 1 month prevalence (%) 
Hogg-Johnson et al., 2008 101 Neck pain 15.4-45.3 
Hoy et al., 2010 5 Low back pain 24.0-49.5 
Luime et al., 2004 19 Shoulder pain 18.6-31.0 
Peat et al., 2001 5 Knee pain* 13.0-28.0 
Thomas et al., 2011 31 Foot pain 28.0 (pooled prevalence) 
*In adults 55 years and over 
 
Pain in one regional site has been shown to increase the likelihood of developing pain in 
other locations (Papageorgiou et al., 1996; Smith, Elliott, Hannaford, Chambers, & Smith, 
2004). People often consult their GP for a single regional pain, most commonly in the 
back or knee, however most people will also be experiencing pain in other anatomical 
areas (Jordan et al., 2010). 
Multisite pain 
Multisite pain is defined as pain in two or more anatomical sites (Carnes et al., 2007; 
Lacey et al., 2014). Multisite pain is associated with greater functional problems than 
single site pain. There are strong linear relationships between an increasing number of 
pain sites and reduced general health, sleep quality, psychological health and functional 
ability (Kamaleri, Natvig, Ihlebaek, & Bruusgaard, 2008). In contrast to chronic widespread 
pain (CWP) (defined in the next section) multisite pain refers only to the number of pain 
sites and not to duration or location.  The findings from a study of 2445 patients (aged 18-
102 years) from 16 general practices (GP) practices in South East England demonstrated 
the difference in the prevalence of these phenotypes; 45% (n=1092) of the study 
population experienced chronic pain defined as pain for more than half of the days in the 
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previous year. Of the 1092 participants with chronic pain, 73% had pain in multiple body 
sites (two or more) but only 33% (n=285) of those with multi-site pain met the criteria for 
chronic widespread pain (Carnes et al., 2007).  
Chronic widespread pain (CWP) 
In 1990, Wolfe and colleagues developed the American College of Rheumatology (ACR) 
criteria for CWP and fibromyalgia. The aim of the criteria was to identify people with pain 
at the high end of the pain spectrum according to the extent, location and chronicity of 
their pain (Wolfe & Smythe, 1990); those with CWP have more pain resulting in higher 
impact than multisite and regional pain. Using these criteria individuals were identified as 
having widespread pain when they experienced pain in the axial skeleton, on the right 
and left sides of the body and above and below the waist. Individuals were identified as 
having fibromyalgia when they experienced widespread pain that is chronic (i.e. has 
lasted for at least three months (CWP) and tenderness in eleven of eighteen designated 
tender point sites (Wolfe & Smythe, 1990). These criteria have become the most widely 
used in epidemiological studies (McBeth & Mulvey, 2012). Prevalence figures for chronic 
widespread pain in studies using these criteria range from 4.2% to 13.2% (Gran, 2003). 
The prevalence of fibromyalgia in the general population has been estimated to range 
from 1 to 11% (McBeth & Mulvey, 2012).  
Macfarlane and colleagues (1996) proposed the Manchester criteria for chronic 
widespread pain as an alternative to the ACR criteria (Macfarlane, Croft, Schollum, & 
Silman, 1996). They argued the ACR criteria were overly inclusive resulting in the 
misclassification of individuals to widespread pain when their pain was not sufficient to 
warrant inclusion. Macfarlane and colleagues proposed more stringent criteria which 
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demonstrated stronger associations with other symptoms such as fatigue, psychological 
distress and sleep problems (Hunt, Silman, Benjamin, McBeth, & Macfarlane, 1999). The 
Manchester definition of chronic widespread pain (CWP-M) defines chronic pain as pain 
that is present for at least three months in both the axial skeleton and at least two 
sections of two contralateral limbs. Macfarlane and colleagues (1996) suggested that the 
Manchester definition provided a more accurate representation of the concept of true 
widespread pain (Macfarlane et al., 1996). The point prevalence for chronic widespread 
pain using the Manchester definition was 4.7% (Hunt et al., 1999).  
In response to a number of practical and philosophical limitations of the original ACR 
1990 criteria including difficulties with the tender point count, the importance of fatigue, 
cognitive and somatic symptoms and variation of these amongst patients, a revised set of 
criteria was proposed in 2010 (Wolfe et al., 2010). Key revisions were that fibromyalgia be 
viewed as a continuous disorder rather than a dichotomous one (Wolfe & Michaud, 2009) 
and removal of the tender point count because in many cases, physicians were carrying 
out the tender point count inconsistently or not at all (Fitzcharles & Boulos, 2003). The 
true value of the tender point count was also questioned due to subjectivity, variable 
reliability and poor correlation with pain report (Fitzcharles & Yunus, 2012). The new 
criteria included a widespread pain index (WPI) and a symptom severity (SS) scale. The 
WPI measured the number of painful body regions ranging from 0-19 and the SS scale 
measured the severity and extent of fatigue, cognition, sleep and somatic symptoms on a 
scale ranging from 0-12. Patients were considered to meet the criteria for fibromyalgia if 
they scored 7 or above on the WPI and 5 or above on the SS scale, or between 3 and 6 on 
the WPI and 9 or above on the symptom severity scale (Wolfe et al., 2010). These 
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revisions to pain classifications demonstrate evolving attempts to accurately capture pain 
phenotypes and their impact. Despite criticisms, established criteria such as the ACR 
definition of CWP allow for some uniformity across studies of pain. 
1.5  Epidemiology of pain 
 
The epidemiology of pain provides information on the natural history and determinants 
of pain; this informs the view of pain as a public health problem, guides policy and 
informs methods to prevent and manage the condition from a clinical and population 
health perspective (Croft et al., 2010). Recognition of a condition as a public health 
problem is determined by the frequency and impact of that condition (Woolf et al., 2012). 
There is substantial literature on the prevalence and impact of pain phenotypes. The 
previous and following sections include a synthesis of recent reviews with the aim of 
providing a summary of current research of the extent of pain and its impact. A title and 
abstract search of PubMed was undertaken to identify articles published in the last five 
years using the search terms ‘pain’ and ‘epidemiology’ or ‘burden’, or ‘impact’ or 
‘consequences’ and ‘review’ with the aim of capturing all recent general reviews of this 
topic. The review articles found are listed in Table 1.2. Reference lists of included reviews 
were also searched for key studies. The search was restricted to non-cancer pain in adults 
and did not include articles focussed on site specific pain or specific geographical 
locations (i.e. country-specific) as these were incorporated into broader reviews (Table 
1.2). (Site-specific and country- specific information is presented in Table 1.1 and 1.3.) 
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Table 1.2 Results of PubMed search for reviews of the prevalence and impact of pain from 2010 
to 2015 
Authors Year Title 
Henschke N, Kamper SJ, 
Maher CG 
2015 The epidemiology and economic consequences of pain 
Molton IR, Terrill AL 2014 Overview of persistent pain in older adults 
Moore R, Derry S, Taylor 
RS, Straube S, Phillips CJ 
2014 The costs and consequences of adequately managed chronic 
non-cancer pain and chronic neuropathic pain 
Breivik H, Eisenberg E, 
O'Brien T 
2013 The individual and societal burden of chronic pain in Europe: the 
case for strategic prioritisation and action to improve knowledge 
and availability of appropriate care 
Patel AS, Farquharson R, 
Carroll D, Moore A, 
Phillips CJ, Taylor RS, 
Barden J 
2012 The impact and burden of chronic pain in the workplace 
Phillips CJ, Harper C. 2011 The economics associated with persistent pain 
Reid KJ, Harker J, Bala 
MM, Truyers C, Kellen E, 
Bekkering GE, Kleijnen J 
2011 Epidemiology of chronic non-cancer pain in Europe: narrative 
review of prevalence, pain treatments and pain impact 
 
1.5.1 Prevalence of pain 
 
The prevalence figures of pain described in previous sections refer to the number of 
people who have existing pain at a particular point in time (point prevalence) or over a 
specified period of time (period prevalence). The prevalence of pain varies according to 
the definition of pain in terms of the length of time it is experienced for (e.g. acute, 
chronic), location, (e.g. site-specific, widespread) and also according to study population 
(e.g. working age (16-65), oldest old (85+) (Croft et al., 2010). Pain intensity is usually 
recorded using verbal rating scales, visual analogue scales or numerical rating scales 
(Croft et al., 2010) which results in heterogeneity between studies (Von Korff, Jensen, & 
Karoly, 2000).  
Focusing on chronic pain, the World Health Organization Mental Health Surveys 
estimated the prevalence in adults in developed and developing countries to be 37.3% 
(95% confidence interval (CI) 36.7, 37.8%) and 41.1% (95%CI 40.3, 41.9%) respectively 
(Tsang et al., 2008). Participants were aged 18 and over in all surveys apart from those 
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from Japan (20 and over), Israel (21 and over) and New Zealand (16 and over).  In these 
surveys, chronic pain was defined as “arthritis or rheumatism”, “chronic back or neck 
problems”, “frequent or severe headaches” or “other chronic pain”.  This indicates 
potential misclassification, for example responders may have “arthritis” but not have 
chronic pain and the use of the term “arthritis” may vary between countries. 
Respondents were asked to indicate if their condition had been present in the 12 months 
prior to the survey (Tsang et al., 2008).  In contrast, estimates from another international 
comparison study (15 European countries and Israel) indicated slightly lower prevalence 
estimates (Breivik, Collett, Ventafridda, Cohen, & Gallacher, 2006). In this large survey of 
chronic pain undertaken in 2003 (where chronic pain was defined as pain that lasts for 
more than six months and which increases to 5 out of 10 in intensity at least twice a 
week) in the general adult population (i.e. adults over 18 years) prevalence estimates 
ranged from 12% to 30% (Breivik et al., 2006). 
A systematic review of the prevalence and impact of chronic non-cancer and neuropathic 
pain reported one in five adults experience at least moderate pain lasting three months 
or longer and one in fourteen adults experience chronic neuropathic pain (i.e. that pain 
occurs as a result of a lesion or disease of the somatosensory nervous system, (IASP, 
2012)) (Moore, Derry, Taylor, Straube, & Phillips, 2014).  
Despite the varying approaches to defining chronic pain, these studies indicate that it 
commonly occurs. Recognising how prevalence varies according to demographic 
characteristics (age, sex and socio-economic status) provides a starting point for 
identifying who are more likely to experience chronic pain.   
 
20 
 
1.5.2 The distribution of pain by age  
 
The prevalence of chronic pain typically increases with age until the seventh decade 
(Thomas, Mottram, Peat, Wilkie, & Croft, 2007; Thomas, Peat, et al., 2004) when it then 
plateaus or decreases in the oldest age groups (Breivik et al., 2006; Helme & Gibson, 
1999; Gran, 2003). The decrease in prevalence may be explained by older people not 
reporting pain because they see it as a normal part of ageing, a decrease in nociception 
with age and reduced activity levels leading to a reduction in stimulus for the experience 
of pain (Helme & Gibson, 1999). The underreporting of pain in older ages has been 
attributed to the presence of other medical problems, cognitive and sensory impairment 
and depression (Ferrell, 1991; Molton & Terrill, 2014). Notably despite the plateau of pain 
prevalence in older adults the impact of pain (i.e. pain that interferes with daily activities 
(work outside the home and housework)) continues to increase with age (Thomas, Peat, 
et al., 2004).    
1.5.3 Distribution of the prevalence of pain by sex 
Pain is more common in females than males for all pain definitions, with the exception of 
cancer pain) (Fillingim et al., 2009). For example, in adults aged 72 and over in the 
Framingham Heart Study, which is an observational cohort study of adults living in the 
community, 63% of women reported pain in one or more locations compared to 52% of 
men (Leveille, Zhang, McMullen, Kelly-Hayes, & Felson, 2005). The increased prevalence 
of pain in women occurs across age groups. One example of this is the prevalence of 
widespread pain in adults aged over 50 years in North Staffordshire (Thomas, Peat, et al., 
2004). Women reported a higher prevalence of widespread pain in all age-stratified 
groups (i.e. 50-69, 60-69, 70-79, 80+ years) (Figure 1.4). 
21 
 
 
Figure 1.4 The prevalence of widespread pain (WP) in the North Staffordshire 
Osteoarthritis Project (NorStOP) stratified by age and sex n=7878. (Thomas et al., 2004) 
 
The difference in prevalence between men and women may be due to biological (e.g. 
hormonal modulation) and psychosocial factors (e.g. women are more likely to 
catastrophise than men and men and women use different coping strategies) (Fillingim et 
al., 2009; Wijnhoven, de Vet, & Picavet, 2006). Irregular or prolonged menstrual cycle, 
hysterectomy, previous pregnancy, duration of oral contraception use and the use of 
estrogens during menopause are associated with low back pain and/or chronic upper 
extremity pain (Wijnhoven et al., 2006). Catastrophising is more common in women and 
this has been shown to explain sex differences in the report of pain (Fillingim et al., 2009). 
Pain coping strategies focussed on the sensory aspects of pain are more beneficial to men 
whereas females respond better to emotional focusing (Keogh & Herdenfeldt, 2002). Pain 
reporting may also be influenced by greater perceived social acceptance to complain 
about pain symptoms, greater exposures to risk factors for musculoskeletal pain (e.g. 
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psychosocial factors), or greater vulnerability to pain symptoms in women compared to 
men (Wijnhoven et al., 2006).  
1.5.4 Distribution of pain by socio-economic status 
 
Socioeconomic position refers to the position individuals or groups hold within the 
structure of society based on social and economic factors (Galobardes, Shaw, Lawlor, 
Lynch, & Davey Smith, 2006). Socioeconomic position can be measured at an individual or 
area level. Individual socio-economic status can be identified by occupation, level of 
education, employment status (unemployed yes/no, number of episodes of 
unemployment), income, housing status and access to a car (Galobardes et al., 2006). 
Area level indicators can be grouped into the domains of income, employment, health 
and disability, education, skills and training, crime, barriers to housing and services, and 
living environment; these can be combined to form a single overall Index of Multiple 
Deprivation (IMD) (Department for Communities and Local Government, 2010). Low 
socioeconomic position is associated with multiple definitions of pain. Macfarlane and 
colleagues demonstrated an association between low socioeconomic status and  
shoulder, forearm, low back, knee and chronic widespread pain (Macfarlane, Norrie, 
Atherton, Power, & Jones, 2009). Jordan et al., (2008) reported a higher incidence and 
prevalence of disabling pain in older adults living in more deprived areas according to IMD 
score which was only partially explained by individual risk factors such as perceived 
adequacy of income and low level of education (Jordan et al., 2008). There are a number 
of ways that socio-economic status can lead to the occurrence of pain. Manual 
occupation (the occupational indicator for low socio-economic status) is a proxy measure 
for physical and heavy jobs which are more likely to lead to pain (Coggon et al., 2013). 
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Low socioeconomic status is also associated with unhealthy lifestyle factors (i.e. poor diet 
and smoking), higher body mass index which also predict chronic widespread pain (Davies 
et al., 2009) and with higher rates of morbidity which are linked with increased 
prevalence of pain. (For example, low socioeconomic position is associated with 
depression (Everson, Maty, Lynch, & Kaplan, 2002) which is linked with increased levels of 
pain  (Davies et al., 2009)).  
1.5.5 Economic consequences of pain 
 
The high prevalence of pain has a substantial impact on society, often described in terms 
of economic consequences. One way of judging the extent of economic consequences of 
a condition is to compare its costs to the Gross Domestic Product (GDP) of the country in 
which the estimate was calculated.  The economic burden of pain is substantial, both in 
terms of direct healthcare costs and indirect costs through loss of economic productivity 
(e.g. lost workdays due to sickness or disability) (Patel et al., 2012; Phillips & Harper, 
2011; Reid et al., 2011; Woolf et al., 2012). In the United States of America in 2010, the 
total cost of pain through healthcare costs and lost workdays was estimated to be 
between $560 and $635 billion (approximately 4% GDP) (Table 1.3). These figures are 
higher than for cancer ($243 billion), heart disease ($309 billion) and diabetes ($188 
billion) (Gaskin & Richard, 2012). As previously stated, back pain is the most commonly 
experienced musculoskeletal pain in the UK (Woolf & Pfleger, 2003). The direct 
healthcare cost of back pain in the UK in 1998 was estimated to be £1,632 million with 
total costs coming to £12,300 million (approximately 5% GDP). The amount attributable 
to employment-related costs was approximately £10,668 million (Maniadakis & Gray, 
2000). Costs are also high in other European countries. The societal costs of back pain in 
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Germany have been estimated to be €48.96 billion (2.2% of GDP) (Wenig, Schmidt, 
Kohlmann, & Schweikert, 2009) and the total indirect costs of chronic back and joint pain 
in Portugal has been estimated at €740 million (0.5% of GDP) (Breivik, Eisenberg, & 
O’Brien, 2013).    
Table 1.3 displays the estimated total (direct plus indirect) annual costs of chronic pain for 
Australia, Denmark, Ireland, Sweden and the United States.  
Table 1.3 Estimated total annual financial costs of chronic pain conditions for selected countries 
Reference Country Year National cost 
estimate/year 
Approximate GBP 
equivalent* 
Approximate 
Proportion 
of GDP 
(The MBF 
Foundation, 2007) 
Australia 2007 A$34.3 billion 17.7 billion 3% 
(Christensen, Bilde, 
& Gustavsson, 2011) 
Denmark 2010 DKK17.8 billion 1.8 billion 1% 
(Raftery et al., 2012) Ireland 2008 €5.34 billion 4.0 billion 3% 
(Gustavsson et al., 
2012) 
Sweden 2008 €32 billion 24.1 billion 10% 
(Gaskin & Richard, 
2012) 
United 
States 
2010 $560-635 billion 372.3-422.2 billion 4% 
*Exchange rates calculated using xe.com February 2015 
GDP = Gross Domestic Product 
 
The biggest contributor to the direct cost of pain is hospitalisation and the greatest 
contributor to the indirect costs are social benefits (e.g. disability allowance and 
unemployment benefits) (Breivik et al., 2013). Differences in definition, time and place of 
data collection and a lack of coding to classify chronic pain hinder the accurate estimation 
of the costs (Breivik et al., 2013; Moore et al., 2014; Patel et al., 2012).  However, the 
figures outlined in Table 1.3 demonstrate the enormity of the economic burden of pain. 
Healthcare costs for patients with chronic pain are at least 2.6 times higher than for those 
without chronic pain irrespective of the location of the study and the types of healthcare 
costs included (Moore et al., 2014). The high economic costs of pain adds further to the 
need to reduce pain and its impact on individuals.   
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1.6  Impact of pain – a focus on mortality 
 
The prevention of pain is often not possible and once established, is likely to persist, 
particularly in older adults (Papageorgiou et al., 2002). Understanding the nature and 
breadth of the consequences of pain is necessary to optimise its management; this will 
involve identifying targets for interventions to reduce its impact and subsequently 
improve the quality of life of those living with pain. 
Whilst the relationship between pain and reduced physical and mental health and quality 
of life are more established, less is known about the natural course of pain. The long term 
health outcomes and links with mortality for people with pain are unclear (Macfarlane, 
McBeth, & Silman, 2001; McBeth et al., 2009). Pain may be a result of an underlying 
disease, or a marker for poor health which may lead to an increased risk of mortality 
(Andersson, 2009; Macfarlane et al., 2001; McBeth et al., 2009; Torrance , Elliot, Lee & 
Smith, 2010). Establishing if pain is associated with mortality and an understanding of 
how this occurs would highlight the need for and inform effective pain management. It 
may also highlight potential opportunities to reduce mortality risk by targeting specific 
impacts of pain. Despite its substantial and increasing impact on society, pain is not 
recognised as a public health problem in the same way as other health conditions such as 
cardiovascular disease and cancer (Woolf et al., 2012). Pain is a feature of many health 
conditions and its impact is obscured because it is the health condition which is the focus 
for research studies and clinicians (Blyth et al., 2015). If people with pain have an 
increased risk of mortality compared to those without pain, this would apply to a high 
number of people. This reinforces the need for a population level approach to the 
prevention of pain and indicates the need for better management of pain and its impact.  
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1.6.1 Studies of pain and mortality 
All-cause mortality 
There is no clear relationship between regional pain and all-cause mortality. Kåreholt and 
Brattberg (1998) reported increased rates of mortality across a 23 year period (1968 to 
1991), in a representative sample of Swedish adults, for headache, chest pain, abdominal 
pain, pain in the extremities and rectal pain. However pain in the back, hips or shoulders 
was not associated with increased mortality during this period (Kåreholt & Brattberg, 
1998). In contrast, using data from a representative sample of adults in the United 
Kingdom, Jordan and Croft (2010) reported significantly higher standardised mortality 
rates, for back, hip and shoulder pain after the first year of follow-up and for back pain 
the higher mortality risk remained over ten years of follow-up (Jordan & Croft, 2010). 
 
Links between pain and mortality have been reported where the focus of the study has 
been on pain intensity or musculoskeletal conditions where pain is often the most 
common symptom. In a study where participants were asked to rate their pain on a scale 
from zero to ten with zero being ‘no pain’ and ten ‘pain as bad as it could be’, greater 
pain (above a score of 4 compared to equal or below 4) was associated with an increased 
risk of mortality over a 5 year follow up period (Sokka & Pincus, 2011). This study did not 
report the location or duration of pain. Increased mortality has also been reported in 
patients with osteoarthritis (Hochberg, 2008; Nuesch et al., 2011) and rheumatoid 
arthritis (Dadoun et al., 2013), although the role of pain is not clear. Although pain is the 
most common symptom of these diseases, they are not always markers for the presence 
of pain; for example, in osteoarthritis radiographic changes are not always present where 
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there are symptoms of joint pain and joint pain is not always reported when radiographic 
changes are present (Woolf et al., 2012). The impact of rheumatoid arthritis on mortality 
will have a number of pathways (e.g. via cardiovascular pathology (Dadoun et al., 2013)). 
 
Cause specific mortality 
An investigation of the relationship between pain and cause-specific mortality provides 
clues about potential mechanisms of a relationship between pain and mortality. Similar to 
all-cause mortality, overall there is no consensus for an association between pain and 
cause specific (cardiovascular disease, cancer) mortality.  
 
For cardiovascular disease mortality, Zhu et al., 2007 reported an increased risk of 
mortality and coronary events for older women (aged 40 to 85 years) with daily back pain 
(Zhu, Devine, Dick, & Prince, 2007) and Penttinen et al., (1994) reported an association 
between back pain and an increased risk of death from ischaemic heart disease in men 
(Penttinen, 1994). Conversely Heliövaara and colleagues (1995) found no association 
between back pain and increased cardiovascular mortality in their study (Heliövaara, 
Mäkelä, & Aromaa, 1995). 
 
For cancer mortality, McBeth et al., (2003) reported a link between pain and the 
incidence of cancer and reduced cancer survival, particularly breast and prostate cancers 
(McBeth, Silman, & Macfarlane, 2003). Jordan and Croft (2010) found an increased 
incidence of cancer diagnosis across all recorded regional pain sites but particularly for 
people with back pain (Jordan & Croft, 2010). In a study of confirmed fibromyalgia 
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patients and possible fibromyalgia patients (those referred for muscle pain and or 
tenderness but not meeting the criteria for fibromyalgia) Dreyer et al., (2007) found an 
increased risk of cancer in possible fibromyalgia patients but not in confirmed 
fibromyalgia patients (Dreyer et al., 2007).  Cancer is associated with a number of lifestyle 
factors, for example the risk of breast cancer is linked with physical inactivity 
(Monninkhof et al., 2007). Physical inactivity is also associated musculoskeletal pain 
(McBeth & Nicholl, 2010) and this may be one mechanism by which those with pain have 
an increased mortality risk. In contrast however, Elliot et al., (2010) found no significant 
association between chronic pain and all cancers and no difference in cancer risk between 
those with severe or mild chronic pain (Elliott, Torrance, Smith, & Lee, 2010). Although 
the study undertaken by McBeth et al., (2003) reported an association between 
widespread pain and cancer mortality rather than chronic pain, 83% of the participants in 
this study met the IASP definition for chronic pain used by Elliot et al., (2010).   
 
Overview of the studies of pain and mortality 
Evidence for a relationship between pain and mortality is unclear. This is likely to be due 
to differences in the study populations and the different putative confounders included 
but particularly as a result of the different definitions of pain used. Chronic pain may be a 
useful starting point to examine the relationship between pain and mortality. There is 
potential for greater uniformity in case definition with use of recognised criteria (Merskey 
& Bogduk, 1994). As previously stated, chronic pain, that is pain that lasts for three 
months or longer (Merskey & Bogduk, 1994) is experienced by one in five adults (Moore 
et al., 2014) and commonly occurs in multiple body sites (Carnes et al., 2007). To evaluate 
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if there is a relationship between chronic pain and mortality, a systematic review was 
undertaken. In addition, the relationship between chronic widespread pain and mortality 
was examined in the review; chronic widespread pain, a sub-group of chronic pain and 
the cardinal symptom of fibromyalgia is linked with a greater impact than pain that is not 
widespread (Croft et al., 1996; Hunt et al., 1999; Kamaleri et al., 2008). Therefore if 
chronic pain is associated with mortality the relationship is likely to be strongest in those 
with chronic widespread pain.  The systematic review of chronic pain and mortality is 
presented in Chapter Two. 
1.7 Key messages 
 
 Pain is a complex, subjective multifactorial experience that is common and has a 
substantial impact on individual health and the economy.  
 It is unclear if pain is associated with an increased risk of mortality.  
 The high prevalence of pain in the general population means that if there is a link 
with mortality the increased risk applies to a substantial number of people.  
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Chapter Two. Chronic pain and mortality: a systematic review and meta-
analysis 
2.1 Chapter summary 
 
Chapter One introduced the prevalence, burden and impact of pain and the need to 
investigate whether people with pain have an increased risk of mortality. Evidence for a 
relationship between pain and mortality is inconsistent and may be due to the different 
definitions of pain applied. A comprehensive evaluation of existing studies on this topic 
would help to provide a clearer understanding of any relationship between pain and 
mortality. This chapter presents a systematic review of literature assessing the 
relationship between chronic pain and mortality; this involved evaluation and integration 
of existing evidence to determine if chronic pain was associated with an increased risk of 
mortality.  
2.2 Introduction 
 
Systematic reviews and meta-analyses are a fundamental part of health research, 
particularly in areas where conflicting findings arise in the literature (Egger, Smith, & 
Altman, 2001). They are undertaken to condense and integrate findings on a particular 
subject or a relationship in a strategic and comprehensive way (Mulrow, 1994). They can 
indicate a consensus, indicate the need for, or inform future studies. Systematic reviews 
provide evidence to aid the development of practice guidelines and government policy 
(Moher, Stewart, & Shekelle, 2012) and play an important role in preventing unnecessary 
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studies which may be expensive and time consuming yet will not contribute anything new 
to the field in question (Mulrow, 1994).    
Systematic reviews of randomised control trials are useful for evaluating medical 
interventions, whereas systematic reviews of observational studies are used to assess 
aetiological hypotheses and assess the long term medical effectiveness of interventions 
(Egger et al., 2001). Systematic reviews do not provide discrete answers to specific 
questions; rather they bring together pieces of evidence to more completely assess and 
describe the topic of interest (Popay, Roberts, & Sowden, 2006).  
2.2.1 Advantages and disadvantages of systematic reviews 
 
The use of systematic reviews in healthcare is firmly established (Moher et al., 2012), and 
considered to be an invaluable scientific activity (Mulrow, 1994) however it is important 
to use some caution when using reviews to make decisions about healthcare. The 
advantages of systematic reviews are evident if the review is carried out 
comprehensively. These include providing an appraisal of literature in a systematic and 
reproducible way (Moher et al., 2012), summarising large amounts of data, identifying 
gaps in the literature, overcoming the limitations of individual studies by increasing 
power and precision and enabling generalisability of findings across different populations 
and settings to be established (Mulrow, 1994). They also help to overcome biases often 
seen in traditional narrative reviews (e.g. subjectivity, unreproducible) by ensuring a 
structured systematic approach, including appraisal of the quality and consistency of 
studies on a particular topic and providing an efficient way to evaluate specific topics 
(Egger et al., 2001). This helps to prevent unnecessary replication of existing work and 
improves the reliability and accuracy of recommendations (Petticrew, 2001).  
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Systematic reviews also have a number of disadvantages. They are time consuming and 
resource intensive (Egger et al., 2001). The inclusion of studies of poor methodological 
quality can compromise the overall findings by leading to poor or imprecise overall 
estimates, there may be a distortion of findings caused by publication bias (significant 
results are more likely to be published, and in English) and prior knowledge of studies can 
influence inclusion criteria when designing the review protocol (Egger et al., 2001). 
Statistical pooling (meta-analysis) is sometimes used inappropriately when it is not 
meaningful to do so (e.g. if the included studies are not directly comparable) and there 
can also be difficulties in identifying and including relevant unpublished literature 
(Petticrew, 2001).  
 
In order to avoid the potential pitfalls involved in undertaking a systematic review it is 
important to have a clearly established protocol clarifying inclusion and exclusion criteria, 
quality assess all included studies using an established appraisal tool and ensure 
procedures are carried out by more than one reviewer (Systematic reviews: CRD’s 
guidance for undertaking reviews in health care, 2009). This systematic review followed 
an a priori determined protocol. 
2.3 Aim 
 
To determine the extent of association between chronic pain (and chronic widespread 
pain) and mortality. 
2.4 Objectives 
 
The objectives of this systematic review were: 
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1. To identify studies which have investigated the association between chronic pain 
and increased mortality. 
2. To evaluate the quality of the evidence of an association between chronic pain 
and mortality. 
3. To determine the strength and consistency of an association between chronic pain 
and mortality. 
2.5 Methods 
 
A protocol for the conduct of this systematic review and meta-analysis was developed 
with reference to Centre for Reviews and Dissemination (CRD) guidelines (Systematic 
reviews: CRD’s guidance for undertaking reviews in health care, 2009) and consisted of 
four phases:   
2.5.1 Phase 1: Search strategy and identification of studies (objective 1) 
 
A comprehensive search strategy was conducted by a single observer (DS). Broad search 
terms were used to maximise the identification of all observational studies that have 
examined the link between mortality and chronic and/or widespread pain. The search 
strategy used subject headings (e.g. MeSH where possible) and text words for death (e.g. 
mortality, death, survival), pain (e.g. musculoskeletal pain, fibromyalgia, joint pain) and 
study type (e.g. cohort studies, longitudinal studies and cross-sectional studies) (see 
Appendix I for full search strategy). The following databases were searched in March 
2012: Ageline, AMED, CINAHL, EMBASE, MEDLINE, PSYCHINFO, Social Sciences Citation 
Index (SSCI) and Science Citation Index Expanded (SCI-EXPANDED) using ISI Web of 
Science. The Cochrane databases (Cochrane Database of Systematic Reviews (Cochrane 
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Reviews) and the Database of Abstracts of Reviews of Effects (Other Reviews) (DARE) 
were searched for relevant reviews. Citation searches and reference list searches were 
undertaken to identify other possible relevant studies. A search of the Open Grey 
database for grey literature (www.opengrey.eu) was undertaken in April 2012 to identify 
any relevant  papers.  Searches in AMED, CINAHL, EMBASE, MEDLINE and PSYCHINFO 
were updated until March 2014.  
2.5.2 Phase 2. Study selection (objective 1) 
 
Identified studies were initially filtered with a title search by a single observer (DS) based 
on the following inclusion criteria:  
 Study type - observational studies  
 Participants – community dwelling adults  
 Exposure – chronic (lasting more than 3 months) or widespread pain including 
fibromyalgia 
 Outcome - mortality 
 Papers published in English 
Exclusion criteria 
 Study type - trials  
 Exposure - musculoskeletal conditions (e.g. osteoarthritis), specific locations of 
pain only (e.g. knee pain, back pain), studies focussed on non-musculoskeletal 
pain (e.g. cancer pain). 
 Outcome – disease incidence.  
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The abstracts and keywords of the remaining studies were screened by two reviewers 
(DS) (RW) in order to minimise human error before the retrieval of full text studies for 
further screening. Any disagreements regarding inclusion were discussed in a consensus 
meeting with a third reviewer (JM) to finalise which papers would be included in the 
review.  
2.5.3 Phase 3: Data extraction and quality assessment (objective 2) 
 
From each included study, data on study population, follow-up period, pain phenotype, 
outcome, cause of death and potential confounding factors, were extracted by one 
reviewer (DS) and checked by two others (RW) (JM) for omissions and accuracy (Table 
2.1). One of the most important aspects of conducting a systematic review is to assess the 
quality of the included studies. Quality can be defined as the extent to which a study 
attempts to minimise bias and error in its design, conduct and analysis (Khan, Kunz, 
Kleijnen, & Antes, 2003). If the included studies in a systematic review were of poor 
quality the overall findings are unlikely to be generalisable and could be potentially 
meaningless. 
 
Sources of bias 
Bias in research studies can produce results that are systematically different from the 
truth (Khan et al., 2003). Observational studies have a number of potential sources of 
bias. These include: 
 Selection bias 
This occurs where the study population differs from, and therefore is not 
representative of, the target population (Grimes & Schulz, 2002). Participants in 
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observational studies are grouped according to their disease status or their 
exposure to a particular risk factor and selection bias can occur due to differential 
surveillance, diagnosis or referral to the study (Hennekens & Buring, 1987).   
 
Non-response bias is one form of selection bias where the participants who don’t 
respond in a study differ from those who do, for example where those who 
choose to take part are healthier than those that do not (i.e. the healthy volunteer 
effect) (Delgado-Rodríguez & Llorca, 2004). Non-response is often greater in males 
and older people and is influenced by level of education, socioeconomic status 
and the perceived benefits of taking part in the study (Silman & Macfarlane, 
2002). In order to assess this form of bias information is needed about individuals 
who choose not to take part. 
 
A similar form of bias in cohort studies can result from loss to follow up (attrition) 
which occurs when participants are followed over time and fewer participants 
respond at later time points than at baseline. Those lost differ from those who 
remain in the study, meaning that any observed association will be an 
overestimate or underestimate of the true effect (Hennekens & Buring, 1987). 
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 Information bias 
Information bias occurs when there is measurement error in the data, that is, the 
true value differs from that which is observed (Hennekens & Buring, 1987). It is 
also referred to as observation, classification or measurement bias (Grimes & 
Schulz, 2002). Forms of information bias include: 
 Recall bias - this occurs when there are differences in the likelihood of 
reporting an event based on context or emotional state. For example, 
individuals who are aware they have been subject to a particular exposure 
may be more likely to report disease symptoms than those not exposed 
(Delgado-Rodríguez & Llorca, 2004). 
 Reporting bias  - this occurs when participants give answers they perceive 
are in the direction of interest; favourably report socially desirable 
behaviours such as physical activity or underreport socially undesirable 
behaviours such as alcohol consumption (Delgado-Rodríguez & Llorca, 
2004).  
 Interviewer bias – this occurs when there are differences in the way that 
information is obtained, recorded or interpreted (Hennekens & Buring, 
1987). For example, previous knowledge of a participant’s exposure status 
may result in leading questioning in favour of an hypothesis of interest 
(Silman & Macfarlane, 2002).  
 Misclassification bias  - this can occur where the procedure to measure the 
exposure or disease of interest is inaccurate resulting in the 
misclassification of participants as exposed or diseased when they are not 
(Delgado-Rodríguez & Llorca, 2004).  Some degree of random 
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misclassification is likely to occur in most epidemiological studies, but 
becomes a problem if the proportion of misclassifications vary between the 
groups being studied (Hennekens & Buring, 1987). 
  
 Confounding 
Confounding occurs when an attempt to measure the relationship between an 
exposure and outcome is actually measuring the effect of a third confounding 
variable (Grimes & Schulz, 2002). It can lead to an overestimation, 
underestimation, or change in direction of the true effect (Hennekens & Buring, 
1987). A confounder is a variable that is associated with the exposure and 
outcome in question but is not on the causal pathway between the exposure and 
the effect (Delgado-Rodríguez & Llorca, 2004). For example, an increased 
incidence of lung cancer in coal miners working at the coal face compared to 
miners working at the surface could be explained by coal face workers smoking 
more than those who work at the surface. Smoking would be the confounding 
factor that explains the observed relationship between coal face working and lung 
cancer (Silman & Macfarlane, 2002).  
 
Quality assessment tools 
An important distinction needs to be made between the quality of the reporting of 
studies and the quality of the design, conduct and analysis of studies (Sanderson, Tatt, & 
Higgins, 2007). A number of checklists are available to guide the reporting of studies for 
example, the Strengthening of Reporting of Observational Studies (STROBE) (Von Elm et 
al., 2007), and Meta-analysis of Observational Studies in Epidemiology (MOOSE) (Stroup, 
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Berlin, & Morton, 2000). These guidelines are designed to help authors ensure 
comprehensive reporting of the study they have undertaken. Tools designed to assess 
susceptibility to bias are aimed at assessing the validity of the studies (Sanderson et al., 
2007). These range from simple checklists (Kmet, Lee, & Cook, 2004) to rating scales such 
as the Newcastle-Ottawa scale (Wells et al., 2000). There is no consensus over which tool 
is the best for assessing the quality of observational studies. Sanderson and colleagues 
(2007) conducted a review of available quality assessment tools and identified 86 in total 
and recommended that quality assessment tools should; include a small number of key 
domains, be as specific as possible (with consideration of the study design and topic 
area), be a simple checklist rather than a scale and show evidence of validity and 
reliability (Sanderson et al., 2007). 
 
Quality in Prognosis Studies tool  
The Quality in Prognosis Studies tool (QUIPs) was chosen for this review as it provides a 
number of criteria for assessing the risk of selection bias, non-response bias, 
measurement bias and confounding and was developed through expert international 
consensus (Appendix II) (Hayden, Côtė & Bombardier, 2006). The following areas are 
assessed: study participation, study attrition, measurement of exposure, measurement of 
and controlling for confounding variables, measurement of outcomes, and analysis 
approaches. For this review, the QUIPs tool was modified slightly for use with cross 
sectional studies. The reviewers assessed for non-response bias in place of attrition and 
the prognostic factor measurement component was used to apply to any factor 
(exposures and outcomes).  For each of the potential areas for bias, reviewers assessed 
whether the study methods satisfied between three and seven general statements (e.g. 
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“the source population or population of interest is adequately described for key 
characteristics”) and one overall statement (e.g. “Is the following statement satisfied 
based on responses to the above questions; the study sample represents the population 
of interest on key characteristics, sufficient to limit potential bias to the results?”). 
Reviewers rated their agreement as “Yes”, “Partly”, “No”, “Unclear”, or “Not Relevant”.  
The assessment of the methodological quality of each of the selected studies was carried 
out independently by two reviewers (DS, RW). A third reviewer (JJ) was asked to review 
selected studies to ensure consistency and enable a consensus to be reached over any 
disagreements. Where reviewers agreed ‘yes’ to the overall statements the risk of bias 
was low, ‘partly’ or ‘unclear’ the risk was moderate and ‘no’ indicated high risk of bias in 
that area. 
 
Inter-rater agreement 
The level of agreement between the two reviewers when assessing potential bias in the 
identified studies was examined using percentage agreement. While this illustrates the 
amount of agreement between reviewers, it does not account for the agreement that 
may be expected by chance (Sim & Wright, 2005). The Kappa statistic calculation is based 
on the difference between the observed agreement (percentage figures) and the level of 
agreement that would be expected by chance alone (Fleiss, 1971). The measure is 
standardised to lie on a scale between -1 and 1 where 1 indicates perfect agreement, 0 
indicates what would be expected by chance and negative values indicate agreement 
worse than would be expected by chance (Viera & Garrett, 2005). An interrater reliability 
analysis using the Kappa statistic was therefore undertaken on the overall scores to 
determine the level of agreement among reviewers. The Kappa statistic can be calculated 
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using weighted or unweighted methods. Weighted methods assign greater importance to 
more serious disagreements in ordinal scales (Sim & Wright, 2005). For example, a 
greater weight would be assigned to the difference between ‘neither agree nor disagree’ 
and ‘strongly agree’ than the difference between ‘agree’ and ‘strongly agree’ in a rating 
scale. This analysis used an unweighted calculation performed in SPSS version 20. 
Although it is more appropriate to use a weighted Kappa for ordinal scales (Sim & Wright, 
2005) an unweighted version was deemed more appropriate for this rating scale because 
one of the response options was ‘not relevant’ which is not equivalent to a one or more 
scale point difference than any of the other options. It was therefore considered more 
appropriate to use unweighted Kappa and treat all disagreements equally. Kappa values 
of ≤0 indicate poor agreement, 0.01–0.20 slight agreement, 0.21–0.40 fair agreement, 
0.41–0.60 moderate agreement, 0.61–0.80 substantial agreement, and 0.81–1.00 
indicates almost perfect agreement (Landis & Koch, 1977).    
2.5.4 Phase 4: Data extraction and analysis (objective 3) 
 
Meta-analyses are not always a part of systematic reviews but can provide useful 
additional information if used appropriately. Meta analyses of observational studies are 
often challenging due to the inherent problems of bias and confounding often seen in 
observational studies, however, they can also be used to help understand and quantify 
sources of variability across studies (Stroup et al., 2000).  
Where a meta-analysis is included as part of a systematic review it can be used to 
statistically combine the findings of a group of studies in order to produce a weighted 
average effect (Khan et al., 2003). The overall pooled effect is calculated and presented 
with the accompanying statistical test of significance (z test and associated p- value) 
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(Gliner, Morgan, & Harmon, 2003). Meta-analyses also provide a statistical test of 
heterogeneity to determine whether the studies are consistent (Higgins, Thompson, 
Deeks, & Altman, 2003). Heterogeneity is defined as the presence of variation in true 
effect sizes across studies (Higgins, 2008) and is quantified using the I2 statistic. The I2 
value lies between 0 and 100% and represents the percentage of the total variation 
across studies that is due to heterogeneity rather than chance (Higgins et al., 2003). 
Higgins and colleagues (2003) suggest I2 values of 25% can be considered low, 50% 
moderate and 75% high (Higgins et al., 2003).   
A chi-squared test of goodness of fit and corresponding p-value are also calculated in 
meta-analyses to determine whether the amount of heterogeneity (I2 value) is significant 
(Gliner et al., 2003). This test assesses whether observed differences in results are the 
result of chance alone. A low p value (or a large chi-squared statistic relative to its degree 
of freedom) indicates variation in the effect estimates beyond what would be expected by 
chance (Higgins, Green, & Collaboration, 2008). Finally, the Tau-squared value is also 
calculated which is a point estimate of the between study variance. The I2 value is 
therefore a measure of the proportion of variability due to Tau squared rather than 
within-study error (Higgins, 2008). 
A meta-analysis was therefore conducted to quantify heterogeneity and where possible 
determine a pooled effect for the relationship between chronic pain and mortality. Meta-
analyses can be undertaken using either a fixed or a random effects statistical model 
(Riley, Higgins, & Deeks, 2011). A fixed effects model assumes all of the included studies 
are measuring the same effect and any differences are due to chance whereas a random 
effects model allows for differences in the effect between the studies (Riley et al., 2011). 
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As the ten studies included in the review included different study populations, different 
measures of potential confounders and different definitions of the exposure it was 
assumed there would be a high degree of heterogeneity between studies, therefore a 
random effects model was used.  
The logarithm of the measure of effect (Mortality Rate Ratio) and accompanying 
confidence intervals were calculated in order to perform the analysis. This transformation 
was used to reduce skewness in the data. For ratio summary statistics the scale is not 
symmetric as the lowest number which it can take is zero and the highest infinity. The log 
transformation makes the scale symmetric and suitable for analysis (Deeks, Higgins & 
Altman, 2008).  
Variation in the definition of chronic pain (pain phenotype) was expected to be a key 
source of heterogeneity and was therefore explored in a sensitivity analysis, only 
including studies using the stricter definition of widespread pain. The pooled effects, chi-
squared tests, corresponding p-values, I2 values and Tau-squared values were calculated 
(described above) combining studies measuring: 
i) Chronic pain and all-cause mortality 
ii) Chronic widespread pain and all-cause mortality 
iii) Chronic pain and cancer mortality 
iv) Chronic widespread pain and cancer mortality 
v) Chronic pain and cardiovascular disease mortality 
vi) Chronic widespread pain and cardiovascular disease mortality 
vii) Chronic pain and respiratory disease mortality 
viii) Chronic widespread pain and respiratory disease mortality 
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All statistical analysis was performed in Stata 12 where the random effects model 
implemented was that of DerSimonian and Laird (1986) (DerSimonian & Laird, 1986).  
Narrative review 
A narrative review was undertaken to explore differences and similarities between 
included studies for age and sex, follow-up time, pain phenotype, population 
characteristics, methods of analysis and potential confounding factors included. Sources 
of heterogeneity are presented and linked to the study findings descriptively and in 
tabular form (Table 2.3).   
Crude results were not available for all studies so the meta-analysis used the maximally 
adjusted results for each study. Two of the studies used standardised mortality ratios 
(SMRs) as their measures of effect (Dreyer, Kendall, Danneskiold-Samsøe, Bartels, & 
Bliddal, 2010; Wolfe, Hassett, Walitt, & Michaud, 2011) and one used adjusted odds 
ratios (AORs) (Smith, Elliott, & Hannaford, 2003). These are not directly comparable to 
mortality rate ratios (MRRs) therefore results from these studies were not included in the 
calculation of pooled estimates.  
2.6 Results 
 
2.6.1 Identification of studies 
 
The search identified 15,057 articles. 15,006 were excluded during the review of titles as 
they did not meet the inclusion criteria (Figure 2.1). The review of abstracts and keywords 
resulted in the exclusion of a further 30 articles. The full texts of 21 articles were 
retrieved for further screening and 9 of these were excluded; for 6 of these studies it was 
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not possible to determine the presence of widespread pain or chronic pain lasting beyond 
three months (Ahmad & Bath, 2005; Elliott, Hannaford, Smith, Wyke, & Hunt, 2006; 
Jordan & Croft, 2010; Kåreholt & Brattberg, 1998; Khang & Kim, 2010; Sha et al., 2005), 
one study was focussed on inpatients in a pain management clinic (Maruta, Malinchoc, 
Offord, & Colligan, 1998), one study focussed on disease incidence as the outcome 
(Dreyer et al., 2007) and one examined the relationship between lifestyle factors and 
chronic widespread pain (Vandenkerkhof et al., 2011). Twelve articles describing nine 
studies remained; three articles were excluded to avoid using results from the same 
cohort multiple times in the analysis (Andersson, 2004; Mäkelä & Heliövaara, 1991; 
McBeth et al., 2003) leaving nine studies for the analysis. An additional study was added 
from the automated database search updates in 2013 (Nitter & Forseth, 2013) resulting in 
10 studies in total. There was wide variation between the identified studies in terms of 
pain phenotype, follow-up time, population characteristics and inclusion of confounders 
(Table 2.1). 
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Figure 2.1 Flow chart of the selection of papers for the systematic review 
  
 
     
 
 
 
 
       
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Papers identified 
through electronic 
database search 
(n=15,057) 
Papers identified by 
bibliography 
searches or other 
sources (n=0) 
Eligible papers for 
abstract review (n=51) 
Eligible papers for full 
text review (n=21) 
Papers included in review 
and meta- analysis (n=10) 
Did not meet inclusion 
criteria (n=15,006) 
Did not meet inclusion 
criteria (n=9) 
Did not meet inclusion 
criteria (n=30) 
Studies based on same 
cohort (n=3) 
Additional papers from 
search updates (n=1) 
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Table 2.1 Summary of the papers included in the systematic review 
Study n Age  % female Location Follow-
up  
Pain phenotype All-cause 
mortality 
Cause specific mortality 
(adjusted results) 
Putative confounders 
Macfarlane, 
G.J. et al. 
(2001) 
6569 18-85 58 North 
West 
England 
8yrs Widespread pain 
ACR (1990) criteria  
MRR (95%CI) 
1.31 (1.05-
1.65) 
MRR (95%CI) Cancer 2.07 (1.37 
- 3.13) Cancer without prior 
diagnosis 2.27 (1.46-3.54) 
Cardiovascular disease 1.12 
(0.78-1.61) Respiratory disease 
1.01 (0.57-1.79) Other diseases 
0.91 (0.45-1.85) All external 
causes 5.21 (0.94-28.78) 
age, sex, study location 
Macfarlane, 
G.J. et al. 
(2007) 
7182 30 and 
over 
54 Finland 14-16yrs Widespread pain - 
in at least 4 sites 
(face validity with 
ACR (1990) criteria) 
MRR (95%CI) 
0.86 (0.74-
1.00)  
MRR (95%CI) Cardiovascular 
disease 0.83 (0.68-1.02) Cancer 
0.64 (0.46-0.91) Respiratory 
diseases 0.89 (0.54-1.49) Other 
disease related 1.39 (0.88-2.19) 
Non disease related 1.39 (0.75-
2.58)  
age, gender, education, 
physical work stress, 
mental work stress, 
alcohol consumption, 
tobacco smoking, BMI 
Andersson, 
H.I. (2009) 
1609  25-74 50 Sweden 14 yrs Widespread pain - 
in more than four 
pain locations 
including upper and 
lower body and 
axial pain (to get 
close to ACR 
criteria) 
MRR (95%CI) 
Crude 1.95 
(1.26-3.03) 
Adjusted 
1.09 (0.62-
1.90) 
MRR (95%CI) Cardiovascular 
disease 2.17 (1.12-4.21) Cancer 
1.15 (0.52-2.55) Other 1.18 
(0.47-2.99) 
Age, sex, living alone, 
contact with friends, club 
membership, chronic 
disease, smoking, physical 
activity, perception of 
stress, BMI, insomnia 
(cause specific results 
adjusted for age and sex) 
McBeth, J. 
et al. (2009) 
4515 16 and 
over 
51.6 North 
West 
England 
8.2yrs Widespread pain 
ACR (1990) criteria. 
Number of pain 
sites 
MRR (95%CI) 
Crude 2.4 
(1.9-2.9) 
Adjusted 1.3 
(1.1-1.5)  
MRR (95%CI) Cancer 1.8 (1.3-
2.6) Cardiovascular disease 1.3 
(0.99-1.6) Respiratory disease 
1.0 (0.7-1.6) All external causes 
0.6 (0.1-3.8) Other 0.8 (0.5-1.4) 
age, sex, practice, ethic 
group, Townsend score of 
deprivation 
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Sjøgren P. et 
al. (2010) 
2242 16 and 
over 
51.3 Denmark 8 years Chronic pain (6 
months or more) 
MRR (95%CI) 
Adjusted 
1.21 (1.02-
1.44) 
 age, sex, education, 
marital status, BMI, 
smoking, antidepressant 
use, anxiolytic use, self-
reported circulatory 
diseases, infectious or 
parasitic diseases, 
diabetes and mental 
disorders 
Torrance N. 
et al. (2010) 
5853 Mean 
58.43 
52.7 North East 
Scotland 
10 years Chronic pain (more 
than 3 months) 
MRR (99%CI) 
Crude 1.32 
(1.14-1.54) 
Adjusted 
0.90 (0.74-
1.07) 
MRR (99% CI) All circulatory 
system 0.86 (0.65-1.14) Acute 
MI 1.11 (0.67-1.83) Ischaemic 
heart disease 1.04 (0.51-2.12) 
Cerebrovascular disease 0.58 
(0.35-0.97) Other circulatory 
system 0.88 (0.47-1.66) All 
neoplasms 0.91 (0.64-1.28) 
Digestive organ neoplasms 0.97 
(0.50-1.87) Respiratory organ 
neoplasms 0.81 (0.43-1.54) 
Other malignant neoplasms 
0.95 (0.58-1.59) All respiratory 
diseases 1.23 (0.67-2.25) 
Pneumonia 1.44 (0.57-3.61) 
Chronic lower respiratory 
disease 1.35 (0.49-3.73) Other 
respiratory disease 1.08 (0.29-
4.04) Diseases of the digestive 
system 0.90 (0.35-2.34) 
Diseases of the nervous system 
0.42 (0.14-1.26) Other 0.96 
(0.57-1.62)   
age, sex, education, 
housing, long term limiting 
illness 
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Nitter A.K. & 
Forseth K.Ø. 
(2013) 
2038 20 -68 
years 
100 Arendal, 
Norway 
18 years Chronic widespread 
pain (in muscles 
and joints and back 
or whole body for 3 
months or longer)  
MRR (95%CI) 
2.8 (1.3-6.1) 
 age, sleep problems, 
feeling anxious, frightened 
or nervous, number of 
non-specific health 
complaints 
Dreyer, L. et 
al. (2010) 
1353  19 and 
over 
94 Denmark 15 yrs 
(Mean 
3.9 
years) 
ACR (1990) 
definition of FM 
SMR (95%CI) 
1.25 (0.9-
1.7) 
SMR (95%CI) Female only: 
Ischemic heart disease 0.3 (0.0-
1.6). Other heart disease 3.0 
(0.6-8.9) Cerebrovascular 
disease 3.1 (1.1-6.8) Cancer 0.6 
(0.3-1.2) Pneumonia 2.7 (0.0-
14.8), COPD 2.0 (0.5-5.2) Liver 
cirrhosis 6.4 (2.3-13.9) Mental 
disorders 2.3 (0.0-12.6) Suicide 
10.5 (4.5-20.7) Other external 
causes 3.9 (0.1-21.7) Other 0.4 
(0.1-1.5) 
Standardised to Danish 
population (according to 
age, sex, calendar month)  
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Wolfe, F. et 
al. (2011) 
8186   Mean 
50.5, 
(SD 
12.4) 
94 USA 35yrs 
(Mean 
7.3 
years) 
Fibromyalgianess 
scale. Widespread 
pain index. ACR 
definition of FM 
1990, 2010. 
SMR (95%CI) 
0.90 (0.61-
1.26) 
SMR (95%CI) Heart diseases 
0.84 (0.68-1.04) Cancer 0.95 
(0.76-1.18) Accidents 1.45 
(1.02-2.06) Chronic lower 
respiratory diseases 1.09 (0.74-
1.62) Influenza and pneumonia 
1.69 (1.12-2.57) Septicaemia 
2.49 (1.61-3.68) Suicide 3.31 
(2.15-5.11) Cerebrovascular 
diseases 0.75 (0.48-1.17) 
Nephritis/nephrotic 
syndrome/nephrosis 0.93 (0.50-
1.72) Alzheimer’s disease 0.57 
(0.29-1.13) Essential 
hypertension/hypertensive 
renal disease 0.95 (0.40-2.23) 
Chronic liver disease and 
cirrhosis 0.47 (0.16-1.38) 
Parkinson’s disease 0.22 (0.00-
1.23) Assault (homicide) 0.26 
(0.00-1.51) 
Standardised to U.S. 
population (according to 
age, sex, calendar month) 
Smith, B.H. 
et al. (2003) 
1007
3 
42-81 
years 
100 UK wide 6 years Chronic pain (more 
than 3 months) 
AOR (95%CI) 
1.1 (0.81-
1.26) 
AOR (95%CI) All cancers 0.85 
(0.62-1.18) Cardiovascular 
disease 0.95 (0.63-1.44) 
Respiratory disease 2.22 (1.12-
4.39) Other diseases 1.08 (0.52-
2.27) All external causes 0.99 
(0.16-5.93) 
age, social class, smoking 
ACR = American College of Rheumatology 
MRR = Mortality Rate Ratio 
SMR = Standardised Mortality Ratio 
AOR = Adjusted Odds Ratio 
CI = Confidence Interval 
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2.6.2 Quality assessment 
 
Table 2.2 presents the agreed level of bias for each area for each study. Across the studies 
there were two areas where reviewers agreed the risk of bias was most likely. The first 
was ‘non-response’; this was due to the lack of information available about participants 
who did not respond to requests to take part in the studies. The second was ‘confounding 
measurement and account’; there are a large number of potential confounders that may 
influence the association between chronic pain and mortality and these were accounted 
for in varying degrees in each of the studies. Where a small number of potential 
confounders were included in the analysis the reviewers considered the risk of bias to be 
high. Despite there being two areas where bias was likely, overall, all papers were 
deemed to be of adequate quality for inclusion in the review.   
 
The level of agreement between the reviewers for all studies was substantial or almost 
perfect (Kappa statistic range 0.66 (95%CI 0.47, 0.86) to 0.96 (95%CI 0.88-1.04) (Table 
2.2). 
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Table 2.2 Summary of agreed level of bias between the two reviewers and percentage agreement for each potential area of bias and overall Kappa for each 
study 
Study Participation Non-response Factor 
Measurement 
Outcome 
Measurement 
Confounding 
Measurement 
and Account 
Analysis Ove
rall  
Overall Kappa 
(95% CI) 
% 
agree
ment 
Agreed 
level of 
bias 
% 
agree
ment 
Agreed 
level of 
bias 
% 
agree
ment 
Agreed 
level of 
bias 
% 
agree
ment 
Agreed 
level of 
bias 
% 
agree
ment 
Agreed 
level of 
bias 
% 
agreem
ent 
Agreed 
level of 
bias 
% 
agree
ment 
Macfarlane, G.J., et al. 
(2001) 
67% Moderate 100% Moderate 100% Low 100% Low 88% High 80% Low 89% 0.85* (0.70, 0.99) 
Smith B.H. et al., (2003) 100% Moderate 100% Moderate 100% Low 100% Low 88% Moderate 80% High 94% 0.86* (0.73, 0.99) 
Macfarlane, G.J. et al. 
(2007) 
83% Low 67% Moderate 100% Low 100% Low 88% Moderate 60% Moderate 83% 0.73* (0.54, 0.92) 
Andersson, H.I. (2009) 67% Moderate 83% Moderate 100% Low 100% Low 100% Low 100% Low 95% 0.85* (0.70, 1.00) 
McBeth, J., et al. (2009) 100% Low 50% Moderate 100% Low 100% Low 100% Moderate 80% Low 89% 0.79* (0.62, 0.97) 
Dreyer, L., et al. (2010) 83% Low 67% Low 86% Low 75% Low 75% High 80% Moderate 78% 0.66* (0.47, 0.86) 
Sjogren, P. et al. (2010) 83% Moderate 67% Moderate 100% Moderate 100% Low 63% Low 100% Low 83% 0.69* (0.48, 0.89)  
Torrance, N. et al. 
(2010)  
100% Moderate 83% Moderate 100% Low 100% Low 100% Low 100%  Low 97% 0.96* (0.88, 1.04) 
Wolfe, F., et al. (2011) 100% Low 100% Low 100% Low 100% Moderate 88% Moderate 80% Low 92% 0.88* (0.74, 1.00) 
Nitter, A.K. et al. (2013) 100% Moderate 100% Moderate 86% Moderate 75% Moderate 75% Moderate 60% Moderate 83% 0.80* (0.64, 0.97) 
* p<0.05 
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2.6.3 Study findings 
 
In crude analyses one study reported that chronic pain was associated with mortality: 
MRR 1.32; 95%CI 1.14, 1.54 (Torrance et al., 2010), and two studies reported that 
widespread pain was associated with all-cause mortality: MRR 2.4; 95%CI 1.9, 2.9 
(McBeth et al., 2009) and MRR 1.95; 95%CI 1.26, 3.03 (Andersson, 2009). In the first of 
these studies the association between chronic pain and mortality was no longer 
significant following adjustment for age and sex, education and housing (MRR 1.15; 95%CI 
0.97, 1.35 (Torrance et al., 2010). In the second of these studies the association remained 
significant following adjustment for age, sex, medical practice, ethnic group and 
Townsend score of deprivation (MRR 1.3; 95%CI 1.1, 1.5) (McBeth et al., 2009). In the 
third study, the association remained significant after adjustment for age and sex (MRR 
1.54; 95%CI 1.01, 2.35) but was not significant following adjustment for living alone, 
contact with friends, club membership, comorbidity, smoking, physical activity, BMI, 
perception of stress and insomnia (MRR 1.09; 95%CI 0.62, 1.90) (Andersson, 2009). 
Macfarlane and colleagues (2001) did not report crude results but did report a significant 
association between widespread pain and all cause-mortality following adjustment for 
age, sex and study location (MRR 1.31; 95%CI 1.05, 1.65) (Macfarlane, McBeth, & Silman, 
2001). In adjusted analyses Sjøgren and Grønbæk (2010) reported a significant association 
between chronic pain and mortality (MRR 1.21; 95%CI 1.02, 1.44) (adjusted for age, sex, 
education, marital status, BMI, smoking, use of antidepressants, use of anxiolytics, self-
reported circulatory diseases, diabetes and mental disorders) (Sjøgren & Grønbæk, 2010) 
and Nitter and Forseth (2013) reported an association between chronic  widespread pain 
and mortality (MRR 2.80; 95%CI 1.3, 6.1) (adjusted for age, sleep problems, feeling 
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anxious, frightened or nervous, number of non-specific health complaints) . Dreyer et al 
(2010) reported borderline significantly increased mortality in participants with 
fibromyalgia (SMR 1.25; 95%CI 0.90, 1.70) (Dreyer et al., 2010). The remaining three 
studies did not report significant or strong associations between chronic or widespread 
pain and all-cause mortality (Macfarlane et al., 2007; Smith et al., 2003; Wolfe, Hassett, et 
al., 2011) (Table 2.1). 
2.6.4 Evidence synthesis: meta-analysis 
 
All-cause mortality 
The results of the seven (of ten) studies which calculated mortality rate ratios (MRR) were 
combined to give pooled estimates.  For the association between chronic pain and all-
cause mortality, the analysis showed high statistical heterogeneity (I2 = 78.8%), with 
MRRs ranging from 0.86 to 2.80. The pooled estimate was modest but not significant: 
MRR 1.14; 95%CI 0.95, 1.37 (p=0.162) (Figure 2.2). The sensitivity analysis including only 
studies measuring widespread pain indicated a slightly higher risk of mortality although 
the association was not significant and heterogeneity remained high (MRRs ranged from 
0.86 to 2.8, I2 = 82.3%, pooled MRR 1.22; 95%CI 0.93, 1.60 (p=0.157)) (Figure 2.3).  
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Figure 2.2 Forest plot of the of the association between chronic pain and all-cause 
mortality in identified studies (effect sizes are MRR only) 
MRR=Mortality Rate Ratio, CI= Confidence Interval, WP = Widespread Pain, CP=Chronic Pain, CWP = Chronic 
Widespread Pain 
 
 
NOTE: Weights are from random effects analysis
Overall  (I-squared = 78.8%, p = 0.000)
Study
Andersson (2009) (WP)
Macfarlane et al. (2007) (WP)
Sjogren et al. (2010) (CP)
Torrance et al. (2010) (CP)
Nitter et al. (2013) (CWP)
McBeth et al. (2009) (WP)
Macfarlane et al. (2001) (WP)
1.14 (0.95, 1.37)
size (95% CI)
1.09 (0.62, 1.91)
0.86 (0.74, 1.00)
Effect
1.21 (1.02, 1.44)
0.90 (0.75, 1.08)
2.80 (1.29, 6.07)
1.30 (1.11, 1.52)
1.31 (1.05, 1.64)
100.00
Weight
7.19
18.54
%
17.85
17.46
4.50
18.40
16.06
  
1.165 6.07
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Figure 2.3 Forest plot of the association between chronic widespread pain and all-cause 
mortality in identified studies (effect sizes are MRR only) 
MRR=Mortality Rate Ratio, CI= Confidence Interval, WP = Widespread Pain, CWP = Chronic Widespread Pain 
 
Cause specific mortality 
Eight of the studies provided information regarding cause specific mortality (Andersson, 
2009; Dreyer et al., 2010; Macfarlane et al., 2007; Macfarlane et al., 2001; McBeth et al., 
2009; Smith et al., 2003; Torrance et al., 2010; Wolfe, Hassett, et al., 2011) (Table 2.1).  
Five of these used MRRs and could be combined to provide pooled estimates. For cancer 
(Figure 2.4), the MRRs ranged from 0.64 to 2.07 (I2 = 85.3%), pooled estimate MRR 1.20; 
95% CI 0.74, 1.93 (p=0.459). For the sub-group of studies measuring widespread pain and 
cancer mortality (Figure 2.5) MRRs ranged from 0.64 to 2.07 (I2 = 87.9%), pooled estimate 
MRR 1.29; 95% CI 0.70, 2.39 (p=0.417). For cardiovascular disease mortality (Figure 2.6), 
the MRRs ranged from 0.83 to 2.17 (I2 =72.5%) pooled estimate MRR 1.09; 95%CI 0.84, 
NOTE: Weights are from random effects analysis
Overall  (I-squared = 82.3%, p = 0.000)
Nitter et al. (2013) (CWP)
Study
Andersson (2009) (WP)
McBeth et al. (2009) (WP)
Macfarlane et al. (2001) (WP)
Macfarlane et al. (2007) (WP)
1.22 (0.93, 1.60)
2.80 (1.29, 6.07)
size (95% CI)
1.09 (0.62, 1.91)
1.30 (1.11, 1.52)
1.31 (1.05, 1.64)
0.86 (0.74, 1.00)
Effect
100.00
8.75
Weight
13.13
26.79
24.42
26.92
%
  
1.165 6.07
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1.41 (p=0.536). In the widespread pain subgroup (Figure 2.7) the MRRs ranged from 0.83 
to 2.17 (I2 = 76.8%), pooled estimate MRR 1.17; 95% CI 0.85, 1.63 (p=0.338). Only four 
studies provided information about respiratory disease mortality (Figure 2.8). The effect 
sizes ranged from 0.89 to 1.23 (I2 = 0.0%), pooled estimate MRR 1.01; 95%CI 0.78, 1.30) 
(p=0.944). For the widespread pain subgroup (Figure 2.9) the MRRs ranged from 0.89 to 
1.01 (I2 = 0.0%), pooled estimate MRR 0.97; 95% CI 0.73, 1.28 (p=0.817). Of the studies 
not included in the meta-analysis, only one study reported an increased risk of mortality 
from one of these three main causes of death was Smith and colleagues (2003) who 
reported an increased risk of respiratory disease mortality for women with chronic pain 
(AOR 2.22; 95%CI 1.1, 4.39).  
 
Figure 2.4 Forest plot of the association between chronic pain and cancer mortality in 
identified studies (MRR only) 
MRR=Mortality Rate Ratio, CI= Confidence Interval, WP = Widespread Pain, CP=Chronic Pain 
NOTE: Weights are from random effects analysis
Overall  (I-squared = 85.3%, p = 0.000)
Torrance et al. (2010) (CP)
Macfarlane et al. (2001) (WP)
Study
Andersson (2009) (WP)
Macfarlane et al. (2007) (WP)
McBeth et al. (2009) (WP)
1.20 (0.74, 1.93)
0.91 (0.64, 1.29)
2.07 (1.37, 3.13)
size (95% CI)
1.15 (0.52, 2.55)
0.64 (0.46, 0.90)
1.80 (1.27, 2.55)
Effect
100.00
21.60
20.61
Weight
14.52
21.68
21.60
%
  
1.32 3.13
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Figure 2.5 Forest plot of the association between chronic widespread pain and cancer 
mortality in identified studies (MRR only) 
MRR=Mortality Rate Ratio, CI= Confidence Interval, WP = Widespread Pain, CP=Chronic Pain 
 
 
NOTE: Weights are from random effects analysis
Overall  (I-squared = 87.9%, p = 0.000)
Macfarlane et al. (2007) (WP)
McBeth et al. (2009) (WP)
Andersson (2009) (WP)
Study
Macfarlane et al. (2001) (WP)
1.29 (0.70, 2.39)
0.64 (0.46, 0.90)
1.80 (1.27, 2.55)
1.15 (0.52, 2.55)
size (95% CI)
2.07 (1.37, 3.13)
Effect
100.00
27.09
27.02
19.81
Weight
26.08
%
  
1.32 3.13
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Figure 2.6 Forest plot of the association between chronic pain and cardiovascular 
disease mortality in identified studies (MRR only) 
MRR=Mortality Rate Ratio, CI= Confidence Interval, WP = Widespread Pain, CP=Chronic Pain 
 
NOTE: Weights are from random effects analysis
Overall  (I-squared = 72.5%, p = 0.006)
Torrance et al. (2010) (CP)
Study
Andersson (2009) (WP)
McBeth et al. (2009) (WP)
Macfarlane et al. (2007) (WP)
Macfarlane et al. (2001) (WP)
1.09 (0.84, 1.41)
0.86 (0.65, 1.14)
size (95% CI)
2.17 (1.12, 4.21)
1.30 (1.02, 1.65)
0.83 (0.68, 1.02)
1.12 (0.78, 1.61)
Effect
100.00
22.08
Weight
10.12
23.75
25.22
18.84
%
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Figure 2.7 Forest plot of the association between chronic widespread pain and 
cardiovascular disease mortality in identified studies (MRR only) 
MRR=Mortality Rate Ratio, CI= Confidence Interval, WP = Widespread Pain 
 
 
  
NOTE: Weights are from random effects analysis
Overall  (I-squared = 76.8%, p = 0.005)
Macfarlane et al. (2007) (WP)
Study
Andersson (2009) (WP)
McBeth et al. (2009) (WP)
Macfarlane et al. (2001) (WP)
1.17 (0.85, 1.63)
0.83 (0.68, 1.02)
size (95% CI)
2.17 (1.12, 4.21)
Effect
1.30 (1.02, 1.65)
1.12 (0.78, 1.61)
100.00
31.17
Weight
14.42
%
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24.67
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Figure 2.8 Forest plot of the association between chronic pain and respiratory disease 
mortality in identified studies (MRR only) 
MRR=Mortality Rate Ratio, CI= Confidence Interval, WP = Widespread Pain, CP=Chronic Pain 
 
NOTE: Weights are from random effects analysis
Overall  (I-squared = 0.0%, p = 0.885)
Macfarlane et al. (2001) (WP)
Torrance et al. (2010) (CP)
McBeth et al. (2009) (WP)
Macfarlane et al. (2007) (WP)
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1.01 (0.78, 1.30)
1.01 (0.57, 1.79)
1.23 (0.67, 2.25)
1.00 (0.66, 1.51)
0.89 (0.54, 1.48)
Effect
size (95% CI)
100.00
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17.57
37.72
25.02
%
Weight
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Figure 2.9 Forest plot of the association between chronic widespread pain and 
respiratory disease mortality in identified studies (MRR only) 
MRR=Mortality Rate Ratio, CI= Confidence Interval, WP = Widespread Pain 
 
  
NOTE: Weights are from random effects analysis
Overall  (I-squared = 0.0%, p = 0.928)
Macfarlane et al. (2001) (WP)
Study
McBeth et al. (2009) (WP)
Macfarlane et al. (2007) (WP)
0.97 (0.73, 1.28)
1.01 (0.57, 1.79)
size (95% CI)
1.00 (0.66, 1.51)
Effect
0.89 (0.54, 1.48)
100.00
23.88
Weight
45.76
%
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2.6.5 Evidence synthesis: narrative review of potential sources of heterogeneity 
 
The high heterogeneity between studies may be explained by the small number of 
identified studies and differences in the age and sex distribution of study samples, follow-
up time, pain phenotype, population characteristics, methods of analysis and potential 
confounding factors included (Table 2.3). 
Age and sex distribution 
The age and sex distribution of the study samples varied between studies however there 
were no clear differences in the results that could be attributed to this. The meta-analysis 
was conducted using results which were adjusted for age and sex limiting the influence of 
these factors on the observed heterogeneity.    
Follow up time 
Follow up time varied between studies (see Table 2.3) ranging from 6 years (Smith et al., 
2003) to 35 years (Wolfe, Hassett, et al., 2011). Length of follow-up was not clearly 
associated with the differences in findings between studies (e.g. longer follow up periods 
were no more likely to be associated with significant mortality risks). 
Pain phenotype 
All of the studies which examined links with widespread pain reported how closely their 
phenotype adhered to the criteria proposed by the American College of Rheumatology 
(ACR) in 1990, (Wolfe et al., 1990) however there were inconsistencies between studies 
(see Table 2.1). The least stringent definition of widespread pain was applied by 
Macfarlane and colleagues (2007) who did not find an association between widespread 
pain and mortality (Macfarlane et al., 2007).   
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Table 2.3 Summary of main sources of heterogeneity between the included studies in the systematic review 
Study Pain 
phenotype 
Age Location Gender 
distribution 
(% female) 
Follow-up Outcome (all-cause 
mortality) 
Factors adjusted for 
Macfarlane, G.J. 
et al. (2001) 
WP 18-85years North West 
England 
58% 8yrs MRR (95%CI) Adjusted 
1.31 (1.05-1.65) 
age, sex, study location  
Macfarlane, G.J. 
et al. (2007) 
WP 30 years and 
over 
Finland 54% 14-16yrs MRR (95%CI) Adjusted 
0.86 (0.74-1.00) 
age, gender, education, physical work stress, 
mental work stress, alcohol consumption, 
tobacco smoking, BMI 
Andersson, H.I. 
(2009) 
WP 25-74 years Sweden 50% 14 yrs MRR (95%CI) Crude 1.95 
(1.26-3.03) Adjusted 1.09 
(0.62-1.90) 
Age, sex, living alone, contact with friends, club 
membership, chronic disease, smoking, physical 
activity, perception of stress, BMI, insomnia  
McBeth, J. et al. 
(2009) 
WP 16 years and 
over 
North West 
England 
51.6% 8.2yrs MRR (95%CI) Crude 2.4 
(1.9-2.9) Adjusted 1.3 (1.1-
1.5) 
age, sex, practice, ethic group, Townsend score 
of deprivation 
Sjøgren P. et al. 
(2010) 
CP 16 years  
and over 
Denmark 51.3% 8 yrs MRR (95%CI) Adjusted 
1.21 (1.02-1.44)  
age, sex, education, marital status, BMI, smoking, 
antidepressant use, anxiolytic use, self-reported 
circulatory diseases, infectious or parasitic 
diseases, diabetes and mental disorders 
Torrance N. et al. 
(2010) 
CP Mean 58.43 
years 
North East 
Scotland 
52.7% 10 yrs MRR (95%CI) Crude 1.32 
(1.14-1.54) Adjusted 0.90 
age, sex, education, housing, long term limiting 
illness 
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(0.74-1.07) 
Nitter A.K. & 
Forseth K.Ø. 
(2013) 
CWP 20 -68 years Arendal, 
Norway 
100% 18 yrs MRR (95%CI) Adjusted 2.8 
(1.3-6.1) 
age, sleep problems, feeling anxious, frightened 
or nervous, number of non-specific health 
complaints 
Dreyer, L. et al. 
(2010) 
FM 19 years and 
over 
Denmark 94% 15 yrs 
(Mean 3.9 
years) 
SMR (95%CI) 1.25 (0.9-1.7) Standardised to Danish population (according to 
age, sex, calendar month) 
Wolfe, F. et al. 
(2011) 
FM Mean 50.5 
years, (SD 
12.4) 
USA 94% 35yrs 
(Mean 7.3 
years) 
SMR (95%CI) 0.90 (0.61-
1.26) 
Standardised to U.S. population (according to 
age, sex, calendar month) 
Smith, B.H. et al. 
(2003) 
CP 42-81 years UK 100% 6 years AOR (95%CI) 1.1 (0.81-
1.26) 
age, social class, smoking  
WP = Widespread Pain, CP = Chronic Pain, CWP = Chronic Widespread Pain, FM = Fibromyalgia  
MRR = Mortality Rate Ratio 
SMR = Standardised Mortality Ratio 
AOR = Adjusted Odds Ratio 
CI = Confidence Interval 
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In contrast, the three studies that defined widespread pain similar to the ACR 1990 
definition (Andersson, 2009; Macfarlane et al., 2001; McBeth et al., 2009) did report an 
association between widespread pain and mortality. Nitter and Forseth (2013) who were 
able to determine chronic widespread pain in all participants reported the strongest 
association with increased risk of mortality after adjusted analyses (Nitter & Forseth, 
2013). Differences in pain phenotype were explored in the sensitivity analysis in the 
meta-analysis, where a slight increase in the pooled estimate was observed when the 
analysis was restricted to widespread pain for all-cause mortality (1.22 cf 1.14), cancer 
mortality (1.29 cf 1.20) and cardiovascular disease mortality (1.17 cf 1.09) but not 
respiratory disease mortality (0.97 cf 1.01).      
Population characteristics 
The study settings were heterogeneous. Four of the studies were carried out in the UK 
(Macfarlane et al., 2001; McBeth et al., 2009; Smith et al., 2003; Torrance et al., 2010),  
two in Denmark (Dreyer et al., 2010; Sjøgren & Grønbæk, 2010), one in Finland 
(Macfarlane et al., 2007), one in Sweden (Andersson, 2009), one in Norway (Nitter & 
Forseth, 2013) and one in the USA (Wolfe, Hassett et al., 2011).  A greater proportion of 
the participants in the Macfarlane and colleagues (2007) study lived in rural settings 
(Macfarlane et al., 2007) compared to the Macfarlane and colleagues (2001) and the 
McBeth and colleagues (2009) studies which although different cohorts, were both 
carried out in the same urban area of the UK (Macfarlane et al., 2001; McBeth et al., 
2009). These two studies in the urban area reported an increased risk of mortality for 
people with widespread pain and an increased risk of cancer mortality which were not 
supported by the study in a rural setting (Macfarlane et al., 2007).  
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Eight of the studies were carried out in population cohorts (Andersson, 2009; Macfarlane 
et al., 2007; Macfarlane et al., 2001; McBeth et al., 2009; Nitter & Forseth, 2013; Sjøgren 
& Grønbæk, 2010; Smith et al., 2003; Torrance et al., 2010) and two were clinical cohorts 
(Dreyer et al., 2010; Wolfe, Hassett, et al., 2011). Both clinical cohorts reported no 
significant increased risk of mortality for fibromyalgia patients.  
Adjustment for potential confounders 
There was wide variability in the type and number of potential confounders adjusted for 
between studies. Only three of the studies reported crude results (Andersson, 2009; 
McBeth et al., 2009; Torrance et al., 2010),  all indicating a  significant association 
between chronic or widespread pain and mortality. It was difficult to determine if 
potential confounders consistently explained the relationship between chronic pain and 
mortality. Andersson (2009) measured and adjusted for the highest number of potentially 
confounding factors (see Table 2.3 for details) and concluded their observed increased 
risk of mortality for people with widespread pain could be explained by lifestyle factors 
such as smoking and physical inactivity together with reported stress and disturbed sleep 
(Andersson, 2009). McBeth and colleagues (2009), and Nitter and Forseth (2013) did not 
include any lifestyle factors in their analyses and the increased risk of mortality observed 
in these studies was robust to adjustment for the factors they included (see Table 2.1) 
(McBeth et al., 2009; Nitter & Forseth, 2013). However, Torrance and colleagues (2010) 
reported the association between chronic pain and mortality attenuated to non-
significance following adjustment without including lifestyle factors (Torrance et al., 2010) 
(Table 2.3). 
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2.7 Discussion 
 
2.7.1 Summary of findings 
The results of this systematic review and meta-analysis suggested that there was a 
modest relationship between chronic pain and increased mortality but this was not 
significant. The results also suggested this relationship may be explained by cancer 
mortality. Confidence in these findings is restricted due to the small number of included 
studies and heterogeneity between them. Restricting the analysis to studies measuring 
widespread pain and mortality resulted in an increase in the size of the pooled estimates 
for all-cause, cancer and cardiovascular disease mortality but these were also non-
significant.  
Very few studies have examined the relationship between chronic pain and mortality. 
Only three studies reported crude results, all of which suggested there was an association 
between chronic or widespread pain and an increased risk of all-cause mortality 
(Andersson, 2009; McBeth et al., 2009; Torrance et al., 2010). However adjustment for 
confounders led to attenuation of the relationship. This suggests that adults with chronic 
or widespread pain have an increased mortality rate which is to some extent explained by 
socio-demographic and lifestyle factors, however the low number of studies and high 
heterogeneity again reduces the certainty of this. Significant associations between 
chronic or widespread pain and increased risk of mortality from cancer, cardiovascular 
disease, cerebrovascular disease, liver cirrhosis, suicide, accidents, influenza and 
pneumonia, septicaemia were reported in single studies.  
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2.7.2 Differences between studies 
 
The differences between the ten studies led to high levels of heterogeneity. The study 
populations differed on a number of characteristics which will have contributed to the 
variance in prevalence rates of widespread pain and mortality, and the relationship 
between them. 
Definition of chronic or widespread pain 
Information regarding the location of pain was lacking in three of the included studies so 
the presence of widespread pain could not be confirmed although chronic pain often 
occurs in multiple sites (Carnes et al., 2007). Similarly, details regarding the chronicity of 
pain were not available in all studies measuring widespread pain but in 80-90% of persons 
reporting widespread pain, the pain has been present for more than three months 
(Macfarlane et al., 2001). Although this means a small proportion of participants may 
have been misclassified it would also lead to an underestimation of the true effect. More 
rigorous definitions of widespread pain were more strongly associated with mortality. In 
additional analysis, Wolfe et al. (2011) reported that within those with fibromyalgia, 
those satisfying the more stringent ACR 2010 criteria (Wolfe et al., 2010) had an increased 
risk of mortality than those who did not meet the new criteria but met the 1990 criteria 
(HR 1.62; 95%CI 1.19, 2.21) (Wolfe et al., 2011). The ACR 2010 criteria extended the scope 
of defining widespread pain beyond the location of pain by including an assessment of 
the severity of accompanying symptoms (Wolfe, Clauw, et al., 2011). Increased severity 
and duration of pain, in addition to extent, increases the risk of mortality (Tang & Crane, 
2006; Torrance et al., 2010). The revised ACR 2010 criteria, which can be measured using 
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self-report tools in epidemiological and clinical studies, offers the potential to harmonise 
definitions of widespread pain in future studies (Wolfe, Clauw, et al., 2011).    
Methods of analysis 
There were differences in the reference group between studies which prevented clear 
comparisons. Eight studies used participants with no pain as the reference group and two 
used standardised populations, one in Denmark (Dreyer et al., 2010) and one in the US 
(Wolfe, Hassett, et al., 2011) which include people both with and without pain. In an 
additional analysis, Wolfe and colleagues (2011) compared mortality rates between 
fibromyalgia and osteoarthritis patients and reported no significant difference (Wolfe, 
Hassett, et al., 2011). Mortality risk is higher in those with osteoarthritis compared to the 
general population (Hochberg, 2008) therefore this finding is not comparable to the 
mortality rate ratios used in other studies. The comparison group (osteoarthritis patients) 
cannot be considered analogous to a no pain group.  
Different methods of analysis were used to calculate the outcome measures (SMR, MRR 
and AOR) due to variations in reference groups. Sufficient data were not available to 
enable conversion to comparable outcome measures for all studies. The effects of these 
different analysis techniques is demonstrated by McBeth et al (2009), who reported a 
30% increased risk of mortality for people with widespread pain compared to a no pain 
group but when compared to the mortality rate for North West England mortality risk 
was lower and not significant (SMR 1.14; 95%CI 0.99, 1.30) (McBeth et al., 2009). The 
more similar the reference group, the less likely a relationship will be observed. Where 
the comparison is with a standardised population the reference group will include 
participants with and without pain. Use of general population cohorts in which a no-pain 
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group can be identified will allow for a sharper contrast between a group most at risk 
(those with widespread pain) with those least at risk (those with no pain).  
Follow-up time 
Variations in follow-up time between studies may influence mortality rates although this 
was not clear from this review. The mortality rate in those with pain has been shown to 
be higher in the earlier periods of follow-up (Jordan & Croft, 2010). Jordan and colleagues 
(2013) have also demonstrated the strength of associations between pain in different 
musculoskeletal sites and cancer diminished with time indicating pain may be a marker of 
rather than a cause of cancer (Jordan, Hayward, Blagojevic-Bucknall, & Croft, 2013). 
However, McBeth et al., (2009) reported no change in the relationship between 
widespread pain and both cancer and cardiovascular death after excluding participants 
who had died in the first year of follow up (McBeth et al., 2009). Standard periods of 
follow-up, allowing both short and long term assessment of risk would enable 
comparisons between studies and allow a more accurate picture of the relationship to be 
determined.  
Mechanisms  
Differences in study setting may contribute to variations in factors associated with the 
presence of pain and mortality. Pain experienced by those in rural settings may be more 
likely to be related to physical labour than those in urban settings (McBeth et al., 2009), 
although this may mean they are more physically active. Physical activity is known to 
reduce the risk of chronic diseases and premature death (Warburton, Nicol, & Bredin, 
2006). Clinical and population cohorts will also have different characteristics of pain, 
health and socio-demographic factors. Depending on how healthcare is accessed, the 
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clinical cohorts may have more severe symptoms and comorbidities compared to general 
population samples, which will impact on mechanisms to and rates of mortality. Wolfe 
and colleagues (2011) report that the fibromyalgia patients in their study may have higher 
socioeconomic status than the general population as the majority had medical insurance 
and received care from specialists rather than general physicians (Wolfe, Hassett, et al., 
2011). Higher socioeconomic status and access to care are associated with survival and 
may explain why no relationship between fibromyalgia and mortality was found in these 
studies (Alter, Naylor, Austin, & Tu, 1999).  
 
The studies included in this review treated covariates as confounders and adjusted for 
them in their analyses. Information regarding the relative contribution of individual 
confounders to the models was not available. However, it may be that these factors are 
instead moderating or mediating the relationship between pain and mortality. Simply 
adjusting for such factors may lead to spurious associations between predictor and 
outcome (Greenland, Pearl, & Robins, 1999). Adjustment for confounders in the ten 
studies, such as age, sex, socio-demographic status and lifestyle factors, indicated that 
they had a role in the relationship between widespread pain and mortality. Comparing 
similarly adjusted results will control for some of the variance in the associations between 
studies due to different population characteristics (e.g. differences in age and sex 
distributions). However differences in how these factors were measured and classified 
will have contributed to the heterogeneity. For example, one study used the Townsend 
score of deprivation as a measure of socioeconomic status; this is an area-level measure 
which is derived from variables representing unemployment, overcrowding within 
households, non-home ownership and lack of car ownership (McBeth et al., 2009). In 
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contrast the other studies included individual level measures of socio-economic status, 
such as educational attainment and owning medical insurance (Wolfe, Hassett, et al., 
2011).  
There were substantial differences in the number of additional factors measured and 
adjusted for between studies (Table 2.3). Notably the significant relationship reported in 
the crude analysis by Andersson and colleagues (2009) attenuated and was no longer 
significant when adjusted for living alone, contact with friends, club membership, 
comorbidity, smoking, physical activity, BMI, perception of stress and insomnia 
(Andersson, 2009) indicating possible pathways between pain and mortality. Pain is 
associated with depression, obesity, a reduction in physical activity (Ray, Lipton, 
Zimmerman, Katz, & Derby, 2011) and smoking motivation (Ditre & Brandon, 2008).  
Wolfe et al., (2011) found BMI and smoking to be significant predictors of mortality in a 
sub-section of participants (Wolfe, Hassett, et al., 2011). Many of the diseases where 
increased mortality was observed have links to lifestyle factors. Cancer and cardiovascular 
disease are associated with reduced physical activity (Warburton et al., 2006) and cancer 
with smoking (Fagerström, 2002). A follow up to the Macfarlane and colleagues (2001) 
study using the same cohort reported the association they observed was with both cancer 
incidence and survival; specifically with breast and prostate cancers (McBeth et al., 2003), 
both of which have been shown to be associated with physical inactivity (Liu et al., 2011; 
Monninkhof et al., 2007).  
 
Consideration of mechanisms between pain and mortality with the appropriate 
designation of potential mediators and moderators rather than confounders would 
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further the understanding of any relationship between pain and mortality. Such analysis 
would identify potentially modifiable targets to reduce an increased risk of mortality. 
There are a number of potential mediators and moderators that were not considered in 
the identified studies in this review which are associated with both pain and mortality, 
such as anxiety and depression (Bair & Robinson, 2003; Mykletun et al., 2009) social 
participation and social isolation (House, 2001; Moulin, Clark, Speechley, & Morley-
Forster, 2002) and fatigue (Fishbain, Cole, & Cutler, 2003; Hardy & Studenski, 2008). 
Examination of their potential role in the link between pain and mortality may identify 
novel targets for healthcare to reduce impact.  
2.7.3 Strengths and limitations 
 
There were a number of strengths in this current study. A systematic approach was 
undertaken to maximise the chances of identifying all relevant studies of chronic pain and 
mortality. The quality of the identified studies was assessed using an established appraisal 
tool designed to focus on potential bias within studies (Hayden et al., 2006). Agreement 
between reviewers of the risk of bias was high (Table 2.2). Including papers written only 
in English may be one weakness and it is possible some relevant findings may have been 
missed. However an additional more recent search of CINAHL, Medline and EMBASE did 
not find any relevant non-English studies.  
The small number of studies (k<20) means that I2 values should be interpreted with 
caution as there is little power to detect true heterogeneity and as such any pooled 
calculation of effect may be misleading (Huedo-Medina, Sánchez-Meca, Marín-Martínez, 
& Botella, 2006). A more complex meta-analysis could have been undertaken to include 
the studies with multiple follow-ups and account for the correlation between them. 
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However, even with a greater number of studies, there is general concern regarding the 
appropriateness of the use of meta-analyses in reviews of observational studies due to 
the likelihood for high heterogeneity as a result of difficulties in overcoming selection and 
confounding biases common to this type of study (Dickersin, 2002). The estimates of 
pooled effects calculated in meta-analyses of observational studies are likely to be flawed 
and it is therefore more useful to have an assessment of the potential sources of 
heterogeneity as the focus of such systematic reviews (which has been included here) 
rather than a statistical combination of the data (Egger et al., 2001). 
2.7.4 Implications for research 
 
This review indicated a modest association between chronic and widespread pain and 
increased mortality, particularly cancer mortality but further research is needed to 
confirm this. Even a small increased risk of cancer mortality is significant when it applies 
to a large proportion of the population (Crombie, 2001).  The findings of this systematic 
review indicate lifestyle factors may have an important role in the association between 
pain and mortality and these may be specific to particular conditions (McBeth et al., 
2003). As previously discussed, research to identify potential mechanisms of a 
relationship between pain and mortality in the general population where specific 
mediators and moderators can be assessed using appropriate statistical methods could 
direct future interventions to reduce pain impact. Attention should also be given to 
previously unmeasured lifestyle, health, social and psychological factors.  
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2.8 Potential pathways from pain to mortality 
 
Lifestyle, health, social and psychological factors may explain the link between pain and 
mortality and may identify potential targets for interventions or populations who are 
particularly vulnerable and would benefit from prevention strategies. The following 
section outlines potential mediators of the link between pain and mortality; this thesis 
will go on to describe the empirical analysis used to determine whether these factors 
mediate the relationship between pain and mortality. The proposed mediating factors 
were selected based on their theoretical plausibility as mediators and the availability of 
data to test this using the databases described in Chapter Four.  
2.8.1 Lifestyle factors 
 
Pain is associated with and predicts an increase in harmful lifestyle factors which are 
linked with increased mortality. Examples of lifestyle factors (i.e. health related 
behaviours or the potential results of those behaviours (van Hecke, Torrance, & Smith, 
2013)) associated with pain are physical inactivity (McBeth & Nicholl, 2010), smoking 
(Ditre & Brandon, 2008), obesity (Heim, Snijder, Deeg, Seidell, & Visser, 2008), sleep 
problems (Moldofsky, 2001) and alcohol consumption in men (Leveille et al., 2005).   
Physical inactivity 
The WHO defines physical activity as “any bodily movement produced by skeletal muscles 
that requires energy expenditure” (WHO website, 2015). Levels of physical activity are 
lower in people with pain often as a result of physical limitation (Kamaleri et al., 2008; 
McBeth & Nicholl, 2010; Vogt, Lauerman, Chirumbole, & Kuller, 2002). While there is 
concern that strenuous activity may cause some musculoskeletal problems, there is 
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consistent evidence that regular moderate physical activity can reduce the persistence of 
pain and improve pain related function (Croft et al., 2010; Dugan et al., 2009). 
Physical inactivity has been reported to be the fourth leading global risk factor for 
mortality, accounting for approximately 3.2 million deaths each year (WHO website, 
2015). Frequent physical activity is protective against the development of chronic 
diseases such as cardiovascular disease, diabetes, cancer, hypertension, obesity, 
osteoporosis, depression and premature death (Warburton et al., 2006). Physical activity 
helps to improve bodily movement, reduce fatigue, control weight and enhance the 
immune system (Liu et al., 2011). Biological mechanisms responsible for the health 
benefits associated with physical activity include reduced abdominal adiposity and 
improved weight control, reduced triglyceride levels, increased high density lipoprotein 
(HDL) cholesterol levels and decreased low-density lipoprotein (LDL)-to-HDL ratios, 
improved glucose homeostasis and insulin sensitivity, reduced blood pressure, improved 
autonomic tone, reduced systemic inflammation; decreased blood coagulation, improved 
coronary blood flow, strengthened cardiac function and enhanced endothelial function 
(Warburton et al., 2006). The empirical analysis described in this thesis tested the 
hypothesis that pain would lead to increased mortality through physical inactivity. 
Smoking  
Cigarette smoking is one of the ten leading risk factors for death worldwide (Gellert, 
Schottker, & Brenner, 2012). Compounds contained in cigarette smoke produce 
significant physiological effects, many of which are detrimental to health (Shi, 
Weingarten, Mantilla, Hooten, & Warner, 2010). Smoking increases the risk of developing 
a large number of diseases including cancer of the lung, oesophagus, bladder, kidney and 
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stomach, chronic obstructive pulmonary disease (COPD), coronary heart disease, stroke, 
peripheral vascular disease and peptic ulcer disease (Doll, Peto, Boreham, & Sutherland, 
2004; Fagerström, 2002) and is associated with the presence of chronically painful 
conditions such as fibromyalgia, rheumatoid arthritis and chronic musculoskeletal pain 
(Ditre & Brandon, 2008; Zvolensky, McMillan, Gonzalez, & Asmundson, 2010).  
The pain-inhibiting effect of smoking through the analgesic properties of nicotine (Shi et 
al., 2010) supports the notion that some pain sufferers use smoking as a way of coping 
with their pain therefore pain is a motivator of smoking behaviour (Ditre & Brandon, 
2008). It was hypothesised that a link between pain and mortality would exist via smoking 
behaviour. 
Alcohol consumption 
Alcohol consumption may explain a relationship between pain and mortality. Excessive 
alcohol consumption is associated with the development of and death from liver cirrhosis 
(Rehm et al., 2010). Dreyer and colleagues (2010) reported increased mortality due to 
liver cirrhosis in fibromyalgia patients which suggests a pathway between pain and 
mortality via increased alcohol consumption (Dreyer et al., 2010). However, the 
relationship between pain and alcohol consumption is unclear. People experiencing pain 
may use alcohol as a way of coping with their pain; the use of alcohol for medicinal 
purposes is common in older people (Aira, Hartikainen, & Sulkava, 2008). However, 
alcohol consumption is often lower in people with pain (Brennan, Schutte, SooHoo, & 
Moos, 2011; McBeth & Nicholl, 2010). This is partly consistent with the findings of Leveille 
et al., (2005) who observed that both men and women with widespread pain reported 
the lowest alcohol consumption, but men with single or multi-site pain were more likely 
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to consume higher amounts of alcohol than men without pain (Leveille et al., 2005). 
Brennan and colleagues (2011) reported an association between more painful conditions 
and greater negative effects of alcohol consumption (e.g. physical or psychological 
problems or social conflicts) in men but not women indicating men and women respond 
differently to painful symptoms (Brennan et al., 2011). It was hypothesised pain would 
lead to mortality via increased alcohol consumption but this relationship would be 
stronger in males compared to females. 
Obesity 
Obesity is an increasing health problem worldwide (WHO website, 2015b). It is commonly 
identified from an individual’s body mass index (BMI) which is determined by dividing the 
weight of a person in kilograms by the square of their height in metres. Typically people 
with a BMI of above 30 are considered to be obese (WHO website, 2015b). Obesity is 
associated with an increased risk of mortality (Flegal, Kit, Orpana, & Graubard, 2013). This 
is likely due to the health risks associated with increased BMI including metabolic 
syndrome, hypertension, type 2 diabetes, coronary artery disease and stroke, respiratory 
problems, cancer, reproductive problems, osteoarthritis and liver and gall bladder disease 
(Kopelman, 2007). Obesity is also associated with low back pain, tension type headache 
or migraine, abdominal pain, chronic widespread pain and fibromyalgia (Johnson Wright 
et al., 2010), pain when standing, moving position, sitting, walking, and “unbearable” or 
“constant” pain (Heim et al., 2008) and work restricting musculoskeletal pain (Peltonen, 
Lindroos, & Torgerson, 2003). It was hypothesised that the impact of pain on mortality 
could be explained through its link with increased levels of obesity. Notably like pain, the 
impact of obesity is likely to be through additional mediators or explanatory factors (for 
example, cardiovascular disease). 
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Sleep problems 
Sleep is comprised of highly organised, complex physiological processes which are 
imperative for maintaining health (Luyster, Strollo, Zee, & Walsh, 2012). Excessive and 
reduced sleep is associated with mortality (Cappuccio, D’Elia, Strazzullo, & Miller, 2010). 
Reduced sleep (less than 6 hours) may contribute to cardiovascular disease, diabetes and 
obesity through impaired glucose tolerance, higher evening cortisol levels, alterations in 
sympathetic nervous system activity, reduced leptin levels (which regulates satiety), 
increased levels of ghrelin (which regulates hunger), increases in inflammatory markers 
such as C-reactive protein and interleukin (IL)-6 (Luyster et al., 2012). The reason for an 
association between mortality and excessive sleep is uncertain but may be explained by 
depression, undiagnosed illness or physical inactivity (Patel, Malhotra, Gottlieb, White, & 
Hu, 2006). 
The relationship between pain and sleep is reciprocal; pain can lead to sleep problems 
and sleep problems can exacerbate pain problems (Moldofsky, 2001). Duration of sleep 
can predict pain report; less than 6 or more than 9 hours of sleep has been shown to be 
associated with greater pain the next day (Edwards, Almeida, Klick, Haythornthwaite, & 
Smith, 2008). It was hypothesised that pain would lead to sleep problems which would 
then lead to increased mortality.   
2.8.2 Health factors 
Pain is associated with and predicts poor health (Blyth et al., 2015; Dominick, Blyth, & 
Nicholas, 2012; Goldberg & McGee, 2011). The World Health Organisation (WHO) defines 
health as “a state of complete physical, mental and social wellbeing and not merely the 
absence of disease and infirmity” (WHO, 1948). For the purposes of this study the 
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secondary definition of health being “the extent to which an individual can realize 
aspirations, satisfy needs and change or cope with the environment” (WHO, 1984) is 
utilised to reflect functional ability. The association between pain and poor physical 
function increases with increasing pain severity (Landi et al., 2009, Ang, Kroenke, & 
McHorney, 2006) and number of pain sites (Kamaleri et al., 2008), and the prevalence of 
pain that interferes with life increases with age (Thomas et al., 2007). Pain also leads to a 
reduction in perceptions of general heath (Reyes-Gibby, Aday, & Cleeland, 2002) and this 
is an important determinant of health outcomes and mortality (Idler & Benyamini, 1997).   
Self-rated health 
Pain predicts poor self-rated health (Reyes-Gibby et al., 2002). Self-rated health is an 
individual’s aggregated reflection of the many dimensions that affect health (Idler & 
Benyamini, 1997; Jylhä, 2009). These include the evaluation of multiple illnesses and 
symptoms within an individual, judgements about illness severity, influences of family 
history and expectations of an individual’s health trajectory, not just their current health 
(Idler & Benyamini, 1997; Jylhä, 2009). Although this construct is based on perception and 
may be driven by mood, when measured using a single item (i.e. how good is your health? 
(Excellent, good, fair or poor)), poor self-rated health consistently predicted mortality and 
there was a dose response relationship between increased mortality and poorer rated 
health in a review of 27 studies using community samples (Idler & Benyamini, 1997). Self-
rated health may also reflect health behaviours, for example, poor perceptions of health 
may result in non-adherence to screening programmes or treatment (Idler & Benyamini, 
1997). It was hypothesised that pain would lead to poor self-rated health which in turn 
would lead to increased mortality through factors associated with poor ratings of health 
(e.g. illnesses, symptoms). 
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Functional limitation 
The International Classification of Functioning, Disability and Health (ICF) identify three 
levels of human functioning; 1) body, 2) individual and 3) societal level. Disability is 
abnormal function at any of the three levels which are known as impairments, activity 
limitations or participation restriction respectively (World Health Organization, 2002). 
This section is focussed on limitation at the individual level (i.e. physical limitation which 
is when an individual has limited capacity to do simple physical tasks for example walk, go 
up and down stairs and pick up objects (World Health Organization, 2002)). Function 
within a social context is considered under the category of social factors.  
Pain predicts functional limitation (Neogi, 2013). There is a dose-response relationship 
between increasing low back pain and increasing functional difficulty (Weiner, Haggerty, 
& Kritchevsky, 2003) and people reporting being often troubled with pain of moderate or 
severe intensity demonstrated higher rates of functional limitation than those without 
pain (Covinsky, Lindquist, Dunlop, & Yelin, 2009). Pain (and conditions that pain is the 
main symptom of) accounts for 5 out of the 10 conditions responsible for the most years 
lived with disability (YLD) globally  with low back pain accounting for 10.7% of all YLD 
(Buchbinder et al., 2013). Limitations in the ability to perform activities necessary for 
independent living and self-care are often used as indicators of disability (Chan, Kasper, 
Brandt, & Pezzin, 2012). Increased functional impairment measured in this way was 
predictive of mortality in men and women over 65 over a 5 year period (Scott & Macera, 
1997) in adult Finnish population (aged 30-91 years, 72% female) over a 5 year period 
(Sokka & Pincus, 2011) and in an Italian population of adults aged over 80 years (Cesari et 
al., 2008). A systematic review of studies using objective measures of physical capability 
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(e.g. walking speed, chair rises) reported low levels of such measures were consistent 
predictors of all-cause mortality in older community dwelling adults (Cooper, Kuh, Hardy, 
& Mortality Review Group, 2010). It was therefore hypothesised pain would lead to 
mortality via functional limitation. 
Allostatic load 
Allostasis is defined as the physiological adaptation of neural, cardiovascular, 
neuroendocrine and immune system mechanisms to maintain stability in response to 
stress (McEwen, 1998). Allostatic load, a dysregulation of these mechanisms, occurs as a 
result of heightened stress, maladaptation to repeated stressful stimuli and a failure to 
terminate or regulate competing allostatic system responses (McEwen, 1998).   
Allostasis is vital to homeostasis which if not sustained results in mortality (Chapman, 
Tuckett, & Song, 2008). High allostatic load is associated with cardiovascular disease and 
cognitive decline (McEwen, 1998) and with frailty (Gruenewald, Seeman, Karlamangla, & 
Sarkisian, 2009; Szanton, Allen, Seplaki, Bandeen-Roche, & Fried, 2009). Physiological 
responses to stress in the form of the release of adrenalin, glucocorticoids and cytokines 
can be damaging if prolonged and can lead to tissue damage and desensitization of 
receptors (McEwen, 2003).  
Pain is a stressor and can lead to the accumulation of allostatic load (Robinson, Edwards, 
& Iyengar, 2009). Both over-activity and underactivity of the hypothalamic pituitary 
adrenal (HPA) axis results in allostatic load (McEwen & Seeman, 1999) and abnormalities 
in the HPA axis have been observed in fibromyalgia patients and low back pain patients 
(Holliday et al., 2009). Growth hormone deficiencies, specifically low levels of insulin-like 
growth factor 1 (IGF-1) evident in fibromyalgia patients are also associated with chronic 
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psychosocial stress (Gupta & Silman, 2004). Chronic pain and high levels of stress in older 
adults are associated with shorter telomeres than in those without chronic pain and low 
stress and telomere length is a marker for cellular aging (Sibille, Witek-Janusek, Mathews, 
& Fillingim, 2012). Shorter telomere length has been shown to be associated with pain in 
female fibromyalgia patients with those exhibiting higher levels of pain having shorter 
telomeres than those with lower levels of pain (Hassett et al., 2012). Age related diseases, 
chronic mental and physical conditions and mortality are also associated with short 
telomere length, whereas greater telomere length is associated with years of healthy life 
(Sibille et al., 2012). It was therefore hypothesised that pain would lead to an increase in 
allostatic load and subsequent mortality. 
Frailty 
Phenotypic frailty is a geriatric syndrome characterised by declining function across a 
number of physiological systems (Fried et al., 2001).  Fried et al., (2001) developed a 
‘clinical phenotype’ of frailty using participants from the Cardiovascular Health Study of 
men and women over 65 years from four communities in the United States. Frailty was 
defined as the presence of three or more of the following characteristics: 
 Shrinking – unintentional weight loss of less than or equal to 10 pounds in the 
previous year  
 Weakness – according to grip strength (in the lowest 20% according to sex and 
BMI) 
 Poor endurance and energy – measured via self-report 
 Slowness – according to walking speed over a distance of 15 feet (slowest 20% 
according to sex and height)   
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 Low physical activity level – measured via self-report (males less than 
383Kcals/week, females less than 270 Kcals per week) 
(Fried et al., 2001) 
Frailty is associated with pain and mortality. In the Cardiovascular Health Study 7% of the 
cohort met the criteria for frailty which was associated with an increased risk of falls, 
disability, hospitalisation and mortality (Fried et al., 2001). Shega and colleagues (2012) 
operationalised frailty in a different way to the phenotype proposed by Fried; 33 self-
reported variables pertaining to health attitudes, illnesses (e.g. heart or circulatory 
problems) functional abilities (e.g. help to take a bath), and living alone were used to 
generate a composite index from which tertiles representing not frail, pre-frail and frail 
were derived. They found that frailty status was significantly associated with the report of 
pain. Participants with moderate or severe pain were over five times more likely to be 
frail than those without pain (Shega, Andrew, Lau, Weiner, & Dale, 2012). Although this 
was a cross sectional analysis, the authors suggest pain leads to frailty as a result of 
reduced physiologic reserve through impaired mobility, depression, decreased nutritional 
intake, and an increase in the burden of comorbidities (Shega et al., 2012). Convergent 
validity between the clinical phenotype of frailty and the accumulation of deficits 
definition has been demonstrated (r=0.65) (Rockwood, Andrew, & Mitnitski, 2007). It was 
hypothesised that people with pain would be more likely to become frail which would 
lead to a subsequent increased risk of mortality. 
2.8.3 Social factors 
Living with pain has a detrimental effect on relationships, interactions with others and on 
the families of the person with pain (Breivik et al., 2013; Henschke et al., 2015). Social 
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participation involves interaction with other people in society or the community 
(Levasseur, Richard, Gauvin, & Raymond, 2010). Participation restriction; difficulties with 
life situations such as working or shopping, is a negative social consequence of pain 
(Wilkie, Peat, Thomas, & Croft, 2007). One in five people with chronic pain in Europe 
reported having lost their job because of pain and one third reported the amount of work 
they could do or whether they could work at all was affected by their pain (Breivik et al., 
2006). 
Pain related interference is associated with a reduction in social networks (Peat, Thomas, 
Handy, & Croft, 2004) and is also associated with neighbourhood deprivation and 
perceived income inadequacy (Jordan et al., 2008) which may reduce the ability and 
willingness to undertake social activities. Individuals with chronic pain report difficulty in 
attending social or family events and participating in recreational activities (Moulin et al., 
2002).  
Social participation   
Participation restriction forms part of the ICF’s definition of disability and refers to 
problems an individual has with involvement in life situations (World Health Organization, 
2002). Most definitions of social participation focus on an individual’s involvement in 
activities which involve interaction with others in society or the community (Levasseur et 
al., 2010). Social participation can help to protect against morbidity and mortality by 
promoting social interaction which positively influences the sympathetic nervous system 
and hormone levels such as cortisol which in turn affect blood pressure and the immune 
system (Holmes & Joseph, 2011). Social participation and social functioning is reduced in 
people with chronic pain. In a study of chronic pain in Canada by Moulin et al., (2002), 
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49% of individuals with chronic pain reported experiencing great difficulty in attending 
social or family events, 61% were unable to participate in their usual recreational 
activities and 58% could not carry out their usual activities at home (Moulin et al., 2002).  
Volunteer work is a form of social participation which provides essential services focussed 
on creating a better community environment (Jenkinson et al., 2013). It is an important 
productive activity in older adults and has been shown to be a predictor of reduced 
mortality (Harris & Thoresen, 2005; Musick, Herzog, & House, 1999) and psychological 
well-being (Greenfield & Marks, 2004). Pain and related functional limitations were 
predictors of restriction in paid or voluntary work in 50-59 year olds in North Staffordshire 
(Wilkie, Blagojevic-Bucknall, Jordan, & Pransky, 2013).   
Social and productive activities like volunteering have been shown to confer equivalent 
survival advantages to fitness activities (Glass, de Leon, Marottoli, & Berkman, 1999). The 
protective effect of volunteering is greatest in older adults with lower levels of informal 
social contact and in those who volunteer in moderate amounts but is less protective at 
higher levels where the detriments associated with role strain may offset any benefits 
(Musick et al., 1999). Proposed mechanisms linking volunteering to improved well-being 
include increased opportunity for social contacts and access to resources such as 
emotional, cognitive or material support and access to health related information (Luoh & 
Herzog, 2002).  It was hypothesised pain would lead to social participation restriction and 
this would in turn lead to an increased risk of mortality. 
2.8.4 Psychological factors 
People with persistent pain are more likely to have anxiety or depressive disorders than 
those without pain (Gureje & Korff, 1998; Robinson et al., 2009). Suicidal ideation is three 
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times more common in people with chronic pain compared to those without chronic pain 
(Tang & Crane, 2006). The psychological processes of helplessness and hopelessness 
about pain, the desire for escape from pain, catastrophizing, avoidance and problem 
solving deficits have been highlighted as important to understanding this suicidality (Tang 
& Crane, 2006). Cognitive function is also reduced in individuals with pain (Moriarty, 
McGuire, & Finn, 2011).   
Quality of life (QoL) and wellbeing are subjective perceptions which overlap with and 
interlink individual consequences of pain. They are closely related concepts and many 
definitions of each concept exist. The World Health Organisation define QoL as “an 
individual’s perception of their position in life, in the context of the culture and value 
systems in which they live, and in relation to their goals, standards and concerns. QoL is a 
broad ranging concept, affected in a complex way by the person’s physical health, 
psychological state, level of independence, social relationships and their relationship to 
salient features of their environment” (WHOQOL Group, 1995). A more recent definition 
of wellbeing describes the concept as “an umbrella term for different valuations people 
make regarding their lives, the events happening to them, their bodies and minds and the 
circumstances in which they live” (Diener, 2006). Both of these definitions take into 
account life circumstances and values and reflect subjective rather than objective 
measures (Camfield & Skevington, 2008). Ratings of QoL and wellbeing are influenced by 
the presence, combination and relative importance of different factors to the individual. 
As already outlined, reductions in a number of indicators of wellbeing are evident in 
individuals with pain and they do not act in isolation. For example physical performance 
and disability levels are strongly associated with pain-related fear in patients with 
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musculoskeletal pain syndromes like fibromyalgia. This can result in fear avoidance and 
depression, reducing daily function and quality of life for those people. These factors 
along with fatigue and sleep disturbance which are also consequences of pain may in turn 
result in a reduction of leisure time activity and social contact (Tüzün, 2007). 
Understanding such processes is important for our understanding of the impact of pain.  
Quality of life 
Historically, measures of health such as activities of daily living have been used as 
indicators of quality of life in older people (Hyde, Wiggins, Higgs, & Blane, 2003) but it is 
recognised as being a complex multidimensional concept with includes both objective and 
subjective aspects (Van Malderen, Mets, & Gorus, 2013). Indicators of quality of life such 
as physical functioning, mental health and emotional and social well-being are reduced in 
people with pain (Ang et al., 2006; Niv & Kreitler, 2001; Tüzün, 2007) and lower scores for 
health related quality of life (HRQOL) are associated with a higher risk of mortality (Kaplan 
et al., 2007; Mapes et al., 2003).  Hearing, mobility and pain are specific components of 
health related quality of life (HRQoL) that are predictive of mortality (Feeny et al., 2012).  
It was hypothesised pain would lead to reduced quality of life and this would predict a 
subsequent increased risk of mortality. 
Anxiety and Depression 
The World Health Organisation define depression as “a common mental disorder, 
characterised by sadness, loss of interest or pleasure, feelings of guilt or low self-worth, 
disturbed sleep or appetite, feelings of tiredness and poor concentration” (WHO, 2015c). 
Anxiety is a broad term used to describe a number of different disorders but general 
anxiety is often characterised by worrying thoughts, feelings of being tense and 
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frightened, restlessness and panic (Mykletun et al., 2009). Symptoms of depression and 
anxiety often co-occur with chronic pain in primary care. Patients with a combination of 
pain and depression or pain and anxiety report greater severity of pain than those with 
pain alone, and those with both anxiety and depression report the most severe pain (Bair 
& Wu, 2008).  
The prevalence of depression is greater in people with pain than in individuals without 
pain (Bair & Robinson, 2003; Robinson et al., 2009). The relationship between pain and 
depression is reciprocal. Pain at baseline was an independent predictor of becoming 
depressed two years later, and depression at baseline predicted pain two years later in a 
study conducted using participants from the English Longitudinal Study of Aging (ELSA) 
(Chou, 2007).      
The presence of pain can be a barrier to the recognition and treatment of depression 
(Bair & Robinson, 2003) however, the conditions of pain and depression have been shown 
to share biological pathways and neurotransmitters and respond to similar treatment 
(Dunne, 2011). Activation of the HPA axis and the ascending and descending pain tracks 
are common to both conditions (Robinson et al., 2009).  
Anxiety and depression are also associated with mortality (Mykletun et al., 2009). 
Increased mortality rates have been observed in both clinically and sub-clinically 
depressed individuals (Mykletun et al., 2009). Proposed mechanisms include suicide, 
increased hazardous health behaviours, higher rates of accidental deaths, and adverse 
effects of depression on endocrine, neurologic and endocrine processes, interference 
with a patient’s motivation for recovery and by affecting compliance with treatment 
(Cuijpers & Smit, 2002).  
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Studies by Dreyer et al., (2010) and Wolfe et al., (2011) reported a significantly increased 
risk of death from suicide in patients with fibromyalgia (Dreyer et al., 2010) (Wolfe, 
Hassett, Walitt, & Michaud, 2011). Many of the risk factors for suicide are also associated 
with chronic pain such as depression and histories of drug and alcohol abuse (Cheatle, 
2011). Often opioids are prescribed for pain problems thus providing a potentially lethal 
medication to vulnerable people (Cheatle, 2011). An increase in the number of deaths 
due to poisoning with opioid analgesics has been observed in the United States between 
1999 and 2006 (Warner, Chen, & Makuc, 2009).  
In a review of literature examining suicidality in chronic pain Tang and Crane (2006) found 
double the risk of suicide in patients with chronic pain relative to controls. They identified 
a number of risk factors associated with suicidality in chronic pain. These include type, 
intensity and duration of pain, insomnia, helplessness and hopelessness about pain, the 
desire for the escape from pain, pain catastrophising and avoidance and problem solving 
deficits (Tang & Crane, 2006).  
Conversely, positive psychological wellbeing is associated with reduced mortality in both 
healthy populations and in those with existing physical illness (Chida & Steptoe, 2008, 
Keyes & Simoes, 2012).  Anxiety and depression were therefore hypothesised to be 
intervening factors on pathways between pain and mortality. 
Cognitive impairment  
Cognitive function refers to attention, learning and memory, speed of information 
processing, psychomotor and executive function (Moriarty et al., 2011). Cognitive 
impairment is common people with pain. It is an important determinant of independence 
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in older adults and therefore an important component of healthy ageing (Llewellyn, Lang, 
Langa, & Huppert, 2008). In a review of clinical and preclinical studies Moriarty et al., 
(2011) concluded that pain was associated with impaired attentional, executive and 
general cognitive functioning. They proposed the mechanisms were a result of pain 
competing with limited cognitive resources, neuroplasticity and dysregulated 
neurochemistry (Moriarty et al., 2011). Severe and mild cognitive impairment and poor 
memory performance is also associated with an increased risk of mortality (Bassuk, Wypij, 
& Berkman, 2000; Shipley, Der, Taylor, & Deary, 1985). Cognitive impairment has been 
shown to be associated with the presence of inflammatory markers and haemostasis 
(Rafnsson et al., 2007) or may be a side effect of analgesic medication (Moriarty et al., 
2011) which may in turn lead to an increased risk of mortality. Cognitive decline is also 
associated with physical decline, an increased likelihood of being placed in a nursing 
home and subsequent increased mortality (Wolinsky et al., 2006). Cognitive impairment 
was therefore hypothesised to provide a link between pain and mortality.  
Perceived control over health 
The way an individual perceives their illness or condition can affect the way they respond 
to it. Leventhal and colleagues proposed a parallel-processing model of illness 
representation and coping mechanisms known as the Self-Regulatory Model (SRM) 
(Leventhal, Diefenbach & Leventhal, 1992). This incorporates cognitive and emotional 
aspects of illness perception and behaviour and posits a framework, which can be used to 
help understand people’s reaction to illnesses and their treatment. The SRM suggests that 
health related behaviour such as adherence to medical treatment is strongly influenced 
by an individual’s representation of the illness threat. Five dimensions of illness 
representation are incorporated into the model. These are: 
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 Identity (what is it? – the name or label given to the conditions and its symptoms)  
 Time-line (how long will it last? Will it be acute or chronic?)  
 Cause (what is perceived to have caused the illness?)  
 Consequences (how will it affect the individual?) 
 Control/cure (can it be controlled or cured and what role does the individual play 
in this?)  
Patient perceptions are an important determinant of future clinical outcomes. Good 
clinical outcomes in low back pain patients were observed for those who perceived less 
serious consequences, reported fewer emotional responses, attributed fewer symptoms 
to their condition and had stronger perceptions regarding their ability to control their 
pain (Foster et al., 2008). Negative illness perceptions were associated with an increased 
risk of mortality in end stage renal disease patients, and in particular their beliefs about 
treatment control (Parfeni, Nistor, & Covic, 2013) and low perceived control explained 
much of the link (51%) between low socioeconomic status and mortality in a study of 
Dutch adults aged 25-74 years over a six year follow up (Bosma et al., 1999).  Low 
perceived control over health as a result of pain was hypothesised to lead to subsequent 
mortality.  
2.9 Potential moderators of a relationship between pain and mortality 
 
The proposed pathways between pain and mortality described above may be different in 
different sub-groups of the population. This can be tested using moderation analysis. Sex 
and the presence of comorbidity were proposed as moderating factors in this thesis.  
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2.9.1 Sex 
 
Pain experience is different in men and women and a clearer understanding of why this 
occurs can inform the management of pain (Greenspan et al., 2007).  As described in 
Section 1.5.3, the prevalence of pain is greater in females and is due to biological (e.g. 
hormonal modulation) and psychosocial factors (e.g. catastrophizing and use of coping 
strategies) (Fillingim et al., 2009; Wijnhoven et al., 2006). The impact of pain is often 
greater in women (Henschke et al., 2015; Reyes-Gibby et al., 2002; Smith et al., 2001) and 
disabling back pain has been linked to an increased risk of mortality in women but not 
men (Docking et al., 2014) suggesting there may be sex differences in pathways from pain 
to mortality. Women are more likely to experience anxiety and depression, physical and 
somatic conditions and disability related to their pain than men (Greenspan et al., 2007). 
Women with pain are more likely to catastrophise than men but are also more likely to 
seek social support and use more coping strategies than men (Fillingim et al., 2009).  
Keefe et al., (2000) found that catastrophising mediated gender differences in 
osteoarthritis (OA) pain-related outcomes (pain intensity, pain behaviour, physical 
disability) even after controlling for depression (Keefe et al., 2000). Pain is associated with 
the negative effects of alcohol consumption (physical or psychological problems or social 
conflicts) in men but not women (Brennan et al., 2011). Sleep problems (which are 
associated with pain (see section 2.8.1)) are associated with greater psychological 
distress, higher fasting insulin, fibrinogen, and inflammatory biomarkers (markers for 
allostatic load) (Suarez, 2008) and hypertension (Cappuccio et al., 2007) in women but 
not men. Other factors associated with pain demonstrate differences between men and 
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women and could influence differences in mortality risk, for example there are stronger 
associations between social participation and survival in women compared to men (Agahi 
& Parker, 2008).  In a systematic review of physical activity in non-institutional adults over 
60 years, women were less likely to achieve regular physical activity (measured by both 
subjective and objective measurements) compared to men (Sun, Norman, & While, 2013). 
Women are more susceptible to smoking related diseases than men irrespective of 
differences in smoking behaviour (Peters, Huxley, & Woodward, 2014) and globally, more 
women than men are obese (10% of men cf 14% of women in 2008) (WHO, 2015c). These 
differences in factors related to pain indicate there may be different indirect pathways 
from pain to mortality in men compared to women. 
2.9.2 Comorbidity   
 
Chronic widespread pain often occurs alongside other symptom based conditions such as 
chronic fatigue syndrome, irritable bowel syndrome and psychiatric disorders such as 
anxiety and depression (Kato & Sullivan, 2006). However, the presence of chronic physical 
conditions is not always accompanied by the report of pain providing support for the 
recognition of chronic pain as an individual condition (Dominick et al., 2012). The 
presence of comorbidity increases the burden of illness and is likely to affect treatment 
outcomes (Greenspan et al., 2007).  Studying comorbidity is complex due to the many 
different combinations of medical conditions that co-exist that may require similar or 
distinct treatment strategies, however additional morbidity is associated with decreased 
quality of life, psychological distress, longer hospital stays, more post-operative 
complications, higher costs of care and higher mortality (Fortin, Soubhi, Hudon, Bayliss, & 
van den Akker, 2007; Valderas & Starfield, 2009).  It was therefore hypothesised the risk 
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of mortality for people with pain would be greater in those who also reported other 
medical conditions (referred to as comorbidity). This indicates there may be differences in 
the strength and nature of the pathways from pain to mortality between those with and 
those without comorbidity. 
 
This thesis will now go on to describe an examination of the influence of pain phenotype 
on the relationship between pain and mortality and an investigation of the role of 
potential mediators and moderators of the relationship (described in this section). The 
specific aims and objectives are presented in Chapter Three. 
2.10 Key messages 
 
 A modest but non-significant relationship between chronic pain and mortality was 
indicated in the systematic review, particularly cancer mortality.  
 Harmonised data collection, consistent pain phenotypes, sample populations and 
methods of analyses which result in comparable outcome measures (e.g. MRR or 
SMR) are required to robustly determine whether chronic pain increases the risk 
of mortality.  
 An investigation of the role of lifestyle, health, social and psychological factors is 
warranted to provide a clearer understanding of the relationship between chronic 
pain and mortality.  
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Chapter Three. Aims and objectives 
 
3.1 Aims 
 
The aims of the analyses presented in this thesis were to gain a better understanding of 
the link between pain and mortality by investigating the role of pain phenotype and to 
investigate potential mechanisms for a relationship between pain and mortality.  
3.2 Specific objectives 
  
The specific objectives addressed in this thesis were to: 
1. Assimilate existing evidence for a relationship between chronic pain and mortality 
through a systematic review and meta-analysis. 
2. Determine: 
a) Which pain phenotypes are associated with mortality (all-cause and cause 
specific)? 
b) Whether the relationship between pain and mortality is mediated by lifestyle 
factors (e.g. physical inactivity), health factors (e.g. poor self-rated health), 
social factors (e.g. low social group membership) and psychological factors 
(e.g. depression). 
c) Whether the relationship between pain and mortality is moderated by sex and 
health status (e.g. comorbidity).  
  
98 
 
3.3 Thesis content 
 
The following section gives a broad overview of the content in each subsequent thesis 
chapter. 
Chapter Four. Data sources 
The empirical analyses in this study used data collected in the English Longitudinal Study 
of Ageing (ELSA) and the North Staffordshire Osteoarthritis Project (NorStOP). This 
chapter provides a critical overview of the ELSA and the NorStOP methods including 
sampling techniques and data collection. It describes the stages of the assessment of the 
suitability of the data to address the objectives of this thesis; this includes evaluation of 
response rates, missing data and power of the data samples to detect a relationship 
between pain and mortality. It also includes evaluation of the internal and external 
validity of results. 
Chapter Five. The influence of pain phenotype on mortality 
This chapter presents the analysis of the associations between pain phenotype and 
mortality in adults aged 50 years and over. It describes survival analysis of the association 
between mortality and the following pain phenotypes: 
 “often troubled” with pain and pain intensity using ELSA data 
 “any pain”, widespread pain (ACR criteria, Manchester criteria), number of pain 
sites and pain interference using NorStOP data.   
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Chapter Six. Mechanisms of association between pain and mortality  
This chapter presents the analyses investigating mediation and moderation of the 
relationship between pain and mortality. 
Chapter Seven. Discussion and conclusions   
This chapter presents a brief overall summary of the thesis and a critical re-examination 
of the findings. Based on this, the implications for future research and ways to reduce the 
impact of pain are discussed.  
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Chapter Four. Data sources 
4.1 Introduction 
 
Chapter Two described a systematic review of studies which had examined the 
relationship between chronic pain and mortality. Differences in the study populations, 
pain phenotypes and confounders may explain the inconsistencies in results. Further 
investigation of the role of pain phenotype and the identification of mediating and 
moderating factors of this relationship would enhance the understanding of the 
relationship between pain and mortality. Large population studies, in which there has 
been extensive data collection, provide the opportunity to examine different pain 
phenotypes and a number of mediators and moderators.    
This chapter describes two population based cohort studies from which data was used to 
fulfil the objectives outlined in Chapter Three; the English Longitudinal Study of Ageing 
(ELSA) and the North Staffordshire Osteoarthritis Project (NorStOP). ELSA was used in this 
study as it was designed to be nationally representative which reduces the likelihood of 
sampling bias and it collected data on a number of lifestyle, health, social and 
psychological factors which could be included in the analyses as potential moderators and 
mediators. NorStOP was designed to study the prevalence and impact of pain in a 
community sample of adults aged 50 years and over. NorStOP contained detailed 
information on pain which allowed a more comprehensive investigation of the effect of 
pain phenotype on the relationship between pain and mortality and further added to the 
ELSA analyses by providing the opportunity to investigate additional mediators not 
examined in the ELSA sample. Additionally, as ELSA and NorStOP are longitudinal studies, 
this provided scope to measure change over time of mediating factors. Both datasets 
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were studies of older adults and the samples derived from them for the current study 
included adults aged over 50 years only. As detailed in Chapter One, the prevalence and 
impact of pain is greater in older age groups, therefore if a relationship between pain and 
mortality exists it may be stronger in this age group and there would be greater scope for 
examining potential mechanisms as a result of the impacts of pain on life reported by 
older adults. 
This chapter presents an overview of data collection methods, sampling techniques and 
the response rates for each dataset. An examination of missing data and power analyses 
were undertaken to determine potential sources of bias and whether the achieved 
samples were of sufficient size to detect the expected effects. More detail regarding the 
measurement of individual variables is provided in Chapters Five and Six.    
4.2 Aims 
The aim of this chapter was to evaluate the capacity of the ELSA and NorStOP datasets to 
achieve the objectives of this thesis. The objectives of the investigations undertaken in 
this chapter were to: 
1) Identify the extent of non-response and potential for selection bias in the samples 
used in the analyses. 
2) Determine if the derived samples had sufficient power to detect the estimated 
effect size of a relationship between pain and mortality.  
3) Assess whether the derived samples were representative of the larger national 
(England and Wales) population. 
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Figure 4.1 Flow diagram of Chapter Four 
 
4.3 Preparation and analysis of datasets  
The author of this thesis (i) planned the analysis, (ii) requested and acquired the data 
from ELSA and NorStOP and (iii) completed the analysis. 
Data from ELSA were downloaded from the UK Data Service website following 
registration with the UK data service (i.e. at 
https://discover.ukdataservice.ac.uk/series/?sn=200011#access). The data were available 
in multiple datasets (for example from different time points and data collected via nurse 
visit) which were then merged by the candidate. The raw data was recoded as variables 
for this analysis. 
 NorStOP data were acquired from the Research Institute for Primary Care and Health 
Sciences at Keele University following an in-house data request. As with ELSA, some 
Description of ELSA and 
NorStOP datasets 
Derivation of samples to 
be used in this thesis 
Assessment of mechanism of missing data 
Power analyses 
Further investigation to ascertain 
potential selection bias 
Comparison of complete case samples with National Statistics 
to ascertain external validity 
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variables were recoded and datasets were merged. Further details of both datasets are 
presented in the current chapter. Details of the recoding of individual variables for both 
datasets are available in Appendix VII. All preparation and subsequent analysis (detailed 
in the current Chapter and Chapters Five and Six) was carried out by the candidate. The R 
code used in Chapter Six to undertake the mediation analysis within survival anlaysis was 
prepared by a statistician (Milica Blagojevic-Bucknall) but all models were run by the 
candidate. Separate datasets were created for each mediation model containing just 
predictor, outcome, confounder and individual mediator data (detailed in Chapter Six) in 
order to reduce the amount of time taken to run the models.      
4.4 Study design 
4.4.1 The English Longitudinal Study of Ageing (ELSA) 
 
The English Longitudinal Study of Ageing (ELSA) is a nationally representative population 
based study of older adults. The primary objective of ELSA is to collect longitudinal data 
from a representative sample of the English population aged 50 years and older (Scholes, 
Taylor, Cheshire, Cox, & Lessof, 2008).  
ELSA is a large scale longitudinal panel study meaning repeated measures are taken at 
regular time intervals (in this case every two years) of the health, economic and social 
circumstances of adults aged 50 years and over drawn from a sample of private 
households that had previously responded to the Health Surveys for England (HSE) in 
1998, 1999 and 2001. ELSA was developed through collaboration between University 
College London, the Institute of Fiscal Studies and the National Centre for Social Research 
(NatCen). Funding for the study was provided by the US National Institute on Aging and a 
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consortium of British Government Departments. Ethical approval for ELSA was granted 
from the London Multicentre Research and Ethics Committee and informed consent was 
obtained from all participants. This was obtained through the use of consent forms where 
participants were asked for their permission to be re-contacted at future waves and give 
consent for their survey data to be linked to National Insurance records, welfare and 
benefit information, tax credits, mortality and cancer registration and hospital episode 
statistics (HES) (Scholes et al., 2008).  
The HSE was designed to be nationally representative of private households. It used the 
Postcode Address File (PAF) to identify eligible households. The PAF is the most 
comprehensive and up-to-date database of UK addresses and postcodes and contains 29 
million business and residential addresses (to which mail can be delivered) and 1.8 million 
postcodes (Royal Mail Ltd, 2015). The HSE ensured every residential address in this file 
had an equal chance of inclusion by using a random probability sample of households. 
The HSE is a series of surveys with a new sample each year.  The HSE years 1998, 1999 
and 2001 were selected as a sampling frame for Wave 1 of ELSA. These were the most 
recent surveys at that time and produced a sufficiently large sample size (23,132 
households). (The 2000 survey focussed on adults over 65 so was not used in the 
sampling frame for ELSA) (NatCen Social Research, 2014a). 
The first Wave of ELSA took place in 2002 and data was subsequently collected at two-
yearly intervals. Participants were eligible for interview if they were born before 1st March 
1952 and were living at a private residential address. Refreshment samples were used at 
Waves 3, 4 and most recently Wave 6 in order to maintain representation of those in 
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their early 50s. These were people sampled from the HSE from 2001 to 2006 who were 
previously too young to take part in ELSA (Banks et al., 2014).  
Method of administration 
Information for the main survey was gathered using a personal face to face interview 
using computer aided personal interviewing (CAPI) and a self-completion questionnaire. 
All interviewers underwent a two-day briefing by a researcher prior to undertaking the 
interview which included how to administer the assessments, an explanation of all 
documents needed and an introduction to the questions for the CAPI interview (Taylor et 
al., 2007). Information was collected about household and individual demographics, 
physical and psychosocial health, work and pensions, income and assets, housing, 
cognitive function, social participation and expectations for the future at each wave. As a 
check, one-in-ten participants were contacted by telephone to verify key details from 
their interview (Taylor et al., 2007). A separate nurse visit was included at Waves 2 and 4 
to collect blood samples and anthropometric and physical measurements. Appointments 
for the nurse visits were made at the time of interview and were only carried out once 
the appropriate consents were obtained. Seven consent forms were presented in a 
booklet which participants were asked to sign allowing blood to be taken, consenting for 
information on blood pressure, lung function, and blood results to be sent to their GP, 
allowing storage of their blood for future use, for extraction and storage of DNA and for 
saliva to be tested for cortisol for use in future research (Scholes et al., 2008).  
Data on potential mediators were collected at multiple waves of ELSA. This offered the 
potential to construct variables which identified change over time in mediating constructs 
(i.e. this would allow modelling of whether the relationship between pain and mortality 
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was mediated by change in potential mediators). The current study used information 
collected at Wave 2, defined here as “baseline” and Wave 4, defined here as “follow-up” 
in order to use biomarker information to generate allostatic load and frailty variables; 
these are proposed mediators, and their methods of measurement are described in 
Section 6.3.3. Fieldwork for Wave 2 took place between June 2004 and July 2005. For 
Wave 4 data was collected between May 2008 and July 2009 (NatCen Social Research, 
2014b). 
Response to the survey was encouraged by an offer of a £10 gift voucher to be provided 
at the end of the interview. Responders were assigned the same interviewer at 
subsequent waves where possible and where members of households were no longer 
living together attempts to contact responders at both old and new addresses were made 
to try and ensure all those eligible had the opportunity to take part. If an individual was 
unable to take part as a result of cognitive impairment or illness a proxy interview was 
attempted with an informant. This was usually a family member but was anyone over the 
age of 16 who could provide the relevant information about the individual (Scholes et al., 
2008).  If the self-completion questionnaire was not returned a reminder was sent and if 
this was also unsuccessful a member of the NatCen Telephone unit would call the 
respondent and complete the form on their behalf from their answers provided via 
telephone (Scholes et al., 2008).  
Data processing 
The coding of closed questions was undertaken through the code frame within the CAPI 
system. Responses to ‘open’ questions were coded into separate variables after the 
interview using a separately developed code frame where a few new answer codes were 
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generated where answers did not fit existing codes. Coding and editing was undertaken 
by the interviewers in the field with some post interview checks where inconsistencies 
arose.  All ELSA data files deposited in the archived dataset were given a unique individual 
serial number to enable users to link different files. Data dropped from the archived 
dataset included the name and address of the respondent and variables such as detailed 
ethnicity, specific country of birth, full interview data and full date of birth to reduce the 
potential of identifying individuals who took part (NatCen Social Research, 2014b). 
Table 4.1 presents the variables obtained from ELSA and their proposed role in this study 
of the relationship between pain and mortality. Details of how each variable was 
measured are presented in Chapters Five and Six.  
Table 4.1 The role of ELSA variables in the survival analysis (Chapter Five) and the mediation 
and moderation analyses (Chapter Six) 
Concept Predictor Outcome Moderator Mediator Confounder 
Pain X     
Mortality  X    
DEMOGRAPHICS 
 Age 
 Sex 
 Education 
 Wealth 
   
 
X 
 
  
X 
X 
X 
X 
LIFESTYLE FACTORS 
 Physical activity 
 Smoking 
 Alcohol consumption 
    
X 
X 
X 
 
HEALTH 
 Self-reported health 
 Functional limitation 
 Comorbidity 
 Allostatic load 
 Frailty 
   
 
 
X 
 
 
X 
X 
 
X 
X 
 
 
 
 
 
 
 
SOCIAL FACTORS 
 Volunteer work 
 Social group membership 
    
X 
X 
 
PSYCHOLOGICAL FACTORS 
 Quality of Life 
 Depression 
 Cognitive impairment 
    
X 
X 
X 
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4.4.2 The North Staffordshire Osteoarthritis Project (NorStOP) 
 
The NorStOP is a population based cohort study designed to assess the prevalence and 
impact of pain in a community sample of adults aged 50 years and over. Data from three 
cohorts of NorStOP (i.e. NorStOP 1, NorStOP 2 and NorStOP 3) were used in this study. 
These were designed as population cohort studies and collected similar data at baseline, 
three and six year follow-ups. The aim of NorStOP 1, 2 and 3 was to examine the natural 
history of joint pain in the general population. NorStOP 2 and 3 additionally aimed to 
identify older adults with knee and hand pain respectively, for clinical studies. For the 
current study, data collected at baseline and three year follow-up were used. Baseline 
data for each cohort was collected at different time points (i.e. NorStOP 1 was collected 
in April 2002, NorStOP 2 was collected from July/August 2002 to July/August 2003 and 
NorStOP 3 was collected from March 2004 to April 2005). Ethical approval for NorStOP 
was granted from the North Staffordshire Local Research Ethics Committee (REC 
reference numbers 1351, 1430 and 05/Q2604/20) (Thomas, et al., 2004). 
Eight practices from the North Staffordshire General Practice Research Network were 
recruited to the study; three for NorStOP 1, three for NorStOP 2 and two for NorStOP 3. 
In 2001 (when NorStOP was developed) North Staffordshire consisted of four Primary 
Care Trusts. It had a combined population of approximately 460,000 (Office For National 
Statistics, 2001). The eight practices were located in urban and rural areas. There were 
101 general practices in North Staffordshire, 16 of which formed the General Practice 
Research Network. These latter practices continuously collated information regarding 
clinical contacts to facilitate epidemiological research and have undergone annual audits 
by Keele’s Primary Care Sciences Research Centre Health Informatics team to assess the 
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quality and completeness of their data. The age-sex registers from the eight practices 
were used to provide a representative sample of the local general population. 98% of 
people in the United Kingdom are registered with a general practitioner (Bowling, 2009) 
and so the registers were a convenient sampling frame for a local population. Overall for 
the three NorStOP cohorts 26,705 adults were included in the original sampling frame 
and were sent baseline questionnaires.  
 
Method of administration 
 
A two-stage methodology was used for each cohort at each data collection (baseline and 
three year follow-up). Prior to each mailing the contact details of all adults aged 50 years 
and over from each practice list were checked by the GPs from the practices for 
exclusions. Patients were excluded if they were unable to complete the questionnaire due 
to illness, were known to have severe learning disabilities or a severe psychological 
disorder, or had indicated previously that they did not wish to take part in research 
projects prior to the mailing procedure.  
 
Keele’s Primary Care Research Centre has robust data security systems and procedures in 
place which achieve the legal obligations set by the Data Protection Act and follow 
General Medical Council (GMC), Caldicott Guardian and British Computer Society 
standards and guidelines. Personally identifiable data was held only for as long as was 
needed (e.g. to undertake mailing) and identifiable data was stripped from research 
databases as soon as was feasible. Each individual in the sample population was allocated 
a unique study number on all questionnaires and survey data was separated from all 
contact details so that only anonymised data was available for analysis.  
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In the first stage, all eligible participants were mailed a “Health Survey” questionnaire. In 
the second stage, responders to the “Health Survey” questionnaire who gave permission 
to be re-contacted and who reported experiencing either a hand problem or pain in at 
least one of four regional sites (hands, hips, knees, or feet) in the previous 12 months 
were mailed a “Regional Pain Survey” questionnaire, which focused on these four 
regional sites. The current study used data from the “Health survey” only. At each stage, 
questionnaires were accompanied by a letter from the GP practice and a study 
information leaflet. Reminders were sent to non-responders after two weeks (postcard 
only) and four weeks (a further questionnaire and letter from the GP). Throughout the 
study, those mailed the questionnaires were offered the opportunity to contact the 
Research Centre to discuss the study in further detail with the Study Co-ordinators. 
 
Questionnaire processing  
On return of the completed questionnaires, the date of birth and sex given by the 
responders were checked against those from the surgery records to ensure replies were 
from the intended responder. Questionnaires were then placed in secure storage, for pre-
scan checking. Data was entered using an automatic data entry system called TeleformTM, 
which demonstrates high levels of data accuracy (Jinks, Jordan, & Croft, 2003).  
 
To establish the accuracy of the scanned data, the data was checked for errors. The paper 
copy of the questionnaire was checked against the exported data in SPSS. The 
questionnaire identification number was noted on a proforma along with any identified 
errors. After the scanning of each of the first five boxes one in five questionnaires were 
checked. After this, data were checked after all data entry had been completed, where 
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again one in five questionnaires were checked. Identified errors were corrected in the 
SPSS file. 
Manikin data entry 
 
The “Health Survey” questionnaire contained a manikin body chart (Chapter Five, Figure 
5.1). Data entered on this could not be processed using the automatic data entry system 
and was processed manually using a Microsoft Access database. Those mailed the “Health 
Survey” were asked to shade in areas of the body chart where they had aches or pains 
that had lasted for one day or longer in the previous four weeks (not including pain 
occurring due to illness such as flu). The areas of pain were coded manually using three 
plastic transparent templates to enable a comprehensive assessment using previously 
published manikin criteria: 
(i) Template 1 scored widespread pain and had 42 areas (Macfarlane, Croft, Schollum, & 
Silman, 1996). 
(ii) Template 2 scored neck pain (area 43) (Papageorgiou et al., 1996) and hip pain (areas 
44-47) (Birrell et al., 2000). 
(iii) Template 3 scored lower back pain (area 48) (Papageorgiou, Croft, Ferry, Jayson, & 
Silman, 1995). 
Manikin data entry was checked by another data clerk, who performed the same 
procedure and noted errors on a proforma. Identified errors were corrected in the 
database.  
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Data cleaning 
 
The data processed in the TeleformTM system was exported to a SPSS file. This file was 
checked to identify anomalies in the full data set. This was particular to items where 
responses were hand-written: 
(i) Date of birth and sex – where the date of birth was missing, the signature on the 
questionnaire was checked against the name on the mailing list to ensure that the correct 
person had returned the questionnaire. The date of birth and sex values were then taken 
from the mailing list and used in the questionnaire database. 
(ii) Height and weight – any unrealistic values were scored as missing, for example heights 
greater than 8 feet or weights greater than 30 stones. 
(iii) Age left school – any unreasonable values were scored as missing, for example ages 
less than 12 or greater than 25 years. 
 
Details of the proposed role of the NorStOP variables used in this study are presented in 
Table 4.2. Measurement methods for individual variables are presented in Chapters Five 
and Six.  
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Table 4.2 The role of NorStOP variables in the survival analysis (Chapter Five) and mediation 
and moderation analyses (Chapter Six) 
Concept Predictor Outcome Moderator Mediator Confounder 
Pain X     
Mortality  X    
DEMOGRAPHICS 
 Age 
 Sex 
 Education 
 Adequacy of income 
   
 
X 
 
 
  
X 
X 
X 
X 
LIFESTYLE FACTORS 
 Smoking 
 Alcohol consumption 
 Obesity 
 Physical activity(walk/go 
out) 
 Sleep 
    
X 
X 
X 
 
X 
X 
 
HEALTH 
 Self-rated health  
 Functional limitation 
 Comorbidities 
   
 
 
X 
 
X 
X 
 
 
 
SOCIAL FACTORS 
 Social Participation  
    
X 
 
PSYCHOLOGICAL FACTORS 
 Anxiety  
 Depression  
 Cognitive impairment 
 Perceived control of health  
    
X 
X 
X 
X 
 
4.5 Participant flow 
4.5.1 ELSA 
The target sample for ELSA consisted only of households containing at least one living 
age-eligible individual (aged 50 years and over) who had agreed to be contacted in the 
future. This resulted in the exclusion of 11,554 households from the original HSE sampling 
frame (n=23,132) resulting in 11,578 households containing 18,813 age-eligible sample 
members or younger partners. Data was obtained from 12,100 of these participants by 
interview. The main reason for non-response to the first wave of ELSA was refusal to take 
part. Other reasons were language difficulties, illness or absence during the survey period 
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or physical or mental difficulties preventing individuals from taking part (Taylor et al., 
2007). 
Table 4.3 displays the age/sex distribution of the target sample (study population) and 
the responders. This is based on the respondent’s age at the time of interview. 
Responders were defined as individuals who gave a full or partial interview in person or 
by proxy. However in addition to sample members, younger partners and new partners 
were also interviewed. The ‘responders’ sample is therefore not a sub-group of the target 
population but from observation the age and sex distribution of both groups is similar. 
However the oldest age group is underrepresented for both men and women compared 
to the national population (Taylor et al., 2007).  
Table 4.3 The anticipated and achieved Wave 1 ELSA sample stratified by age and sex 
Age group Study population n=18,813 Responders n=12,100* 
Male Female Total Male Female Total 
Under 50 220 (3%) 822 (8%) 1042 (6%) 104 (2%) 472 (7%) 576 (5%) 
50-59 3224 (38%) 3528 (34%) 6752 (36%) 1930 (36%) 2327 (34%) 4277 (35%) 
60-69 2450 (29%) 2556 (25%) 5006 (27%) 1619 (30%) 1795 (26%) 3414 (28%) 
70-79 1792 (21%) 2077 (20%) 3869 (21%) 1178 (22%) 1393 (21%) 2571 (21%) 
80+ 802 (10%) 1329 (13%) 2131 (12%) 485 (9%) 777 (11%) 1262 (10%) 
Unknown 9 (0%) 4 (0%) 13 (0%) - - - 
Total 8497 10316 18813 5336 6764 12100 
* The ELSA Wave 1 technical report (Taylor et al., 2007) was written before the data were fully reconciled 
and it has subsequently been noted there were some small errors in the original report (e.g. duplicate 
households, changes to outcome codes). As a result of this the total number of responders at Wave 1 was 
reduced to 12,099 and is reported as such in later written material (Institute for Fiscal Studies, 2015). 
 
Wave 2 took place in 2004. All responders at Wave 1 were approached and 8781 were 
retained in Wave 2. Non responders (n=3318) at Wave 2 were more likely to have a long 
term limiting illness, be of lower socioeconomic status, be non-white, female and aged 
over 85 at Wave 1 (Scholes et al., 2008).  The Wave 2 sample for analysis also included 
652 additional participants (core, young and new partners) to provide a total sample of 
9432. The reporting of response rates and attrition in ELSA is challenging because there 
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were variations in the responses to different elements of the study, deaths, differences 
between core and refreshment cohorts, and some individuals failed to respond at one 
wave but re-joined the study at later waves (Steptoe, Breeze, Banks, & Nazroo, 2012). 
People lost to follow-up tended to be older, less wealthy and less educated, come from a 
non-managerial occupation and suffer from a long standing limited illness (Steptoe et al., 
2012). The number of participants who provided complete data at each wave of ELSA is 
illustrated in Figure 4.2.  
As previously stated Wave 2 (2004) of ELSA was used as baseline in this study and Wave 4 
(2008) as the follow-up time point to use biomarker information collected during these 
waves. The two time points were necessary to examine the effect of the change over time 
of potential mediators of the association between pain and mortality. 9432 interviews 
took place at Wave 2 and of these participants, 7666 had nurse visits. Reasons for non-
completion of the nurse visit included refusal, unable to contact to arrange a visit, being 
too ill or being away at the time of the planned visit (Scholes et al., 2008). 
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Figure 4.2 Number of participants at each wave of ELSA (Steptoe et al., 2012) 
 
Data collection for Wave 2 took place between June 2004 and July 2005. Participants 
were included in the analyses if they were age 50 years or over at baseline and had 
complete data for pain, vital status and proposed mediators, moderators and 
confounders.  
The number of participants for whom information was available at each stage and the 
proportion of participants with missing data per variable in the ELSA dataset are displayed 
in Figure 4.3. The variables of allostatic load and frailty are omitted as these factors were 
treated separately (as described in section 4.6.5). Of the 9432 participants at baseline, 
8572 (90.1%) had complete predictor (pain), outcome (vital status) and confounder (age, 
sex, education and wealth) data and were aged 50 years and over. 238 (2.5%) of the 9432 
were aged less than 50 years. Individuals under 50 years were interviewed if they were 
part of a couple where one member was aged over 50 years. This was to allow the 
2010/11 
2006/7 
2004/5 
2002/3 
2008/9 
Wave 1 
N=12099 
Wave 2 
N=9432 
Wave 3 
N=9771 
Wave 4 
N=11050 
Wave 5 
N=10317 
Nurse visit 
N=7666 
Nurse visit 
N=8643 
Original sample interviewed 
in HSE 1998/1999/2001 
Age 50+ on 1 March 2002 
New cohort sample HSE 
2001/02/03/04 
Age 50 -52 on 1 March 2006 
Refreshment sample from 
HSE 2006 
Age 50 -74 on 1 March 2008 
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collection of financial information at benefit unit level where couples keep their finances 
together. This is considered more useful for considering economic circumstances than 
using indicators based on the individual (Steptoe et al., 2012). It was also to allow for 
analyses of intra-couple dynamics regarding health, employment, retirement, and quality 
of life (Steptoe et al., 2012). This study was not concerned with these issues and was 
focussed on older adults (50 years and over) so these participants were excluded.  Of the 
8572 participants with complete predictor, outcome and confounder information, 6324 
(67.0% of the total) had complete data for all potential mediators at baseline. At follow 
up 3915 (41.5%) participants had complete data for all variables (Figure 4.3).  
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Variable n with missing 
data  
Proportion of 
8572 with 
missing values 
Physical activity 0 0% 
Symptoms preventing 
walking) 
0 0% 
Functional limitation 
(ADL/IADL difficulties) 
1 0.01% 
Smoking 2 0.02% 
Volunteer work 2 0.02% 
Self-rated health 5 0.06% 
Depression (CESD) 19 0.22% 
Cognitive impairment 50 0.58% 
Alcohol 1012 11.81% 
Social group membership 1370 15.98% 
Quality of life (CASP 19) 1758 20.51% 
Cumulative total 2248 26.22% 
 
Variable n with missing 
data 
Proportion of 
6071 with missing 
values 
Physical activity  1269 20.90% 
Symptoms preventing 
walking) 
1269 20.90% 
Function (ADL/IADL 
difficulties) 
1269 20.90% 
Volunteer work  1277 21.03% 
Smoking  1304 21.48% 
Self-rated health  1347 22.19% 
Cognitive impairment 1352 22.27% 
Alcohol  1360 22.40% 
Depression (CESD) 1389 22.88% 
Social group 
membership 
1460 24.05% 
Quality of Life (CASP 19) 1866 30.74% 
Cumulative total 2156 35.51% 
 
Participants at baseline with 
complete predictor, outcome 
and confounder data 
n= 8572 
Complete data at baseline 
and follow-up  
n= 3915 
Complete data at baseline 
(predictor, outcome, 
confounders and all mediators)  
n = 6324 
Total number of 
participants at baseline 
n=9432 
Died between 2004 and 2008 n=253   
Variable n with missing 
data  
Proportion of 
total with 
missing values 
Sex (n=9432) 0 0% 
Pain (n=9424) 8 0.08% 
Education (n=9415) 17 0.18% 
Excluded as age (below 
50) 
238 2.52% 
Mortality (n=8799) 633 6.71% 
Wealth (n=8661) 771 8.17% 
Cumulative total 860 9.12% 
 
Figure 4.3 Number and proportion of participants with missing data at each 
stage of ELSA 
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4.5.2 NorStOP 
 
At baseline, for the three NorStOP cohorts a total of 26,705 adults aged over 50 years 
were identified from 8 GP practices in North Staffordshire. 576 (2.2%) were excluded (242 
died, 24 were excluded by their GP, 69 withdrew and 241 questionnaires were returned 
as addressee unknown) either prior to or during the mailing process leaving 26,129 adults 
eligible for the baseline survey. Of these, 18,497 (70.8%) responded at baseline (Figure 
4.4).  
 
 
 
 
 
 
 
 
 
 
 
Figure 4.4 Flowchart of baseline response in NorStOP 
 
The number of participants for whom information was available and the proportion of 
participants remaining at each stage with missing data per variable from the NorStOP 
dataset are displayed in Figure 4.5. Of the 18,497 participants at baseline 14,023 (75.8%) 
had complete predictor, outcome and confounder data and 10,985 (59.4%) had   
Identified from 8 GP 
practices (n=26,705) 
Mailed baseline health 
survey (n=26,625) 
Eligible baseline health 
survey (n=26,129) 
Responders (n=18,497)  
Adjusted baseline health 
survey response 70.8% 
 
Excluded prior to 
mailing (n=80) 
56 deaths and departures  
24 GP screening 
 
Excluded during mailing 
(n=496) 
186 deaths and departures 
69 withdrawn 
241 returned addressee 
unknown 
 
Non-responders (n=7632) 
241 ill health 
587 refused 
6804 non-response 
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Variable n with 
missing data 
Proportion of 
14023 with 
missing values 
Alcohol consumption (n=13966) 57 0.41% 
Smoking (n=13922) 101 0.72% 
Control (n=13900) 123 0.88% 
Self-rated  health (n=13883) 140 1.00% 
Frequency walk (n=13768) 255 1.82% 
Depression (n=13759) 264 1.88% 
Anxiety (n=13747) 276 1.97% 
Trouble falling asleep (n=13734) 289 2.06% 
Frequency go out (n=13728) 295 2.10% 
Wake in the night (n=13705) 318 2.27% 
Wake up unrefreshed (n=13676) 347 2.47% 
Participation (n=13605) 418 2.98% 
Obesity (n=13535) 488 3.48% 
Trouble staying asleep (n=13506) 517 3.69% 
Functional limitation (SF-36) 
(n=13386) 
637 4.54% 
Cognitive impairment (n=13383) 640 4.56% 
Cumulative total 3038 21.66% 
 
Variable n with 
missing data 
Proportion of 
10617 with 
missing values 
Obesity (n=9354) 1263 11.90% 
Depression (n=6569) 4048 38.13% 
Anxiety (n=6567) 4050 38.15% 
General  health (n=6554) 4063 38.27% 
Cognitive impairment (n=6530) 4087 38.49% 
Participation (n=6506) 4111 38.72% 
Functional limitation (n=6502) 4115 38.76% 
Sleep (4 items) (n=5967) 4650 43.80% 
Cumulative total 6324 59.56% 
 
Participants at baseline with 
complete predictor, 
outcome and confounder 
data 
n=14023 
Complete data at baseline 
and follow-up  
n= 4293 
Complete data at baseline 
(predictor, outcome, confounders 
and all mediators)  
n=10985 
Total number of 
participants at baseline 
n=18497 
Died between baseline and 3 year follow-up n=368  
Variable n with 
missing data  
Proportion of 
total with 
missing values 
Age (n=18475) 22 0.12% 
Sex (n=18475) 22 0.12% 
Pain interference (n=18006) 491 2.65% 
Education (n=17997) 500 2.70% 
Adequacy of income (n=17978) 519 2.81% 
Any pain (n=16774) 1723 9.32% 
Mortality (n=16460) 2037 11.01% 
Pain ACR/MCR (n=16412) 2085 11.27% 
Cumulative total 4474 24.19% 
 
Figure 4.5 Number and proportion of participants with missing data at each stage 
of NorStOP 
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complete data for all proposed mediating factors. At follow up (3 years) only a limited 
number of the potential mediating factors were measured and only 4293 (23.2%) 
participants had complete data for all of these mediators at baseline and follow-up 
(Figure 4.5).  
4.6 Missing data 
4.6.1 Introduction 
 
The term ‘missing data’ refers to the absence of information or missing values for a 
variable of interest (Kang, 2013) and can occur for a number of reasons. Participants may 
be lost to follow-up over time in a longitudinal study, individuals may not respond to 
certain questions on a survey as they feel it is not relevant to them, they do not 
understand the question or they feel it is of a sensitive nature (Goldstein, 2009; Schafer & 
Graham, 2002). Missing data can be described in terms of unit/whole person non-
response where an entire set of data values are missing or as item non-response where 
individual data values are missing but partial data are available (Schafer & Graham, 2002).  
Attrition is a term used to describe loss of data from participants over time in a 
longitudinal study (Goldstein, 2009). Participants may drop out during a study, they may 
not consent to contact at follow-up time points or they may have moved house or be 
impossible to contact for another reason (e.g. death, illness). 
As described above Figures 4.3 and 4.5 outline the variables for which there were missing 
data in this study. In ELSA the quality of life measure resulted in the greatest amount of 
missing data (20.51% at baseline and 30.74% at follow up). This was a composite measure 
of 22 items; if data for one item was missing a score could not be calculated. Similarly 
physical function in the NorStOP dataset resulted in a large amount of missing data. This 
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was measured using the 10 item physical functioning scale of the Short Form (SF)-36 and 
resulted in 5.54% of missing data at baseline and 38.80% of missing data at follow-up).  
The greatest amount of missing data at follow up in the NorStOP sample was for the four 
questions regarding sleep (43.80%). These variables are described in more detail in 
Section 6 3.3 and Appendix VII.   
The implications of missing data are reduced statistical power to detect an existing effect, 
selection bias in the estimation of parameters (e.g. if data is missing from older 
participants the resulting estimate will be biased in favour of younger participants as any 
measure of effect will be calculated from the data of younger participants only which may 
differ from those of older participants) leading to reduced representativeness of the 
sample to the target population (the study sample may differ in some way from the target 
population) and the need for complicated analysis techniques (see below) (Kang, 2013). 
These factors may threaten the internal and external validity of the study (Kang, 2013).   
Missing data can occur by three mechanisms; missing completely at random (MCAR), 
missing at random (MAR) and missing not at random (MNAR) (Graham, 2009). Data that is 
MCAR occurs when the missingness does not depend on the values of observed or 
missing data (Schafer & Graham, 2002). An example of this would be a blood sample that 
is accidentally dropped. The reason for missingness is not due to any characteristic of the 
person from whom the blood was taken nor to any value of any test undertaken on the 
blood sample.  For data that is MAR the missingness depends on values of observed data 
but not missing data, for example if older people are more likely to have their blood 
pressure recorded. Data that is MNAR is dependent on values of missing data. An 
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example of this would be if those with high blood pressure were more likely to have it 
recorded than those with normal or low blood pressure (Carpenter & Kenward, 2013).  
If data is MCAR analysing complete cases will not result in biased parameter estimates 
but there may not be sufficient power to detect an effect should one exist if there is a 
large amount of missing data. If data is MAR or MNAR complete case analysis may result 
in biased estimates (Kang, 2013). 
There are a number of techniques available to manage missing data to attempt to reduce 
potential biases including: 
 Listwise deletion which involves discarding any observations with missing values 
resulting in complete case analysis. This results in a loss of data and can lead to 
inefficient parameter estimates. It also requires data to be MCAR (Enders & 
Bandalos, 2001). Listwise deletion has been shown to give unbiased parameter 
estimates under MCAR but biased estimates under MAR (Kang, 2013).  
 Pairwise deletion discards cases on a variable by variable basis and therefore 
attempts to use all available information. This also requires data to be MCAR 
(Enders & Bandalos, 2001).  
 Weighting is a technique which involves estimation of an effect for a larger sample 
by weighting the reduced sample according to values of available information in 
the larger dataset. Each participant is assigned a’ sampling weight’ which refers to 
the number of participants in the larger sample that are represented by each 
participant in the reduced sample (Dunn, Pickles, Tansella, & Vazquez-Barquero, 
1999). Weighting can eliminate bias due to differential response on the items used 
to create the weighting probabilities but cannot correct for biases on items that 
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are not used or measured (Schafer & Graham, 2002). Further detail regarding this 
technique is presented in Section 5.5.3.   
 Multiple imputation (MI) involves imputing or replacing missing data with a set of 
plausible values based on the observed data. Several datasets are constructed and 
analysed separately and their results are combined allowing for the uncertainty 
introduced as part of the imputation (Clark, Bradburn, Love, & Altman, 2003b). MI 
assumes missing data is at least MAR (Schafer & Graham, 2002).  
Identifying the mechanism of missing data in a study is necessary in order to determine 
how best to restrict potential biases as a result of that missing data. The procedure 
undertaken to do this in this study is described below. 
4.6.2 Aim 
To determine the mechanism of missing data for each sample used in this study from 
each dataset.  
4.6.3 Methods 
 
It is not possible to definitively distinguish between MAR, MCAR and MNAR data 
(www.missingdata.org.uk) and often in large datasets all three mechanisms of 
missingness will occur. To examine for the mechanism of missing data logistic regression 
was used to identify if any of the variables included in the analysis predicted missingness. 
For each variable with missing data additional binary variables (called indicator variables) 
were created where values were defined as missing (score of 1) or not missing (score of 
0). Correlations between the indicator variables and other variables would indicate the 
data is MAR (i.e. could be predicted by observed data). If no or low correlations are 
observed this indicates the data is either MCAR or MNAR (correlation coefficients of less 
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than 0.35 are generally considered to be low or weak correlations, 0.36 to 0.67 modest or 
moderate correlations, and 0.68 to 1.0 strong or high correlations (Taylor, 1990)). This 
whole process was undertaken in Stata 13 using a loop which generated the binary 
indicator variables and then correlated those variables with all possible variables that may 
predict the missingness simultaneously, omitting the variable whose indicator is being 
examined. Details of this method and examples of Stata syntax can be found at 
“http://www.ats.ucla.edu/stat/stata/seminars/missing_data/mi_in_stata_pt1.htm,”. The 
technique described here helps to provide information about the potential mechanism of 
missingness which affects the way the data should be treated.  
4.6.4 Results 
 
The majority of the coefficients from the correlation analysis to investigate the 
mechanism of missing data were low (<0.35) for both the ELSA and NorStOP datasets. The 
complete set of correlations for this analysis can be seen in Appendix III.  
4.6.5 Implications 
 
The missingness of variables could not be predicted by the values of observed data which 
indicated the data were not MAR. Therefore the data were either MCAR or MNAR. It is 
not possible to determine MNAR as this type of missingness requires information about 
unobserved values (Schafer & Graham, 2002). As the data in this study were not MAR 
(required for multiple imputation techniques) and the analysis technique used to perform 
the mediation analysis (described in Section 6.3.2) would not recognise an imputed 
dataset, listwise deletion was used to remove those participants with any missing data on 
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any of the variables to be used in the models. This is a common technique for dealing 
with missing data which results in complete-case analysis as described above.  
In cases where the data can be assumed to be MCAR, complete case analysis produces 
unbiased estimates and conservative results (Kang, 2013). This technique reduces the size 
of the sample and subsequently the power to detect an effect where one exists. The 
amount of missing data at follow up was high in this study (38% missing in the ELSA 
sample, 61% missing in the NorStOP sample). It was therefore important to calculate the 
power (to correctly detect an effect where one exists) in the reduced sample sizes.  
4.7 Power analysis 
4.7.1 Introduction 
 
Larger samples reduce the likelihood of making a type I error (finding an effect where 
there isn’t one) or a type II error (not detecting an effect when one exists) (Jones, Carley, 
& Harrison, 2003). The probability of a type I error, α, is determined by the researcher 
and commonly set to 0.05 meaning there is a 5% chance of falsely rejecting a null 
hypothesis. The power of a test refers to the probability of obtaining a significant result if 
a real difference exists (denoted by 1-β where β is the probability of a type II error) (Le, 
1997). Generally a power level of 0.8 (80% chance of detecting an existing effect) or 
above is accepted as sufficient power to detect an existing effect (Jones et al., 2003). 
Power analysis determines the minimum sample size necessary to detect an effect of a 
particular size.  
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4.7.2 Aim 
 
To determine if the following samples had sufficient power to detect the expected effect 
size for a relationship between pain and mortality: 
In ELSA: 
i) the baseline sample with complete predictor, outcome and confounder 
information (n=8572) 
ii) the complete case sample at baseline (n=6324) 
iii) the complete case sample with complete data at baseline and follow-
up (n=3915) 
iv) the allostatic load sample at baseline (n=4627) (see section 4.6.5) 
v) the allostatic load sample with complete baseline and follow-up data 
(n=2392) (see section 4.6.5)  
vi) the frailty sample at baseline (n=4375) (see section 4.6.5) 
vii) the frailty sample with complete baseline and follow-up data (n=2483) 
(see section 4.6.5)  
In NorStOP: 
i) the baseline sample with complete predictor, outcome and confounder 
information (n=14023) 
ii) the complete case sample at baseline (n=10985) 
iii) the complete case sample with complete data at baseline and follow-
up (n=4293) 
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4.7.3 Methods 
 
In survival analysis, calculations of power are determined by the number of events that 
take place because censored observations (i.e. those who drop out or who survive until 
the end of the study period) do not contribute to the power of the test in the 
proportional hazards model (Hsieh & Lavori, 2000). There are a number of ways to 
calculate optimum sample sizes in Stata using the stpower command. This command 
enables the calculation of the number of events and sample size when the power and 
effect size are known; the calculation of power when the number of events and the effect 
size are known or the calculation of the effect size when the number of events and power 
are known. The stpower command is based on the formula by Hseih and Lavori (2000): 
𝐸 =
(𝑧1 − 𝛼/𝑘 + 𝑧1 − 𝛽)
2
𝜎2𝛽1
2(1 − 𝑅2)
 
Where E is the total number of events, 𝛽1 is the regression coefficient for the covariate of interest x1, σ is 
the standard deviation of x1, α is the significance level, 𝛽is the probability of a type II error, 𝑅
2 is the 
proportion of variance explained, 𝑧1 − 𝛼/𝑘 and 𝑧1 − 𝛽 are the  (1- 𝛼/𝑘 )th  and the (1-𝛽)th quantiles of the 
standard normal distribution with k=1 for a one sided test and k=2 for a two sided test (Hseih and Lavori, 
2000) (http://www.ats.ucla.edu/stat/stata/seminars/missing_data/mi_in_stata_pt1.htm)).  
 
For all of these tests, the default probability of a type I error (α) was set at 0.05 (Stata 
Press, 2013). From the literature it was estimated that the approximate mortality rate 
ratio comparing those with pain to those without pain in English samples would be in the 
region of 1.3 to 1.4 (Macfarlane et al., 2001; McBeth et al., 2009).  As the expected effect 
size (in this case the mortality rate ratio) and the number of events (observed deaths in 
each study sample) were known for this study the stpower command was used to 
calculate the power for each sample listed in the section 4.6.2. Details regarding the 
methods of collection of mortality data are presented in Section 5.4.  
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4.7.4 Results from ELSA 
 
Table 4.4 displays the number of deaths in the first three ELSA samples (described in 
section 4.6.2). For the baseline sample (n=8572) the power to detect a hazard ratio of 1.3 
with the probability of a type I error set to 0.05 is 0.998. This means there is a 99.8% 
chance of detecting an effect of this size should one exist. In this sample it was estimated 
there was 100% chance of detecting a hazard ratio of 1.4. For the complete case sample 
(n=6324) there was 95.2% chance of detecting a hazard ratio of 1.3 and 99.6% chance of 
detecting a hazard ratio of 1.4. However for the complete case sample with follow up 
data (n=3915) there was only a 44.9% chance of detecting a hazard ratio of 1.3 and 65.2% 
chance of detecting a hazard ratio of 1.4. 
Table 4.4 Power to detect expected hazard ratios per sample size in the achieved samples from 
the ELSA dataset; α=0.05 
Sample N Number of 
events 
(deaths) 
Power 
Hazard ratio = 1.3 Hazard ratio = 1.4 
Baseline (predictor, 
outcome and 
confounder 
information) 
8572 1390 0.998 1.000 
Complete case 6324 764 0.952 0.996 
Complete case plus 
follow up 
3915 195 0.449 0.652 
 
4.7.5 Allostatic load and frailty 
 
The calculation of the indices of allostatic load and frailty required biomarker data 
collected during the nurse visits (the data used to create these indices along with the 
method of calculation is described in Chapter 6). This greatly reduced the number of 
participants for whom data was available and to include these variables in the complete 
case analysis along with all other variables would have resulted in a drastically reduced 
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total sample size. The analyses for allostatic load and frailty were therefore presented as 
separate analyses. 
Power calculations were also carried out to determine if there was sufficient power to 
detect the expected effect size in the allostatic load and frailty samples. In the allostatic 
load sample (n=4627) there were 567 deaths resulting in an 87.8% chance of detecting a 
hazard ratio of 1.3 and a 98.0% chance of detecting a hazard ratio of 1.4. In the frailty 
sample (n=4375) there were 792 deaths resulting in a 95.8% chance of detecting a hazard 
ratio of 1.3 and a 99.7% chance of detecting a hazard ratio of 1.4 (all α=0.05).  
Change over time 
Of the participants at baseline with allostatic load data, only 2392 had data at the time of 
follow up and only 91 participants died. With so few deaths, the power to detect a hazard 
ratio of 1.3 was only 23.9% and to detect a hazard ratio of 1.4 was only 36.1% (α=0.05).  
There were few changes in frailty status between baseline (2004) and follow-up (2008). 
Including participants who had frailty data at baseline and follow up reduced the sample 
size to n=2483. Within this group only 169 deaths occurred resulting in 40.0% power to 
detect a hazard ratio of 1.3 and 59.0% power to detect a hazard ratio of 1.4 (α=0.05).  
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4.7.6 Results from NorStOP   
 
The results of the power calculations for the NorStOP samples are displayed in table 4.5. 
Table 4.5 Power to detect expected hazard ratios per sample size in the achieved samples from 
the NorStOP dataset; α=0.05 
Sample N Number of 
events 
(deaths) 
Power 
Hazard ratio = 1.3 Hazard ratio = 1.4 
Baseline (predictor, 
outcome and 
confounder 
information) 
14023 1990 1.000 1.000 
Complete case 10985 1484 0.999 1.000 
Complete case plus 
follow up 
4293 330 0.664 0.864 
 
It was estimated the baseline sample (n=14023) had 100% chance of detecting a hazard 
ratio of 1.3 or 1.4. In the complete case sample there was 99.9% chance of detecting a 
hazard ratio of 1.3 and 100% chance of detecting a hazard ratio of 1.4. In the complete 
case sample with follow up data there was 66.4% chance of detecting a hazard ratio of 1.3 
and 86.4% chance of detecting a hazard ratio of 1.4.     
4.7.7 Implications 
 
ELSA 
There was insufficient power to identify an association between pain and mortality in the 
sample with complete data at baseline and follow-up (n=3915) but the sample with all 
predictor, outcome and confounder information (n=8572) and the complete case sample 
at baseline (n=6324) were sufficiently powered to detect a hazard ratio of 1.3 or 1.4. The 
complete case sample (n=6324) was therefore the focus for all subsequent analyses to 
allow comparison between the survival (described in Chapter Five) and mediation 
analyses (described in Chapter Six). 
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The sample size was sufficiently powered to detect a hazard ratio of 1.3 or 1.4 for the 
allostatic load sample (n=4627) and the frailty sample (n=4375) at baseline. However, as 
above, there was insufficient power to carry out mediation analysis using change scores 
between baseline and follow up for those with complete allostatic load data (n=2392) or 
for those with complete frailty data (n=2483). 
NorStOP 
For the NorStOP sample the power analysis revealed the sample with all predictor, 
outcome and confounder information (n=14023) and the sample with all predictor, 
outcome, confounder and mediator information at baseline (complete case) (n=10985) 
were sufficiently powered to detect a hazard ratio of 1.3 or 1.4. The complete case 
(n=10985) was the focus of subsequent NorStOP analyses. There was insufficient power in 
the sample of participants who had information on mediating factors at both baseline and 
follow up (n=4293) to detect a hazard ratio of 1.3 but sufficient power to detect a hazard 
ratio of 1.4. 
4.8 Comparisons between samples 
 
4.8.1 Introduction 
 
Although missing data in the current study were assumed to be MCAR (section 4.5) and 
the complete case samples were therefore considered to be random sub-samples of the 
larger samples, data that is MCAR is difficult to definitively distinguish. For the current 
analyses it was possible to investigate the potential for selection bias further by 
comparing some key characteristics of participants with and without missing mediator 
data.    
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4.8.2 Aim 
 
To examine for selection bias by ascertaining if there were statistically significant 
differences in predictor and confounder information between those with complete data 
and those with missing mediator data for each sample.  
4.8.3 Methods 
 
The participants with complete data at baseline in each dataset (ELSA n=6324, NorStOP 
n=10985) were compared to the participants with complete predictor and confounder 
information but missing mediator data (ELSA n=2248, NorStOP n=3038) to determine if 
there were differences in predictor and confounder information between those with and 
without missing data. The baseline allostatic load sample (n=4627) and frailty sample 
(n=4375) from the ELSA dataset were also compared to those with missing allostatic load 
(n=3945) and frailty (n= 4197) data.  Chi-squared tests for binary/categorical variables and 
the Mann Whitney test for continuous variables (due to non-parametric distribution) 
were used to test for significant differences between groups (those with and without 
missing data) in terms of pain phenotype, age, sex, education and wealth (ELSA) or 
adequacy of income (NorStOP).   
4.8.4 Results from ELSA 
 
Table 4.6 displays a comparison between those participants for whom complete baseline 
data was available (n=6324) and those with missing data (n=2248). Participants with 
missing data at baseline were significantly more likely to be troubled with pain (43.51% 
compared to 35.93%, p<0.001), have greater severity of pain (moderate pain 22.91% 
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compared to 18.71%, severe pain 11.61% compared to 6.47%, p<0.001) be older (median 
age 71 years compared to 63 years, p<0.001), female (58.19% compared to 54.57%, 
p=0.003), had lower levels of education (5.92% in the highest education category 
compared to 14.42%, p<0.001) and were financially poorer (11.57% in the highest wealth 
bracket compared to 23.02%, p<0.001) than those with complete data. 
Table 4.6 Comparison of participants with complete data to those with missing mediator 
data from ELSA 
Variable Complete case at baseline 
(n=6324) 
Participants with missing 
data (n=2248) 
p 
Pain 
Not often troubled 
(reference) 
 
Often troubled 
 
Mild 
Moderate 
Severe 
 
 
4052 (64.07%) 
 
 2272 (35.93%) 
 
680 (10.75%) 
1183 (18.71%) 
409 (6.47%) 
 
 
1270 (56.49%) 
 
978 (43.51%) 
 
202 (8.99% 
515 (22.91%) 
261 (11.61% 
 
 
 
 
<0.001
1
 
 
 
 
<0.001
1
 
Age (years) 63 (57-71)* 71 (61-79)* <0.001
2
 
Female 3451 (54.57%) 1308 (58.19%) 0.003
1
 
Education 
None 
Foreign other 
NVQ1/CSE or equivalent 
NVQ2/GCE O level or 
equivalent 
NVQ3/GCE  A level or 
equivalent 
Higher education below 
degree 
NVQ 4/5/Degree or 
equivalent 
 
2004 (31.69%) 
570 (9.01%) 
289 (4.57% 
 
1226 (19.39%) 
 
480 (7.59%) 
 
837 (13.24%) 
 
918 (14.52%) 
 
1314 (58.45%) 
168 (7.47%) 
113 (5.03%) 
 
250 (11.12%) 
 
94 (4.18%) 
 
176 (7.83%) 
 
133 (5.92%) 
 
 
 
 
 
 
 
 
 
 
 
<0.001
1
 
Wealth (quintiles based 
on n= 8572 sample) 
Group 1 (lowest) 
Group 2 
Group 3 
Group 4 
Group 5 (highest) 
 
 
1011 (15.99%) 
1173 (18.55%) 
1292 (20.43%) 
1392 (22.01%) 
1456 (23.02%) 
 
 
703 (31.27%) 
535 (23.80%) 
424 (18.86%) 
326 (14.50%) 
260 (11.57%) 
 
 
 
 
 
 
<0.001
1
 
1
Chi squared test, 
2
Mann Whitney test 
Figures refer to n(%), *indicates Median (Inter Quartile Range (IQR)) 
NVQ = National Vocational Qualification 
CSE = Certificate of Secondary Education 
GCE= General Certificate of Education 
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4.8.5 Allostatic load  
 
Table 4.7 displays a comparison between those participants for whom complete allostatic 
load information was available at baseline (n=4627) compared to those with missing data 
(n=3945).  
Table 4.7 The number and proportion of participants with complete allostatic load data in 
ELSA at baseline and those with missing data 
Variable Compete allostatic load 
data at baseline (n=4627) 
 
Participants with missing 
allostatic load data 
(n=3945) 
p 
Pain 
Not often troubled 
(reference) 
  
Often troubled 
 
Mild 
Moderate 
Severe 
 
 
2968 (64.15%) 
 
1659 (35.85%) 
 
494 (10.68%) 
868 (18.76%) 
297 (6.42%) 
 
 
2354 (59.67%) 
 
1591 (40.33%) 
 
388 (9.84%) 
830 (21.04%) 
373 (9.46%) 
 
 
 
 
<0.001
1
 
 
 
 
<0.001
1
 
Age (years) 65 (58-73)* 65 (57-75)* 0.283
2
 
Female 2539 (54.87%) 2220 (56.27%) 0.194
1
 
Education 
 None 
Foreign other 
NVQ1/CSE or equivalent 
NVQ2/GCE O level or 
equivalent 
NVQ3/GCE  A level or 
equivalent 
Higher education below 
degree 
NVQ 4/5/Degree or 
equivalent 
 
1652 (35.70%) 
405 (8.75%) 
217 (4.69%) 
 
843 (18.22%) 
 
322 (6.96%) 
 
601 (12.99%) 
 
587 (12.69%) 
 
1666 (42.23%) 
333 (8.44%) 
185 (4.69%)  
 
633 (16.05%) 
 
252 (6.39%) 
 
412 (10.44%) 
 
464 (11.76%) 
 
 
 
 
 
 
 
 
 
 
 
<0.001
1
 
Wealth (quintiles based 
on n= 8572 sample)  
Group 1 (lowest) 
Group 2 
Group 3 
Group 4 
Group 5 (highest) 
 
 
737 (15.93%) 
871 (18.82%) 
973 (21.03%) 
1038 (22.43%) 
1008 (21.79%) 
 
 
977 (24.77%) 
837 (21.22%) 
743 (18.83%) 
680 (17.24%) 
708 (17.95%) 
 
 
 
 
 
 
<0.001
1
 
1
Chi squared test, 
2
Mann Whitney test 
Figures refer to n(%), *indicates Median (Inter Quartile Range (IQR)) 
NVQ = National Vocational Qualification 
CSE = Certificate of Secondary Education 
GCE= General Certificate of Education 
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There was a significant difference between those with complete allostatic load data and 
those who didn’t have complete allostatic load data for pain (often troubled and 
severity), education and wealth (all p<0.001). A lower proportion of participants with 
complete allostatic load data reported being troubled with pain compared to those with 
missing data (35.85% compared to 40.33%, p<0.001). They also reported less severe pain 
(6.42% compared to 9.46%, p<0.001), were more highly educated (12.69% in the highest 
category compared to 11.76%, p<0.001) and reported greater wealth 21.79% in the 
highest category compared to 17.95%, p<0.001) than those with missing data. There were 
no significant differences between the groups for age (p=0.283) or sex (p=0.194).  
4.8.6 Frailty 
 
Table 4.8 displays a comparison between those participants for whom frailty information 
was available at baseline (n=4375) compared to those with missing data for those 
variables (n=4197) from the original baseline sample (n=8572).   
There was a significant difference between those with complete frailty data and those 
who didn’t have complete frailty for pain (often troubled (p=0.003) and severity 
p<0.001)), age (p<0.001), education (p<0.001) and wealth (p=0.002). A smaller proportion 
of participants with complete frailty data reported being troubled with pain compared to 
those with missing data (36.41% compared to 39.48%, p=0.003). They also reported less 
severe pain (6.42% compared to 9.27%, p<0.001), were less highly educated (10.22% in 
the highest category compared to 14.39%, p<0.001) and reported greater wealth (20.27% 
in the highest category compared to 19.75%, p=0.002) than those with missing data. 
There were no significant differences between the groups according to sex (p=0.209) but 
those with complete frailty data were significantly older than those with missing frailty 
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data (median=69 years compared to 58 years, p<0.001). (Note: This was a result of the 
inclusion of a walking test as part of the frailty index (see section 6.3.3) that was only 
carried out on participants over 60 years).  
Table 4.8 The number and proportion of participants with complete frailty data in ELSA at 
baseline to those with missing data 
Variable Complete Frailty data at 
baseline (n=4375) 
Participants with missing 
frailty data (n=4197) 
p 
Pain 
Not often troubled 
(reference) 
 
Often troubled 
 
Mild 
Moderate 
Severe 
 
 
2782 (63.59%) 
 
1593 (36.41%) 
 
436 (9.97%) 
876 (20.02%) 
281 (6.42%) 
 
 
2540 (60.52%) 
 
1657 (39.48%) 
 
446 (10.63%) 
822 (19.59%) 
389 (9.27%) 
 
 
 
 
0.003
1
 
 
 
 
<0.001
1
 
Age 69 (64-76)* 58 (55-66)* <0.001
2
 
Female 2400 (54.86%) 359 (56.21%) 0.209
1
 
Education 
None 
Foreign other 
NVQ1/CSE or equivalent 
NVQ2/GCE O level or 
equivalent 
NVQ3/GCE  A level or 
equivalent 
Higher education below 
degree 
NVQ 4/5/Degree or 
equivalent 
 
1867 (42.67%) 
414 (9.46%) 
224 (5.12%) 
 
685 (15.66%) 
 
233 (5.33%) 
 
505 (11.54%) 
 
447 (10.22%) 
 
1451 (34.57%) 
324 (7.72%) 
178 (4.24%) 
 
791 (18.85%) 
 
341 (8.12%) 
 
508 (12.10%) 
 
604 (14.39%) 
 
 
 
 
 
 
 
 
 
 
 
<0.001
1
 
Wealth (quintiles based 
on n= 8572 sample) 
Group 1 (lowest) 
Group 2 
Group 3 
Group 4 
Group 5 (highest) 
 
 
810 (18.51%) 
854 (19.52%) 
900 (20.57%) 
924 (21.12%) 
887 (20.27%) 
 
 
904 (21.54%) 
854 (20.35%) 
816 (19.44%) 
794 (18.92%) 
829 (19.75%) 
 
 
 
 
 
 
0.002
1
 
1
Chi squared test, 
2
Mann Whitney test 
Figures refer to n(%), *indicates Median (Inter Quartile Range (IQR)) 
NVQ = National Vocational Qualification 
CSE = Certificate of Secondary Education 
GCE= General Certificate of Education 
 
4.8.7 Results from NorStOP 
 
Table 4.9 displays a comparison between those participants for whom baseline mediator 
information was available (n=10985) compared to those with missing mediator data 
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(n=3038) according to pain and demographic information. The method of measurement 
of these variables measured is described in Chapter Five.   
Table 4.9 Comparison of participants with complete data to those with missing mediator 
data in NorStOP 
Variable Complete case at 
baseline (n=10985) 
Participants with 
missing data (n=3038) 
p 
Pain 
No (reference) 
Any pain 
 
Pain but not ACR WP 
ACR WP 
 
Pain but not Manchester WP 
Manchester WP 
 
Number of pain sites 
0 
1-3 
4-6 
7-11 
12+ 
 
Pain interference 
None 
A little 
Moderately 
Quite a bit 
Extremely 
 
3166 (28.82% 
7819 (71.18%) 
 
5070 (46.15%) 
2749 (25.03%) 
 
6094 (55.48%) 
1725 (15.70%) 
 
 
3197 (29.10%) 
1953 (17.78%) 
1942 (17.68%) 
1833 (16.69%) 
2060 (18.75%) 
 
 
3688 (33.57%) 
2899 (26.39%) 
1728 (15.73%) 
2058 (18.73%) 
612 (5.57%) 
 
850 (27.98%) 
2188 (72.02%) 
 
1413 (46.51%) 
775 (25.51%) 
 
1718 (56.55%) 
470 (15.47%) 
 
 
865 (28.47%) 
609 (20.05%) 
517 (17.02%) 
497 (16.36%) 
550 (18.10%) 
 
 
960 (31.60%) 
723 (23.80%) 
518 (17.05%) 
661 (21.76%) 
176 (5.79%) 
 
 
0.363
1
 
 
 
0.645
1
 
 
 
0.558
1
 
 
 
 
 
 
 
0.081
1
 
 
 
 
 
 
 
<0.001
1
 
Age 63 (56-71)* 66 (58-74)* <0.001
2
 
Female 5967 (54.32%) 1823 (60.01%) <0.001
1
 
Further education 1417 (12.90%) 338 (11.13%) 0.009
1
 
Adequacy of income 
Find it a strain 
Have to be careful 
Able to manage 
Comfortable 
 
402 (3.66%) 
4271 (38.88%) 
4549 (41.41%) 
1763 (16.05%) 
 
129 (4.25%) 
1307 (43.02%) 
1181 (38.87%) 
421 (13.86%) 
 
 
 
 
<0.001
1
 
1
Chi squared test, 
2
Mann Whitney test 
Figures refer to n(%), *indicates Median (Inter Quartile Range (IQR)) 
 
Participants with complete data at baseline were significantly more likely to be younger 
(median 63 years in the complete case sample compared to 66 years in those with 
missing data, p<0.001), less likely to be female (54.32% in the complete case sample 
compared to 60.01% in those with missing data, p<0.001), be better educated (12.90% in 
the highest category compared to 11.13%, p=0.009) and have greater adequacy of 
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income than those with missing data (16.05% in the ‘comfortable’ bracket compared to 
13.86%, p<0.001). They were also significant differences in report of pain interference 
(p<0.001). 
4.8.8 Implications 
 
ELSA 
Differences between participants with complete data and those with missing data in the 
ELSA samples reduce the representativeness of the samples to the target population (i.e. 
the general population of adults aged 50 years and over). Those with missing mediator 
data were more likely to be troubled with and experience more severe pain. They were 
more likely to be older, female, less well educated and financially poorer all of which are 
associated with the report of pain (Breivik et al., 2006; Fillingim et al., 2009; Henschke et 
al., 2015;  Jordan et al., 2008; Macfarlane et al., 2009; Thomas et al., 2007) This 
underrepresentation of participants who report pain in the complete case sample may 
mean that if there is a relationship between pain and mortality, the observed relationship 
in the complete case sample may be an underestimate. For the allostatic load sample 
there were no differences in age and sex but those with missing data were more likely to 
be often troubled with pain, experience more severe pain and have lower levels of 
education and be financially poorer. For the frailty sample participants with missing data 
were more likely to report troubling pain, be female and financially poorer but were 
younger and had higher levels of education. The difference in the median age between 
those with and without missing data is a result of the walking test only being carried out 
on participants aged over 60 years. This means the risk of mortality in the frailty sample 
may be higher than would be expected if the sample contained participants aged 
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between 50 and 60 years. However, it is likely only healthier older adults were able to 
perform the walking test which would result in an underestimate of the mortality risk. 
The frailty sample is therefore not a representative sub-sample of the population from 
which it was derived.  
NorStOP 
In the NorStOP sample those with missing data were older, more likely to be female, have 
lower levels of education and be financially poorer, however there were no differences 
between groups for any of the pain phenotypes with the exception of pain interference. 
The potential influence of these differences between participants with and without 
missing mediator data on the observed relationships between pain phenotypes and 
mortality is unclear but the presence of selection bias indicates the sample may not be 
representative of the population from which it was derived.  
4.9 Comparison of the ELSA and NorStOP baseline complete case samples with 
national statistics 
4.9.1 Introduction 
Both the ELSA and NorStOP samples are from the UK population. The ELSA study purports 
to be representative of the English population and the NorStOP sample representative of 
North Staffordshire. To ascertain external validity an investigation of whether the derived 
samples used for this study were representative of the wider national population in terms 
of age and sex was performed. Comparisons between the complete case samples from 
each dataset (ELSA n=6324, NorStOP n= 10985) and the population of England and Wales 
from the 2001 census (Office for National Statistics, 2001) were undertaken.    
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4.9.2 Aim 
 
To determine if the baseline complete case samples (the main focus for subsequent 
analyses) were representative of the national (England and Wales) population in terms of 
age and sex. 
4.9.3 Methods 
 
Chi-squared tests were used to test for significant differences in age and sex distribution 
(overall and according to age band (50-59, 60-69, 70-79 and 80+years)) of participants in 
the ELSA and NorStOP complete case samples compared to the national population 
(England and Wales). Looking across age categories allows for a more detailed 
investigation of the representativeness of the sample as it would highlight potentially 
important differences in age and sex structure that would be undetectable if considering 
the sample as a whole. National figures were obtained from the Office of National 
Statistics 2001 census (Office for National Statistics, 2001).  
4.9.4 ELSA 
 
There was a significant difference in the age structure of the ELSA complete case sample 
and the national population of England and Wales (Chi2 =278.8; p<0.001) (Table 4.10). The 
proportion of the ELSA sample aged between 50 and 69 years was lower than in the 
national population but in total a higher proportion of the ELSA complete case sample 
were in the two younger age groups compared to the national population (70.3% below 
age 69 cf 65.6%) and a lower proportion of adults were in the oldest age group (8.2% cf 
12.5%).  
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Table 4.10 Comparison of the ELSA complete case sample (n=6324) with National 
statistics according to age group 
Age group 
(years) 
ELSA complete case 
sample n (%) 
National statistics (ONS 2001 
census) n (Thousands) (%) 
p 
50-59 2272 (35.9%) 7412.9 (37.7%)  
 
 
<0.001 
60-69 2175 (34.4%) 5488.1 (27.9%) 
70-79 1361 (21.5%) 4310.3 (21.9%) 
80+ 516 (8.2%) 2458.6 (12.5%) 
Total 6324 (100.0%) 19669.9 (100.0%) 
 
Overall, the proportion of men and women in the ELSA complete case sample was similar 
to the national population (proportion of females: 54.6% cf 54.2%, p=0.304) (Table 4.11). 
However, within age-strata there were significant differences in the proportion of males 
and females in the oldest and youngest age groups between the ELSA sample and the 
national population; there was a greater proportion of females in the youngest age group 
in the ELSA sample compared to the national population (55.6% cf 50.5%; p<0.001)) and a 
lower proportion of females in the oldest age group (60.5% cf 67.4%; p=0.002). 
Table 4.11 Comparison of the ELSA complete case sample  (n=6324) with National 
statistics according to sex distribution per age group 
Age 
group 
(years) 
ELSA complete case sample National statistics (ONS 2001 
census) (Thousands) 
p 
Male n (%) Female n (%) Male n (%) Female n (%) 
50-59 1010 (44.5%) 1262 (55.5%) 3671.1 (49.5%) 3741.8 (50.5%) <0.001 
60-69 1018 (46.8%) 1157 (53.2%) 2657.4 (48.4%) 2830.7 (51.6%) 0.106 
70-79 641 (47.1%) 720 (52.9%) 1881 (43.6%) 2429.3 (56.4%) 0.014 
80+ 204 (39.5%) 312 (60.5%) 801.8 (32.6%) 1656.8 (67.4%) 0.002 
Total 2873 (45.4%) 3451 (54.6%) 9011.3 (45.8%) 10,658.6 (54.2%) 0.304 
 
4.9.5 NorStOP 
 
The age structure of NorStOP complete case was significantly different from the overall 
the national population (Chi2=278.8, p<0.001) (Table 4.12).  There were higher 
proportions of participants aged between 50 and 69 years (71.8% cf 65.6%) and a lower 
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proportion in the 80 years and over group (6.9% cf 12.5%) in the NorStOP sample 
compared to the national population. 
Table 4.12 Comparison of the NorStOP complete case sample (n=10985) with 
National statistics according to age group 
Age group 
(years) 
NorStOP complete case 
sample n (%) 
National statistics (ONS 2001 
census) n (Thousands) (%) 
p 
50-59 4241 (38.6%) 7412.9 (37.7%)  
 
 
<0.001 
60-69 3648 (33.2%) 5488.1 (27.9%) 
70-79 2336 (21.3%) 4310.3 (21.9%) 
80+ 760 (6.9%) 2458.6 (12.5%) 
Total 10985 (100%) 19669.9 (100%) 
 
Overall the proportion of males and females in the NorStOP sample was similar to the 
national population (proportion of females: 54.3% cf 54.2%) but there was a significant 
difference in the proportion of males and females in the youngest age group (proportion 
of females: 53.2% cf 50.5%; p=0.003) (Table 4.13).  
Table 4.13 Comparison of the NorStOP complete case sample (n=10985) with National 
statistics according to sex distribution per age group 
Age 
group 
(years) 
NorStOP complete case sample National statistics (ONS 2001 census) 
(Thousands) 
p 
Male n (%) Female n (%) Male n (%) Female n (%) 
50-59 1985 (46.8%) 2256 (53.2%) 3671.1 (49.5%) 3741.8 (50.5%) 0.003 
60-69 1740 (47.7%) 1908 (52.3%) 2657.4 (48.4%) 2830.7 (51.6%) 0.258 
70-79 1034 (44.3%) 1302 (55.7%) 1881 (43.6%) 2429.3 (56.4%) 0.322 
80+ 259 (34.1%) 501 (65.9%) 801.8 (32.6%) 1656.8 (67.4%) 0.240 
Total 5018 (45.7%) 5967 (54.3%) 9011.3 (45.8%) 10,658.6 (54.2%) 0.418 
  
4.9.6 Implications 
 
The NorStOP complete case sample was representative of the national population in 
terms of sex distribution in all age groups apart from in those in the youngest age group. 
The sex distribution in the youngest and two oldest age groups for the ELSA sample were 
significantly different from the national population. The higher proportion of females in 
the younger age group but lower proportion of females in the oldest age groups meant 
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that overall the sex distribution was not statistically different from the national 
population, however, the age group structure in both samples was not representative of 
the national population.  
4.10 Discussion 
 
4.10.1 Summary of findings 
 
This chapter introduced the datasets used in this thesis, the response rates to those 
studies and the samples derived from them for use in this thesis. The mechanisms of 
missing data were explored and power calculations were undertaken to determine if the 
samples analysed were of sufficient size to detect the expected size of association 
between pain and mortality and to ascertain potential sources of bias. The datasets were 
selected as they provided sufficient information to examine the effect of different 
phenotypes of pain on the relationship between pain and mortality and the role of 
potential mediating factors. An examination of the mechanism of missingness for data 
missing from the complete case samples indicated the complete case sub-samples could 
be considered as random samples of the larger samples, however a comparison between 
those with and without mediator data indicated the presence of selection bias. Power 
analysis confirmed there was sufficient power to detect the expected effect sizes in the 
complete case samples (ELSA n=6324, allostatic load n=4627, frailty n= 4375, NorStOP n= 
10985) but not in follow-up samples for the ELSA complete case analysis (n=3915) or for 
the allostatic load (n=2392) and frailty samples (n=2483). Only the NorStOP follow-up 
sample (n=4293) had sufficient power to detect a hazard ratio of 1.4. 
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Adults over 80 years were underrepresented in both datasets compared to the 
population of England and Wales, particularly females in the ELSA sample.    
4.10.2 Implications 
 
The English Longitudinal Study of Ageing (ELSA) was chosen as it was intended to be a 
nationally representative dataset and contains data on pain, vital status and a number of 
potential mediators (of the relationship between pain and mortality) (Steptoe et al., 
2012). A criticism of ELSA is that the HSE was used as a sampling frame and this limits 
participants to those living in private households and excludes those living in residential 
and nursing homes; which is a common problem with national surveys (Scholes et al., 
2008). It is estimated 3.2% of adults in England and Wales aged over 65 years were living 
in care homes in 2011 (Office for National Statistics, 2014). Care home residents are likely 
to be older, less healthy and have a higher risk of mortality (Kelfve, Thorslund, & 
Lennartsson, 2013; Shah, Carey, Harris, Dewilde, & Cook, 2013) therefore any estimate of 
mortality in community samples is likely to be conservative compared to a population 
including care home residents.  
The North Staffordshire Osteoarthritis project (NorStOP) was chosen as an additional 
dataset as it included detailed pain data to identify individuals with different pain 
phenotypes and additional potential mediating factors. Both ELSA and NorStOP are 
longitudinal studies and are therefore susceptible to attrition. With decreasing sample 
size at later waves of surveys the precision of the estimates derived from that sample 
reduce. If non-response is not random the sample may be unrepresentative of the target 
population, particularly if the reasons for non-response are related to the outcomes of 
interest (Uhrig, 2008). In the current study the mechanism of missing data and the 
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potential for selection bias were investigated and reported to ensure this could be 
considered in the interpretation of the results.  Analyses were also only undertaken 
where it was confirmed there was sufficient power to detect an existing effect reducing 
the possibility that any findings were a result of chance (Jones et al., 2003).  
There were some differences in the age and sex structure of the complete case samples 
compared to the population of England and Wales but the implications of these 
differences are difficult to determine. Adjusting for age and sex as potential confounders 
would minimise the effect of these factors but the presence of other differences between 
participants with and without missing data may result in the introduction of additional 
selection bias. It is difficult to definitively determine the effect of missing data on this 
study as the factors which have missing data are related to both pain and mortality. An 
advantage of this study is that it investigates the specific role of a number of different 
factors on the relationship between pain and mortality. Analysis of this kind has not 
previously been undertaken. The potential mediating factors are assessed individually to 
determine their effect on the relationship. The use of two different datasets in which 
some measures are comparable helps to provide a more accurate representation of the 
influence of those factors.   
The sample size was reduced considerably when biomarker information and objective 
physical characteristics measured at the nurse visit were required to form a composite 
measure for frailty (n=4375) and allostatic load (n=4637). However, the prevalence of 
frailty in the ELSA frailty sample (7.54%) was similar to that reported in other studies that 
have applied the same definition (6.9% (Fried et al., 2001), 6.0% (Gruenewald et al., 
2009)). The composite measure of allostatic load is more difficult to compare across 
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populations as different measures are used to form the index depending on what 
biomarker information is available and different criteria for scoring the indices are also 
used. The allostatic load and frailty samples must be considered separately and are not 
representative of the sample from which they were drawn. The way these composite 
measures were derived along with a discussion of the strengths and limitations of these 
measures are presented in Chapter Six.  
4.11 Key messages 
 
 This study used two large population based datasets which allowed for the 
examination of the effect of pain phenotype on the relationship between pain and 
mortality (Chapter Five) and enabled the investigation of a number of different 
potentially mediating factors (Chapter Six)  
 The mechanism of missing data suggested the complete case samples were 
random sub-samples of the larger samples but further analysis indicated the 
presence of selection bias.  
 The complete case samples at baseline were of sufficient size to detect the 
expected effect size in survival analyses. 
 The amount of attrition in both the ELSA and NorStOP datasets meant it was not 
possible to conduct analysis examining the effect of change over time of the 
mediating factors. 
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Chapter Five. The influence of pain phenotype on mortality 
5.1 Introduction 
The relationship between pain and mortality is unclear. One of the key findings of the 
systematic review described in Chapter Two was that between-study inconsistency in 
findings may arise from the application of different pain phenotypes across studies. The 
primary aim of this chapter was to investigate the effect of pain phenotype on the 
relationship between pain and mortality.   
Survival analysis was used to test the relationship between pain phenotype and mortality 
in the ELSA and NorStOP complete case samples (see Chapter Four for details of these 
datasets). This chapter presents the definitions of exposures, outcomes and putative 
confounding variables, the results of the survival analyses, and a critical discussion of the 
findings. 
5.2 Aims 
 
The overall aim of this chapter was to test if the association between pain and mortality 
was dependent on how pain is defined.  
The specific objectives were to test the hypotheses that: 
1. Pain is associated with an increased risk of mortality. 
2. The relationship would be independent of age, sex and socioeconomic status. 
3. The relationship would be dependent on the pain classification used. 
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5.3 Methods 
 
The main outcome under investigation in this thesis was mortality. Rather than simply 
assessing whether or not participants died, the time to death can be used to define the 
mortality risk in terms of the probability of mortality over the period of follow-up. 
However, not all participants may die in a study, participants may enter the study at 
different time points and the time to death is unlikely to follow a normal distribution. 
Survival analysis was developed to deal with these features of data (Clark, Bradburn, 
Love, & Altman, 2003a) and is described below. 
5.3.1 Survival analysis 
 
Survival time and censoring 
Survival analysis involves the modelling of survival time, which is the time from a fixed 
point until a specific event (e.g. death) (Bradburn, Clark, Love, & Altman, 2003; Cox & 
Oakes, 1984). Participants may enter a study at different times. A participant’s survival 
time is measured from their individual time of entry into the study (as opposed to the 
date of commencement of the study) until they experience the event in question (Figure 
5.1), in this case mortality (Cox & Oakes, 1984).  
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For some participants the survival time is not known; some will survive beyond the end of 
the follow-up period, some will be lost to follow-up, and for some the experience of a 
different event makes it impossible for them to be followed-up. This “censoring” of 
participants should be uninformative, that is those who are censored should have the 
same survival prospects as those who continue to be followed (Clark et al., 2003a). For 
example, if those that are censored are unhealthier than those who continue to be 
observed (i.e. they drop out because they are too sick to continue in the study) the 
remaining study population would consist of healthier individuals with an increasingly 
lower risk of mortality and survival would be overestimated (Szklo & Nieto, 2014). The 
form of censoring where the period of observation ends or the participant ‘drops out’ 
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Figure 5.1 Representation of 7 participants with staggered entry and follow up 
over 10 years in survival analysis (adapted from Cox and Oakes, 1984) 
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before the event occurs is known as right censoring (Fox, 2002). Other forms of censoring 
can also occur. Left censoring occurs when the total time at risk is unknown (Fox, 2002); 
an outcome is observed but it is not possible to determine when it began. One example of 
left censoring is identifying the reoccurrence of a tumour. If patients have a tumour 
removed which then regrows soon after but the patient is not examined until three 
months after the date of removal, the exact time of reoccurrence of the tumour (should it 
occur within that time period) would be unknown. It would only be possible to say the 
time to reoccurrence was less than three months (Clark et al., 2003a). Interval censoring 
occurs when both right and left censoring occur simultaneously, that is, participants come 
in and out of observation (Fox, 2002). In this study, only participants whose vital status 
was known by the end of the study time were included so all censored participants were 
those who survived until the end of the follow-up period.  
 
Analysing differences in survival 
Survival data are often described and analysed in terms of survival or hazard probabilities. 
The survival probability is the probability that an individual survives from the time of 
origin (i.e.when they enter a study) to a specified future time (e.g the end of the study 
period) (Clark et al., 2003a). Survival probability can be estimated from the survival times 
of censored and uncensored participants using the Kaplan Meier (or product limit) 
method (Kaplan & Meier, 1958). As events (in this case deaths) are assumed to occur 
independently of each other the probability of surviving from the time of one event to the 
time of the next event can be multiplied together to give the cumulative survival 
probability (denoted as S(t)). This can be assessed graphically using a Kaplan Meier curve 
which shows the survival probability against time (Figure 5.2). The survival curve is drawn 
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as a step function; that is, the estimated probability changes only at the time of each 
event and is constant between times of events (Clark et al., 2003a). 
 
Figure 5.2 Example of a Kaplan Meier survival curve 
* Survival probability is calculated for each time point. Censored observations are counted among those 
who survived until the end of that particular time point but are not included from the number of 
participants at risk in the next time period. 
 
This method can be used to describe survival according to a factor under investigation 
and differences in survival curves between groups can be compared using the logrank 
test. This test compares the number of expected events at each time point in each group 
if there were no difference between the groups. The total value of expected events is 
then compared to the number of observed events by calculating a test statistic which is 
compared to a chi-squared distribution to obtain a p-value to indicate the statistical 
significance of the difference between survival curves (Clark et al., 2003a). This method 
does not provide a measure of effect size and does not easily accommodate the impact of 
other factors such as potential confounders (Bradburn et al., 2003).  More complicated 
multivariate analysis is required to adjust for the impact of other factors (Bradburn et al., 
2003; Nieto & Coresh, 1996), the most common of which is the Cox proportional hazard 
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model (Cox, 1972) which involves use of the hazard function (denoted as h(t)) (Fox, 2002). 
The hazard function is defined as the instantaneous risk of death (or event in question) at 
time t, assuming survival to that time (Fox, 2002).  There is a clearly defined relationship 
between the cumulative survival probability (denoted as S(t)) and the hazard function 
given by the formula: 
ℎ(𝑡) = −
𝑑
𝑑𝑡
[log  𝑆(𝑡)]. 
Where   ℎ(𝑡) = hazard function, 𝑆(𝑡)  = cumulative survival probability, 
𝑑
𝑑𝑡
 =differentiation (change in the 
slope over time)  
 
The Cox proportional hazard model (Cox, 1972) is a regression model which describes the 
relationship between an event and a set of covariates expressed by the hazard function 
(Bradburn et al., 2003). Within the Cox’s model, the hazard function is estimated 
nonparametrically so survival times are not assumed to follow a particular distribution. 
The formula for the Cox model is: 
ℎ(𝑡) = ℎ𝑜(𝑡) exp{𝑏1 𝑥1 +  𝑏2𝑥2 + ⋯ + 𝑏𝑝𝑥𝑝} 
Where ℎ(𝑡) = the hazard function, (𝑥1, 𝑥2 … 𝑥𝑝) = set of covariates  (𝑏1, 𝑏2, … 𝑏𝑝) = size of coefficients 
ℎ𝑜(𝑡) = the baseline hazard  
 
The baseline hazard is common to all individuals but is adjusted by the second function; 
the exponential of the coefficients of the covariates in the model. The hazard function or 
hazard rate, gives the risk of failure (event) per unit of time (Lee & Wang, 2003) and can 
be compared across groups of a variable of interest to give a hazard ratio. For example, if 
comparing group A to group B: 
Hazard ratio = 
ℎ𝐴(𝑡)
ℎ𝐵(𝑡)
  
Where ℎ𝐴(𝑡) = the hazard function in group A and ℎ𝐵(𝑡) is the hazard function in group B 
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Where the event in question is mortality, the hazard ratio is referred to as the Mortality 
Rate Ratio (MRR).   A hazard ratio (or MRR) of 1 indicates no difference in the risk of the 
event in question (or survival) in the comparison group compared to the reference group. 
Hazard ratios above 1 indicate an increased risk and below 1 indicate a reduced risk at 
any one point in time (Kay, 2004).  
Examining for proportionality 
A key assumption of Cox’s proportional hazard modelling is that of proportional hazards 
over time. That is, the hazard in any one group is a constant multiple of the hazard in 
another so the hazard curves for each group do not cross (Bradburn et al., 2003). If the 
hazards are not proportional it is inappropriate to use a single hazard ratio to represent 
the whole follow- up period. It is important to verify this assumption to ensure a 
proportional hazards model is appropriate. In the analysis used for this study this 
assumption is tested using the Schoenfeld test which tests for a non-zero slope in a 
generalised linear regression of scaled Schoenfeld residuals against time (Schoenfeld, 
1982). Residuals are the difference between the value predicted by a model and the value 
observed in the data on which the model is based (Field, 2009). However, the presence of 
censoring means the usual concept of residuals is not applicable in the proportional 
hazards model (Lee & Wang, 2003). The Shoenfeld residual is the difference between the 
observed and expected values conditional on the risk faced by individuals at each time 
point. Schoenfeld residuals are defined only at uncensored survival times and are set as 
missing for censored observations (Lee & Wang, 2003). Large residuals indicate the event 
at time t is unlikely in the model based on the covariates of the individual who died 
compared to the individuals at risk. Schoenfeld residuals can be plotted against time to 
test the proportional hazards assumption visually (Schoenfeld, 1982). Deviation from a 
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straight line indicates a problem with the proportionality assumption as it implies an 
association between the residuals and time indicating different hazards at different time 
points (Grambsch & Therneau, 1994). As graphical methods of assessing these 
assumptions are subjective it is useful to combine them with a statistical test. The null 
hypothesis for the Schoenfeld test is that that the slope is non-zero, thus rejection of the 
null hypothesis indicates the proportional hazards assumption does not hold. The test for 
a  non-zero slope implemented in Stata is based on the work of Grambsch and Therneau, 
(1994) (Grambsch & Therneau, 1994). Tests are performed for each predictor as well as a 
global test. In a simulation test which examined increasing or decreasing relative hazards, 
crossing hazards, diverging hazards and non-monotonic hazards, the Schoenfeld test was 
shown to be one of the most powerful to detect departures from proportionality along 
with the time dependent covariate test and linear correlation test (compared to score 
process or omnibus tests) (Ng’andu, 1997). Methods to overcome the problems of non-
proportionality include including an interaction term with time or splitting the analysis 
time into blocks and assessing proportionality within each of those time blocks (BaŞar, 
2007).  
5.3.2 Applying survival analysis to ELSA and NorStOP data 
  
In analysis of both the ELSA and NorStOP datasets, Cox’s proportional hazard modelling 
was undertaken to assess the risk of death according to pain phenotype (Table 5.1). In 
order to calculate hazard ratios it was necessary to determine the length of time until the 
event (in this case death) or censoring takes place. In ELSA, information about vital status 
was available until the end of February 2012. Only year of death was available for 
participants in ELSA, therefore the time in the study was calculated in months from the 
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date of interview until the 31st December in the year the participant was known to have 
died (or 28th February if they died in 2012). (A request was made to obtain month of 
death data but this involved an up-front fee of £1000 and permission to use the more 
detailed mortality data could not be guaranteed so the decision was made to use the 
available year of death data). The censor date for those who survived was the 28th 
February 2012. Only participants whose vital status was known were included in the 
study. In the NorStOP analyses it was possible to calculate the number of days 
participants remained in the study from the date of questionnaire completion to the date 
of death or censoring. Information about vital status was available until 1st October 2012.  
The pain phenotypes investigated are presented in section 5.5.2. The method of data 
collection for exposures and outcomes is described below. 
5.4 Exposures and outcomes 
 
This section describes how information regarding the exposure (pain) and outcome (vital 
status) were obtained in each dataset. It also describes the data collection methods for 
the demographic details (age, sex, education and wealth/adequacy of income) which 
were treated as potential confounders in the survival analysis models.  
5.4.1 The English Longitudinal Study of Ageing (ELSA) 
 
Vital status (outcome) 
Vital status and cause of death for the ELSA sample was obtained from the Office of 
National Statistics (ONS). Participants were identified using the National Health Service 
Central Register (NHSCR), run by the ONS, which keeps track of registrations with general 
practitioners, with official death registrations and with people who leave the national 
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health system. The registration of deaths in England and Wales is carried out by the Local 
Registration Service in partnership with the General Register Office (GRO). Information is 
usually supplied by an informant, who is often a close relative, and cause of death is 
obtained from the Medical Certificate of Cause of Death (MCCD) which is completed by a 
medical practitioner when the death is certified. The ONS record the underlying cause of 
death identified by a four digit code from the Tenth Revision of the International 
Classification of Diseases and Related health problems (ICD-10). Automatic validation 
checks on variables such as date of death, sex, year of birth and marital status which 
highlight inconsistencies are undertaken once the deaths are recorded in the ONS 
database. The underlying cause of death is coded automatically for the majority of deaths 
(approximately 80%) with the remainder being coded manually by experienced coders 
(Mortality Statistics in England and Wales, 2013). 95% of participants gave consent for 
their records to be accessed so most of the deaths recorded in ELSA were confirmed by 
the NHSCR. For the remaining participants deaths were reported by relatives of the 
deceased or by interviewers who learned of deaths when trying to make contact with the 
household (Banks, Breeze, Lessof, & Nazroo, 2006). In ELSA cause of death was grouped 
according to 1) the three most common causes of death: cancer, cardiovascular diseases, 
respiratory diseases, 2) known causes other than the most common (“other”) or 3) 
unknown cause of death (“unknown”).   
Pain (predictor) 
Participants were asked whether they were often troubled with pain and responded “yes” 
or “no”. Those who responded “yes” were then asked how bad their pain was most of the 
time with the response options of ‘mild’, ‘moderate’ or ‘severe’. Previous studies have 
recorded the presence and location of pain (Andersson, 2009;  Macfarlane et al., 2007; 
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Macfarlane et al., 2001; McBeth et al., 2009) and some have also included a measure of 
chronicity (Sjøgren & Grønbæk, 2010; Smith et al., 2003; Torrance et al., 2010). It was not 
possible to determine the extent or duration of pain in this dataset.  
Confounders 
Demographic variables were included in the current analysis as confounders. They were 
age, sex and socio-economic status indicated by educational attainment and current 
wealth.  These are all factors which are associated with both pain and mortality 
(described in Section 1.5). 
Age and sex 
For age and sex, participants were asked to confirm their sex and date of birth. If they did 
not know their date of birth they were asked what their age was on their last birthday. 
Age was categorised into year bands 50-59, 60-69, 70-79 and 80+; a standard method of 
categorising age that has been used in other studies (Dreyer et al., 2010; Kamiya, Whelan, 
Timonen, & Kenny, 2010; Thomas et al., 2007). 
Education and wealth 
Socioeconomic position is a complex construct (Galobardes et al., 2006). Education is 
often used as a measure of socioeconomic status as it can help determine a person’s 
occupation and income in adulthood. It reflects access to and performance in 
school/college/university in childhood and young adulthood hence it captures early life 
circumstances and the influence of adult resources (Galobardes et al., 2006). A measure 
of education can also reflect a number of non-socioeconomic factors pertinent to health 
research such as health-related knowledge and health literacy (Braveman et al., 2005). 
However, education should not be used as a sole measure of socioeconomic position as 
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income levels can vary greatly at similar educational levels especially across different 
social groups (e.g. sex, age, ethnic) reflecting different levels of access to material 
resources (Braveman et al., 2005). In older adults, wealth is considered to be a good 
indicator of socioeconomic status. It reflects an accumulation of economic resources and 
an ability to withstand periods of low income which may result from unemployment or 
illness (Braveman et al., 2005). In the current analysis, measures of education and wealth 
were both included as measures of socioeconomic status.  
For educational attainment in ELSA, participants were asked to look at a card listing 
educational qualifications and indicate which, if any, they held. The highest educational 
level attained was categorised according to the following categories; National Vocational 
Qualification (NVQ)4/5 or degree or equivalent, higher education below degree, NVQ3/A 
level equivalent, NVQ2/O level equivalent, NVQ1/Certificate of Secondary education (CSE) 
or equivalent or foreign/other or no qualification. For wealth, net total non-pension 
wealth, was categorised by using quintiles to provide five groups labelled from low to 
high. Five categories were considered adequate to capture information contained in a 
continuous variable and minimise bias due to a loss of information that may arise due to 
the sub-categorisation (Cochran, 1968). The quintiles were empirically defined based on 
the distribution. The wealth variable was measured at business unit level which 
represents an individual or couple along with any dependent children (as opposed to 
individual wealth alone). It is calculated from answers to questions regarding house or 
property wealth, businesses and any form of savings or investment minus any debt 
(Steptoe et al., 2012). This measure of wealth has been found to be the strongest 
160 
 
socioeconomic predictor of health in the ELSA sample (Demakakos, Nazroo, Breeze, & 
Marmot, 2008).  
5.4.2 The North Staffordshire Osteoarthritis Project (NorStOP) 
 
Vital status (outcome) 
Information regarding participants’ vital status was collated from two sources. Firstly, 
data was obtained from the Exeter patient registration system held at the local Primary 
Care Trust in October 2012. The Exeter system is a database of all patients registered with 
a GP in England and Wales. It is used to trace people as they move and register with a 
new GP and to calculate payments to GP practices. Patients are removed from the 
register if they emigrate or die. In recording deaths, the date of death is the only 
information required (http://staffs-sbs.nhs.uk/registration/faqs/#faq58). Secondly, these 
dates were supplemented with the dates of death notified to the NorStOP project team 
during the six year follow up period. Manual tracing of the NHS Summary Care Record 
Demographic system was used to confirm the dates notified to the project team. 
Participants whose vital status could not be confirmed in 2012 were excluded from the 
dataset ensuring that the vital status of all participants was known. Days in the study 
were calculated from the date of response to the questionnaire until the date of death or 
until census date (1st October 2012). 
Pain (predictor) 
A filter question was used which asked participants “In the past 4 weeks have you had 
pain that has lasted for one day or longer in any part of your body (not including pain 
from illnesses such as flu)?” Response options were “yes/no". Responders were 
categorised into those with bodily pain and those without. Responders who indicated 
161 
 
that they had body pain were asked to shade their painful areas on a full body manikin 
(front and back views) (see Figure 5.3). 
 
 
Figure 5.3 NorStOP Manikin 
Five phenotypes of pain were derived from the NorStOP dataset: 
Any pain 
Based on the filter question participants who responded “yes” were categorised as having 
“any pain”. This question was used to determine the presence of pain, irrespective of 
whether participants had indicated the site of their pain on the blank body manikin. 
Those participants who indicated ‘yes’ to the filter question but indicated no sites on the 
manikin were classified as having pain. If participants indicated ‘no’ to the filter question 
but did shade parts of the manikin they were classified as having no pain. 
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Widespread pain 
1. American College of Rheumatology (ACR) criteria  
The location of pain indicated on the manikin was used to classify whether or not 
participants met the ACR criteria (pain in the axial skeleton, on the right and left sides of 
the body and above and below the waist) for widespread pain (Wolfe et al., 1990). The 
ACR criteria are a widely used method of capturing widespread pain and have been used 
in other studies investigating pain and mortality (Macfarlane et al., 2001; McBeth et al., 
2009).  
2. Manchester criteria 
Manikin data was also used to determine if participants met the Manchester criteria for 
widespread pain (pain in both the axial skeleton and at least two sections of two 
contralateral limbs) (described in Section 1.4) (Hunt et al., 1999).  
Number of pain sites 
A template dividing the body into 44 sites (Figure 5.4) was used to provide a count of the 
number of shaded areas on the body manikin from which a number of pain sites variable 
was constructed. This was divided into five categories; no sites of pain, 1-3 sites, 4-6 sites, 
7-11 sites and 12+ sites of pain. These categories have been used previously in NorStOP 
as they contained approximately equal numbers of people in each category (Thomas, 
Peat, et al., 2004). (Detail regarding single and multi-site pain is presented in Section 
1.4.2).  
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Figure 5.4 NorStOP template for calculating pain sites/widespread pain 
  
Pain interference 
A single item from the Medical Outcomes Study (MOS) Short Form (SF)-12 (Ware, 
Kosinski, & Bayliss, 1995) was used as a measure of current interference of pain in 
everyday life. All participants were asked: “During the past 4 weeks how much did pain 
interfere with your normal work (including both work outside the home and 
housework)?” There were 5 available responses to the question: ‘Extremely’, ‘Quite a bit’, 
‘Moderately’, ‘A little bit’ or ‘Not at all’. This single item has been used in previous 
population studies as a measure of pain interference (Blyth et al., 2001; Teh et al., 2009) 
and is associated with increasing age (Thomas et al., 2007; Thomas, Peat, et al., 2004) and 
a reduction in social networks (Peat et al., 2004) in the NorStOP dataset. The reference 
group for this item in the survival analysis was ‘no pain interference’ which included 
participants who indicated they had pain but this did not interfere with their life.   
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Demographic details  
Information about age, sex, education and adequacy of income were collected and used 
as potential confounders. Education and adequacy of income were included as a measure 
of socioeconomic status.  
Age and sex 
Participants were asked to confirm their sex and date of birth to enable the calculation of 
their current age. Age was categorised into to the year bands 50-59, 60-69, 70-79 and 80+ 
in line with the approach applied to the ELSA data.  
Education and adequacy of income 
Measures of education and financial resources were again used to capture the 
multidimensional nature of socioeconomic position. To assess educational attainment 
participants were asked to indicate whether they had continued full-time education 
beyond school (response options ‘yes/no’) which formed a dichotomous variable 
indicating school education/further education. Although this item lacks detail regarding 
specific qualifications it provides information regarding different levels of educational 
attainment (high (further education) or low (school education only)) for comparison and 
is comparable to the measure used in ELSA which included school level and further 
education qualifications. Perceived adequacy of income was measured with a single item. 
Participants were asked to think about the cost of living as it affected them and describe 
their situation using one of the following responses: 
1) Find it a strain to get by from week to week  
2) Have to be careful with money  
3) Able to manage without much difficulty  
4) Quite comfortably off 
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It measures a range of financial circumstances (from affluence to poverty) without 
eliciting details of responders’ income. This item was developed by Thomas (1999) and 
provides an account of whether the responder feels that they are under financial strain 
(Thomas, 1999). Perceived adequacy of income has been demonstrated to be a robust 
indicator of financial capacity in older adults (Litwin & Sapir, 2009).  
5.5 Statistical analysis 
5.5.1 Sample characteristics 
 
The ELSA sample consisted of those participants who had complete data for the predictor 
(pain), outcome (vital status), confounder (age, sex, education and wealth) and for all 
proposed mediators (apart from allostatic load and frailty) (see Table 4.1). This was 
referred to as the ELSA complete case sample (n=6324). The NorStOP sample included 
participants with complete predictor (pain), outcome (vital status), confounder (age, sex, 
education and adequacy of income) and mediator information (see table 4.2) (n=10985) 
and is referred to as the NorStOP complete case sample.  
First of all, the complete case samples from ELSA and NorStOP were described according 
to demographic, socioeconomic, lifestyle, health, social and psychological factors (the 
method of data collection for the included lifestyle, health, social and psychological 
factors is described in Section 6.3.3). The samples were then stratified according to vital 
status. Chi-squared or Mann Whitney tests (for non-parametric distributions) were 
undertaken where appropriate to determine differences between those participants who 
died and those who remained alive at the end of the study period.  
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5.5.2 Survival analysis 
 
Cox’s proportional hazard modelling (see section 5.3.1) was used to test the risk of all-
cause mortality and cause-specific mortality (ELSA only) according to pain phenotype. The 
phenotypes examined are displayed in Table 5.1.  
Table 5.1 Pain phenotypes tested for their relationship with mortality 
Dataset Pain phenotype Reference group Categories 
ELSA “Often 
troubled” 
Not often troubled with pain 1) often troubled 
ELSA Severity Not often troubled with pain 1) Mild 
2) Moderate 
3) Severe 
NorStOP “Any pain” No pain 1) “any pain” 
NorStOP ACR criteria No pain 1) Pain not meeting ACR WP 
 
2) ACR WP 
NorStOP Manchester 
criteria 
No pain 1) Pain not meeting Manchester 
WP 
 
2) Manchester WP 
NorStOP Number of pain 
sites 
No pain sites (equivalent to 
‘no pain’) 
1) 1-3 sites 
2) 4-6 sites 
3) 7-11 sites  
4) 12+ sites 
NorStOP Pain 
interference 
No pain interference 1) ‘a little’ 
2) ‘moderately’ 
3) ‘quite a bit’ 
4) ‘extremely’ 
NorStOP = North Staffordshire Osteoarthritis Project 
ELSA = English Longitudinal Study of Ageing 
ACR = American College of Rheumatology 
WP = Widespread Pain 
 
In ELSA it was also possible to examine the effect of pain phenotype (often troubled and 
severity) on cause-specific mortality. Analyses were undertaken to assess the risk of 
mortality from cancer, cardiovascular disease and respiratory disease, other causes of 
death and unknown causes of death.  
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All analyses are presented as unadjusted “crude” analyses (Model 1) and then 
cumulatively adjusted for age and sex (Model 2) and education and wealth 
(ELSA)/adequacy of income (NorStOP) (Model 3). The results of the Cox’s proportional 
hazard models are presented as Mortality Rate Ratios (MRRs) with 95% confidence 
intervals (CI).  
5.5.3 Weighting 
 
There are a number of practical disadvantages when using longitudinal surveys, in 
particular non-response and attrition at subsequent waves resulting in a reduced sample 
size. Mechanisms of missing data (e.g. missing at random) and some ways of dealing with 
it (e.g. imputation) are described in Section 4.5.1. One way to examine the sensitivity of 
the relationship of interest (in this case the association between pain and mortality) to 
participant attrition and missing data is to complete a probability weighted analysis. The 
analysis in Chapter Four indicated there were differences between those with complete 
data and those with missing data. An investigation of whether weighted analysis could be 
used in order to represent those with missing data (that could also be used in the 
mediation analysis) was undertaken.   
Weighting involves the removal of participants with incomplete data from the dataset 
and the subsequent weighting of the remaining complete cases so that the distribution of 
the reduced sample resembles the full sample with respect to specified variables (Schafer 
& Graham, 2002). Each participant in the complete case sample is assigned a number 
representing a ’sampling weight’. This refers to the number of participants in the original 
(full) sample who were eligible to provide a response that are represented by each 
individual participant in the reduced (complete case) sample who did provide a response 
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(Dunn et al., 1999). These weights represent the probability of response and are 
determined from the full sample using logistic regression. It is possible to weight 
responses using information from the complete case sample in a similar way to using data 
from the second phase of a two phase survey by deeming all participants who responded 
(complete data) as representative of all participants who were eligible to respond. For 
example if 60 out of a possible 100 participants have complete data, a sampling weight 
can be assigned to those 60 to additionally represent the 40 who did not complete the 
data. In this case, the sampling weight would be the inverse of the sampling fraction 
(i.e.100/60= 1.67) (Dunn et al., 1999). 
In the ELSA sample weights were calculated from the age, sex, education and wealth 
variables. These variables were used to calculate the weights as they were potential 
confounders in the analysis and were used to determine differences between the 
complete case samples and those with missing mediator data. Binary variables for age 
(above and below the median), wealth (above and below the median) and education 
(further education or not) were created. For the NorStOP sample the variables were 
dichotomised in the same way but perceived adequacy of income replaced wealth and 
was dichotomised as “find it a strain/have to be careful with money versus little 
difficulty/comfortable”. Participants scored 1 if they were female, in the oldest age 
category and highest wealth/income and education categories. Altogether sixteen 
combinations of these categories were possible. The number of participants in each of 
these categories was counted in each of the samples. Weights for each of the sixteen 
categories were calculated by dividing the number in the smaller (complete case) sample 
by the number in the larger sample (including those with missing mediator data) and 
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adding one. These figures were then used to form a weighting variable to weight the 
complete case sample to the baseline sample with predictor, outcome and confounder 
information only. That is, each participant in the complete case sample was allocated one 
of the 16 weight values to indicate how many baseline sample participants were 
represented by each participant based on the combination of those variables.  
The survival analyses to examine the risk of mortality according to pain phenotype were 
undertaken in the weighted samples by including the weighting variable in the survival 
models as an additional covariate. The weighted results were then compared to the 
results of the complete case samples. There were no differences between the MRRs in 
the weighted analyses and the complete case samples for either the ELSA or the NorStOP 
datasets (Appendix IV). The focus of all subsequent analyses was therefore the 
unweighted complete case samples for each dataset. The results of the survival analyses 
for the baseline samples with predictor, outcome and confounder information only and 
the weighted analyses can be seen in Appendix IV. 
5.5.4 Assumption testing 
 
The assumption of proportionality for the Cox’s models was tested using Schoenfeld tests 
for the crude (Model 1) and fully adjusted models (Model 3) and plots of Schoenfeld 
residuals (see section 5.3.1). Results of these are presented in Appendix V. Survival 
probability for each pain phenotype was also presented graphically using Kaplan Meier 
plots.  
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5.6 Results of the descriptive analysis 
5.6.1 The ELSA complete case sample 
 
Sample characteristics 
Table 5.2 presents descriptive characteristics of the complete case sample for the ELSA 
dataset and a comparison between those participants who died and those who did not 
before the end of the study. Participants who died during 8 years of follow-up (n=764) 
compared to those who remained alive (n=5560) were older, more likely to be male and 
of lower socioeconomic status (i.e. lower education and wealth). Participants who died 
were also more likely to be often troubled with pain, report greater severity of pain, 
lower physical activity levels, poorer self-rated health and quality of life, more likely to 
smoke, drink less alcohol, report functional limitation and symptoms preventing walking. 
Participants who died also had more depressive symptoms and greater cognitive 
impairment, were less likely to undertake volunteer work and were members of fewer 
social groups, were more likely to report the presence of any comorbidity and each of the 
four categories of comorbidities (p<0.001 for all comparisons) (Table 5.2). 
Table 5.2 Characteristics of the ELSA complete case sample overall and stratified by vital 
status 
Variable Total 
(n=6324) 
Alive  
(n=5560) 
Dead  
(n=764) 
 
p 
PAIN 
Often troubled with pain 
No (reference) 
Yes 
Severity 
Mild 
Moderate 
Severe 
 
 
4052 (64.07%) 
2272 (35.93%) 
 
680 (10.75%) 
1183 (18.71%) 
409 (6.47%) 
 
 
3624 (65.18%) 
1936 (34.82%) 
 
620 (11.15%) 
982 (17.66%) 
334 (6.01%) 
 
 
428 (56.02%) 
336 (43.98%) 
 
60 (7.85%) 
201 (26.31%) 
75 (9.82%) 
 
 
 
<0.001
1
 
 
 
 
<0.001
1
 
DEMOGRAPHICS 
Age (years) 
50-59 
60-69 
70-79 
80+ 
 
 
2272 (35.93%) 
2175 (34.39%) 
1361 (21.52%) 
516 (8.16%) 
 
 
2204 (39.64%) 
2019 (36.31%) 
1081 (19.44%) 
256 (4.60%) 
 
 
68 (8.90%) 
156 (20.42%) 
280 (36.65%) 
260 (34.03%) 
 
 
 
 
 
<0.001
1
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Sex 
Female 
 
3451 (54.57%) 
 
3105 (55.85%) 
 
346 (45.29%) 
 
<0.001
1
 
Education 
None 
Foreign/other 
NVQ1/CSE or equivalent 
NVQ2/GCE O level or 
equivalent 
NVQ3/GCE  A level or 
equivalent 
Higher education below 
degree 
NVQ 4/5/Degree or 
equivalent 
 
Wealth (quintiles based on n 
= 8572 sample) 
Group 1 (lowest) 
Group 2 
Group 3 
Group 4 
Group 5 (highest) 
 
2004 (31.69%) 
570 (9.01%) 
289 (4.57%) 
 
1226 (19.39%) 
 
480 (7.59%) 
 
837 (13.24%) 
 
918 (14.52%) 
 
 
 
1011 (15.99%) 
1173 (18.55%) 
1292 (20.43%) 
1392 (22.01%) 
1456 (23.02%) 
 
1658 (29.82%) 
478 (8.60%) 
243 (4.37%) 
 
1140 (20.50%) 
 
434 (7.81%) 
 
771 (13.87%) 
 
836 (15.04%) 
 
 
 
796 (14.32%) 
1011 (18.18%) 
1160 (20.86%) 
1252 (22.52%) 
1341 (24.12%) 
 
346 (45.29%) 
92 (12.04%) 
46 (6.02%) 
 
86 (11.26%) 
 
46 (6.02%) 
 
66 (8.64%) 
 
82 (10.73%) 
 
 
 
215 (28.14%) 
162 (21.20%) 
132 (17.28%) 
140 (18.33%) 
115 (15.05%) 
 
 
 
 
 
 
 
 
 
 
 
<0.001
1
 
 
 
 
 
 
 
 
<0.001
1
 
LIFESTYLE FACTORS 
Physical activity at least once 
a week  
None 
Mild 
Moderate 
Vigorous 
 
Smoking 
Never 
Ex-smoker  
Current smoker 
 
Alcohol in the last 12 months  
Less than weekly 
Weekly or more 
 
 
 
377 (5.96%) 
859 (13.58%) 
3125 (49.42%) 
1963 (31.04%) 
 
 
2361 (37.33%) 
3053 (48.28%) 
910 (14.39%) 
 
 
2313 (36.58%) 
4011 (63.43%) 
 
 
 
248 (4.46%) 
678 (12.19%) 
2787 (49.24%) 
1847 (33.22%) 
 
 
2159 (38.83%) 
2633 (47.36%) 
768 (12.14%) 
 
 
1970 (35.43%) 
3590 (64.57%) 
 
 
 
129 (16.89%) 
181 (23.69%) 
338 (44.24%) 
116 (15.18%) 
 
 
202 (26.44%) 
420 (54.97%) 
142 (18.59%) 
 
 
343 (44.90%) 
421 (55.11%) 
 
 
 
 
 
 
<0.001
1
 
 
 
 
 
<0.001
1
 
 
 
 
<0.001
1
 
HEALTH FACTORS 
Self-reported health  
Excellent 
Very good 
Good 
Fair 
Poor 
 
Functional limitation 
Difficulties with activities of 
daily living (0-13) 
>1 indicated difficulty 
 
Symptoms preventing 
walking (0-13) 
>1 symptom 
 
 
 
 
886 (14.01%) 
1927 (30.47%) 
2031 (32.12%) 
1098 (17.36%) 
382 (6.04%) 
 
 
 
0 (0-0)* 
1554 (24.57%) 
 
 
0 (0-0)* 
1483 (23.45%) 
 
 
 
 
844 (15.18%) 
1793 (32.25%) 
1779 (32.00%) 
879 (15.81%) 
265 (4.77%) 
 
 
 
0 (0-0)* 
1188 (21.37%) 
 
 
0 (0-0)* 
1077 (19.37%) 
 
 
 
 
42 (5.50%) 
134 (17.54%) 
252 (32.98%) 
219 (28.67%) 
117 (15.31%) 
 
 
 
0 (0-2)* 
366 (47.91%) 
 
 
1 (0-2)* 
406 (53.14%) 
 
 
 
 
 
 
 
 
<0.001
1
 
 
 
 
<0.001
2
 
<0.001
1
 
 
 
<0.001
2 
<0.001
1
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Comorbidity 
Cancer 
Cardiovascular disease 
Respiratory disease 
Other 
 
No comorbidity 
Any comorbidity 
 
182 (2.88%) 
2307 (36.48%) 
685 (10.83%) 
2011 (31.80%) 
 
2585 (40.88%) 
3739 (59.12%) 
 
118 (2.12%) 
1971 (35.45%) 
570 (10.25%) 
1698 (30.54%) 
 
2365 (42.54%) 
3195 (57.46%) 
 
64 (8.38%) 
336 (43.98%) 
115 (15.05%) 
313 (40.97%) 
 
220 (28.80%) 
544 (71.20%) 
 
<0.001
1
 
<0.001
1
 
<0.001
1
 
<0.001
1
 
 
 
<0.001
1
 
SOCIAL FACTORS 
Volunteer work  
No 
Yes 
 
Social group membership (0-
8) 
 
 
4363 (68.99%) 
1961 (31.01%) 
 
 
1 (1-2)* 
 
 
3757 (67.57%) 
1803 (32.43%) 
 
 
1 (1-2)* 
 
 
606 (79.32%) 
158 (20.68%) 
 
 
1 (0-2)* 
 
 
 
<0.001
1
 
 
 
<0.001
2
 
PSYCHOLOGICAL FACTORS 
Quality of Life (CASP-19) 
Control (0-12)  
Autonomy (0-15)  
Pleasure (0-15)  
Self-realisation (0-15)  
 
Total (0-57) 
 
 
Depression (CESD) (0-8) 
Depression (binary)  
<4 depressive symptoms 
=>4 depressive symptoms 
 
Cognitive impairment 
Number of words recalled (0-
20) 
 
 
9 (7-10)* 
11 (9-13)* 
14 (13-15)* 
11 (8-13)* 
 
44 (38-50)* 
 
 
3 (2-4)* 
 
4619 (73.04%) 
1705 (26.96%) 
 
 
 
11 (8-13)* 
 
 
9 (7-11)* 
11 (9-13)* 
14 (13-15)* 
11 (9-13)* 
 
45 (39-50)* 
 
 
3 (2-4)* 
 
4161 (74.84%) 
1399 (25.16%) 
 
 
 
11 (9-13)* 
 
 
7 (5-9)* 
10 (8-12)* 
14 (12-15)* 
9 (6-11)* 
 
40 (33-46)* 
 
 
3(2-4)* 
 
458 (59.95%) 
306 (40.05%) 
 
 
 
9 (6-11)* 
 
 
<0.001
2
 
<0.001
2
 
<0.001
2
 
<0.001
2
 
 
<0.001
2
 
 
 
<0.001
2 
 
 
<0.001
1
 
 
 
 
<0.001
2
 
CASP= Control, Autonomy, Self-realisation and Pleasure scale  
CESD=Centre for Epidemiologic Studies Depression scale 
NVQ = National Vocational Qualification 
CSE = Certificate of Secondary Education 
GCE= General Certificate of Education 
 
1 
Chi squared test
 , 2 
Mann Whitney test 
Figures refer to n(%), * indicates Median (Inter Quartile Range (IQR))  
 
5.6.2 The NorStOP complete case sample  
Sample characteristics 
Participants who died in the NorStOP complete case sample were more likely to be older, 
male, of lower socioeconomic status (measured according to education and income 
(p<0.001 for all comparisons)), more likely to report pain interference (p<0.001), sleep 
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problems (trouble falling asleep p=0.005, wake in the night p<0.001, trouble staying 
asleep p=0.031, wake up unrefreshed p=0.014), participation restriction (p<0.001) and be 
obese (p<0.001). Participants who died were also less likely to go out (p<0.001) or walk 
for 10 minutes (p<0.001), have lower self-rated health (p<0.001), greater functional 
limitation (p<0.001), higher depressive symptoms (p<0.001), greater cognitive 
impairment (p<0.001) and reported less control over their health (p=0.001).  However, 
participants who died were less likely to be current smokers (p<0.001) and drank alcohol 
less frequently (p<0.001) than those who remained alive.  There were no statistically 
significant differences in the report of any pain (p=0.333), ACR WP (p=0.155), Manchester 
WP (p=0.627), number of pain sites (p=0.201) or anxiety (p=0.247) between those who 
died and those who remained alive (Table 5.3). 
Table 5.3 Descriptive characteristics of the total NorStOP complete case sample and stratified 
according to mortality status 
Variable Total  
 (n=10985) 
Alive  
 (n=9501) 
Dead  
(n=1484) 
 
p 
PAIN 
No (reference) 
Any pain 
 
Pain but not ACR WP 
ACR WP 
Missing
+
 
 
Pain but not Manchester WP 
Manchester WP 
Missing
+
 
 
Number of pain sites 
0 
1-3 
4-6 
7-11 
12+ 
Missing 
 
Pain interference 
None 
A little 
Moderately 
Quite a bit 
 
3166 (28.82%) 
7819 (71.18%) 
 
5038 (45.86%) 
2749 (25.03%) 
32 (0.29%) 
 
6062 (55.18%) 
1725 (15.70%) 
32 (0.29%) 
 
 
3166 (28.82%) 
1952 (17.77%) 
1942 (17.68%) 
1833 (16.69%) 
2060 (18.75%) 
32 (0.29%) 
 
 
4501 (40.97%) 
2316 (21.08%) 
1562 (14.22%) 
2004 (18.24%) 
 
2754 (28.99%) 
6747 (71.01%) 
 
4324 (45.51%) 
2397 (25.23%) 
26 (0.27%) 
 
5235 (55.10%) 
1486 (15.64%) 
26 (0.27%) 
 
 
2754 (28.99%) 
1707 (17.97%) 
1666 (17.53%) 
1592 (16.76%) 
1756 (18.48%) 
26 (0.27%) 
 
 
4002 (42.12%) 
2089 (21.99%) 
1328 (13.98%) 
1634 (17.20%) 
 
412 (27.76%) 
1072 (72.24%) 
 
714 (48.11%) 
352 (23.72%) 
6 (0.40%) 
 
827 (55.73%) 
239 (16.11%) 
6 (0.40%) 
 
 
412 (27.76%) 
245 (16.51%) 
276 (18.60%) 
241 (16.24%) 
304 (20.49%) 
6 (0.40%) 
 
 
499 (33.63%) 
227 (15.30%) 
234 (15.77%) 
370 (24.93%) 
 
 
0.333
1
 
 
 
0.155
1
 
 
 
 
0.627
1
 
 
 
 
 
 
 
 
0.201
1
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Extremely 602 (5.48%) 448 (4.72%) 154 (10.38%) <0.001
1
 
DEMOGRAPHICS 
Age (years) 
50-59 
60-69 
70-79 
80+ 
 
 
4241 (38.61%) 
3648 (33.21%) 
2336 (21.27%) 
760 (6.92%) 
 
 
4086 (43.01%) 
3300 (34.73%) 
1766 (18.59%) 
349 (3.67%) 
 
 
155 (10.44%) 
348 (23.45%) 
570 (38.41%) 
411 (27.70%) 
 
 
 
 
 
<0.001
1
 
Sex 
Female 
 
5967 (54.32%) 
 
5275 (55.52%) 
 
692 (46.63%) 
 
<0.001
1
 
Further Education 
Yes 
 
Adequacy of income 
Find it a strain 
Have to be careful 
Able to manage 
Comfortable 
 
1417 (12.90%) 
 
 
402 (3.66%) 
4271 (38.88%) 
4549 (41.41%) 
1763 (16.05%) 
 
1298 (13.66%) 
 
 
360 (3.79%) 
3638 (38.29%) 
3924 (41.30%) 
1579 (16.62%) 
 
119 (8.02%) 
 
 
42 (2.83%) 
633 (42.65%) 
625 (42.12%) 
184 (12.40%) 
 
<0.001
1
 
 
 
 
 
 
<0.001
1
 
LIFESTYLE FACTORS 
Smoking   
Never/Previous 
Current 
 
Alcohol  
Monthly or less 
Weekly 
 
Obesity  
Yes  
 
Frequency go out  
All days 
Most days 
Some days 
Few days 
No days 
 
Frequency walk for 10 minutes 
Every day 
Every other day 
Twice a week 
Less than weekly 
Never 
 
Sleep 
Trouble falling asleep  
Some/none 
Most nights 
Wake in the night  
Some/none 
Most nights 
Trouble staying asleep 
Some/none 
Most nights 
Wake up unrefreshed 
Some/none 
Most nights 
 
 
7099 (64.62%) 
3886 (35.38%) 
 
 
4660 (42.42%) 
6325 (57.58%) 
 
 
2093 (19.05%) 
 
 
3557 (32.38%) 
3486 (31.73%) 
2468 (22.47%) 
1236 (11.25%) 
238 (2.17%) 
 
 
1599 (14.56%) 
2146 (19.54%) 
2452 (22.32%) 
2285 (20.80%) 
2503 (22.79%) 
 
 
 
9563 (87.06%) 
1422 (12.94%) 
 
8454 (76.96%) 
2531 (23.04%) 
 
8871 (80.76%) 
2114 (19.24%) 
 
9204 (83.79%) 
1781 (16.21%) 
 
 
6049 (63.67%) 
3452 (36.33%) 
 
 
3939 (41.465) 
5562 (58.54%) 
 
 
1863 (19.61%) 
 
 
3325 (35.00%) 
3096 (32.59%) 
2056 (21.64%) 
904 (9.51%) 
120 (1.26%) 
 
 
1462 (15.39%) 
1936 (20.38%) 
2220 (23.37%) 
1987 (20.91%) 
1896 (19.96%) 
 
 
 
8305 (87.41%) 
1196 (12.59%) 
 
7423 (78.13%) 
2078 (21.87%) 
 
7703 (81.08%) 
1798 (18.92%) 
 
7993 (84.13%) 
1508 (15.87%) 
 
 
1050 (70.75%) 
434 (29.25%) 
 
 
721 (48.58%) 
763 (51.42%) 
 
 
230 (15.50%) 
 
 
232 (15.63%) 
390 (26.28%) 
412 (27.76%) 
332 (22.37%) 
118 (7.95%) 
 
 
137 (9.23%) 
210 (14.15%) 
232 (15.63%) 
298 (20.08%) 
607 (40.90%) 
 
 
 
1258 (84.77%) 
226 (15.23%) 
 
1031 (69.47%) 
453 (30.53%) 
 
1168 (78.71%) 
316 (21.29%) 
 
1211 (81.60%) 
273 (18.40%) 
 
 
 
<0.001
1
 
 
 
 
<0.001
1
 
 
 
<0.001
1
 
 
 
 
 
 
 
<0.001
1
 
 
 
 
 
 
 
<0.001
1
 
 
 
 
 
0.005
1
 
 
 
<0.001
1
 
 
 
0.031
1
 
 
 
0.014
1
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HEALTH FACTORS 
Self-rated health  
Excellent 
Very good 
Good 
Fair 
Poor 
 
 
436 (3.97%) 
2653 (24.15%) 
4490 (40.87%) 
2750 (25.03%) 
656 (5.97%) 
 
 
413 (4.35%) 
2468 (25.98%) 
3998 (42.08%) 
2180 (22.94%) 
442 (4.65%) 
 
 
23 (1.55%) 
185 (12.47%) 
492 (33.15%) 
570 (38.41%) 
214 (14.42%) 
 
 
 
 
 
 
<0.001
1
 
SOCIAL FACTORS 
 
Social participation restriction 
(KAP) 
None 
Any 
 
Functional limitation (SF36) 
 
 
 
 
5879 (53.52%) 
5106 (46.48%) 
 
75 (45- 90)* 
 
 
 
 
5337 (56.17%) 
4164 (43.83%) 
 
80 (50-95)* 
 
 
 
 
542 (36.52%) 
942 (63.48%) 
 
45 (15-80)* 
 
 
 
 
 
<0.001
1
 
 
<0.001
2
 
PSYCHOLOGICAL FACTORS 
Anxiety (HADS) 
No 
Possible/probable 
 
Depression (HADS) 
No 
Possible/probable 
 
Cognitive impairment 
No 
Yes 
 
Control (from IPQ-R) 
Disagree 
Agree 
 
 
6914 (62.94%) 
4071 (37.06%) 
 
 
8918 (81.18%) 
2067 (18.82%) 
 
 
6330 (57.62%) 
4655 (42.38%) 
 
 
7916 (72.06%) 
3069 (27.94%) 
 
 
6000 (63.15%) 
3501 (36.85%) 
 
 
7874 (82.88%) 
1627 (17.12%) 
 
 
5656 (59.53%) 
3845 (40.47%) 
 
 
6792 (71.49%) 
2709 (28.51%) 
 
 
914 (61.59%) 
570 (38.41%) 
 
 
1044 (70.35%) 
440 (29.65%) 
 
 
674 (45.42%) 
810 (54.52%) 
 
 
1124 (75.74%) 
360 (24.26%) 
 
 
 
0.247
1
 
 
 
 
<0.001
1
 
 
 
 
<0.001
1
 
 
 
 
0.001
1
 
IQR = Inter Quartile Range 
ACR = American College of Rheumatology 
WP = Widespread Pain 
KAP = Keele Assessment of Participation 
SF 36 = Short Form 36 
HADS = Hospital Anxiety and Depression Scale 
IPQ-R = Illness Perception Questionnaire (Revised) 
 
1 
Chi squared test
 , 2 
Mann Whitney test  
Figures refer to n(%), * indicates Median (Inter Quartile Range (IQR)) 
+
 the complete case samples were based on those responding to the filter question regarding ‘any pain’   
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5.7 Results of the survival analysis 
 
5.7.1 Often troubled with pain (ELSA) and mortality 
 
Tests of proportionality 
For the ELSA complete case sample (n=6324) the length of time in the study for those 
who died (n=764) ranged from 0 months to 90 months from the date of interview with a 
mean survival time of 54.1 months (SD 24.7). 5.2% (n = 40) of deaths occurred within 12 
months from the date of interview. For “often troubled” with pain the result of the 
Schoenfeld tests were not statistically significant in the crude model (Model 1) (often 
troubled with pain compared to not often troubled (Chi2=2.48 p=0.11)) or in the fully 
adjusted model (Model 3). The global test was also not statistically significant for Model 3 
indicating the association between “often troubled” with pain and mortality was constant 
across the 8 years of follow up. The assumption of proportionality was therefore 
considered to be valid. Results of the Schoenfeld tests for Model 3 and the plots of the 
Schoenfeld residuals can be seen in Appendix V.   
Survival probability over time 
The rate of mortality was higher in those often troubled with pain when compared to 
those not often troubled with pain (Figure 5.5).  
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Figure 5.5 Survival probability over 92 months for often troubled with pain and those 
not often troubled by pain; Kaplan Meier plots in the ELSA complete case sample 
(n=6324) 
 
Mortality risk 
Those “often troubled” with pain had a 43% increased risk of mortality when compared to 
those not “often troubled” with pain (Model 1: MRR 1.43; 95%CI 1.24, 1.65) and this 
remained significant when adjusted for age and sex (Model 2: MRR1.36; 95%CI 1.18, 1.58) 
and for age, sex, education and wealth (Model 3: MRR 1.29; 95%CI 1.12, 1.49) (Table 5.4). 
5.7.2 Severity of pain (ELSA) 
 
Tests of proportionality 
For severity of pain the Schoenfeld tests for the crude (Model 1) and fully adjusted 
(Model 3) models were not statistically significant indicating the assumption of 
proportionality was valid (Appendix V).   
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Survival probability over time 
When the relationship between pain severity and mortality was examined, it was clear 
that the rate of mortality was highest in those with moderate and severe pain (Figure 
5.6). 
 
Figure 5.6 Survival probability over 92 months for levels of pain severity; Kaplan Meier 
estimates in the ELSA complete case sample (n=6324) 
 
Mortality risk 
When compared to those reporting they were not “often troubled” with pain, 
participants who reported mild pain were not more likely to die over the follow up period 
(MRR 0.83; 95%CI 0.63, 1.09). However participants reporting moderate (MRR 1.65; 
95%CI 1.40, 1.95) or severe (MRR 1.81; 95%CI 1.41, 2.31) pain had a 70% and 80% 
increased risk of death. The association between moderate and severe pain and a higher 
risk of mortality attenuated slightly when adjusted for age and sex (Model 2: moderate 
pain: MRR 1.52; 95%CI 1.28, 1.80, severe pain: MRR 1.42; 95%CI 1.20, 1.68) and when 
adjusted for age, sex, education and wealth (Model 3: moderate pain: MRR 1.42; 95%CI 
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1.20, 1.68, severe pain: MRR 1.54; 95%CI 1.20, 1.97) although the elevated risk persisted 
and remained significant (Table 5.4). 
5.7.3 Any pain (NorStOP) 
 
Tests of proportionality 
In the NorStOP analysis (n=10985), the length of time in the study for participants who 
died (n=1484) ranged from 7 days to 3823 days from the date of response with a mean 
survival time of 2036 days (SD 1052). 6.54% (n=97) of deaths occurred within 12 months 
from the date of response.   
The results of the Schoenfeld test for the crude model (Model 1) for “any pain” 
(Chi2=2.74, p=0.098) and the fully adjusted model (Model 3) (Chi2=9.63, p=0.086) were 
not statistically significant indicating the assumption of proportionality was valid 
(Appendix V).  
Survival probability over time 
 
Survival probability over time was lower across the study period for those with “any pain” 
compared to those with no pain (Figure 5.7). 
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Table 5.4  Risk of all-cause mortality in the ELSA complete case sample according to pain phenotype (n=6324) 
Pain phenotype N Person 
years of 
follow up 
Number of 
deaths 
Mortality 
rate*  
Model 1 MRR 
(95% CI) 
Model 2 MRR 
(95% CI) 
Model 3 MRR 
(95% CI) 
Not often troubled 4052 28048 428 15.26 Reference Reference Reference 
Often troubled  2272 15414 336 21.80 1.43 (1.24, 1.65) 1.36 (1.18, 1.58) 1.29 (1.12, 1.49) 
Not often troubled 4052 28048 428 15.26 Reference Reference Reference 
Mild  680 4737 60 12.67 0.83 (0.63, 1.09) 0.87 (0.66, 1.14) 0.89 (0.68, 1.16) 
Moderate  1183 7943 201 25.31 1.65 (1.40, 1.95) 1.52 (1.28, 1.80) 1.42 (1.20, 1.68) 
Severe  409 2734 75 27.43 1.81 (1.41, 2.31) 1.70 (1.33, 2.18) 1.54 (1.20, 1.97) 
MRR=Mortality Rate Ratio, 95% CI = 95% confidence interval 
Model 1: Crude 
Model 2: Adjusted for age, sex  
Model 3: Adjusted for age, sex, education and wealth 
*per 1000 person-years 
MRRs in bold indicate significant associations 
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Figure 5.7 Survival probability over 10 years for any pain and those with no pain; Kaplan 
Meier plots in the NorStOP complete case sample (n=10985) 
 
Mortality risk 
There was no statistically significant increased risk of mortality for participants with “any 
pain” (Model 1: MRR 1.05; 95%CI 0.94, 1.18) which demonstrated minimal change after 
adjustment for potential confounders (Model 2: MRR 1.08; 95%CI 0.96, 1.21, Model 3: 
MRR 1.06; 95%CI 0.95, 1.19) (Table 5.5).   
5.7.4 ACR WP (NorStOP) 
Tests of proportionality 
For ACR WP criteria the Schoenfeld test for Model 1 (Chi2=2.84, p=0.241) and Model 3 
(Chi2=9.64, p=0.141) were not statistically significant indicating the assumption of 
proportionality was reasonable (Appendix V). 
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Survival probability for those with ACR WP was similar to that for those with no pain; 
survival probability for those with pain that did not meet the ACR criteria was lower than 
for those with widespread pain (Figure 5.8). 
 
Figure 5.8 Survival probability over 10 years for American College of Rheumatology 
Widespread Pain (ACR WP) criteria; Kaplan Meier estimates in the NorStOP complete 
case sample (n=10953)  
 
Mortality risk 
There was no statistically significant increased risk of mortality for participants with pain 
that was not ACR WP (Model 1: MRR 1.09; 95%CI 0.97, 1.23, Model 2: MRR 1.06; 95%CI 
0.94, 1.20, Model 3: MRR 1.05; 95%CI 0.93, 1.19) or for participants with ACR WP (Model 
1: MRR 0.97; 95%CI 0.85, 1.12, Model 2: MRR 1.10; 95%CI 0.95, 1.26, Model 3: MRR 1.07; 
95%CI 0.92, 1.23) (Table 5.5).  
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5.7.5 Manchester WP (NorStOP) 
 
For Manchester WP criteria the Schoenfeld tests for Model 1 (Chi2=4.50, p=0.105) and 
Model 3 (Chi2=12.45, p=0.053) were not statistically significant indicating the risk of 
mortality was proportional over time. 
Survival probability over time 
 
The survival probability for those with Manchester WP was lower than for those with no 
pain or pain that did not meet the Manchester criteria for widespread pain (Figure 5.9). 
 
Figure 5.9 Survival probability over 10 years for Manchester Widespread Pain criteria 
(Manchester WP); Kaplan Meier estimates in the NorStOP complete case sample 
(n=10953)  
 
Mortality risk 
For participants with Manchester WP there was an increased risk of mortality in the 
analyses adjusted for age and sex only (Model 2: MRR 1.19; 95%CI 1.02, 1.40). There was 
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no statistically significant increased risk of mortality for pain that was not Manchester WP 
(Table 5.5). 
5.7.6 Number of pain sites (NorStOP) 
 
Tests of proportionality 
For the number of pain sites the Schoenfeld test for Model 1 (Chi2=6.36, p=0.174) and 
Model 3 (Chi2=13.24, p=0.104) indicated the proportionality assumption was valid.  
Survival probability over time 
 
There was no trend between increasing number of pain sites and survival probability. 
Survival probability was lowest in those with 12+ sites but those with 7-11 sites of pain 
had a similar survival probability over time to those reporting no pain (Figure 5.10).   
 
Figure 5.10 Survival probability over 10 years for number of pain sites; Kaplan Meier 
estimates in the NorStOP complete case sample (n=10953)  
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Mortality risk 
There was a significant increased risk of mortality for participants with 12+ sites adjusted 
for age and sex only (MRR 1.18; 95%CI 1.02, 1.37). There was no trend of increased 
mortality risk with increased number of pain sites (Table 5.5). 
5.7.7 Pain interference (NorStOP) 
Tests of proportionality 
For pain interference, the Schoenfeld tests for both the crude model (Model 1) 
(Chi2=18.06, p=0.001), and the model adjusted for age, sex, education and adequacy of 
income (Model 3) (Chi2=21.43, p=0.006) were statistically significant indicating the 
assumption of proportionality did not hold (Appendix V). To overcome the problems 
caused by non-proportionality it was necessary to split the analysis time into periods. In 
accordance with previous research that has shown increased mortality for people with 
pain in the first year of follow up (Jordan & Croft, 2010), the first time period ranged from 
0-365 days (0-1 year) and the second time period was from the second year of follow up 
onwards >366 days (i.e. 2-10 years). The proportionality assumption was met for both of 
these time periods. In the first time period the Schoenfeld test for the crude model 
(Model 1) (Chi2 0.66, p=0.416) and for Model 3 (Chi2=10.88, p=0.209) were not 
statistically significant. In the second time period the Schoenfeld test for the Model 1 
(Chi2=6.80, p=0.147) and Model 3 (Chi2=14.87, p=0.061) were also not statistically 
significant (Appendix V). 
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Table 5.5 Risk of all-cause mortality in the NorStOP complete case sample according to pain phenotype (n=10985) 
Pain phenotype N 
 
Person 
years of 
follow up 
Number of 
deaths 
Mortality 
rate*  
Model 1 MRR 
(95% CI) 
Model 2 MRR 
(95% CI) 
Model 3 MRR 
(95% CI) 
No pain  3166 28813 412 14.30 Reference Reference Reference 
Any pain  7819 71116 1072 15.07 1.05 (0.94, 1.18) 1.08 (0.96, 1.21) 1.06 (0.95, 1.19) 
No pain 3166 28813 412 14.30 Reference Reference Reference 
Pain but not ACR WP 5038 45709 714 15.62 1.09 (0.97, 1.23) 1.06 (0.94, 1.20) 1.05 (0.93, 1.19) 
ACR WP 2749 25158 352 13.99 0.97 (0.85, 1.12) 1.10 (0.95, 1.26) 1.07 (0.92, 1.23) 
No pain 3166 28813 412 14.30 Reference Reference Reference 
Pain but not 
Manchester WP 
6062 55194 827 14.98 1.05 (0.93, 1.18) 1.05 (0.93, 1.18) 1.03 (0.92, 1.16) 
Manchester WP 1725 15673 239 15.25 1.06 (0.91, 1.25) 1.19 (1.02, 1.40) 1.16 (0.99, 1.36) 
No sites 3166 28813 412 14.30 Reference Reference Reference 
1-3 sites 1952 17843 245 13.73 0.96 (0.82, 1.12) 0.95 (0.81, 1.11) 0.95 (0.81, 1.11) 
4-6 sites 1942 17559 276 15.72 1.10 (0.94, 1.28) 1.09 (0.94, 1.27) 1.08 (0.93, 1.26) 
7-11 sites 1833 16836 241 14.31 1.00 (0.85, 1.17) 1.07 (0.92, 1.26) 1.05 (0.90, 1.24) 
12+ sites 2060 18630 304 16.32 1.14 (0.98, 1.32) 1.18 (1.02, 1.37) 1.15 (0.99, 1.34) 
MRR= Mortality Rate Ratio, 95% CI = 95% confidence interval 
ACR = American College of Rheumatology,  WP = Widespread pain 
Model 1: Crude 
Model 2: Adjusted for age, sex  
Model 3: Adjusted for age, sex, education, adequacy of income 
*per 1000 person-years 
MRRs in bold indicate significant associations 
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Survival probability over time 
There was an observable trend between increased pain interference and decreased 
survival probability over time (Figure 5.11).   
 
Figure 5.11 Survival probability over 10 years for pain interference; Kaplan Meier 
estimates in the NorStOP complete case sample (n=10985)  
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There was no statistically significant increased risk of mortality for participants with “a 
little” or “moderate” pain interference in crude or adjusted models. There was a 
statistically significant increased risk of mortality for pain that interfered “quite a bit” in 
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significant when adjusted for age, sex, education and adequacy of income (Model 3: MRR 
1.54; 95%CI 0.88, 2.68). “Extreme” pain interference was statistically significantly 
associated with an increased risk of mortality in all models (Model 1: MRR 6.49; 95%CI 
3.72, 11.33, Model 2: MRR 5.49; 95%CI 3.12, 9.65, Model 3: MRR 4.69; 95%CI 2.64, 8.34) 
(Table 5.6).   
Table 5.7 displays the risk of all-cause mortality according to pain interference from 2 to 
10 years of follow up. There was no increased risk of mortality for participants with “a 
little” pain interference in the crude or adjusted models. For participants who indicated 
“moderate” pain interference there was a statistically significant increased risk of 
mortality in the crude model only (Model 1: MRR 1.35; 95%CI 1.15, 1.58) which 
attenuated and became non-significant when adjusted for age and sex (Model 2: MRR 
1.13; 95%CI 0.96, 1.33) and when adjusted for age, sex, education and adequacy of 
income (Model 3: MRR 1.13; 95%CI 0.96, 1.32). Compared to those with no pain 
participants reporting “quite a bit” or “extreme” pain interference had an increased risk 
of mortality in all models and were 38% and 88% respectively more likely to die after 
adjusting for all covariates in Model 3 (“quite a bit” Model 3: MRR 1.38; 95%CI 1.20, 1.59, 
“extremely” Model 3: MRR 1.88; 95%CI 1.54, 2.29) (Table 5.7).    
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Table 5.6 Risk of all-cause mortality in the NorStOP complete case sample according to pain interference in the first year of follow up (0-
365 days) 
Pain interference N  
 
Person 
years of 
follow up 
Number of 
deaths 
Mortality 
rate*  
Model 1 MRR 
(95% CI) 
Model 2 MRR 
(95% CI) 
Model 3 MRR 
(95% CI) 
No interference 4501 4489 27 5.01 Reference Reference Reference 
A little 2316 2313 8 3.46 0.57 (0.26, 1.27) 0.61 (0.28, 1.35) 0.60 (0.27, 1.32) 
Moderately 1562 1557 14 8.99 1.49 (0.78, 2.85) 1.31 (0.69, 2.50) 1.20 (0.63, 2.30) 
Quite a bit 2004 1993 25 12.54 2.09 (1.21, 3.59) 1.78 (1.03, 3.08) 1.54 (0.88, 2.68) 
Extremely 602 590 23 38.98 6.49 (3.72, 11.33) 5.49 (3.12, 9.65) 4.69 (2.64, 8.34) 
MRR= Mortality Rate Ratio, 95% CI = 95% confidence interval 
Model 1: Crude 
Model 2: Adjusted for age, sex  
Model 3: Adjusted for age, sex, education, adequacy of income 
*per 1000 person-years 
MRRs in bold indicate significant associations 
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Table 5.7 Risk of all-cause mortality in the NorStOP complete case sample according to pain interference after the first year of follow 
up (365 to 3483 days)  
Pain interference N  
 
Person 
years of 
follow up 
Number of 
deaths 
Mortality 
rate*  
Model 1 MRR 
(95% CI) 
Model 2 MRR 
(95% CI) 
Model 3 MRR 
(95% CI) 
No interference 4474 41269 472 11.44 Reference Reference Reference 
A little 2308 21473 219 10.20 0.89 (0.76, 1.04) 0.94 (0.80, 1.10) 0.94 (0.80, 1.10) 
Moderately 1548 14238 220 15.45 1.35 (1.15, 1.58) 1.13 (0.96, 1.33) 1.13 (0.96, 1.32) 
Quite a bit 1979 17817 345 19.36 1.70 (1.48, 1.95) 1.39 (1.21, 1.60) 1.38 (1.20, 1.59) 
Extremely 579 5078 131 25.80 2.27 (1.87, 2.76) 1.89 (1.55, 2.30) 1.88 (1.54, 2.29) 
MRR= Mortality Rate Ratio, 95% CI = 95% confidence interval 
Model 1: Crude 
Model 2: Adjusted for age, sex  
Model 3: Adjusted for age, sex, education, adequacy of income 
*per 1000 person-years 
MRRs in bold indicate significant associations 
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5.7.8 Cause-specific mortality (ELSA only) 
 
Hypothesis addressed: 
The association between pain and cause-specific mortality is influenced by pain 
phenotype.  
In ELSA cause of death was identified as cancer, cardiovascular disease, respiratory 
diseases, ‘other’ cause of death and ‘unknown’ cause of death. The results of the survival 
analyses for each of these causes are presented in this section.  
Tests of proportionality 
The tests of proportionality and associated plots are presented in Appendix V. The 
Schoenfeld plots and tests indicated there may be a problem with the proportionality 
assumption for: 
 1) Participants “often troubled” with pain and respiratory disease mortality  
2) Participants with moderate pain and respiratory disease mortality 
3) Moderate pain and cancer mortality  
However, the global tests for Model 3 in both cases were non-significant indicating the 
proportionality assumption was reasonable in the fully adjusted models (Appendix V).  
The reduction in the number of events when using cause specific deaths as the outcome 
resulted in reduced power to detect a relationship. The power to detect a HR 1.3 for 
cancer deaths = 0.5271, cardiovascular diseases = 0.4490, respiratory diseases = 0.2243, 
other cause of death = 0.2393. This problem would be compounded by splitting up the 
follow-up period to overcome any proportionality issues. The sample was therefore not 
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split and the results are presented for information but should be interpreted with 
caution. 
Cancer mortality 
1) Often troubled with pain 
When compared to those not often troubled with pain, participants reporting they were 
“often troubled” with pain were not more likely to die from cancer over the follow up 
period (Model 3: MRR 1.08; 95%CI 0.83, 1.41) (Table 5.8).  
2) Severity of pain 
Participants with mild, moderate or severe pain were also not more likely to die from 
cancer over the follow-up period compared to those not often troubled with pain (Model 
3: Mild: MRR 0.75; 95%CI 0.46, 1.23, moderate: MRR 1.19; 95%CI 0.87, 1.64, severe: MRR 
1.32; 95%CI 0.82, 2.12) (Table 5.8).  
Cardiovascular disease mortality 
1) Often troubled with pain 
Those “often troubled” with pain were more likely to die from cardiovascular disease 
(Model 1: MRR 1.48; 95%CI 1.12, 1.97) when compared to those not often troubled with 
pain. This increased risk was attenuated but remained statistically significant following 
adjustment for age and sex in Model 2 (MRR 1.39; 95%CI 1.05, 1.85), and attenuated 
further and was no longer statistically significant in Model 3 when additionally adjusted 
for education and wealth (MRR 1.30; 95%CI 0.98, 1.74) (Table 5.9).  
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Table 5.8 Risk of cancer mortality in the ELSA complete case sample according to pain phenotype (n=6324) 
Pain phenotype N Person years of 
follow up 
Number 
of deaths 
Mortality rate* Model 1 MRR 
(95% CI) 
Model 2 MRR 
(95% CI) 
Model 3 MRR 
(95% CI) 
Not often troubled 4052 28048 148 5.28 Reference Reference Reference 
Often troubled 2272 15414 91 5.90 1.12 (0.86, 1.46) 1.10 (0.84, 1.43) 1.08 (0.83, 1.41) 
Not often troubled 4052 28048 148 5.28 Reference Reference Reference 
Mild 680 4737 18 3.80 0.72 (0.44, 1.17) 0.75 (0.46, 1.23) 0.75 (0.46, 1.23) 
Moderate 1183 7943 53 6.67 1.27 (0.93, 1.74) 1.20 (0.88, 1.65) 1.19 (0.87, 1.64) 
Severe 409 2734 20 7.32 1.39 (0.87, 2.22) 1.34 (0.84, 2.13) 1.32 (0.82, 2.12) 
MRR=Mortality Rate Ratio, 95% CI = 95% confidence interval 
Model 1: Crude 
Model 2: Adjusted for age, sex  
Model 3: Adjusted for age, sex, education and wealth 
*per 1000 person-years 
MRRs in bold indicate significant associations 
 
Table 5.9 Risk of cardiovascular disease mortality in the ELSA complete case sample according to pain phenotype (n=6324) 
Pain phenotype N  Person years of 
follow up 
Number 
of deaths 
Mortality rate* Model 1 MRR 
(95% CI) 
Model 2 MRR 
(95% CI) 
Model 3 MRR 
(95% CI) 
Not often troubled 4052 28048 107 3.81 Reference Reference Reference 
Often troubled 2272 15414 88 5.71 1.48 (1.12, 1.97) 1.39 (1.05, 1.85) 1.30 (0.98, 1.74) 
Not often troubled 4052 28048 107 3.81 Reference Reference Reference 
Mild 680 4737 16 3.38 0.88 (0.52, 1.50) 0.91 (0.54, 1.55) 0.97 (0.57, 1.63) 
Moderate 1183 7943 52 6.55 1.69 (1.21, 2.36) 1.51 (1.08, 2.11) 1.37 (0.97, 1.92) 
Severe 409 2734 20 7.32 1.93 (1.19, 3.10) 1.82 (1.13, 2.95) 1.61 (0.99, 2.61) 
MRR=Mortality Rate Ratio, 95% CI = 95% confidence interval 
Model 1: Crude 
Model 2: Adjusted for age, sex  
Model 3: Adjusted for age, sex, education and wealth 
*per 1000 person-years 
MRRs in bold indicate significant associations 
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2) Severity of pain  
There was a trend of increased risk of mortality due to cardiovascular disease with 
increased severity of pain. Those reporting mild pain did not have an increased risk of 
cardiovascular mortality (Model 1: MRR 0.88; 95%CI 0.52, 1.50, Model 2: MRR 0.91; 
95%CI 0.54, 1.55, Model 3: MRR 0.97; 95%CI 0.57, 1.63).  Moderate and severe pain were 
associated with an increased cardiovascular mortality risk which was robust to 
adjustment for age and sex (Model 2: moderate MRR 1.51; 95%CI 1.08, 2.11, severe MRR 
1.93; 95%CI 1.19, 3.10) (Table 5.9). However, although an increased risk remained for 
moderate and severe pain, it was not statistically significant when adjusted for age, sex, 
education and wealth (Model 3: MRR 1.37; 95%CI 0.97, 1.92 and MRR 1.61; 95%CI 0.99, 
2.61 respectively) (Table 5.9). 
Respiratory disease mortality 
1) Often troubled with pain 
A significant increased risk of respiratory disease mortality was observed for those “often 
troubled” with pain (Model 1: MRR 1.92; 95%CI 1.25, 2.94) which remained statistically 
significant following adjustment for age, sex, education and wealth (Model 3: MRR 1.63; 
95%CI 1.06, 2.51) (Table 5.10).  
2) Severity of pain 
Mild pain was not associated with increased respiratory disease mortality (Model 1: MRR 
0.72; 95%CI 0.29, 1.83, Model 2: MRR 0.75; 95%CI 0.30, 1.90, Model 3: MRR 0.83; 95%CI 
0.33, 2.10). Moderate and severe pain were associated with an increased risk of 
respiratory disease mortality which remained statistically significant following adjustment 
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for age, sex, education and wealth (Model 3: moderate pain: MRR 1.76; 95%CI 1.07, 2.89, 
severe pain: MRR 2.26; 95%CI 1.17, 4.34) (Table 5.10). 
Other causes of mortality 
1) Often troubled with pain 
Table 5.11 displays the results of the survival analyses for known causes of death other 
than cancer, cardiovascular diseases or respiratory diseases. Being often troubled with 
pain was associated with other causes of mortality in the crude analysis only (Model 1: 
MRR 1.56; 95%CI 1.04, 2.36).  The association between often troubled and mortality 
became non-significant following adjustment for confounders (Model 2: MRR 1.46; 95%CI 
0.97, 2.22, Model 3: MRR 1.45; 95%CI 0.95, 2.19)    
2) Severity of pain  
Only moderate pain was associated with an increased risk of mortality for other known 
causes of death and this relationship was robust to adjustment for confounders (Model 1: 
MRR 2.03; 95%CI 1.27, 3.22, Model 2: MRR 1.81; 95%CI 1.13, 2.88, Model 3: (MRR 1.79; 
95%CI 1.11, 2.88). Mild or severe pain was not associated with increased mortality risk 
from other known causes in any of the models (Table 5.11).   
Unknown causes of mortality 
1) Often troubled with pain 
Participants “often troubled” with pain had a 41% increased risk of mortality from an 
unknown cause compared to those without pain after adjustment for age, sex, education 
and wealth (Model 3: MRR 1.41; 95%CI 1.03, 1.95) (Table 5.12).  
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2) Severity of pain 
There was a trend of increasing risk of mortality from unknown causes with increasing 
severity of pain in crude analyses. Mild pain was again not associated with an increased 
mortality risk from unknown causes (Model 1: MRR 1.07; 95%CI 0.62, 1.85, Model 2: MRR 
1.12; 95%CI 0.65, 1.94, Model 3: MRR 1.15; 95%CI 0.66, 1.99). Moderate and severe pain 
were associated with an increased risk of mortality from unknown causes in the crude 
analysis (Model 1: moderate pain: MRR 1.77; 95%CI 1.22, 2.56, severe pain: MRR 1.86; 
95%CI 1.07, 3.22). For moderate pain the association remained significant when adjusted 
for age and sex (Model 2: MRR 1.66; 95%CI 1.14, 2.41) and when adjusted for age, sex, 
education and wealth (Model 3: MRR 1.52; 95%CI 1.04, 2.21). For severe pain this 
association attenuated and became non-significant when adjusted for age and sex (Model 
2: MRR 1.72; 95%CI 0.99, 2.98) and age, sex, education and wealth (Model 3: MRR 1.50; 
95%CI 0.86, 2.62) (Table 5.12). 
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Table 5.10 Risk of respiratory disease mortality in the ELSA complete case sample according to pain phenotype (n=6324) 
Pain phenotype N Person years 
of follow up 
Number of deaths Mortality rate* Model 1 MRR 
(95% CI) 
Model 2 MRR 
(95% CI) 
Model 3 MRR 
(95% CI) 
Not often troubled  4052 28048 41 1.46 Reference Reference Reference 
Often troubled 2272 15414 43 2.79 1.92 (1.25, 2.94) 1.86 (1.21, 2.86) 1.63 (1.06, 2.51) 
Not often troubled  4052 28048 41 1.46 Reference Reference Reference 
Mild 680 4737 5 1.06 0.72 (0.29, 1.83) 0.75 (0.30, 1.90) 0.83 (0.33, 2.10) 
Moderate 1183 7943 26 3.27 2.26 (1.38, 3.69) 2.11 (1.29, 3.46) 1.76 (1.07, 2.89) 
Severe 409 2734 12 4.39 3.03 (1.59, 5.76) 2.99 (1.56, 5.70) 2.26 (1.17, 4.34) 
MRR=Mortality Rate Ratio, 95% CI = 95% confidence interval 
Model 1: Crude 
Model 2: Adjusted for age, sex  
Model 3: Adjusted for age, sex, education and wealth 
*per 1000 person-years 
MRRs in bold indicate significant associations 
 
Table 5.11 Risk of other mortality in the ELSA complete case sample according to pain phenotype (n=6324)  
Pain phenotype N Person years of 
follow up 
Number 
of deaths 
Mortality rate* Model 1 MRR 
(95% CI) 
Model 2 MRR 
(95% CI) 
Model 3 MRR 
(95% CI) 
Not often troubled 4052 28048 49 1.75 Reference Reference Reference 
Often troubled 2272 15414 42 2.72 1.56 (1.04, 2.36) 1.46 (0.97, 2.22) 1.45 (0.95, 2.19) 
Not often troubled 4052 28048 49 1.75 Reference Reference Reference 
Mild 680 4737 6 1.27 0.72 (0.31, 1.69) 0.75 (0.32, 1.74) 0.75 (0.32, 1.76) 
Moderate 1183 7943 28 3.53 2.03 (1.27, 3.22) 1.81 (1.13, 2.88) 1.79 (1.11, 2.88) 
Severe 409 2734 8 2.93 1.68 (0.80, 3.55) 1.59 (0.75, 3.38) 1.57 (0.73, 3.34) 
MRR=Mortality Rate Ratio, 95% CI = 95% confidence interval 
Model 1: Crude 
Model 2: Adjusted for age, sex  
Model 3: Adjusted for age, sex, education and wealth 
*per 1000 person-years 
MRRs in bold indicate significant associations 
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Table 5.12 Risk of unknown mortality in the ELSA complete case sample according to pain phenotype (n=6324) 
Pain phenotype N Person years of 
follow up 
Number 
of deaths 
Mortality rate* Model 1 MRR 
(95% CI) 
Model 2 MRR 
(95% CI) 
Model 3 MRR 
(95% CI) 
Not often troubled 4052 28048 83 2.96 Reference Reference Reference 
Often troubled 2272 15414 72 4.67 1.57 (1.14, 2.15) 1.51 (1.10, 2.08) 1.41 (1.03, 1.95) 
Not often troubled 4052 28048 83 2.96 Reference Reference Reference 
Mild 680 4737 15 3.17 1.07 (0.62, 1.85) 1.12 (0.65, 1.94) 1.15 (0.66, 1.99) 
Moderate 1183 7943 42 5.29 1.77 (1.22, 2.56) 1.66 (1.14, 2.41) 1.52 (1.04, 2.21) 
Severe 409 2734 15 5.49 1.86 (1.07, 3.22) 1.72 (0.99, 2.98) 1.50 (0.86, 2.62) 
MRR=Mortality Rate Ratio, 95% CI = 95% confidence interval 
Model 1: Crude 
Model 2: Adjusted for age, sex  
Model 3: Adjusted for age, sex, education and wealth 
*per 1000 person-years 
MRRs in bold indicate significant associations 
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5.8 Discussion 
 
5.8.1 Summary of results 
 
The results of the survival analyses indicated the risk of mortality for people with pain 
was influenced by pain phenotype.  
There was an increased risk of mortality for people who reported being “often troubled” 
with pain. This mortality risk increased with increased pain severity. Participants who 
were “often troubled” with pain had an increased risk of mortality from cardiovascular 
diseases, respiratory diseases, ‘other’ diseases and from unknown causes but not from 
cancer. For cardiovascular and respiratory disease mortality there was a trend of 
increased mortality risk with increased severity of pain. 
There was no increased risk of mortality for people reporting “any pain” or with the 
majority of the definitions of the number of locations of pain (ACR WP, Manchester WP, 
number of pain sites) exceptions being Manchester WP criteria and 12 or more pain sites 
when adjusted for age and sex.  
Pain interference was associated with an increased risk of mortality and this was higher in 
people reporting greater pain interference. The risk of mortality associated with pain 
interference was also greater in the first year of follow up.  “Quite a bit” and “extreme” 
pain interference were associated with an increased risk of mortality in the first year of 
follow up and “moderate”, “quite a bit” and “extreme” pain interference were associated 
with increased mortality after the first year of follow up in crude models. The association 
between “extreme” pain interference and increased mortality was robust to adjustment 
for age, sex, education and adequacy of income in both time bands.  
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Overall these findings indicated that it was not simply the presence or number of 
locations of pain that was important for the relationship between pain and mortality but 
rather the impact of pain for the individual.  
5.8.2 Methodological considerations 
 
Although the findings of the current study indicate pain phenotype is important in the 
relationship between pain and mortality it was not possible to test all of the different pain 
phenotypes within one dataset. In order to test a range of phenotypes two datasets were 
used. Differences between the ELSA and NorStOP datasets may have influenced the 
pattern of findings: 
Differences in sample structure  
Differences in the structure of the study population between datasets may have 
influenced the observed relationships between pain phenotype and mortality risk. ELSA 
samples are generated with the intention of being representative of the English 
population of adults aged 50 years and over (i.e. representative at national level). In 
contrast the NorStOP dataset is sampled from a small number (n=8) of general practices 
in North Staffordshire and is less likely to be nationally representative. The geographical 
area covered by the NorStOP study is more deprived in terms of health, education and 
employment than England as a whole but with fewer barriers to housing and services 
(Wilkie, Blagojevic-Bucknall, Jordan, & Pransky, 2013).  However, the age and sex 
structure of the participating NorStOP population is similar to that of North Staffordshire 
and to England and Wales (Thomas et al., 2007). Investigation of the age and sex 
distribution of the samples used for this study detailed in Chapter Four revealed that the 
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ELSA and NorStOP samples had similar structures to each other but the oldest age groups 
were under-represented in both datasets compared to national statistics. Other 
differences between the ELSA and NorStOP study samples may have influenced the 
observed relationships but these are difficult to quantify due to differences in the way 
variables were measured. Where measures were comparable i.e. for current smoking 
(ELSA =14.39%, NorStOP = 35.68%) and self-rated health rated as “excellent” (ELSA = 
14.01%, NorStOP = 3.97%) these indicated the NorStOP sample may be a less healthy 
sample than the ELSA sample. Stronger associations between pain and mortality might 
therefore be expected in the NorStOP sample compared to the ELSA sample. However, in 
the current study this was not the case indicating other factors were influencing the 
relationship between pain and mortality.   
Identification of vital status 
The accuracy of the recording of vital status of participants was imperative to the current 
study. Misclassifications may result in an inaccurate representation of the true 
relationships between pain phenotype and mortality. Random-misclassification across 
pain phenotypes would lead to an underestimate of the true relationship between pain 
and mortality, whereas non-random misclassification could lead to an under or 
overestimate (Delgado-Rodríguez & Llorca, 2004). Vital status in the ELSA sample was 
determined using records from the Office of National Statistics whereas in NorStOP 
information was collated from two sources, the Exeter Patient registration system held at 
the local Primary Care Trust and through manual tracing of the NHS Summary Care 
Record Demographic system (see section 5.4.1). It is possible some misclassifications may 
have occurred; some deaths may have been missed or recorded in error, or the cause of 
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death may have been inaccurately documented. Although the recording of deaths is 
highly structured and standardised in developed countries, death certificates are 
sometimes not properly completed and discrepancies between the causes of death on 
death certificates compared to medical records have been observed (Johansson, 
Westerling, & Rosenberg, 2006). However, the United Kingdom is considered to have high 
quality death registration data (Mathers, Fat, Inoue, Rao, & Lopez, 2005) so any 
inaccuracies should be minimal. Despite differences in the sources of vital status 
information between the datasets, the proportion of deaths identified in the NorStOP and 
ELSA was similar (12.08% of the ELSA sample and 13.51% of the NorStOP sample died) 
over an approximately comparable follow-up period (8-10 years). 
5.8.3 Comparison with other studies 
 
The influence of pain phenotype 
The current study examined mortality risk for novel pain phenotypes in addition to those 
previously examined in existing literature. The pain phenotypes tested in the NorStOP 
sample to measure the presence and location of pain were comparable to some 
phenotypes used in other studies (Macfarlane et al., 2001; McBeth et al., 2009), however 
the results were inconsistent with those studies. Macfarlane et al., 2001 used the ACR 
criteria to categorise widespread pain and found an increased risk of mortality for those 
meeting the criteria (MRR 1.31; 95%CI 1.05, 1.65, adjusted for age, sex and study 
location) (Macfarlane et al., 2001). Similarly McBeth et al., (2009) found an increased risk 
of mortality in participants meeting the ACR criteria for widespread pain (MRR 1.3; 95%CI 
1.1, 1.5, adjusted for age, sex, practice, ethnic group and Townsend score of deprivation) 
(McBeth et al., 2009). However, in the current study, participants in the NorStOP sample 
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who met the ACR criteria for widespread pain did not have an increased risk of mortality 
compared to those with no pain (MRR 1.07; 95%CI 0.92, 1.23 adjusted for age, sex, 
education and adequacy of income). 
Pain coding  
Differences in the way widespread pain was coded between the current and previous 
studies may account for some of the differences in findings. In each of the above 
mentioned studies (including the current study), participants were asked to indicate the 
location of their pain on a blank body manikin so that pain according to ACR criteria for 
widespread pain (pain in the axial skeleton, on the right and left sides of the body and 
above and below the waist) could be determined. It is more practical and cost effective to 
use several raters to score completed pain drawings meaning the quality of the data is 
dependent on inter-rater reliability (Lacey, Lewis, Jordan, Jinks, & Sim, 2005). In a study 
carried out using the NorStOP dataset, the scoring of pain drawings by multiple raters was 
found to be highly reliable (agreement ranged from 82% to 100%) for all body areas 
excluding the back area of the head (Lacey et al., 2005). Other studies using the NorStOP 
dataset have reported a prevalence of Manchester WP of 12.5% (Thomas, Peat, et al., 
2004), ACR WP 22.3% (McBeth, Lacey, & Wilkie, 2014) and 26.4 % (Wilkie, Tajar, & 
McBeth, 2013) which are similar to the figures reported in the current study; 25.03% met 
the criteria for widespread pain according to the ACR criteria, 15.70% met the 
Manchester criteria for widespread pain. Information regarding the way in which the 
drawings were scored in the Macfarlane et al., (2001) and the McBeth et al., (2009) 
studies was not available, but as detailed in Chapter Two, these studies were well 
conducted and the prevalence of widespread pain was consistent with other population 
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studies (Hunt et al., 1999; Wolfe, Ross, & Anderson, 1995). The Macfarlane et al., (2001) 
study reported the prevalence of widespread pain to be 15% (Macfarlane et al., 2001), 
the McBeth et al., 2009 study reported a prevalence of widespread pain of 16.9% 
(McBeth et al., 2009).   
The higher prevalence of widespread pain (ACR and Manchester definitions) observed in 
NorStOP is likely due to the sample being restricted to adults aged 50 years and over. 
Good access to healthcare in the geographical area covered by NorStOP (North 
Staffordshire) despite its deprivation status (Wilkie, Blagojevic-Bucknall, Jordan, Lacey, & 
McBeth, 2013) may mean that despite the high prevalence of pain, these participants 
receive effective treatment for their pain which explains the lower mortality risk 
compared to the other studies. The Macfarlane et al., (2001) and the McBeth et al., 
(2009) studies were also both carried out in the Greater Manchester area of the UK which 
has one of the highest age standardised mortality rates in England and Wales (Office For 
National Statistics, 2012) which may also contribute to the observed differences in 
mortality between the studies. 
Pain impact 
The magnitude of the relationship observed in the ELSA dataset between “troubling” pain 
and all-cause mortality (MRR 1.29; 95% CI 1.12, 1.49) was comparable with the studies 
using a measure of widespread pain (see above) (Macfarlane et al., 2001; McBeth et al., 
2009) and with those measuring chronic pain ((MRR 1.21; 95%CI 1.02, 1.44) (Sjøgren & 
Grønbæk, 2010) (Crude MRR 1.32; 95%CI 1.14, 1.54) (Torrance et al., 2010)). Consistent 
with the current study, Torrance and colleagues (2010)  also reported a trend of increased 
mortality risk with greater pain severity (Torrance et al., 2010).  The pain phenotypes in 
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ELSA dataset did not contain information regarding location or chronicity but participants 
were asked to indicate if they were “often troubled” with pain. It has been suggested this 
measure of pain may be an underrepresentation of the construct of pain as a positive 
response to the question “Are you often troubled with pain?” may only be forthcoming if 
pain is significant enough to be considered frequent (Reyes-Gibby et al., 2002). This way 
of assessing pain may therefore capture both the presence and some indication of the 
impact of pain. The NorStOP participants were asked if they had “any pain” and then 
asked to indicate the location. This is a validated approach to identifying the presence of 
pain and its location (Lacey et al., 2005; Margolis, Chibnall, & Tait, 1988; Weiner, 
Peterson, & Keefe, 1998) but does not necessarily capture the impact of pain. This may 
help to explain why the ELSA pain phenotypes were associated with mortality but the 
NorStOP phenotypes describing the presence and location of pain were not. In contrast, 
pain interference (a measure of pain impact) was associated with an increased risk of 
mortality in the NorStOP sample. The results of the current study indicate being “often 
troubled” with pain and pain interference are similar constructs and that the link between 
pain and mortality is dependent on pain impact rather than the presence or number of 
locations of pain. 
Unexpected findings 
The findings from the NorStOP sample are unexpected as an increasing number of pain 
sites has previously been reported to be associated with a reduction in overall health, 
sleep quality, psychological health and decreased function (Kamaleri et al., 2008) and with 
increased mortality (McBeth et al., 2009). However, the number of pain sites is not 
predictive of the rising impact of pain of daily life with age in this population (Thomas et 
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al., 2004). The use of a single item to capture pain interference has limitations. It has 
been suggested that older participants conflate reasons for ‘interference with life’ and do 
not distinguish pain as the main factor when answering the question (Thomas et al., 
2007). An exploration of the relationship between the number of pain sites and pain 
interference variable used in this study is presented in Table 5.13. The highest proportion 
of deaths occurred for those reporting only 1-3 sites of pain but extreme pain 
interference (37.50%), although there were only a small number of participants in this 
category. There is some correlation between a greater number of pain sites and the 
extent of pain interference (Table 5.13). However in contrast to pain interference, the 
number of pain sites was not associated with increased mortality in this study.   
Within the NorStOP questionnaire the question regarding pain interference was 
positioned in a general health section separate to the questions regarding the presence 
and location of pain; the pain interference question was asked early on in the survey 
(Section A, Part 1 (of 8), question 5). The question about the presence and location of 
pain was much later in the survey (Section B, Part 1) and was preceded by a statement 
saying the section was about any pains they may have or any problems with their joints. If 
the questions were positioned closer together in the survey, (i.e. the pain interference 
question followed the presence and location questions), responders may have focussed 
more on ‘pain’ as opposed to other reasons for interference with life when responding to 
the interference item. This may have reduced some of the contrasting relationships with 
mortality between the number of pain sites and pain interference in NorStOP. The 
findings from the current study indicate the measure of the number of pain sites is not a 
good proxy for the impact of pain in the NorStOP sample and that overall, in terms of the  
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Table 5.13 Cross tabulation of the number of pain sites and pain interference categories presenting the proportion of those who died in the 
NorStOP complete case sample (n= 10953) *   
 % who died (Number of deaths/N) per cell 
No sites 1-3 sites 4-6 sites 7-11 sites 12+ sites Total 
No interference 13.01% (412/3166) 6.73% (46/683)  6.91% (26/376) 6.15% (12/195) 4.00% (3/75) 11.10% (499/4495) 
A little - 11.34% (81/714) 10.06% (72/716) 8.50% (48/565) 7.91% (25/316) 9.78% (226/2311) 
Moderately - 19.80% (59/298) 17.15% (71/414) 12.95% (57/440) 11.39% (46/404) 14.97% (233/1556) 
Quite a bit - 20.89% (47/225) 24.51% (87/355) 17.45% (89/510) 15.93% (144/904) 18.41% (367/1994) 
Extremely - 37.50% (12/32) 24.69% (20/81) 28.46% (35/123) 23.82% (86/361) 25.63% (153/597) 
Total 13.01% (412/3166) 12.55% (245/1952) 14.21% (276/1942) 13.15% (241/1833) 14.76% (304/2060) 13.49% (1478/10953) 
*excludes n=32 who indicated the presence of pain but did not indicate any pain sites on the pain manikin 
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risk of mortality, the presence of pain is less important than the impact of that pain on 
the individual, irrespective of the amount.  
Cause specific mortality 
Previous studies have reported an increased risk of cancer mortality for people with pain 
(Macfarlane et al., 2001; McBeth et al., 2009). In the analysis of ELSA data in the current 
study there was no increased risk of cancer mortality for any of the pain phenotypes; 
rather the increased mortality risk from known causes was due to cardiovascular disease 
and respiratory disease mortality. Andersson (2009) reported an increased risk of 
cardiovascular disease mortality but no increased risk of cancer mortality for people with 
widespread pain (Andersson, 2009). Smith and colleagues (2003) also did not find an 
increased risk of mortality from cancer but did report increased mortality from 
respiratory diseases for people with chronic pain (Smith et al., 2003).  
There was also an increased risk of mortality from ‘other’ and ‘unknown’ causes of death 
in the ELSA sample in the current study. This may include suicide, death from liver 
cirrhosis, cerebrovascular disease and accidents. These causes of death have been shown 
to be increased in patients with fibromyalgia (Dreyer et al., 2010; Wolfe et al., 2011). The 
‘unknown’ category refers to participants that were known to have died but whose cause 
of death could not be determined. It is therefore possible these participants could fit into 
any of the categories of causes of death meaning the reported associations could be an 
underestimation of the true risk of those causes of death for people with pain. The lack of 
consistency or specificity of cause of death implies there is little evidence for any causal 
associations between pain and a specific cause of death (Hill, 1965); rather pain 
contributes to reduced survival more generally. The differences in the observed cause 
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specific deaths between studies may therefore be due to the different populations 
studied.  
5.8.4 Strengths and limitations 
Datasets 
The current study was conducted using data obtained from two large population-based 
surveys with high response rates. It was possible to investigate the relationship between 
a number of different pain phenotypes and mortality.  Although complete case analysis 
often results in a reduced sample size and reduced statistical power, the complete case 
samples in the current study had sufficient power to detect the expected effect sizes and 
the weighted analyses indicated the missing data did not introduce bias to the results. 
However, it was only possible to investigate cause-specific mortality in one of the data 
samples (ELSA) and the reduction in the number of deaths per cause meant these 
analyses were underpowered (described in section 5.7.8) and the results should be 
interpreted with caution.         
As described in section 5.8.2, a potential limitation for the investigation of pain 
phenotype in the current study was the inability to test all of the phenotypes in the same 
data sample. However, the pattern of findings observed was contrary to what might have 
been expected given some of the observable differences between the datasets i.e. 
NorStOP participants were less healthy but those with pain did not have increased 
mortality. This suggests the use of two different samples was not responsible for the 
pattern of findings.  
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Mortality information 
Only year of death information was available from the ELSA dataset. This has implications 
for the accuracy of the MRRs reported for the ELSA sample. For participants who died, the 
time in the study was calculated from their date of interview until 31st December in the 
year the participant was known to have died. The actual date of death may have been 
earlier meaning survival time was overestimated and mortality risk was underestimated 
for ELSA participants in the current study.  
Pain phenotype 
Although seven different phenotypes (and their sub-categories) of pain were examined in 
the current study, it was not possible to determine pain that was chronic (i.e. lasting for 
three months or more) in either the ELSA or NorStOP datasets. Pain was measured at one 
point in time only and it is possible participants may have been misclassified or changed 
pain state over the follow-up period. This would result in an inaccurate representation of 
the relationship between pain and mortality (either an under or over-estimation) but the 
number of misclassifications of pain state is likely to be small, resulting in minimal effect 
on the overall findings. 
5.8.5 Implications for further research 
 
The findings from the survival analyses in the current study demonstrated an increased 
risk of mortality for people who had pain that impacted on their life. The presence of pain 
alone or an increased number of sites of pain was not associated with an increased risk of 
mortality. An investigation of potential mechanisms for a relationship, which would 
establish how pain impacts on a person’s life, may identify potential targets to prevent 
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mortality. As described in Chapter Two, previous studies of the relationship between pain 
and mortality considered lifestyle factors and psychological factors as potential 
confounders. Following on from this chapter, this thesis further adds to the existing body 
of knowledge by investigating the specific role of lifestyle, health, social and psychological 
factors by treating them as potential mediators or moderators of the relationship 
between pain and mortality (presented in Chapter Six). A better understanding of the 
mechanism between pain and mortality could guide strategies to reduce the impact of 
pain and prevent mortality by identifying targets for interventions.  
5.9 Key messages 
 
 Pain phenotype influenced the strength of association between pain and mortality 
 Pain impact is key to understanding the relationship between pain and mortality 
 Pain considered to be “troubling” was associated with mortality from 
cardiovascular disease, respiratory disease, other known causes and unknown 
causes of death  
 An investigation of potential mechanisms of a relationship between pain and 
mortality is warranted   
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Chapter Six. Mechanisms of association between pain and mortality 
6.1 Introduction 
 
Mortality risk was greater in people who had pain which impacted on their life (Chapter 
Five) highlighting a need to identify how the increased risk of mortality in those with pain 
occurred. In previous studies of pain and mortality (described in Chapters One and Two) 
covariates (e.g. physical activity, smoking etc.) were included in the analysis as 
confounders and simply adjusted for in the survival models. No previous studies have 
examined the roles these factors might play. This chapter presents novel analyses which 
tested if lifestyle, health, social and psychological factors were mediators of the 
relationship (i.e. lay on a pathway) between pain and mortality. In addition, as the 
pathways between pain and mortality may differ in different subgroups, potential 
moderators of the pathways from pain to mortality were tested to investigate in whom 
the relationships existed. The specific hypotheses are presented in section 6.2.  
Understanding how the relationship between pain and mortality may work has important 
implications for the management of pain by providing information on where to target 
interventions. 
6.2 Aims 
 
The aims of the analysis presented in this chapter were to: 
1. Identify mediators of the association between pain and mortality  
2. Examine the potential moderating effects of sex and comorbidity on the proposed 
pathways from pain to mortality 
The following hypotheses were tested: 
213 
 
Hypothesis 1 
The relationship between pain and mortality was mediated by lifestyle, health, social and 
psychological factors.  
Hypothesis 2  
The pathways from pain to mortality were different in males and females 
Hypothesis 3 
The pathways from pain to mortality were different in those with existing comorbidity 
compared to those without 
6.3 Methods 
6.3.1 Mediation 
  
The aim of mediation analysis is to test how a predictor exerts influence on an outcome. 
Hypothesised relationships between variables can be represented using path diagrams 
which indicate the direction of influence in relationships between variables (Figure 6.1). 
Links from causes to effects are represented by single headed arrows and directed (or 
causal) paths can be followed through a sequence of single-headed arrows (Greenland et 
al., 1999).  
Mediation analysis involves the estimation of two effects: The direct effect of an exposure 
on an outcome (c’) and the indirect effect (ab) which acts through an intervening variable 
that is hypothesised to be on a causal pathway from the exposure to the outcome 
(Rochon, du Bois, & Lange, 2014). The sum of these two effects equals the total effect 
(Rochon et al., 2014) (Figure 6.1).  
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Figure 6.1 Simple mediation model 
X= exposure, Y = outcome, M= mediator, c’ = direct effect, a = effect of exposure on the mediator, b = effect 
of the mediator on the outcome, ab = the indirect effect, ab + c’ = total effect (c)  
 
A mediating variable may explain part of an observed effect where a predictor variable (X) 
and outcome (Y) are associated and the mediator variable (M) accounts for at least some 
of that association, in other words there are direct (c’) and indirect effects (ab) of the 
predictor on the outcome (Figure 6.1) (Hayes, 2009). Alternatively, it may be that X only 
influences Y indirectly through the mediator(s) M (i.e. there is an indirect effect only) 
(Hayes, 2009) (Figure 6.1).  
The terms mediating effect and indirect effect are often used interchangeably (Hayes, 
2007) and both terms are used in this thesis. The term mediating effect is used when 
there is an effect to be mediated (i.e. in the presence of a statistically significant total 
effect). The term indirect effect is used where there is a statistically significant indirect 
effect only (Hayes, 2009) (i.e. the predictor influences the outcome only through the 
intervening variable). In both instances the mediating/indirect effect may also be 
described as a ‘pathway’ from predictor to outcome via the intervening variable (Emsley, 
Dunn, & White, 2010; Hayes, 2009; Kline, 2015; Rucker, Preacher, Tormala, & Petty, 
2011). To help answer questions about causal relationships the proposed pathways in 
mediation analysis have a temporal element; the mediator is assumed to be a 
X 
M 
Y 
c’ 
b a 
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consequence of the predictor and a precursor to the outcome (Hayes, 2013).  For 
example, pain may lead to physical inactivity which in turn leads to subsequent mortality. 
A change in the mediator (i.e. through a health intervention to increase physical activity) 
would subsequently result in a change in the outcome (i.e. reduce the risk of mortality). 
Investigation of whether a third factor “mediates” the link between an exposure and 
outcome enhances the understanding of how and why the relationship exists by providing 
insight into potential causal mechanisms and (when combined with moderation analysis) 
the circumstances under which interventions will work (Hafeman & Schwartz, 2009;  
Hayes, 2013).  
6.3.2 Mediation analysis 
There are traditionally two approaches to mediation analysis. The first is the ‘product 
method’ initially proposed by Baron and Kenny (1986) whereby the indirect effect is 
determined from the product of the coefficient for the exposure in the model for the 
mediator (path a, Figure 6.1) and the coefficient for the mediator in the model for the 
outcome (path b, Figure 6.1) (ab = indirect effect) (Baron & Kenny, 1986). The second is 
the ‘difference method’ where a model is fitted with and without the mediating variable 
and the difference in the coefficients for the exposure is taken to be the measure of the 
mediated effect (Judd & Kenny, 1981). Where the variables are continuous these results 
are equivalent but with categorical and binary data the two methods diverge (Preacher, 
2015) and an alternative approach may be more appropriate. Different techniques for 
undertaking mediation analysis are described below. 
Structural equation modelling (SEM) is commonly used to analyse mediation between an 
exposure and an outcome (Streiner, 2005). SEM estimates the strength of relationships 
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between variables using a combination of confirmatory factor analysis and path analysis 
to form a model which can be tested statistically (Streiner, 2005). Variables in structural 
equation models can be both measured (observed) and latent. Latent variables are not 
directly observed, rather they are hypothetical constructs represented by a number of 
observed variables (MacCallum & Austin, 2000). Direct (c’) and indirect relationships (ab) 
(see Figure 6.1) between these variables can be estimated (Hays, Revicki, & Coyne, 2005). 
Path analysis techniques work in a similar way but use only observed variables in the 
model. Path analysis is undertaken when it is the observed variable that is of primary 
interest or if there are too few observed variables to construct a latent variable 
(MacCallum & Austin, 2000). 
Procedures to estimate direct and indirect effects are influenced by different types of 
data (binary, continuous, categorical, survival etc.) As the outcome (dead or alive) in this 
study was binary it was not possible to use traditional structural equation modelling 
techniques in order to conduct the analysis as these assume continuous normally 
distributed data (MacCallum & Austin, 2000). It was therefore necessary to investigate 
different methods to find the most appropriate. The following approaches were 
considered: 
Karlson Holm Breen (KHB) 
The Karlson-Holm-Breen (KHB) method was specifically designed for use in Stata to 
extend the decomposition features of linear models to binary non-linear probability 
models (Karlson, Holm, & Breen, 2010). The KHB method decomposes the total effect of 
an exposure on an outcome in a logistic model into direct and indirect effects. It was 
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developed for use with binary models, but can decompose effects for discrete and 
continuous variables. It also provides statistical tests by which to assess the models. 
In linear models decomposing direct and indirect effects involves comparing a ‘reduced 
model’ with no mediator present to a ‘full model’ which includes the mediating variable. 
The difference between the two models equates to the direct effect (i.e. the difference 
method, see section 6.3.1). However, in nonlinear models the estimated coefficients are 
not comparable between models due to a rescaling as a result of joint identification of the 
coefficients and error variances (Karlson & Holm, 2011). In linear models the regression 
coefficients and error variances for the direct and indirect effect are separately identified. 
In non-linear models the coefficients in the model are a ratio of the true regression 
coefficient divided by a scale parameter dependent on the error standard deviation 
(Karlson et al., 2010) resulting in coefficients for the direct and indirect effects which, 
when summed, do not equal the total effect. The KHB method overcomes this problem by 
substituting the mediators by the residuals of the mediators from a regression of those 
mediators on the key variables of interest. This then allows comparison of the full model 
to the reduced model as in linear models and a calculation of the proportion of the total 
effect that is explained by the indirect effect (Karlson & Holm, 2011). However, this 
method was not designed for use in survival analysis and does not allow for the influence 
of time in the study.   
Generalised Structural Equation Modelling (GSEM) 
Generalised linear modelling (GLM) allows for non-linear functional forms and non-
normal response distributions and unifies disparate statistical techniques such as linear 
regression, logistic regression and Poisson regression under a single framework 
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(Tomarken & Waller, 2005). This framework is utilised by GSEM in Stata  version 13 and 
allows for different types of response processes including continuous, censored, grouped, 
ordinal and dichotomous and automatically accommodates missing data (Rabe-Hesketh, 
Skrondal, & Pickles, 2004). GSEM in Stata 13 is a powerful package that enables very 
complex data analysis of multilevel models and allows for the inclusion of both measured 
and latent variables. However, it is in the early stages of development and at present 
there are a number of limitations. Firstly, whilst it was possible to produce exponentiated 
coefficients in the form of odds ratios, these can be difficult to interpret due to the joint 
identification issue described above (where the direct and indirect effects do not sum to 
equal the total effect) and as with the KHB method, the output is not comparable to the 
hazard ratios produced when using survival analysis. GSEM has not yet been extended to 
include syntax which enables mediation analysis to be undertaken with survival data. 
GSEM also does not currently calculate model fit statistics and does not have the multiple 
group comparison techniques offered by SEM so it was deemed there would be no 
advantages of using this package for this study.  
Mediation analysis within survival analysis 
The major limitation of the techniques described above is that they share an inability to 
account for time, and as a consequence the results from these approaches are not 
comparable to those from survival analysis.  
Within the proportional hazards model neither the ‘product method’ nor the ‘difference 
method’ have a clear causal interpretation as a measure of effect (Vanderweele, 2012). In 
response to these limitations Lange and colleagues (2012) suggested a unified model 
which can be used for any type of outcome and any type of mediator. It does not work by 
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combining parameter estimates from standard models for the mediator and outcome, 
rather the approach is based on the counterfactual framework and directly models the 
direct and indirect effects of interest. 
Counterfactual framework 
In time-to-event analysis, such as a Cox’s proportional hazards model with a binary 
exposure and mediator, Lange and colleagues (2012) showed that a weighted Cox 
regression produces unbiased estimates for the direct and indirect effects (Lange, 
Vansteelandt, & Bekaert, 2012). Within the counterfactual framework each participant is 
observed under one set of circumstances but consideration is also given to what would 
have happened to that participant under counterfactual circumstances (those that did not 
occur) (Robins & Greenland, 1992). This involves replication of analyses whereby, in the 
first instance the exposure takes the original value and in the second replication it takes 
the opposite or counterfactual value. Weights are derived from logistic regression of the 
binary mediator on the exposure and baseline confounders as follows:  
𝑊𝑖
𝑐 =
𝑃(𝑀 = 𝑀𝑖 |𝐴 = 𝐴𝑖
∗, 𝐶 = 𝐶𝑖)
𝑃(𝑀 = 𝑀𝑖 |𝐴 = 𝐴𝑖 , 𝐶 = 𝐶𝑖)
. 
Where A is the observed exposure of interest; M is the mediator and C, a set of baseline confounders. 
* represents the counterfactual value(s) 
 
Where the assumptions of proportional hazards and non-informative censoring are met, 
the weighted Cox regression model will give hazard ratios which are estimates for the 
direct and indirect effects. The product of these two hazard ratios provides the hazard 
ratio for the total effect. This is the approach used by Rochon et al., (2014) in their 
development of code for mediation analysis for the statistical package R. Standard error 
and confidence intervals are calculated using bootstrapping (Rochon et al., 2014). 
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Bootstrapping 
Bootstrapping is a resampling procedure which is used to determine the accuracy of a 
parameter through the calculation of confidence intervals (Preacher & Hayes, 2008a). The 
process involves taking a new sample size from the original sample and estimating the 
values of the indirect effect (Preacher & Hayes, 2008a). An individual case may be 
selected as part of a bootstrap sample any number of times; referred to as bootstrapping 
with replacement (cases are ‘replaced’ into the original sample each time) (Preacher & 
Hayes, 2008a). This resampling process is repeated k number of times. The distribution of 
the k values of the indirect effects generated serves as a non-parametric estimation of 
that distribution, the mean can be considered as a point estimate of the indirect effect, 
the standard deviation as a the standard error of the sampling distribution and 
confidence intervals are derived by sorting the k values of the indirect effect from low to 
high (Preacher & Hayes, 2008b).  For the calculation of confidence intervals it is 
recommended the resampling procedure is undertaken at least 1000 times (Efron & 
Tibshirani, 1986; Preacher & Hayes, 2008b). A disadvantage of using bootstrapping is that 
it can be time consuming to carry out the ideal number of replications. This was one 
limitation of this study. Due to time constraints only 100 replications were undertaken for 
each model. However, for the model demonstrating the most uncertainty (widest 
confidence interval) the analysis was re-run using 1000 replications which resulted in 
minimal changes to the confidence intervals.1 
                                                     
1
 This was the model for females in ELSA with symptoms preventing walking as the mediating 
variable. In the analysis using 100 bootstrap replications the results were: Direct effect: HR 0.87; 
95%CI 0.69, 1.15; indirect effect: HR 1.43; 95%CI 1.26, 1.57: total effect: HR 1.24; 95%CI 0.98, 
1.55. In the model using 1000 replications the results were: Direct effect: HR 0.87; 95%CI 0.68, 
1.10; indirect effect: HR 1.43; 95%CI 1.27, 1.61: total effect: HR 1.24; 95%CI 0.99, 1.54). 
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6.3.3 Measurement of the proposed mediators in the ELSA and NorStOP datasets 
 
There are a number of factors that are potential mediators of the relationship between 
pain and mortality; those examined in this study were chosen as they have been shown to 
be associated with both pain and mortality, and theoretically could occur as a 
consequence of pain and lead to mortality (described in section 2.8). Whilst the analyses 
in the current study were restricted by the use of secondary data and the information 
available, the ELSA and NorStOP datasets provided data on a wide range of factors that 
could be investigated. Variables from lifestyle, health, social and psychological domains 
were tested as potential mediating variables in the relationship between pain and 
mortality. The factors are grouped into the above domains as defined in Chapter Two 
(Section 2.8) in order to structure the presentation of this chapter.  
Tables 6.1 to 6.4 summarise the proposed mediators in the ELSA and NorStOP datasets. 
The statistical technique used to undertake the mediation analysis in this study (described 
in section 6.3.2) required the mediators to be binary variables. The tables therefore 
include the following information: 
a) The method used to measure each mediator  
b) The range of scores or included categories (where appropriate) 
c) The way in which the variables were dichotomised  
Further information about the measurement of each variable, including detail of scales 
and psychometric properties (where appropriate) is presented in Appendix VII. 
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Table 6.1 Measures of the proposed mediating lifestyle factors in the ELSA and NorStOP datasets 
Proposed 
mediator 
Dataset Measure Categories/ Range Dichotomy 
Physical 
activity 
 
ELSA Mild, moderate or vigorous activity   More than once a week 
Once a week 
One to three times a month 
Hardly ever 
No/mild activity at least once a week (reference) 
 
Moderate/vigorous activity at least once a week 
NorStOP Single item: Frequency go out 
 
 
All days 
Most days 
Some days 
Few days 
No days 
Few / no days (reference) 
 
All/most/some days 
Single item: Frequency walk for 10 minutes Daily 
Every other day 
Twice per week 
Less than twice per week 
Not at all 
Less than weekly (reference) 
 
Weekly or more 
Smoking ELSA Single item: Smoker status Never 
Used to be an occasional 
smoker 
Regular or frequent smoker 
Current smoker 
Never and past smoker (reference) 
 
Current smoker 
NorStOP Single item: Smoker status “never smoked” 
“previously smoked” 
“currently smoking”  
Never/previous smoker (reference) 
 
Current smoker 
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Alcohol  ELSA Single item: Frequency of alcohol 
consumption over the last 12 months 
Not at all 
Once or twice a year 
Once every couple of months 
Once or twice a month 
Once or twice a week 
Three or four times a week 
Five or six days a week 
Almost every day 
Less than weekly (reference) 
 
Weekly or more 
NorStOP Single item: On average how often do you 
drink alcohol? 
Daily or most days 
Once or twice a week 
Once or twice a month 
Once or twice a year 
Never 
Less than weekly (reference) 
 
Weekly or more 
Obesity NorStOP BMI = weight (kg)/[height(m)]
2
 Underweight ( < 18.5 kg/m
2
) 
Normal (18.5-24.9 kg/m
2
) 
Overweight (25.0-29.9 kg/m
2
) 
Obese (≥30 kg/ m
2
) 
Not obese (reference) 
 
Obese 
Sleep NorStOP JSQ: Number of days in the past month: 
1) Trouble falling asleep 
2) Wake in the night 
3) Trouble staying asleep 
4) Wake up unrefreshed 
 
Not at all 
Some nights 
Most nights 
None/some (reference) 
 
Most nights 
JSQ = Jenkins sleep questionnaire (Jenkins, Stanton, Niemcryk, & Rose, 1988). 
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Table 6.2 Measures of the proposed mediating health factors in the ELSA and NorStOP datasets 
Proposed 
mediator 
Dataset Measure Categories/ Range Dichotomy 
Self-
reported 
health 
ELSA  Single item: Health rating Excellent 
Very good 
Good 
Fair 
Poor 
Fair/Poor 
(reference) 
 
Good/Very 
good/Excellent 
NorStOP Single item (MOS-SF12) Excellent 
Very good 
Good 
Fair 
Poor 
Fair/Poor 
(reference) 
 
Good/Very 
good/Excellent 
Functional 
limitation  
ELSA Difficulties with ADL and IADL  0-13 No difficulties 
(reference) 
 
Any difficulties 
NorStOP MOS SF-36 10 item physical functioning scale 0-100 <median (low 
function) 
(reference) 
 
>median (high 
function) 
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Symptoms 
preventing 
walking ¼ 
mile 
ELSA Items combined to form a single item  Chest pain 
Fatigue/too tired 
Shortness of breath 
Tremor 
Pain in leg or foot 
Swelling in leg or foot 
Incontinence 
Seeing difficulty 
Hearing difficulty 
Confusion 
Difficulty concentrating 
Memory problems 
Unsteady on feet or balance problems 
Lightheaded or dizziness 
Fear of falling 
Anxiety or fear 
Other problem or symptom 
No difficulties 
(reference) 
 
Any difficulties 
Allostatic 
load (AL) 
ELSA Biomarkers: 
1) Systolic blood pressure 
2) Diastolic blood pressure 
3) Mean arterial pressure 
4) Resting pulse rate 
5) Fibrinogen 
6) High density lipid cholesterol (HDL) 
7) Low density lipid cholesterol (LDL) 
8) C-reactive protein (CRP) 
9) Glycosylated haemoglobin (HBA1C) 
10) Waist/hip ratio 
0-10  
(Participants were allocated a score of 1 when their score was 
above the highest 25
th
 percentile for nine of the measures 
and below the 75
th
 percentile for HDL) 
<median (low AL) 
(Reference) 
 
>median (High 
AL) 
  
226 
 
Frailty ELSA Frailty criteria (Fried et al., 2001). Presence of 
3 or more of the following:  
 
Weight loss 
 
Low grip strength 
 
 
 
Low walking speed 
 
 
Low physical activity levels 
 
 
Exhaustion 
 
 
 
 
 
loss of ≥10% body weight since Wave 0 survey or BMI<18.5  
 
in the lowest 20% of the distribution of scores, adjusted for 
age and sex, for maximum grip strength tested using a 
dynamometer 
 
in the lowest 20% of the distribution for time taken to walk 8 
feet at “usual” pace 
 
in the lowest sex specific 20% distribution for activity level 
(derived from the 3 questions about activity levels) 
 
Positive response to 2 CES-D questions (‘felt everything was 
an effort’ and ‘could not get going’ in the last week). 
Not frail 
(reference)  
 
Frail 
MOS SF-12 = Medical Outcomes Study Short Form 12 (Ware et al., 1995) 
ADL = Activities of Daily Living 
IADL = Instrumental Activities of Daily Living 
MOS SF-36 = Medical Outcomes Study Short Form 36, 10 item physical functioning scale (Ware & Sherbourne, 1992) 
CES-D = Centre for Epidemiological Studies Depression Scale (Radloff, 1977) 
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Table 6.3 Measures of the proposed mediating social factors in the ELSA and NorStOP datasets 
Proposed 
mediator 
Dataset Measure Categories/ Range Dichotomy 
Social group 
membership 
ELSA Current membership or participation in: 
 
1) Political party, trade union or environmental group 
2) Tenants groups, resident groups or neighbourhood watch 
3) Church or other religious groups 
4) Charitable associations 
5) Education, art or music groups or evening classes 
6) Social club 
7) Sports club, gym or exercise classes 
8) Any other organisations, clubs or societies 
0-8 <median (low) 
(reference) 
 
>median (high) 
Social 
participation 
restriction 
NorStOP KAP 0-11 No restriction (0) 
(reference) 
 
Any restriction (1-
11) 
Volunteer 
work 
ELSA Frequency of volunteer work Twice a month or more 
About once a month 
Every few months 
Once or twice a year 
Less than once a year 
Never 
None (reference) 
 
Any 
KAP = Keele Assessment of Participation (Wilkie, Peat, Thomas, Hooper, & Croft, 2005)  
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Table 6.4 Measures of the proposed mediating psychological factors in the ELSA and NorStOP datasets 
Proposed 
mediator 
Dataset Measure Categories/Range Dichotomy 
Quality of life   
 
ELSA CASP-19: 
Control (e.g. ‘I feel free to plan for the future’) (4 items) 
Autonomy (e.g. ‘I feel that I can please myself what I do’) (5 items) 
Self-realisation (e.g. I feel that life is full of opportunities’) (5 items) 
Pleasure (e.g. ‘I enjoy the things that I do’) (5 items) 
Often 
Sometimes 
Not often 
Never 
 
(Scored 3-0 unless negatively 
worded where reversed) 
< median (low) 
(reference) 
 
>median (high) 
Anxiety NorStOP HADS 0-21 
Non cases 0-7 
Possible cases 8-10 
Probable cases 11-21 
Non cases 
(reference) 
 
Possible/probable 
cases 
Depression ELSA Eight item version of CES-D 0-8 No depression (0-3) 
(reference) 
 
Possible case (4-8) 
NorStOP HADS 0-21 
Non cases 0-7 
Possible cases 8-10 
Probable cases 11-21 
Non cases 
(reference) 
 
Possible/probable 
cases 
Cognitive 
impairment 
ELSA Memory test. Immediate and delayed recall of 10 words 0-20 < median (low)  
(reference) 
 
>median (high) 
NorStOP 10 item Cognitive and Alertness Behaviour Scale from the FLP 0-100% 0  (no cognitive 
impairment) 
(reference) 
 
>0  Impairment 
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Perceived 
control over 
health 
NorStOP Single item from the IPQ-R: 
‘There is a lot I can do to control my health’ 
No  
 
Yes 
No (reference) 
 
Yes 
CASP-19 = Control, Autonomy Self-realisation, Pleasure scale (Hyde et al., 2003) 
CES-D = Centre for Epidemiological Studies Depression Scale (Radloff, 1977) 
FLP = Functional Limitations Profile (British version of the Sickness Impact Profile) (Bergner, Bobbitt, Carter, & Gilson, 1981) 
IPQ-R = Illness Perceptions Questionnaire (Moss-Morris et al., 2002) 
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6.3.4 Mediation analysis within the ELSA and NorStOP samples 
 
Predictor variables 
The pain phenotypes used in this analysis were; from ELSA the variable “often troubled 
with pain/not often troubled with pain” and from NorStOP the “any pain/no pain” 
variable. This was to ensure the dichotomous predictor variables were comparing a 
“pain” group to a “no pain” group and that the analyses included the highest number of 
participants as possible to maximise the power to detect effects where they existed. It 
would have been preferable to dichotomise the pain interference (“pain interference/no 
pain interference”) variable to use as the predictor variable as pain interference was 
associated with increased mortality.  However, the risk of mortality was not proportional 
across the whole follow-up period (see section 5.7.7) so it was impractical to use this 
variable as the predictor in the mediation analysis. Although the report of “any pain” was 
not associated with mortality it was possible indirect pathways from pain to mortality 
would still exist (Hayes, 2009).  
Available sample sizes for mediation analysis 
Mediation analysis was carried out using the technique developed by Rochon et al., 
(2014) described in section 6.3.2 using R.  The R code used to perform the analysis is 
presented in Appendix VIII. Analysis was conducted on all participants with complete data 
at baseline (ELSA n=6234, NorStOP n=10985). The potential mediating role of allostatic 
load and frailty were examined in separate “allostatic load” (n=4627) and “frailty” 
(n=4375) samples from the ELSA dataset. 
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Procedure 
First, associations between the predictor and each mediating variable were examined 
using logistic regression to explain the direction of any mediating effect (i.e. a negative 
association (odds ratio less than 1) between pain and greater physical activity means the 
hazard ratio (above 1) of the indirect effect refers to an increased risk of mortality as a 
result of pain and lower levels of physical inactivity). The association between the 
mediator and outcome is not reported due to the use of the counterfactual framework to 
calculate the indirect effect directly (described in section 6.3.2) i.e. without combining 
parameter estimates from standard models for the mediator and outcome. All 
associations between pain phenotype and mediator variable are presented as odds ratios 
(OR) with 95% confidence intervals. All analyses were adjusted for putative confounders 
(age, sex education and wealth (ELSA)/ adequacy of income (NorStOP)). Results of the 
mediation analyses are presented as hazard ratios (HR) for the direct, indirect and total 
effects with associated 95% confidence intervals. 
6.3.5 Moderation 
 
In addition to examining the pathways from pain to mortality, the current study also 
tested the effects of potential moderators on these relationships. Moderation occurs 
when the effect of a predictor (X) on an outcome (Y) varies as a function of a third 
(moderating) variable; also known as an effect modifier (Figure 6.2) (Hayes, 2009; 
Rothman, 1986; Ryu, West, & Sousa, 2009). For example, in this thesis sex was proposed 
as a moderator of the relationship between pain and mortality. If the relationship 
between pain and mortality was significantly different in females compared to males, sex 
would be considered as an effect modifier or moderator of the relationship between pain 
232 
 
and mortality. Effect modification contributes to a more detailed description of the effect 
under investigation by determining in whom relationships exist (Rothman, 1986).   
 
 
 
 
Figure 6.2 Simple moderation model 
X=predictor, Y = outcome  
 
6.3.6 Moderation analysis 
 
The most common statistical way to test for moderation is to include an interaction term 
which is the product of X (predictor) and M (moderator) in a model of Y (outcome) 
(Hayes, 2013). For example, in a model which includes X (pain) and M (sex) as predictors 
of Y (mortality), if the product of X x M (pain x sex) is also entered into the model and is 
significantly associated with Y (mortality) then the relationship between X (pain) and Y 
(mortality) is moderated by M (sex). 
An alternative approach to investigating moderating effects is sub-group analysis and is 
described in section 6.3.7. 
6.3.7 Combining mediation and moderation 
 
Combining mediation and moderation analyses allows the assessment of both how and in 
whom a relationship exists (Figure 6.3). Moderated mediation is said to occur when the 
strength of an indirect effect is dependent on the level of another variable, the moderator 
X 
Moderator 
Y 
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(Hayes, 2007). This could be the result of an interaction between the predictor (X) and the 
moderator (as in the example in section 6.3.6) or the mediator and the moderator (Hayes, 
2013). For example the moderator (sex) might interact with a proposed mediator (alcohol 
consumption) leading to a difference in the magnitude of an indirect effect from pain to 
mortality via alcohol consumption between males and females.  The method of mediation 
analysis used in this study (described in section 6.3.2) is an emerging technique in which it 
was not possible to include interaction terms. Moderation was therefore assessed using 
sub-group analysis2.  
Sub-group analysis involves dividing the sample into groups according to levels of the 
moderator variable (e.g. males and females) and observing the relationship of interest in 
each of those groups (Edwards & Lambert, 2007). This approach is not generally 
recommended as a test of moderation as a statistical significance in one group but not in 
another does not imply a significant difference between the two groups. Similarly, 
significance or non-significance in both groups does not imply there is no difference 
between them (Hayes, 2013). However, statistical significance is linked to hypothesis 
testing and decision making but provides little information about the size of an effect and 
therefore can be misleading (Rothman, 1986). The calculation of confidence intervals 
around a point estimate (as has been done in this study), whilst also giving an indication 
of statistical significance (if the interval does not contain the null value e.g. a hazard ratio 
of 1) also provides an estimate of magnitude of the effect and the precision of the 
estimate (Rothman, 1986). Where confidence intervals are calculated in sub group 
                                                     
2 Interaction terms were included in the adjusted survival models presented in Chapter 5 to test 
for a significant interaction between pain phenotype and sex and between pain phenotype and 
comorbidity and the results are reported for information in Appendix VI. 
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analysis, if the confidence intervals for each group do not overlap, the difference between 
the groups is statistically significant (Bland & Peacock, 2002). Sub-group analysis was 
therefore used in this study to assess the possible moderating effects of sex and 
comorbidity on any mediated relationships between pain and mortality.  
 
 
 
 
 
 
Figure 6.3 Moderation and mediation model 
X= exposure, Y = outcome 
 
6.3.8 Measurement of the proposed moderators in the ELSA and NorStOP datasets 
 
Sex and the presence of comorbidity were hypothesised to moderate the pathways 
between pain and mortality (see section 2.9). The method used to measure sex in each of 
the datasets is described in Section 5.4. The method of measurement for comorbidity is 
described below.  
  
Moderators 
X 
Confounders 
Y 
Mediators 
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Co-morbidity  
In ELSA, participants were asked to indicate if a doctor had ever told them they had or 
have a number of chronic conditions. Participants were asked to choose from a list of 22 
possible conditions and could indicate other conditions that were not on the list. 
Responses were recoded into dichotomous variables (present or absent) for 
cardiovascular disease (present if participants reported having or having had high blood 
pressure or hypertension, angina, heart attack (including myocardial infarction or 
coronary thrombosis), congestive heart failure, a heart murmur, abnormal heart rhythm, 
diabetes or high blood sugar, a stroke or any other heart trouble), respiratory diseases 
(participants report having or having had chronic lung disease (i.e. chronic bronchitis, 
emphysema or asthma), cancer or malignant tumour (excluding minor skin cancers)) or 
other comorbidity (arthritis (including osteoarthritis and rheumatism), osteoporosis, 
Parkinson’s disease, any emotional or psychiatric problems, Alzheimer’s disease or 
dementia) (NatCen Social Research, 2014b).  To examine for possible moderation by 
comorbidity, the sample was divided into two groups; those who did not indicate any 
morbidities (a score of 0) and those who indicated any of the listed conditions (score >0). 
In NorStOP, participants were asked to report the presence of three common chronic 
health conditions (chest problems, heart problems, diabetes), two impairments most 
commonly associated with disability (deafness, problems with eyesight) and seven other 
impairments likely to restrict activity or mobility in older people (falls, memory 
difficulties, cough with spit, breathless when walking, dizziness, weakness in arms/legs, 
raised blood pressure). From these single items, counts of health conditions and 
impairments were calculated (0-12). Those indicating no conditions were compared to 
those who indicated any of the conditions. 
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6.4 Results of the mediation analyses 
 
Tables 6.5 (ELSA) and 6.6 (NorStOP) display results of logistic regression testing the 
association between the predictor (“often troubled” with pain in ELSA and “any pain“ in 
NorStOP) and each proposed mediator. The total, direct and indirect effects for each 
mediation model is also presented using all participants at baseline with complete data 
for all predictor, confounder and mediator information (ELSA n=6324, NorStOP n=10985).   
6.4.1 Lifestyle factors 
“Often troubled” with pain was associated with lower levels of physical activity and low 
alcohol consumption but was not associated with smoking in the ELSA dataset (Table 6.5). 
In the NorStOP dataset “any pain” was associated with not smoking, low alcohol 
consumption, obesity, low physical activity (frequency go out/walk for 10 minutes) and 
with sleep problems (Table 6.6).  
In ELSA the relationship between “often troubled” with pain and mortality was mediated 
by physical inactivity and low alcohol consumption but not smoking (Table 6.5). 
In NorStOP there was an indirect effect from “any pain” to mortality via all lifestyle 
factors with the exception of alcohol consumption and obesity (Table 6.6).  
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Table 6.5 Pathways between ‘often troubled with pain’ and mortality via lifestyle, health, social 
and psychological factors for the for the ELSA complete case sample (n=6324): Direct, indirect 
and total effects.  
 
 
 
 
 
Mediator 
Association 
between often 
troubled with pain 
and potential 
mediator 
Adjusted OR (95%CI) 
 
 
 
 
 
Pathway 
 
 
 
 
 
Adjusted HR (95%CI) 
Model - Total 
effect (no 
mediators) 
 
 
1.30 (1.12, 1.50) 
LIFESTYLE FACTORS 
Physical  activity  
none/mild 
moderate/vigorous 
 
 
Reference 
0.34 (0.30, 0.39) 
 
Direct 
Indirect 
Total 
 
1.14 (0.98, 1.33) 
1.14 (1.10, 1.20) 
1.30 (1.14, 1.51) 
Smoking  
Non-smoker  
Current smoker 
 
Reference 
1.07 (0.92, 1.25) 
Direct 
Indirect 
Total 
1.29 (1.12, 1.50) 
1.01 (0.99, 1.02) 
1.30 (1.14, 1.51) 
Alcohol consumption 
< weekly (low) 
> weekly (high) 
 
Reference 
0.71 (0.64, 0.80) 
Direct 
Indirect 
Total 
1.28 (1.12, 1.49) 
1.01 (1.00, 1.02) 
1.30 (1.14, 1.51) 
HEALTH 
Self-reported health 
Poor/Fair 
Good/Very good/Excellent 
 
 
Reference 
0.18 (0.16, 0.21) 
 
Direct 
Indirect 
Total 
 
0.99 (0.84, 1.16) 
1.32 (1.23, 1.41) 
1.30 (1.14, 1.52) 
Functional limitation 
(ADL/IADL difficulties) 
No difficulties 
Any difficulties  
 
 
Reference 
6.40 (5.61, 7.31) 
 
Direct 
Indirect 
Total 
 
1.00 (0.86, 1.16) 
1.31 (1.20, 1.39) 
1.31 (1.14, 1.51) 
Symptoms preventing walking ¼ 
mile 
No symptoms 
Any symptoms 
 
 
Reference 
8.17 (7.08, 9.45) 
 
Direct 
Indirect 
Total 
 
0.89 (0.78, 1.04) 
1.45 (1.35, 1.58) 
1.30 (1.13, 1.51) 
SOCIAL FACTORS 
Social group membership  
0-1 group 
2 or more groups 
 
 
Reference 
0.86 (0.77, 0.96) 
 
Direct 
Indirect 
Total 
 
1.29 (1.12, 1.50) 
1.01 (1.00, 1.02) 
1.30 (1.14, 1.51) 
Volunteer work  
None   
Any 
 
Reference 
0.85 (0.76, 0.96) 
Direct 
Indirect 
Total 
1.29 (1.12, 1.50) 
1.01 (1.00, 1.02) 
1.30 (1.14, 1.51) 
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PSYCHOLOGICAL FACTORS 
Quality of life  
< median (low)  
 >median (high) 
 
Control  
< median (low) 
>median (high) 
 
Autonomy  
< median(low) 
 >median(high) 
 
Pleasure  
< median (low) 
 >median (high) 
 
Self-realisation  
< median (low)  
 >median (high) 
 
 
Reference 
0.37 (0.33, 0.41) 
 
 
Reference 
0.46 (0.41, 0.52) 
 
 
Reference 
0.38 (0.34, 0.42) 
 
 
Reference 
0.63 (0.56, 0.70) 
 
 
Reference 
0.48 (0.43, 0.54) 
 
Direct 
Indirect 
Total 
 
Direct 
Indirect 
Total 
 
Direct 
Indirect 
Total 
 
Direct 
Indirect 
Total 
 
Direct 
Indirect 
Total 
 
1.18 (1.02, 1.36) 
1.10 (1.07, 1.14) 
1.30 (1.13, 1.51) 
 
1.23 (1.07, 1.44) 
1.06 (1.03, 1.08) 
1.30 (1.14, 1.51) 
 
1.22 (1.06, 1.41) 
1.07 (1.03, 1.10) 
1.30 (1.14, 1.51) 
 
1.27 (1.11, 1.49) 
1.02 (1.00, 1.04) 
1.30 (1.14, 1.51) 
 
1.24 (1.06, 1.41) 
1.05 (1.03, 1.08) 
1.30 (1.14, 1.51) 
Depression  
Not depressed (CESD score ) <4  
Depressed  >4 
 
Reference 
2.62 (2.33, 2.95) 
Direct 
Indirect 
Total 
1.20 (1.04, 1.38) 
1.09 (1.05, 1.12) 
1.30 (1.13, 1.51) 
Cognitive impairment 
< median (low ability) 
 > median (high ability) 
 
Reference 
0.83 (0.74, 0.93) 
Direct 
Indirect 
Total 
1.29 (1.12, 1.49) 
1.01 (1.00, 1.02) 
1.30 (1.13, 1.51) 
All models adjusted for age, sex, education and wealth 
OR = Odds ratio 
HR = Hazard ratio 
CI = Confidence Intervals 
Significant associations between predictor and mediator and indirect effects are in bold 
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Table 6.6 Pathways between ’any pain’ and mortality via lifestyle, health, social and 
psychological factors for the NorStOP complete case baseline sample (n=10985): Direct, indirect 
and total effects. 
Mediator  Association 
between any pain 
and potential 
mediator 
Adjusted OR 
(95%CI) 
 
 
 
 
 
Pathway 
 
 
 
 
 
Adjusted HR (95%CI) 
Model - Total 
effect (no 
mediators) 
 
 
1.06 (0.95, 1.19) 
LIFESTYLE FACTORS 
Smoking   
Never/Previous 
 Current 
 
 
Reference 
0.88 (0.81, 0.97) 
 
Direct 
Indirect 
Total 
 
1.05 (0.96, 1.17) 
1.01 (1.00, 1.02) 
1.06 (0.96, 1.18) 
Alcohol consumption 
Monthly or less (low)  
Weekly (high) 
 
Reference 
0.89 (0.81, 0.97) 
Direct 
Indirect 
Total 
1.06 (0.96, 1.18) 
1.00 (1.00, 1.01) 
1.06 (0.96, 1.18) 
Obesity  
Not obese  
Obese  
 
Reference 
1.77 (1.57, 1.99) 
Direct 
Indirect 
Total 
1.06 (0.96, 1.18) 
1.00 (0.99, 1.01) 
1.06 (0.96, 1.18) 
Frequency go out  
Few/No days (low)  
 All/Most/Some days (high)  
 
Frequency walk for 10 minutes 
< weekly (low) 
>weekly (high) 
 
Reference 
0.41 (0.35, 0.48) 
 
 
Reference 
0.53 (0.49, 0.58) 
Direct 
Indirect 
Total 
 
Direct 
Indirect 
Total 
0.96 (0.88, 1.07) 
1.09 (1.07, 1.12) 
1.05 (0.96, 1.17) 
 
0.98 (0.88, 1.09) 
1.09 (1.07, 1.10) 
1.06 (0.97, 1.19) 
Sleep 
Trouble falling asleep  
Some/none 
Most nights 
 
Wake in the night  
Some/none  
 Most nights 
 
Trouble staying asleep 
Some/none  
Most nights 
 
Wake up unrefreshed 
Some/none  
 Most nights 
 
 
Reference 
3.37 (2.84, 4.02) 
 
 
Reference 
2.56 (2.28, 2.88) 
 
 
Reference 
2.87 (2.51, 3.28) 
 
 
Reference 
3.99 (3.40, 4.71) 
 
Direct 
Indirect 
Total 
 
Direct 
Indirect 
Total 
 
Direct 
Indirect 
Total 
 
Direct 
Indirect 
Total 
 
1.04 (0.94, 1.16) 
1.02 (1.00, 1.04) 
1.05 (0.96, 1.17) 
 
1.01 (0.92, 1.12) 
1.03 (1.01, 1.06) 
1.05 (0.95, 1.17) 
 
1.04 (0.95, 1.15) 
1.02 (1.00, 1.04) 
1.06 (0.96, 1.18) 
 
0.99 (0.90, 1.10) 
1.06 (1.03, 1.08) 
1.04 (0.96, 1.16) 
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HEALTH FACTORS 
Self-rated health  
Fair/Poor  
Excellent/Very good/Good  
 
Functional limitation (SF36) 
< median  (low)  
 > median (high) 
 
 
Reference 
0.28 (0.25, 0.31) 
 
 
Reference 
0.15 (0.14, 0.17) 
 
Direct 
Indirect 
Total 
 
Direct 
Indirect 
Total 
 
0.84 (0.77, 0.93) 
1.23 (1.20, 1.29) 
1.03 (0.94, 1.15) 
 
0.84 (0.77, 0.93) 
1.22 (1.16, 1.28) 
1.02 (0.93, 1.14) 
SOCIAL FACTORS 
Social participation (restriction) (KAP) 
None  
Any 
 
 
Reference 
1.98 (1.81, 2.16) 
 
Direct 
Indirect 
Total 
 
0.97 (0.89, 1.09) 
1.09 (1.07, 1.11) 
1.05 (0.96, 1.18) 
PSYCHOLOGICAL FACTORS 
Anxiety (HADS) 
No anxiety  
Possible/probable 
 
 
Reference 
2.58 (2.34, 2.85) 
 
Direct 
Indirect 
Total 
 
1.03 (0.93, 1.15) 
1.04 (1.02, 1.06) 
1.07 (0.97, 1.19) 
Depression (HADS) 
No depression 
Possible/probable 
 
Reference 
2.88 (2.51, 3.31) 
Direct 
Indirect 
Total 
0.98 (0.89, 1.10) 
1.08 (1.06, 1.11) 
1.06 (0.96, 1.19) 
Cognitive impairment 
No impairment  
Impairment 
 
Reference 
2.62 (2.39, 2.87) 
Direct 
Indirect 
Total 
0.99 (0.90, 1.10) 
1.06 (1.04, 1.10) 
1.05 (0.96, 1.17) 
Control (from IPQ-R) 
Disagree (low control)  
Agree (high control) 
 
Reference 
0.91 (0.83, 1.00) 
Direct 
Indirect 
Total 
1.06 (0.97, 1.18) 
1.00 (1.00, 1.00) 
1.06 (0.97, 1.18) 
All models adjusted for age, sex, education and wealth 
OR = Odds ratio 
HR = Hazard ratio 
CI = Confidence Intervals 
Significant associations between predictor and mediator and indirect effects are in bold 
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6.4.2 Health factors 
In both ELSA and NorStOP all health factors were detrimentally associated with “often 
troubled” with pain and “any pain” respectively. There were statistically significant 
mediating/indirect effects of all health factors in both data samples (Table 6.5 and 6.6). 
6.4.3 Social factors 
All social factors were adversely associated with pain report in ELSA and NorStOP. There 
were statistically significant mediating effects of low social group membership and no 
volunteer work in ELSA and a statistically significant indirect effect via social participation 
restriction in NorStOP (Table 6.5 and 6.6).   
6.4.4 Psychological factors 
“Often troubled” with pain was associated with lower quality of life across all domains 
and with depression and cognitive impairment in the ELSA sample (Table 6.5). In NorStOP, 
“any pain” was associated with anxiety, depression, cognitive impairment and low 
perceived control of health (Table 6.6). There were statistically significant 
mediating/indirect effects of all psychological factors with the exception of perceived 
control of health in the NorStOP sample (Tables 6.5 and 6.6). 
6.5 Results of the moderation analyses 
6.5.1 Stratification by sex 
Table 6.7 and 6.8 display the results of the logistic regression and mediation analyses 
stratified by sex in the ELSA and NorStOP samples respectively. 
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Table 6.7 Pathways between ‘often troubled with pain’ and mortality via lifestyle, health, social and psychological factors in the ELSA complete case 
sample (n=6324) stratified by sex: Direct, indirect and total effects. 
  Females (n=3451) Males (n=2873) 
Association 
between often 
troubled with pain 
and potential 
mediator 
Adjusted OR 
(95%CI) 
 
 
 
 
 
 
Pathway 
 
 
 
 
 
Adjusted HR 
(95%CI) 
Association 
between often 
troubled with pain 
and potential 
mediator 
Adjusted OR 
(95%CI) 
 
 
 
 
 
 
Pathway 
 
 
 
 
 
Adjusted HR 
(95%CI) 
Model - Total effect (no 
mediators) 
 
1.24 (1.00, 1.53) 
- Total effect (no 
mediators)  
 
1.36 (1.12, 1.66) 
LIFESTYLE FACTORS 
Physical  activity  
none/mild 
moderate/vigorous 
 
 
Reference 
0.33 (0.28, 0.40) 
 
Direct 
Indirect 
Total 
 
1.07 (0.87, 1.34) 
1.16 (1.09, 1.22) 
1.24 (1.00, 1.54) 
 
 
Reference 
0.34 (0.28, 0.43) 
 
Direct 
Indirect 
Total 
 
1.21 (0.98, 1.41) 
1.13 (1.08, 1.19) 
1.36 (1.12, 1.62) 
Smoking  
Non-smoker 
Current smoker 
 
Reference 
1.05 (0.85, 1.29) 
Direct 
Indirect 
Total 
1.23 (0.99, 1.55) 
1.00 (0.99, 1.02) 
1.24 (1.00, 1.54) 
 
Reference 
1.10 (0.88, 1.37) 
Direct 
Indirect 
Total 
1.35 (1.10, 1.60) 
1.01 (0.99, 1.02) 
1.36 (1.11, 1.61) 
Alcohol consumption 
< weekly (low)  
> weekly (high) 
 
Reference 
0.75 (0.65, 0.87) 
Direct 
Indirect 
Total 
1.21 (0.98, 1.51) 
1.02 (1.00, 1.04) 
1.24 (1.00, 1.54) 
 
Reference 
0.65 (0.55, 0.78) 
Direct 
Indirect 
Total 
1.36 (1.11, 1.61) 
1.00 (0.99, 1.02) 
1.36 (1.11, 1.61) 
HEALTH 
Self-reported health 
Poor/Fair  
Good/Very good/Excellent 
 
 
Reference 
0.18 (0.15, 0.22) 
 
Direct 
Indirect 
Total 
 
0.97 (0.78, 1.25) 
1.27 (1.16, 1.38) 
1.24 (1.00, 1.53) 
 
 
Reference 
0.18 (0.15, 0.22) 
 
Direct 
Indirect 
Total 
 
1.00 (0.81, 1.24) 
1.36 (1.26, 1.45) 
1.36 (1.12, 1.63) 
Functional limitation 
(ADL/IADL difficulties) 
No difficulties 
Any difficulties  
 
 
Reference 
6.02 (5.07, 7.17) 
 
Direct 
Indirect 
Total 
 
0.95 (0.75, 1.25) 
1.30 (1.19, 1.41) 
1.24 (1.00, 1.53) 
 
 
Reference 
6.97 (5.68, 8.56) 
 
Direct 
Indirect 
Total 
 
1.04 (0.84, 1.23) 
1.32 (1.21, 1.45) 
1.37 (1.13, 1.61) 
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Symptoms preventing walking ¼ mile 
No symptoms 
Any symptoms 
 
Reference 
7.33 (6.06, 8.89) 
Direct 
Indirect 
Total 
0.87 (0.69, 1.15) 
1.43 (1.26, 1.57) 
1.24 (0.98, 1.55) 
 
Reference 
9.44 (7.60, 11.78) 
Direct 
Indirect 
Total 
0.91 (0.74, 1.11) 
1.48 (1.36, 1.64) 
1.35 (1.11, 1.59) 
SOCIAL FACTORS 
Social group membership  
0-1 group  
2 or more groups 
 
 
Reference 
0.91 (0.79, 1.06) 
 
Direct 
Indirect 
Total 
 
1.23 (0.99, 1.53) 
1.00 (1.00, 1.01) 
1.24 (1.00,1.54) 
 
 
Reference 
0.79 (0.67, 0.94) 
 
Direct 
Indirect 
Total 
 
1.34 (1.09, 1.60) 
1.01 (1.00, 1.03) 
1.36 (1.11, 1.61) 
Volunteer work  
None  
Any 
 
Reference 
0.87 (0.74, 1.01) 
Direct 
Indirect 
Total 
1.23 (1.00, 1.53) 
1.01 (1.00, 1.02) 
1.24 (1.00, 1.54) 
 
Reference 
0.83 (0.69, 1.00) 
Direct 
Indirect 
Total 
1.35 (1.10, 1.59) 
1.01 (1.00, 1.02) 
1.36 (1.11, 1.61) 
PSYCHOLOGICAL FACTORS 
Quality of life  
< median (low)  
>median (high) 
 
Control  
< median (low) 
>median (high) 
 
Autonomy  
< median(low)  
>median(high) 
 
Pleasure  
< median (low)  
>median (high) 
 
Self-realisation  
< median (low)  
>median (high) 
 
 
Reference 
0.37 (0.32, 0.42) 
 
 
Reference 
0.46 (0.39, 0.53) 
 
 
Reference 
0.37 (0.31, 0.42) 
 
 
Reference 
0.62 (0.54, 0.71) 
 
 
Reference 
0.49 (0.42, 0.56) 
 
Direct 
Indirect 
Total 
 
Direct 
Indirect 
Total 
 
Direct 
Indirect 
Total 
 
Direct 
Indirect 
Total 
 
Direct 
Indirect 
Total 
 
1.11 (0.89, 1.40) 
1.11 (1.05, 1.16) 
1.24 (1.00, 1.54) 
 
1.16 (0.95, 1.44) 
1.07 (1.03, 1.10) 
1.24 (1.00, 1.55) 
 
1.16 (0.93, 1.42) 
1.07 (1.01, 1.12) 
1.23 (0.99, 1.55) 
 
1.19 (0.95, 1.44) 
1.04 (1.01, 1.07) 
1.24 (1.00, 1.55) 
 
1.17 (0.95, 1.46) 
1.06 (1.03, 1.09) 
1.24 (1.00, 1.54) 
 
 
Reference 
0.36 (0.31, 0.43) 
 
 
Reference 
0.46 (0.39, 0.55) 
 
 
Reference 
0.40 (0.33, 0.47) 
 
 
Reference 
0.64 (0.54, 0.75) 
 
 
Reference 
0.47 (0.40, 0.57) 
 
Direct 
Indirect 
Total 
 
Direct 
Indirect 
Total 
 
Direct 
Indirect 
Total 
 
Direct 
Indirect 
Total 
 
Direct 
Indirect 
Total 
 
1.24 (0.99, 1.49) 
1.09 (1.04, 1.14) 
1.36 (1.11, 1.61) 
 
1.30 (1.06, 1.56) 
1.04 (1.02, 1.07) 
1.36 (1.11, 1.61) 
 
1.28 (1.03, 1.53) 
1.07 (1.02, 1.11) 
1.37 (1.11, 1.61) 
 
1.35 (1.10, 1.62) 
1.01 (0.99, 1.03) 
1.36 (1.11, 1.61) 
 
1.30 (1.05, 1.55) 
1.05 (1.02, 1.08) 
1.37 (1.12, 1.62) 
Depression  
Not depressed (CESD score ) <4  
Depressed  >4 
 
Reference 
2.42 (2.08, 2.82) 
Direct 
Indirect 
Total 
1.21 (1.00, 1.51) 
1.02 (0.99, 1.07) 
1.24 (1.00, 1.54) 
 
Reference 
2.97 (2.45, 3.59) 
Direct 
Indirect 
Total 
1.18 (0.98, 1.42) 
1.15 (1.10, 1.22) 
1.36 (1.12, 1.62) 
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Cognitive impairment 
< median (low ability)  
> median (high ability) 
 
Reference 
0.89 (0.76, 1.03) 
Direct 
Indirect 
Total 
1.23 (0.99, 1.53) 
1.01 (1.00, 1.02) 
1.24 (1.00, 1.54) 
 
Reference 
0.76 (0.64, 0.90) 
Direct 
Indirect 
Total 
1.35 (1.09, 1.60) 
1.01 (1.00, 1.02) 
1.36 (1.11, 1.61) 
All models adjusted for age, sex, education and wealth 
OR = Odds ratio 
HR = Hazard ratio 
CI = Confidence Intervals 
Significant associations between predictor and mediator and indirect effects are in bold 
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Table 6.8 Pathways between ’any pain’ and mortality via lifestyle, health, social and psychological factors for the NorStOP complete case baseline 
sample (n=10985): Direct, indirect and total effects stratified by sex. 
 Females (n=5967) Males (n=5018) 
 Association 
between any pain 
and potential 
mediator 
Adjusted OR 
(95%CI) 
 
 
 
 
 
Pathway 
 
 
 
 
Adjusted HR 
(95%CI) 
Association 
between any pain 
and potential 
mediator 
Adjusted OR 
(95%CI) 
 
 
 
 
 
Pathway 
 
 
 
 
Adjusted HR 
(95%CI) 
Model - Total effect (no 
mediators) 
 
1.03 (0.87, 1.21) 
- Total effect (no 
mediators) 
 
1.08 (0.92, 1.26) 
LIFESTYLE FACTORS 
Smoking   
Never/Previous  
Current 
 
 
Reference 
0.98 (0.88,1.10) 
 
Direct 
Indirect 
Total 
 
1.02 (0.87, 1.17) 
1.00 (0.99, 1.01) 
1.03 (0.88, 1.17) 
 
 
Reference 
0.75 (0.66, 0.87) 
 
Direct 
Indirect 
Total 
 
1.06 (0.94, 1.28) 
1.02 (1.01, 1.03) 
1.08 (0.96, 1.30) 
Alcohol consumption 
Monthly or less (low)  
Weekly (high) 
 
Reference 
0.86 (0.77, 0.97) 
Direct 
Indirect 
Total 
1.02 (0.88, 1.17) 
1.00 (1.00, 1.01) 
1.03 (0.88, 1.18) 
 
Reference 
0.92 (0.80, 1.06) 
Direct 
Indirect 
Total 
1.08 (0.96, 1.30) 
1.00 (1.00, 1.00) 
1.08 (0.96, 1.30) 
Obesity  
Not obese  
Obese  
 
Reference 
2.04 (1.73, 2.41) 
Direct 
Indirect 
Total 
1.02 (0.87, 1.17) 
1.01 (0.98, 1.02) 
1.03 (0.88, 1.18) 
 
Reference 
1.50 (1.26, 1.78) 
Direct 
Indirect 
Total 
1.08 (0.96, 1.30) 
1.00 (0.99, 1.01) 
1.08 (0.96, 1.30) 
Frequency go out  
Few/No days (low)  
All/Most/Some days (high)  
 
Frequency walk for 10 minutes 
< weekly (low) 
>weekly (high) 
 
Reference 
0.38 (0.31, 0.46) 
 
 
Reference 
0.49 (0.42, 0.54) 
Direct 
Indirect 
Total 
 
Direct 
Indirect 
Total 
0.89 (0.76, 1.01) 
1.14 (1.10, 1.18) 
1.02 (0.87, 1.17) 
 
0.92 (0.79, 1.05) 
1.12 (1.08, 1.15) 
1.03 (0.88, 1.19) 
 
Reference 
0.47 (0.37, 0.59) 
 
 
Reference 
0.60 (0.53, 0.68) 
Direct 
Indirect 
Total 
 
Direct 
Indirect 
Total 
1.02 (0.90, 1.22) 
1.03 (1.04, 1.08) 
1.07 (0.96, 1.29) 
 
1.02 (0.90, 1.21) 
1.06 (1.04, 1.08) 
1.08 (0.96, 1.29) 
  
246 
 
Sleep 
Trouble falling asleep  
Some/none  
Most nights 
 
Wake in the night  
Some/none  
Most nights 
 
Trouble staying asleep 
Some/none  
Most nights 
 
Wake up unrefreshed 
Some/none  
Most nights 
 
 
Reference 
3.27 (2.66, 4.06) 
 
 
Reference 
2.62 (2.24, 3.07) 
 
 
Reference 
2.76 (2.34, 3.28) 
 
 
Reference 
4.07 (3.32, 5.04) 
 
Direct 
Indirect 
Total 
 
Direct 
Indirect 
Total 
 
Direct 
Indirect 
Total 
 
Direct 
Indirect 
Total 
 
0.98 (0.85, 1.13) 
1.03 (1.01, 1.06) 
1.01 (0.87, 1.15) 
 
0.97 (0.84, 1.13) 
1.03 (1.01, 1.06) 
1.00 (0.86, 1.15) 
 
0.99 (0.85, 1.14) 
1.03 (1.00, 1.05) 
1.01 (0.87, 1.16) 
 
0.95 (0.82, 1.10) 
1.05 (1.02, 1.10) 
1.00 (0.87, 1.15) 
 
 
Reference 
3.56 (2.65, 4.88) 
 
 
Reference 
2.48 (2.08, 2.99) 
 
 
Reference 
3.03 (2.45, 3.79) 
 
 
Reference 
3.86 (3.00, 5.05) 
 
Direct 
Indirect 
Total 
 
Direct 
Indirect 
Total 
 
Direct 
Indirect 
Total 
 
Direct 
Indirect 
Total 
 
1.08 (0.96, 1.32) 
1.00 (0.98, 1.03) 
1.08 (0.96, 1.31) 
 
1.04 (0.91, 1.27) 
1.04 (1.01, 1.06) 
1.08 (0.95, 1.31) 
 
1.08 (0.96,1.30) 
1.01 (0.99, 1.03) 
1.09 (0.97, 1.32) 
 
1.01 (0.90, 1.22) 
1.06 (1.03, 1.08) 
1.07 (0.95, 1.29) 
HEALTH FACTORS 
Self-rated health  
Fair/Poor  
Excellent/Very good/Good  
 
Functional ability (SF36) 
< median  (low) 
> median (high) 
 
 
Reference 
0.25 (0.21, 0.29) 
 
 
Reference 
0.14 (0.12, 0.16) 
 
Direct 
Indirect 
Total 
 
Direct 
Indirect 
Total 
 
0.81 (0.70, 0.95) 
1.24 (1.18, 1.30) 
1.01 (0.86, 1.16) 
 
0.84 (0.70, 0.96) 
1.17 (1.10, 1.25) 
0.99 (0.85, 1.12) 
 
 
Reference 
0.32 (0.27, 0.37) 
 
 
Reference 
0.18 (0.15, 0.21) 
 
Direct 
Indirect 
Total 
 
Direct 
Indirect 
Total 
 
0.87 (0.77, 1.05) 
1.22 (1.17, 1.28) 
1.05 (0.95, 1.26) 
 
0.84 (0.73, 0.99) 
1.25 (1.18, 1.33) 
1.05 (0.93, 1.24) 
SOCIAL FACTORS 
Social participation (restriction) (KAP) 
None 
Any 
 
 
Reference 
2.17 (1.92, 2.45) 
 
Direct 
Indirect 
Total 
 
0.92 (0.79, 1.04) 
1.10 (1.08, 1.15) 
1.02 (0.87, 1.16) 
 
 
Reference 
1.78 (1.56, 2.02) 
 
Direct 
Indirect 
Total 
 
1.01 (0.89, 1.23) 
1.06 (1.04, 1.09) 
1.08 (0.96, 1.30) 
PSYCHOLOGICAL FACTORS 
Anxiety (HADS) 
No anxiety 
Possible/probable 
 
 
Reference 
2.45 (2.16, 2.78) 
 
Direct 
Indirect 
Total 
 
0.99 (0.86, 1.16) 
1.04 (1.01, 1.07) 
1.03 (0.86, 1.19) 
 
 
Reference 
2.80 (2.39, 3.29) 
 
Direct 
Indirect 
Total 
 
1.05 (0.93, 1.29) 
1.04 (1.00, 1.06) 
1.09 (0.97, 1.34) 
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Depression (HADS) 
No depression 
Possible/probable 
 
Reference 
3.13 (2.60, 3.81) 
Direct 
Indirect 
Total 
0.92 (0.79, 1.06) 
1.11 (1.08, 1.16) 
1.01 (0.87, 1.17) 
 
Reference 
2.62 (2.16, 3.20) 
Direct 
Indirect 
Total 
1.02 (0.90, 1.24) 
1.06 (1.03, 1.08) 
1.08 (0.96, 1.31) 
Cognitive impairment 
No impairment 
Impairment 
 
Reference 
2.66 (2.35, 3.02) 
Direct 
Indirect 
Total 
0.92 (0.78, 1.08) 
1.10 (1.06, 1.13) 
1.01 (0.88, 1.16) 
 
Reference 
2.56 (2.23, 2.95) 
Direct 
Indirect 
Total 
1.04 (0.92, 1.24) 
1.04 (1.00, 1.06) 
1.08 (0.96, 1.30) 
Control (from IPQ-R) 
Disagree (low control) 
Agree (high control) 
 
Reference 
0.87 (0.77, 0.99) 
Direct 
Indirect 
Total 
1.03 (0.88, 1.18) 
1.00 (0.99, 1.00) 
1.03 (0.88, 1.18) 
 
Reference 
0.96 (0.84, 1.10) 
Direct 
Indirect 
Total 
1.08 (0.96, 1.30) 
1.00 (1.00, 1.00) 
1.08 (0.96, 1.30) 
All models adjusted for age, sex, education and adequacy of income 
OR = Odds ratio 
HR = Hazard ratio 
CI = Confidence Intervals 
Significant associations between predictor and mediator and indirect effects are in bold 
 
248 
 
“Often troubled” with pain was associated with all proposed mediating factors in females 
in the ELSA sample with the exception of smoking, social group membership, volunteer 
work and cognitive impairment. In males, only smoking was not associated with “often 
troubled” with pain (Table 6.7). In the NorStOP sample, in females all proposed mediators 
with the exception of smoking were associated with “any pain”. In males, alcohol 
consumption and perceived control over health were the only proposed mediators not 
statistically significantly associated with “any pain” (Table 6.8). 
Sex did not moderate the relationship between “often troubled” with pain in ELSA or 
between “any pain” and mortality in NorStOP. 
In ELSA, sex moderated the relationship between “often troubled” with pain and 
mortality via depression. There was a significant mediating effect in males but not in 
females and this difference was statistically significant as the confidence intervals did not 
overlap between strata (Table 6.7). Conversely, in the NorStOP sample, there was a 
statistically significant indirect effect of depression in females and males but the effect 
size was larger in females. Again the confidence intervals did not overlap between strata 
indicating a statistically significant difference between the groups (Table 6.8). 
In the NorStOP sample sex moderated the indirect effects between “any pain” and 
mortality via (not) smoking (stronger in males), low frequency of going out, low frequency 
of walking for 10 minutes and cognitive impairment (stronger in females) (Table 6.8).  
6.5.2 Stratification by comorbidity 
Tables 6.9 and 6.10 display the results of logistic regression and of the mediation analyses 
of the ELSA and NorStOP samples described in section 6.5 stratified by comorbidity. 
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In ELSA, “often troubled” with pain was adversely associated with social group 
membership and volunteer work in participants with comorbidity but not in those 
without. All other proposed mediators were associated with “often troubled” with pain in 
both strata with the exception of smoking which was not significantly associated with 
“often troubled” with pain in either stratum (Table 6.9). 
In NorStOP, smoking was not associated with “any pain” in participants with comorbidity 
and alcohol consumption and perceived control over health were not associated with 
“any pain” in participants without comorbidity. All other proposed mediators were 
associated with “any pain” in both strata (Table 6.10). 
Comorbidity did not moderate the relationship between “often troubled” with pain and 
mortality in ELSA or the relationship between “any pain” and mortality in NorStOP (Tables 
6.9 and 6.10). 
Comorbidity did not significantly moderate any of the mediated pathways in the ELSA  
samples as the confidence intervals for the indirect effects of all variables overlapped 
between sub-groups with the exception of the ‘pleasure’ domain of quality of life. Low 
‘pleasure’ mediated the relationship between “often troubled” with pain and mortality in 
participants without comorbidity only (Table 6.9).  
In NorStOP, comorbidity moderated the indirect effects between “any pain” and mortality 
via low frequency of going out, low frequency of walking for 10 minutes, 
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Table 6.9 Pathways between ‘often troubled with pain’ and mortality via lifestyle, health, social and psychological factors in the ELSA complete case 
sample (n=6324) stratified by comorbidity: Direct, indirect and total effects. 
  With comorbidity (n=3739) No comorbidity (n=2585) 
Association 
between often 
troubled with pain 
and potential 
mediator 
Adjusted OR 
(95%CI) 
 
 
 
 
 
 
Pathway 
 
 
 
 
 
Adjusted HR 
(95%CI) 
Association 
between often 
troubled with 
pain and 
potential 
mediator 
OR (95%CI) 
 
 
 
 
 
 
Pathway 
 
 
 
 
 
Adjusted HR 
(95%CI) 
Model - Total effect (no 
mediators)  
 
1.26 (1.06, 1.49) 
- Total effect (no 
mediators)  
 
1.19 (0.85, 1.67) 
LIFESTYLE FACTORS 
Physical  activity  
none/mild  
moderate/vigorous 
 
 
Reference 
0.35 (0.30, 0.42) 
 
Direct 
Indirect 
Total 
 
1.11 (0.95, 1.32) 
1.13 (1.09, 1.18) 
1.26 (1.05, 1.48) 
 
 
Reference 
0.39 (0.30, 0.51) 
 
Direct 
Indirect 
Total 
 
1.08 (0.72, 1.50) 
1.14 (1.07, 1.20) 
1.23 (0.79, 1.69) 
Smoking  
Non-smoker  
Current smoker 
 
Reference 
1.18 (0.97, 1.44) 
Direct 
Indirect 
Total 
1.24 (1.04, 1.46) 
1.01 (1.00, 1.03) 
1.26 (1.05, 1.48) 
 
Reference 
0.95 (0.72, 1.25) 
Direct 
Indirect 
Total 
1.20 (0.78, 1.70) 
1.00 (0.98, 1.01) 
1.19 (0.76, 1.68) 
Alcohol consumption 
< weekly (low)  
> weekly (high) 
 
Reference 
0.75 (0.65, 0.86) 
Direct 
Indirect 
Total 
1.24 (1.03, 1.45) 
1.02 (1.00, 1.03) 
1.26 (1.05, 1.48) 
 
Reference 
0.69 (0.56, 0.85) 
Direct 
Indirect 
Total 
1.20 (0.75, 1.73) 
1.00 (0.97, 1.02) 
1.19 (0.76, 1.69) 
HEALTH 
Self-reported health 
Poor/Fair  
Good/Very good/Excellent 
 
 
Reference 
0.23 (0.19, 0.25) 
 
Direct 
Indirect 
Total 
 
0.96 (0.81, 1.13) 
1.29 (1.21, 1.40) 
1.25 (1.05, 1.47) 
 
 
Reference 
0.25 (0.19, 0.33) 
 
Direct 
Indirect 
Total 
 
1.00 (0.65, 1.39) 
1.17 (1.08, 1.31) 
1.17 (0.73, 1.69) 
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Functional limitation 
(ADL/IADL difficulties) 
No difficulties  
Any difficulties  
 
 
Reference 
5.76 (4.92, 6.76) 
 
Direct 
Indirect 
Total 
 
1.00 (0.82, 1.17) 
1.25 (1.16, 1.34) 
1.25 (1.05, 1.46) 
 
 
Reference 
4.67 (3.57, 6.11) 
 
Direct 
Indirect 
Total 
 
0.95 (0.59, 1.34) 
1.27 (1.16, 1.43) 
1.20 (0.76, 1.75) 
Symptoms preventing walking ¼ mile 
No symptoms  
Any symptoms 
 
Reference 
6.83 (5.78, 8.10) 
Direct 
Indirect 
Total 
0.86 (0.72, 1.06) 
1.45 (1.34, 1.55) 
1.25 (1.04, 1.47) 
 
Reference 
6.39 (4.70, 8.73) 
Direct 
Indirect 
Total 
0.95 (0.58, 1.36) 
1.21 (1.08, 1.36) 
1.15 (0.76, 1.64) 
SOCIAL FACTORS 
Social group membership  
0-1 group  
2 or more groups 
 
 
Reference 
0.80 (0.69, 0.92) 
 
Direct 
Indirect 
Total 
 
1.24 (1.04, 1.46) 
1.01 (1.00, 1.02) 
1.26 (1.05, 1.48) 
 
 
Reference 
0.94 (0.77, 1.15) 
 
Direct 
Indirect 
Total 
 
1.19 (0.76, 1.66) 
1.00 (0.99, 1.02) 
1.19 (0.76, 1.68) 
Volunteer work  
None   
Any 
 
Reference 
0.80 (0.69, 0.93) 
Direct 
Indirect 
Total 
1.24 (1.04, 1.45) 
1.01 (1.00, 1.02) 
1.26 (1.05, 1.48) 
 
Reference 
0.98 (0.79, 1.21) 
Direct 
Indirect 
Total 
1.19 (0.76, 1.66) 
1.00 (0.99, 1.02) 
1.19 (0.76, 1.67) 
PSYCHOLOGICAL FACTORS 
Quality of life  
< median (low)  
>median (high) 
 
Control  
< median (low) 
>median (high) 
 
Autonomy  
< median(low)  
>median(high) 
 
Pleasure  
< median (low)  
>median (high) 
 
Self-realisation  
< median (low)  
>median (high) 
 
 
Reference 
0.37 (0.32, 0.43) 
 
 
Reference 
0.48 (0.41, 0.56) 
 
 
Reference 
0.37 (0.32, 0.43) 
 
 
Reference 
0.66 (0.57, 0.75) 
 
 
Reference 
0.49 (0.42, 0.56) 
 
Direct 
Indirect 
Total 
 
Direct 
Indirect 
Total 
 
Direct 
Indirect 
Total 
 
Direct 
Indirect 
Total 
 
Direct 
Indirect 
Total 
 
1.15 (0.97, 1.39) 
1.09 (1.05, 1.13) 
1.25 (1.05, 1.47) 
 
1.19 (1.00, 1.41) 
1.05 (1.03, 1.08) 
1.26 (1.05, 1.47) 
 
1.19 (1.01, 1.42) 
1.05 (1.02, 1.09) 
1.26 (1.06, 1.48) 
 
1.25 (1.05, 1.47) 
1.01 (0.99, 1.02) 
1.26 (1.05, 1.48) 
 
1.20 (1.00, 1.43) 
1.04 (1.02, 1.07) 
1.26 (1.05, 1.48) 
 
 
Reference 
0.50 (0.41, 0.62) 
 
 
Reference 
0.56 (0.46, 0.68) 
 
 
Reference 
0.53 (0.44, 0.65) 
 
 
Reference 
0.64 (0.53, 0.78) 
 
 
Reference 
0.61 (0.50, 0.75) 
 
Direct 
Indirect 
Total 
 
Direct 
Indirect 
Total 
 
Direct 
Indirect 
Total 
 
Direct 
Indirect 
Total 
 
Direct 
Indirect 
Total 
 
1.10 (0.69, 1.52) 
1.09 (1.04, 1.15) 
1.20 (0.75, 1.70) 
 
1.15 (0.72, 1.62) 
1.03 (1.00, 1.07) 
1.18 (0.74, 1.68) 
 
1.12 (0.71, 1.56) 
1.06 (1.02, 1.11) 
1.20 (0.76, 1.69) 
 
1.14 (0.73, 1.61) 
1.06 (1.02, 1.10) 
1.20 (0.76, 1.72) 
 
1.16 (0.73, 1.60) 
1.05 (1.02, 1.08) 
1.21 (0.77, 1.70) 
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Depression  
Not depressed (CESD score ) <4  
Depressed  >4 
 
Reference 
2.58 (2.23, 2.99) 
Direct 
Indirect 
Total 
1.16 (0.96, 1.36) 
1.08 (1.03, 1.12) 
1.25 (1.05, 1.46) 
 
Reference 
1.90 (1.51, 2.38) 
Direct 
Indirect 
Total 
1.14 (0.74, 1.57) 
1.05 (1.01, 1.10) 
1.20 (0.77, 1.68) 
Cognitive impairment 
< median (low ability)  
> median (high ability) 
 
Reference 
0.84 (0.73, 0.97) 
Direct 
Indirect 
Total 
1.25 (1.05, 1.47) 
1.01 (1.00, 1.02) 
1.26 (1.05, 1.48) 
 
Reference 
0.80 (0.65, 0.98) 
Direct 
Indirect 
Total 
1.18 (0.76, 1.68) 
1.02 (1.00, 1.04) 
1.20 (0.76, 1.70) 
All models adjusted for age, sex, education and wealth 
OR = Odds ratio 
HR = Hazard ratio 
CI = Confidence Intervals 
Significant associations between predictor and mediator and indirect effects are in bold 
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Table 6.10 Pathways between ’any pain’ and mortality via lifestyle, health, social and psychological factors for the NorStOP complete case baseline 
sample (n=10985): Direct, indirect and total effects stratified by comorbidity. 
 Comorbidity (n=9001) No comorbidity (n=1984) 
 Association 
between any pain 
and potential 
mediator 
Adjusted OR 
(95%CI) 
 
 
 
 
 
Pathway 
 
 
 
 
Adjusted HR 
(95%CI) 
Association 
between any pain 
and potential 
mediator 
Adjusted OR 
(95%CI) 
 
 
 
 
 
Pathway 
 
 
 
 
Adjusted HR 
(95%CI) 
Model - Total effect (no 
mediators) 
0.97 (0.86, 1.09) - Total effect (no 
mediators) 
1.44 (0.98, 2.12) 
LIFESTYLE FACTORS 
Smoking   
Never/Previous 
Current 
 
 
Reference 
0.97 (0.87, 1.07) 
 
Direct 
Indirect 
Total 
 
0.96 (0.86, 1.09) 
1.00 (1.00, 1.01) 
0.97 (0.86, 1.09) 
 
 
Reference 
0.85 (0.71, 1.02) 
 
Direct 
Indirect 
Total 
 
1.42 (0.99, 2.07) 
1.02 (1.00, 1.05) 
1.44 (1.00, 2.12) 
Alcohol consumption 
Monthly or less (low) 
Weekly (high) 
 
Reference 
0.85 (0.76, 0.94) 
Direct 
Indirect 
Total 
0.97 (0.86, 1.09) 
1.00 (1.00, 1.01) 
0.97 (0.86, 1.09) 
 
Reference 
1.14 (0.94, 1.37) 
Direct 
Indirect 
Total 
1.45 (1.01, 2.13) 
0.99 (0.98, 1.01) 
1.44 (1.00, 2.10) 
Obesity  
Not obese 
Obese  
 
Reference 
1.60 (1.40, 1.83) 
Direct 
Indirect 
Total 
0.97 (0.86, 1.09) 
1.00 (0.99, 1.01) 
0.97 (0.87, 1.09) 
 
Reference 
1.44 (1.08, 1.92) 
Direct 
Indirect 
Total 
1.43 (0.99, 2.09) 
1.00 (0.98, 1.03) 
1.44 (1.00, 2.09) 
Frequency go out  
Few/No days (low)  
All/Most/Some days (high)  
 
Frequency walk for 10 minutes 
< weekly (low) 
>weekly (high) 
 
Reference 
0.44 (0.37, 0.52) 
 
 
Reference 
0.54 (0.49, 0.60) 
Direct 
Indirect 
Total 
 
Direct 
Indirect 
Total 
0.88 (0.78, 0.99) 
1.09 (1.07, 1.12) 
0.96 (0.86, 1.08) 
 
0.89 (0.79, 1.01) 
1.09 (1.07, 1.11) 
0.97 (0.86, 1.09) 
 
Reference 
0.62 (0.40, 0.95) 
 
 
Reference 
0.71 (0.59, 0.86) 
Direct 
Indirect 
Total 
 
Direct 
Indirect 
Total 
1.44 (1.01, 2.11) 
1.01 (0.98, 1.04) 
1.45 (1.00, 2.12) 
 
1.45 (1.01, 2.10) 
1.00 (0.97, 1.03) 
1.44 (1.00, 2.13) 
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Sleep 
Trouble falling asleep  
Some/none  
Most nights 
 
Wake in the night  
Some/none  
Most nights 
 
Trouble staying asleep 
Some/none  
Most nights 
 
Wake up unrefreshed 
Some/none  
Most nights 
 
 
Reference 
3.01 (2.50, 3.65) 
 
 
Reference 
2.19 (1.93, 2.50) 
 
 
Reference 
2.56 (2.21, 2.97) 
 
 
Reference 
3.32 (2.80, 3.97) 
 
Direct 
Indirect 
Total 
 
Direct 
Indirect 
Total 
 
Direct 
Indirect 
Total 
 
Direct 
Indirect 
Total 
 
0.95 (0.86, 1.07) 
1.01 (0.99, 1.03) 
0.96 (0.87, 1.08) 
 
0.94 (0.84, 1.05) 
1.02 (1.01, 1.04) 
0.96 (0.86, 1.08) 
 
0.95 (0.86, 1.07) 
1.01 (0.99, 1.03) 
0.96 (0.87, 1.08) 
 
0.91 (0.81, 1.02) 
1.05 (1.03, 1.07) 
0.95 (0.86, 1.07) 
 
 
Reference 
2.62 (1.64, 4.30) 
 
 
Reference 
2.85 (2.08, 3.95) 
 
 
Reference 
2.37 (1.68, 3.38) 
 
 
Reference 
4.08 (2.55, 6.84) 
 
Direct 
Indirect 
Total 
 
Direct 
Indirect 
Total 
 
Direct 
Indirect 
Total 
 
Direct 
Indirect 
Total 
 
1.42 (0.99, 2.08) 
1.02 (0.98, 1.07) 
1.44 (1.00, 2.13) 
 
1.41 (0.97, 2.08) 
1.03 (0.96, 1.10) 
1.44 (1.01, 2.12) 
 
1.47 (1.01, 2.14) 
0.97 (0.95, 1.02) 
1.45 (1.00, 2.12) 
 
1.49 (1.04, 2.18) 
0.97 (0.94, 1.00) 
1.45 (1.00, 2.12) 
HEALTH FACTORS 
Self-rated health 
Fair/Poor  
Excellent/Very good/Good  
 
Functional limitation (SF36) 
< median  (low) 
> median (high) 
 
 
Reference 
0.34 (0.30, 0.38) 
 
 
Reference 
0.18 (0.16, 0.20) 
 
Direct 
Indirect 
Total 
 
Direct 
Indirect 
Total 
 
0.79 (0.70, 0.89) 
1.20 (1.16, 1.23) 
0.95 (0.85, 1.07) 
 
0.80 (0.71, 0.90) 
1.18 (1.14, 1.23) 
0.94 (0.84, 1.05) 
 
 
Reference 
0.24 (0.15, 0.37) 
 
 
Reference 
0.15 (0.11, 0.21) 
 
Direct 
Indirect 
Total 
 
Direct 
Indirect 
Total 
 
1.43 (1.02, 2.00) 
1.01 (0.97, 1.06) 
1.44 (1.02, 1.99)  
 
1.28 (0.79, 1.73) 
1.11 (0.94, 1.30) 
1.43 (1.00, 1.93) 
SOCIAL FACTORS 
Social participation (restriction) (KAP) 
None  
Any 
 
 
Reference 
1.98 (1.78, 2.19) 
 
Direct 
Indirect 
Total 
 
0.89 (0.79, 1.00) 
1.08 (1.06, 1.11) 
0.96 (0.86, 1.08) 
 
 
Reference 
1.30 (1.07, 1.58) 
 
Direct 
Indirect 
Total 
 
1.41 (0.99, 1.95) 
1.02 (1.00, 1.05) 
1.44 (1.02, 1.96) 
PSYCHOLOGICAL FACTORS 
Anxiety (HADS) 
No anxiety 
Possible/probable 
 
 
Reference 
2.32 (2.08, 2.60) 
 
Direct 
Indirect 
Total 
 
0.94 (0.84, 1.05) 
1.04 (1.02, 1.05) 
0.98 (0.88, 1.09) 
 
 
Reference 
2.07 (1.65, 2.61) 
 
Direct 
Indirect 
Total 
 
1.50 (1.06, 2.06) 
0.96 (0.92, 1.00) 
1.44 (1.02, 1.95) 
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Depression (HADS) 
No depression 
Possible/probable 
 
Reference 
2.46 (2.13, 2.85) 
Direct 
Indirect 
Total 
0.90 (0.81, 1.01) 
1.07 (1.06, 1.09) 
0.97 (0.87, 1.09) 
 
Reference 
2.48 (1.61, 3.93) 
Direct 
Indirect 
Total 
1.42 (1.00, 1.94) 
1.02 (0.98, 1.06) 
1.44 (1.02, 1.96) 
Cognitive impairment 
No impairment 
Impairment 
 
Reference 
2.26 (2.04, 2.51) 
Direct 
Indirect 
Total 
0.92 (0.82, 1.03)  
1.04 (1.02, 1.07) 
0.96 (0.86, 1.08) 
 
Reference 
1.70 (1.30, 2.22) 
Direct 
Indirect 
Total 
1.37 (0.97, 1.87) 
1.05 (1.01, 1.12) 
1.43 (1.01, 1.94) 
Control (from IPQ-R) 
Disagree (low control) (Reference) 
Agree (high control) 
 
Reference 
0.93 (0.83, 1.04) 
Direct 
Indirect 
Total 
0.97 (0.86, 1.07) 
1.00 (1.00, 1.00) 
0.97 (0.86, 1.09) 
 
Reference 
0.89 (0.73, 1.08) 
Direct 
Indirect 
Total 
1.44 (1.02, 1.97) 
1.00 (0.99, 1.02) 
1.44 (1.02, 1.97) 
All models adjusted for age, sex, education and adequacy of income 
OR = Odds ratio 
HR = Hazard ratio 
CI = Confidence Intervals 
Significant associations between predictor and mediator and indirect effects are in bold 
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waking up unrefreshed, poor self-rated health, social participation restriction, anxiety and 
depression. For all of these mediators the indirect effects were greater in participants 
with comorbidity.  
6.6 Allostatic load and Frailty (ELSA only) 
 
6.6.1 Mediation by allostatic load 
 
“Often troubled” with pain was significantly associated with high allostatic load (Table 
6.11).  There was a significant association between “often troubled” with pain and 
mortality in the allostatic load sample (n=4627). Allostatic load was a statistically 
significant mediator of the relationship between “often troubled” with pain and mortality 
in the total sample, and in males and females, but not in participants with or without 
comorbidity.  There were no moderating effects of sex and comorbidity (Table 6.11). 
6.6.2 Mediation by frailty 
 
Frailty was strongly associated with “often troubled” with pain in the frailty sample 
(n=4375) (Table 6.12). Although there was not a significant association between “often 
troubled” with pain and mortality in this sample, there were significant indirect effects via 
frailty in females, males and in participants with and without comorbidity. There were no 
significant moderating effects of sex or comorbidity in this sample (Table 6.12). 
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Table 6.11 Pathways between ‘often troubled with pain’ and mortality via allostatic load in ELSA: Direct, indirect and 
total effects. 
Model Complete sample 
 (n=4627) 
 
Females 
(n=2539) 
 
Males 
(n=2088) 
 
With comorbidity 
(n=2704) 
 
Without 
comorbidity 
(n=1923) 
Association between ‘often 
troubled’ with pain and 
allostatic load 
 Adjusted OR (95%CI) 
<median (low)  
> median(high)  
 
 
 
Reference 
1.20 ( 1.06, 1.37) 
 
 
 
Reference 
1.20 (1.01,1.41) 
 
 
 
Reference 
1.22 (1.00, 1.48) 
 
 
 
Reference 
1.13 (0.96, 1.32) 
 
 
 
Reference 
1.16 (0.92, 1.46) 
Total effect (no mediator)  
Adjusted HR (95%CI) 
 
1.21 (1.03, 1.44) 
 
1.08 (0.84, 1.38) 
 
1.35 (1.07, 1.69)  
 
1.18 (0.97, 1.44) 
 
1.13 (0.78, 1.63) 
Pathway Adjusted HR(95%CI) 
Direct 
Indirect 
Total 
 
1.20 (1.02, 1.41) 
1.01 (1.00, 1.02) 
1.21 (1.03, 1.42) 
 
1.07 (0.85, 1.42)  
1.01 (1.00, 1.03) 
1.08 (0.85, 1.44) 
 
1.33 (1.07, 1.71) 
1.01 (1.00, 1.02) 
1.34 (1.07, 1.71) 
 
1.17 (0.96, 1.45) 
1.01(0.99, 1.03) 
1.18 (0.98, 1.48) 
 
1.14 (0.78, 1.53) 
0.99 (0.76, 1.53) 
1.13 (0.77, 1.53) 
All models adjusted for age, sex, education and wealth 
OR = Odds ratio 
HR = Hazard ratio 
CI = Confidence Intervals 
Significant associations between predictor and mediator and indirect effects are in bold 
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Table 6.12 Pathways between ‘often troubled with pain’ and mortality via frailty in ELSA: Direct, indirect and total 
effects. 
Model Complete sample 
(n=4375) 
 
Females 
(n=2400) 
 
Males 
(n=1975) 
 
With comorbidity 
(n=2835) 
 
Without 
comorbidity 
(n=1540)  
Association between ‘often 
troubled and frailty 
Adjusted OR (95%CI) 
Not frail  
vs frail 
 
 
 
Reference 
3.33 (2.61, 4.27) 
 
 
 
Reference 
3.58 (2.64, 4.91) 
 
 
 
Reference 
2.97 (1.99, 4.46) 
 
 
 
Reference 
3.22 (2.42, 4.34) 
 
 
 
Reference 
2.95 (1.72, 5.00) 
Total effect (no mediator)  
Adjusted HR (95%CI) 
 
1.10 (0.96, 1.27) 
 
1.07 (0.87, 1.31) 
 
1.15 (0.94, 1.41) 
 
1.01 (0.86, 1.20) 
 
1.31 (0.95, 1.81) 
Pathway Adjusted HR(95%CI) 
Direct 
Indirect 
Total 
 
1.02 (0.88, 1.21) 
1.08 (1.05, 1.12) 
1.11 (0.95, 1.29) 
 
0.97 (0.82, 1.16) 
1.11 (1.05, 1.17) 
1.07 (0.90, 1.27) 
 
1.09 (0.89, 1.34) 
1.06 (1.02, 1.11) 
1.15 (0.92, 1.42) 
 
0.94 (0.77, 1.13) 
1.08 (1.05, 1.12) 
1.01 (0.84, 1.22) 
 
1.24 (0.88, 1.65) 
1.07 (1.02, 1.14) 
1.34 (0.93, 1.76) 
All models adjusted for age, sex, education and wealth 
OR = Odds ratio 
HR = Hazard ratio 
CI = Confidence Intervals 
Significant associations between predictor and mediator and indirect effects are in bold 
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6.7 Discussion 
6.7.1 Summary of findings 
 
Table 6.13 summarises which factors were mediators in each of the samples from each 
dataset.  
6.7.2 Interpretation of findings 
 
In general, a larger indirect effect indicates a more powerful explanation of the 
relationship under investigation (Keele, 2015). Based on this, the most powerful 
explanatory factors for a relationship between pain and mortality in the current study 
were those which measure physical limitation and inactivity. A pathway from pain to 
mortality via physical inactivity was strongly supported.  This could be through a number 
of mechanisms as physical inactivity is linked to a wide number of chronic diseases 
(cardiovascular disease, cancer, diabetes, hypertension, obesity, osteoporosis and 
depression) (Warburton et al., 2006) (see section 1.6.4). Interventions to increase physical 
activity in people with pain where possible would help to reduce their risk of mortality by 
helping to control weight and maintain the function of body systems (Warburton et al., 
2006), in addition to reducing the persistence of pain and improving pain related function 
(Croft et al., 2010).   
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Table 6.13 Significant mediating factors in each sample from each dataset 
ELSA NorStOP 
Variables Co
m
p
le
te
 
case
 
Females Males W
ith
 
co
m
o
rb
id
ity 
N
o
 
co
m
o
rb
id
ity 
Variables Co
m
p
le
te
 
case
 
Females Males W
ith
 
co
m
o
rb
id
ity 
N
o
 
co
m
o
rb
id
ity 
LIFESTYLE FACTORS 
Physical  inactivity       Current smoking   X  X X 
Current smoking  X X X  X Low alcohol 
consumption 
X X X X X 
Low alcohol 
consumption 
  X  X Obesity   X X X X X 
 Low frequency go out      X 
Low frequency walk for 
10 minutes 
    X 
Trouble falling asleep    X X X 
Wake in the night      X 
Trouble staying asleep   X X X 
Wake up unrefreshed      
HEALTH 
Poor self-rated health      Poor self-rated health     X 
Functional limitation       Functional limitation     X 
Symptoms preventing 
walking ¼ mile 
      
Quality of life (low)       
Control      
Autonomy       
Pleasure    X X  
Self-realisation      
Allostatic load *    X X 
Frailty*      
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SOCIAL FACTORS 
Low social group 
membership  
 X   X Social participation 
restriction 
     
Volunteer work      X  
PSYCHOLOGICAL FACTORS 
Depression   X    Anxiety       
Cognitive impairment      Depression      X 
 Cognitive impairment      
Poor control of health  X X X X X 
 Significant mediating factor 
 Significant mediating factor but with a small indirect effect and confidence interval including 1.00 
 Significant mediating factor with a Hazard Ratio for the indirect effect of below 1.00 
X not a significant mediating factor  
* analyses conducted on separate samples with complete biomarker information 
262 
 
Measures of functional limitation resulted in the strongest mediating effects (i.e. resulted 
in the largest hazard ratios for indirect effects). This is consistent with previous studies 
reporting reduced functional difficulty in people with pain (Weiner et al., 2003) and 
associations between functional impairment and mortality (Scott & Macera, 1997). It also 
supports the work of Docking et al., (2014) who reported increased mortality for women 
with disabling back pain but no increased risk of mortality in people (men or women) 
whose back pain was not disabling (Docking et al., 2014).   
Self-reported assessments of functional impairment measure perceived limitations in 
physical capacity rather than the amount of physical activity (Tang et al., 2014) but the 
former has inevitable consequences for the latter. Functional limitation will lead to 
physical inactivity and this emphasises the importance of physical capacity and managing 
functional limitation for people in pain through interventions such as physiotherapy, 
exercise classes and psychological therapies that address barriers to physical activity 
(Tang et al., 2014). 
Moderating effects 
The observed moderating effects of sex and comorbidity for some of the indirect 
pathways from pain to mortality suggest sub-groups which may respond differently to 
interventions to reduce mortality risk. However, the moderation analysis should be 
interpreted with caution due to the reduction in power as a result of the sub-group 
analysis. The effects observed in the current study were not consistent between the two 
datasets. Any notable differences between sub-groups (males and females/people with or 
without comorbidity) are discussed separately for specific mediators in the remainder of 
this section.    
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Allostatic load 
A small mediating effect of allostatic load was observed in the current study. However, 
there are a number of limitations regarding this proposed mediator that need to be 
considered. Debate continues over which grouping of biomarkers optimally represent 
allostatic load (Gallo, Fortmann, & Mattei, 2014). The constituents of the allostatic load 
index in this study were determined by the available data; a limitation of secondary data 
analysis. Another limitation of the measure of allostatic load in this study was that it was 
measured at one time point only. It therefore does not take into account what would be 
considered “resting” or “usual” scores on each of the biomarkers for each individual, 
which an optimal assessment of allostatic load would incorporate (McEwen & Seeman, 
1999). Allostatic load refers to an accumulation of maladaptation to stress over time in a 
number of physiological systems and the need for longitudinal analysis is consistently 
emphasised in the allostatic load literature but few studies exist (Gallo et al., 2014). A 
more accurate mediating effect of allostatic load may therefore have been observed in 
longitudinal analyses measuring change in allostatic load over time. As detailed in Section 
4.6, there was insufficient power to conduct analyses examining change over time due to 
the level of attrition at follow up.  
Sex differences in allostatic load have been observed in the biomarkers that make up 
allostatic load. Neuroendocrine dysregulation is greater in women and cardiovascular 
system biomarkers show greater dysregulation in men (Beckie, 2012). Therefore different 
biomarker combinations may result in differences in risk of mortality between men and 
women rather than any differences in the count of the number of biomarkers. 
Interventions to reduce stress by improving sleep quality, social support, self-esteem, 
sense of purpose, healthy diet and physical activity combined with beneficial practices in 
264 
 
the workplace, cleaner safer neighbourhoods and education may help to reduce allostatic 
load (Juster, McEwen, & Lupien, 2010) and therefore mortality risk in those with pain. 
 
Frailty 
The role of frailty in the relationship between pain and mortality warrants further 
investigation. People with pain are more likely to be frail than those without pain (Shega 
et al., 2012), but it may be that frailty is a moderator of the relationship between pain 
and mortality. Instead of frailty as a result of pain, the risk of mortality for those with pain 
may be greater for those who are frail than for those who are not frail. Longitudinal 
analysis is necessary to more accurately determine the role of frailty. 
As with all composite measures, interventions to target specific factors within those 
measures are subsequently likely to result in an improvement in that measure if 
successful. Interventions to improve the characteristics of frailty (e.g. increase weight, 
strength, endurance, walking speed and physical activity (Fried et al., 2001)) may reduce 
the risk of mortality for people with pain.   
Depression 
The potential difference in the mediated pathways from pain to mortality via depression 
between males and females is not clear. Sex moderated the relationship via depression in 
ELSA and NorStOP but in ELSA the effect was in males but not females and in NorStOP the 
effect was greater in females compared to males. Depression in ELSA was measured using 
the Centre for Epidemiological Studies depression Scale (CES-D) and in NorStOP the 
Hospital Anxiety and Depression Scale (HADS) was used. However, these measures are 
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both screening rather than diagnostic tools for depression, are widely used and validated 
in different populations (Smarr & Keefer, 2011) and have been shown to measure the 
same underlying construct and be adequate and equivalent in detecting depression 
problems (Stafford et al., 2014). As previously stated the reduction in power in the 
stratified analysis is likely to contribute to the differences in findings between the ELSA 
and NorStOP datasets. Depression is an important target for intervention in people with 
pain and the results of this study indicate successful treatment of depression may reduce 
the risk of mortality in both males and female with pain.  
Unexpected findings 
a) Alcohol consumption 
There was no mediating effect of alcohol consumption in the current study. However, the 
association between pain and reduced alcohol intake observed in the current study is 
consistent with previous research (Brennan et al., 2011; McBeth & Nicholl, 2010) and 
suggests low alcohol consumption may be a proxy for poor health. The symptoms older 
adults experience, their associated medication use and possibly a subsequent reduction in 
social activities where alcohol is consumed (Brennan et al., 2011) may explain why pain is 
associated with lower alcohol consumption.   
b) Obesity 
The lack of a mediating effect of obesity is surprising considering obesity is associated 
with an increased risk of mortality (Flegal et al., 2013). BMI has poor sensitivity and 
specificity as a measure of obesity as it does not take into account age, sex, bone 
structure, fat distribution or muscle mass (Rothman, 2008). Nonetheless, BMI remains a 
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commonly used measure of obesity and 23.5% of the NorStOP study sample was 
classified as obese which is comparable to the national average (26.0% of men and 23.8% 
of women in 2013) (Health and Social Care Information Centre, 2015). However, people at 
the lower end of the obesity scale (BMI=30.0-34.9) have been shown to have no 
increased risk of mortality and those classified as overweight (BMI=25-29.9) demonstrate 
reduced mortality compared to those of normal weight (BMI=18.5-24.9) (Flegal et al., 
2013; Romero-Corral et al., 2006). This study compared people who were obese to those 
who were not obese so the reference group also included those who were underweight 
who also have an increased risk of mortality (Flegal, Graubard, Williamson, & Gail, 2005) 
which may act to dilute any mediating effect of obesity. There may also be some 
unmeasured factor(s) serving to protect obese people which are successfully reducing 
their risk of mortality compared to non-obese people. Such factors might include earlier 
presentation to medical care (Oreopoulos et al., 2009), optimal medication (e.g. statins, 
blood pressure medication), (Schenkeveld et al., 2012) cardio protective metabolic effects 
of increased body fat (Hastie et al., 2010) and benefits of higher metabolic reserves 
(Doehner, Clark, & Anker, 2010) which may be particularly important in older people. 
c) Sleep 
There was an increase in the direct effect compared to the total effect of ‘waking up 
unrefreshed’ in participants without comorbidity in the NorStOP sample which indicated 
a suppressing effect (where the magnitude of a relationship becomes larger with the 
inclusion of a third variable) (MacKinnon, Krull, & Lockwood, 2000). This should be 
interpreted with caution due to the small sample size of this group. This study measured 
pain and sleep problems at the same time point so it was not possible to determine which 
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came first, however, sleep is an important target for health interventions in people with 
pain as restorative sleep has been shown to predict the resolution of chronic widespread 
pain after 15 months (Davies et al., 2008). This study indicates successful interventions to 
improve sleep may also reduce mortality risk for people with pain.  
d) Smoking 
In NorStOP the observed mediating effect of smoking suggested that being a current 
smoker was protective for males with any pain. Smoking is consistently associated with an 
increased risk of all-cause mortality in older people (Gellert et al., 2012) therefore the 
finding for males in the current study is unusual. However, the extent of mediation is 
small. The dichotomy of current smoker/non-smoker used in this analysis is a limitation as 
it only measures current smoking status. Mortality from smoking is linked to the number 
of cigarettes smoked and to when people stopped (Doll et al., 2004), and this comparison 
between never/previous smokers and current smokers does not provide an account of 
this. It may be more likely that a current smoker with pain may increase the amount they 
smoked as a way to cope with their pain (Ditre & Brandon, 2008); however this 
hypothesis could not be tested in this study. It was also not possible to test the direction 
of the relationship between pain and smoking. Pain may be associated with not being a 
current smoker as a result of other health conditions prompting an individual to quit, and 
those other health conditions may account for the increased risk of mortality in those 
people. However, there was also an indirect effect of not being a current smoker in those 
without comorbidity in the NorStOP sample but there was insufficient power to detect an 
effect in this group (only n=1984 people indicated they did not have any comorbidities 
and only 107 died resulting in power of only 27.33% to detect a hazard ratio of 1.3).  
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6.7.3 Interventons to reduce mortality risk 
The mediating factors identified in this study such as physical activity, physical function, 
sleep and depression are all factors which are already targeted in pain management 
(Main et al., 2007). The purpose of the current study was to demonstrate and explain the 
potential long term consequences for people with pain rather than identify novel targets 
for intervention. The mediating factors identified are modifiable and as such an 
improvement in those factors could act to reduce the risk of mortality for people with 
pain. The mediators in this study were assessed individually but factors such as 
depression, sleep, allostatic load and frailty overlap and interventions to improve one of 
these factors may also act to improve others. The implications of the current study for 
practice are discussed further in section 7.4.     
6.7.4 Comparison with other studies         
 
This was the first study to investigate potential mediators of a relationship between pain 
and mortality, and one of only a small number of studies that have examined mediating 
effects within survival analysis. Andersson (2009) reported an association between 
widespread pain and mortality that was explained by lifestyle factors; specifically 
smoking, physical activity, stress and sleep disorders (Andersson, 2009). However, 
Andersson’s study did not test pathways from pain to mortality; factors were adjusted for 
as confounders within survival analysis. In the current study physical inactivity, stress 
(measured by allostatic load, anxiety and depression) and sleep problems were all shown 
to be significant mediators of the relationship between pain and mortality which both 
supports and adds to Andersson’s findings. However, smoking was not shown to be 
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associated with pain in this study. This may also in part account for the lack of association 
between pain and cancer mortality reported in Chapter Five.    
6.7.5 Methodological considerations 
 
Dichotomising 
The method used to undertake the mediation analysis within survival analysis is an 
emerging technique, and the R code used to perform the analysis can currently only 
calculate outcomes using dichotomous predictors and mediators. It was therefore 
necessary to dichotomise these variables. This is a major limitation of this study. 
Dichotomising results in a loss of information, particularly for continuous variables where 
dichotomising treats some scores that are almost indistinguishable i.e. those near the cut 
point, as though they are distinct from each other (Altman & Royston, 2006; Streiner, 
2002). All observed values in a study incorporate some measurement error and for 
individuals near a cut point this measurement error may result in misclassification into 
the wrong group rather than just an inaccurate score (Streiner, 2002). Approximately one-
third of information is lost as a result of dichotomising variables resulting in a loss of 
power to detect an existing effect (Altman & Royston, 2006; Royston, Altman, & 
Sauerbrei, 2006).  
Dichotomisation can result in a loss of effect size and statistical significance when 
examining bivariate relationships but spurious statistical significance and an 
overestimation of effect size in analyses where there are two independent variables 
(MacCallum, Zhang, Preacher, & Rucker, 2002).  Relationships that are not linear also 
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have the potential to be overlooked when variables are dichotomised (MacCallum et al., 
2002).  
The cut-off  to determine where to dichotomise a variable is often arbitrarily determined 
and produces groups that are not psychometrically meaningfully (i.e. reliable, repeatable, 
valid measures) (Hayes, 2013). For example, the median is often used to determine the 
cut point when dichotomising which means different studies will use different cut points 
based on their sample medians therefore cannot be compared (Altman & Royston, 2006; 
Royston et al., 2006).  However, dichotomising may be justifiable in cases where prior 
analyses provide clear support for the existence of two groups with a clearly identifiable 
scale point differentiating the groups, or where the data is highly skewed and there are a 
large number of scores at the most extreme end of the distribution (MacCallum et al., 
2002; Streiner, 2002).   
Table 6.13 summarises all statistically significant mediating factors in the current study 
but also highlights those factors where the hazard ratio for the indirect effect is close to 
1.00. The loss of information as a result of dichotomising reduces confidence these 
variables are true mediators of the relationship between pain and mortality. 
Multiple testing 
When multiple hypotheses are considered simultaneously (as in this study) the 
probability of falsely detecting a significant effect where there isn’t one increases with 
each additional test performed (Bender & Lange, 2001). It was not possible to correct for 
this potential problem in the current analyses. This is commonly done by adjusting the p-
values or confidence intervals to account for the number of tests run (Sainani, 2009).  
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Further development of the method to undertake mediation analysis within survival 
analysis should enable this to be possible in future studies using this technique. However, 
although adjusting the criterion for significance in this way reduces the risk of a type I 
error (false –positive) it increases the risk of type II error (not finding an existing effect) 
(Rothman, 1986). Often datasets are used to test many hypotheses, but these are 
reported in separate papers and adjustment for the number of tests is not performed as 
each individual hypothesis is examined as the sole focus of a study (Rothman, 1986). 
Although many tests were performed in this thesis, all results are presented and 
statistically significant findings should be interpreted as suggestive only (Rothman, 1986). 
Effect sizes should be taken into consideration, that is, larger effect sizes are less likely to 
be chance findings and where findings are replicated in different data samples (such as 
with the mediating/indirect effects of the functional limitation and physical inactivity 
measures in this study) there can be more confidence about the true existence of those 
effects (Sainani, 2009). Adjustment for multiple testing is more important when the 
results of the multiple tests are combined in one final conclusion or decision (Bender & 
Lange, 2001) which was not the case in this thesis.      
Self-report 
Most of the variables in this study were measured using self-report methods. Information 
obtained by self-report is limited by inaccuracies due to problems with recall and with 
differing interpretations of questions which affects face validity. A particular example of 
this is with the report of physical activity levels in the ELSA dataset. A high proportion of 
the sample (31.04%) reported engaging in vigorous activities at least once a week. This 
could be a result of information bias; one person’s idea of what constitutes vigorous 
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activity may differ greatly from another person’s opinion, recall bias where an inaccurate 
recollection of activity is reported or response bias where participants provide what they 
perceive to be more favourable answers (e.g. higher activity levels) (Delgado-Rodríguez & 
Llorca, 2004). Or it may indeed be that the ELSA sample is in fact an active group of older 
adults (as has been reported elsewhere (Lang, Guralnik, & Melzer, 2007)).  
Overlapping measures 
There will also be overlap between some of the variables used in this study with regards 
to the constructs being measured. Of note are the moderating effects of comorbidity in 
the NorStOP analyses. The method used to capture morbidities in NorStOP is likely to 
measure some of the same elements captured by the variables ‘frequency go out’, 
‘frequency walk for 10 minutes’, ‘self-rated health’, ‘anxiety’ and ‘depression’, where a 
significant moderating effect of comorbidity was observed. However, measuring these 
items separately (i.e. as moderator and individual mediators) allows a more detailed 
investigation of how and in whom pathways from pain to mortality exist. Indirect 
pathways from pain to mortality were observed in participants both with and without 
comorbidity indicating that interventions to target identified mediating factors are 
important to reduce mortality risk in everyone with pain, not just in those with 
comorbidity.     
Use of single items 
This study used a number of single items to measure potential mediators. The use of a 
single item is limited compared to multi-item measures as it is difficult to capture multi-
dimensional concepts using just one question. The information ascertained from a single 
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item lacks detail if the targeted concept is broad (i.e. health status). Multi-item measures 
are considered more reliable, stable and precise and they are likely to produce more 
consistent responses and are less prone to sociopsychological biases (e.g. response bias)  
(Bowling, 2005).  
An example of this in the current study was the attempt to measure ‘control’. The lack of 
a significant indirect effect of perceived control in NorStOP may be due to inadequacy of 
the single item used to accurately capture the concept of control. A comparison could be 
made between the item used from the IPQ-R in NorStOP and the control domain from the 
CASP-19 that was used in the ELSA dataset (which did mediate the relationship between 
being often troubled with pain and mortality). The item from the IPQ-R attempted to 
capture an individual’s belief over their ability to control their health whereas the control 
domain of the CASP-19 attempts to capture the ability to actively intervene in one’s 
environment (Hyde et al., 2003). A control-positive domain (i.e. positive feelings of 
control) from the Aging Perceptions Questionnaire (APQ) (developed from the IPQ-R) has 
been shown to have a weak association with the control/autonomy domains of quality of 
life measured using the CASP-R12 (developed from the CASP-19) (Sexton, King-Kallimanis, 
Morgan, & McGee, 2014). It is likely therefore these are measuring different constructs 
which would explain the difference in findings. Control may be useful as a direct target for 
intervention but similar to the quality of life measure, it is also likely to be influenced by 
interventions to improve other factors (e.g. depression, functional limitation). 
Advantages of the use of single items include ease of administration, interpretation and 
reduced costs (Bowling, 2005). The single-item self-reported health measure (a version of 
which was used in each of the datasets in this study) has been acknowledged as a robust 
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measure of health status following application in a large number of population surveys 
(Bowling, 2005; Chandola, Tarani, Jenkinson, 2000). Other single item measures were 
used to capture narrower concepts (e.g. individual sleep items) which provide 
information about more precise targets for intervention. The use of single items therefore 
has advantages and disadvantages and these should be considered in the interpretation 
of results using these items.  
Composite measures 
Measures which capture broad constructs such as general health and quality of life may 
not be direct targets for intervention but would be influenced by the management of 
other targets. Consideration must be given to what is actually being measured in the 
assessment of self-rated health for example, as it is a concept which encompasses a 
number of domains. Improvements in self-rated health are therefore likely to be 
dependent on a broad range of factors. Self-rated health is a measurement of the 
presence of illnesses, symptoms, beliefs about severity, family influences, past and 
current health (Idler & Benyamini, 1997; Jylhä, 2009). It also overlaps with concepts such 
as quality of life. When people rate concepts such as health or quality of life they conduct 
an appraisal process which involves 1) the induction of a frame of reference they deem 
relevant based on their understanding of the question, 2) the recall and sampling of 
salient experiences which are 3) judged against standards of comparison. These may be 
based on personal reference points such as prior functioning and lost capabilities or on 
observations of others, past experiences with illnesses or external communication from 
healthcare providers. 4) Individuals then use a subjective algorithm to combine these 
appraisals and experiences into their response to the question (Rapkin & Schwartz, 2004). 
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Interventions to improve the individual lifestyle, health, social and psychological factors 
indicated as mediators in this study are likely to subsequently result in improved quality 
of life/self-rated health ratings in addition to reduced mortality risk.  
Sub-group analysis 
Despite having previously been recommended as an approach to assess moderation in 
mediation analysis (Reis & Judd, 2000) and in structural equation modelling (Rigdon, 
Schumacker, & Wothke, 1998), analysing sub-groups separately has a number of 
limitations. Each sub-group will have lower statistical power than the full sample and sub-
group analysis does not provide significance tests of differences in mediation across levels 
of the moderator variable (Edwards & Lambert, 2007). As described above, the method to 
undertake mediation analysis within survival analysis used in this study is an emerging 
technique. Further development of the technique and the statistical packages used to 
perform the analyses is necessary to enable the use of non-binary variables and allow for 
multiple group comparisons which would mean more comprehensive models could be 
tested, including moderated mediation models (see section 7.3).   
6.7.6 Strengths and limitations 
 
This study has a number of strengths. This is the first study to use mediation analysis to 
examine potential mechanisms for a relationship between pain and mortality. A cutting-
edge technique was used to estimate the extent of mediation by the proposed mediators 
within survival analysis accounting for time. The study was conducted in two large 
population surveys which provided adequate total sample sizes to detect the predicted 
effects and enabled a number of factors to be investigated as potential mediators of the 
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relationship between pain and mortality. Key targets and potential subpopulations were 
identified to reduce mortality in older adults with pain.  
A single mediator cannot fully explain a relationship between an exposure and outcome 
but testing individual mediators helps to determine which different factors may 
contribute to a more complex relationship. In the analysis undertaken in this study from 
the ELSA dataset, pain described as “often troubling” continued to have a significant 
direct effect on mortality in some of the mediation models. This description of pain may 
capture a number of different ways pain impacts on an individual’s life and the individual 
mediators examined account for only some of this impact. In the NorStOP analyses, the 
report of “any pain” did not have a significant direct effect on mortality, therefore the 
significant mediators identified in the NorStOP analyses help to confirm how pain impacts 
on an individual and subsequently leads to increased mortality. Where similar mediators 
were measured in each dataset, those with stronger mediating effects in the ELSA dataset 
were the same mediating factors that had significant indirect effects in the NorStOP 
dataset (e.g. poor self-rated health, physical inactivity, functional limitation). This implies 
these findings were not a result of chance.  
Limitations of mediation analysis are discussed further in section 7.3 but most notable is 
the need for longitudinal data. Mediation analysis is carried out in an attempt to elucidate 
mechanisms for relationships between exposures and outcomes. Often, as in this study, 
mediators are considered individually and have been measured at the same time as the 
exposure. Causal inference based on observational data, particularly cross-sectional data 
should be made with caution (Grimes & Schulz, 2002).   
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6.7.7 Implications for research and practice 
 
This study has identified a number of factors that explain the relationship between pain 
and mortality and are potential targets for reducing the risk of death. Further 
development of the technique used to undertake the mediation analysis would allow for 
a more detailed and precise investigation of mediating factors, particularly with 
categorical and continuous variables. This would provide a more accurate representation 
of the relationships investigated in this study. However, this study has provided a strong 
indication that factors affecting mobility, physical activity and perception of health are 
important mediators of the relationship between pain and mortality. Interventions to 
increase physical function, physical activity and perceived general health may help to 
reduce the risk of death in those with pain. 
6.8 Key messages 
 
 Physical inactivity, functional limitation and self-rated health were notable 
mediators of the relationship between pain and mortality. 
 Indirect pathways from pain to mortality were evident in the absence of a total 
effect. 
 Sex and comorbidity were indicated as potential moderators for some of 
pathways between pain and mortality. 
 Further development of the technique to undertake mediation analysis within 
survival analysis is imperative to provide a more precise description of the 
relationships indicated by this study. 
  
278 
 
Chapter Seven. Discussion 
7.1 Thesis summary 
 
This thesis presents the results of a large population based study of the relationship 
between pain and mortality. A systematic review of the current literature identified ten 
studies which had investigated the relationship between pain and mortality. These 
studies had differing population characteristics, methods of analysis and included 
different covariates and pain phenotypes which prevented clear conclusions from being 
drawn. The current study added to existing work by examining how the classification of 
pain, i.e. the pain phenotype, impacted on the relationship between pain and mortality 
and expanded the investigation of the role of covariates by assessing whether they 
mediated or moderated the relationship. A detailed interpretation of the analyses 
undertaken in this thesis are presented in Chapters Five and Six and here a summary of 
the key points are presented to critically re-evaluate notable findings and implications for 
research and practice. 
7.2 General discussion 
7.2.1 Summary of findings 
 
The analysis in this thesis reported that in support of previous studies people with pain 
had an increased risk of mortality, pain that had an impact on daily life was an important 
predictor of death rather than the presence of pain per se, and suggested that important 
mechanisms from pain to mortality were functional limitation and physical inactivity.  
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7.3 Implications for research 
This was the first study to formally test potential mechanisms of a relationship between 
pain and mortality. A novel technique to conduct mediation analyses within a survival 
model was undertaken. Important points to consider in the interpretation of the findings 
are detailed below.    
7.3.1 Mediation analysis 
 
Multiple mediators 
This study identified factors that mediated and could explain the relationship between 
pain and mortality. There are a number of important caveats to that observation. A single 
mediator is unlikely to act in isolation and may instead be part of a longer “causal 
pathway” that includes many potential mediators. For example pain is associated with a 
reduction in physical activity (McBeth & Nicholl, 2010), which in turn may increase the 
risk of depression (Teychenne, Ball, & Salmon, 2008) and subsequent death (for example 
through hazardous health behaviours, suicide or an interference with motivation for 
recovery)  (Cuijpers & Smit, 2002). A number of factors may also contribute 
simultaneously to a reduction in health and subsequent mortality (parallel mediation) 
(Hayes, 2013). Studying mediators individually does not inform us of the relative influence 
of a number of different mediators. 
Longitudinal analysis 
In order to study potential causal chains longitudinal analysis is needed. Hill (1965) 
specified criteria to be considered to determine whether an association is causal; 1) the 
strength of the association, 2) the consistency of the association (replicable), (3) 
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specificity (the cause leads to a single, not multiple effects), 4) temporality (the cause 
precedes the effect), 5) biological gradient (a dose-response effect), 6) plausibility (makes 
sense biologically), 7) coherence (consistent with what is already known), 8) experimental 
evidence (involving the manipulation of variables) and 9) analogy (similar relationships 
have been observed elsewhere) (Hill, 1965). Although the current study fulfilled some of 
these criteria the mediation analyses did not meet criterion 4) which is indisputable (in 
the current study the predictor and mediator were measured at the same time point); if 
the cause does not precede the effect then the association cannot be causal (Rothman, 
1986) and longitudinal analysis is necessary to determine temporality.  
Although the current study used data from longitudinal studies it was not possible to use 
the data at different time points for the mediation analyses due to attrition. The power 
analysis conducted in Chapter Four indicated sufficient power (86.35%) to detect a HR of 
1.4 in the NorStOP follow up sample, but the observed effect size was only HR 1.05 
(95%CI 0.94, 1.18) in the complete case sample (n=10985). The power to detect an effect 
of this size in the follow-up sample for NorStOP (n=4293) was only 6.47%. It was therefore 
not possible to conduct mediation analyses including change scores over time in this 
study.  
Alternative explanations 
Mediator and moderator analyses are based on theoretical events or processes that 
unfold over time and the sequence is determined by what is theoretically plausible. 
However, there are often multiple ways of defining the relationships between the 
variables (Roe, 2012).  Many relationships are reciprocal (e.g. pain and depression (Chou, 
2007), pain and sleep problems (Moldofsky, 2001)). In reality, models of relationships 
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between variables are non-recursive, that is, they involve feedback loops, but these 
models are problematic to test (Streiner, 2005). The pathways between pain and 
mortality identified by the current study are useful for suggesting potential targets for 
intervention but the true complexity of relationships and processes can never be 
modelled exactly using statistical techniques. The use of longitudinal analysis and a 
combination of quantitative and qualitative methods would help to support and clarify 
the mediational processes suggested by this study (Mackinnon, Fairchild, & Fritz, 2007).  
7.3.2 Mediation analysis within survival analysis  
 
Current limitations 
The analysis performed in this thesis was greatly restricted by the requirement to use 
only dichotomous variables for the mediation analysis due to the limitations in the novel 
technique employed. The assessment of categorical/continuous mediators would provide 
a more accurate and precise evaluation of the relationships involved by overcoming the 
problems associated with dichotomising (discussed in section 6.7.4).  
Assessing moderation 
It was possible to include interaction terms in the survival models (presented in Appendix 
VI) which revealed no significant moderating effects of sex or comorbidity on the 
relationship between any of the pain phenotypes and mortality. However, it was not 
possible to include interaction terms in the mediation models. Moderated mediation was 
therefore tested by stratifying the mediation analyses and describing the differences 
between the groups observing where confidence intervals did not overlap (presented in 
Chapter Six). A more accurate way of assessing moderated mediation would have been to 
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perform multiple group analysis. This was not possible in the current study. Multiple 
group analysis is a statistical technique which analyses groups simultaneously, provides 
more accurate parameter estimates than sub-group analyses and tests for statistically 
significant differences between groups (Arbuckle, 2012). Further development of 
statistical packages and techniques to conduct mediation analysis within survival analysis 
are necessary to allow categorical and continuous variables to be entered into the 
models, to allow for multiple group comparisons to be undertaken assessing moderated 
mediation models and to include model fit statistics to indicate how well the models fit 
the data.  
7.3.3 Secondary data analysis 
 
Established datasets such as ELSA and NorStOP provide scope for researching a number 
of issues relating to the health and lives of older adults; they are large databases which 
have data on a broad range of factors. Using such data increases cost efficiency and 
reduces the amount of time necessary to undertake research. However, the questions 
that can be asked on a particular topic are restricted by the available data. Secondary 
data analyses are unlikely to be ideal for answering research questions compared to if the 
database had been designed specifically to answer those proposed questions. For 
example, in order to optimally investigate mediation, the predictor variables should be 
measured before the mediator which in turn should be measured before the outcome 
(Kline, 2015). Baseline measures of the mediator and outcome variable are also necessary 
(where possible) to control for those values in order to isolate the effect of the proposed 
mediator (Keele, 2015). Also, the intervening time intervals should be appropriate (i.e. 
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not too long and not too short) to allow for a measureable change to have occurred 
(Mathieu & Taylor, 2006).  
Measurement issues  
The way in which factors are measured in an existing dataset may not be optimal to 
answer the research questions of a proposed study and may not be comparable to other 
studies. For example, in the current study the measures of physical activity from both the 
ELSA and NorStOP databases had limitations. ELSA asked participants how often they took 
part in mild, moderate or vigorous activity. This is potentially limited by the subjective 
interpretation of what ‘mild’, ‘moderate’ or ‘vigorous’ activity constitutes and by 
reporting bias where the participants may specify greater activity as this is seen as socially 
desirable.  A high proportion of ELSA participants (31.04% ELSA) reported weekly vigorous 
activity. Mean percent differences between subjective and objective measures of physical 
activity are greater when activity is categorised by levels of exertion with differences 
becoming greater with higher categories of intensity (i.e. participants indicate higher 
levels of vigorous activity when using self-report) (Prince et al., 2008). Misclassification of 
activity levels in the current study was therefore likely but the impact of this 
misclassification is unclear due to the need to dichotomise variables for the analysis. The 
resulting loss of information means the interpretation of the mediating effect of physical 
inactivity lacks detail. This is also true of the NorStOP measures of activity; ‘frequency of 
going out’ and ‘frequency of walking for 10 minutes’. ‘Going out’ does not necessarily 
reflect physical activity and although walking for 10 minutes does detail the type and 
duration of the activity, it is only one form of activity the participant may undertake and 
may be performed at varying levels of intensity (e.g. briskly or leisurely). In order to get a 
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more accurate representation of activity levels and the effect these may have on the 
relationship between pain and mortality objective measures such as pedometers or 
accelerometers could have been used to validate the reports of physical activities 
undertaken. However, these again are limited as they do not monitor activities such as 
swimming or upper body activities (Prince et al., 2008). The current study provides little 
information on the amount or type of physical activity that would be beneficial in 
reducing mortality risk in people with pain. Despite the limitations of different methods of 
measurement, designing a dataset with specific research questions in mind would enable 
a more valid and comprehensive assessment of the factors under investigation, provided 
the analysis technique used could accommodate the measures.      
7.3.4 Generalisability of findings 
 
This study provides evidence for a relationship between pain and mortality and identified 
potential mechanisms for that relationship. There were differences between the two 
samples used in the current study but the mediating effects of functional limitation, 
physical inactivity and poor self-rated health resulted in large effect sizes and was 
replicated in two different datasets. Data from ELSA is harmonised with data from other 
studies of ageing populations around the world (www.g2aging.org). These studies have 
common measures across surveys which would enable future replication attempts of the 
analyses from the current study. This would provide opportunities for cross national 
comparisons and the investigation of the effect of different national and policy contexts 
on the relationship between pain and mortality to determine if the relationships observed 
were generalisable (Chan et al., 2012).   
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7.4 Implications for practice 
The high prevalence of pain means the risk of mortality affects a large number of people. 
A population approach to the management of pain may be effective in reducing the 
population burden with respect to mortality. The effective treatment of pain itself is not 
always possible; the source of pain (e.g. serious injury) may not be treatable; symptoms 
often do not resolve; and pain trajectories may be stable over time, persons with 
persistent back pain have been shown to remain in the same trajectory (recovering, 
persistent mild, fluctuating and severe chronic) over 7 years (Dunn, Campbell, & Jordan, 
2013). There is a need instead to minimise the negative consequences of pain and this 
study identified a number of potential targets for interventions. 
7.4.1 Interventions to reduce mortality risk 
 
The findings from the current study indicate interventions targeted at improving 
functional capacity and increasing physical activity are particularly important for reducing 
mortality risk in people with pain. Increasing functional capacity and physical activity 
levels is difficult in people with pain; activity may increase the pain experienced by the 
individual (Soldato et al., 2007) or the reasons for inactivity may be as a result of disability 
(McGuire, Strine, Okoro, Ahluwalia, & Ford, 2007). In a systematic review Jack et al., 
(2008) reported lower previous activity levels, low-self-efficacy, depression, anxiety, poor 
social support or activity, greater perceived number of barriers to physical activity and 
increased pain levels during exercise were barriers to treatment adherence in 
physiotherapy outpatient clinics. They also acknowledged their review included a range of 
musculoskeletal conditions and that barriers may vary according to condition and 
population (Jack, McLean, Moffett, & Gardiner, 2010). The findings from the current study 
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suggest that if improvement in one target is not realistically achievable (i.e. an increase in 
physical activity) other target areas (i.e. depression, social participation) could be 
focussed upon which would also help to reduce mortality risk for people with pain. 
Interventions to reduce mortality risk for people with pain should also aim to reduce 
medication use; a recent study in Denmark demonstrated long term opioid use was 
associated with a greater increased risk of mortality than short-term or no opioid use in 
participants with chronic non-cancer pain compared to those with no chronic pain 
(Ekholm, Kurita, Hjsted, Juel, & Sjgren, 2014).    
7.4.2 Obstacles to effective pain management 
 
Many of the mediating factors identified in the current study are already targeted in pain 
management programmes to improve health outcomes. However, pain is inadequately 
treated as a result of cultural, attitudinal, educational, legal and political system related 
reasons (Brennan, Carr, & Cousins, 2007). For example, patients often do not challenge 
health professionals and patients with chronic non-cancer pain can be seen as 
malingerers or be deemed to have only psychological problems (Brennan et al., 2007). 
The co-ordinated integration of medical, psychosocial, and physical treatment in 
interdisciplinary care offers the best clinical care for the individual with pain and is a cost 
effective option for long term treatment (Gatchel, McGeary, McGeary, & Lippe, 2014). 
However, the up-front costs and the complexities of creating an interdisciplinary service 
mean this type of treatment is a resource that is available to only a few of those who may 
benefit (Gatchel et al., 2014). In an interview survey with 504 General Practitioners (GPs) 
in the UK about the management of chronic non-malignant pain, 91% of GPs considered 
specialised pain services to be beneficial but only 14% of patients were referred to 
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hospital for symptom management, 96% felt that pain services in their locality could be 
improved and 81% expressed an interest in relevant training (Stannard & Johnson, 2003). 
This indicates scope for the improvement of pain services.  
There is evidence that mortality risk for people with pain could be reduced with effective 
pain management.  In a thirteen year follow up of chronic pain patients in a pain 
management programme in the United States, Maruta et al., (1998) found the survival of 
the patients to be virtually identical to that of the general US population. Patients in this 
study were required to have a pain problem of six months duration or longer. The 
programme was designed to help patients and family members cope effectively, help 
patients reduce medication to a minimum and teach self-management methods (Maruta 
et al., 1998).  The findings of this thesis provide supporting evidence that at a population 
level, mortality risk for people with pain could be reduced by the effective management 
of pain and its impact. 
7.5 Concluding messages 
 People with pain which impacted on their life had an increased risk of mortality. 
 Pain was not associated with any specific cause of mortality.  
 The relationship between pain and mortality was dependent on pain phenotype. 
 Physical inactivity, functional limitation and poor self-rated health were indicated 
as important mediators of the relationship between pain and mortality but many 
factors were identified as potential targets to reduce mortality risk. 
 There were differences between males and females in the mediated pathways 
from pain to mortality and between those with and without comorbidity which 
warrant further investigation. 
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 Development of the statistical techniques to undertake mediation analysis within 
survival analysis is necessary to enable a more detailed investigation of 
relationships using this form of analysis. 
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Appendix I - Full search strategy 
MEDLINE using OVID SP (1946 to present) 
1 mortality.ti,ab. 380773  
2 mortality/ 31524  
3 cause of death/ 31017  
4 fatal outcome/ 43948  
5 hospital mortality/ 17629  
6 "cause of death".ti,ab. 31705  
7 fatal*.ti,ab. 89282  
8 death.ti,ab. 389950  
9 death/ 10928  
10 death,sudden/ 10434  
11 dead.ti,ab. 32464  
12 died.ti,ab. 165667  
13 survival/ 3445  
14 survival.ti,ab. 485299  
15 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 1296926  
16 (widespread adj3 pain).ti,ab. 979  
17 arthralgia.ti,ab. 3547  
18 fibromyalgia.ti,ab. 5476  
19 myalgia.ti,ab. 4138  
20 (chronic adj3 pain).ti,ab. 29541  
21 (joint adj pain).ti,ab. 3430  
22 (radicular adj pain).ti,ab. 1362  
23 (regional adj3 pain).ti,ab. 2046  
24 "presence of pain".ti,ab. 630  
25 (mult* adj3 pain).ti,ab. 3132  
26 (comorbid* adj3 pain).ti,ab. 376  
27 musculoskeletal pain/ 81  
28 chronic pain/ 281  
29 exp joint pain/ 5916  
30 fibromyalgia/ 5322  
31 pain measurement/ 50607  
32 "non* cancer pain".ti,ab. 291  
33 "non* malignant pain".ti,ab. 239  
34 pain/mo 70  
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35 arthralgia/ 3670  
36 complex regional pain syndromes/ 676  
37 myofascial pain syndromes/ 1079  
38 ((NECK or CERVICAL) adj3 PAIN).ti,ab. 6779  
39 ((KNEE* or HIP or HIPS or SHOULDER*) adj3 PAIN).ti,ab. 10990  
40 ((FOOT or FEET or ANKLE* or ELBOW*) adj3 PAIN).ti,ab. 2364  
41 ((MUSCULO* or MUSCULAR) adj3 PAIN).ti,ab. 3624  
42 ((BACK or LUMBAR or LUMBO* or SPINE or SPINAL) adj3 PAIN).ti,ab. 29792  
43 Back Pain/mo [Mortality] 9  
44 Shoulder Pain/mo [Mortality] 1  
45 
16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 
or 30 or 31 or 32 or 33 or 34 or 35 or 36 or 37 or 38 or 39 or 40 or 41 or 42 or 
43 or 44 
132018  
46 Longitudinal Studies/ 68770  
47 Cohort Studies/ 129164  
48 Prospective Studies/ 310346  
49 Family Practice/ or General Practice/ 59151  
50 Retrospective Studies/ 403154  
51 Case-Control Studies/ or Epidemiologic Methods/ 170484  
52 Cross-Sectional Studies/ 134718  
53 "family pract*".ti,ab. 8324  
54 "general pract*".ti,ab. 54841  
55 
(observ* or cohort or prospectiv* or retrospectiv* or population or longitud* or 
community or case* control or cross* section*).ti,ab. 
3556111  
56 46 or 47 or 48 or 49 or 50 or 51 or 52 or 53 or 54 or 55 3957958  
57 15 and 45 and 56 2342  
58 limit 57 to (english language and humans) 1935  
 
   
  
EMBASE using OVID SP (1980 to present) 
 
1 mortality.ti,ab. 455842  
2 mortality/ 400684  
3 cancer mortality/ 40133  
4 standardized mortality ratio/ 470  
5 "cause of death".ti,ab. 38288  
6 exp cause of death/ 54041  
7 death.ti,ab. 454083  
8 death/ or fatality/ 143765  
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9 dead.ti,ab. 36715  
10 sudden death/ 30665  
11 died.ti,ab. 191213  
12 fatal*.ti,ab. 101502  
13 survival/ 130224  
14 survival.ti,ab. 571242  
15 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 1668788  
16 (widespread adj3 pain).ti,ab. 1352  
17 fibromyalgia/ 10368  
18 chronic pain/ 25260  
19 arthralgia/ 28014  
20 arthralgia.ti,ab. 4703  
21 pain assessment/ 53996  
22 fibromyalgia.ti,ab. 7996  
23 myalgia/ 27190  
24 myalgia.ti,ab. 5341  
25 (chronic adj3 pain).ti,ab. 39396  
26 exp musculoskeletal pain/ 3051  
27 (joint adj pain).ti,ab. 4397  
28 radicular pain/ 1671  
29 (regional adj3 pain).ti,ab. 3222  
30 (radicular adj pain).ti,ab. 1724  
31 "presence of pain".ti,ab. 802  
32 (mult* adj3 pain).ti,ab. 4492  
33 (comorbid* adj3 pain).ti,ab. 520  
34 "non* cancer pain".ti,ab. 477  
35 "non* malignant pain".ti,ab. 375  
36 complex regional pain syndrome/ 1807  
37 myofascial pain/ 6245  
38 ((NECK or CERVICAL) adj3 PAIN).ti,ab. 8353  
39 ((KNEE* or HIP or HIPS or SHOULDER*) adj3 PAIN).ti,ab. 13404  
40 ((BACK or LUMBAR or LUMBO* or SPINE or SPINAL) adj3 PAIN).ti,ab. 37797  
41 ((FOOT or FEET or ANKLE* or ELBOW*) adj3 PAIN).ti,ab. 2952  
42 ((MUSCULO* or MUSCULAR) adj3 PAIN).ti,ab. 4840  
43 
hip pain/ or low back pain/ or spinal pain/ or foot pain/ or ankle pain/ or bone 
pain/ or knee pain/ or shoulder pain/ or neck pain/ 
59850  
44 
16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 
30 or 31 or 32 or 33 or 34 or 35 or 36 or 37 or 38 or 39 or 40 or 41 or 42 or 43 
229400  
45 prospective study/ 183136  
326 
 
46 cohort analysis/ 109928  
47 population research/ 55964  
48 longitudinal study/ 48485  
49 observational study/ 26687  
50 community assessment/ 1090  
51 general practice/ 62244  
52 retrospective study/ 251160  
53 case control study/ 57709  
54 cross-sectional study/ 63425  
55 "family pract*".ti,ab. 8406  
56 "general pract*".ti,ab. 65835  
57 
(observ* or cohort or prospectiv* or retrospectiv* or population or longitud* or 
community or case* control or cross* section*).ti,ab. 
4024951  
58 45 or 46 or 47 or 48 or 49 or 50 or 51 or 52 or 53 or 54 or 55 or 56 or 57 4238696  
59 15 and 44 and 58 5684  
60 limit 59 to (human and english language) 4651  
 
 
AMED using OVID SP (1985 to present) 
 
1 mortality.ti,ab. 1718  
2 Mortality/ 776  
3 Death/ 1564  
4 "cause of death".ti,ab. 235  
5 death.ti,ab. 4905  
6 fatal outcome/ 4  
7 Death sudden/ 41  
8 dead.ti,ab. 207  
9 died.ti,ab. 1176  
10 survival.ti,ab. 1982  
11 fatal*.ti,ab. 305  
12 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 9383  
13 (widespread adj3 pain).ti,ab. 206  
14 Arthralgia/ 100  
15 arthralgia.ti,ab. 39  
16 fibromyalgia/ 1448  
17 fibromyalgia.ti,ab. 1542  
18 myalgia.ti,ab. 61  
19 (chronic adj3 pain).ti,ab. 3521  
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20 (joint adj pain).ti,ab. 195  
21 (radicular adj pain).ti,ab. 64  
22 complex regional pain syndromes/ 28  
23 (regional adj3 pain).ti,ab. 183  
24 "presence of pain".ti,ab. 52  
25 (mult* adj3 pain).ti,ab. 500  
26 (comorbid* adj3 pain).ti,ab. 41  
27 Pain measurement/ 806  
28 "non* cancer pain".ti,ab. 17  
29 "non* malignant pain".ti,ab. 21  
30 Myofascial pain syndromes/ 230  
31 ((NECK or CERVICAL) adj3 PAIN).ti,ab. 1252  
32 ((KNEE* or HIP or HIPS or SHOULDER*) adj3 PAIN).ti,ab. 1602  
33 ((FOOT or FEET or ANKLE* or ELBOW*) adj3 PAIN).ti,ab. 620  
34 ((BACK or LUMBAR or LUMBO* or SPINE or SPINAL) adj3 PAIN).ti,ab. 5461  
35 ((MUSCULO* or MUSCULAR) adj3 PAIN).ti,ab. 674  
36 Low back pain/ or Backache/ 5091  
37 shoulder pain/ 183  
38 Neck pain/ 705  
39 
13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 
27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36 or 37 or 38 
13771  
40 cohort studies/ or prospective studies/ 622  
41 Family practice/ 803  
42 epidemiologic methods/ 479  
43 "family pract*".ti,ab. 132  
44 "general pract*".ti,ab. 1149  
45 
(observ* or cohort or prospectiv* or retrospectiv* or population or longitud* or 
community or case* control or cross* section*).ti,ab. 
40041  
46 40 or 41 or 42 or 43 or 44 or 45 41539  
47 12 and 39 and 46 42  
 
    
 
PSYCHINFO using OVID SP (1802 to present) 
 
1 mortality.ti,ab. 19078  
2 Mortality Rate/ 4561  
3 "cause of death".ti,ab. 2333  
4 "Death and Dying"/ 19022  
5 fatal*.ti,ab. 6614  
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6 death.ti,ab. 48028  
7 dead.ti,ab. 3838  
8 died.ti,ab. 8193  
9 survival.ti,ab. 20460  
10 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 95102  
11 (widespread adj3 pain).ti,ab. 286  
12 arthralgia.ti,ab. 47  
13 fibromyalgia.ti,ab. 1787  
14 myalgia.ti,ab. 150  
15 (chronic adj3 pain).ti,ab. 10512  
16 (joint adj pain).ti,ab. 264  
17 (radicular adj pain).ti,ab. 64  
18 (regional adj3 pain).ti,ab. 481  
19 "presence of pain".ti,ab. 150  
20 (mult* adj3 pain).ti,ab. 1357  
21 (comorbid* adj3 pain).ti,ab. 205  
22 "non* cancer pain".ti,ab. 103  
23 "non* malignant pain".ti,ab. 81  
24 Myofascial Pain/ 255  
25 ((NECK or CERVICAL) adj3 PAIN).ti,ab. 764  
26 ((KNEE* or HIP or HIPS or SHOULDER*) adj3 PAIN).ti,ab. 521  
27 ((FOOT or FEET or ANKLE* or ELBOW*) adj3 PAIN).ti,ab. 104  
28 ((BACK or LUMBAR or LUMBO* or SPINE or SPINAL) adj3 PAIN).ti,ab. 3806  
29 ((MUSCULO* or MUSCULAR) adj3 PAIN).ti,ab. 908  
30 Back Pain/ 2408  
31 Pain Measurement/ 914  
32 fibromyalgia/ 929  
33 Chronic Pain/ 7980  
34 
11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 
25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 
18034  
35 prospective studies/ or longitudinal studies/ 15006  
36 cohort analysis/ 889  
37 general practitioners/ 3988  
38 Retrospective Studies/ 315  
39 "family pract*".ti,ab. 1935  
40 "general pract*".ti,ab. 8495  
41 
(observ* or cohort or prospectiv* or retrospectiv* or population or longitud* or 
community or case* control or cross* section*).ti,ab. 
614867  
329 
 
42 35 or 36 or 37 or 38 or 39 or 40 or 41 627780  
43 10 and 34 and 42 112  
44 limit 43 to (human and english language) 100  
 
   
 
     
CINAHL using NHS interface (1980 to present) 
 
1 MORTALITY/ OR HOSPITAL MORTALITY/  15154 
2 mortality.ti,ab  45926 
3 CAUSE OF DEATH/  4018 
4 "cause of death".ti,ab  3680 
5 FATAL OUTCOME/  2216 
6 fatal*.ti,ab  8192 
7 DEATH/  7876 
8 death.ti,ab  41030 
9 dead.ti,ab  2172 
10 died.ti,ab  9386 
11 SURVIVAL/  13840 
12 survival.ti,ab  29672 
13 1 OR 2 OR 3 OR 4 OR 5 OR 6 OR 7 OR 8 OR 9 OR 10 OR 11 OR 12  129406 
14 
NECK PAIN/ OR CHRONIC PAIN/ OR BACK PAIN/ OR PAIN 
MEASUREMENT/  
30783 
15 (widespread adj3 pain).ti,ab  329 
16 ARTHRALGIA/  500 
17 arthralgia.ti,ab  244 
18 FIBROMYALGIA/  2503 
19 fibromyalgia.ti,ab  2218 
20 myalgia.ti,ab  305 
21 (chronic adj3 pain).ti,ab  9552 
22 (joint ADJ pain).ti,ab  1301 
23 (radicular ADJ pain).ti,ab  258 
24 COMPLEX REGIONAL PAIN SYNDROMES/  398 
25 (regional adj3 pain).ti,ab  742 
26 "presence of pain".ti,ab  181 
27 (mult* adj3 pain).ti,ab  1376 
28 (comorbid* adj3 pain).ti,ab  176 
29 "non* cancer pain".ti,ab  69 
30 "non* malignant pain".ti,ab  49 
31 MYOFASCIAL PAIN SYNDROMES/  717 
32 (neck OR cervical adj3 pain).ti,ab  12840 
33 (knee* OR hip OR hips OR shoulder* adj3 pain).ti,ab  29176 
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34 (foot OR feet OR ankle* OR elbow* adj3 pain).ti,ab  19010 
35 (back OR lumbar OR lumbo* OR spine OR spinal adj3 pain).ti,ab  38544 
36 (musculo* OR muscular adj3 pain).ti,ab  8239 
37 PELVIC PAIN/  848 
38 
14 OR 15 OR 16 OR 17 OR 18 OR 19 OR 20 OR 21 OR 22 OR 23 OR 24 
OR 25 OR 26 OR 27 OR 28 OR 29 OR 30 OR 31 OR 32 OR 33 OR 34 OR 
35 OR 36 OR 37  
123270 
39 
NONEXPERIMENTAL STUDIES/ OR CASE CONTROL STUDIES/ OR 
PROSPECTIVE STUDIES/  
149517 
40 
CONCURRENT PROSPECTIVE STUDIES/ OR PSEUDOLONGITUDINAL 
STUDIES/  
55 
41 RETROSPECTIVE PANEL STUDIES/ OR RETROSPECTIVE DESIGN/  55085 
42 
NONCONCURRENT PROSPECTIVE STUDIES/ OR CROSS SECTIONAL 
STUDIES/  
46988 
43 FAMILY PRACTICE/  8926 
44 COMMUNITY HEALTH CENTERS/  2088 
45 OBSERVATIONAL METHODS/  7756 
46 EPIDEMIOLOGICAL RESEARCH/  17635 
47 "family pract*".ti,ab  1499 
48 "general pract*".ti,ab  9561 
51 
(observ* OR cohort OR prospectiv* OR retrospectiv* OR population 
OR longitud* OR community OR (case* AND control) OR (cross* AND 
section*)).ti,ab  
336270 
52 39 OR 40 OR 41 OR 42 OR 43 OR 44 OR 45 OR 46 OR 47 OR 48 OR 51  461010 
53 13 AND 38 AND 52  3263 
54 53 [Limit to: (Language English)]  3232 
 
 
     
 
Social Sciences Citation Index (SSCI)  
Science Citation Index Expanded (SCI-EXPANDED)  
using Web of Science (1970 to present) 
# 40 (#39) AND Language=(English)    3,242  
# 39 #38 AND #34 AND #11    3,388  
# 38 #37 OR #36 OR #35    5,130,729  
# 37 ts=(observ* OR cohort or prospectiv* OR retrospectiv* OR population OR 
longitud* OR community OR "case* control" OR "cross* section*")   
 5,066,908  
# 36 ts=general pract*    101,275  
# 35 ts=family pract*,ti,ab    2  
# 34 #33 OR #32 OR #31 OR #30 OR #29 OR #28 OR #27 OR #26 OR #25 OR #24 
OR #23 OR #22 OR #21 OR #20 OR #19 OR #18 OR #17 OR #16 OR #15 OR 
#14 OR #13 OR #12   
 123,535  
# 33 (ts= ("back pain" or "spine pain" or "spinal pain" or "lumbar pain" or  30,018  
   
331 
 
"lumbo* pain")) AND Language=(English)   
# 32 (ts=("foot pain" or "ankle pain" or "elbow pain")) AND Language=(English)    1,183  
# 31 (ts=("knee pain" or "hip pain" or "shoulder pain")) AND Language=(English)    7,143  
# 30 (ts=("neck pain" or "cervical pain")) AND Language=(English)    4,716  
# 29 (ts=("back pain" OR "lumbar pain" OR "lumbo* pain" OR "spine pain" OR 
"spinal pain")) AND Language=(English)   
 30,018  
# 28 ts=(musculo* OR muscular near pain)    30,199  
# 27 ts="pain measurement"    892  
# 26 ts="myofascial pain syndromes"    134  
# 25 ts="complex regional pain syndromes"    120  
# 24 ts="non* malignant pain"    232  
# 23 ts="non* cancer pain"    277  
# 22 ts=(comorbid* near pain)    1,501  
# 21 ts=(mult* near pain)    12,498  
# 20 ts="presence of pain"    437  
# 19 ts=(regional near pain)    3,406  
# 18 ts=(radicular near pain)    1,558  
# 17 ts=(joint near pain)    11,612  
# 16 ts=(chronic near pain)    36,863  
# 15 ts=myalgia    4,384  
# 14 ts=fibromyalgia    8,943  
# 13 ts=arthralgia    3,282  
# 12 ts=(widespread NEAR pain)    1,613  
# 11 #10 OR #9 OR #8 OR #7 OR #6 OR #5 OR #4 OR #3 OR #2 OR #1    1,408,621  
# 10 ts=survival    559,536  
# 9 ts="sudden death"    17,548  
# 8 ts=died    177,790  
# 7 ts=dead   50,560  
# 6 ts=fatal*    70,550  
# 5 ts="hospital mortality"   13,410  
# 4 ts="fatal outcome"   3,360  
# 3 ts="cause of death"   19,405  
# 2 ts=death   458,758  
# 1 ts=mortality   432,078  
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Cochrane library: (Cochrane Database of Systematic Reviews (Cochrane Reviews), 
Database of Abstracts of Reviews of Effects (Other Reviews) 
 
#1 (mortality.ti,ab) 9513 
#2 mortality/ 38650 
#3 cause of death/ 8828 
#4 fatal outcome/ 2323 
#5 hospital mortality/ 16276 
#6 cause of death.ti,ab 3421 
#7 fatal*.ti,ab 9513 
#8 death.ti,ab 9513 
#9 died.ti,ab 9513 
#10 death/ 24789 
#11 death,sudden/ 25554 
#12 dead.ti,ab 9513 
#13 survival/ 36976 
#14 survival.ti,ab 9513 
#15 widespread adj3 pain.ti,ab 141 
#16 arthralgia.ti,ab 9513 
#17 fibromyalgia.ti,ab 9513 
#18 myalgia.ti,ab 9513 
#19 chronic adj3 pain.ti,ab 564 
#20 joint adj pain.ti,ab 346 
#21 radicular adj pain.ti,ab 31 
#22 regional adj3 pain.ti,ab 218 
#23 presence of pain.ti,ab 2168 
#24 mult* adj3 pain.ti,ab 884 
#25 musculoskeletal pain/ 1887 
#26 chronic pain/ 8610 
#27 exp joint pain/ 662 
#28 fibromyalgia/ 930 
#29 pain measurement/ 17607 
#30 non* cancer pain.ti,ab 1659 
#31 non* malignant pain.ti,ab 524 
#32 arthralgia/ 997 
#33 complex regional pain syndromes/ 290 
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#34 myofascial pain syndromes/ 379 
#35 neck or cervical adj3 pain.ti,ab 10404 
#36 knee* or hip or hips or shoulder* adj3 pain.ti,ab  15826 
#37 foot or feet or ankle* or elbow* adj3 pain.ti,ab 7150 
#38 back or lumbar or lumbo* or spine or spinal adj3 pain.ti,ab  16659 
#39 musculo* or muscular adj3 pain.ti,ab 3443 
#40 longitudinal studies/ 7733 
#41 cohort studies/ 18545 
#42 prospective studies/ 96203 
#43 family practice/ or general practice/ 18426 
#44 retrospective studies/ 12135 
#45 Case-Control Studies/ or Epidemiologic Methods/  8036 
#46 Cross-Sectional Studies/ 5307 
#47 family pract*.ti,ab 9513 
#48 general pract*.ti,ab 9513 
#49 
observ* or cohort or prospectiv* or retrospectiv* or population or longitud* or 
community or case* control or cross* section*.ti,ab. 
267548 
#50 
(#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 
OR #13 OR #14) 
74562 
#51 
(#15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22 OR #23 OR #24 OR 
#25 OR #26 OR #27 OR #28 OR #29 OR #30 OR #31 OR #32 OR #33 OR #34 OR 
#35 OR #36 OR #37 OR #38 OR #39) 
68424 
#52 (#40 OR #41 OR #42 OR #43 OR #44 OR #45 OR #46 OR #47 OR #48 OR #49)  275080 
#53 (#50 AND #51 AND #52) 13097 
#54 (#53) 5104 
 
 
 
Ageline using EBSCO (1978 to present) 
 
S33 S9 and S27 and S32 77 
S32 S28 or S29 or S30 or S31 51780 
S31 
observ* or cohort or prospectiv* or retrospectiv* or population or 
longitud* or community or case* control or cross* section* 
51142 
S30 family pract* 616 
S29 general pract* 778 
S28 (DE "Longitudinal Studies") OR (DE "Cohorts") 6281 
S27 S10 or S11 or S12 or S13 or S14 or S15 or S16 or S17 or S18 or S19 or 1294 
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S20 or S21 or S22 or S23 or S24 or S25 or S26 
S26 (BACK or LUMBAR or LUMBO* or SPINE or SPINAL) and PAIN 203 
S25 (FOOT or FEET or ANKLE* or ELBOW*) and PAIN 63 
S24 (KNEE* or HIP or HIPS or SHOULDER*) and PAIN 173 
S23 (NECK or CERVICAL) and PAIN 40 
S22 Myofascial pain syndrome 1 
S21 (musculo* or muscular) and pain 97 
S20 comorbid* and pain 119 
S19 mult* and pain 506 
S18 "presence of pain" 18 
S17 regional and pain 22 
S16 joint and pain 189 
S15 chronic and pain 541 
S14 Myalgia 2 
S13 Fibromyalgia 20 
S12 Arthralgia 1 
S11 widespread and pain 20 
S10 DE "Chronic Pain" 209 
S9 S1 or S2 or S3 or S4 or S5 or S6 or S7 or S8 11051 
S8 Survival 1486 
S7 Died 1455 
S6 Dead 211 
S5 Death 8341 
S4 fatal* 339 
S3 "cause of death" 229 
S2 DE "Death" OR DE "Death Causes" OR DE "Death Rates" 3519 
S1 Mortality 3532 
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Database No of items Duplicates per 
database 
Total Duplicates Total items 
Ageline 77 0 0 77 
AMED 42 0 0 119 
CINAHL 3232 33 33 3318 
Cochrane  4775 48 81 8045 
DARE 329 8 89 8366 
EMBASE 4651 394 483 12623 
Medline 1935 1478 1961 13080 
PsychInfo 100 61 2022 13119 
Web of 
Science 
3242 1304 3326 15057 
Total 18383 3326 3326 15057 
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Appendix II - Quality in Prognosis Studies (QUIPS)  
 
QUality In Prognosis Studies (QUIPS) – Quality Appraisal Exercise 
 
Primary Goal: Generate a list of specific issues related to potential biases in prognosis 
studies 
Steps (for each assigned study): 
 - Review the methods of the assigned prognosis study 
 - Decide if the study methods satisfy each general statement below for the 6 
biases 
 - Explain WHY you chose that rating under ‘Comments’ (good or bad methods 
achieved) 
 - Provide explanation (important points or exceptions) relevant to assess studies 
 - Citations to methods publications are encouraged and will be extremely helpful 
 
Study (First author, year):       
Bias related to Study Participation  
1. The source population or population of interest is 
adequately described for key characteristics. 
Comments: For example, what are 
the 'key characteristics' that need to 
be described for the source 
population?  
Yes 
 
Partly 
 
No 
 
Unclear 
 Not 
relevant 
2. The sampling frame and recruitment are adequately 
described, possibly including: 
- Methods to identify the sample (number and type 
used, e.g. referral patterns in healthcare settings) 
- Time period of recruitment 
- Place of recruitment (setting and geographic location) 
Comments:      
 
Yes 
 
Partly 
 
No 
 
Unclear 
 Not 
relevant 
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3. Inclusion and exclusion criteria are adequately 
described, including explicit diagnostic criteria or 'zero 
time' description. 
Comments:      
 
Yes 
 
Partly 
 
No 
 
Unclear 
 Not 
relevant 
4. There is adequate participation in the study by eligible 
individuals. 
Comments:      
 
Yes 
 
Partly 
 
No 
 
Unclear 
 Not 
relevant 
5. The baseline study sample (i.e. individuals entering into 
the study) is adequately described for key characteristics. 
Comments:      
 
Yes 
 
Partly 
 
No 
 
Unclear 
 Not 
relevant 
6. Study Participation Summary:  
Is the following statement satisfied based on responses to 
the above questions, "The study sample represents the 
population of interest on key characteristics, sufficient to 
limit potential bias to the results"? 
Comments: Which of the above 
questions did you consider to make 
this judgment? 
 
Yes 
 
Partly 
 
No 
 
Unclear 
 
 
Bias related to Study Attrition  
7. Response rate (i.e. proportion of study sample 
completing the study and providing outcome data) is 
adequate. 
Comments:      
 
Yes 
 
Partly 
 
No 
 
Unclear 
 Not 
relevant 
8. Attempts to collect information on drop-outs are 
described. 
Comments:      
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Yes 
 
Partly 
 
No 
 
Unclear 
 Not 
relevant 
9. Reasons for 'loss to follow-up' are provided. Comments:      
 
Yes 
 
Partly 
 
No 
 
Unclear 
 Not 
relevant 
10. Subjects lost to follow-up are adequately described 
for key characteristics. 
Comments:      
 
Yes 
 
Partly 
 
No 
 
Unclear 
 Not 
relevant 
11. There are no important differences between 
completers and non-completers on key characteristics 
and outcomes. 
Comments:      
 
Yes 
 
Partly 
 
No 
 
Unclear 
 Not 
relevant 
12. Study Attrition Summary:  
The following statement is satisfied based on responses to 
the above questions, "Loss to follow-up (from sample to 
study population) is not associated with key 
characteristics (i.e. the study data adequately represents 
the sample), sufficient to limit potential bias"? 
 
Comments:      
 
Yes 
 
Partly 
 
No 
 
Unclear 
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Bias related to Prognostic Factor Measurement  
13. A clear definition or description of the prognostic 
factor measured is provided (e.g. including dose, level, 
duration of exposure, and clear specification of the 
method of measurement). 
 
Comments:      
 
Yes 
 
Partly 
 
No 
 
Unclear 
 Not 
relevant 
14. Continuous variables are reported or appropriate (i.e. 
not data dependent) cut-points are used. 
Comments:      
 
Yes 
 
Partly 
 
No 
 
Unclear 
 Not 
relevant 
15. The prognostic factor measure and method used is 
adequately valid and reliable to limit misclassification bias 
(e.g. may include relevant outside sources of information 
on measurement properties, also characteristics such as 
blind measurement, limited reliance on recall). 
 
Comments:      
 
Yes 
 
Partly 
 
No 
 
Unclear 
 Not 
relevant 
16. Adequate proportion of sample has complete data for 
all relevant outcome periods. 
Comments:      
 
Yes 
 
Partly 
 
No 
 
Unclear 
 Not 
relevant 
17. The method and setting of measurement is the same 
for all study participants. 
Comments:      
 
Yes 
 
Partly 
 
No 
 
Unclear 
 Not 
relevant 
18. Appropriate methods are used if imputation is used 
for missing prognostic factor data. 
Comments:      
340 
 
 
Yes 
 
Partly 
 
No 
 
Unclear 
 Not 
relevant 
19. Prognostic Factor Measurement Summary:  
The following statement is satisfied based on responses to 
the above questions, "The prognostic factor of interest is 
adequately measured in study participants to sufficiently 
limit potential bias"? 
Comments:      
 
Yes 
 
Partly 
 
No 
 
Unclear 
 
 
Bias related to Outcome Measurement  
20. A clear definition of the outcome of interest is 
provided including duration of follow-up, the level and 
extent of the outcome construct. 
Comments:      
 
Yes 
 
Partly 
 
No 
 
Unclear 
 Not 
relevant 
21. The outcome measure and method used is adequately 
valid and reliable to limit misclassification bias (e.g. may 
include 
relevant outside sources of information on measurement 
properties, also characteristics such as blind 
measurement, confirmation of outcome with valid and 
reliable test). 
Comments:      
 
Yes 
 
Partly 
 
No 
 
Unclear 
 Not 
relevant 
22. The method and setting of measurement is the same 
for all study participants. 
Comments:      
 
Yes 
 
Partly 
 
No 
 
Unclear 
 Not 
relevant 
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23. Outcome Measurement Summary:  
The following statement is satisfied based on responses to 
the above questions, "The outcome of interest is 
adequately measured in study participants to sufficiently 
limit potential bias"? 
Comments:      
 
Yes 
 
Partly 
 
No 
 
Unclear 
 
 
Bias related to Confounding Measurement and Account  
24. All important confounders, including treatments (key 
variables in conceptual model) are measured. 
 
Comments:      
 
Yes 
 
Partly 
 
No 
 
Unclear 
 Not 
relevant 
25. Clear definitions of the important confounders 
measured are provided (e.g. including dose, level, and 
duration of exposures). 
Comments:      
 
Yes 
 
Partly 
 
No 
 
Unclear 
 Not 
relevant 
26. Measurement of all important confounders is 
adequately valid and reliable (e.g. may include relevant 
outside sources of information on measurement 
properties, also characteristics such as blind 
measurement, limited reliance on recall). 
 
Comments:      
 
Yes 
 
Partly 
 
No 
 
Unclear 
 Not 
relevant 
27. The method and setting of confounding measurement 
is the same for all study participants. 
Comments:      
 
Yes 
 
Partly 
 
No 
 
Unclear 
 Not 
relevant 
28. Appropriate methods are used if imputation is used 
for missing confounder data. 
Comments:      
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Yes 
 
Partly 
 
No 
 
Unclear 
 Not 
relevant 
29. Important potential confounders are accounted for in 
the study design (i.e. matching for key variables, 
stratification, or initial assembly of comparable groups). 
Comments:      
 
Yes 
 
Partly 
 
No 
 
Unclear 
 Not 
relevant 
30. Important potential confounders are accounted for in 
the analysis (i.e. appropriate adjustment). 
Comments:      
 
Yes 
 
Partly 
 
No 
 
Unclear 
 Not 
relevant 
31. Confounding Measurement and Account Summary:  
The following statement is satisfied based on responses to 
the above questions, "Important potential confounders 
are appropriately accounted for, limiting potential bias 
with respect to the prognostic factor of interest"? 
Comments:      
 
Yes 
 
Partly 
 
No 
 
Unclear 
 
 
Bias related to Analysis  
32. There is sufficient presentation of data to assess the 
adequacy of the analysis. 
Comments:      
 
Yes 
 
Partly 
 
No 
 
Unclear 
 Not 
relevant 
33. The strategy for model building (i.e. inclusion of 
variables) is appropriate and based on a conceptual 
framework or model. 
Comments:      
 
Yes 
 
Partly 
 
No 
 
Unclear 
 Not 
relevant 
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34. The selected model is adequate for the design of the 
study. 
Comments:      
 
Yes 
 
Partly 
 
No 
 
Unclear 
 Not 
relevant 
35. There is no selective reporting of results. Comments:      
 
Yes 
 
Partly 
 
No 
 
Unclear 
 Not 
relevant 
36. Analysis Summary:  
The following statement is satisfied based on the 
responses to the above questions, "The statistical analysis 
is appropriate for the design of the study, limiting 
potential for presentation of invalid results"? 
 
Comments:      
 
Yes 
 
Partly 
 
No 
 
Unclear 
 
 
Overall comments on methods in LBP prognosis 
studies:     ____________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________ 
Comments on this 
project:     ____________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
_________________________________________________________________ 
 
 
THANK YOU! 
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Appendix III - Missing data correlations 
 
ELSA 
---------------------------------------------------------------------------------------- 
      name:  <unnamed> 
       log:  S:\Data\ELSAmissing.log 
  log type:  text 
 opened on:  26 Jun 2015, 10:37:48 
 
. local corrvars "Pain2 cen2 age2 sex2 education wealth phact symptomcount function smok 
> e volunteerwork hehelf dep cognitiveability alc groupmem tot w4physact w4symptom w4fun 
> ction w4vol w4smoke w4srhealth w4cogability w4alc w4dep w4groupmem w4casp19" 
 
.  
. foreach var of varlist Pain2 cen2 age2 sex2 education wealth phact symptomcount functi 
> on smoke volunteerwork hehelf dep cognitiveability alc groupmem tot w4physact w4sympto 
> m w4function w4vol w4smoke w4srhealth w4cogability w4alc w4dep w4groupmem w4casp19{ 
  2.  
. gen m_`var' = missing(`var') 
  3.  
. pwcorr m_`var' `: list corrvars - var' 
  4.  
. } 
 
             |  m_Pain2     cen2     age2     sex2 educat~n   wealth    phact 
-------------+--------------------------------------------------------------- 
     m_Pain2 |   1.0000  
        cen2 |  -0.0977   1.0000  
        age2 |  -0.5931  -0.3038   1.0000  
        sex2 |  -0.0233   0.0656   0.0013   1.0000  
   education |        .   0.1479  -0.2689  -0.1542   1.0000  
      wealth |        .   0.1653  -0.1523  -0.0508   0.4057   1.0000  
       phact |        .   0.2767  -0.2889  -0.0687   0.2443   0.2821   1.0000  
symptomcount |        .  -0.2519   0.2414   0.0453  -0.1771  -0.2402  -0.4302  
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    function |        .  -0.2439   0.2113   0.0546  -0.1470  -0.2166  -0.4586  
       smoke |        .  -0.0686  -0.0585  -0.1252  -0.0932  -0.1678  -0.0898  
volunteerw~k |        .   0.1177  -0.0762   0.0374   0.2576   0.2199   0.1790  
      hehelf |        .   0.2348  -0.1705   0.0083   0.2288   0.2923   0.4010  
         dep |        .  -0.1243   0.1089   0.1295  -0.1816  -0.2160  -0.2502  
cognitivea~y |        .   0.2814  -0.4438   0.0898   0.3377   0.2667   0.2555  
         alc |        .   0.0818  -0.1267  -0.2121   0.2098   0.2320   0.1693  
    groupmem |        .   0.0577   0.0230   0.0049   0.2824   0.2516   0.2066  
         tot |        .   0.1849  -0.1193   0.0296   0.1667   0.2999   0.3254  
   w4physact |        .   0.2696  -0.3264  -0.0864   0.2446   0.2815   0.4955  
   w4symptom |        .  -0.1675   0.2411   0.0576  -0.1934  -0.2553  -0.3448  
  w4function |        .  -0.3181   0.2918   0.0516  -0.1542  -0.1956  -0.3641  
       w4vol |        .   0.1317  -0.1403   0.0161   0.3207   0.2604   0.1968  
     w4smoke |        .  -0.0240  -0.1209  -0.0003  -0.0991  -0.1907  -0.0850  
  w4srhealth |        .   0.1637  -0.1844  -0.0163   0.2372   0.2792   0.3293  
w4cogability |        .   0.2381  -0.4596   0.0826   0.3437   0.2499   0.2177  
       w4alc |        .   0.1360  -0.1656  -0.1897   0.2321   0.2593   0.1916  
       w4dep |        .  -0.1126   0.1379   0.1317  -0.1856  -0.2248  -0.2306  
  w4groupmem |        .   0.1253  -0.0535   0.0151   0.3304   0.3169   0.2408  
    w4casp19 |        .   0.1443  -0.1731   0.0056   0.1832   0.2683   0.2718  
 
             | sympto~t function    smoke volunt~k   hehelf      dep cognit~y 
-------------+--------------------------------------------------------------- 
symptomcount |   1.0000  
    function |   0.6330   1.0000  
       smoke |   0.0605   0.0548   1.0000  
volunteerw~k |  -0.1572  -0.1548  -0.1019   1.0000  
      hehelf |  -0.4896  -0.4521  -0.1365   0.1831   1.0000  
         dep |   0.3456   0.3358   0.0705  -0.1114  -0.3694   1.0000  
cognitivea~y |  -0.2164  -0.2124  -0.0399   0.1667   0.2406  -0.1498   1.0000  
         alc |  -0.1749  -0.1609   0.0332   0.0578   0.1800  -0.1334   0.1248  
    groupmem |  -0.1269  -0.1213  -0.1321   0.3689   0.1653  -0.1013   0.1113  
         tot |  -0.4203  -0.4205  -0.1107   0.1556   0.4946  -0.4144   0.1868  
   w4physact |  -0.3741  -0.3713  -0.1037   0.1568   0.3641  -0.2203   0.2583  
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   w4symptom |   0.5781   0.4665   0.1035  -0.1259  -0.4425   0.2953  -0.1835  
  w4function |   0.4616   0.6061   0.0457  -0.1312  -0.3676   0.2434  -0.2572  
       w4vol |  -0.1532  -0.1557  -0.1270   0.4751   0.1804  -0.1174   0.2362  
     w4smoke |   0.0820   0.0701   0.6205  -0.0939  -0.1259   0.0904  -0.0144  
  w4srhealth |  -0.4043  -0.3770  -0.1459   0.1316   0.6283  -0.3088   0.2265  
w4cogability |  -0.2020  -0.1807  -0.0621   0.1604   0.2079  -0.1462   0.5832  
       w4alc |  -0.1981  -0.1814   0.0024   0.0811   0.1990  -0.1427   0.1610  
       w4dep |   0.3054   0.3136   0.0792  -0.0928  -0.3247   0.4339  -0.1584  
  w4groupmem |  -0.1603  -0.1481  -0.1700   0.3838   0.2160  -0.1263   0.1986  
    w4casp19 |  -0.3465  -0.3317  -0.1100   0.1247   0.4354  -0.3439   0.1802  
 
             |      alc groupmem      tot w4phys~t w4symp~m w4func~n    w4vol 
-------------+--------------------------------------------------------------- 
         alc |   1.0000  
    groupmem |   0.1321   1.0000  
         tot |   0.1640   0.1924   1.0000  
   w4physact |   0.1807   0.1749   0.2924   1.0000  
   w4symptom |  -0.1758  -0.1076  -0.3523  -0.4082   1.0000  
  w4function |  -0.1572  -0.0850  -0.3393  -0.4680   0.4652   1.0000  
       w4vol |   0.0961   0.3600   0.1745   0.2554  -0.1635  -0.1903   1.0000  
     w4smoke |  -0.0651  -0.1439  -0.1311  -0.1032   0.0859   0.0307  -0.1131  
  w4srhealth |   0.1763   0.1400   0.4413   0.4106  -0.5202  -0.4396   0.2104  
w4cogability |   0.1205   0.1198   0.1618   0.2829  -0.2429  -0.2520   0.2455  
       w4alc |   0.6525   0.1198   0.1660   0.2581  -0.1895  -0.2446   0.1459  
       w4dep |  -0.1353  -0.0975  -0.3725  -0.2827   0.3858   0.3388  -0.1389  
  w4groupmem |   0.1384   0.5966   0.2120   0.2814  -0.1526  -0.1867   0.4572  
    w4casp19 |   0.1590   0.1558   0.7096   0.3211  -0.4019  -0.3917   0.1796  
 
             |  w4smoke w4srhe~h w4coga~y    w4alc    w4dep w4grou~m w4casp19 
-------------+--------------------------------------------------------------- 
     w4smoke |   1.0000  
  w4srhealth |  -0.1211   1.0000  
w4cogability |  -0.0345   0.2585   1.0000  
       w4alc |  -0.0792   0.2169   0.1786   1.0000  
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       w4dep |   0.0800  -0.4030  -0.1927  -0.1755   1.0000  
  w4groupmem |  -0.1745   0.2151   0.2155   0.2824  -0.1467   1.0000  
    w4casp19 |  -0.1122   0.5114   0.2105   0.1696  -0.4561   0.2110   1.0000  
 
             |   m_cen2    Pain2     age2     sex2 educat~n   wealth    phact 
-------------+--------------------------------------------------------------- 
      m_cen2 |   1.0000  
       Pain2 |   0.0039   1.0000  
        age2 |  -0.0402   0.0692   1.0000  
        sex2 |   0.0021   0.0794   0.0013   1.0000  
   education |        .  -0.1299  -0.2689  -0.1542   1.0000  
      wealth |        .  -0.1706  -0.1523  -0.0508   0.4057   1.0000  
       phact |        .  -0.2480  -0.2889  -0.0687   0.2443   0.2821   1.0000  
symptomcount |        .   0.3735   0.2414   0.0453  -0.1771  -0.2402  -0.4302  
    function |        .   0.3496   0.2113   0.0546  -0.1470  -0.2166  -0.4586  
       smoke |        .   0.0516  -0.0585  -0.1252  -0.0932  -0.1678  -0.0898  
volunteerw~k |        .  -0.0818  -0.0762   0.0374   0.2576   0.2199   0.1790  
      hehelf |        .  -0.4115  -0.1705   0.0083   0.2288   0.2923   0.4010  
         dep |        .   0.2854   0.1089   0.1295  -0.1816  -0.2160  -0.2502  
cognitivea~y |        .  -0.0932  -0.4438   0.0898   0.3377   0.2667   0.2555  
         alc |        .  -0.1295  -0.1267  -0.2121   0.2098   0.2320   0.1693  
    groupmem |        .  -0.0801   0.0230   0.0049   0.2824   0.2516   0.2066  
         tot |        .  -0.3145  -0.1193   0.0296   0.1667   0.2999   0.3254  
   w4physact |        .  -0.2261  -0.3264  -0.0864   0.2446   0.2815   0.4955  
   w4symptom |        .   0.3604   0.2411   0.0576  -0.1934  -0.2553  -0.3448  
  w4function |        .   0.2406   0.2918   0.0516  -0.1542  -0.1956  -0.3641  
       w4vol |        .  -0.0874  -0.1403   0.0161   0.3207   0.2604   0.1968  
     w4smoke |        .   0.0586  -0.1209  -0.0003  -0.0991  -0.1907  -0.0850  
  w4srhealth |        .  -0.3547  -0.1844  -0.0163   0.2372   0.2792   0.3293  
w4cogability |        .  -0.1047  -0.4596   0.0826   0.3437   0.2499   0.2177  
       w4alc |        .  -0.1273  -0.1656  -0.1897   0.2321   0.2593   0.1916  
       w4dep |        .   0.2778   0.1379   0.1317  -0.1856  -0.2248  -0.2306  
  w4groupmem |        .  -0.1070  -0.0535   0.0151   0.3304   0.3169   0.2408  
    w4casp19 |        .  -0.2925  -0.1731   0.0056   0.1832   0.2683   0.2718  
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             | sympto~t function    smoke volunt~k   hehelf      dep cognit~y 
-------------+--------------------------------------------------------------- 
symptomcount |   1.0000  
    function |   0.6330   1.0000  
       smoke |   0.0605   0.0548   1.0000  
volunteerw~k |  -0.1572  -0.1548  -0.1019   1.0000  
      hehelf |  -0.4896  -0.4521  -0.1365   0.1831   1.0000  
         dep |   0.3456   0.3358   0.0705  -0.1114  -0.3694   1.0000  
cognitivea~y |  -0.2164  -0.2124  -0.0399   0.1667   0.2406  -0.1498   1.0000  
         alc |  -0.1749  -0.1609   0.0332   0.0578   0.1800  -0.1334   0.1248  
    groupmem |  -0.1269  -0.1213  -0.1321   0.3689   0.1653  -0.1013   0.1113  
         tot |  -0.4203  -0.4205  -0.1107   0.1556   0.4946  -0.4144   0.1868  
   w4physact |  -0.3741  -0.3713  -0.1037   0.1568   0.3641  -0.2203   0.2583  
   w4symptom |   0.5781   0.4665   0.1035  -0.1259  -0.4425   0.2953  -0.1835  
  w4function |   0.4616   0.6061   0.0457  -0.1312  -0.3676   0.2434  -0.2572  
       w4vol |  -0.1532  -0.1557  -0.1270   0.4751   0.1804  -0.1174   0.2362  
     w4smoke |   0.0820   0.0701   0.6205  -0.0939  -0.1259   0.0904  -0.0144  
  w4srhealth |  -0.4043  -0.3770  -0.1459   0.1316   0.6283  -0.3088   0.2265  
w4cogability |  -0.2020  -0.1807  -0.0621   0.1604   0.2079  -0.1462   0.5832  
       w4alc |  -0.1981  -0.1814   0.0024   0.0811   0.1990  -0.1427   0.1610  
       w4dep |   0.3054   0.3136   0.0792  -0.0928  -0.3247   0.4339  -0.1584  
  w4groupmem |  -0.1603  -0.1481  -0.1700   0.3838   0.2160  -0.1263   0.1986  
    w4casp19 |  -0.3465  -0.3317  -0.1100   0.1247   0.4354  -0.3439   0.1802  
 
             |      alc groupmem      tot w4phys~t w4symp~m w4func~n    w4vol 
-------------+--------------------------------------------------------------- 
         alc |   1.0000  
    groupmem |   0.1321   1.0000  
         tot |   0.1640   0.1924   1.0000  
   w4physact |   0.1807   0.1749   0.2924   1.0000  
   w4symptom |  -0.1758  -0.1076  -0.3523  -0.4082   1.0000  
  w4function |  -0.1572  -0.0850  -0.3393  -0.4680   0.4652   1.0000  
       w4vol |   0.0961   0.3600   0.1745   0.2554  -0.1635  -0.1903   1.0000  
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     w4smoke |  -0.0651  -0.1439  -0.1311  -0.1032   0.0859   0.0307  -0.1131  
  w4srhealth |   0.1763   0.1400   0.4413   0.4106  -0.5202  -0.4396   0.2104  
w4cogability |   0.1205   0.1198   0.1618   0.2829  -0.2429  -0.2520   0.2455  
       w4alc |   0.6525   0.1198   0.1660   0.2581  -0.1895  -0.2446   0.1459  
       w4dep |  -0.1353  -0.0975  -0.3725  -0.2827   0.3858   0.3388  -0.1389  
  w4groupmem |   0.1384   0.5966   0.2120   0.2814  -0.1526  -0.1867   0.4572  
    w4casp19 |   0.1590   0.1558   0.7096   0.3211  -0.4019  -0.3917   0.1796  
 
             |  w4smoke w4srhe~h w4coga~y    w4alc    w4dep w4grou~m w4casp19 
-------------+--------------------------------------------------------------- 
     w4smoke |   1.0000  
  w4srhealth |  -0.1211   1.0000  
w4cogability |  -0.0345   0.2585   1.0000  
       w4alc |  -0.0792   0.2169   0.1786   1.0000  
       w4dep |   0.0800  -0.4030  -0.1927  -0.1755   1.0000  
  w4groupmem |  -0.1745   0.2151   0.2155   0.2824  -0.1467   1.0000  
    w4casp19 |  -0.1122   0.5114   0.2105   0.1696  -0.4561   0.2110   1.0000  
 
             |   m_age2    Pain2     cen2     sex2 educat~n   wealth    phact 
-------------+--------------------------------------------------------------- 
      m_age2 |        .  
       Pain2 |        .   1.0000  
        cen2 |        .  -0.0615   1.0000  
        sex2 |        .   0.0794   0.0656   1.0000  
   education |        .  -0.1299   0.1479  -0.1542   1.0000  
      wealth |        .  -0.1706   0.1653  -0.0508   0.4057   1.0000  
       phact |        .  -0.2480   0.2767  -0.0687   0.2443   0.2821   1.0000  
symptomcount |        .   0.3735  -0.2519   0.0453  -0.1771  -0.2402  -0.4302  
    function |        .   0.3496  -0.2439   0.0546  -0.1470  -0.2166  -0.4586  
       smoke |        .   0.0516  -0.0686  -0.1252  -0.0932  -0.1678  -0.0898  
volunteerw~k |        .  -0.0818   0.1177   0.0374   0.2576   0.2199   0.1790  
      hehelf |        .  -0.4115   0.2348   0.0083   0.2288   0.2923   0.4010  
         dep |        .   0.2854  -0.1243   0.1295  -0.1816  -0.2160  -0.2502  
cognitivea~y |        .  -0.0932   0.2814   0.0898   0.3377   0.2667   0.2555  
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         alc |        .  -0.1295   0.0818  -0.2121   0.2098   0.2320   0.1693  
    groupmem |        .  -0.0801   0.0577   0.0049   0.2824   0.2516   0.2066  
         tot |        .  -0.3145   0.1849   0.0296   0.1667   0.2999   0.3254  
   w4physact |        .  -0.2261   0.2696  -0.0864   0.2446   0.2815   0.4955  
   w4symptom |        .   0.3604  -0.1675   0.0576  -0.1934  -0.2553  -0.3448  
  w4function |        .   0.2406  -0.3181   0.0516  -0.1542  -0.1956  -0.3641  
       w4vol |        .  -0.0874   0.1317   0.0161   0.3207   0.2604   0.1968  
     w4smoke |        .   0.0586  -0.0240  -0.0003  -0.0991  -0.1907  -0.0850  
  w4srhealth |        .  -0.3547   0.1637  -0.0163   0.2372   0.2792   0.3293  
w4cogability |        .  -0.1047   0.2381   0.0826   0.3437   0.2499   0.2177  
       w4alc |        .  -0.1273   0.1360  -0.1897   0.2321   0.2593   0.1916  
       w4dep |        .   0.2778  -0.1126   0.1317  -0.1856  -0.2248  -0.2306  
  w4groupmem |        .  -0.1070   0.1253   0.0151   0.3304   0.3169   0.2408  
    w4casp19 |        .  -0.2925   0.1443   0.0056   0.1832   0.2683   0.2718  
 
             | sympto~t function    smoke volunt~k   hehelf      dep cognit~y 
-------------+--------------------------------------------------------------- 
symptomcount |   1.0000  
    function |   0.6330   1.0000  
       smoke |   0.0605   0.0548   1.0000  
volunteerw~k |  -0.1572  -0.1548  -0.1019   1.0000  
      hehelf |  -0.4896  -0.4521  -0.1365   0.1831   1.0000  
         dep |   0.3456   0.3358   0.0705  -0.1114  -0.3694   1.0000  
cognitivea~y |  -0.2164  -0.2124  -0.0399   0.1667   0.2406  -0.1498   1.0000  
         alc |  -0.1749  -0.1609   0.0332   0.0578   0.1800  -0.1334   0.1248  
    groupmem |  -0.1269  -0.1213  -0.1321   0.3689   0.1653  -0.1013   0.1113  
         tot |  -0.4203  -0.4205  -0.1107   0.1556   0.4946  -0.4144   0.1868  
   w4physact |  -0.3741  -0.3713  -0.1037   0.1568   0.3641  -0.2203   0.2583  
   w4symptom |   0.5781   0.4665   0.1035  -0.1259  -0.4425   0.2953  -0.1835  
  w4function |   0.4616   0.6061   0.0457  -0.1312  -0.3676   0.2434  -0.2572  
       w4vol |  -0.1532  -0.1557  -0.1270   0.4751   0.1804  -0.1174   0.2362  
     w4smoke |   0.0820   0.0701   0.6205  -0.0939  -0.1259   0.0904  -0.0144  
  w4srhealth |  -0.4043  -0.3770  -0.1459   0.1316   0.6283  -0.3088   0.2265  
w4cogability |  -0.2020  -0.1807  -0.0621   0.1604   0.2079  -0.1462   0.5832  
351 
 
       w4alc |  -0.1981  -0.1814   0.0024   0.0811   0.1990  -0.1427   0.1610  
       w4dep |   0.3054   0.3136   0.0792  -0.0928  -0.3247   0.4339  -0.1584  
  w4groupmem |  -0.1603  -0.1481  -0.1700   0.3838   0.2160  -0.1263   0.1986  
    w4casp19 |  -0.3465  -0.3317  -0.1100   0.1247   0.4354  -0.3439   0.1802  
 
             |      alc groupmem      tot w4phys~t w4symp~m w4func~n    w4vol 
-------------+--------------------------------------------------------------- 
         alc |   1.0000  
    groupmem |   0.1321   1.0000  
         tot |   0.1640   0.1924   1.0000  
   w4physact |   0.1807   0.1749   0.2924   1.0000  
   w4symptom |  -0.1758  -0.1076  -0.3523  -0.4082   1.0000  
  w4function |  -0.1572  -0.0850  -0.3393  -0.4680   0.4652   1.0000  
       w4vol |   0.0961   0.3600   0.1745   0.2554  -0.1635  -0.1903   1.0000  
     w4smoke |  -0.0651  -0.1439  -0.1311  -0.1032   0.0859   0.0307  -0.1131  
  w4srhealth |   0.1763   0.1400   0.4413   0.4106  -0.5202  -0.4396   0.2104  
w4cogability |   0.1205   0.1198   0.1618   0.2829  -0.2429  -0.2520   0.2455  
       w4alc |   0.6525   0.1198   0.1660   0.2581  -0.1895  -0.2446   0.1459  
       w4dep |  -0.1353  -0.0975  -0.3725  -0.2827   0.3858   0.3388  -0.1389  
  w4groupmem |   0.1384   0.5966   0.2120   0.2814  -0.1526  -0.1867   0.4572  
    w4casp19 |   0.1590   0.1558   0.7096   0.3211  -0.4019  -0.3917   0.1796  
 
             |  w4smoke w4srhe~h w4coga~y    w4alc    w4dep w4grou~m w4casp19 
-------------+--------------------------------------------------------------- 
     w4smoke |   1.0000  
  w4srhealth |  -0.1211   1.0000  
w4cogability |  -0.0345   0.2585   1.0000  
       w4alc |  -0.0792   0.2169   0.1786   1.0000  
       w4dep |   0.0800  -0.4030  -0.1927  -0.1755   1.0000  
  w4groupmem |  -0.1745   0.2151   0.2155   0.2824  -0.1467   1.0000  
    w4casp19 |  -0.1122   0.5114   0.2105   0.1696  -0.4561   0.2110   1.0000  
 
             |   m_sex2    Pain2     cen2     age2 educat~n   wealth    phact 
-------------+--------------------------------------------------------------- 
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      m_sex2 |        .  
       Pain2 |        .   1.0000  
        cen2 |        .  -0.0615   1.0000  
        age2 |        .   0.0692  -0.3038   1.0000  
   education |        .  -0.1299   0.1479  -0.2689   1.0000  
      wealth |        .  -0.1706   0.1653  -0.1523   0.4057   1.0000  
       phact |        .  -0.2480   0.2767  -0.2889   0.2443   0.2821   1.0000  
symptomcount |        .   0.3735  -0.2519   0.2414  -0.1771  -0.2402  -0.4302  
    function |        .   0.3496  -0.2439   0.2113  -0.1470  -0.2166  -0.4586  
       smoke |        .   0.0516  -0.0686  -0.0585  -0.0932  -0.1678  -0.0898  
volunteerw~k |        .  -0.0818   0.1177  -0.0762   0.2576   0.2199   0.1790  
      hehelf |        .  -0.4115   0.2348  -0.1705   0.2288   0.2923   0.4010  
         dep |        .   0.2854  -0.1243   0.1089  -0.1816  -0.2160  -0.2502  
cognitivea~y |        .  -0.0932   0.2814  -0.4438   0.3377   0.2667   0.2555  
         alc |        .  -0.1295   0.0818  -0.1267   0.2098   0.2320   0.1693  
    groupmem |        .  -0.0801   0.0577   0.0230   0.2824   0.2516   0.2066  
         tot |        .  -0.3145   0.1849  -0.1193   0.1667   0.2999   0.3254  
   w4physact |        .  -0.2261   0.2696  -0.3264   0.2446   0.2815   0.4955  
   w4symptom |        .   0.3604  -0.1675   0.2411  -0.1934  -0.2553  -0.3448  
  w4function |        .   0.2406  -0.3181   0.2918  -0.1542  -0.1956  -0.3641  
       w4vol |        .  -0.0874   0.1317  -0.1403   0.3207   0.2604   0.1968  
     w4smoke |        .   0.0586  -0.0240  -0.1209  -0.0991  -0.1907  -0.0850  
  w4srhealth |        .  -0.3547   0.1637  -0.1844   0.2372   0.2792   0.3293  
w4cogability |        .  -0.1047   0.2381  -0.4596   0.3437   0.2499   0.2177  
       w4alc |        .  -0.1273   0.1360  -0.1656   0.2321   0.2593   0.1916  
       w4dep |        .   0.2778  -0.1126   0.1379  -0.1856  -0.2248  -0.2306  
  w4groupmem |        .  -0.1070   0.1253  -0.0535   0.3304   0.3169   0.2408  
    w4casp19 |        .  -0.2925   0.1443  -0.1731   0.1832   0.2683   0.2718  
 
             | sympto~t function    smoke volunt~k   hehelf      dep cognit~y 
-------------+--------------------------------------------------------------- 
symptomcount |   1.0000  
    function |   0.6330   1.0000  
       smoke |   0.0605   0.0548   1.0000  
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volunteerw~k |  -0.1572  -0.1548  -0.1019   1.0000  
      hehelf |  -0.4896  -0.4521  -0.1365   0.1831   1.0000  
         dep |   0.3456   0.3358   0.0705  -0.1114  -0.3694   1.0000  
cognitivea~y |  -0.2164  -0.2124  -0.0399   0.1667   0.2406  -0.1498   1.0000  
         alc |  -0.1749  -0.1609   0.0332   0.0578   0.1800  -0.1334   0.1248  
    groupmem |  -0.1269  -0.1213  -0.1321   0.3689   0.1653  -0.1013   0.1113  
         tot |  -0.4203  -0.4205  -0.1107   0.1556   0.4946  -0.4144   0.1868  
   w4physact |  -0.3741  -0.3713  -0.1037   0.1568   0.3641  -0.2203   0.2583  
   w4symptom |   0.5781   0.4665   0.1035  -0.1259  -0.4425   0.2953  -0.1835  
  w4function |   0.4616   0.6061   0.0457  -0.1312  -0.3676   0.2434  -0.2572  
       w4vol |  -0.1532  -0.1557  -0.1270   0.4751   0.1804  -0.1174   0.2362  
     w4smoke |   0.0820   0.0701   0.6205  -0.0939  -0.1259   0.0904  -0.0144  
  w4srhealth |  -0.4043  -0.3770  -0.1459   0.1316   0.6283  -0.3088   0.2265  
w4cogability |  -0.2020  -0.1807  -0.0621   0.1604   0.2079  -0.1462   0.5832  
       w4alc |  -0.1981  -0.1814   0.0024   0.0811   0.1990  -0.1427   0.1610  
       w4dep |   0.3054   0.3136   0.0792  -0.0928  -0.3247   0.4339  -0.1584  
  w4groupmem |  -0.1603  -0.1481  -0.1700   0.3838   0.2160  -0.1263   0.1986  
    w4casp19 |  -0.3465  -0.3317  -0.1100   0.1247   0.4354  -0.3439   0.1802  
 
             |      alc groupmem      tot w4phys~t w4symp~m w4func~n    w4vol 
-------------+--------------------------------------------------------------- 
         alc |   1.0000  
    groupmem |   0.1321   1.0000  
         tot |   0.1640   0.1924   1.0000  
   w4physact |   0.1807   0.1749   0.2924   1.0000  
   w4symptom |  -0.1758  -0.1076  -0.3523  -0.4082   1.0000  
  w4function |  -0.1572  -0.0850  -0.3393  -0.4680   0.4652   1.0000  
       w4vol |   0.0961   0.3600   0.1745   0.2554  -0.1635  -0.1903   1.0000  
     w4smoke |  -0.0651  -0.1439  -0.1311  -0.1032   0.0859   0.0307  -0.1131  
  w4srhealth |   0.1763   0.1400   0.4413   0.4106  -0.5202  -0.4396   0.2104  
w4cogability |   0.1205   0.1198   0.1618   0.2829  -0.2429  -0.2520   0.2455  
       w4alc |   0.6525   0.1198   0.1660   0.2581  -0.1895  -0.2446   0.1459  
       w4dep |  -0.1353  -0.0975  -0.3725  -0.2827   0.3858   0.3388  -0.1389  
  w4groupmem |   0.1384   0.5966   0.2120   0.2814  -0.1526  -0.1867   0.4572  
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    w4casp19 |   0.1590   0.1558   0.7096   0.3211  -0.4019  -0.3917   0.1796  
 
             |  w4smoke w4srhe~h w4coga~y    w4alc    w4dep w4grou~m w4casp19 
-------------+--------------------------------------------------------------- 
     w4smoke |   1.0000  
  w4srhealth |  -0.1211   1.0000  
w4cogability |  -0.0345   0.2585   1.0000  
       w4alc |  -0.0792   0.2169   0.1786   1.0000  
       w4dep |   0.0800  -0.4030  -0.1927  -0.1755   1.0000  
  w4groupmem |  -0.1745   0.2151   0.2155   0.2824  -0.1467   1.0000  
    w4casp19 |  -0.1122   0.5114   0.2105   0.1696  -0.4561   0.2110   1.0000  
 
             | m_educ~n    Pain2     cen2     age2     sex2   wealth    phact 
-------------+--------------------------------------------------------------- 
 m_education |   1.0000  
       Pain2 |  -0.0072   1.0000  
        cen2 |  -0.0015  -0.0615   1.0000  
        age2 |  -0.3721   0.0692  -0.3038   1.0000  
        sex2 |   0.0488   0.0794   0.0656   0.0013   1.0000  
      wealth |  -0.0001  -0.1706   0.1653  -0.1523  -0.0508   1.0000  
       phact |   0.0078  -0.2480   0.2767  -0.2889  -0.0687   0.2821   1.0000  
symptomcount |  -0.0050   0.3735  -0.2519   0.2414   0.0453  -0.2402  -0.4302  
    function |   0.0028   0.3496  -0.2439   0.2113   0.0546  -0.2166  -0.4586  
       smoke |  -0.0156   0.0516  -0.0686  -0.0585  -0.1252  -0.1678  -0.0898  
volunteerw~k |   0.0124  -0.0818   0.1177  -0.0762   0.0374   0.2199   0.1790  
      hehelf |   0.0056  -0.4115   0.2348  -0.1705   0.0083   0.2923   0.4010  
         dep |  -0.0052   0.2854  -0.1243   0.1089   0.1295  -0.2160  -0.2502  
cognitivea~y |  -0.0084  -0.0932   0.2814  -0.4438   0.0898   0.2667   0.2555  
         alc |   0.0111  -0.1295   0.0818  -0.1267  -0.2121   0.2320   0.1693  
    groupmem |  -0.0160  -0.0801   0.0577   0.0230   0.0049   0.2516   0.2066  
         tot |   0.0007  -0.3145   0.1849  -0.1193   0.0296   0.2999   0.3254  
   w4physact |  -0.0019  -0.2261   0.2696  -0.3264  -0.0864   0.2815   0.4955  
   w4symptom |  -0.0094   0.3604  -0.1675   0.2411   0.0576  -0.2553  -0.3448  
  w4function |   0.0125   0.2406  -0.3181   0.2918   0.0516  -0.1956  -0.3641  
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       w4vol |   0.0106  -0.0874   0.1317  -0.1403   0.0161   0.2604   0.1968  
     w4smoke |   0.0136   0.0586  -0.0240  -0.1209  -0.0003  -0.1907  -0.0850  
  w4srhealth |  -0.0061  -0.3547   0.1637  -0.1844  -0.0163   0.2792   0.3293  
w4cogability |  -0.0152  -0.1047   0.2381  -0.4596   0.0826   0.2499   0.2177  
       w4alc |  -0.0023  -0.1273   0.1360  -0.1656  -0.1897   0.2593   0.1916  
       w4dep |  -0.0051   0.2778  -0.1126   0.1379   0.1317  -0.2248  -0.2306  
  w4groupmem |   0.0045  -0.1070   0.1253  -0.0535   0.0151   0.3169   0.2408  
    w4casp19 |  -0.0130  -0.2925   0.1443  -0.1731   0.0056   0.2683   0.2718  
 
             | sympto~t function    smoke volunt~k   hehelf      dep cognit~y 
-------------+--------------------------------------------------------------- 
symptomcount |   1.0000  
    function |   0.6330   1.0000  
       smoke |   0.0605   0.0548   1.0000  
volunteerw~k |  -0.1572  -0.1548  -0.1019   1.0000  
      hehelf |  -0.4896  -0.4521  -0.1365   0.1831   1.0000  
         dep |   0.3456   0.3358   0.0705  -0.1114  -0.3694   1.0000  
cognitivea~y |  -0.2164  -0.2124  -0.0399   0.1667   0.2406  -0.1498   1.0000  
         alc |  -0.1749  -0.1609   0.0332   0.0578   0.1800  -0.1334   0.1248  
    groupmem |  -0.1269  -0.1213  -0.1321   0.3689   0.1653  -0.1013   0.1113  
         tot |  -0.4203  -0.4205  -0.1107   0.1556   0.4946  -0.4144   0.1868  
   w4physact |  -0.3741  -0.3713  -0.1037   0.1568   0.3641  -0.2203   0.2583  
   w4symptom |   0.5781   0.4665   0.1035  -0.1259  -0.4425   0.2953  -0.1835  
  w4function |   0.4616   0.6061   0.0457  -0.1312  -0.3676   0.2434  -0.2572  
       w4vol |  -0.1532  -0.1557  -0.1270   0.4751   0.1804  -0.1174   0.2362  
     w4smoke |   0.0820   0.0701   0.6205  -0.0939  -0.1259   0.0904  -0.0144  
  w4srhealth |  -0.4043  -0.3770  -0.1459   0.1316   0.6283  -0.3088   0.2265  
w4cogability |  -0.2020  -0.1807  -0.0621   0.1604   0.2079  -0.1462   0.5832  
       w4alc |  -0.1981  -0.1814   0.0024   0.0811   0.1990  -0.1427   0.1610  
       w4dep |   0.3054   0.3136   0.0792  -0.0928  -0.3247   0.4339  -0.1584  
  w4groupmem |  -0.1603  -0.1481  -0.1700   0.3838   0.2160  -0.1263   0.1986  
    w4casp19 |  -0.3465  -0.3317  -0.1100   0.1247   0.4354  -0.3439   0.1802  
 
             |      alc groupmem      tot w4phys~t w4symp~m w4func~n    w4vol 
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-------------+--------------------------------------------------------------- 
         alc |   1.0000  
    groupmem |   0.1321   1.0000  
         tot |   0.1640   0.1924   1.0000  
   w4physact |   0.1807   0.1749   0.2924   1.0000  
   w4symptom |  -0.1758  -0.1076  -0.3523  -0.4082   1.0000  
  w4function |  -0.1572  -0.0850  -0.3393  -0.4680   0.4652   1.0000  
       w4vol |   0.0961   0.3600   0.1745   0.2554  -0.1635  -0.1903   1.0000  
     w4smoke |  -0.0651  -0.1439  -0.1311  -0.1032   0.0859   0.0307  -0.1131  
  w4srhealth |   0.1763   0.1400   0.4413   0.4106  -0.5202  -0.4396   0.2104  
w4cogability |   0.1205   0.1198   0.1618   0.2829  -0.2429  -0.2520   0.2455  
       w4alc |   0.6525   0.1198   0.1660   0.2581  -0.1895  -0.2446   0.1459  
       w4dep |  -0.1353  -0.0975  -0.3725  -0.2827   0.3858   0.3388  -0.1389  
  w4groupmem |   0.1384   0.5966   0.2120   0.2814  -0.1526  -0.1867   0.4572  
    w4casp19 |   0.1590   0.1558   0.7096   0.3211  -0.4019  -0.3917   0.1796  
 
             |  w4smoke w4srhe~h w4coga~y    w4alc    w4dep w4grou~m w4casp19 
-------------+--------------------------------------------------------------- 
     w4smoke |   1.0000  
  w4srhealth |  -0.1211   1.0000  
w4cogability |  -0.0345   0.2585   1.0000  
       w4alc |  -0.0792   0.2169   0.1786   1.0000  
       w4dep |   0.0800  -0.4030  -0.1927  -0.1755   1.0000  
  w4groupmem |  -0.1745   0.2151   0.2155   0.2824  -0.1467   1.0000  
    w4casp19 |  -0.1122   0.5114   0.2105   0.1696  -0.4561   0.2110   1.0000  
 
             | m_wealth    Pain2     cen2     age2     sex2 educat~n    phact 
-------------+--------------------------------------------------------------- 
    m_wealth |   1.0000  
       Pain2 |  -0.0114   1.0000  
        cen2 |   0.0165  -0.0615   1.0000  
        age2 |  -0.3578   0.0692  -0.3038   1.0000  
        sex2 |   0.0516   0.0794   0.0656   0.0013   1.0000  
   education |   0.0336  -0.1299   0.1479  -0.2689  -0.1542   1.0000  
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       phact |   0.0244  -0.2480   0.2767  -0.2889  -0.0687   0.2443   1.0000  
symptomcount |  -0.0248   0.3735  -0.2519   0.2414   0.0453  -0.1771  -0.4302  
    function |  -0.0274   0.3496  -0.2439   0.2113   0.0546  -0.1470  -0.4586  
       smoke |  -0.0018   0.0516  -0.0686  -0.0585  -0.1252  -0.0932  -0.0898  
volunteerw~k |  -0.0042  -0.0818   0.1177  -0.0762   0.0374   0.2576   0.1790  
      hehelf |   0.0140  -0.4115   0.2348  -0.1705   0.0083   0.2288   0.4010  
         dep |  -0.0229   0.2854  -0.1243   0.1089   0.1295  -0.1816  -0.2502  
cognitivea~y |   0.0411  -0.0932   0.2814  -0.4438   0.0898   0.3377   0.2555  
         alc |   0.0167  -0.1295   0.0818  -0.1267  -0.2121   0.2098   0.1693  
    groupmem |   0.0194  -0.0801   0.0577   0.0230   0.0049   0.2824   0.2066  
         tot |   0.0121  -0.3145   0.1849  -0.1193   0.0296   0.1667   0.3254  
   w4physact |   0.0171  -0.2261   0.2696  -0.3264  -0.0864   0.2446   0.4955  
   w4symptom |  -0.0179   0.3604  -0.1675   0.2411   0.0576  -0.1934  -0.3448  
  w4function |  -0.0294   0.2406  -0.3181   0.2918   0.0516  -0.1542  -0.3641  
       w4vol |   0.0187  -0.0874   0.1317  -0.1403   0.0161   0.3207   0.1968  
     w4smoke |  -0.0067   0.0586  -0.0240  -0.1209  -0.0003  -0.0991  -0.0850  
  w4srhealth |   0.0187  -0.3547   0.1637  -0.1844  -0.0163   0.2372   0.3293  
w4cogability |   0.0364  -0.1047   0.2381  -0.4596   0.0826   0.3437   0.2177  
       w4alc |   0.0031  -0.1273   0.1360  -0.1656  -0.1897   0.2321   0.1916  
       w4dep |  -0.0339   0.2778  -0.1126   0.1379   0.1317  -0.1856  -0.2306  
  w4groupmem |   0.0060  -0.1070   0.1253  -0.0535   0.0151   0.3304   0.2408  
    w4casp19 |   0.0185  -0.2925   0.1443  -0.1731   0.0056   0.1832   0.2718  
 
             | sympto~t function    smoke volunt~k   hehelf      dep cognit~y 
-------------+--------------------------------------------------------------- 
symptomcount |   1.0000  
    function |   0.6330   1.0000  
       smoke |   0.0605   0.0548   1.0000  
volunteerw~k |  -0.1572  -0.1548  -0.1019   1.0000  
      hehelf |  -0.4896  -0.4521  -0.1365   0.1831   1.0000  
         dep |   0.3456   0.3358   0.0705  -0.1114  -0.3694   1.0000  
cognitivea~y |  -0.2164  -0.2124  -0.0399   0.1667   0.2406  -0.1498   1.0000  
         alc |  -0.1749  -0.1609   0.0332   0.0578   0.1800  -0.1334   0.1248  
    groupmem |  -0.1269  -0.1213  -0.1321   0.3689   0.1653  -0.1013   0.1113  
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         tot |  -0.4203  -0.4205  -0.1107   0.1556   0.4946  -0.4144   0.1868  
   w4physact |  -0.3741  -0.3713  -0.1037   0.1568   0.3641  -0.2203   0.2583  
   w4symptom |   0.5781   0.4665   0.1035  -0.1259  -0.4425   0.2953  -0.1835  
  w4function |   0.4616   0.6061   0.0457  -0.1312  -0.3676   0.2434  -0.2572  
       w4vol |  -0.1532  -0.1557  -0.1270   0.4751   0.1804  -0.1174   0.2362  
     w4smoke |   0.0820   0.0701   0.6205  -0.0939  -0.1259   0.0904  -0.0144  
  w4srhealth |  -0.4043  -0.3770  -0.1459   0.1316   0.6283  -0.3088   0.2265  
w4cogability |  -0.2020  -0.1807  -0.0621   0.1604   0.2079  -0.1462   0.5832  
       w4alc |  -0.1981  -0.1814   0.0024   0.0811   0.1990  -0.1427   0.1610  
       w4dep |   0.3054   0.3136   0.0792  -0.0928  -0.3247   0.4339  -0.1584  
  w4groupmem |  -0.1603  -0.1481  -0.1700   0.3838   0.2160  -0.1263   0.1986  
    w4casp19 |  -0.3465  -0.3317  -0.1100   0.1247   0.4354  -0.3439   0.1802  
 
             |      alc groupmem      tot w4phys~t w4symp~m w4func~n    w4vol 
-------------+--------------------------------------------------------------- 
         alc |   1.0000  
    groupmem |   0.1321   1.0000  
         tot |   0.1640   0.1924   1.0000  
   w4physact |   0.1807   0.1749   0.2924   1.0000  
   w4symptom |  -0.1758  -0.1076  -0.3523  -0.4082   1.0000  
  w4function |  -0.1572  -0.0850  -0.3393  -0.4680   0.4652   1.0000  
       w4vol |   0.0961   0.3600   0.1745   0.2554  -0.1635  -0.1903   1.0000  
     w4smoke |  -0.0651  -0.1439  -0.1311  -0.1032   0.0859   0.0307  -0.1131  
  w4srhealth |   0.1763   0.1400   0.4413   0.4106  -0.5202  -0.4396   0.2104  
w4cogability |   0.1205   0.1198   0.1618   0.2829  -0.2429  -0.2520   0.2455  
       w4alc |   0.6525   0.1198   0.1660   0.2581  -0.1895  -0.2446   0.1459  
       w4dep |  -0.1353  -0.0975  -0.3725  -0.2827   0.3858   0.3388  -0.1389  
  w4groupmem |   0.1384   0.5966   0.2120   0.2814  -0.1526  -0.1867   0.4572  
    w4casp19 |   0.1590   0.1558   0.7096   0.3211  -0.4019  -0.3917   0.1796  
 
             |  w4smoke w4srhe~h w4coga~y    w4alc    w4dep w4grou~m w4casp19 
-------------+--------------------------------------------------------------- 
     w4smoke |   1.0000  
  w4srhealth |  -0.1211   1.0000  
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w4cogability |  -0.0345   0.2585   1.0000  
       w4alc |  -0.0792   0.2169   0.1786   1.0000  
       w4dep |   0.0800  -0.4030  -0.1927  -0.1755   1.0000  
  w4groupmem |  -0.1745   0.2151   0.2155   0.2824  -0.1467   1.0000  
    w4casp19 |  -0.1122   0.5114   0.2105   0.1696  -0.4561   0.2110   1.0000  
 
             |  m_phact    Pain2     cen2     age2     sex2 educat~n   wealth 
-------------+--------------------------------------------------------------- 
     m_phact |   1.0000  
       Pain2 |  -0.0091   1.0000  
        cen2 |  -0.0044  -0.0615   1.0000  
        age2 |  -0.3759   0.0692  -0.3038   1.0000  
        sex2 |   0.0532   0.0794   0.0656   0.0013   1.0000  
   education |        .  -0.1299   0.1479  -0.2689  -0.1542   1.0000  
      wealth |        .  -0.1706   0.1653  -0.1523  -0.0508   0.4057   1.0000  
symptomcount |        .   0.3735  -0.2519   0.2414   0.0453  -0.1771  -0.2402  
    function |        .   0.3496  -0.2439   0.2113   0.0546  -0.1470  -0.2166  
       smoke |        .   0.0516  -0.0686  -0.0585  -0.1252  -0.0932  -0.1678  
volunteerw~k |        .  -0.0818   0.1177  -0.0762   0.0374   0.2576   0.2199  
      hehelf |        .  -0.4115   0.2348  -0.1705   0.0083   0.2288   0.2923  
         dep |        .   0.2854  -0.1243   0.1089   0.1295  -0.1816  -0.2160  
cognitivea~y |        .  -0.0932   0.2814  -0.4438   0.0898   0.3377   0.2667  
         alc |        .  -0.1295   0.0818  -0.1267  -0.2121   0.2098   0.2320  
    groupmem |        .  -0.0801   0.0577   0.0230   0.0049   0.2824   0.2516  
         tot |        .  -0.3145   0.1849  -0.1193   0.0296   0.1667   0.2999  
   w4physact |        .  -0.2261   0.2696  -0.3264  -0.0864   0.2446   0.2815  
   w4symptom |        .   0.3604  -0.1675   0.2411   0.0576  -0.1934  -0.2553  
  w4function |        .   0.2406  -0.3181   0.2918   0.0516  -0.1542  -0.1956  
       w4vol |        .  -0.0874   0.1317  -0.1403   0.0161   0.3207   0.2604  
     w4smoke |        .   0.0586  -0.0240  -0.1209  -0.0003  -0.0991  -0.1907  
  w4srhealth |        .  -0.3547   0.1637  -0.1844  -0.0163   0.2372   0.2792  
w4cogability |        .  -0.1047   0.2381  -0.4596   0.0826   0.3437   0.2499  
       w4alc |        .  -0.1273   0.1360  -0.1656  -0.1897   0.2321   0.2593  
       w4dep |        .   0.2778  -0.1126   0.1379   0.1317  -0.1856  -0.2248  
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  w4groupmem |        .  -0.1070   0.1253  -0.0535   0.0151   0.3304   0.3169  
    w4casp19 |        .  -0.2925   0.1443  -0.1731   0.0056   0.1832   0.2683  
 
             | sympto~t function    smoke volunt~k   hehelf      dep cognit~y 
-------------+--------------------------------------------------------------- 
symptomcount |   1.0000  
    function |   0.6330   1.0000  
       smoke |   0.0605   0.0548   1.0000  
volunteerw~k |  -0.1572  -0.1548  -0.1019   1.0000  
      hehelf |  -0.4896  -0.4521  -0.1365   0.1831   1.0000  
         dep |   0.3456   0.3358   0.0705  -0.1114  -0.3694   1.0000  
cognitivea~y |  -0.2164  -0.2124  -0.0399   0.1667   0.2406  -0.1498   1.0000  
         alc |  -0.1749  -0.1609   0.0332   0.0578   0.1800  -0.1334   0.1248  
    groupmem |  -0.1269  -0.1213  -0.1321   0.3689   0.1653  -0.1013   0.1113  
         tot |  -0.4203  -0.4205  -0.1107   0.1556   0.4946  -0.4144   0.1868  
   w4physact |  -0.3741  -0.3713  -0.1037   0.1568   0.3641  -0.2203   0.2583  
   w4symptom |   0.5781   0.4665   0.1035  -0.1259  -0.4425   0.2953  -0.1835  
  w4function |   0.4616   0.6061   0.0457  -0.1312  -0.3676   0.2434  -0.2572  
       w4vol |  -0.1532  -0.1557  -0.1270   0.4751   0.1804  -0.1174   0.2362  
     w4smoke |   0.0820   0.0701   0.6205  -0.0939  -0.1259   0.0904  -0.0144  
  w4srhealth |  -0.4043  -0.3770  -0.1459   0.1316   0.6283  -0.3088   0.2265  
w4cogability |  -0.2020  -0.1807  -0.0621   0.1604   0.2079  -0.1462   0.5832  
       w4alc |  -0.1981  -0.1814   0.0024   0.0811   0.1990  -0.1427   0.1610  
       w4dep |   0.3054   0.3136   0.0792  -0.0928  -0.3247   0.4339  -0.1584  
  w4groupmem |  -0.1603  -0.1481  -0.1700   0.3838   0.2160  -0.1263   0.1986  
    w4casp19 |  -0.3465  -0.3317  -0.1100   0.1247   0.4354  -0.3439   0.1802  
 
             |      alc groupmem      tot w4phys~t w4symp~m w4func~n    w4vol 
-------------+--------------------------------------------------------------- 
         alc |   1.0000  
    groupmem |   0.1321   1.0000  
         tot |   0.1640   0.1924   1.0000  
   w4physact |   0.1807   0.1749   0.2924   1.0000  
   w4symptom |  -0.1758  -0.1076  -0.3523  -0.4082   1.0000  
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  w4function |  -0.1572  -0.0850  -0.3393  -0.4680   0.4652   1.0000  
       w4vol |   0.0961   0.3600   0.1745   0.2554  -0.1635  -0.1903   1.0000  
     w4smoke |  -0.0651  -0.1439  -0.1311  -0.1032   0.0859   0.0307  -0.1131  
  w4srhealth |   0.1763   0.1400   0.4413   0.4106  -0.5202  -0.4396   0.2104  
w4cogability |   0.1205   0.1198   0.1618   0.2829  -0.2429  -0.2520   0.2455  
       w4alc |   0.6525   0.1198   0.1660   0.2581  -0.1895  -0.2446   0.1459  
       w4dep |  -0.1353  -0.0975  -0.3725  -0.2827   0.3858   0.3388  -0.1389  
  w4groupmem |   0.1384   0.5966   0.2120   0.2814  -0.1526  -0.1867   0.4572  
    w4casp19 |   0.1590   0.1558   0.7096   0.3211  -0.4019  -0.3917   0.1796  
 
             |  w4smoke w4srhe~h w4coga~y    w4alc    w4dep w4grou~m w4casp19 
-------------+--------------------------------------------------------------- 
     w4smoke |   1.0000  
  w4srhealth |  -0.1211   1.0000  
w4cogability |  -0.0345   0.2585   1.0000  
       w4alc |  -0.0792   0.2169   0.1786   1.0000  
       w4dep |   0.0800  -0.4030  -0.1927  -0.1755   1.0000  
  w4groupmem |  -0.1745   0.2151   0.2155   0.2824  -0.1467   1.0000  
    w4casp19 |  -0.1122   0.5114   0.2105   0.1696  -0.4561   0.2110   1.0000  
 
             | m_symp~t    Pain2     cen2     age2     sex2 educat~n   wealth 
-------------+--------------------------------------------------------------- 
m_symptomc~t |   1.0000  
       Pain2 |  -0.0091   1.0000  
        cen2 |  -0.0044  -0.0615   1.0000  
        age2 |  -0.3759   0.0692  -0.3038   1.0000  
        sex2 |   0.0532   0.0794   0.0656   0.0013   1.0000  
   education |        .  -0.1299   0.1479  -0.2689  -0.1542   1.0000  
      wealth |        .  -0.1706   0.1653  -0.1523  -0.0508   0.4057   1.0000  
       phact |        .  -0.2480   0.2767  -0.2889  -0.0687   0.2443   0.2821  
    function |        .   0.3496  -0.2439   0.2113   0.0546  -0.1470  -0.2166  
       smoke |        .   0.0516  -0.0686  -0.0585  -0.1252  -0.0932  -0.1678  
volunteerw~k |        .  -0.0818   0.1177  -0.0762   0.0374   0.2576   0.2199  
      hehelf |        .  -0.4115   0.2348  -0.1705   0.0083   0.2288   0.2923  
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         dep |        .   0.2854  -0.1243   0.1089   0.1295  -0.1816  -0.2160  
cognitivea~y |        .  -0.0932   0.2814  -0.4438   0.0898   0.3377   0.2667  
         alc |        .  -0.1295   0.0818  -0.1267  -0.2121   0.2098   0.2320  
    groupmem |        .  -0.0801   0.0577   0.0230   0.0049   0.2824   0.2516  
         tot |        .  -0.3145   0.1849  -0.1193   0.0296   0.1667   0.2999  
   w4physact |        .  -0.2261   0.2696  -0.3264  -0.0864   0.2446   0.2815  
   w4symptom |        .   0.3604  -0.1675   0.2411   0.0576  -0.1934  -0.2553  
  w4function |        .   0.2406  -0.3181   0.2918   0.0516  -0.1542  -0.1956  
       w4vol |        .  -0.0874   0.1317  -0.1403   0.0161   0.3207   0.2604  
     w4smoke |        .   0.0586  -0.0240  -0.1209  -0.0003  -0.0991  -0.1907  
  w4srhealth |        .  -0.3547   0.1637  -0.1844  -0.0163   0.2372   0.2792  
w4cogability |        .  -0.1047   0.2381  -0.4596   0.0826   0.3437   0.2499  
       w4alc |        .  -0.1273   0.1360  -0.1656  -0.1897   0.2321   0.2593  
       w4dep |        .   0.2778  -0.1126   0.1379   0.1317  -0.1856  -0.2248  
  w4groupmem |        .  -0.1070   0.1253  -0.0535   0.0151   0.3304   0.3169  
    w4casp19 |        .  -0.2925   0.1443  -0.1731   0.0056   0.1832   0.2683  
 
             |    phact function    smoke volunt~k   hehelf      dep cognit~y 
-------------+--------------------------------------------------------------- 
       phact |   1.0000  
    function |  -0.4586   1.0000  
       smoke |  -0.0898   0.0548   1.0000  
volunteerw~k |   0.1790  -0.1548  -0.1019   1.0000  
      hehelf |   0.4010  -0.4521  -0.1365   0.1831   1.0000  
         dep |  -0.2502   0.3358   0.0705  -0.1114  -0.3694   1.0000  
cognitivea~y |   0.2555  -0.2124  -0.0399   0.1667   0.2406  -0.1498   1.0000  
         alc |   0.1693  -0.1609   0.0332   0.0578   0.1800  -0.1334   0.1248  
    groupmem |   0.2066  -0.1213  -0.1321   0.3689   0.1653  -0.1013   0.1113  
         tot |   0.3254  -0.4205  -0.1107   0.1556   0.4946  -0.4144   0.1868  
   w4physact |   0.4955  -0.3713  -0.1037   0.1568   0.3641  -0.2203   0.2583  
   w4symptom |  -0.3448   0.4665   0.1035  -0.1259  -0.4425   0.2953  -0.1835  
  w4function |  -0.3641   0.6061   0.0457  -0.1312  -0.3676   0.2434  -0.2572  
       w4vol |   0.1968  -0.1557  -0.1270   0.4751   0.1804  -0.1174   0.2362  
     w4smoke |  -0.0850   0.0701   0.6205  -0.0939  -0.1259   0.0904  -0.0144  
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  w4srhealth |   0.3293  -0.3770  -0.1459   0.1316   0.6283  -0.3088   0.2265  
w4cogability |   0.2177  -0.1807  -0.0621   0.1604   0.2079  -0.1462   0.5832  
       w4alc |   0.1916  -0.1814   0.0024   0.0811   0.1990  -0.1427   0.1610  
       w4dep |  -0.2306   0.3136   0.0792  -0.0928  -0.3247   0.4339  -0.1584  
  w4groupmem |   0.2408  -0.1481  -0.1700   0.3838   0.2160  -0.1263   0.1986  
    w4casp19 |   0.2718  -0.3317  -0.1100   0.1247   0.4354  -0.3439   0.1802  
 
             |      alc groupmem      tot w4phys~t w4symp~m w4func~n    w4vol 
-------------+--------------------------------------------------------------- 
         alc |   1.0000  
    groupmem |   0.1321   1.0000  
         tot |   0.1640   0.1924   1.0000  
   w4physact |   0.1807   0.1749   0.2924   1.0000  
   w4symptom |  -0.1758  -0.1076  -0.3523  -0.4082   1.0000  
  w4function |  -0.1572  -0.0850  -0.3393  -0.4680   0.4652   1.0000  
       w4vol |   0.0961   0.3600   0.1745   0.2554  -0.1635  -0.1903   1.0000  
     w4smoke |  -0.0651  -0.1439  -0.1311  -0.1032   0.0859   0.0307  -0.1131  
  w4srhealth |   0.1763   0.1400   0.4413   0.4106  -0.5202  -0.4396   0.2104  
w4cogability |   0.1205   0.1198   0.1618   0.2829  -0.2429  -0.2520   0.2455  
       w4alc |   0.6525   0.1198   0.1660   0.2581  -0.1895  -0.2446   0.1459  
       w4dep |  -0.1353  -0.0975  -0.3725  -0.2827   0.3858   0.3388  -0.1389  
  w4groupmem |   0.1384   0.5966   0.2120   0.2814  -0.1526  -0.1867   0.4572  
    w4casp19 |   0.1590   0.1558   0.7096   0.3211  -0.4019  -0.3917   0.1796  
 
             |  w4smoke w4srhe~h w4coga~y    w4alc    w4dep w4grou~m w4casp19 
-------------+--------------------------------------------------------------- 
     w4smoke |   1.0000  
  w4srhealth |  -0.1211   1.0000  
w4cogability |  -0.0345   0.2585   1.0000  
       w4alc |  -0.0792   0.2169   0.1786   1.0000  
       w4dep |   0.0800  -0.4030  -0.1927  -0.1755   1.0000  
  w4groupmem |  -0.1745   0.2151   0.2155   0.2824  -0.1467   1.0000  
    w4casp19 |  -0.1122   0.5114   0.2105   0.1696  -0.4561   0.2110   1.0000  
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             | m_func~n    Pain2     cen2     age2     sex2 educat~n   wealth 
-------------+--------------------------------------------------------------- 
  m_function |   1.0000  
       Pain2 |  -0.0095   1.0000  
        cen2 |  -0.0057  -0.0615   1.0000  
        age2 |  -0.3750   0.0692  -0.3038   1.0000  
        sex2 |   0.0535   0.0794   0.0656   0.0013   1.0000  
   education |  -0.0110  -0.1299   0.1479  -0.2689  -0.1542   1.0000  
      wealth |   0.0152  -0.1706   0.1653  -0.1523  -0.0508   0.4057   1.0000  
       phact |  -0.0239  -0.2480   0.2767  -0.2889  -0.0687   0.2443   0.2821  
symptomcount |   0.0159   0.3735  -0.2519   0.2414   0.0453  -0.1771  -0.2402  
       smoke |   0.0033   0.0516  -0.0686  -0.0585  -0.1252  -0.0932  -0.1678  
volunteerw~k |  -0.0065  -0.0818   0.1177  -0.0762   0.0374   0.2576   0.2199  
      hehelf |  -0.0208  -0.4115   0.2348  -0.1705   0.0083   0.2288   0.2923  
         dep |  -0.0011   0.2854  -0.1243   0.1089   0.1295  -0.1816  -0.2160  
cognitivea~y |   0.0002  -0.0932   0.2814  -0.4438   0.0898   0.3377   0.2667  
         alc |  -0.0143  -0.1295   0.0818  -0.1267  -0.2121   0.2098   0.2320  
    groupmem |        .  -0.0801   0.0577   0.0230   0.0049   0.2824   0.2516  
         tot |  -0.0165  -0.3145   0.1849  -0.1193   0.0296   0.1667   0.2999  
   w4physact |  -0.0260  -0.2261   0.2696  -0.3264  -0.0864   0.2446   0.2815  
   w4symptom |   0.0423   0.3604  -0.1675   0.2411   0.0576  -0.1934  -0.2553  
  w4function |   0.0305   0.2406  -0.3181   0.2918   0.0516  -0.1542  -0.1956  
       w4vol |  -0.0101  -0.0874   0.1317  -0.1403   0.0161   0.3207   0.2604  
     w4smoke |  -0.0047   0.0586  -0.0240  -0.1209  -0.0003  -0.0991  -0.1907  
  w4srhealth |  -0.0136  -0.3547   0.1637  -0.1844  -0.0163   0.2372   0.2792  
w4cogability |  -0.0212  -0.1047   0.2381  -0.4596   0.0826   0.3437   0.2499  
       w4alc |  -0.0134  -0.1273   0.1360  -0.1656  -0.1897   0.2321   0.2593  
       w4dep |   0.0192   0.2778  -0.1126   0.1379   0.1317  -0.1856  -0.2248  
  w4groupmem |        .  -0.1070   0.1253  -0.0535   0.0151   0.3304   0.3169  
    w4casp19 |  -0.0115  -0.2925   0.1443  -0.1731   0.0056   0.1832   0.2683  
 
             |    phact sympto~t    smoke volunt~k   hehelf      dep cognit~y 
-------------+--------------------------------------------------------------- 
       phact |   1.0000  
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symptomcount |  -0.4302   1.0000  
       smoke |  -0.0898   0.0605   1.0000  
volunteerw~k |   0.1790  -0.1572  -0.1019   1.0000  
      hehelf |   0.4010  -0.4896  -0.1365   0.1831   1.0000  
         dep |  -0.2502   0.3456   0.0705  -0.1114  -0.3694   1.0000  
cognitivea~y |   0.2555  -0.2164  -0.0399   0.1667   0.2406  -0.1498   1.0000  
         alc |   0.1693  -0.1749   0.0332   0.0578   0.1800  -0.1334   0.1248  
    groupmem |   0.2066  -0.1269  -0.1321   0.3689   0.1653  -0.1013   0.1113  
         tot |   0.3254  -0.4203  -0.1107   0.1556   0.4946  -0.4144   0.1868  
   w4physact |   0.4955  -0.3741  -0.1037   0.1568   0.3641  -0.2203   0.2583  
   w4symptom |  -0.3448   0.5781   0.1035  -0.1259  -0.4425   0.2953  -0.1835  
  w4function |  -0.3641   0.4616   0.0457  -0.1312  -0.3676   0.2434  -0.2572  
       w4vol |   0.1968  -0.1532  -0.1270   0.4751   0.1804  -0.1174   0.2362  
     w4smoke |  -0.0850   0.0820   0.6205  -0.0939  -0.1259   0.0904  -0.0144  
  w4srhealth |   0.3293  -0.4043  -0.1459   0.1316   0.6283  -0.3088   0.2265  
w4cogability |   0.2177  -0.2020  -0.0621   0.1604   0.2079  -0.1462   0.5832  
       w4alc |   0.1916  -0.1981   0.0024   0.0811   0.1990  -0.1427   0.1610  
       w4dep |  -0.2306   0.3054   0.0792  -0.0928  -0.3247   0.4339  -0.1584  
  w4groupmem |   0.2408  -0.1603  -0.1700   0.3838   0.2160  -0.1263   0.1986  
    w4casp19 |   0.2718  -0.3465  -0.1100   0.1247   0.4354  -0.3439   0.1802  
 
             |      alc groupmem      tot w4phys~t w4symp~m w4func~n    w4vol 
-------------+--------------------------------------------------------------- 
         alc |   1.0000  
    groupmem |   0.1321   1.0000  
         tot |   0.1640   0.1924   1.0000  
   w4physact |   0.1807   0.1749   0.2924   1.0000  
   w4symptom |  -0.1758  -0.1076  -0.3523  -0.4082   1.0000  
  w4function |  -0.1572  -0.0850  -0.3393  -0.4680   0.4652   1.0000  
       w4vol |   0.0961   0.3600   0.1745   0.2554  -0.1635  -0.1903   1.0000  
     w4smoke |  -0.0651  -0.1439  -0.1311  -0.1032   0.0859   0.0307  -0.1131  
  w4srhealth |   0.1763   0.1400   0.4413   0.4106  -0.5202  -0.4396   0.2104  
w4cogability |   0.1205   0.1198   0.1618   0.2829  -0.2429  -0.2520   0.2455  
       w4alc |   0.6525   0.1198   0.1660   0.2581  -0.1895  -0.2446   0.1459  
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       w4dep |  -0.1353  -0.0975  -0.3725  -0.2827   0.3858   0.3388  -0.1389  
  w4groupmem |   0.1384   0.5966   0.2120   0.2814  -0.1526  -0.1867   0.4572  
    w4casp19 |   0.1590   0.1558   0.7096   0.3211  -0.4019  -0.3917   0.1796  
 
             |  w4smoke w4srhe~h w4coga~y    w4alc    w4dep w4grou~m w4casp19 
-------------+--------------------------------------------------------------- 
     w4smoke |   1.0000  
  w4srhealth |  -0.1211   1.0000  
w4cogability |  -0.0345   0.2585   1.0000  
       w4alc |  -0.0792   0.2169   0.1786   1.0000  
       w4dep |   0.0800  -0.4030  -0.1927  -0.1755   1.0000  
  w4groupmem |  -0.1745   0.2151   0.2155   0.2824  -0.1467   1.0000  
    w4casp19 |  -0.1122   0.5114   0.2105   0.1696  -0.4561   0.2110   1.0000  
 
             |  m_smoke    Pain2     cen2     age2     sex2 educat~n   wealth 
-------------+--------------------------------------------------------------- 
     m_smoke |   1.0000  
       Pain2 |  -0.0092   1.0000  
        cen2 |  -0.0036  -0.0615   1.0000  
        age2 |  -0.3754   0.0692  -0.3038   1.0000  
        sex2 |   0.0533   0.0794   0.0656   0.0013   1.0000  
   education |   0.0058  -0.1299   0.1479  -0.2689  -0.1542   1.0000  
      wealth |   0.0162  -0.1706   0.1653  -0.1523  -0.0508   0.4057   1.0000  
       phact |   0.0010  -0.2480   0.2767  -0.2889  -0.0687   0.2443   0.2821  
symptomcount |  -0.0089   0.3735  -0.2519   0.2414   0.0453  -0.1771  -0.2402  
    function |  -0.0085   0.3496  -0.2439   0.2113   0.0546  -0.1470  -0.2166  
volunteerw~k |   0.0026  -0.0818   0.1177  -0.0762   0.0374   0.2576   0.2199  
      hehelf |   0.0137  -0.4115   0.2348  -0.1705   0.0083   0.2288   0.2923  
         dep |  -0.0019   0.2854  -0.1243   0.1089   0.1295  -0.1816  -0.2160  
cognitivea~y |  -0.0014  -0.0932   0.2814  -0.4438   0.0898   0.3377   0.2667  
         alc |   0.0129  -0.1295   0.0818  -0.1267  -0.2121   0.2098   0.2320  
    groupmem |   0.0048  -0.0801   0.0577   0.0230   0.0049   0.2824   0.2516  
         tot |  -0.0085  -0.3145   0.1849  -0.1193   0.0296   0.1667   0.2999  
   w4physact |   0.0104  -0.2261   0.2696  -0.3264  -0.0864   0.2446   0.2815  
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   w4symptom |  -0.0114   0.3604  -0.1675   0.2411   0.0576  -0.1934  -0.2553  
  w4function |  -0.0099   0.2406  -0.3181   0.2918   0.0516  -0.1542  -0.1956  
       w4vol |  -0.0026  -0.0874   0.1317  -0.1403   0.0161   0.3207   0.2604  
     w4smoke |  -0.0081   0.0586  -0.0240  -0.1209  -0.0003  -0.0991  -0.1907  
  w4srhealth |   0.0038  -0.3547   0.1637  -0.1844  -0.0163   0.2372   0.2792  
w4cogability |   0.0194  -0.1047   0.2381  -0.4596   0.0826   0.3437   0.2499  
       w4alc |   0.0211  -0.1273   0.1360  -0.1656  -0.1897   0.2321   0.2593  
       w4dep |  -0.0108   0.2778  -0.1126   0.1379   0.1317  -0.1856  -0.2248  
  w4groupmem |   0.0113  -0.1070   0.1253  -0.0535   0.0151   0.3304   0.3169  
    w4casp19 |   0.0053  -0.2925   0.1443  -0.1731   0.0056   0.1832   0.2683  
 
             |    phact sympto~t function volunt~k   hehelf      dep cognit~y 
-------------+--------------------------------------------------------------- 
       phact |   1.0000  
symptomcount |  -0.4302   1.0000  
    function |  -0.4586   0.6330   1.0000  
volunteerw~k |   0.1790  -0.1572  -0.1548   1.0000  
      hehelf |   0.4010  -0.4896  -0.4521   0.1831   1.0000  
         dep |  -0.2502   0.3456   0.3358  -0.1114  -0.3694   1.0000  
cognitivea~y |   0.2555  -0.2164  -0.2124   0.1667   0.2406  -0.1498   1.0000  
         alc |   0.1693  -0.1749  -0.1609   0.0578   0.1800  -0.1334   0.1248  
    groupmem |   0.2066  -0.1269  -0.1213   0.3689   0.1653  -0.1013   0.1113  
         tot |   0.3254  -0.4203  -0.4205   0.1556   0.4946  -0.4144   0.1868  
   w4physact |   0.4955  -0.3741  -0.3713   0.1568   0.3641  -0.2203   0.2583  
   w4symptom |  -0.3448   0.5781   0.4665  -0.1259  -0.4425   0.2953  -0.1835  
  w4function |  -0.3641   0.4616   0.6061  -0.1312  -0.3676   0.2434  -0.2572  
       w4vol |   0.1968  -0.1532  -0.1557   0.4751   0.1804  -0.1174   0.2362  
     w4smoke |  -0.0850   0.0820   0.0701  -0.0939  -0.1259   0.0904  -0.0144  
  w4srhealth |   0.3293  -0.4043  -0.3770   0.1316   0.6283  -0.3088   0.2265  
w4cogability |   0.2177  -0.2020  -0.1807   0.1604   0.2079  -0.1462   0.5832  
       w4alc |   0.1916  -0.1981  -0.1814   0.0811   0.1990  -0.1427   0.1610  
       w4dep |  -0.2306   0.3054   0.3136  -0.0928  -0.3247   0.4339  -0.1584  
  w4groupmem |   0.2408  -0.1603  -0.1481   0.3838   0.2160  -0.1263   0.1986  
    w4casp19 |   0.2718  -0.3465  -0.3317   0.1247   0.4354  -0.3439   0.1802  
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             |      alc groupmem      tot w4phys~t w4symp~m w4func~n    w4vol 
-------------+--------------------------------------------------------------- 
         alc |   1.0000  
    groupmem |   0.1321   1.0000  
         tot |   0.1640   0.1924   1.0000  
   w4physact |   0.1807   0.1749   0.2924   1.0000  
   w4symptom |  -0.1758  -0.1076  -0.3523  -0.4082   1.0000  
  w4function |  -0.1572  -0.0850  -0.3393  -0.4680   0.4652   1.0000  
       w4vol |   0.0961   0.3600   0.1745   0.2554  -0.1635  -0.1903   1.0000  
     w4smoke |  -0.0651  -0.1439  -0.1311  -0.1032   0.0859   0.0307  -0.1131  
  w4srhealth |   0.1763   0.1400   0.4413   0.4106  -0.5202  -0.4396   0.2104  
w4cogability |   0.1205   0.1198   0.1618   0.2829  -0.2429  -0.2520   0.2455  
       w4alc |   0.6525   0.1198   0.1660   0.2581  -0.1895  -0.2446   0.1459  
       w4dep |  -0.1353  -0.0975  -0.3725  -0.2827   0.3858   0.3388  -0.1389  
  w4groupmem |   0.1384   0.5966   0.2120   0.2814  -0.1526  -0.1867   0.4572  
    w4casp19 |   0.1590   0.1558   0.7096   0.3211  -0.4019  -0.3917   0.1796  
 
             |  w4smoke w4srhe~h w4coga~y    w4alc    w4dep w4grou~m w4casp19 
-------------+--------------------------------------------------------------- 
     w4smoke |   1.0000  
  w4srhealth |  -0.1211   1.0000  
w4cogability |  -0.0345   0.2585   1.0000  
       w4alc |  -0.0792   0.2169   0.1786   1.0000  
       w4dep |   0.0800  -0.4030  -0.1927  -0.1755   1.0000  
  w4groupmem |  -0.1745   0.2151   0.2155   0.2824  -0.1467   1.0000  
    w4casp19 |  -0.1122   0.5114   0.2105   0.1696  -0.4561   0.2110   1.0000  
 
             | m_volu~k    Pain2     cen2     age2     sex2 educat~n   wealth 
-------------+--------------------------------------------------------------- 
m_voluntee~k |   1.0000  
       Pain2 |  -0.0089   1.0000  
        cen2 |  -0.0039  -0.0615   1.0000  
        age2 |  -0.3755   0.0692  -0.3038   1.0000  
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        sex2 |   0.0530   0.0794   0.0656   0.0013   1.0000  
   education |   0.0014  -0.1299   0.1479  -0.2689  -0.1542   1.0000  
      wealth |   0.0108  -0.1706   0.1653  -0.1523  -0.0508   0.4057   1.0000  
       phact |   0.0008  -0.2480   0.2767  -0.2889  -0.0687   0.2443   0.2821  
symptomcount |  -0.0072   0.3735  -0.2519   0.2414   0.0453  -0.1771  -0.2402  
    function |  -0.0069   0.3496  -0.2439   0.2113   0.0546  -0.1470  -0.2166  
       smoke |  -0.0173   0.0516  -0.0686  -0.0585  -0.1252  -0.0932  -0.1678  
      hehelf |  -0.0091  -0.4115   0.2348  -0.1705   0.0083   0.2288   0.2923  
         dep |  -0.0124   0.2854  -0.1243   0.1089   0.1295  -0.1816  -0.2160  
cognitivea~y |   0.0108  -0.0932   0.2814  -0.4438   0.0898   0.3377   0.2667  
         alc |   0.0129  -0.1295   0.0818  -0.1267  -0.2121   0.2098   0.2320  
    groupmem |   0.0048  -0.0801   0.0577   0.0230   0.0049   0.2824   0.2516  
         tot |   0.0043  -0.3145   0.1849  -0.1193   0.0296   0.1667   0.2999  
   w4physact |   0.0014  -0.2261   0.2696  -0.3264  -0.0864   0.2446   0.2815  
   w4symptom |  -0.0066   0.3604  -0.1675   0.2411   0.0576  -0.1934  -0.2553  
  w4function |  -0.0057   0.2406  -0.3181   0.2918   0.0516  -0.1542  -0.1956  
       w4vol |   0.0157  -0.0874   0.1317  -0.1403   0.0161   0.3207   0.2604  
     w4smoke |  -0.0047   0.0586  -0.0240  -0.1209  -0.0003  -0.0991  -0.1907  
  w4srhealth |  -0.0018  -0.3547   0.1637  -0.1844  -0.0163   0.2372   0.2792  
w4cogability |   0.0066  -0.1047   0.2381  -0.4596   0.0826   0.3437   0.2499  
       w4alc |   0.0122  -0.1273   0.1360  -0.1656  -0.1897   0.2321   0.2593  
       w4dep |  -0.0094   0.2778  -0.1126   0.1379   0.1317  -0.1856  -0.2248  
  w4groupmem |   0.0065  -0.1070   0.1253  -0.0535   0.0151   0.3304   0.3169  
    w4casp19 |   0.0112  -0.2925   0.1443  -0.1731   0.0056   0.1832   0.2683  
 
             |    phact sympto~t function    smoke   hehelf      dep cognit~y 
-------------+--------------------------------------------------------------- 
       phact |   1.0000  
symptomcount |  -0.4302   1.0000  
    function |  -0.4586   0.6330   1.0000  
       smoke |  -0.0898   0.0605   0.0548   1.0000  
      hehelf |   0.4010  -0.4896  -0.4521  -0.1365   1.0000  
         dep |  -0.2502   0.3456   0.3358   0.0705  -0.3694   1.0000  
cognitivea~y |   0.2555  -0.2164  -0.2124  -0.0399   0.2406  -0.1498   1.0000  
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         alc |   0.1693  -0.1749  -0.1609   0.0332   0.1800  -0.1334   0.1248  
    groupmem |   0.2066  -0.1269  -0.1213  -0.1321   0.1653  -0.1013   0.1113  
         tot |   0.3254  -0.4203  -0.4205  -0.1107   0.4946  -0.4144   0.1868  
   w4physact |   0.4955  -0.3741  -0.3713  -0.1037   0.3641  -0.2203   0.2583  
   w4symptom |  -0.3448   0.5781   0.4665   0.1035  -0.4425   0.2953  -0.1835  
  w4function |  -0.3641   0.4616   0.6061   0.0457  -0.3676   0.2434  -0.2572  
       w4vol |   0.1968  -0.1532  -0.1557  -0.1270   0.1804  -0.1174   0.2362  
     w4smoke |  -0.0850   0.0820   0.0701   0.6205  -0.1259   0.0904  -0.0144  
  w4srhealth |   0.3293  -0.4043  -0.3770  -0.1459   0.6283  -0.3088   0.2265  
w4cogability |   0.2177  -0.2020  -0.1807  -0.0621   0.2079  -0.1462   0.5832  
       w4alc |   0.1916  -0.1981  -0.1814   0.0024   0.1990  -0.1427   0.1610  
       w4dep |  -0.2306   0.3054   0.3136   0.0792  -0.3247   0.4339  -0.1584  
  w4groupmem |   0.2408  -0.1603  -0.1481  -0.1700   0.2160  -0.1263   0.1986  
    w4casp19 |   0.2718  -0.3465  -0.3317  -0.1100   0.4354  -0.3439   0.1802  
 
             |      alc groupmem      tot w4phys~t w4symp~m w4func~n    w4vol 
-------------+--------------------------------------------------------------- 
         alc |   1.0000  
    groupmem |   0.1321   1.0000  
         tot |   0.1640   0.1924   1.0000  
   w4physact |   0.1807   0.1749   0.2924   1.0000  
   w4symptom |  -0.1758  -0.1076  -0.3523  -0.4082   1.0000  
  w4function |  -0.1572  -0.0850  -0.3393  -0.4680   0.4652   1.0000  
       w4vol |   0.0961   0.3600   0.1745   0.2554  -0.1635  -0.1903   1.0000  
     w4smoke |  -0.0651  -0.1439  -0.1311  -0.1032   0.0859   0.0307  -0.1131  
  w4srhealth |   0.1763   0.1400   0.4413   0.4106  -0.5202  -0.4396   0.2104  
w4cogability |   0.1205   0.1198   0.1618   0.2829  -0.2429  -0.2520   0.2455  
       w4alc |   0.6525   0.1198   0.1660   0.2581  -0.1895  -0.2446   0.1459  
       w4dep |  -0.1353  -0.0975  -0.3725  -0.2827   0.3858   0.3388  -0.1389  
  w4groupmem |   0.1384   0.5966   0.2120   0.2814  -0.1526  -0.1867   0.4572  
    w4casp19 |   0.1590   0.1558   0.7096   0.3211  -0.4019  -0.3917   0.1796  
 
             |  w4smoke w4srhe~h w4coga~y    w4alc    w4dep w4grou~m w4casp19 
-------------+--------------------------------------------------------------- 
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     w4smoke |   1.0000  
  w4srhealth |  -0.1211   1.0000  
w4cogability |  -0.0345   0.2585   1.0000  
       w4alc |  -0.0792   0.2169   0.1786   1.0000  
       w4dep |   0.0800  -0.4030  -0.1927  -0.1755   1.0000  
  w4groupmem |  -0.1745   0.2151   0.2155   0.2824  -0.1467   1.0000  
    w4casp19 |  -0.1122   0.5114   0.2105   0.1696  -0.4561   0.2110   1.0000  
 
             | m_hehelf    Pain2     cen2     age2     sex2 educat~n   wealth 
-------------+--------------------------------------------------------------- 
    m_hehelf |   1.0000  
       Pain2 |  -0.0081   1.0000  
        cen2 |  -0.0062  -0.0615   1.0000  
        age2 |  -0.3740   0.0692  -0.3038   1.0000  
        sex2 |   0.0516   0.0794   0.0656   0.0013   1.0000  
   education |   0.0032  -0.1299   0.1479  -0.2689  -0.1542   1.0000  
      wealth |  -0.0205  -0.1706   0.1653  -0.1523  -0.0508   0.4057   1.0000  
       phact |  -0.0207  -0.2480   0.2767  -0.2889  -0.0687   0.2443   0.2821  
symptomcount |   0.0262   0.3735  -0.2519   0.2414   0.0453  -0.1771  -0.2402  
    function |   0.0024   0.3496  -0.2439   0.2113   0.0546  -0.1470  -0.2166  
       smoke |  -0.0065   0.0516  -0.0686  -0.0585  -0.1252  -0.0932  -0.1678  
volunteerw~k |  -0.0038  -0.0818   0.1177  -0.0762   0.0374   0.2576   0.2199  
         dep |  -0.0059   0.2854  -0.1243   0.1089   0.1295  -0.1816  -0.2160  
cognitivea~y |  -0.0143  -0.0932   0.2814  -0.4438   0.0898   0.3377   0.2667  
         alc |  -0.0052  -0.1295   0.0818  -0.1267  -0.2121   0.2098   0.2320  
    groupmem |  -0.0129  -0.0801   0.0577   0.0230   0.0049   0.2824   0.2516  
         tot |  -0.0343  -0.3145   0.1849  -0.1193   0.0296   0.1667   0.2999  
   w4physact |  -0.0054  -0.2261   0.2696  -0.3264  -0.0864   0.2446   0.2815  
   w4symptom |   0.0121   0.3604  -0.1675   0.2411   0.0576  -0.1934  -0.2553  
  w4function |   0.0041   0.2406  -0.3181   0.2918   0.0516  -0.1542  -0.1956  
       w4vol |  -0.0175  -0.0874   0.1317  -0.1403   0.0161   0.3207   0.2604  
     w4smoke |  -0.0081   0.0586  -0.0240  -0.1209  -0.0003  -0.0991  -0.1907  
  w4srhealth |  -0.0303  -0.3547   0.1637  -0.1844  -0.0163   0.2372   0.2792  
w4cogability |  -0.0166  -0.1047   0.2381  -0.4596   0.0826   0.3437   0.2499  
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       w4alc |  -0.0084  -0.1273   0.1360  -0.1656  -0.1897   0.2321   0.2593  
       w4dep |   0.0167   0.2778  -0.1126   0.1379   0.1317  -0.1856  -0.2248  
  w4groupmem |  -0.0210  -0.1070   0.1253  -0.0535   0.0151   0.3304   0.3169  
    w4casp19 |  -0.0186  -0.2925   0.1443  -0.1731   0.0056   0.1832   0.2683  
 
             |    phact sympto~t function    smoke volunt~k      dep cognit~y 
-------------+--------------------------------------------------------------- 
       phact |   1.0000  
symptomcount |  -0.4302   1.0000  
    function |  -0.4586   0.6330   1.0000  
       smoke |  -0.0898   0.0605   0.0548   1.0000  
volunteerw~k |   0.1790  -0.1572  -0.1548  -0.1019   1.0000  
         dep |  -0.2502   0.3456   0.3358   0.0705  -0.1114   1.0000  
cognitivea~y |   0.2555  -0.2164  -0.2124  -0.0399   0.1667  -0.1498   1.0000  
         alc |   0.1693  -0.1749  -0.1609   0.0332   0.0578  -0.1334   0.1248  
    groupmem |   0.2066  -0.1269  -0.1213  -0.1321   0.3689  -0.1013   0.1113  
         tot |   0.3254  -0.4203  -0.4205  -0.1107   0.1556  -0.4144   0.1868  
   w4physact |   0.4955  -0.3741  -0.3713  -0.1037   0.1568  -0.2203   0.2583  
   w4symptom |  -0.3448   0.5781   0.4665   0.1035  -0.1259   0.2953  -0.1835  
  w4function |  -0.3641   0.4616   0.6061   0.0457  -0.1312   0.2434  -0.2572  
       w4vol |   0.1968  -0.1532  -0.1557  -0.1270   0.4751  -0.1174   0.2362  
     w4smoke |  -0.0850   0.0820   0.0701   0.6205  -0.0939   0.0904  -0.0144  
  w4srhealth |   0.3293  -0.4043  -0.3770  -0.1459   0.1316  -0.3088   0.2265  
w4cogability |   0.2177  -0.2020  -0.1807  -0.0621   0.1604  -0.1462   0.5832  
       w4alc |   0.1916  -0.1981  -0.1814   0.0024   0.0811  -0.1427   0.1610  
       w4dep |  -0.2306   0.3054   0.3136   0.0792  -0.0928   0.4339  -0.1584  
  w4groupmem |   0.2408  -0.1603  -0.1481  -0.1700   0.3838  -0.1263   0.1986  
    w4casp19 |   0.2718  -0.3465  -0.3317  -0.1100   0.1247  -0.3439   0.1802  
 
             |      alc groupmem      tot w4phys~t w4symp~m w4func~n    w4vol 
-------------+--------------------------------------------------------------- 
         alc |   1.0000  
    groupmem |   0.1321   1.0000  
         tot |   0.1640   0.1924   1.0000  
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   w4physact |   0.1807   0.1749   0.2924   1.0000  
   w4symptom |  -0.1758  -0.1076  -0.3523  -0.4082   1.0000  
  w4function |  -0.1572  -0.0850  -0.3393  -0.4680   0.4652   1.0000  
       w4vol |   0.0961   0.3600   0.1745   0.2554  -0.1635  -0.1903   1.0000  
     w4smoke |  -0.0651  -0.1439  -0.1311  -0.1032   0.0859   0.0307  -0.1131  
  w4srhealth |   0.1763   0.1400   0.4413   0.4106  -0.5202  -0.4396   0.2104  
w4cogability |   0.1205   0.1198   0.1618   0.2829  -0.2429  -0.2520   0.2455  
       w4alc |   0.6525   0.1198   0.1660   0.2581  -0.1895  -0.2446   0.1459  
       w4dep |  -0.1353  -0.0975  -0.3725  -0.2827   0.3858   0.3388  -0.1389  
  w4groupmem |   0.1384   0.5966   0.2120   0.2814  -0.1526  -0.1867   0.4572  
    w4casp19 |   0.1590   0.1558   0.7096   0.3211  -0.4019  -0.3917   0.1796  
 
             |  w4smoke w4srhe~h w4coga~y    w4alc    w4dep w4grou~m w4casp19 
-------------+--------------------------------------------------------------- 
     w4smoke |   1.0000  
  w4srhealth |  -0.1211   1.0000  
w4cogability |  -0.0345   0.2585   1.0000  
       w4alc |  -0.0792   0.2169   0.1786   1.0000  
       w4dep |   0.0800  -0.4030  -0.1927  -0.1755   1.0000  
  w4groupmem |  -0.1745   0.2151   0.2155   0.2824  -0.1467   1.0000  
    w4casp19 |  -0.1122   0.5114   0.2105   0.1696  -0.4561   0.2110   1.0000  
 
             |    m_dep    Pain2     cen2     age2     sex2 educat~n   wealth 
-------------+--------------------------------------------------------------- 
       m_dep |   1.0000  
       Pain2 |  -0.0066   1.0000  
        cen2 |  -0.0141  -0.0615   1.0000  
        age2 |  -0.3660   0.0692  -0.3038   1.0000  
        sex2 |   0.0466   0.0794   0.0656   0.0013   1.0000  
   education |  -0.0140  -0.1299   0.1479  -0.2689  -0.1542   1.0000  
      wealth |  -0.0147  -0.1706   0.1653  -0.1523  -0.0508   0.4057   1.0000  
       phact |  -0.0444  -0.2480   0.2767  -0.2889  -0.0687   0.2443   0.2821  
symptomcount |   0.0254   0.3735  -0.2519   0.2414   0.0453  -0.1771  -0.2402  
    function |   0.0723   0.3496  -0.2439   0.2113   0.0546  -0.1470  -0.2166  
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       smoke |  -0.0111   0.0516  -0.0686  -0.0585  -0.1252  -0.0932  -0.1678  
volunteerw~k |  -0.0049  -0.0818   0.1177  -0.0762   0.0374   0.2576   0.2199  
      hehelf |  -0.0302  -0.4115   0.2348  -0.1705   0.0083   0.2288   0.2923  
cognitivea~y |  -0.0421  -0.0932   0.2814  -0.4438   0.0898   0.3377   0.2667  
         alc |   0.0223  -0.1295   0.0818  -0.1267  -0.2121   0.2098   0.2320  
    groupmem |   0.0082  -0.0801   0.0577   0.0230   0.0049   0.2824   0.2516  
         tot |   0.0006  -0.3145   0.1849  -0.1193   0.0296   0.1667   0.2999  
   w4physact |  -0.0324  -0.2261   0.2696  -0.3264  -0.0864   0.2446   0.2815  
   w4symptom |  -0.0020   0.3604  -0.1675   0.2411   0.0576  -0.1934  -0.2553  
  w4function |   0.0191   0.2406  -0.3181   0.2918   0.0516  -0.1542  -0.1956  
       w4vol |  -0.0142  -0.0874   0.1317  -0.1403   0.0161   0.3207   0.2604  
     w4smoke |   0.0023   0.0586  -0.0240  -0.1209  -0.0003  -0.0991  -0.1907  
  w4srhealth |   0.0005  -0.3547   0.1637  -0.1844  -0.0163   0.2372   0.2792  
w4cogability |  -0.0039  -0.1047   0.2381  -0.4596   0.0826   0.3437   0.2499  
       w4alc |  -0.0161  -0.1273   0.1360  -0.1656  -0.1897   0.2321   0.2593  
       w4dep |   0.0045   0.2778  -0.1126   0.1379   0.1317  -0.1856  -0.2248  
  w4groupmem |  -0.0109  -0.1070   0.1253  -0.0535   0.0151   0.3304   0.3169  
    w4casp19 |   0.0037  -0.2925   0.1443  -0.1731   0.0056   0.1832   0.2683  
 
             |    phact sympto~t function    smoke volunt~k   hehelf cognit~y 
-------------+--------------------------------------------------------------- 
       phact |   1.0000  
symptomcount |  -0.4302   1.0000  
    function |  -0.4586   0.6330   1.0000  
       smoke |  -0.0898   0.0605   0.0548   1.0000  
volunteerw~k |   0.1790  -0.1572  -0.1548  -0.1019   1.0000  
      hehelf |   0.4010  -0.4896  -0.4521  -0.1365   0.1831   1.0000  
cognitivea~y |   0.2555  -0.2164  -0.2124  -0.0399   0.1667   0.2406   1.0000  
         alc |   0.1693  -0.1749  -0.1609   0.0332   0.0578   0.1800   0.1248  
    groupmem |   0.2066  -0.1269  -0.1213  -0.1321   0.3689   0.1653   0.1113  
         tot |   0.3254  -0.4203  -0.4205  -0.1107   0.1556   0.4946   0.1868  
   w4physact |   0.4955  -0.3741  -0.3713  -0.1037   0.1568   0.3641   0.2583  
   w4symptom |  -0.3448   0.5781   0.4665   0.1035  -0.1259  -0.4425  -0.1835  
  w4function |  -0.3641   0.4616   0.6061   0.0457  -0.1312  -0.3676  -0.2572  
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       w4vol |   0.1968  -0.1532  -0.1557  -0.1270   0.4751   0.1804   0.2362  
     w4smoke |  -0.0850   0.0820   0.0701   0.6205  -0.0939  -0.1259  -0.0144  
  w4srhealth |   0.3293  -0.4043  -0.3770  -0.1459   0.1316   0.6283   0.2265  
w4cogability |   0.2177  -0.2020  -0.1807  -0.0621   0.1604   0.2079   0.5832  
       w4alc |   0.1916  -0.1981  -0.1814   0.0024   0.0811   0.1990   0.1610  
       w4dep |  -0.2306   0.3054   0.3136   0.0792  -0.0928  -0.3247  -0.1584  
  w4groupmem |   0.2408  -0.1603  -0.1481  -0.1700   0.3838   0.2160   0.1986  
    w4casp19 |   0.2718  -0.3465  -0.3317  -0.1100   0.1247   0.4354   0.1802  
 
             |      alc groupmem      tot w4phys~t w4symp~m w4func~n    w4vol 
-------------+--------------------------------------------------------------- 
         alc |   1.0000  
    groupmem |   0.1321   1.0000  
         tot |   0.1640   0.1924   1.0000  
   w4physact |   0.1807   0.1749   0.2924   1.0000  
   w4symptom |  -0.1758  -0.1076  -0.3523  -0.4082   1.0000  
  w4function |  -0.1572  -0.0850  -0.3393  -0.4680   0.4652   1.0000  
       w4vol |   0.0961   0.3600   0.1745   0.2554  -0.1635  -0.1903   1.0000  
     w4smoke |  -0.0651  -0.1439  -0.1311  -0.1032   0.0859   0.0307  -0.1131  
  w4srhealth |   0.1763   0.1400   0.4413   0.4106  -0.5202  -0.4396   0.2104  
w4cogability |   0.1205   0.1198   0.1618   0.2829  -0.2429  -0.2520   0.2455  
       w4alc |   0.6525   0.1198   0.1660   0.2581  -0.1895  -0.2446   0.1459  
       w4dep |  -0.1353  -0.0975  -0.3725  -0.2827   0.3858   0.3388  -0.1389  
  w4groupmem |   0.1384   0.5966   0.2120   0.2814  -0.1526  -0.1867   0.4572  
    w4casp19 |   0.1590   0.1558   0.7096   0.3211  -0.4019  -0.3917   0.1796  
 
             |  w4smoke w4srhe~h w4coga~y    w4alc    w4dep w4grou~m w4casp19 
-------------+--------------------------------------------------------------- 
     w4smoke |   1.0000  
  w4srhealth |  -0.1211   1.0000  
w4cogability |  -0.0345   0.2585   1.0000  
       w4alc |  -0.0792   0.2169   0.1786   1.0000  
       w4dep |   0.0800  -0.4030  -0.1927  -0.1755   1.0000  
  w4groupmem |  -0.1745   0.2151   0.2155   0.2824  -0.1467   1.0000  
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    w4casp19 |  -0.1122   0.5114   0.2105   0.1696  -0.4561   0.2110   1.0000  
 
             | m_cogn~y    Pain2     cen2     age2     sex2 educat~n   wealth 
-------------+--------------------------------------------------------------- 
m_cognitiv~y |   1.0000  
       Pain2 |   0.0002   1.0000  
        cen2 |  -0.0233  -0.0615   1.0000  
        age2 |  -0.3558   0.0692  -0.3038   1.0000  
        sex2 |   0.0429   0.0794   0.0656   0.0013   1.0000  
   education |  -0.0024  -0.1299   0.1479  -0.2689  -0.1542   1.0000  
      wealth |  -0.0074  -0.1706   0.1653  -0.1523  -0.0508   0.4057   1.0000  
       phact |  -0.0554  -0.2480   0.2767  -0.2889  -0.0687   0.2443   0.2821  
symptomcount |   0.0321   0.3735  -0.2519   0.2414   0.0453  -0.1771  -0.2402  
    function |   0.0787   0.3496  -0.2439   0.2113   0.0546  -0.1470  -0.2166  
       smoke |  -0.0071   0.0516  -0.0686  -0.0585  -0.1252  -0.0932  -0.1678  
volunteerw~k |  -0.0224  -0.0818   0.1177  -0.0762   0.0374   0.2576   0.2199  
      hehelf |  -0.0368  -0.4115   0.2348  -0.1705   0.0083   0.2288   0.2923  
         dep |  -0.0751   0.2854  -0.1243   0.1089   0.1295  -0.1816  -0.2160  
         alc |   0.0051  -0.1295   0.0818  -0.1267  -0.2121   0.2098   0.2320  
    groupmem |  -0.0183  -0.0801   0.0577   0.0230   0.0049   0.2824   0.2516  
         tot |  -0.0239  -0.3145   0.1849  -0.1193   0.0296   0.1667   0.2999  
   w4physact |  -0.0518  -0.2261   0.2696  -0.3264  -0.0864   0.2446   0.2815  
   w4symptom |  -0.0058   0.3604  -0.1675   0.2411   0.0576  -0.1934  -0.2553  
  w4function |   0.0191   0.2406  -0.3181   0.2918   0.0516  -0.1542  -0.1956  
       w4vol |  -0.0124  -0.0874   0.1317  -0.1403   0.0161   0.3207   0.2604  
     w4smoke |   0.0051   0.0586  -0.0240  -0.1209  -0.0003  -0.0991  -0.1907  
  w4srhealth |  -0.0103  -0.3547   0.1637  -0.1844  -0.0163   0.2372   0.2792  
w4cogability |  -0.0396  -0.1047   0.2381  -0.4596   0.0826   0.3437   0.2499  
       w4alc |  -0.0199  -0.1273   0.1360  -0.1656  -0.1897   0.2321   0.2593  
       w4dep |   0.0103   0.2778  -0.1126   0.1379   0.1317  -0.1856  -0.2248  
  w4groupmem |  -0.0293  -0.1070   0.1253  -0.0535   0.0151   0.3304   0.3169  
    w4casp19 |   0.0005  -0.2925   0.1443  -0.1731   0.0056   0.1832   0.2683  
 
             |    phact sympto~t function    smoke volunt~k   hehelf      dep 
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-------------+--------------------------------------------------------------- 
       phact |   1.0000  
symptomcount |  -0.4302   1.0000  
    function |  -0.4586   0.6330   1.0000  
       smoke |  -0.0898   0.0605   0.0548   1.0000  
volunteerw~k |   0.1790  -0.1572  -0.1548  -0.1019   1.0000  
      hehelf |   0.4010  -0.4896  -0.4521  -0.1365   0.1831   1.0000  
         dep |  -0.2502   0.3456   0.3358   0.0705  -0.1114  -0.3694   1.0000  
         alc |   0.1693  -0.1749  -0.1609   0.0332   0.0578   0.1800  -0.1334  
    groupmem |   0.2066  -0.1269  -0.1213  -0.1321   0.3689   0.1653  -0.1013  
         tot |   0.3254  -0.4203  -0.4205  -0.1107   0.1556   0.4946  -0.4144  
   w4physact |   0.4955  -0.3741  -0.3713  -0.1037   0.1568   0.3641  -0.2203  
   w4symptom |  -0.3448   0.5781   0.4665   0.1035  -0.1259  -0.4425   0.2953  
  w4function |  -0.3641   0.4616   0.6061   0.0457  -0.1312  -0.3676   0.2434  
       w4vol |   0.1968  -0.1532  -0.1557  -0.1270   0.4751   0.1804  -0.1174  
     w4smoke |  -0.0850   0.0820   0.0701   0.6205  -0.0939  -0.1259   0.0904  
  w4srhealth |   0.3293  -0.4043  -0.3770  -0.1459   0.1316   0.6283  -0.3088  
w4cogability |   0.2177  -0.2020  -0.1807  -0.0621   0.1604   0.2079  -0.1462  
       w4alc |   0.1916  -0.1981  -0.1814   0.0024   0.0811   0.1990  -0.1427  
       w4dep |  -0.2306   0.3054   0.3136   0.0792  -0.0928  -0.3247   0.4339  
  w4groupmem |   0.2408  -0.1603  -0.1481  -0.1700   0.3838   0.2160  -0.1263  
    w4casp19 |   0.2718  -0.3465  -0.3317  -0.1100   0.1247   0.4354  -0.3439  
 
             |      alc groupmem      tot w4phys~t w4symp~m w4func~n    w4vol 
-------------+--------------------------------------------------------------- 
         alc |   1.0000  
    groupmem |   0.1321   1.0000  
         tot |   0.1640   0.1924   1.0000  
   w4physact |   0.1807   0.1749   0.2924   1.0000  
   w4symptom |  -0.1758  -0.1076  -0.3523  -0.4082   1.0000  
  w4function |  -0.1572  -0.0850  -0.3393  -0.4680   0.4652   1.0000  
       w4vol |   0.0961   0.3600   0.1745   0.2554  -0.1635  -0.1903   1.0000  
     w4smoke |  -0.0651  -0.1439  -0.1311  -0.1032   0.0859   0.0307  -0.1131  
  w4srhealth |   0.1763   0.1400   0.4413   0.4106  -0.5202  -0.4396   0.2104  
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w4cogability |   0.1205   0.1198   0.1618   0.2829  -0.2429  -0.2520   0.2455  
       w4alc |   0.6525   0.1198   0.1660   0.2581  -0.1895  -0.2446   0.1459  
       w4dep |  -0.1353  -0.0975  -0.3725  -0.2827   0.3858   0.3388  -0.1389  
  w4groupmem |   0.1384   0.5966   0.2120   0.2814  -0.1526  -0.1867   0.4572  
    w4casp19 |   0.1590   0.1558   0.7096   0.3211  -0.4019  -0.3917   0.1796  
 
             |  w4smoke w4srhe~h w4coga~y    w4alc    w4dep w4grou~m w4casp19 
-------------+--------------------------------------------------------------- 
     w4smoke |   1.0000  
  w4srhealth |  -0.1211   1.0000  
w4cogability |  -0.0345   0.2585   1.0000  
       w4alc |  -0.0792   0.2169   0.1786   1.0000  
       w4dep |   0.0800  -0.4030  -0.1927  -0.1755   1.0000  
  w4groupmem |  -0.1745   0.2151   0.2155   0.2824  -0.1467   1.0000  
    w4casp19 |  -0.1122   0.5114   0.2105   0.1696  -0.4561   0.2110   1.0000  
 
             |    m_alc    Pain2     cen2     age2     sex2 educat~n   wealth 
-------------+--------------------------------------------------------------- 
       m_alc |   1.0000  
       Pain2 |   0.0155   1.0000  
        cen2 |  -0.1327  -0.0615   1.0000  
        age2 |  -0.1389   0.0692  -0.3038   1.0000  
        sex2 |   0.0332   0.0794   0.0656   0.0013   1.0000  
   education |  -0.1161  -0.1299   0.1479  -0.2689  -0.1542   1.0000  
      wealth |  -0.1488  -0.1706   0.1653  -0.1523  -0.0508   0.4057   1.0000  
       phact |  -0.1453  -0.2480   0.2767  -0.2889  -0.0687   0.2443   0.2821  
symptomcount |   0.1098   0.3735  -0.2519   0.2414   0.0453  -0.1771  -0.2402  
    function |   0.1445   0.3496  -0.2439   0.2113   0.0546  -0.1470  -0.2166  
       smoke |   0.0383   0.0516  -0.0686  -0.0585  -0.1252  -0.0932  -0.1678  
volunteerw~k |  -0.0939  -0.0818   0.1177  -0.0762   0.0374   0.2576   0.2199  
      hehelf |  -0.1246  -0.4115   0.2348  -0.1705   0.0083   0.2288   0.2923  
         dep |   0.0919   0.2854  -0.1243   0.1089   0.1295  -0.1816  -0.2160  
cognitivea~y |  -0.2158  -0.0932   0.2814  -0.4438   0.0898   0.3377   0.2667  
    groupmem |  -0.0103  -0.0801   0.0577   0.0230   0.0049   0.2824   0.2516  
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         tot |  -0.0224  -0.3145   0.1849  -0.1193   0.0296   0.1667   0.2999  
   w4physact |  -0.1482  -0.2261   0.2696  -0.3264  -0.0864   0.2446   0.2815  
   w4symptom |   0.0710   0.3604  -0.1675   0.2411   0.0576  -0.1934  -0.2553  
  w4function |   0.1552   0.2406  -0.3181   0.2918   0.0516  -0.1542  -0.1956  
       w4vol |  -0.1054  -0.0874   0.1317  -0.1403   0.0161   0.3207   0.2604  
     w4smoke |   0.0591   0.0586  -0.0240  -0.1209  -0.0003  -0.0991  -0.1907  
  w4srhealth |  -0.1060  -0.3547   0.1637  -0.1844  -0.0163   0.2372   0.2792  
w4cogability |  -0.1486  -0.1047   0.2381  -0.4596   0.0826   0.3437   0.2499  
       w4alc |  -0.1506  -0.1273   0.1360  -0.1656  -0.1897   0.2321   0.2593  
       w4dep |   0.0825   0.2778  -0.1126   0.1379   0.1317  -0.1856  -0.2248  
  w4groupmem |  -0.1488  -0.1070   0.1253  -0.0535   0.0151   0.3304   0.3169  
    w4casp19 |  -0.0723  -0.2925   0.1443  -0.1731   0.0056   0.1832   0.2683  
 
             |    phact sympto~t function    smoke volunt~k   hehelf      dep 
-------------+--------------------------------------------------------------- 
       phact |   1.0000  
symptomcount |  -0.4302   1.0000  
    function |  -0.4586   0.6330   1.0000  
       smoke |  -0.0898   0.0605   0.0548   1.0000  
volunteerw~k |   0.1790  -0.1572  -0.1548  -0.1019   1.0000  
      hehelf |   0.4010  -0.4896  -0.4521  -0.1365   0.1831   1.0000  
         dep |  -0.2502   0.3456   0.3358   0.0705  -0.1114  -0.3694   1.0000  
cognitivea~y |   0.2555  -0.2164  -0.2124  -0.0399   0.1667   0.2406  -0.1498  
    groupmem |   0.2066  -0.1269  -0.1213  -0.1321   0.3689   0.1653  -0.1013  
         tot |   0.3254  -0.4203  -0.4205  -0.1107   0.1556   0.4946  -0.4144  
   w4physact |   0.4955  -0.3741  -0.3713  -0.1037   0.1568   0.3641  -0.2203  
   w4symptom |  -0.3448   0.5781   0.4665   0.1035  -0.1259  -0.4425   0.2953  
  w4function |  -0.3641   0.4616   0.6061   0.0457  -0.1312  -0.3676   0.2434  
       w4vol |   0.1968  -0.1532  -0.1557  -0.1270   0.4751   0.1804  -0.1174  
     w4smoke |  -0.0850   0.0820   0.0701   0.6205  -0.0939  -0.1259   0.0904  
  w4srhealth |   0.3293  -0.4043  -0.3770  -0.1459   0.1316   0.6283  -0.3088  
w4cogability |   0.2177  -0.2020  -0.1807  -0.0621   0.1604   0.2079  -0.1462  
       w4alc |   0.1916  -0.1981  -0.1814   0.0024   0.0811   0.1990  -0.1427  
       w4dep |  -0.2306   0.3054   0.3136   0.0792  -0.0928  -0.3247   0.4339  
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  w4groupmem |   0.2408  -0.1603  -0.1481  -0.1700   0.3838   0.2160  -0.1263  
    w4casp19 |   0.2718  -0.3465  -0.3317  -0.1100   0.1247   0.4354  -0.3439  
 
             | cognit~y groupmem      tot w4phys~t w4symp~m w4func~n    w4vol 
-------------+--------------------------------------------------------------- 
cognitivea~y |   1.0000  
    groupmem |   0.1113   1.0000  
         tot |   0.1868   0.1924   1.0000  
   w4physact |   0.2583   0.1749   0.2924   1.0000  
   w4symptom |  -0.1835  -0.1076  -0.3523  -0.4082   1.0000  
  w4function |  -0.2572  -0.0850  -0.3393  -0.4680   0.4652   1.0000  
       w4vol |   0.2362   0.3600   0.1745   0.2554  -0.1635  -0.1903   1.0000  
     w4smoke |  -0.0144  -0.1439  -0.1311  -0.1032   0.0859   0.0307  -0.1131  
  w4srhealth |   0.2265   0.1400   0.4413   0.4106  -0.5202  -0.4396   0.2104  
w4cogability |   0.5832   0.1198   0.1618   0.2829  -0.2429  -0.2520   0.2455  
       w4alc |   0.1610   0.1198   0.1660   0.2581  -0.1895  -0.2446   0.1459  
       w4dep |  -0.1584  -0.0975  -0.3725  -0.2827   0.3858   0.3388  -0.1389  
  w4groupmem |   0.1986   0.5966   0.2120   0.2814  -0.1526  -0.1867   0.4572  
    w4casp19 |   0.1802   0.1558   0.7096   0.3211  -0.4019  -0.3917   0.1796  
 
             |  w4smoke w4srhe~h w4coga~y    w4alc    w4dep w4grou~m w4casp19 
-------------+--------------------------------------------------------------- 
     w4smoke |   1.0000  
  w4srhealth |  -0.1211   1.0000  
w4cogability |  -0.0345   0.2585   1.0000  
       w4alc |  -0.0792   0.2169   0.1786   1.0000  
       w4dep |   0.0800  -0.4030  -0.1927  -0.1755   1.0000  
  w4groupmem |  -0.1745   0.2151   0.2155   0.2824  -0.1467   1.0000  
    w4casp19 |  -0.1122   0.5114   0.2105   0.1696  -0.4561   0.2110   1.0000  
 
             | m_grou~m    Pain2     cen2     age2     sex2 educat~n   wealth 
-------------+--------------------------------------------------------------- 
  m_groupmem |   1.0000  
       Pain2 |   0.0360   1.0000  
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        cen2 |  -0.1228  -0.0615   1.0000  
        age2 |  -0.1071   0.0692  -0.3038   1.0000  
        sex2 |   0.0410   0.0794   0.0656   0.0013   1.0000  
   education |  -0.1648  -0.1299   0.1479  -0.2689  -0.1542   1.0000  
      wealth |  -0.1762  -0.1706   0.1653  -0.1523  -0.0508   0.4057   1.0000  
       phact |  -0.1556  -0.2480   0.2767  -0.2889  -0.0687   0.2443   0.2821  
symptomcount |   0.1341   0.3735  -0.2519   0.2414   0.0453  -0.1771  -0.2402  
    function |   0.1528   0.3496  -0.2439   0.2113   0.0546  -0.1470  -0.2166  
       smoke |   0.0465   0.0516  -0.0686  -0.0585  -0.1252  -0.0932  -0.1678  
volunteerw~k |  -0.1337  -0.0818   0.1177  -0.0762   0.0374   0.2576   0.2199  
      hehelf |  -0.1418  -0.4115   0.2348  -0.1705   0.0083   0.2288   0.2923  
         dep |   0.1170   0.2854  -0.1243   0.1089   0.1295  -0.1816  -0.2160  
cognitivea~y |  -0.2122  -0.0932   0.2814  -0.4438   0.0898   0.3377   0.2667  
         alc |  -0.0769  -0.1295   0.0818  -0.1267  -0.2121   0.2098   0.2320  
         tot |  -0.0651  -0.3145   0.1849  -0.1193   0.0296   0.1667   0.2999  
   w4physact |  -0.1637  -0.2261   0.2696  -0.3264  -0.0864   0.2446   0.2815  
   w4symptom |   0.0898   0.3604  -0.1675   0.2411   0.0576  -0.1934  -0.2553  
  w4function |   0.1427   0.2406  -0.3181   0.2918   0.0516  -0.1542  -0.1956  
       w4vol |  -0.1487  -0.0874   0.1317  -0.1403   0.0161   0.3207   0.2604  
     w4smoke |   0.0740   0.0586  -0.0240  -0.1209  -0.0003  -0.0991  -0.1907  
  w4srhealth |  -0.1196  -0.3547   0.1637  -0.1844  -0.0163   0.2372   0.2792  
w4cogability |  -0.1562  -0.1047   0.2381  -0.4596   0.0826   0.3437   0.2499  
       w4alc |  -0.1421  -0.1273   0.1360  -0.1656  -0.1897   0.2321   0.2593  
       w4dep |   0.0985   0.2778  -0.1126   0.1379   0.1317  -0.1856  -0.2248  
  w4groupmem |  -0.1836  -0.1070   0.1253  -0.0535   0.0151   0.3304   0.3169  
    w4casp19 |  -0.0805  -0.2925   0.1443  -0.1731   0.0056   0.1832   0.2683  
 
             |    phact sympto~t function    smoke volunt~k   hehelf      dep 
-------------+--------------------------------------------------------------- 
       phact |   1.0000  
symptomcount |  -0.4302   1.0000  
    function |  -0.4586   0.6330   1.0000  
       smoke |  -0.0898   0.0605   0.0548   1.0000  
volunteerw~k |   0.1790  -0.1572  -0.1548  -0.1019   1.0000  
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      hehelf |   0.4010  -0.4896  -0.4521  -0.1365   0.1831   1.0000  
         dep |  -0.2502   0.3456   0.3358   0.0705  -0.1114  -0.3694   1.0000  
cognitivea~y |   0.2555  -0.2164  -0.2124  -0.0399   0.1667   0.2406  -0.1498  
         alc |   0.1693  -0.1749  -0.1609   0.0332   0.0578   0.1800  -0.1334  
         tot |   0.3254  -0.4203  -0.4205  -0.1107   0.1556   0.4946  -0.4144  
   w4physact |   0.4955  -0.3741  -0.3713  -0.1037   0.1568   0.3641  -0.2203  
   w4symptom |  -0.3448   0.5781   0.4665   0.1035  -0.1259  -0.4425   0.2953  
  w4function |  -0.3641   0.4616   0.6061   0.0457  -0.1312  -0.3676   0.2434  
       w4vol |   0.1968  -0.1532  -0.1557  -0.1270   0.4751   0.1804  -0.1174  
     w4smoke |  -0.0850   0.0820   0.0701   0.6205  -0.0939  -0.1259   0.0904  
  w4srhealth |   0.3293  -0.4043  -0.3770  -0.1459   0.1316   0.6283  -0.3088  
w4cogability |   0.2177  -0.2020  -0.1807  -0.0621   0.1604   0.2079  -0.1462  
       w4alc |   0.1916  -0.1981  -0.1814   0.0024   0.0811   0.1990  -0.1427  
       w4dep |  -0.2306   0.3054   0.3136   0.0792  -0.0928  -0.3247   0.4339  
  w4groupmem |   0.2408  -0.1603  -0.1481  -0.1700   0.3838   0.2160  -0.1263  
    w4casp19 |   0.2718  -0.3465  -0.3317  -0.1100   0.1247   0.4354  -0.3439  
 
             | cognit~y      alc      tot w4phys~t w4symp~m w4func~n    w4vol 
-------------+--------------------------------------------------------------- 
cognitivea~y |   1.0000  
         alc |   0.1248   1.0000  
         tot |   0.1868   0.1640   1.0000  
   w4physact |   0.2583   0.1807   0.2924   1.0000  
   w4symptom |  -0.1835  -0.1758  -0.3523  -0.4082   1.0000  
  w4function |  -0.2572  -0.1572  -0.3393  -0.4680   0.4652   1.0000  
       w4vol |   0.2362   0.0961   0.1745   0.2554  -0.1635  -0.1903   1.0000  
     w4smoke |  -0.0144  -0.0651  -0.1311  -0.1032   0.0859   0.0307  -0.1131  
  w4srhealth |   0.2265   0.1763   0.4413   0.4106  -0.5202  -0.4396   0.2104  
w4cogability |   0.5832   0.1205   0.1618   0.2829  -0.2429  -0.2520   0.2455  
       w4alc |   0.1610   0.6525   0.1660   0.2581  -0.1895  -0.2446   0.1459  
       w4dep |  -0.1584  -0.1353  -0.3725  -0.2827   0.3858   0.3388  -0.1389  
  w4groupmem |   0.1986   0.1384   0.2120   0.2814  -0.1526  -0.1867   0.4572  
    w4casp19 |   0.1802   0.1590   0.7096   0.3211  -0.4019  -0.3917   0.1796  
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             |  w4smoke w4srhe~h w4coga~y    w4alc    w4dep w4grou~m w4casp19 
-------------+--------------------------------------------------------------- 
     w4smoke |   1.0000  
  w4srhealth |  -0.1211   1.0000  
w4cogability |  -0.0345   0.2585   1.0000  
       w4alc |  -0.0792   0.2169   0.1786   1.0000  
       w4dep |   0.0800  -0.4030  -0.1927  -0.1755   1.0000  
  w4groupmem |  -0.1745   0.2151   0.2155   0.2824  -0.1467   1.0000  
    w4casp19 |  -0.1122   0.5114   0.2105   0.1696  -0.4561   0.2110   1.0000  
 
             |    m_tot    Pain2     cen2     age2     sex2 educat~n   wealth 
-------------+--------------------------------------------------------------- 
       m_tot |   1.0000  
       Pain2 |   0.0458   1.0000  
        cen2 |  -0.1635  -0.0615   1.0000  
        age2 |  -0.0333   0.0692  -0.3038   1.0000  
        sex2 |   0.0493   0.0794   0.0656   0.0013   1.0000  
   education |  -0.1964  -0.1299   0.1479  -0.2689  -0.1542   1.0000  
      wealth |  -0.1911  -0.1706   0.1653  -0.1523  -0.0508   0.4057   1.0000  
       phact |  -0.1977  -0.2480   0.2767  -0.2889  -0.0687   0.2443   0.2821  
symptomcount |   0.1614   0.3735  -0.2519   0.2414   0.0453  -0.1771  -0.2402  
    function |   0.1795   0.3496  -0.2439   0.2113   0.0546  -0.1470  -0.2166  
       smoke |   0.0267   0.0516  -0.0686  -0.0585  -0.1252  -0.0932  -0.1678  
volunteerw~k |  -0.1274  -0.0818   0.1177  -0.0762   0.0374   0.2576   0.2199  
      hehelf |  -0.1715  -0.4115   0.2348  -0.1705   0.0083   0.2288   0.2923  
         dep |   0.1458   0.2854  -0.1243   0.1089   0.1295  -0.1816  -0.2160  
cognitivea~y |  -0.2644  -0.0932   0.2814  -0.4438   0.0898   0.3377   0.2667  
         alc |  -0.0928  -0.1295   0.0818  -0.1267  -0.2121   0.2098   0.2320  
    groupmem |  -0.0633  -0.0801   0.0577   0.0230   0.0049   0.2824   0.2516  
   w4physact |  -0.1890  -0.2261   0.2696  -0.3264  -0.0864   0.2446   0.2815  
   w4symptom |   0.1143   0.3604  -0.1675   0.2411   0.0576  -0.1934  -0.2553  
  w4function |   0.1713   0.2406  -0.3181   0.2918   0.0516  -0.1542  -0.1956  
       w4vol |  -0.1365  -0.0874   0.1317  -0.1403   0.0161   0.3207   0.2604  
     w4smoke |   0.0372   0.0586  -0.0240  -0.1209  -0.0003  -0.0991  -0.1907  
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  w4srhealth |  -0.1494  -0.3547   0.1637  -0.1844  -0.0163   0.2372   0.2792  
w4cogability |  -0.2044  -0.1047   0.2381  -0.4596   0.0826   0.3437   0.2499  
       w4alc |  -0.1658  -0.1273   0.1360  -0.1656  -0.1897   0.2321   0.2593  
       w4dep |   0.1267   0.2778  -0.1126   0.1379   0.1317  -0.1856  -0.2248  
  w4groupmem |  -0.1604  -0.1070   0.1253  -0.0535   0.0151   0.3304   0.3169  
    w4casp19 |  -0.0987  -0.2925   0.1443  -0.1731   0.0056   0.1832   0.2683  
 
             |    phact sympto~t function    smoke volunt~k   hehelf      dep 
-------------+--------------------------------------------------------------- 
       phact |   1.0000  
symptomcount |  -0.4302   1.0000  
    function |  -0.4586   0.6330   1.0000  
       smoke |  -0.0898   0.0605   0.0548   1.0000  
volunteerw~k |   0.1790  -0.1572  -0.1548  -0.1019   1.0000  
      hehelf |   0.4010  -0.4896  -0.4521  -0.1365   0.1831   1.0000  
         dep |  -0.2502   0.3456   0.3358   0.0705  -0.1114  -0.3694   1.0000  
cognitivea~y |   0.2555  -0.2164  -0.2124  -0.0399   0.1667   0.2406  -0.1498  
         alc |   0.1693  -0.1749  -0.1609   0.0332   0.0578   0.1800  -0.1334  
    groupmem |   0.2066  -0.1269  -0.1213  -0.1321   0.3689   0.1653  -0.1013  
   w4physact |   0.4955  -0.3741  -0.3713  -0.1037   0.1568   0.3641  -0.2203  
   w4symptom |  -0.3448   0.5781   0.4665   0.1035  -0.1259  -0.4425   0.2953  
  w4function |  -0.3641   0.4616   0.6061   0.0457  -0.1312  -0.3676   0.2434  
       w4vol |   0.1968  -0.1532  -0.1557  -0.1270   0.4751   0.1804  -0.1174  
     w4smoke |  -0.0850   0.0820   0.0701   0.6205  -0.0939  -0.1259   0.0904  
  w4srhealth |   0.3293  -0.4043  -0.3770  -0.1459   0.1316   0.6283  -0.3088  
w4cogability |   0.2177  -0.2020  -0.1807  -0.0621   0.1604   0.2079  -0.1462  
       w4alc |   0.1916  -0.1981  -0.1814   0.0024   0.0811   0.1990  -0.1427  
       w4dep |  -0.2306   0.3054   0.3136   0.0792  -0.0928  -0.3247   0.4339  
  w4groupmem |   0.2408  -0.1603  -0.1481  -0.1700   0.3838   0.2160  -0.1263  
    w4casp19 |   0.2718  -0.3465  -0.3317  -0.1100   0.1247   0.4354  -0.3439  
 
             | cognit~y      alc groupmem w4phys~t w4symp~m w4func~n    w4vol 
-------------+--------------------------------------------------------------- 
cognitivea~y |   1.0000  
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         alc |   0.1248   1.0000  
    groupmem |   0.1113   0.1321   1.0000  
   w4physact |   0.2583   0.1807   0.1749   1.0000  
   w4symptom |  -0.1835  -0.1758  -0.1076  -0.4082   1.0000  
  w4function |  -0.2572  -0.1572  -0.0850  -0.4680   0.4652   1.0000  
       w4vol |   0.2362   0.0961   0.3600   0.2554  -0.1635  -0.1903   1.0000  
     w4smoke |  -0.0144  -0.0651  -0.1439  -0.1032   0.0859   0.0307  -0.1131  
  w4srhealth |   0.2265   0.1763   0.1400   0.4106  -0.5202  -0.4396   0.2104  
w4cogability |   0.5832   0.1205   0.1198   0.2829  -0.2429  -0.2520   0.2455  
       w4alc |   0.1610   0.6525   0.1198   0.2581  -0.1895  -0.2446   0.1459  
       w4dep |  -0.1584  -0.1353  -0.0975  -0.2827   0.3858   0.3388  -0.1389  
  w4groupmem |   0.1986   0.1384   0.5966   0.2814  -0.1526  -0.1867   0.4572  
    w4casp19 |   0.1802   0.1590   0.1558   0.3211  -0.4019  -0.3917   0.1796  
 
             |  w4smoke w4srhe~h w4coga~y    w4alc    w4dep w4grou~m w4casp19 
-------------+--------------------------------------------------------------- 
     w4smoke |   1.0000  
  w4srhealth |  -0.1211   1.0000  
w4cogability |  -0.0345   0.2585   1.0000  
       w4alc |  -0.0792   0.2169   0.1786   1.0000  
       w4dep |   0.0800  -0.4030  -0.1927  -0.1755   1.0000  
  w4groupmem |  -0.1745   0.2151   0.2155   0.2824  -0.1467   1.0000  
    w4casp19 |  -0.1122   0.5114   0.2105   0.1696  -0.4561   0.2110   1.0000  
 
             | m_w4ph~t    Pain2     cen2     age2     sex2 educat~n   wealth 
-------------+--------------------------------------------------------------- 
 m_w4physact |   1.0000  
       Pain2 |   0.0454   1.0000  
        cen2 |  -0.3317  -0.0615   1.0000  
        age2 |  -0.0516   0.0692  -0.3038   1.0000  
        sex2 |  -0.0050   0.0794   0.0656   0.0013   1.0000  
   education |  -0.1308  -0.1299   0.1479  -0.2689  -0.1542   1.0000  
      wealth |  -0.1265  -0.1706   0.1653  -0.1523  -0.0508   0.4057   1.0000  
       phact |  -0.1673  -0.2480   0.2767  -0.2889  -0.0687   0.2443   0.2821  
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symptomcount |   0.1390   0.3735  -0.2519   0.2414   0.0453  -0.1771  -0.2402  
    function |   0.1210   0.3496  -0.2439   0.2113   0.0546  -0.1470  -0.2166  
       smoke |   0.0528   0.0516  -0.0686  -0.0585  -0.1252  -0.0932  -0.1678  
volunteerw~k |  -0.1142  -0.0818   0.1177  -0.0762   0.0374   0.2576   0.2199  
      hehelf |  -0.1494  -0.4115   0.2348  -0.1705   0.0083   0.2288   0.2923  
         dep |   0.0624   0.2854  -0.1243   0.1089   0.1295  -0.1816  -0.2160  
cognitivea~y |  -0.1791  -0.0932   0.2814  -0.4438   0.0898   0.3377   0.2667  
         alc |  -0.0391  -0.1295   0.0818  -0.1267  -0.2121   0.2098   0.2320  
    groupmem |  -0.0830  -0.0801   0.0577   0.0230   0.0049   0.2824   0.2516  
         tot |  -0.0884  -0.3145   0.1849  -0.1193   0.0296   0.1667   0.2999  
   w4symptom |        .   0.3604  -0.1675   0.2411   0.0576  -0.1934  -0.2553  
  w4function |        .   0.2406  -0.3181   0.2918   0.0516  -0.1542  -0.1956  
       w4vol |        .  -0.0874   0.1317  -0.1403   0.0161   0.3207   0.2604  
     w4smoke |        .   0.0586  -0.0240  -0.1209  -0.0003  -0.0991  -0.1907  
  w4srhealth |        .  -0.3547   0.1637  -0.1844  -0.0163   0.2372   0.2792  
w4cogability |        .  -0.1047   0.2381  -0.4596   0.0826   0.3437   0.2499  
       w4alc |        .  -0.1273   0.1360  -0.1656  -0.1897   0.2321   0.2593  
       w4dep |        .   0.2778  -0.1126   0.1379   0.1317  -0.1856  -0.2248  
  w4groupmem |        .  -0.1070   0.1253  -0.0535   0.0151   0.3304   0.3169  
    w4casp19 |        .  -0.2925   0.1443  -0.1731   0.0056   0.1832   0.2683  
 
             |    phact sympto~t function    smoke volunt~k   hehelf      dep 
-------------+--------------------------------------------------------------- 
       phact |   1.0000  
symptomcount |  -0.4302   1.0000  
    function |  -0.4586   0.6330   1.0000  
       smoke |  -0.0898   0.0605   0.0548   1.0000  
volunteerw~k |   0.1790  -0.1572  -0.1548  -0.1019   1.0000  
      hehelf |   0.4010  -0.4896  -0.4521  -0.1365   0.1831   1.0000  
         dep |  -0.2502   0.3456   0.3358   0.0705  -0.1114  -0.3694   1.0000  
cognitivea~y |   0.2555  -0.2164  -0.2124  -0.0399   0.1667   0.2406  -0.1498  
         alc |   0.1693  -0.1749  -0.1609   0.0332   0.0578   0.1800  -0.1334  
    groupmem |   0.2066  -0.1269  -0.1213  -0.1321   0.3689   0.1653  -0.1013  
         tot |   0.3254  -0.4203  -0.4205  -0.1107   0.1556   0.4946  -0.4144  
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   w4symptom |  -0.3448   0.5781   0.4665   0.1035  -0.1259  -0.4425   0.2953  
  w4function |  -0.3641   0.4616   0.6061   0.0457  -0.1312  -0.3676   0.2434  
       w4vol |   0.1968  -0.1532  -0.1557  -0.1270   0.4751   0.1804  -0.1174  
     w4smoke |  -0.0850   0.0820   0.0701   0.6205  -0.0939  -0.1259   0.0904  
  w4srhealth |   0.3293  -0.4043  -0.3770  -0.1459   0.1316   0.6283  -0.3088  
w4cogability |   0.2177  -0.2020  -0.1807  -0.0621   0.1604   0.2079  -0.1462  
       w4alc |   0.1916  -0.1981  -0.1814   0.0024   0.0811   0.1990  -0.1427  
       w4dep |  -0.2306   0.3054   0.3136   0.0792  -0.0928  -0.3247   0.4339  
  w4groupmem |   0.2408  -0.1603  -0.1481  -0.1700   0.3838   0.2160  -0.1263  
    w4casp19 |   0.2718  -0.3465  -0.3317  -0.1100   0.1247   0.4354  -0.3439  
 
             | cognit~y      alc groupmem      tot w4symp~m w4func~n    w4vol 
-------------+--------------------------------------------------------------- 
cognitivea~y |   1.0000  
         alc |   0.1248   1.0000  
    groupmem |   0.1113   0.1321   1.0000  
         tot |   0.1868   0.1640   0.1924   1.0000  
   w4symptom |  -0.1835  -0.1758  -0.1076  -0.3523   1.0000  
  w4function |  -0.2572  -0.1572  -0.0850  -0.3393   0.4652   1.0000  
       w4vol |   0.2362   0.0961   0.3600   0.1745  -0.1635  -0.1903   1.0000  
     w4smoke |  -0.0144  -0.0651  -0.1439  -0.1311   0.0859   0.0307  -0.1131  
  w4srhealth |   0.2265   0.1763   0.1400   0.4413  -0.5202  -0.4396   0.2104  
w4cogability |   0.5832   0.1205   0.1198   0.1618  -0.2429  -0.2520   0.2455  
       w4alc |   0.1610   0.6525   0.1198   0.1660  -0.1895  -0.2446   0.1459  
       w4dep |  -0.1584  -0.1353  -0.0975  -0.3725   0.3858   0.3388  -0.1389  
  w4groupmem |   0.1986   0.1384   0.5966   0.2120  -0.1526  -0.1867   0.4572  
    w4casp19 |   0.1802   0.1590   0.1558   0.7096  -0.4019  -0.3917   0.1796  
 
             |  w4smoke w4srhe~h w4coga~y    w4alc    w4dep w4grou~m w4casp19 
-------------+--------------------------------------------------------------- 
     w4smoke |   1.0000  
  w4srhealth |  -0.1211   1.0000  
w4cogability |  -0.0345   0.2585   1.0000  
       w4alc |  -0.0792   0.2169   0.1786   1.0000  
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       w4dep |   0.0800  -0.4030  -0.1927  -0.1755   1.0000  
  w4groupmem |  -0.1745   0.2151   0.2155   0.2824  -0.1467   1.0000  
    w4casp19 |  -0.1122   0.5114   0.2105   0.1696  -0.4561   0.2110   1.0000  
 
             | m_w4sy~m    Pain2     cen2     age2     sex2 educat~n   wealth 
-------------+--------------------------------------------------------------- 
 m_w4symptom |   1.0000  
       Pain2 |   0.0454   1.0000  
        cen2 |  -0.3317  -0.0615   1.0000  
        age2 |  -0.0516   0.0692  -0.3038   1.0000  
        sex2 |  -0.0050   0.0794   0.0656   0.0013   1.0000  
   education |  -0.1308  -0.1299   0.1479  -0.2689  -0.1542   1.0000  
      wealth |  -0.1265  -0.1706   0.1653  -0.1523  -0.0508   0.4057   1.0000  
       phact |  -0.1673  -0.2480   0.2767  -0.2889  -0.0687   0.2443   0.2821  
symptomcount |   0.1390   0.3735  -0.2519   0.2414   0.0453  -0.1771  -0.2402  
    function |   0.1210   0.3496  -0.2439   0.2113   0.0546  -0.1470  -0.2166  
       smoke |   0.0528   0.0516  -0.0686  -0.0585  -0.1252  -0.0932  -0.1678  
volunteerw~k |  -0.1142  -0.0818   0.1177  -0.0762   0.0374   0.2576   0.2199  
      hehelf |  -0.1494  -0.4115   0.2348  -0.1705   0.0083   0.2288   0.2923  
         dep |   0.0624   0.2854  -0.1243   0.1089   0.1295  -0.1816  -0.2160  
cognitivea~y |  -0.1791  -0.0932   0.2814  -0.4438   0.0898   0.3377   0.2667  
         alc |  -0.0391  -0.1295   0.0818  -0.1267  -0.2121   0.2098   0.2320  
    groupmem |  -0.0830  -0.0801   0.0577   0.0230   0.0049   0.2824   0.2516  
         tot |  -0.0884  -0.3145   0.1849  -0.1193   0.0296   0.1667   0.2999  
   w4physact |        .  -0.2261   0.2696  -0.3264  -0.0864   0.2446   0.2815  
  w4function |        .   0.2406  -0.3181   0.2918   0.0516  -0.1542  -0.1956  
       w4vol |        .  -0.0874   0.1317  -0.1403   0.0161   0.3207   0.2604  
     w4smoke |        .   0.0586  -0.0240  -0.1209  -0.0003  -0.0991  -0.1907  
  w4srhealth |        .  -0.3547   0.1637  -0.1844  -0.0163   0.2372   0.2792  
w4cogability |        .  -0.1047   0.2381  -0.4596   0.0826   0.3437   0.2499  
       w4alc |        .  -0.1273   0.1360  -0.1656  -0.1897   0.2321   0.2593  
       w4dep |        .   0.2778  -0.1126   0.1379   0.1317  -0.1856  -0.2248  
  w4groupmem |        .  -0.1070   0.1253  -0.0535   0.0151   0.3304   0.3169  
    w4casp19 |        .  -0.2925   0.1443  -0.1731   0.0056   0.1832   0.2683  
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             |    phact sympto~t function    smoke volunt~k   hehelf      dep 
-------------+--------------------------------------------------------------- 
       phact |   1.0000  
symptomcount |  -0.4302   1.0000  
    function |  -0.4586   0.6330   1.0000  
       smoke |  -0.0898   0.0605   0.0548   1.0000  
volunteerw~k |   0.1790  -0.1572  -0.1548  -0.1019   1.0000  
      hehelf |   0.4010  -0.4896  -0.4521  -0.1365   0.1831   1.0000  
         dep |  -0.2502   0.3456   0.3358   0.0705  -0.1114  -0.3694   1.0000  
cognitivea~y |   0.2555  -0.2164  -0.2124  -0.0399   0.1667   0.2406  -0.1498  
         alc |   0.1693  -0.1749  -0.1609   0.0332   0.0578   0.1800  -0.1334  
    groupmem |   0.2066  -0.1269  -0.1213  -0.1321   0.3689   0.1653  -0.1013  
         tot |   0.3254  -0.4203  -0.4205  -0.1107   0.1556   0.4946  -0.4144  
   w4physact |   0.4955  -0.3741  -0.3713  -0.1037   0.1568   0.3641  -0.2203  
  w4function |  -0.3641   0.4616   0.6061   0.0457  -0.1312  -0.3676   0.2434  
       w4vol |   0.1968  -0.1532  -0.1557  -0.1270   0.4751   0.1804  -0.1174  
     w4smoke |  -0.0850   0.0820   0.0701   0.6205  -0.0939  -0.1259   0.0904  
  w4srhealth |   0.3293  -0.4043  -0.3770  -0.1459   0.1316   0.6283  -0.3088  
w4cogability |   0.2177  -0.2020  -0.1807  -0.0621   0.1604   0.2079  -0.1462  
       w4alc |   0.1916  -0.1981  -0.1814   0.0024   0.0811   0.1990  -0.1427  
       w4dep |  -0.2306   0.3054   0.3136   0.0792  -0.0928  -0.3247   0.4339  
  w4groupmem |   0.2408  -0.1603  -0.1481  -0.1700   0.3838   0.2160  -0.1263  
    w4casp19 |   0.2718  -0.3465  -0.3317  -0.1100   0.1247   0.4354  -0.3439  
 
             | cognit~y      alc groupmem      tot w4phys~t w4func~n    w4vol 
-------------+--------------------------------------------------------------- 
cognitivea~y |   1.0000  
         alc |   0.1248   1.0000  
    groupmem |   0.1113   0.1321   1.0000  
         tot |   0.1868   0.1640   0.1924   1.0000  
   w4physact |   0.2583   0.1807   0.1749   0.2924   1.0000  
  w4function |  -0.2572  -0.1572  -0.0850  -0.3393  -0.4680   1.0000  
       w4vol |   0.2362   0.0961   0.3600   0.1745   0.2554  -0.1903   1.0000  
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     w4smoke |  -0.0144  -0.0651  -0.1439  -0.1311  -0.1032   0.0307  -0.1131  
  w4srhealth |   0.2265   0.1763   0.1400   0.4413   0.4106  -0.4396   0.2104  
w4cogability |   0.5832   0.1205   0.1198   0.1618   0.2829  -0.2520   0.2455  
       w4alc |   0.1610   0.6525   0.1198   0.1660   0.2581  -0.2446   0.1459  
       w4dep |  -0.1584  -0.1353  -0.0975  -0.3725  -0.2827   0.3388  -0.1389  
  w4groupmem |   0.1986   0.1384   0.5966   0.2120   0.2814  -0.1867   0.4572  
    w4casp19 |   0.1802   0.1590   0.1558   0.7096   0.3211  -0.3917   0.1796  
 
             |  w4smoke w4srhe~h w4coga~y    w4alc    w4dep w4grou~m w4casp19 
-------------+--------------------------------------------------------------- 
     w4smoke |   1.0000  
  w4srhealth |  -0.1211   1.0000  
w4cogability |  -0.0345   0.2585   1.0000  
       w4alc |  -0.0792   0.2169   0.1786   1.0000  
       w4dep |   0.0800  -0.4030  -0.1927  -0.1755   1.0000  
  w4groupmem |  -0.1745   0.2151   0.2155   0.2824  -0.1467   1.0000  
    w4casp19 |  -0.1122   0.5114   0.2105   0.1696  -0.4561   0.2110   1.0000  
 
             | m_w4fu~n    Pain2     cen2     age2     sex2 educat~n   wealth 
-------------+--------------------------------------------------------------- 
m_w4function |   1.0000  
       Pain2 |   0.0454   1.0000  
        cen2 |  -0.3317  -0.0615   1.0000  
        age2 |  -0.0516   0.0692  -0.3038   1.0000  
        sex2 |  -0.0050   0.0794   0.0656   0.0013   1.0000  
   education |  -0.1308  -0.1299   0.1479  -0.2689  -0.1542   1.0000  
      wealth |  -0.1265  -0.1706   0.1653  -0.1523  -0.0508   0.4057   1.0000  
       phact |  -0.1673  -0.2480   0.2767  -0.2889  -0.0687   0.2443   0.2821  
symptomcount |   0.1390   0.3735  -0.2519   0.2414   0.0453  -0.1771  -0.2402  
    function |   0.1210   0.3496  -0.2439   0.2113   0.0546  -0.1470  -0.2166  
       smoke |   0.0528   0.0516  -0.0686  -0.0585  -0.1252  -0.0932  -0.1678  
volunteerw~k |  -0.1142  -0.0818   0.1177  -0.0762   0.0374   0.2576   0.2199  
      hehelf |  -0.1494  -0.4115   0.2348  -0.1705   0.0083   0.2288   0.2923  
         dep |   0.0624   0.2854  -0.1243   0.1089   0.1295  -0.1816  -0.2160  
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cognitivea~y |  -0.1791  -0.0932   0.2814  -0.4438   0.0898   0.3377   0.2667  
         alc |  -0.0391  -0.1295   0.0818  -0.1267  -0.2121   0.2098   0.2320  
    groupmem |  -0.0830  -0.0801   0.0577   0.0230   0.0049   0.2824   0.2516  
         tot |  -0.0884  -0.3145   0.1849  -0.1193   0.0296   0.1667   0.2999  
   w4physact |        .  -0.2261   0.2696  -0.3264  -0.0864   0.2446   0.2815  
   w4symptom |        .   0.3604  -0.1675   0.2411   0.0576  -0.1934  -0.2553  
       w4vol |        .  -0.0874   0.1317  -0.1403   0.0161   0.3207   0.2604  
     w4smoke |        .   0.0586  -0.0240  -0.1209  -0.0003  -0.0991  -0.1907  
  w4srhealth |        .  -0.3547   0.1637  -0.1844  -0.0163   0.2372   0.2792  
w4cogability |        .  -0.1047   0.2381  -0.4596   0.0826   0.3437   0.2499  
       w4alc |        .  -0.1273   0.1360  -0.1656  -0.1897   0.2321   0.2593  
       w4dep |        .   0.2778  -0.1126   0.1379   0.1317  -0.1856  -0.2248  
  w4groupmem |        .  -0.1070   0.1253  -0.0535   0.0151   0.3304   0.3169  
    w4casp19 |        .  -0.2925   0.1443  -0.1731   0.0056   0.1832   0.2683  
 
             |    phact sympto~t function    smoke volunt~k   hehelf      dep 
-------------+--------------------------------------------------------------- 
       phact |   1.0000  
symptomcount |  -0.4302   1.0000  
    function |  -0.4586   0.6330   1.0000  
       smoke |  -0.0898   0.0605   0.0548   1.0000  
volunteerw~k |   0.1790  -0.1572  -0.1548  -0.1019   1.0000  
      hehelf |   0.4010  -0.4896  -0.4521  -0.1365   0.1831   1.0000  
         dep |  -0.2502   0.3456   0.3358   0.0705  -0.1114  -0.3694   1.0000  
cognitivea~y |   0.2555  -0.2164  -0.2124  -0.0399   0.1667   0.2406  -0.1498  
         alc |   0.1693  -0.1749  -0.1609   0.0332   0.0578   0.1800  -0.1334  
    groupmem |   0.2066  -0.1269  -0.1213  -0.1321   0.3689   0.1653  -0.1013  
         tot |   0.3254  -0.4203  -0.4205  -0.1107   0.1556   0.4946  -0.4144  
   w4physact |   0.4955  -0.3741  -0.3713  -0.1037   0.1568   0.3641  -0.2203  
   w4symptom |  -0.3448   0.5781   0.4665   0.1035  -0.1259  -0.4425   0.2953  
       w4vol |   0.1968  -0.1532  -0.1557  -0.1270   0.4751   0.1804  -0.1174  
     w4smoke |  -0.0850   0.0820   0.0701   0.6205  -0.0939  -0.1259   0.0904  
  w4srhealth |   0.3293  -0.4043  -0.3770  -0.1459   0.1316   0.6283  -0.3088  
w4cogability |   0.2177  -0.2020  -0.1807  -0.0621   0.1604   0.2079  -0.1462  
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       w4alc |   0.1916  -0.1981  -0.1814   0.0024   0.0811   0.1990  -0.1427  
       w4dep |  -0.2306   0.3054   0.3136   0.0792  -0.0928  -0.3247   0.4339  
  w4groupmem |   0.2408  -0.1603  -0.1481  -0.1700   0.3838   0.2160  -0.1263  
    w4casp19 |   0.2718  -0.3465  -0.3317  -0.1100   0.1247   0.4354  -0.3439  
 
             | cognit~y      alc groupmem      tot w4phys~t w4symp~m    w4vol 
-------------+--------------------------------------------------------------- 
cognitivea~y |   1.0000  
         alc |   0.1248   1.0000  
    groupmem |   0.1113   0.1321   1.0000  
         tot |   0.1868   0.1640   0.1924   1.0000  
   w4physact |   0.2583   0.1807   0.1749   0.2924   1.0000  
   w4symptom |  -0.1835  -0.1758  -0.1076  -0.3523  -0.4082   1.0000  
       w4vol |   0.2362   0.0961   0.3600   0.1745   0.2554  -0.1635   1.0000  
     w4smoke |  -0.0144  -0.0651  -0.1439  -0.1311  -0.1032   0.0859  -0.1131  
  w4srhealth |   0.2265   0.1763   0.1400   0.4413   0.4106  -0.5202   0.2104  
w4cogability |   0.5832   0.1205   0.1198   0.1618   0.2829  -0.2429   0.2455  
       w4alc |   0.1610   0.6525   0.1198   0.1660   0.2581  -0.1895   0.1459  
       w4dep |  -0.1584  -0.1353  -0.0975  -0.3725  -0.2827   0.3858  -0.1389  
  w4groupmem |   0.1986   0.1384   0.5966   0.2120   0.2814  -0.1526   0.4572  
    w4casp19 |   0.1802   0.1590   0.1558   0.7096   0.3211  -0.4019   0.1796  
 
             |  w4smoke w4srhe~h w4coga~y    w4alc    w4dep w4grou~m w4casp19 
-------------+--------------------------------------------------------------- 
     w4smoke |   1.0000  
  w4srhealth |  -0.1211   1.0000  
w4cogability |  -0.0345   0.2585   1.0000  
       w4alc |  -0.0792   0.2169   0.1786   1.0000  
       w4dep |   0.0800  -0.4030  -0.1927  -0.1755   1.0000  
  w4groupmem |  -0.1745   0.2151   0.2155   0.2824  -0.1467   1.0000  
    w4casp19 |  -0.1122   0.5114   0.2105   0.1696  -0.4561   0.2110   1.0000  
 
             |  m_w4vol    Pain2     cen2     age2     sex2 educat~n   wealth 
-------------+--------------------------------------------------------------- 
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     m_w4vol |   1.0000  
       Pain2 |   0.0448   1.0000  
        cen2 |  -0.3340  -0.0615   1.0000  
        age2 |  -0.0490   0.0692  -0.3038   1.0000  
        sex2 |  -0.0054   0.0794   0.0656   0.0013   1.0000  
   education |  -0.1319  -0.1299   0.1479  -0.2689  -0.1542   1.0000  
      wealth |  -0.1287  -0.1706   0.1653  -0.1523  -0.0508   0.4057   1.0000  
       phact |  -0.1698  -0.2480   0.2767  -0.2889  -0.0687   0.2443   0.2821  
symptomcount |   0.1397   0.3735  -0.2519   0.2414   0.0453  -0.1771  -0.2402  
    function |   0.1219   0.3496  -0.2439   0.2113   0.0546  -0.1470  -0.2166  
       smoke |   0.0513   0.0516  -0.0686  -0.0585  -0.1252  -0.0932  -0.1678  
volunteerw~k |  -0.1155  -0.0818   0.1177  -0.0762   0.0374   0.2576   0.2199  
      hehelf |  -0.1507  -0.4115   0.2348  -0.1705   0.0083   0.2288   0.2923  
         dep |   0.0608   0.2854  -0.1243   0.1089   0.1295  -0.1816  -0.2160  
cognitivea~y |  -0.1827  -0.0932   0.2814  -0.4438   0.0898   0.3377   0.2667  
         alc |  -0.0399  -0.1295   0.0818  -0.1267  -0.2121   0.2098   0.2320  
    groupmem |  -0.0841  -0.0801   0.0577   0.0230   0.0049   0.2824   0.2516  
         tot |  -0.0890  -0.3145   0.1849  -0.1193   0.0296   0.1667   0.2999  
   w4physact |  -0.0533  -0.2261   0.2696  -0.3264  -0.0864   0.2446   0.2815  
   w4symptom |   0.0446   0.3604  -0.1675   0.2411   0.0576  -0.1934  -0.2553  
  w4function |   0.0767   0.2406  -0.3181   0.2918   0.0516  -0.1542  -0.1956  
     w4smoke |  -0.0115   0.0586  -0.0240  -0.1209  -0.0003  -0.0991  -0.1907  
  w4srhealth |  -0.0416  -0.3547   0.1637  -0.1844  -0.0163   0.2372   0.2792  
w4cogability |  -0.0746  -0.1047   0.2381  -0.4596   0.0826   0.3437   0.2499  
       w4alc |  -0.0427  -0.1273   0.1360  -0.1656  -0.1897   0.2321   0.2593  
       w4dep |        .   0.2778  -0.1126   0.1379   0.1317  -0.1856  -0.2248  
  w4groupmem |  -0.0501  -0.1070   0.1253  -0.0535   0.0151   0.3304   0.3169  
    w4casp19 |  -0.0012  -0.2925   0.1443  -0.1731   0.0056   0.1832   0.2683  
 
             |    phact sympto~t function    smoke volunt~k   hehelf      dep 
-------------+--------------------------------------------------------------- 
       phact |   1.0000  
symptomcount |  -0.4302   1.0000  
    function |  -0.4586   0.6330   1.0000  
394 
 
       smoke |  -0.0898   0.0605   0.0548   1.0000  
volunteerw~k |   0.1790  -0.1572  -0.1548  -0.1019   1.0000  
      hehelf |   0.4010  -0.4896  -0.4521  -0.1365   0.1831   1.0000  
         dep |  -0.2502   0.3456   0.3358   0.0705  -0.1114  -0.3694   1.0000  
cognitivea~y |   0.2555  -0.2164  -0.2124  -0.0399   0.1667   0.2406  -0.1498  
         alc |   0.1693  -0.1749  -0.1609   0.0332   0.0578   0.1800  -0.1334  
    groupmem |   0.2066  -0.1269  -0.1213  -0.1321   0.3689   0.1653  -0.1013  
         tot |   0.3254  -0.4203  -0.4205  -0.1107   0.1556   0.4946  -0.4144  
   w4physact |   0.4955  -0.3741  -0.3713  -0.1037   0.1568   0.3641  -0.2203  
   w4symptom |  -0.3448   0.5781   0.4665   0.1035  -0.1259  -0.4425   0.2953  
  w4function |  -0.3641   0.4616   0.6061   0.0457  -0.1312  -0.3676   0.2434  
     w4smoke |  -0.0850   0.0820   0.0701   0.6205  -0.0939  -0.1259   0.0904  
  w4srhealth |   0.3293  -0.4043  -0.3770  -0.1459   0.1316   0.6283  -0.3088  
w4cogability |   0.2177  -0.2020  -0.1807  -0.0621   0.1604   0.2079  -0.1462  
       w4alc |   0.1916  -0.1981  -0.1814   0.0024   0.0811   0.1990  -0.1427  
       w4dep |  -0.2306   0.3054   0.3136   0.0792  -0.0928  -0.3247   0.4339  
  w4groupmem |   0.2408  -0.1603  -0.1481  -0.1700   0.3838   0.2160  -0.1263  
    w4casp19 |   0.2718  -0.3465  -0.3317  -0.1100   0.1247   0.4354  -0.3439  
 
             | cognit~y      alc groupmem      tot w4phys~t w4symp~m w4func~n 
-------------+--------------------------------------------------------------- 
cognitivea~y |   1.0000  
         alc |   0.1248   1.0000  
    groupmem |   0.1113   0.1321   1.0000  
         tot |   0.1868   0.1640   0.1924   1.0000  
   w4physact |   0.2583   0.1807   0.1749   0.2924   1.0000  
   w4symptom |  -0.1835  -0.1758  -0.1076  -0.3523  -0.4082   1.0000  
  w4function |  -0.2572  -0.1572  -0.0850  -0.3393  -0.4680   0.4652   1.0000  
     w4smoke |  -0.0144  -0.0651  -0.1439  -0.1311  -0.1032   0.0859   0.0307  
  w4srhealth |   0.2265   0.1763   0.1400   0.4413   0.4106  -0.5202  -0.4396  
w4cogability |   0.5832   0.1205   0.1198   0.1618   0.2829  -0.2429  -0.2520  
       w4alc |   0.1610   0.6525   0.1198   0.1660   0.2581  -0.1895  -0.2446  
       w4dep |  -0.1584  -0.1353  -0.0975  -0.3725  -0.2827   0.3858   0.3388  
  w4groupmem |   0.1986   0.1384   0.5966   0.2120   0.2814  -0.1526  -0.1867  
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    w4casp19 |   0.1802   0.1590   0.1558   0.7096   0.3211  -0.4019  -0.3917  
 
             |  w4smoke w4srhe~h w4coga~y    w4alc    w4dep w4grou~m w4casp19 
-------------+--------------------------------------------------------------- 
     w4smoke |   1.0000  
  w4srhealth |  -0.1211   1.0000  
w4cogability |  -0.0345   0.2585   1.0000  
       w4alc |  -0.0792   0.2169   0.1786   1.0000  
       w4dep |   0.0800  -0.4030  -0.1927  -0.1755   1.0000  
  w4groupmem |  -0.1745   0.2151   0.2155   0.2824  -0.1467   1.0000  
    w4casp19 |  -0.1122   0.5114   0.2105   0.1696  -0.4561   0.2110   1.0000  
 
             | m_w4sm~e    Pain2     cen2     age2     sex2 educat~n   wealth 
-------------+--------------------------------------------------------------- 
   m_w4smoke |   1.0000  
       Pain2 |   0.0442   1.0000  
        cen2 |  -0.3303  -0.0615   1.0000  
        age2 |  -0.0451   0.0692  -0.3038   1.0000  
        sex2 |  -0.0041   0.0794   0.0656   0.0013   1.0000  
   education |  -0.1335  -0.1299   0.1479  -0.2689  -0.1542   1.0000  
      wealth |  -0.1279  -0.1706   0.1653  -0.1523  -0.0508   0.4057   1.0000  
       phact |  -0.1679  -0.2480   0.2767  -0.2889  -0.0687   0.2443   0.2821  
symptomcount |   0.1433   0.3735  -0.2519   0.2414   0.0453  -0.1771  -0.2402  
    function |   0.1229   0.3496  -0.2439   0.2113   0.0546  -0.1470  -0.2166  
       smoke |   0.0529   0.0516  -0.0686  -0.0585  -0.1252  -0.0932  -0.1678  
volunteerw~k |  -0.1152  -0.0818   0.1177  -0.0762   0.0374   0.2576   0.2199  
      hehelf |  -0.1479  -0.4115   0.2348  -0.1705   0.0083   0.2288   0.2923  
         dep |   0.0622   0.2854  -0.1243   0.1089   0.1295  -0.1816  -0.2160  
cognitivea~y |  -0.1804  -0.0932   0.2814  -0.4438   0.0898   0.3377   0.2667  
         alc |  -0.0399  -0.1295   0.0818  -0.1267  -0.2121   0.2098   0.2320  
    groupmem |  -0.0879  -0.0801   0.0577   0.0230   0.0049   0.2824   0.2516  
         tot |  -0.0881  -0.3145   0.1849  -0.1193   0.0296   0.1667   0.2999  
   w4physact |  -0.0376  -0.2261   0.2696  -0.3264  -0.0864   0.2446   0.2815  
   w4symptom |   0.0333   0.3604  -0.1675   0.2411   0.0576  -0.1934  -0.2553  
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  w4function |   0.0067   0.2406  -0.3181   0.2918   0.0516  -0.1542  -0.1956  
       w4vol |  -0.0267  -0.0874   0.1317  -0.1403   0.0161   0.3207   0.2604  
  w4srhealth |  -0.0035  -0.3547   0.1637  -0.1844  -0.0163   0.2372   0.2792  
w4cogability |  -0.0593  -0.1047   0.2381  -0.4596   0.0826   0.3437   0.2499  
       w4alc |  -0.0213  -0.1273   0.1360  -0.1656  -0.1897   0.2321   0.2593  
       w4dep |   0.0139   0.2778  -0.1126   0.1379   0.1317  -0.1856  -0.2248  
  w4groupmem |  -0.0383  -0.1070   0.1253  -0.0535   0.0151   0.3304   0.3169  
    w4casp19 |  -0.0210  -0.2925   0.1443  -0.1731   0.0056   0.1832   0.2683  
 
             |    phact sympto~t function    smoke volunt~k   hehelf      dep 
-------------+--------------------------------------------------------------- 
       phact |   1.0000  
symptomcount |  -0.4302   1.0000  
    function |  -0.4586   0.6330   1.0000  
       smoke |  -0.0898   0.0605   0.0548   1.0000  
volunteerw~k |   0.1790  -0.1572  -0.1548  -0.1019   1.0000  
      hehelf |   0.4010  -0.4896  -0.4521  -0.1365   0.1831   1.0000  
         dep |  -0.2502   0.3456   0.3358   0.0705  -0.1114  -0.3694   1.0000  
cognitivea~y |   0.2555  -0.2164  -0.2124  -0.0399   0.1667   0.2406  -0.1498  
         alc |   0.1693  -0.1749  -0.1609   0.0332   0.0578   0.1800  -0.1334  
    groupmem |   0.2066  -0.1269  -0.1213  -0.1321   0.3689   0.1653  -0.1013  
         tot |   0.3254  -0.4203  -0.4205  -0.1107   0.1556   0.4946  -0.4144  
   w4physact |   0.4955  -0.3741  -0.3713  -0.1037   0.1568   0.3641  -0.2203  
   w4symptom |  -0.3448   0.5781   0.4665   0.1035  -0.1259  -0.4425   0.2953  
  w4function |  -0.3641   0.4616   0.6061   0.0457  -0.1312  -0.3676   0.2434  
       w4vol |   0.1968  -0.1532  -0.1557  -0.1270   0.4751   0.1804  -0.1174  
  w4srhealth |   0.3293  -0.4043  -0.3770  -0.1459   0.1316   0.6283  -0.3088  
w4cogability |   0.2177  -0.2020  -0.1807  -0.0621   0.1604   0.2079  -0.1462  
       w4alc |   0.1916  -0.1981  -0.1814   0.0024   0.0811   0.1990  -0.1427  
       w4dep |  -0.2306   0.3054   0.3136   0.0792  -0.0928  -0.3247   0.4339  
  w4groupmem |   0.2408  -0.1603  -0.1481  -0.1700   0.3838   0.2160  -0.1263  
    w4casp19 |   0.2718  -0.3465  -0.3317  -0.1100   0.1247   0.4354  -0.3439  
 
             | cognit~y      alc groupmem      tot w4phys~t w4symp~m w4func~n 
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-------------+--------------------------------------------------------------- 
cognitivea~y |   1.0000  
         alc |   0.1248   1.0000  
    groupmem |   0.1113   0.1321   1.0000  
         tot |   0.1868   0.1640   0.1924   1.0000  
   w4physact |   0.2583   0.1807   0.1749   0.2924   1.0000  
   w4symptom |  -0.1835  -0.1758  -0.1076  -0.3523  -0.4082   1.0000  
  w4function |  -0.2572  -0.1572  -0.0850  -0.3393  -0.4680   0.4652   1.0000  
       w4vol |   0.2362   0.0961   0.3600   0.1745   0.2554  -0.1635  -0.1903  
  w4srhealth |   0.2265   0.1763   0.1400   0.4413   0.4106  -0.5202  -0.4396  
w4cogability |   0.5832   0.1205   0.1198   0.1618   0.2829  -0.2429  -0.2520  
       w4alc |   0.1610   0.6525   0.1198   0.1660   0.2581  -0.1895  -0.2446  
       w4dep |  -0.1584  -0.1353  -0.0975  -0.3725  -0.2827   0.3858   0.3388  
  w4groupmem |   0.1986   0.1384   0.5966   0.2120   0.2814  -0.1526  -0.1867  
    w4casp19 |   0.1802   0.1590   0.1558   0.7096   0.3211  -0.4019  -0.3917  
 
             |    w4vol w4srhe~h w4coga~y    w4alc    w4dep w4grou~m w4casp19 
-------------+--------------------------------------------------------------- 
       w4vol |   1.0000  
  w4srhealth |   0.2104   1.0000  
w4cogability |   0.2455   0.2585   1.0000  
       w4alc |   0.1459   0.2169   0.1786   1.0000  
       w4dep |  -0.1389  -0.4030  -0.1927  -0.1755   1.0000  
  w4groupmem |   0.4572   0.2151   0.2155   0.2824  -0.1467   1.0000  
    w4casp19 |   0.1796   0.5114   0.2105   0.1696  -0.4561   0.2110   1.0000  
 
             | m_w4sr~h    Pain2     cen2     age2     sex2 educat~n   wealth 
-------------+--------------------------------------------------------------- 
m_w4srhealth |   1.0000  
       Pain2 |   0.0456   1.0000  
        cen2 |  -0.3522  -0.0615   1.0000  
        age2 |  -0.0319   0.0692  -0.3038   1.0000  
        sex2 |  -0.0067   0.0794   0.0656   0.0013   1.0000  
   education |  -0.1412  -0.1299   0.1479  -0.2689  -0.1542   1.0000  
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      wealth |  -0.1342  -0.1706   0.1653  -0.1523  -0.0508   0.4057   1.0000  
       phact |  -0.1813  -0.2480   0.2767  -0.2889  -0.0687   0.2443   0.2821  
symptomcount |   0.1459   0.3735  -0.2519   0.2414   0.0453  -0.1771  -0.2402  
    function |   0.1432   0.3496  -0.2439   0.2113   0.0546  -0.1470  -0.2166  
       smoke |   0.0557   0.0516  -0.0686  -0.0585  -0.1252  -0.0932  -0.1678  
volunteerw~k |  -0.1231  -0.0818   0.1177  -0.0762   0.0374   0.2576   0.2199  
      hehelf |  -0.1610  -0.4115   0.2348  -0.1705   0.0083   0.2288   0.2923  
         dep |   0.0672   0.2854  -0.1243   0.1089   0.1295  -0.1816  -0.2160  
cognitivea~y |  -0.2069  -0.0932   0.2814  -0.4438   0.0898   0.3377   0.2667  
         alc |  -0.0438  -0.1295   0.0818  -0.1267  -0.2121   0.2098   0.2320  
    groupmem |  -0.0885  -0.0801   0.0577   0.0230   0.0049   0.2824   0.2516  
         tot |  -0.1013  -0.3145   0.1849  -0.1193   0.0296   0.1667   0.2999  
   w4physact |  -0.1730  -0.2261   0.2696  -0.3264  -0.0864   0.2446   0.2815  
   w4symptom |  -0.0814   0.3604  -0.1675   0.2411   0.0576  -0.1934  -0.2553  
  w4function |   0.3606   0.2406  -0.3181   0.2918   0.0516  -0.1542  -0.1956  
       w4vol |  -0.1249  -0.0874   0.1317  -0.1403   0.0161   0.3207   0.2604  
     w4smoke |  -0.0059   0.0586  -0.0240  -0.1209  -0.0003  -0.0991  -0.1907  
w4cogability |   0.0031  -0.1047   0.2381  -0.4596   0.0826   0.3437   0.2499  
       w4alc |  -0.1631  -0.1273   0.1360  -0.1656  -0.1897   0.2321   0.2593  
       w4dep |   0.0192   0.2778  -0.1126   0.1379   0.1317  -0.1856  -0.2248  
  w4groupmem |  -0.1497  -0.1070   0.1253  -0.0535   0.0151   0.3304   0.3169  
    w4casp19 |  -0.0310  -0.2925   0.1443  -0.1731   0.0056   0.1832   0.2683  
 
             |    phact sympto~t function    smoke volunt~k   hehelf      dep 
-------------+--------------------------------------------------------------- 
       phact |   1.0000  
symptomcount |  -0.4302   1.0000  
    function |  -0.4586   0.6330   1.0000  
       smoke |  -0.0898   0.0605   0.0548   1.0000  
volunteerw~k |   0.1790  -0.1572  -0.1548  -0.1019   1.0000  
      hehelf |   0.4010  -0.4896  -0.4521  -0.1365   0.1831   1.0000  
         dep |  -0.2502   0.3456   0.3358   0.0705  -0.1114  -0.3694   1.0000  
cognitivea~y |   0.2555  -0.2164  -0.2124  -0.0399   0.1667   0.2406  -0.1498  
         alc |   0.1693  -0.1749  -0.1609   0.0332   0.0578   0.1800  -0.1334  
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    groupmem |   0.2066  -0.1269  -0.1213  -0.1321   0.3689   0.1653  -0.1013  
         tot |   0.3254  -0.4203  -0.4205  -0.1107   0.1556   0.4946  -0.4144  
   w4physact |   0.4955  -0.3741  -0.3713  -0.1037   0.1568   0.3641  -0.2203  
   w4symptom |  -0.3448   0.5781   0.4665   0.1035  -0.1259  -0.4425   0.2953  
  w4function |  -0.3641   0.4616   0.6061   0.0457  -0.1312  -0.3676   0.2434  
       w4vol |   0.1968  -0.1532  -0.1557  -0.1270   0.4751   0.1804  -0.1174  
     w4smoke |  -0.0850   0.0820   0.0701   0.6205  -0.0939  -0.1259   0.0904  
w4cogability |   0.2177  -0.2020  -0.1807  -0.0621   0.1604   0.2079  -0.1462  
       w4alc |   0.1916  -0.1981  -0.1814   0.0024   0.0811   0.1990  -0.1427  
       w4dep |  -0.2306   0.3054   0.3136   0.0792  -0.0928  -0.3247   0.4339  
  w4groupmem |   0.2408  -0.1603  -0.1481  -0.1700   0.3838   0.2160  -0.1263  
    w4casp19 |   0.2718  -0.3465  -0.3317  -0.1100   0.1247   0.4354  -0.3439  
 
             | cognit~y      alc groupmem      tot w4phys~t w4symp~m w4func~n 
-------------+--------------------------------------------------------------- 
cognitivea~y |   1.0000  
         alc |   0.1248   1.0000  
    groupmem |   0.1113   0.1321   1.0000  
         tot |   0.1868   0.1640   0.1924   1.0000  
   w4physact |   0.2583   0.1807   0.1749   0.2924   1.0000  
   w4symptom |  -0.1835  -0.1758  -0.1076  -0.3523  -0.4082   1.0000  
  w4function |  -0.2572  -0.1572  -0.0850  -0.3393  -0.4680   0.4652   1.0000  
       w4vol |   0.2362   0.0961   0.3600   0.1745   0.2554  -0.1635  -0.1903  
     w4smoke |  -0.0144  -0.0651  -0.1439  -0.1311  -0.1032   0.0859   0.0307  
w4cogability |   0.5832   0.1205   0.1198   0.1618   0.2829  -0.2429  -0.2520  
       w4alc |   0.1610   0.6525   0.1198   0.1660   0.2581  -0.1895  -0.2446  
       w4dep |  -0.1584  -0.1353  -0.0975  -0.3725  -0.2827   0.3858   0.3388  
  w4groupmem |   0.1986   0.1384   0.5966   0.2120   0.2814  -0.1526  -0.1867  
    w4casp19 |   0.1802   0.1590   0.1558   0.7096   0.3211  -0.4019  -0.3917  
 
             |    w4vol  w4smoke w4coga~y    w4alc    w4dep w4grou~m w4casp19 
-------------+--------------------------------------------------------------- 
       w4vol |   1.0000  
     w4smoke |  -0.1131   1.0000  
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w4cogability |   0.2455  -0.0345   1.0000  
       w4alc |   0.1459  -0.0792   0.1786   1.0000  
       w4dep |  -0.1389   0.0800  -0.1927  -0.1755   1.0000  
  w4groupmem |   0.4572  -0.1745   0.2155   0.2824  -0.1467   1.0000  
    w4casp19 |   0.1796  -0.1122   0.2105   0.1696  -0.4561   0.2110   1.0000  
 
             | m_w4co~y    Pain2     cen2     age2     sex2 educat~n   wealth 
-------------+--------------------------------------------------------------- 
m_w4cogabi~y |   1.0000  
       Pain2 |   0.0453   1.0000  
        cen2 |  -0.3540  -0.0615   1.0000  
        age2 |  -0.0288   0.0692  -0.3038   1.0000  
        sex2 |  -0.0068   0.0794   0.0656   0.0013   1.0000  
   education |  -0.1426  -0.1299   0.1479  -0.2689  -0.1542   1.0000  
      wealth |  -0.1373  -0.1706   0.1653  -0.1523  -0.0508   0.4057   1.0000  
       phact |  -0.1838  -0.2480   0.2767  -0.2889  -0.0687   0.2443   0.2821  
symptomcount |   0.1467   0.3735  -0.2519   0.2414   0.0453  -0.1771  -0.2402  
    function |   0.1431   0.3496  -0.2439   0.2113   0.0546  -0.1470  -0.2166  
       smoke |   0.0545   0.0516  -0.0686  -0.0585  -0.1252  -0.0932  -0.1678  
volunteerw~k |  -0.1248  -0.0818   0.1177  -0.0762   0.0374   0.2576   0.2199  
      hehelf |  -0.1621  -0.4115   0.2348  -0.1705   0.0083   0.2288   0.2923  
         dep |   0.0671   0.2854  -0.1243   0.1089   0.1295  -0.1816  -0.2160  
cognitivea~y |  -0.2090  -0.0932   0.2814  -0.4438   0.0898   0.3377   0.2667  
         alc |  -0.0451  -0.1295   0.0818  -0.1267  -0.2121   0.2098   0.2320  
    groupmem |  -0.0889  -0.0801   0.0577   0.0230   0.0049   0.2824   0.2516  
         tot |  -0.1007  -0.3145   0.1849  -0.1193   0.0296   0.1667   0.2999  
   w4physact |  -0.1818  -0.2261   0.2696  -0.3264  -0.0864   0.2446   0.2815  
   w4symptom |  -0.0633   0.3604  -0.1675   0.2411   0.0576  -0.1934  -0.2553  
  w4function |   0.3580   0.2406  -0.3181   0.2918   0.0516  -0.1542  -0.1956  
       w4vol |  -0.1257  -0.0874   0.1317  -0.1403   0.0161   0.3207   0.2604  
     w4smoke |  -0.0065   0.0586  -0.0240  -0.1209  -0.0003  -0.0991  -0.1907  
  w4srhealth |  -0.0236  -0.3547   0.1637  -0.1844  -0.0163   0.2372   0.2792  
       w4alc |  -0.1703  -0.1273   0.1360  -0.1656  -0.1897   0.2321   0.2593  
       w4dep |   0.0147   0.2778  -0.1126   0.1379   0.1317  -0.1856  -0.2248  
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  w4groupmem |  -0.1556  -0.1070   0.1253  -0.0535   0.0151   0.3304   0.3169  
    w4casp19 |  -0.0357  -0.2925   0.1443  -0.1731   0.0056   0.1832   0.2683  
 
             |    phact sympto~t function    smoke volunt~k   hehelf      dep 
-------------+--------------------------------------------------------------- 
       phact |   1.0000  
symptomcount |  -0.4302   1.0000  
    function |  -0.4586   0.6330   1.0000  
       smoke |  -0.0898   0.0605   0.0548   1.0000  
volunteerw~k |   0.1790  -0.1572  -0.1548  -0.1019   1.0000  
      hehelf |   0.4010  -0.4896  -0.4521  -0.1365   0.1831   1.0000  
         dep |  -0.2502   0.3456   0.3358   0.0705  -0.1114  -0.3694   1.0000  
cognitivea~y |   0.2555  -0.2164  -0.2124  -0.0399   0.1667   0.2406  -0.1498  
         alc |   0.1693  -0.1749  -0.1609   0.0332   0.0578   0.1800  -0.1334  
    groupmem |   0.2066  -0.1269  -0.1213  -0.1321   0.3689   0.1653  -0.1013  
         tot |   0.3254  -0.4203  -0.4205  -0.1107   0.1556   0.4946  -0.4144  
   w4physact |   0.4955  -0.3741  -0.3713  -0.1037   0.1568   0.3641  -0.2203  
   w4symptom |  -0.3448   0.5781   0.4665   0.1035  -0.1259  -0.4425   0.2953  
  w4function |  -0.3641   0.4616   0.6061   0.0457  -0.1312  -0.3676   0.2434  
       w4vol |   0.1968  -0.1532  -0.1557  -0.1270   0.4751   0.1804  -0.1174  
     w4smoke |  -0.0850   0.0820   0.0701   0.6205  -0.0939  -0.1259   0.0904  
  w4srhealth |   0.3293  -0.4043  -0.3770  -0.1459   0.1316   0.6283  -0.3088  
       w4alc |   0.1916  -0.1981  -0.1814   0.0024   0.0811   0.1990  -0.1427  
       w4dep |  -0.2306   0.3054   0.3136   0.0792  -0.0928  -0.3247   0.4339  
  w4groupmem |   0.2408  -0.1603  -0.1481  -0.1700   0.3838   0.2160  -0.1263  
    w4casp19 |   0.2718  -0.3465  -0.3317  -0.1100   0.1247   0.4354  -0.3439  
 
             | cognit~y      alc groupmem      tot w4phys~t w4symp~m w4func~n 
-------------+--------------------------------------------------------------- 
cognitivea~y |   1.0000  
         alc |   0.1248   1.0000  
    groupmem |   0.1113   0.1321   1.0000  
         tot |   0.1868   0.1640   0.1924   1.0000  
   w4physact |   0.2583   0.1807   0.1749   0.2924   1.0000  
402 
 
   w4symptom |  -0.1835  -0.1758  -0.1076  -0.3523  -0.4082   1.0000  
  w4function |  -0.2572  -0.1572  -0.0850  -0.3393  -0.4680   0.4652   1.0000  
       w4vol |   0.2362   0.0961   0.3600   0.1745   0.2554  -0.1635  -0.1903  
     w4smoke |  -0.0144  -0.0651  -0.1439  -0.1311  -0.1032   0.0859   0.0307  
  w4srhealth |   0.2265   0.1763   0.1400   0.4413   0.4106  -0.5202  -0.4396  
       w4alc |   0.1610   0.6525   0.1198   0.1660   0.2581  -0.1895  -0.2446  
       w4dep |  -0.1584  -0.1353  -0.0975  -0.3725  -0.2827   0.3858   0.3388  
  w4groupmem |   0.1986   0.1384   0.5966   0.2120   0.2814  -0.1526  -0.1867  
    w4casp19 |   0.1802   0.1590   0.1558   0.7096   0.3211  -0.4019  -0.3917  
 
             |    w4vol  w4smoke w4srhe~h    w4alc    w4dep w4grou~m w4casp19 
-------------+--------------------------------------------------------------- 
       w4vol |   1.0000  
     w4smoke |  -0.1131   1.0000  
  w4srhealth |   0.2104  -0.1211   1.0000  
       w4alc |   0.1459  -0.0792   0.2169   1.0000  
       w4dep |  -0.1389   0.0800  -0.4030  -0.1755   1.0000  
  w4groupmem |   0.4572  -0.1745   0.2151   0.2824  -0.1467   1.0000  
    w4casp19 |   0.1796  -0.1122   0.5114   0.1696  -0.4561   0.2110   1.0000  
 
             |  m_w4alc    Pain2     cen2     age2     sex2 educat~n   wealth 
-------------+--------------------------------------------------------------- 
     m_w4alc |   1.0000  
       Pain2 |   0.0475   1.0000  
        cen2 |  -0.3245  -0.0615   1.0000  
        age2 |  -0.0407   0.0692  -0.3038   1.0000  
        sex2 |  -0.0035   0.0794   0.0656   0.0013   1.0000  
   education |  -0.1430  -0.1299   0.1479  -0.2689  -0.1542   1.0000  
      wealth |  -0.1351  -0.1706   0.1653  -0.1523  -0.0508   0.4057   1.0000  
       phact |  -0.1721  -0.2480   0.2767  -0.2889  -0.0687   0.2443   0.2821  
symptomcount |   0.1387   0.3735  -0.2519   0.2414   0.0453  -0.1771  -0.2402  
    function |   0.1203   0.3496  -0.2439   0.2113   0.0546  -0.1470  -0.2166  
       smoke |   0.0513   0.0516  -0.0686  -0.0585  -0.1252  -0.0932  -0.1678  
volunteerw~k |  -0.1118  -0.0818   0.1177  -0.0762   0.0374   0.2576   0.2199  
403 
 
      hehelf |  -0.1529  -0.4115   0.2348  -0.1705   0.0083   0.2288   0.2923  
         dep |   0.0706   0.2854  -0.1243   0.1089   0.1295  -0.1816  -0.2160  
cognitivea~y |  -0.1879  -0.0932   0.2814  -0.4438   0.0898   0.3377   0.2667  
         alc |  -0.0509  -0.1295   0.0818  -0.1267  -0.2121   0.2098   0.2320  
    groupmem |  -0.0871  -0.0801   0.0577   0.0230   0.0049   0.2824   0.2516  
         tot |  -0.0888  -0.3145   0.1849  -0.1193   0.0296   0.1667   0.2999  
   w4physact |  -0.0617  -0.2261   0.2696  -0.3264  -0.0864   0.2446   0.2815  
   w4symptom |   0.0470   0.3604  -0.1675   0.2411   0.0576  -0.1934  -0.2553  
  w4function |   0.0261   0.2406  -0.3181   0.2918   0.0516  -0.1542  -0.1956  
       w4vol |  -0.0470  -0.0874   0.1317  -0.1403   0.0161   0.3207   0.2604  
     w4smoke |  -0.0084   0.0586  -0.0240  -0.1209  -0.0003  -0.0991  -0.1907  
  w4srhealth |  -0.0570  -0.3547   0.1637  -0.1844  -0.0163   0.2372   0.2792  
w4cogability |  -0.0986  -0.1047   0.2381  -0.4596   0.0826   0.3437   0.2499  
       w4dep |   0.0254   0.2778  -0.1126   0.1379   0.1317  -0.1856  -0.2248  
  w4groupmem |  -0.0113  -0.1070   0.1253  -0.0535   0.0151   0.3304   0.3169  
    w4casp19 |  -0.0411  -0.2925   0.1443  -0.1731   0.0056   0.1832   0.2683  
 
             |    phact sympto~t function    smoke volunt~k   hehelf      dep 
-------------+--------------------------------------------------------------- 
       phact |   1.0000  
symptomcount |  -0.4302   1.0000  
    function |  -0.4586   0.6330   1.0000  
       smoke |  -0.0898   0.0605   0.0548   1.0000  
volunteerw~k |   0.1790  -0.1572  -0.1548  -0.1019   1.0000  
      hehelf |   0.4010  -0.4896  -0.4521  -0.1365   0.1831   1.0000  
         dep |  -0.2502   0.3456   0.3358   0.0705  -0.1114  -0.3694   1.0000  
cognitivea~y |   0.2555  -0.2164  -0.2124  -0.0399   0.1667   0.2406  -0.1498  
         alc |   0.1693  -0.1749  -0.1609   0.0332   0.0578   0.1800  -0.1334  
    groupmem |   0.2066  -0.1269  -0.1213  -0.1321   0.3689   0.1653  -0.1013  
         tot |   0.3254  -0.4203  -0.4205  -0.1107   0.1556   0.4946  -0.4144  
   w4physact |   0.4955  -0.3741  -0.3713  -0.1037   0.1568   0.3641  -0.2203  
   w4symptom |  -0.3448   0.5781   0.4665   0.1035  -0.1259  -0.4425   0.2953  
  w4function |  -0.3641   0.4616   0.6061   0.0457  -0.1312  -0.3676   0.2434  
       w4vol |   0.1968  -0.1532  -0.1557  -0.1270   0.4751   0.1804  -0.1174  
404 
 
     w4smoke |  -0.0850   0.0820   0.0701   0.6205  -0.0939  -0.1259   0.0904  
  w4srhealth |   0.3293  -0.4043  -0.3770  -0.1459   0.1316   0.6283  -0.3088  
w4cogability |   0.2177  -0.2020  -0.1807  -0.0621   0.1604   0.2079  -0.1462  
       w4dep |  -0.2306   0.3054   0.3136   0.0792  -0.0928  -0.3247   0.4339  
  w4groupmem |   0.2408  -0.1603  -0.1481  -0.1700   0.3838   0.2160  -0.1263  
    w4casp19 |   0.2718  -0.3465  -0.3317  -0.1100   0.1247   0.4354  -0.3439  
 
             | cognit~y      alc groupmem      tot w4phys~t w4symp~m w4func~n 
-------------+--------------------------------------------------------------- 
cognitivea~y |   1.0000  
         alc |   0.1248   1.0000  
    groupmem |   0.1113   0.1321   1.0000  
         tot |   0.1868   0.1640   0.1924   1.0000  
   w4physact |   0.2583   0.1807   0.1749   0.2924   1.0000  
   w4symptom |  -0.1835  -0.1758  -0.1076  -0.3523  -0.4082   1.0000  
  w4function |  -0.2572  -0.1572  -0.0850  -0.3393  -0.4680   0.4652   1.0000  
       w4vol |   0.2362   0.0961   0.3600   0.1745   0.2554  -0.1635  -0.1903  
     w4smoke |  -0.0144  -0.0651  -0.1439  -0.1311  -0.1032   0.0859   0.0307  
  w4srhealth |   0.2265   0.1763   0.1400   0.4413   0.4106  -0.5202  -0.4396  
w4cogability |   0.5832   0.1205   0.1198   0.1618   0.2829  -0.2429  -0.2520  
       w4dep |  -0.1584  -0.1353  -0.0975  -0.3725  -0.2827   0.3858   0.3388  
  w4groupmem |   0.1986   0.1384   0.5966   0.2120   0.2814  -0.1526  -0.1867  
    w4casp19 |   0.1802   0.1590   0.1558   0.7096   0.3211  -0.4019  -0.3917  
 
             |    w4vol  w4smoke w4srhe~h w4coga~y    w4dep w4grou~m w4casp19 
-------------+--------------------------------------------------------------- 
       w4vol |   1.0000  
     w4smoke |  -0.1131   1.0000  
  w4srhealth |   0.2104  -0.1211   1.0000  
w4cogability |   0.2455  -0.0345   0.2585   1.0000  
       w4dep |  -0.1389   0.0800  -0.4030  -0.1927   1.0000  
  w4groupmem |   0.4572  -0.1745   0.2151   0.2155  -0.1467   1.0000  
    w4casp19 |   0.1796  -0.1122   0.5114   0.2105  -0.4561   0.2110   1.0000  
 
405 
 
             |  m_w4dep    Pain2     cen2     age2     sex2 educat~n   wealth 
-------------+--------------------------------------------------------------- 
     m_w4dep |   1.0000  
       Pain2 |   0.0476   1.0000  
        cen2 |  -0.3528  -0.0615   1.0000  
        age2 |  -0.0266   0.0692  -0.3038   1.0000  
        sex2 |  -0.0069   0.0794   0.0656   0.0013   1.0000  
   education |  -0.1409  -0.1299   0.1479  -0.2689  -0.1542   1.0000  
      wealth |  -0.1380  -0.1706   0.1653  -0.1523  -0.0508   0.4057   1.0000  
       phact |  -0.1861  -0.2480   0.2767  -0.2889  -0.0687   0.2443   0.2821  
symptomcount |   0.1507   0.3735  -0.2519   0.2414   0.0453  -0.1771  -0.2402  
    function |   0.1495   0.3496  -0.2439   0.2113   0.0546  -0.1470  -0.2166  
       smoke |   0.0550   0.0516  -0.0686  -0.0585  -0.1252  -0.0932  -0.1678  
volunteerw~k |  -0.1184  -0.0818   0.1177  -0.0762   0.0374   0.2576   0.2199  
      hehelf |  -0.1688  -0.4115   0.2348  -0.1705   0.0083   0.2288   0.2923  
         dep |   0.0725   0.2854  -0.1243   0.1089   0.1295  -0.1816  -0.2160  
cognitivea~y |  -0.2112  -0.0932   0.2814  -0.4438   0.0898   0.3377   0.2667  
         alc |  -0.0448  -0.1295   0.0818  -0.1267  -0.2121   0.2098   0.2320  
    groupmem |  -0.0889  -0.0801   0.0577   0.0230   0.0049   0.2824   0.2516  
         tot |  -0.1118  -0.3145   0.1849  -0.1193   0.0296   0.1667   0.2999  
   w4physact |  -0.1723  -0.2261   0.2696  -0.3264  -0.0864   0.2446   0.2815  
   w4symptom |  -0.0512   0.3604  -0.1675   0.2411   0.0576  -0.1934  -0.2553  
  w4function |   0.3338   0.2406  -0.3181   0.2918   0.0516  -0.1542  -0.1956  
       w4vol |  -0.1062  -0.0874   0.1317  -0.1403   0.0161   0.3207   0.2604  
     w4smoke |  -0.0001   0.0586  -0.0240  -0.1209  -0.0003  -0.0991  -0.1907  
  w4srhealth |  -0.0679  -0.3547   0.1637  -0.1844  -0.0163   0.2372   0.2792  
w4cogability |  -0.0657  -0.1047   0.2381  -0.4596   0.0826   0.3437   0.2499  
       w4alc |  -0.1564  -0.1273   0.1360  -0.1656  -0.1897   0.2321   0.2593  
  w4groupmem |  -0.1515  -0.1070   0.1253  -0.0535   0.0151   0.3304   0.3169  
    w4casp19 |  -0.0801  -0.2925   0.1443  -0.1731   0.0056   0.1832   0.2683  
 
             |    phact sympto~t function    smoke volunt~k   hehelf      dep 
-------------+--------------------------------------------------------------- 
       phact |   1.0000  
406 
 
symptomcount |  -0.4302   1.0000  
    function |  -0.4586   0.6330   1.0000  
       smoke |  -0.0898   0.0605   0.0548   1.0000  
volunteerw~k |   0.1790  -0.1572  -0.1548  -0.1019   1.0000  
      hehelf |   0.4010  -0.4896  -0.4521  -0.1365   0.1831   1.0000  
         dep |  -0.2502   0.3456   0.3358   0.0705  -0.1114  -0.3694   1.0000  
cognitivea~y |   0.2555  -0.2164  -0.2124  -0.0399   0.1667   0.2406  -0.1498  
         alc |   0.1693  -0.1749  -0.1609   0.0332   0.0578   0.1800  -0.1334  
    groupmem |   0.2066  -0.1269  -0.1213  -0.1321   0.3689   0.1653  -0.1013  
         tot |   0.3254  -0.4203  -0.4205  -0.1107   0.1556   0.4946  -0.4144  
   w4physact |   0.4955  -0.3741  -0.3713  -0.1037   0.1568   0.3641  -0.2203  
   w4symptom |  -0.3448   0.5781   0.4665   0.1035  -0.1259  -0.4425   0.2953  
  w4function |  -0.3641   0.4616   0.6061   0.0457  -0.1312  -0.3676   0.2434  
       w4vol |   0.1968  -0.1532  -0.1557  -0.1270   0.4751   0.1804  -0.1174  
     w4smoke |  -0.0850   0.0820   0.0701   0.6205  -0.0939  -0.1259   0.0904  
  w4srhealth |   0.3293  -0.4043  -0.3770  -0.1459   0.1316   0.6283  -0.3088  
w4cogability |   0.2177  -0.2020  -0.1807  -0.0621   0.1604   0.2079  -0.1462  
       w4alc |   0.1916  -0.1981  -0.1814   0.0024   0.0811   0.1990  -0.1427  
  w4groupmem |   0.2408  -0.1603  -0.1481  -0.1700   0.3838   0.2160  -0.1263  
    w4casp19 |   0.2718  -0.3465  -0.3317  -0.1100   0.1247   0.4354  -0.3439  
 
             | cognit~y      alc groupmem      tot w4phys~t w4symp~m w4func~n 
-------------+--------------------------------------------------------------- 
cognitivea~y |   1.0000  
         alc |   0.1248   1.0000  
    groupmem |   0.1113   0.1321   1.0000  
         tot |   0.1868   0.1640   0.1924   1.0000  
   w4physact |   0.2583   0.1807   0.1749   0.2924   1.0000  
   w4symptom |  -0.1835  -0.1758  -0.1076  -0.3523  -0.4082   1.0000  
  w4function |  -0.2572  -0.1572  -0.0850  -0.3393  -0.4680   0.4652   1.0000  
       w4vol |   0.2362   0.0961   0.3600   0.1745   0.2554  -0.1635  -0.1903  
     w4smoke |  -0.0144  -0.0651  -0.1439  -0.1311  -0.1032   0.0859   0.0307  
  w4srhealth |   0.2265   0.1763   0.1400   0.4413   0.4106  -0.5202  -0.4396  
w4cogability |   0.5832   0.1205   0.1198   0.1618   0.2829  -0.2429  -0.2520  
407 
 
       w4alc |   0.1610   0.6525   0.1198   0.1660   0.2581  -0.1895  -0.2446  
  w4groupmem |   0.1986   0.1384   0.5966   0.2120   0.2814  -0.1526  -0.1867  
    w4casp19 |   0.1802   0.1590   0.1558   0.7096   0.3211  -0.4019  -0.3917  
 
             |    w4vol  w4smoke w4srhe~h w4coga~y    w4alc w4grou~m w4casp19 
-------------+--------------------------------------------------------------- 
       w4vol |   1.0000  
     w4smoke |  -0.1131   1.0000  
  w4srhealth |   0.2104  -0.1211   1.0000  
w4cogability |   0.2455  -0.0345   0.2585   1.0000  
       w4alc |   0.1459  -0.0792   0.2169   0.1786   1.0000  
  w4groupmem |   0.4572  -0.1745   0.2151   0.2155   0.2824   1.0000  
    w4casp19 |   0.1796  -0.1122   0.5114   0.2105   0.1696   0.2110   1.0000  
 
             | m_w4gr~m    Pain2     cen2     age2     sex2 educat~n   wealth 
-------------+--------------------------------------------------------------- 
m_w4groupmem |   1.0000  
       Pain2 |   0.0527   1.0000  
        cen2 |  -0.3098  -0.0615   1.0000  
        age2 |  -0.0402   0.0692  -0.3038   1.0000  
        sex2 |   0.0051   0.0794   0.0656   0.0013   1.0000  
   education |  -0.1536  -0.1299   0.1479  -0.2689  -0.1542   1.0000  
      wealth |  -0.1408  -0.1706   0.1653  -0.1523  -0.0508   0.4057   1.0000  
       phact |  -0.1681  -0.2480   0.2767  -0.2889  -0.0687   0.2443   0.2821  
symptomcount |   0.1455   0.3735  -0.2519   0.2414   0.0453  -0.1771  -0.2402  
    function |   0.1209   0.3496  -0.2439   0.2113   0.0546  -0.1470  -0.2166  
       smoke |   0.0567   0.0516  -0.0686  -0.0585  -0.1252  -0.0932  -0.1678  
volunteerw~k |  -0.1255  -0.0818   0.1177  -0.0762   0.0374   0.2576   0.2199  
      hehelf |  -0.1565  -0.4115   0.2348  -0.1705   0.0083   0.2288   0.2923  
         dep |   0.0722   0.2854  -0.1243   0.1089   0.1295  -0.1816  -0.2160  
cognitivea~y |  -0.1846  -0.0932   0.2814  -0.4438   0.0898   0.3377   0.2667  
         alc |  -0.0585  -0.1295   0.0818  -0.1267  -0.2121   0.2098   0.2320  
    groupmem |  -0.1089  -0.0801   0.0577   0.0230   0.0049   0.2824   0.2516  
         tot |  -0.0903  -0.3145   0.1849  -0.1193   0.0296   0.1667   0.2999  
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   w4physact |  -0.0606  -0.2261   0.2696  -0.3264  -0.0864   0.2446   0.2815  
   w4symptom |   0.0723   0.3604  -0.1675   0.2411   0.0576  -0.1934  -0.2553  
  w4function |   0.0176   0.2406  -0.3181   0.2918   0.0516  -0.1542  -0.1956  
       w4vol |  -0.1106  -0.0874   0.1317  -0.1403   0.0161   0.3207   0.2604  
     w4smoke |   0.0422   0.0586  -0.0240  -0.1209  -0.0003  -0.0991  -0.1907  
  w4srhealth |  -0.0635  -0.3547   0.1637  -0.1844  -0.0163   0.2372   0.2792  
w4cogability |  -0.0760  -0.1047   0.2381  -0.4596   0.0826   0.3437   0.2499  
       w4alc |  -0.0198  -0.1273   0.1360  -0.1656  -0.1897   0.2321   0.2593  
       w4dep |   0.0483   0.2778  -0.1126   0.1379   0.1317  -0.1856  -0.2248  
    w4casp19 |  -0.0418  -0.2925   0.1443  -0.1731   0.0056   0.1832   0.2683  
 
             |    phact sympto~t function    smoke volunt~k   hehelf      dep 
-------------+--------------------------------------------------------------- 
       phact |   1.0000  
symptomcount |  -0.4302   1.0000  
    function |  -0.4586   0.6330   1.0000  
       smoke |  -0.0898   0.0605   0.0548   1.0000  
volunteerw~k |   0.1790  -0.1572  -0.1548  -0.1019   1.0000  
      hehelf |   0.4010  -0.4896  -0.4521  -0.1365   0.1831   1.0000  
         dep |  -0.2502   0.3456   0.3358   0.0705  -0.1114  -0.3694   1.0000  
cognitivea~y |   0.2555  -0.2164  -0.2124  -0.0399   0.1667   0.2406  -0.1498  
         alc |   0.1693  -0.1749  -0.1609   0.0332   0.0578   0.1800  -0.1334  
    groupmem |   0.2066  -0.1269  -0.1213  -0.1321   0.3689   0.1653  -0.1013  
         tot |   0.3254  -0.4203  -0.4205  -0.1107   0.1556   0.4946  -0.4144  
   w4physact |   0.4955  -0.3741  -0.3713  -0.1037   0.1568   0.3641  -0.2203  
   w4symptom |  -0.3448   0.5781   0.4665   0.1035  -0.1259  -0.4425   0.2953  
  w4function |  -0.3641   0.4616   0.6061   0.0457  -0.1312  -0.3676   0.2434  
       w4vol |   0.1968  -0.1532  -0.1557  -0.1270   0.4751   0.1804  -0.1174  
     w4smoke |  -0.0850   0.0820   0.0701   0.6205  -0.0939  -0.1259   0.0904  
  w4srhealth |   0.3293  -0.4043  -0.3770  -0.1459   0.1316   0.6283  -0.3088  
w4cogability |   0.2177  -0.2020  -0.1807  -0.0621   0.1604   0.2079  -0.1462  
       w4alc |   0.1916  -0.1981  -0.1814   0.0024   0.0811   0.1990  -0.1427  
       w4dep |  -0.2306   0.3054   0.3136   0.0792  -0.0928  -0.3247   0.4339  
    w4casp19 |   0.2718  -0.3465  -0.3317  -0.1100   0.1247   0.4354  -0.3439  
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             | cognit~y      alc groupmem      tot w4phys~t w4symp~m w4func~n 
-------------+--------------------------------------------------------------- 
cognitivea~y |   1.0000  
         alc |   0.1248   1.0000  
    groupmem |   0.1113   0.1321   1.0000  
         tot |   0.1868   0.1640   0.1924   1.0000  
   w4physact |   0.2583   0.1807   0.1749   0.2924   1.0000  
   w4symptom |  -0.1835  -0.1758  -0.1076  -0.3523  -0.4082   1.0000  
  w4function |  -0.2572  -0.1572  -0.0850  -0.3393  -0.4680   0.4652   1.0000  
       w4vol |   0.2362   0.0961   0.3600   0.1745   0.2554  -0.1635  -0.1903  
     w4smoke |  -0.0144  -0.0651  -0.1439  -0.1311  -0.1032   0.0859   0.0307  
  w4srhealth |   0.2265   0.1763   0.1400   0.4413   0.4106  -0.5202  -0.4396  
w4cogability |   0.5832   0.1205   0.1198   0.1618   0.2829  -0.2429  -0.2520  
       w4alc |   0.1610   0.6525   0.1198   0.1660   0.2581  -0.1895  -0.2446  
       w4dep |  -0.1584  -0.1353  -0.0975  -0.3725  -0.2827   0.3858   0.3388  
    w4casp19 |   0.1802   0.1590   0.1558   0.7096   0.3211  -0.4019  -0.3917  
 
             |    w4vol  w4smoke w4srhe~h w4coga~y    w4alc    w4dep w4casp19 
-------------+--------------------------------------------------------------- 
       w4vol |   1.0000  
     w4smoke |  -0.1131   1.0000  
  w4srhealth |   0.2104  -0.1211   1.0000  
w4cogability |   0.2455  -0.0345   0.2585   1.0000  
       w4alc |   0.1459  -0.0792   0.2169   0.1786   1.0000  
       w4dep |  -0.1389   0.0800  -0.4030  -0.1927  -0.1755   1.0000  
    w4casp19 |   0.1796  -0.1122   0.5114   0.2105   0.1696  -0.4561   1.0000  
 
             | m_w4c~19    Pain2     cen2     age2     sex2 educat~n   wealth 
-------------+--------------------------------------------------------------- 
  m_w4casp19 |   1.0000  
       Pain2 |   0.0654   1.0000  
        cen2 |  -0.3207  -0.0615   1.0000  
        age2 |   0.0325   0.0692  -0.3038   1.0000  
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        sex2 |   0.0080   0.0794   0.0656   0.0013   1.0000  
   education |  -0.1727  -0.1299   0.1479  -0.2689  -0.1542   1.0000  
      wealth |  -0.1829  -0.1706   0.1653  -0.1523  -0.0508   0.4057   1.0000  
       phact |  -0.2148  -0.2480   0.2767  -0.2889  -0.0687   0.2443   0.2821  
symptomcount |   0.1655   0.3735  -0.2519   0.2414   0.0453  -0.1771  -0.2402  
    function |   0.1691   0.3496  -0.2439   0.2113   0.0546  -0.1470  -0.2166  
       smoke |   0.0649   0.0516  -0.0686  -0.0585  -0.1252  -0.0932  -0.1678  
volunteerw~k |  -0.1305  -0.0818   0.1177  -0.0762   0.0374   0.2576   0.2199  
      hehelf |  -0.1909  -0.4115   0.2348  -0.1705   0.0083   0.2288   0.2923  
         dep |   0.1044   0.2854  -0.1243   0.1089   0.1295  -0.1816  -0.2160  
cognitivea~y |  -0.2489  -0.0932   0.2814  -0.4438   0.0898   0.3377   0.2667  
         alc |  -0.0603  -0.1295   0.0818  -0.1267  -0.2121   0.2098   0.2320  
    groupmem |  -0.0916  -0.0801   0.0577   0.0230   0.0049   0.2824   0.2516  
         tot |  -0.1338  -0.3145   0.1849  -0.1193   0.0296   0.1667   0.2999  
   w4physact |  -0.2369  -0.2261   0.2696  -0.3264  -0.0864   0.2446   0.2815  
   w4symptom |   0.0982   0.3604  -0.1675   0.2411   0.0576  -0.1934  -0.2553  
  w4function |   0.2574   0.2406  -0.3181   0.2918   0.0516  -0.1542  -0.1956  
       w4vol |  -0.1484  -0.0874   0.1317  -0.1403   0.0161   0.3207   0.2604  
     w4smoke |   0.0519   0.0586  -0.0240  -0.1209  -0.0003  -0.0991  -0.1907  
  w4srhealth |  -0.1612  -0.3547   0.1637  -0.1844  -0.0163   0.2372   0.2792  
w4cogability |  -0.2034  -0.1047   0.2381  -0.4596   0.0826   0.3437   0.2499  
       w4alc |  -0.3776  -0.1273   0.1360  -0.1656  -0.1897   0.2321   0.2593  
       w4dep |   0.1213   0.2778  -0.1126   0.1379   0.1317  -0.1856  -0.2248  
  w4groupmem |  -0.3328  -0.1070   0.1253  -0.0535   0.0151   0.3304   0.3169  
 
             |    phact sympto~t function    smoke volunt~k   hehelf      dep 
-------------+--------------------------------------------------------------- 
       phact |   1.0000  
symptomcount |  -0.4302   1.0000  
    function |  -0.4586   0.6330   1.0000  
       smoke |  -0.0898   0.0605   0.0548   1.0000  
volunteerw~k |   0.1790  -0.1572  -0.1548  -0.1019   1.0000  
      hehelf |   0.4010  -0.4896  -0.4521  -0.1365   0.1831   1.0000  
         dep |  -0.2502   0.3456   0.3358   0.0705  -0.1114  -0.3694   1.0000  
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cognitivea~y |   0.2555  -0.2164  -0.2124  -0.0399   0.1667   0.2406  -0.1498  
         alc |   0.1693  -0.1749  -0.1609   0.0332   0.0578   0.1800  -0.1334  
    groupmem |   0.2066  -0.1269  -0.1213  -0.1321   0.3689   0.1653  -0.1013  
         tot |   0.3254  -0.4203  -0.4205  -0.1107   0.1556   0.4946  -0.4144  
   w4physact |   0.4955  -0.3741  -0.3713  -0.1037   0.1568   0.3641  -0.2203  
   w4symptom |  -0.3448   0.5781   0.4665   0.1035  -0.1259  -0.4425   0.2953  
  w4function |  -0.3641   0.4616   0.6061   0.0457  -0.1312  -0.3676   0.2434  
       w4vol |   0.1968  -0.1532  -0.1557  -0.1270   0.4751   0.1804  -0.1174  
     w4smoke |  -0.0850   0.0820   0.0701   0.6205  -0.0939  -0.1259   0.0904  
  w4srhealth |   0.3293  -0.4043  -0.3770  -0.1459   0.1316   0.6283  -0.3088  
w4cogability |   0.2177  -0.2020  -0.1807  -0.0621   0.1604   0.2079  -0.1462  
       w4alc |   0.1916  -0.1981  -0.1814   0.0024   0.0811   0.1990  -0.1427  
       w4dep |  -0.2306   0.3054   0.3136   0.0792  -0.0928  -0.3247   0.4339  
  w4groupmem |   0.2408  -0.1603  -0.1481  -0.1700   0.3838   0.2160  -0.1263  
 
             | cognit~y      alc groupmem      tot w4phys~t w4symp~m w4func~n 
-------------+--------------------------------------------------------------- 
cognitivea~y |   1.0000  
         alc |   0.1248   1.0000  
    groupmem |   0.1113   0.1321   1.0000  
         tot |   0.1868   0.1640   0.1924   1.0000  
   w4physact |   0.2583   0.1807   0.1749   0.2924   1.0000  
   w4symptom |  -0.1835  -0.1758  -0.1076  -0.3523  -0.4082   1.0000  
  w4function |  -0.2572  -0.1572  -0.0850  -0.3393  -0.4680   0.4652   1.0000  
       w4vol |   0.2362   0.0961   0.3600   0.1745   0.2554  -0.1635  -0.1903  
     w4smoke |  -0.0144  -0.0651  -0.1439  -0.1311  -0.1032   0.0859   0.0307  
  w4srhealth |   0.2265   0.1763   0.1400   0.4413   0.4106  -0.5202  -0.4396  
w4cogability |   0.5832   0.1205   0.1198   0.1618   0.2829  -0.2429  -0.2520  
       w4alc |   0.1610   0.6525   0.1198   0.1660   0.2581  -0.1895  -0.2446  
       w4dep |  -0.1584  -0.1353  -0.0975  -0.3725  -0.2827   0.3858   0.3388  
  w4groupmem |   0.1986   0.1384   0.5966   0.2120   0.2814  -0.1526  -0.1867  
 
             |    w4vol  w4smoke w4srhe~h w4coga~y    w4alc    w4dep w4grou~m 
-------------+--------------------------------------------------------------- 
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       w4vol |   1.0000  
     w4smoke |  -0.1131   1.0000  
  w4srhealth |   0.2104  -0.1211   1.0000  
w4cogability |   0.2455  -0.0345   0.2585   1.0000  
       w4alc |   0.1459  -0.0792   0.2169   0.1786   1.0000  
       w4dep |  -0.1389   0.0800  -0.4030  -0.1927  -0.1755   1.0000  
  w4groupmem |   0.4572  -0.1745   0.2151   0.2155   0.2824  -0.1467   1.0000  
 
.  
. log close 
      name:  <unnamed> 
       log:  S:\Data\ELSAmissing.log 
  log type:  text 
 closed on:  26 Jun 2015, 10:39:10 
 
NorStOP 
-------------------------------------------------------------------------------------------
--- 
      name:  <unnamed> 
       log:  S:\Data\NORSTOP\NorStOPmissingdata.log 
  log type:  text 
 opened on:  22 Dec 2014, 10:44:02 
 
. local corrvars "pain numpain censor age sex education income alcohol smoke control health 
wa 
> lk depression anxiety sleep1 sleep2 sleep3 sleep4 out partic obesity physfunct painint 
cogni 
> tive slp3 bmi3 pf3 anx3 dep3 cog3 gh3 part3" 
 
.  
. foreach var of varlist pain censor age sex education income alcohol smoke control health 
wal 
> k depression anxiety sleep1 sleep2 sleep3 sleep4 out partic obesity physfunct painint 
cognit 
> ive slp3 bmi3 pf3 anx3 dep3 cog3 gh3 part3{ 
  2.  
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. gen m_`var' = missing(`var') 
  3.  
. pwcorr m_`var' `: list corrvars - var' 
  4.  
. } 
 
             |   m_pain  numpain   censor      age      sex educat~n   income 
-------------+--------------------------------------------------------------- 
      m_pain |   1.0000  
     numpain |  -0.0003   1.0000  
      censor |   0.0466   0.0262   1.0000  
         age |   0.1254  -0.0068   0.3915   1.0000  
         sex |  -0.0145  -0.0747   0.0518  -0.0690   1.0000  
   education |   0.0133   0.0448   0.0574   0.1316   0.0546   1.0000  
      income |   0.0189   0.1639   0.0205   0.0011  -0.0089   0.0854   1.0000  
     alcohol |   0.0331   0.1042   0.0612   0.1774  -0.2396   0.0480   0.1104  
       smoke |  -0.0089  -0.0282  -0.0447   0.0234  -0.2045  -0.0207  -0.0153  
     control |   0.0355  -0.0253  -0.0355   0.0079   0.0004  -0.0231  -0.0183  
      health |   0.0474   0.4020   0.2056   0.2392  -0.0032   0.1192   0.2131  
        walk |   0.0207   0.2255   0.1543   0.1947  -0.0922   0.0467   0.0898  
  depression |   0.0137   0.2844   0.1168   0.1129  -0.0088   0.0480   0.1843  
     anxiety |   0.0043   0.2686   0.0126  -0.0272  -0.1434   0.0266   0.1966  
      sleep1 |   0.0092   0.2471   0.0228   0.0352  -0.1027   0.0326   0.1366  
      sleep2 |  -0.0152   0.2151   0.0735   0.0713  -0.0598   0.0371   0.1028  
      sleep3 |   0.0017   0.2480   0.0230   0.0142  -0.0818   0.0269   0.1277  
      sleep4 |  -0.0014   0.3014   0.0247  -0.0337  -0.0705   0.0200   0.1580  
         out |   0.0491   0.2502   0.2320   0.3669  -0.1078   0.1013   0.1423  
      partic |   0.0636   0.2308   0.1396   0.1966  -0.0606   0.0759   0.1802  
     obesity |  -0.0151   0.1349  -0.0401  -0.1006  -0.0384   0.0088   0.0809  
   physfunct |  -0.0414  -0.4878  -0.2653  -0.3937   0.1320  -0.1142  -0.2186  
     painint |   0.0013   0.5589   0.1571   0.1977  -0.0374   0.0939   0.2139  
   cognitive |   0.0114   0.2688   0.1076   0.1484  -0.0455   0.0247   0.1619  
        slp3 |        .        .        .        .        .        .        .  
        bmi3 |        .        .        .        .        .        .        .  
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         pf3 |        .        .        .        .        .        .        .  
        anx3 |        .        .        .        .        .        .        .  
        dep3 |        .        .        .        .        .        .        .  
        cog3 |        .        .        .        .        .        .        .  
         gh3 |        .        .        .        .        .        .        .  
       part3 |        .        .        .        .        .        .        .  
 
             |  alcohol    smoke  control   health     walk depres~n  anxiety 
-------------+--------------------------------------------------------------- 
     alcohol |   1.0000  
       smoke |   0.1158   1.0000  
     control |   0.0002  -0.1999   1.0000  
      health |   0.1598  -0.0613  -0.0208   1.0000  
        walk |   0.1398  -0.0122  -0.0217   0.3826   1.0000  
  depression |   0.1205  -0.0228  -0.0093   0.4413   0.2985   1.0000  
     anxiety |   0.0856   0.0093  -0.0463   0.3234   0.1692   0.4194   1.0000  
      sleep1 |   0.0943   0.0159  -0.0210   0.2494   0.1541   0.2458   0.2644  
      sleep2 |   0.0764   0.0773  -0.2186   0.2480   0.1485   0.2141   0.2287  
      sleep3 |   0.0701   0.0020  -0.0150   0.2533   0.1502   0.2595   0.2775  
      sleep4 |   0.0853  -0.0090  -0.0167   0.3126   0.1934   0.3434   0.3157  
         out |   0.1925  -0.0011  -0.0112   0.4615   0.5116   0.3932   0.2236  
      partic |   0.1316  -0.0131   0.0373   0.3890   0.2798   0.3266   0.2428  
     obesity |   0.0709  -0.0148  -0.0148   0.1423   0.1125   0.0809   0.0592  
   physfunct |  -0.2143   0.0236   0.0378  -0.6629  -0.5167  -0.4536  -0.3021  
     painint |   0.1430  -0.0337  -0.0276   0.5991   0.3743   0.4082   0.3212  
   cognitive |   0.0893  -0.0113  -0.0263   0.3374   0.1898   0.3500   0.3471  
        slp3 |        .        .        .        .        .        .        .  
        bmi3 |        .        .        .        .        .        .        .  
         pf3 |        .        .        .        .        .        .        .  
        anx3 |        .        .        .        .        .        .        .  
        dep3 |        .        .        .        .        .        .        .  
        cog3 |        .        .        .        .        .        .        .  
         gh3 |        .        .        .        .        .        .        .  
       part3 |        .        .        .        .        .        .        .  
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             |   sleep1   sleep2   sleep3   sleep4      out   partic  obesity 
-------------+--------------------------------------------------------------- 
      sleep1 |   1.0000  
      sleep2 |   0.4145   1.0000  
      sleep3 |   0.5954   0.5615   1.0000  
      sleep4 |   0.4645   0.3710   0.5106   1.0000  
         out |   0.1898   0.1781   0.1792   0.2070   1.0000  
      partic |   0.1729   0.1439   0.1654   0.2007   0.3858   1.0000  
     obesity |   0.0710   0.0755   0.0821   0.0925   0.0588   0.0663   1.0000  
   physfunct |  -0.2685  -0.2789  -0.2762  -0.3075  -0.5691  -0.4574  -0.1629  
     painint |   0.2669   0.2630   0.2840   0.3106   0.4388   0.4100   0.1405  
   cognitive |   0.2026   0.2101   0.2179   0.2623   0.2751   0.2715   0.0497  
        slp3 |        .        .        .        .        .        .        .  
        bmi3 |        .        .        .        .        .        .        .  
         pf3 |        .        .        .        .        .        .        .  
        anx3 |        .        .        .        .        .        .        .  
        dep3 |        .        .        .        .        .        .        .  
        cog3 |        .        .        .        .        .        .        .  
         gh3 |        .        .        .        .        .        .        .  
       part3 |        .        .        .        .        .        .        .  
 
             | physfu~t  painint cognit~e     slp3     bmi3      pf3     anx3 
-------------+--------------------------------------------------------------- 
   physfunct |   1.0000  
     painint |  -0.7328   1.0000  
   cognitive |  -0.3703   0.3374   1.0000  
        slp3 |        .        .        .        .  
        bmi3 |        .        .        .        .        .  
         pf3 |        .        .        .        .        .        .  
        anx3 |        .        .        .        .        .        .        .  
        dep3 |        .        .        .        .        .        .        .  
        cog3 |        .        .        .        .        .        .        .  
         gh3 |        .        .        .        .        .        .        .  
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       part3 |        .        .        .        .        .        .        .  
 
             |     dep3     cog3      gh3    part3 
-------------+------------------------------------ 
        dep3 |        .  
        cog3 |        .        .  
         gh3 |        .        .        .  
       part3 |        .        .        .        .  
 
             | m_censor     pain  numpain      age      sex educat~n   income 
-------------+--------------------------------------------------------------- 
    m_censor |   1.0000  
        pain |   0.0116   1.0000  
     numpain |  -0.0072  -0.5166   1.0000  
         age |   0.3003   0.0064  -0.0068   1.0000  
         sex |   0.0086   0.0328  -0.0747  -0.0690   1.0000  
   education |   0.0395  -0.0491   0.0448   0.1316   0.0546   1.0000  
      income |   0.0132  -0.1015   0.1639   0.0011  -0.0089   0.0854   1.0000  
     alcohol |   0.0613  -0.0345   0.1042   0.1774  -0.2396   0.0480   0.1104  
       smoke |  -0.0093   0.0179  -0.0282   0.0234  -0.2045  -0.0207  -0.0153  
     control |  -0.0096   0.0340  -0.0253   0.0079   0.0004  -0.0231  -0.0183  
      health |   0.1619  -0.2913   0.4020   0.2392  -0.0032   0.1192   0.2131  
        walk |   0.1226  -0.1561   0.2255   0.1947  -0.0922   0.0467   0.0898  
  depression |   0.1189  -0.1664   0.2844   0.1129  -0.0088   0.0480   0.1843  
     anxiety |   0.0212  -0.2060   0.2686  -0.0272  -0.1434   0.0266   0.1966  
      sleep1 |   0.0124  -0.1532   0.2471   0.0352  -0.1027   0.0326   0.1366  
      sleep2 |   0.0466  -0.1648   0.2151   0.0713  -0.0598   0.0371   0.1028  
      sleep3 |   0.0146  -0.1675   0.2480   0.0142  -0.0818   0.0269   0.1277  
      sleep4 |   0.0210  -0.1813   0.3014  -0.0337  -0.0705   0.0200   0.1580  
         out |   0.1881  -0.1554   0.2502   0.3669  -0.1078   0.1013   0.1423  
      partic |   0.1265  -0.1608   0.2308   0.1966  -0.0606   0.0759   0.1802  
     obesity |  -0.0361  -0.0988   0.1349  -0.1006  -0.0384   0.0088   0.0809  
   physfunct |  -0.1836   0.3525  -0.4878  -0.3937   0.1320  -0.1142  -0.2186  
     painint |   0.1062  -0.4996   0.5589   0.1977  -0.0374   0.0939   0.2139  
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   cognitive |   0.0773  -0.1985   0.2688   0.1484  -0.0455   0.0247   0.1619  
        slp3 |        .        .        .        .        .        .        .  
        bmi3 |        .        .        .        .        .        .        .  
         pf3 |        .        .        .        .        .        .        .  
        anx3 |        .        .        .        .        .        .        .  
        dep3 |        .        .        .        .        .        .        .  
        cog3 |        .        .        .        .        .        .        .  
         gh3 |        .        .        .        .        .        .        .  
       part3 |        .        .        .        .        .        .        .  
 
             |  alcohol    smoke  control   health     walk depres~n  anxiety 
-------------+--------------------------------------------------------------- 
     alcohol |   1.0000  
       smoke |   0.1158   1.0000  
     control |   0.0002  -0.1999   1.0000  
      health |   0.1598  -0.0613  -0.0208   1.0000  
        walk |   0.1398  -0.0122  -0.0217   0.3826   1.0000  
  depression |   0.1205  -0.0228  -0.0093   0.4413   0.2985   1.0000  
     anxiety |   0.0856   0.0093  -0.0463   0.3234   0.1692   0.4194   1.0000  
      sleep1 |   0.0943   0.0159  -0.0210   0.2494   0.1541   0.2458   0.2644  
      sleep2 |   0.0764   0.0773  -0.2186   0.2480   0.1485   0.2141   0.2287  
      sleep3 |   0.0701   0.0020  -0.0150   0.2533   0.1502   0.2595   0.2775  
      sleep4 |   0.0853  -0.0090  -0.0167   0.3126   0.1934   0.3434   0.3157  
         out |   0.1925  -0.0011  -0.0112   0.4615   0.5116   0.3932   0.2236  
      partic |   0.1316  -0.0131   0.0373   0.3890   0.2798   0.3266   0.2428  
     obesity |   0.0709  -0.0148  -0.0148   0.1423   0.1125   0.0809   0.0592  
   physfunct |  -0.2143   0.0236   0.0378  -0.6629  -0.5167  -0.4536  -0.3021  
     painint |   0.1430  -0.0337  -0.0276   0.5991   0.3743   0.4082   0.3212  
   cognitive |   0.0893  -0.0113  -0.0263   0.3374   0.1898   0.3500   0.3471  
        slp3 |        .        .        .        .        .        .        .  
        bmi3 |        .        .        .        .        .        .        .  
         pf3 |        .        .        .        .        .        .        .  
        anx3 |        .        .        .        .        .        .        .  
        dep3 |        .        .        .        .        .        .        .  
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        cog3 |        .        .        .        .        .        .        .  
         gh3 |        .        .        .        .        .        .        .  
       part3 |        .        .        .        .        .        .        .  
 
             |   sleep1   sleep2   sleep3   sleep4      out   partic  obesity 
-------------+--------------------------------------------------------------- 
      sleep1 |   1.0000  
      sleep2 |   0.4145   1.0000  
      sleep3 |   0.5954   0.5615   1.0000  
      sleep4 |   0.4645   0.3710   0.5106   1.0000  
         out |   0.1898   0.1781   0.1792   0.2070   1.0000  
      partic |   0.1729   0.1439   0.1654   0.2007   0.3858   1.0000  
     obesity |   0.0710   0.0755   0.0821   0.0925   0.0588   0.0663   1.0000  
   physfunct |  -0.2685  -0.2789  -0.2762  -0.3075  -0.5691  -0.4574  -0.1629  
     painint |   0.2669   0.2630   0.2840   0.3106   0.4388   0.4100   0.1405  
   cognitive |   0.2026   0.2101   0.2179   0.2623   0.2751   0.2715   0.0497  
        slp3 |        .        .        .        .        .        .        .  
        bmi3 |        .        .        .        .        .        .        .  
         pf3 |        .        .        .        .        .        .        .  
        anx3 |        .        .        .        .        .        .        .  
        dep3 |        .        .        .        .        .        .        .  
        cog3 |        .        .        .        .        .        .        .  
         gh3 |        .        .        .        .        .        .        .  
       part3 |        .        .        .        .        .        .        .  
 
             | physfu~t  painint cognit~e     slp3     bmi3      pf3     anx3 
-------------+--------------------------------------------------------------- 
   physfunct |   1.0000  
     painint |  -0.7328   1.0000  
   cognitive |  -0.3703   0.3374   1.0000  
        slp3 |        .        .        .        .  
        bmi3 |        .        .        .        .        .  
         pf3 |        .        .        .        .        .        .  
        anx3 |        .        .        .        .        .        .        .  
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        dep3 |        .        .        .        .        .        .        .  
        cog3 |        .        .        .        .        .        .        .  
         gh3 |        .        .        .        .        .        .        .  
       part3 |        .        .        .        .        .        .        .  
 
             |     dep3     cog3      gh3    part3 
-------------+------------------------------------ 
        dep3 |        .  
        cog3 |        .        .  
         gh3 |        .        .        .  
       part3 |        .        .        .        .  
 
             |    m_age     pain  numpain   censor      sex educat~n   income 
-------------+--------------------------------------------------------------- 
       m_age |   1.0000  
        pain |        .   1.0000  
     numpain |  -0.0003  -0.5166   1.0000  
      censor |        .  -0.0124   0.0262   1.0000  
         sex |        .   0.0328  -0.0747   0.0518   1.0000  
   education |        .  -0.0491   0.0448   0.0574   0.0546   1.0000  
      income |        .  -0.1015   0.1639   0.0205  -0.0089   0.0854   1.0000  
     alcohol |  -0.0035  -0.0345   0.1042   0.0612  -0.2396   0.0480   0.1104  
       smoke |   0.0011   0.0179  -0.0282  -0.0447  -0.2045  -0.0207  -0.0153  
     control |   0.0049   0.0340  -0.0253  -0.0355   0.0004  -0.0231  -0.0183  
      health |   0.0144  -0.2913   0.4020   0.2056  -0.0032   0.1192   0.2131  
        walk |   0.0014  -0.1561   0.2255   0.1543  -0.0922   0.0467   0.0898  
  depression |        .  -0.1664   0.2844   0.1168  -0.0088   0.0480   0.1843  
     anxiety |        .  -0.2060   0.2686   0.0126  -0.1434   0.0266   0.1966  
      sleep1 |   0.0098  -0.1532   0.2471   0.0228  -0.1027   0.0326   0.1366  
      sleep2 |   0.0080  -0.1648   0.2151   0.0735  -0.0598   0.0371   0.1028  
      sleep3 |  -0.0001  -0.1675   0.2480   0.0230  -0.0818   0.0269   0.1277  
      sleep4 |  -0.0061  -0.1813   0.3014   0.0247  -0.0705   0.0200   0.1580  
         out |   0.0055  -0.1554   0.2502   0.2320  -0.1078   0.1013   0.1423  
      partic |   0.0077  -0.1608   0.2308   0.1396  -0.0606   0.0759   0.1802  
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     obesity |  -0.0168  -0.0988   0.1349  -0.0401  -0.0384   0.0088   0.0809  
   physfunct |        .   0.3525  -0.4878  -0.2653   0.1320  -0.1142  -0.2186  
     painint |        .  -0.4996   0.5589   0.1571  -0.0374   0.0939   0.2139  
   cognitive |        .  -0.1985   0.2688   0.1076  -0.0455   0.0247   0.1619  
        slp3 |        .        .        .        .        .        .        .  
        bmi3 |        .        .        .        .        .        .        .  
         pf3 |        .        .        .        .        .        .        .  
        anx3 |        .        .        .        .        .        .        .  
        dep3 |        .        .        .        .        .        .        .  
        cog3 |        .        .        .        .        .        .        .  
         gh3 |        .        .        .        .        .        .        .  
       part3 |        .        .        .        .        .        .        .  
 
             |  alcohol    smoke  control   health     walk depres~n  anxiety 
-------------+--------------------------------------------------------------- 
     alcohol |   1.0000  
       smoke |   0.1158   1.0000  
     control |   0.0002  -0.1999   1.0000  
      health |   0.1598  -0.0613  -0.0208   1.0000  
        walk |   0.1398  -0.0122  -0.0217   0.3826   1.0000  
  depression |   0.1205  -0.0228  -0.0093   0.4413   0.2985   1.0000  
     anxiety |   0.0856   0.0093  -0.0463   0.3234   0.1692   0.4194   1.0000  
      sleep1 |   0.0943   0.0159  -0.0210   0.2494   0.1541   0.2458   0.2644  
      sleep2 |   0.0764   0.0773  -0.2186   0.2480   0.1485   0.2141   0.2287  
      sleep3 |   0.0701   0.0020  -0.0150   0.2533   0.1502   0.2595   0.2775  
      sleep4 |   0.0853  -0.0090  -0.0167   0.3126   0.1934   0.3434   0.3157  
         out |   0.1925  -0.0011  -0.0112   0.4615   0.5116   0.3932   0.2236  
      partic |   0.1316  -0.0131   0.0373   0.3890   0.2798   0.3266   0.2428  
     obesity |   0.0709  -0.0148  -0.0148   0.1423   0.1125   0.0809   0.0592  
   physfunct |  -0.2143   0.0236   0.0378  -0.6629  -0.5167  -0.4536  -0.3021  
     painint |   0.1430  -0.0337  -0.0276   0.5991   0.3743   0.4082   0.3212  
   cognitive |   0.0893  -0.0113  -0.0263   0.3374   0.1898   0.3500   0.3471  
        slp3 |        .        .        .        .        .        .        .  
        bmi3 |        .        .        .        .        .        .        .  
421 
 
         pf3 |        .        .        .        .        .        .        .  
        anx3 |        .        .        .        .        .        .        .  
        dep3 |        .        .        .        .        .        .        .  
        cog3 |        .        .        .        .        .        .        .  
         gh3 |        .        .        .        .        .        .        .  
       part3 |        .        .        .        .        .        .        .  
 
             |   sleep1   sleep2   sleep3   sleep4      out   partic  obesity 
-------------+--------------------------------------------------------------- 
      sleep1 |   1.0000  
      sleep2 |   0.4145   1.0000  
      sleep3 |   0.5954   0.5615   1.0000  
      sleep4 |   0.4645   0.3710   0.5106   1.0000  
         out |   0.1898   0.1781   0.1792   0.2070   1.0000  
      partic |   0.1729   0.1439   0.1654   0.2007   0.3858   1.0000  
     obesity |   0.0710   0.0755   0.0821   0.0925   0.0588   0.0663   1.0000  
   physfunct |  -0.2685  -0.2789  -0.2762  -0.3075  -0.5691  -0.4574  -0.1629  
     painint |   0.2669   0.2630   0.2840   0.3106   0.4388   0.4100   0.1405  
   cognitive |   0.2026   0.2101   0.2179   0.2623   0.2751   0.2715   0.0497  
        slp3 |        .        .        .        .        .        .        .  
        bmi3 |        .        .        .        .        .        .        .  
         pf3 |        .        .        .        .        .        .        .  
        anx3 |        .        .        .        .        .        .        .  
        dep3 |        .        .        .        .        .        .        .  
        cog3 |        .        .        .        .        .        .        .  
         gh3 |        .        .        .        .        .        .        .  
       part3 |        .        .        .        .        .        .        .  
 
             | physfu~t  painint cognit~e     slp3     bmi3      pf3     anx3 
-------------+--------------------------------------------------------------- 
   physfunct |   1.0000  
     painint |  -0.7328   1.0000  
   cognitive |  -0.3703   0.3374   1.0000  
        slp3 |        .        .        .        .  
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        bmi3 |        .        .        .        .        .  
         pf3 |        .        .        .        .        .        .  
        anx3 |        .        .        .        .        .        .        .  
        dep3 |        .        .        .        .        .        .        .  
        cog3 |        .        .        .        .        .        .        .  
         gh3 |        .        .        .        .        .        .        .  
       part3 |        .        .        .        .        .        .        .  
 
             |     dep3     cog3      gh3    part3 
-------------+------------------------------------ 
        dep3 |        .  
        cog3 |        .        .  
         gh3 |        .        .        .  
       part3 |        .        .        .        .  
 
             |    m_sex     pain  numpain   censor      age educat~n   income 
-------------+--------------------------------------------------------------- 
       m_sex |   1.0000  
        pain |        .   1.0000  
     numpain |  -0.0003  -0.5166   1.0000  
      censor |        .  -0.0124   0.0262   1.0000  
         age |        .   0.0064  -0.0068   0.3915   1.0000  
   education |        .  -0.0491   0.0448   0.0574   0.1316   1.0000  
      income |        .  -0.1015   0.1639   0.0205   0.0011   0.0854   1.0000  
     alcohol |  -0.0035  -0.0345   0.1042   0.0612   0.1774   0.0480   0.1104  
       smoke |   0.0011   0.0179  -0.0282  -0.0447   0.0234  -0.0207  -0.0153  
     control |   0.0049   0.0340  -0.0253  -0.0355   0.0079  -0.0231  -0.0183  
      health |   0.0144  -0.2913   0.4020   0.2056   0.2392   0.1192   0.2131  
        walk |   0.0014  -0.1561   0.2255   0.1543   0.1947   0.0467   0.0898  
  depression |        .  -0.1664   0.2844   0.1168   0.1129   0.0480   0.1843  
     anxiety |        .  -0.2060   0.2686   0.0126  -0.0272   0.0266   0.1966  
      sleep1 |   0.0098  -0.1532   0.2471   0.0228   0.0352   0.0326   0.1366  
      sleep2 |   0.0080  -0.1648   0.2151   0.0735   0.0713   0.0371   0.1028  
      sleep3 |  -0.0001  -0.1675   0.2480   0.0230   0.0142   0.0269   0.1277  
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      sleep4 |  -0.0061  -0.1813   0.3014   0.0247  -0.0337   0.0200   0.1580  
         out |   0.0055  -0.1554   0.2502   0.2320   0.3669   0.1013   0.1423  
      partic |   0.0077  -0.1608   0.2308   0.1396   0.1966   0.0759   0.1802  
     obesity |  -0.0168  -0.0988   0.1349  -0.0401  -0.1006   0.0088   0.0809  
   physfunct |        .   0.3525  -0.4878  -0.2653  -0.3937  -0.1142  -0.2186  
     painint |        .  -0.4996   0.5589   0.1571   0.1977   0.0939   0.2139  
   cognitive |        .  -0.1985   0.2688   0.1076   0.1484   0.0247   0.1619  
        slp3 |        .        .        .        .        .        .        .  
        bmi3 |        .        .        .        .        .        .        .  
         pf3 |        .        .        .        .        .        .        .  
        anx3 |        .        .        .        .        .        .        .  
        dep3 |        .        .        .        .        .        .        .  
        cog3 |        .        .        .        .        .        .        .  
         gh3 |        .        .        .        .        .        .        .  
       part3 |        .        .        .        .        .        .        .  
 
             |  alcohol    smoke  control   health     walk depres~n  anxiety 
-------------+--------------------------------------------------------------- 
     alcohol |   1.0000  
       smoke |   0.1158   1.0000  
     control |   0.0002  -0.1999   1.0000  
      health |   0.1598  -0.0613  -0.0208   1.0000  
        walk |   0.1398  -0.0122  -0.0217   0.3826   1.0000  
  depression |   0.1205  -0.0228  -0.0093   0.4413   0.2985   1.0000  
     anxiety |   0.0856   0.0093  -0.0463   0.3234   0.1692   0.4194   1.0000  
      sleep1 |   0.0943   0.0159  -0.0210   0.2494   0.1541   0.2458   0.2644  
      sleep2 |   0.0764   0.0773  -0.2186   0.2480   0.1485   0.2141   0.2287  
      sleep3 |   0.0701   0.0020  -0.0150   0.2533   0.1502   0.2595   0.2775  
      sleep4 |   0.0853  -0.0090  -0.0167   0.3126   0.1934   0.3434   0.3157  
         out |   0.1925  -0.0011  -0.0112   0.4615   0.5116   0.3932   0.2236  
      partic |   0.1316  -0.0131   0.0373   0.3890   0.2798   0.3266   0.2428  
     obesity |   0.0709  -0.0148  -0.0148   0.1423   0.1125   0.0809   0.0592  
   physfunct |  -0.2143   0.0236   0.0378  -0.6629  -0.5167  -0.4536  -0.3021  
     painint |   0.1430  -0.0337  -0.0276   0.5991   0.3743   0.4082   0.3212  
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   cognitive |   0.0893  -0.0113  -0.0263   0.3374   0.1898   0.3500   0.3471  
        slp3 |        .        .        .        .        .        .        .  
        bmi3 |        .        .        .        .        .        .        .  
         pf3 |        .        .        .        .        .        .        .  
        anx3 |        .        .        .        .        .        .        .  
        dep3 |        .        .        .        .        .        .        .  
        cog3 |        .        .        .        .        .        .        .  
         gh3 |        .        .        .        .        .        .        .  
       part3 |        .        .        .        .        .        .        .  
 
             |   sleep1   sleep2   sleep3   sleep4      out   partic  obesity 
-------------+--------------------------------------------------------------- 
      sleep1 |   1.0000  
      sleep2 |   0.4145   1.0000  
      sleep3 |   0.5954   0.5615   1.0000  
      sleep4 |   0.4645   0.3710   0.5106   1.0000  
         out |   0.1898   0.1781   0.1792   0.2070   1.0000  
      partic |   0.1729   0.1439   0.1654   0.2007   0.3858   1.0000  
     obesity |   0.0710   0.0755   0.0821   0.0925   0.0588   0.0663   1.0000  
   physfunct |  -0.2685  -0.2789  -0.2762  -0.3075  -0.5691  -0.4574  -0.1629  
     painint |   0.2669   0.2630   0.2840   0.3106   0.4388   0.4100   0.1405  
   cognitive |   0.2026   0.2101   0.2179   0.2623   0.2751   0.2715   0.0497  
        slp3 |        .        .        .        .        .        .        .  
        bmi3 |        .        .        .        .        .        .        .  
         pf3 |        .        .        .        .        .        .        .  
        anx3 |        .        .        .        .        .        .        .  
        dep3 |        .        .        .        .        .        .        .  
        cog3 |        .        .        .        .        .        .        .  
         gh3 |        .        .        .        .        .        .        .  
       part3 |        .        .        .        .        .        .        .  
 
             | physfu~t  painint cognit~e     slp3     bmi3      pf3     anx3 
-------------+--------------------------------------------------------------- 
   physfunct |   1.0000  
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     painint |  -0.7328   1.0000  
   cognitive |  -0.3703   0.3374   1.0000  
        slp3 |        .        .        .        .  
        bmi3 |        .        .        .        .        .  
         pf3 |        .        .        .        .        .        .  
        anx3 |        .        .        .        .        .        .        .  
        dep3 |        .        .        .        .        .        .        .  
        cog3 |        .        .        .        .        .        .        .  
         gh3 |        .        .        .        .        .        .        .  
       part3 |        .        .        .        .        .        .        .  
 
             |     dep3     cog3      gh3    part3 
-------------+------------------------------------ 
        dep3 |        .  
        cog3 |        .        .  
         gh3 |        .        .        .  
       part3 |        .        .        .        .  
 
             | m_educ~n     pain  numpain   censor      age      sex   income 
-------------+--------------------------------------------------------------- 
 m_education |   1.0000  
        pain |   0.0008   1.0000  
     numpain |   0.0008  -0.5166   1.0000  
      censor |   0.0373  -0.0124   0.0262   1.0000  
         age |   0.0740   0.0064  -0.0068   0.3915   1.0000  
         sex |  -0.0236   0.0328  -0.0747   0.0518  -0.0690   1.0000  
      income |   0.0107  -0.1015   0.1639   0.0205   0.0011  -0.0089   1.0000  
     alcohol |   0.0331  -0.0345   0.1042   0.0612   0.1774  -0.2396   0.1104  
       smoke |   0.0141   0.0179  -0.0282  -0.0447   0.0234  -0.2045  -0.0153  
     control |   0.0010   0.0340  -0.0253  -0.0355   0.0079   0.0004  -0.0183  
      health |   0.0316  -0.2913   0.4020   0.2056   0.2392  -0.0032   0.2131  
        walk |  -0.0020  -0.1561   0.2255   0.1543   0.1947  -0.0922   0.0898  
  depression |   0.0252  -0.1664   0.2844   0.1168   0.1129  -0.0088   0.1843  
     anxiety |   0.0065  -0.2060   0.2686   0.0126  -0.0272  -0.1434   0.1966  
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      sleep1 |   0.0208  -0.1532   0.2471   0.0228   0.0352  -0.1027   0.1366  
      sleep2 |   0.0156  -0.1648   0.2151   0.0735   0.0713  -0.0598   0.1028  
      sleep3 |   0.0137  -0.1675   0.2480   0.0230   0.0142  -0.0818   0.1277  
      sleep4 |   0.0023  -0.1813   0.3014   0.0247  -0.0337  -0.0705   0.1580  
         out |   0.0350  -0.1554   0.2502   0.2320   0.3669  -0.1078   0.1423  
      partic |   0.0399  -0.1608   0.2308   0.1396   0.1966  -0.0606   0.1802  
     obesity |  -0.0054  -0.0988   0.1349  -0.0401  -0.1006  -0.0384   0.0809  
   physfunct |  -0.0339   0.3525  -0.4878  -0.2653  -0.3937   0.1320  -0.2186  
     painint |   0.0227  -0.4996   0.5589   0.1571   0.1977  -0.0374   0.2139  
   cognitive |   0.0273  -0.1985   0.2688   0.1076   0.1484  -0.0455   0.1619  
        slp3 |        .        .        .        .        .        .        .  
        bmi3 |        .        .        .        .        .        .        .  
         pf3 |        .        .        .        .        .        .        .  
        anx3 |        .        .        .        .        .        .        .  
        dep3 |        .        .        .        .        .        .        .  
        cog3 |        .        .        .        .        .        .        .  
         gh3 |        .        .        .        .        .        .        .  
       part3 |        .        .        .        .        .        .        .  
 
             |  alcohol    smoke  control   health     walk depres~n  anxiety 
-------------+--------------------------------------------------------------- 
     alcohol |   1.0000  
       smoke |   0.1158   1.0000  
     control |   0.0002  -0.1999   1.0000  
      health |   0.1598  -0.0613  -0.0208   1.0000  
        walk |   0.1398  -0.0122  -0.0217   0.3826   1.0000  
  depression |   0.1205  -0.0228  -0.0093   0.4413   0.2985   1.0000  
     anxiety |   0.0856   0.0093  -0.0463   0.3234   0.1692   0.4194   1.0000  
      sleep1 |   0.0943   0.0159  -0.0210   0.2494   0.1541   0.2458   0.2644  
      sleep2 |   0.0764   0.0773  -0.2186   0.2480   0.1485   0.2141   0.2287  
      sleep3 |   0.0701   0.0020  -0.0150   0.2533   0.1502   0.2595   0.2775  
      sleep4 |   0.0853  -0.0090  -0.0167   0.3126   0.1934   0.3434   0.3157  
         out |   0.1925  -0.0011  -0.0112   0.4615   0.5116   0.3932   0.2236  
      partic |   0.1316  -0.0131   0.0373   0.3890   0.2798   0.3266   0.2428  
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     obesity |   0.0709  -0.0148  -0.0148   0.1423   0.1125   0.0809   0.0592  
   physfunct |  -0.2143   0.0236   0.0378  -0.6629  -0.5167  -0.4536  -0.3021  
     painint |   0.1430  -0.0337  -0.0276   0.5991   0.3743   0.4082   0.3212  
   cognitive |   0.0893  -0.0113  -0.0263   0.3374   0.1898   0.3500   0.3471  
        slp3 |        .        .        .        .        .        .        .  
        bmi3 |        .        .        .        .        .        .        .  
         pf3 |        .        .        .        .        .        .        .  
        anx3 |        .        .        .        .        .        .        .  
        dep3 |        .        .        .        .        .        .        .  
        cog3 |        .        .        .        .        .        .        .  
         gh3 |        .        .        .        .        .        .        .  
       part3 |        .        .        .        .        .        .        .  
 
             |   sleep1   sleep2   sleep3   sleep4      out   partic  obesity 
-------------+--------------------------------------------------------------- 
      sleep1 |   1.0000  
      sleep2 |   0.4145   1.0000  
      sleep3 |   0.5954   0.5615   1.0000  
      sleep4 |   0.4645   0.3710   0.5106   1.0000  
         out |   0.1898   0.1781   0.1792   0.2070   1.0000  
      partic |   0.1729   0.1439   0.1654   0.2007   0.3858   1.0000  
     obesity |   0.0710   0.0755   0.0821   0.0925   0.0588   0.0663   1.0000  
   physfunct |  -0.2685  -0.2789  -0.2762  -0.3075  -0.5691  -0.4574  -0.1629  
     painint |   0.2669   0.2630   0.2840   0.3106   0.4388   0.4100   0.1405  
   cognitive |   0.2026   0.2101   0.2179   0.2623   0.2751   0.2715   0.0497  
        slp3 |        .        .        .        .        .        .        .  
        bmi3 |        .        .        .        .        .        .        .  
         pf3 |        .        .        .        .        .        .        .  
        anx3 |        .        .        .        .        .        .        .  
        dep3 |        .        .        .        .        .        .        .  
        cog3 |        .        .        .        .        .        .        .  
         gh3 |        .        .        .        .        .        .        .  
       part3 |        .        .        .        .        .        .        .  
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             | physfu~t  painint cognit~e     slp3     bmi3      pf3     anx3 
-------------+--------------------------------------------------------------- 
   physfunct |   1.0000  
     painint |  -0.7328   1.0000  
   cognitive |  -0.3703   0.3374   1.0000  
        slp3 |        .        .        .        .  
        bmi3 |        .        .        .        .        .  
         pf3 |        .        .        .        .        .        .  
        anx3 |        .        .        .        .        .        .        .  
        dep3 |        .        .        .        .        .        .        .  
        cog3 |        .        .        .        .        .        .        .  
         gh3 |        .        .        .        .        .        .        .  
       part3 |        .        .        .        .        .        .        .  
 
             |     dep3     cog3      gh3    part3 
-------------+------------------------------------ 
        dep3 |        .  
        cog3 |        .        .  
         gh3 |        .        .        .  
       part3 |        .        .        .        .  
 
             | m_income     pain  numpain   censor      age      sex educat~n 
-------------+--------------------------------------------------------------- 
    m_income |   1.0000  
        pain |  -0.0116   1.0000  
     numpain |   0.0092  -0.5166   1.0000  
      censor |   0.0495  -0.0124   0.0262   1.0000  
         age |   0.0807   0.0064  -0.0068   0.3915   1.0000  
         sex |  -0.0033   0.0328  -0.0747   0.0518  -0.0690   1.0000  
   education |  -0.0002  -0.0491   0.0448   0.0574   0.1316   0.0546   1.0000  
     alcohol |   0.0360  -0.0345   0.1042   0.0612   0.1774  -0.2396   0.0480  
       smoke |   0.0019   0.0179  -0.0282  -0.0447   0.0234  -0.2045  -0.0207  
     control |   0.0108   0.0340  -0.0253  -0.0355   0.0079   0.0004  -0.0231  
      health |   0.0643  -0.2913   0.4020   0.2056   0.2392  -0.0032   0.1192  
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        walk |   0.0231  -0.1561   0.2255   0.1543   0.1947  -0.0922   0.0467  
  depression |   0.0465  -0.1664   0.2844   0.1168   0.1129  -0.0088   0.0480  
     anxiety |   0.0282  -0.2060   0.2686   0.0126  -0.0272  -0.1434   0.0266  
      sleep1 |   0.0449  -0.1532   0.2471   0.0228   0.0352  -0.1027   0.0326  
      sleep2 |   0.0310  -0.1648   0.2151   0.0735   0.0713  -0.0598   0.0371  
      sleep3 |   0.0349  -0.1675   0.2480   0.0230   0.0142  -0.0818   0.0269  
      sleep4 |   0.0299  -0.1813   0.3014   0.0247  -0.0337  -0.0705   0.0200  
         out |   0.0589  -0.1554   0.2502   0.2320   0.3669  -0.1078   0.1013  
      partic |   0.0683  -0.1608   0.2308   0.1396   0.1966  -0.0606   0.0759  
     obesity |   0.0027  -0.0988   0.1349  -0.0401  -0.1006  -0.0384   0.0088  
   physfunct |  -0.0593   0.3525  -0.4878  -0.2653  -0.3937   0.1320  -0.1142  
     painint |   0.0507  -0.4996   0.5589   0.1571   0.1977  -0.0374   0.0939  
   cognitive |   0.0445  -0.1985   0.2688   0.1076   0.1484  -0.0455   0.0247  
        slp3 |        .        .        .        .        .        .        .  
        bmi3 |        .        .        .        .        .        .        .  
         pf3 |        .        .        .        .        .        .        .  
        anx3 |        .        .        .        .        .        .        .  
        dep3 |        .        .        .        .        .        .        .  
        cog3 |        .        .        .        .        .        .        .  
         gh3 |        .        .        .        .        .        .        .  
       part3 |        .        .        .        .        .        .        .  
 
             |  alcohol    smoke  control   health     walk depres~n  anxiety 
-------------+--------------------------------------------------------------- 
     alcohol |   1.0000  
       smoke |   0.1158   1.0000  
     control |   0.0002  -0.1999   1.0000  
      health |   0.1598  -0.0613  -0.0208   1.0000  
        walk |   0.1398  -0.0122  -0.0217   0.3826   1.0000  
  depression |   0.1205  -0.0228  -0.0093   0.4413   0.2985   1.0000  
     anxiety |   0.0856   0.0093  -0.0463   0.3234   0.1692   0.4194   1.0000  
      sleep1 |   0.0943   0.0159  -0.0210   0.2494   0.1541   0.2458   0.2644  
      sleep2 |   0.0764   0.0773  -0.2186   0.2480   0.1485   0.2141   0.2287  
      sleep3 |   0.0701   0.0020  -0.0150   0.2533   0.1502   0.2595   0.2775  
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      sleep4 |   0.0853  -0.0090  -0.0167   0.3126   0.1934   0.3434   0.3157  
         out |   0.1925  -0.0011  -0.0112   0.4615   0.5116   0.3932   0.2236  
      partic |   0.1316  -0.0131   0.0373   0.3890   0.2798   0.3266   0.2428  
     obesity |   0.0709  -0.0148  -0.0148   0.1423   0.1125   0.0809   0.0592  
   physfunct |  -0.2143   0.0236   0.0378  -0.6629  -0.5167  -0.4536  -0.3021  
     painint |   0.1430  -0.0337  -0.0276   0.5991   0.3743   0.4082   0.3212  
   cognitive |   0.0893  -0.0113  -0.0263   0.3374   0.1898   0.3500   0.3471  
        slp3 |        .        .        .        .        .        .        .  
        bmi3 |        .        .        .        .        .        .        .  
         pf3 |        .        .        .        .        .        .        .  
        anx3 |        .        .        .        .        .        .        .  
        dep3 |        .        .        .        .        .        .        .  
        cog3 |        .        .        .        .        .        .        .  
         gh3 |        .        .        .        .        .        .        .  
       part3 |        .        .        .        .        .        .        .  
 
             |   sleep1   sleep2   sleep3   sleep4      out   partic  obesity 
-------------+--------------------------------------------------------------- 
      sleep1 |   1.0000  
      sleep2 |   0.4145   1.0000  
      sleep3 |   0.5954   0.5615   1.0000  
      sleep4 |   0.4645   0.3710   0.5106   1.0000  
         out |   0.1898   0.1781   0.1792   0.2070   1.0000  
      partic |   0.1729   0.1439   0.1654   0.2007   0.3858   1.0000  
     obesity |   0.0710   0.0755   0.0821   0.0925   0.0588   0.0663   1.0000  
   physfunct |  -0.2685  -0.2789  -0.2762  -0.3075  -0.5691  -0.4574  -0.1629  
     painint |   0.2669   0.2630   0.2840   0.3106   0.4388   0.4100   0.1405  
   cognitive |   0.2026   0.2101   0.2179   0.2623   0.2751   0.2715   0.0497  
        slp3 |        .        .        .        .        .        .        .  
        bmi3 |        .        .        .        .        .        .        .  
         pf3 |        .        .        .        .        .        .        .  
        anx3 |        .        .        .        .        .        .        .  
        dep3 |        .        .        .        .        .        .        .  
        cog3 |        .        .        .        .        .        .        .  
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         gh3 |        .        .        .        .        .        .        .  
       part3 |        .        .        .        .        .        .        .  
 
             | physfu~t  painint cognit~e     slp3     bmi3      pf3     anx3 
-------------+--------------------------------------------------------------- 
   physfunct |   1.0000  
     painint |  -0.7328   1.0000  
   cognitive |  -0.3703   0.3374   1.0000  
        slp3 |        .        .        .        .  
        bmi3 |        .        .        .        .        .  
         pf3 |        .        .        .        .        .        .  
        anx3 |        .        .        .        .        .        .        .  
        dep3 |        .        .        .        .        .        .        .  
        cog3 |        .        .        .        .        .        .        .  
         gh3 |        .        .        .        .        .        .        .  
       part3 |        .        .        .        .        .        .        .  
 
             |     dep3     cog3      gh3    part3 
-------------+------------------------------------ 
        dep3 |        .  
        cog3 |        .        .  
         gh3 |        .        .        .  
       part3 |        .        .        .        .  
 
             | m_alco~l     pain  numpain   censor      age      sex educat~n 
-------------+--------------------------------------------------------------- 
   m_alcohol |   1.0000  
        pain |  -0.0052   1.0000  
     numpain |   0.0015  -0.5166   1.0000  
      censor |   0.0379  -0.0124   0.0262   1.0000  
         age |   0.0469   0.0064  -0.0068   0.3915   1.0000  
         sex |  -0.0065   0.0328  -0.0747   0.0518  -0.0690   1.0000  
   education |   0.0002  -0.0491   0.0448   0.0574   0.1316   0.0546   1.0000  
      income |  -0.0029  -0.1015   0.1639   0.0205   0.0011  -0.0089   0.0854  
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       smoke |   0.0059   0.0179  -0.0282  -0.0447   0.0234  -0.2045  -0.0207  
     control |  -0.0052   0.0340  -0.0253  -0.0355   0.0079   0.0004  -0.0231  
      health |   0.0285  -0.2913   0.4020   0.2056   0.2392  -0.0032   0.1192  
        walk |  -0.0057  -0.1561   0.2255   0.1543   0.1947  -0.0922   0.0467  
  depression |   0.0049  -0.1664   0.2844   0.1168   0.1129  -0.0088   0.0480  
     anxiety |  -0.0046  -0.2060   0.2686   0.0126  -0.0272  -0.1434   0.0266  
      sleep1 |   0.0066  -0.1532   0.2471   0.0228   0.0352  -0.1027   0.0326  
      sleep2 |   0.0010  -0.1648   0.2151   0.0735   0.0713  -0.0598   0.0371  
      sleep3 |   0.0018  -0.1675   0.2480   0.0230   0.0142  -0.0818   0.0269  
      sleep4 |   0.0013  -0.1813   0.3014   0.0247  -0.0337  -0.0705   0.0200  
         out |   0.0214  -0.1554   0.2502   0.2320   0.3669  -0.1078   0.1013  
      partic |   0.0254  -0.1608   0.2308   0.1396   0.1966  -0.0606   0.0759  
     obesity |  -0.0006  -0.0988   0.1349  -0.0401  -0.1006  -0.0384   0.0088  
   physfunct |  -0.0214   0.3525  -0.4878  -0.2653  -0.3937   0.1320  -0.1142  
     painint |   0.0141  -0.4996   0.5589   0.1571   0.1977  -0.0374   0.0939  
   cognitive |   0.0129  -0.1985   0.2688   0.1076   0.1484  -0.0455   0.0247  
        slp3 |        .        .        .        .        .        .        .  
        bmi3 |        .        .        .        .        .        .        .  
         pf3 |        .        .        .        .        .        .        .  
        anx3 |        .        .        .        .        .        .        .  
        dep3 |        .        .        .        .        .        .        .  
        cog3 |        .        .        .        .        .        .        .  
         gh3 |        .        .        .        .        .        .        .  
       part3 |        .        .        .        .        .        .        .  
 
             |   income    smoke  control   health     walk depres~n  anxiety 
-------------+--------------------------------------------------------------- 
      income |   1.0000  
       smoke |  -0.0153   1.0000  
     control |  -0.0183  -0.1999   1.0000  
      health |   0.2131  -0.0613  -0.0208   1.0000  
        walk |   0.0898  -0.0122  -0.0217   0.3826   1.0000  
  depression |   0.1843  -0.0228  -0.0093   0.4413   0.2985   1.0000  
     anxiety |   0.1966   0.0093  -0.0463   0.3234   0.1692   0.4194   1.0000  
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      sleep1 |   0.1366   0.0159  -0.0210   0.2494   0.1541   0.2458   0.2644  
      sleep2 |   0.1028   0.0773  -0.2186   0.2480   0.1485   0.2141   0.2287  
      sleep3 |   0.1277   0.0020  -0.0150   0.2533   0.1502   0.2595   0.2775  
      sleep4 |   0.1580  -0.0090  -0.0167   0.3126   0.1934   0.3434   0.3157  
         out |   0.1423  -0.0011  -0.0112   0.4615   0.5116   0.3932   0.2236  
      partic |   0.1802  -0.0131   0.0373   0.3890   0.2798   0.3266   0.2428  
     obesity |   0.0809  -0.0148  -0.0148   0.1423   0.1125   0.0809   0.0592  
   physfunct |  -0.2186   0.0236   0.0378  -0.6629  -0.5167  -0.4536  -0.3021  
     painint |   0.2139  -0.0337  -0.0276   0.5991   0.3743   0.4082   0.3212  
   cognitive |   0.1619  -0.0113  -0.0263   0.3374   0.1898   0.3500   0.3471  
        slp3 |        .        .        .        .        .        .        .  
        bmi3 |        .        .        .        .        .        .        .  
         pf3 |        .        .        .        .        .        .        .  
        anx3 |        .        .        .        .        .        .        .  
        dep3 |        .        .        .        .        .        .        .  
        cog3 |        .        .        .        .        .        .        .  
         gh3 |        .        .        .        .        .        .        .  
       part3 |        .        .        .        .        .        .        .  
 
             |   sleep1   sleep2   sleep3   sleep4      out   partic  obesity 
-------------+--------------------------------------------------------------- 
      sleep1 |   1.0000  
      sleep2 |   0.4145   1.0000  
      sleep3 |   0.5954   0.5615   1.0000  
      sleep4 |   0.4645   0.3710   0.5106   1.0000  
         out |   0.1898   0.1781   0.1792   0.2070   1.0000  
      partic |   0.1729   0.1439   0.1654   0.2007   0.3858   1.0000  
     obesity |   0.0710   0.0755   0.0821   0.0925   0.0588   0.0663   1.0000  
   physfunct |  -0.2685  -0.2789  -0.2762  -0.3075  -0.5691  -0.4574  -0.1629  
     painint |   0.2669   0.2630   0.2840   0.3106   0.4388   0.4100   0.1405  
   cognitive |   0.2026   0.2101   0.2179   0.2623   0.2751   0.2715   0.0497  
        slp3 |        .        .        .        .        .        .        .  
        bmi3 |        .        .        .        .        .        .        .  
         pf3 |        .        .        .        .        .        .        .  
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        anx3 |        .        .        .        .        .        .        .  
        dep3 |        .        .        .        .        .        .        .  
        cog3 |        .        .        .        .        .        .        .  
         gh3 |        .        .        .        .        .        .        .  
       part3 |        .        .        .        .        .        .        .  
 
             | physfu~t  painint cognit~e     slp3     bmi3      pf3     anx3 
-------------+--------------------------------------------------------------- 
   physfunct |   1.0000  
     painint |  -0.7328   1.0000  
   cognitive |  -0.3703   0.3374   1.0000  
        slp3 |        .        .        .        .  
        bmi3 |        .        .        .        .        .  
         pf3 |        .        .        .        .        .        .  
        anx3 |        .        .        .        .        .        .        .  
        dep3 |        .        .        .        .        .        .        .  
        cog3 |        .        .        .        .        .        .        .  
         gh3 |        .        .        .        .        .        .        .  
       part3 |        .        .        .        .        .        .        .  
 
             |     dep3     cog3      gh3    part3 
-------------+------------------------------------ 
        dep3 |        .  
        cog3 |        .        .  
         gh3 |        .        .        .  
       part3 |        .        .        .        .  
 
             |  m_smoke     pain  numpain   censor      age      sex educat~n 
-------------+--------------------------------------------------------------- 
     m_smoke |   1.0000  
        pain |  -0.0090   1.0000  
     numpain |  -0.0037  -0.5166   1.0000  
      censor |   0.0226  -0.0124   0.0262   1.0000  
         age |   0.0617   0.0064  -0.0068   0.3915   1.0000  
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         sex |  -0.0023   0.0328  -0.0747   0.0518  -0.0690   1.0000  
   education |   0.0053  -0.0491   0.0448   0.0574   0.1316   0.0546   1.0000  
      income |   0.0030  -0.1015   0.1639   0.0205   0.0011  -0.0089   0.0854  
     alcohol |   0.0170  -0.0345   0.1042   0.0612   0.1774  -0.2396   0.0480  
     control |   0.0068   0.0340  -0.0253  -0.0355   0.0079   0.0004  -0.0231  
      health |   0.0241  -0.2913   0.4020   0.2056   0.2392  -0.0032   0.1192  
        walk |   0.0046  -0.1561   0.2255   0.1543   0.1947  -0.0922   0.0467  
  depression |   0.0108  -0.1664   0.2844   0.1168   0.1129  -0.0088   0.0480  
     anxiety |   0.0034  -0.2060   0.2686   0.0126  -0.0272  -0.1434   0.0266  
      sleep1 |   0.0021  -0.1532   0.2471   0.0228   0.0352  -0.1027   0.0326  
      sleep2 |   0.0027  -0.1648   0.2151   0.0735   0.0713  -0.0598   0.0371  
      sleep3 |  -0.0008  -0.1675   0.2480   0.0230   0.0142  -0.0818   0.0269  
      sleep4 |  -0.0037  -0.1813   0.3014   0.0247  -0.0337  -0.0705   0.0200  
         out |   0.0150  -0.1554   0.2502   0.2320   0.3669  -0.1078   0.1013  
      partic |   0.0352  -0.1608   0.2308   0.1396   0.1966  -0.0606   0.0759  
     obesity |  -0.0043  -0.0988   0.1349  -0.0401  -0.1006  -0.0384   0.0088  
   physfunct |  -0.0293   0.3525  -0.4878  -0.2653  -0.3937   0.1320  -0.1142  
     painint |   0.0168  -0.4996   0.5589   0.1571   0.1977  -0.0374   0.0939  
   cognitive |   0.0211  -0.1985   0.2688   0.1076   0.1484  -0.0455   0.0247  
        slp3 |        .        .        .        .        .        .        .  
        bmi3 |        .        .        .        .        .        .        .  
         pf3 |        .        .        .        .        .        .        .  
        anx3 |        .        .        .        .        .        .        .  
        dep3 |        .        .        .        .        .        .        .  
        cog3 |        .        .        .        .        .        .        .  
         gh3 |        .        .        .        .        .        .        .  
       part3 |        .        .        .        .        .        .        .  
 
             |   income  alcohol  control   health     walk depres~n  anxiety 
-------------+--------------------------------------------------------------- 
      income |   1.0000  
     alcohol |   0.1104   1.0000  
     control |  -0.0183   0.0002   1.0000  
      health |   0.2131   0.1598  -0.0208   1.0000  
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        walk |   0.0898   0.1398  -0.0217   0.3826   1.0000  
  depression |   0.1843   0.1205  -0.0093   0.4413   0.2985   1.0000  
     anxiety |   0.1966   0.0856  -0.0463   0.3234   0.1692   0.4194   1.0000  
      sleep1 |   0.1366   0.0943  -0.0210   0.2494   0.1541   0.2458   0.2644  
      sleep2 |   0.1028   0.0764  -0.2186   0.2480   0.1485   0.2141   0.2287  
      sleep3 |   0.1277   0.0701  -0.0150   0.2533   0.1502   0.2595   0.2775  
      sleep4 |   0.1580   0.0853  -0.0167   0.3126   0.1934   0.3434   0.3157  
         out |   0.1423   0.1925  -0.0112   0.4615   0.5116   0.3932   0.2236  
      partic |   0.1802   0.1316   0.0373   0.3890   0.2798   0.3266   0.2428  
     obesity |   0.0809   0.0709  -0.0148   0.1423   0.1125   0.0809   0.0592  
   physfunct |  -0.2186  -0.2143   0.0378  -0.6629  -0.5167  -0.4536  -0.3021  
     painint |   0.2139   0.1430  -0.0276   0.5991   0.3743   0.4082   0.3212  
   cognitive |   0.1619   0.0893  -0.0263   0.3374   0.1898   0.3500   0.3471  
        slp3 |        .        .        .        .        .        .        .  
        bmi3 |        .        .        .        .        .        .        .  
         pf3 |        .        .        .        .        .        .        .  
        anx3 |        .        .        .        .        .        .        .  
        dep3 |        .        .        .        .        .        .        .  
        cog3 |        .        .        .        .        .        .        .  
         gh3 |        .        .        .        .        .        .        .  
       part3 |        .        .        .        .        .        .        .  
 
             |   sleep1   sleep2   sleep3   sleep4      out   partic  obesity 
-------------+--------------------------------------------------------------- 
      sleep1 |   1.0000  
      sleep2 |   0.4145   1.0000  
      sleep3 |   0.5954   0.5615   1.0000  
      sleep4 |   0.4645   0.3710   0.5106   1.0000  
         out |   0.1898   0.1781   0.1792   0.2070   1.0000  
      partic |   0.1729   0.1439   0.1654   0.2007   0.3858   1.0000  
     obesity |   0.0710   0.0755   0.0821   0.0925   0.0588   0.0663   1.0000  
   physfunct |  -0.2685  -0.2789  -0.2762  -0.3075  -0.5691  -0.4574  -0.1629  
     painint |   0.2669   0.2630   0.2840   0.3106   0.4388   0.4100   0.1405  
   cognitive |   0.2026   0.2101   0.2179   0.2623   0.2751   0.2715   0.0497  
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        slp3 |        .        .        .        .        .        .        .  
        bmi3 |        .        .        .        .        .        .        .  
         pf3 |        .        .        .        .        .        .        .  
        anx3 |        .        .        .        .        .        .        .  
        dep3 |        .        .        .        .        .        .        .  
        cog3 |        .        .        .        .        .        .        .  
         gh3 |        .        .        .        .        .        .        .  
       part3 |        .        .        .        .        .        .        .  
 
             | physfu~t  painint cognit~e     slp3     bmi3      pf3     anx3 
-------------+--------------------------------------------------------------- 
   physfunct |   1.0000  
     painint |  -0.7328   1.0000  
   cognitive |  -0.3703   0.3374   1.0000  
        slp3 |        .        .        .        .  
        bmi3 |        .        .        .        .        .  
         pf3 |        .        .        .        .        .        .  
        anx3 |        .        .        .        .        .        .        .  
        dep3 |        .        .        .        .        .        .        .  
        cog3 |        .        .        .        .        .        .        .  
         gh3 |        .        .        .        .        .        .        .  
       part3 |        .        .        .        .        .        .        .  
 
             |     dep3     cog3      gh3    part3 
-------------+------------------------------------ 
        dep3 |        .  
        cog3 |        .        .  
         gh3 |        .        .        .  
       part3 |        .        .        .        .  
 
             | m_cont~l     pain  numpain   censor      age      sex educat~n 
-------------+--------------------------------------------------------------- 
   m_control |   1.0000  
        pain |  -0.0109   1.0000  
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     numpain |   0.0002  -0.5166   1.0000  
      censor |   0.0436  -0.0124   0.0262   1.0000  
         age |   0.0784   0.0064  -0.0068   0.3915   1.0000  
         sex |  -0.0281   0.0328  -0.0747   0.0518  -0.0690   1.0000  
   education |  -0.0061  -0.0491   0.0448   0.0574   0.1316   0.0546   1.0000  
      income |   0.0144  -0.1015   0.1639   0.0205   0.0011  -0.0089   0.0854  
     alcohol |   0.0377  -0.0345   0.1042   0.0612   0.1774  -0.2396   0.0480  
       smoke |   0.0132   0.0179  -0.0282  -0.0447   0.0234  -0.2045  -0.0207  
      health |   0.0498  -0.2913   0.4020   0.2056   0.2392  -0.0032   0.1192  
        walk |   0.0334  -0.1561   0.2255   0.1543   0.1947  -0.0922   0.0467  
  depression |   0.0373  -0.1664   0.2844   0.1168   0.1129  -0.0088   0.0480  
     anxiety |   0.0134  -0.2060   0.2686   0.0126  -0.0272  -0.1434   0.0266  
      sleep1 |   0.0204  -0.1532   0.2471   0.0228   0.0352  -0.1027   0.0326  
      sleep2 |  -0.0061  -0.1648   0.2151   0.0735   0.0713  -0.0598   0.0371  
      sleep3 |   0.0006  -0.1675   0.2480   0.0230   0.0142  -0.0818   0.0269  
      sleep4 |   0.0127  -0.1813   0.3014   0.0247  -0.0337  -0.0705   0.0200  
         out |   0.0439  -0.1554   0.2502   0.2320   0.3669  -0.1078   0.1013  
      partic |   0.0403  -0.1608   0.2308   0.1396   0.1966  -0.0606   0.0759  
     obesity |  -0.0084  -0.0988   0.1349  -0.0401  -0.1006  -0.0384   0.0088  
   physfunct |  -0.0592   0.3525  -0.4878  -0.2653  -0.3937   0.1320  -0.1142  
     painint |   0.0377  -0.4996   0.5589   0.1571   0.1977  -0.0374   0.0939  
   cognitive |   0.0117  -0.1985   0.2688   0.1076   0.1484  -0.0455   0.0247  
        slp3 |        .        .        .        .        .        .        .  
        bmi3 |        .        .        .        .        .        .        .  
         pf3 |        .        .        .        .        .        .        .  
        anx3 |        .        .        .        .        .        .        .  
        dep3 |        .        .        .        .        .        .        .  
        cog3 |        .        .        .        .        .        .        .  
         gh3 |        .        .        .        .        .        .        .  
       part3 |        .        .        .        .        .        .        .  
 
             |   income  alcohol    smoke   health     walk depres~n  anxiety 
-------------+--------------------------------------------------------------- 
      income |   1.0000  
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     alcohol |   0.1104   1.0000  
       smoke |  -0.0153   0.1158   1.0000  
      health |   0.2131   0.1598  -0.0613   1.0000  
        walk |   0.0898   0.1398  -0.0122   0.3826   1.0000  
  depression |   0.1843   0.1205  -0.0228   0.4413   0.2985   1.0000  
     anxiety |   0.1966   0.0856   0.0093   0.3234   0.1692   0.4194   1.0000  
      sleep1 |   0.1366   0.0943   0.0159   0.2494   0.1541   0.2458   0.2644  
      sleep2 |   0.1028   0.0764   0.0773   0.2480   0.1485   0.2141   0.2287  
      sleep3 |   0.1277   0.0701   0.0020   0.2533   0.1502   0.2595   0.2775  
      sleep4 |   0.1580   0.0853  -0.0090   0.3126   0.1934   0.3434   0.3157  
         out |   0.1423   0.1925  -0.0011   0.4615   0.5116   0.3932   0.2236  
      partic |   0.1802   0.1316  -0.0131   0.3890   0.2798   0.3266   0.2428  
     obesity |   0.0809   0.0709  -0.0148   0.1423   0.1125   0.0809   0.0592  
   physfunct |  -0.2186  -0.2143   0.0236  -0.6629  -0.5167  -0.4536  -0.3021  
     painint |   0.2139   0.1430  -0.0337   0.5991   0.3743   0.4082   0.3212  
   cognitive |   0.1619   0.0893  -0.0113   0.3374   0.1898   0.3500   0.3471  
        slp3 |        .        .        .        .        .        .        .  
        bmi3 |        .        .        .        .        .        .        .  
         pf3 |        .        .        .        .        .        .        .  
        anx3 |        .        .        .        .        .        .        .  
        dep3 |        .        .        .        .        .        .        .  
        cog3 |        .        .        .        .        .        .        .  
         gh3 |        .        .        .        .        .        .        .  
       part3 |        .        .        .        .        .        .        .  
 
             |   sleep1   sleep2   sleep3   sleep4      out   partic  obesity 
-------------+--------------------------------------------------------------- 
      sleep1 |   1.0000  
      sleep2 |   0.4145   1.0000  
      sleep3 |   0.5954   0.5615   1.0000  
      sleep4 |   0.4645   0.3710   0.5106   1.0000  
         out |   0.1898   0.1781   0.1792   0.2070   1.0000  
      partic |   0.1729   0.1439   0.1654   0.2007   0.3858   1.0000  
     obesity |   0.0710   0.0755   0.0821   0.0925   0.0588   0.0663   1.0000  
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   physfunct |  -0.2685  -0.2789  -0.2762  -0.3075  -0.5691  -0.4574  -0.1629  
     painint |   0.2669   0.2630   0.2840   0.3106   0.4388   0.4100   0.1405  
   cognitive |   0.2026   0.2101   0.2179   0.2623   0.2751   0.2715   0.0497  
        slp3 |        .        .        .        .        .        .        .  
        bmi3 |        .        .        .        .        .        .        .  
         pf3 |        .        .        .        .        .        .        .  
        anx3 |        .        .        .        .        .        .        .  
        dep3 |        .        .        .        .        .        .        .  
        cog3 |        .        .        .        .        .        .        .  
         gh3 |        .        .        .        .        .        .        .  
       part3 |        .        .        .        .        .        .        .  
 
             | physfu~t  painint cognit~e     slp3     bmi3      pf3     anx3 
-------------+--------------------------------------------------------------- 
   physfunct |   1.0000  
     painint |  -0.7328   1.0000  
   cognitive |  -0.3703   0.3374   1.0000  
        slp3 |        .        .        .        .  
        bmi3 |        .        .        .        .        .  
         pf3 |        .        .        .        .        .        .  
        anx3 |        .        .        .        .        .        .        .  
        dep3 |        .        .        .        .        .        .        .  
        cog3 |        .        .        .        .        .        .        .  
         gh3 |        .        .        .        .        .        .        .  
       part3 |        .        .        .        .        .        .        .  
 
             |     dep3     cog3      gh3    part3 
-------------+------------------------------------ 
        dep3 |        .  
        cog3 |        .        .  
         gh3 |        .        .        .  
       part3 |        .        .        .        .  
 
             | m_health     pain  numpain   censor      age      sex educat~n 
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-------------+--------------------------------------------------------------- 
    m_health |   1.0000  
        pain |  -0.0034   1.0000  
     numpain |   0.0112  -0.5166   1.0000  
      censor |   0.0191  -0.0124   0.0262   1.0000  
         age |   0.0479   0.0064  -0.0068   0.3915   1.0000  
         sex |  -0.0144   0.0328  -0.0747   0.0518  -0.0690   1.0000  
   education |   0.0070  -0.0491   0.0448   0.0574   0.1316   0.0546   1.0000  
      income |   0.0185  -0.1015   0.1639   0.0205   0.0011  -0.0089   0.0854  
     alcohol |   0.0278  -0.0345   0.1042   0.0612   0.1774  -0.2396   0.0480  
       smoke |   0.0091   0.0179  -0.0282  -0.0447   0.0234  -0.2045  -0.0207  
     control |  -0.0122   0.0340  -0.0253  -0.0355   0.0079   0.0004  -0.0231  
        walk |  -0.0016  -0.1561   0.2255   0.1543   0.1947  -0.0922   0.0467  
  depression |   0.0164  -0.1664   0.2844   0.1168   0.1129  -0.0088   0.0480  
     anxiety |   0.0171  -0.2060   0.2686   0.0126  -0.0272  -0.1434   0.0266  
      sleep1 |   0.0058  -0.1532   0.2471   0.0228   0.0352  -0.1027   0.0326  
      sleep2 |  -0.0032  -0.1648   0.2151   0.0735   0.0713  -0.0598   0.0371  
      sleep3 |  -0.0005  -0.1675   0.2480   0.0230   0.0142  -0.0818   0.0269  
      sleep4 |  -0.0025  -0.1813   0.3014   0.0247  -0.0337  -0.0705   0.0200  
         out |   0.0176  -0.1554   0.2502   0.2320   0.3669  -0.1078   0.1013  
      partic |   0.0178  -0.1608   0.2308   0.1396   0.1966  -0.0606   0.0759  
     obesity |  -0.0009  -0.0988   0.1349  -0.0401  -0.1006  -0.0384   0.0088  
   physfunct |  -0.0290   0.3525  -0.4878  -0.2653  -0.3937   0.1320  -0.1142  
     painint |   0.0163  -0.4996   0.5589   0.1571   0.1977  -0.0374   0.0939  
   cognitive |   0.0015  -0.1985   0.2688   0.1076   0.1484  -0.0455   0.0247  
        slp3 |        .        .        .        .        .        .        .  
        bmi3 |        .        .        .        .        .        .        .  
         pf3 |        .        .        .        .        .        .        .  
        anx3 |        .        .        .        .        .        .        .  
        dep3 |        .        .        .        .        .        .        .  
        cog3 |        .        .        .        .        .        .        .  
         gh3 |        .        .        .        .        .        .        .  
       part3 |        .        .        .        .        .        .        .  
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             |   income  alcohol    smoke  control     walk depres~n  anxiety 
-------------+--------------------------------------------------------------- 
      income |   1.0000  
     alcohol |   0.1104   1.0000  
       smoke |  -0.0153   0.1158   1.0000  
     control |  -0.0183   0.0002  -0.1999   1.0000  
        walk |   0.0898   0.1398  -0.0122  -0.0217   1.0000  
  depression |   0.1843   0.1205  -0.0228  -0.0093   0.2985   1.0000  
     anxiety |   0.1966   0.0856   0.0093  -0.0463   0.1692   0.4194   1.0000  
      sleep1 |   0.1366   0.0943   0.0159  -0.0210   0.1541   0.2458   0.2644  
      sleep2 |   0.1028   0.0764   0.0773  -0.2186   0.1485   0.2141   0.2287  
      sleep3 |   0.1277   0.0701   0.0020  -0.0150   0.1502   0.2595   0.2775  
      sleep4 |   0.1580   0.0853  -0.0090  -0.0167   0.1934   0.3434   0.3157  
         out |   0.1423   0.1925  -0.0011  -0.0112   0.5116   0.3932   0.2236  
      partic |   0.1802   0.1316  -0.0131   0.0373   0.2798   0.3266   0.2428  
     obesity |   0.0809   0.0709  -0.0148  -0.0148   0.1125   0.0809   0.0592  
   physfunct |  -0.2186  -0.2143   0.0236   0.0378  -0.5167  -0.4536  -0.3021  
     painint |   0.2139   0.1430  -0.0337  -0.0276   0.3743   0.4082   0.3212  
   cognitive |   0.1619   0.0893  -0.0113  -0.0263   0.1898   0.3500   0.3471  
        slp3 |        .        .        .        .        .        .        .  
        bmi3 |        .        .        .        .        .        .        .  
         pf3 |        .        .        .        .        .        .        .  
        anx3 |        .        .        .        .        .        .        .  
        dep3 |        .        .        .        .        .        .        .  
        cog3 |        .        .        .        .        .        .        .  
         gh3 |        .        .        .        .        .        .        .  
       part3 |        .        .        .        .        .        .        .  
 
             |   sleep1   sleep2   sleep3   sleep4      out   partic  obesity 
-------------+--------------------------------------------------------------- 
      sleep1 |   1.0000  
      sleep2 |   0.4145   1.0000  
      sleep3 |   0.5954   0.5615   1.0000  
      sleep4 |   0.4645   0.3710   0.5106   1.0000  
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         out |   0.1898   0.1781   0.1792   0.2070   1.0000  
      partic |   0.1729   0.1439   0.1654   0.2007   0.3858   1.0000  
     obesity |   0.0710   0.0755   0.0821   0.0925   0.0588   0.0663   1.0000  
   physfunct |  -0.2685  -0.2789  -0.2762  -0.3075  -0.5691  -0.4574  -0.1629  
     painint |   0.2669   0.2630   0.2840   0.3106   0.4388   0.4100   0.1405  
   cognitive |   0.2026   0.2101   0.2179   0.2623   0.2751   0.2715   0.0497  
        slp3 |        .        .        .        .        .        .        .  
        bmi3 |        .        .        .        .        .        .        .  
         pf3 |        .        .        .        .        .        .        .  
        anx3 |        .        .        .        .        .        .        .  
        dep3 |        .        .        .        .        .        .        .  
        cog3 |        .        .        .        .        .        .        .  
         gh3 |        .        .        .        .        .        .        .  
       part3 |        .        .        .        .        .        .        .  
 
             | physfu~t  painint cognit~e     slp3     bmi3      pf3     anx3 
-------------+--------------------------------------------------------------- 
   physfunct |   1.0000  
     painint |  -0.7328   1.0000  
   cognitive |  -0.3703   0.3374   1.0000  
        slp3 |        .        .        .        .  
        bmi3 |        .        .        .        .        .  
         pf3 |        .        .        .        .        .        .  
        anx3 |        .        .        .        .        .        .        .  
        dep3 |        .        .        .        .        .        .        .  
        cog3 |        .        .        .        .        .        .        .  
         gh3 |        .        .        .        .        .        .        .  
       part3 |        .        .        .        .        .        .        .  
 
             |     dep3     cog3      gh3    part3 
-------------+------------------------------------ 
        dep3 |        .  
        cog3 |        .        .  
         gh3 |        .        .        .  
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       part3 |        .        .        .        .  
 
             |   m_walk     pain  numpain   censor      age      sex educat~n 
-------------+--------------------------------------------------------------- 
      m_walk |   1.0000  
        pain |   0.0100   1.0000  
     numpain |  -0.0158  -0.5166   1.0000  
      censor |   0.0256  -0.0124   0.0262   1.0000  
         age |   0.0533   0.0064  -0.0068   0.3915   1.0000  
         sex |  -0.0125   0.0328  -0.0747   0.0518  -0.0690   1.0000  
   education |   0.0200  -0.0491   0.0448   0.0574   0.1316   0.0546   1.0000  
      income |   0.0058  -0.1015   0.1639   0.0205   0.0011  -0.0089   0.0854  
     alcohol |   0.0242  -0.0345   0.1042   0.0612   0.1774  -0.2396   0.0480  
       smoke |  -0.0007   0.0179  -0.0282  -0.0447   0.0234  -0.2045  -0.0207  
     control |  -0.0047   0.0340  -0.0253  -0.0355   0.0079   0.0004  -0.0231  
      health |   0.0124  -0.2913   0.4020   0.2056   0.2392  -0.0032   0.1192  
  depression |   0.0088  -0.1664   0.2844   0.1168   0.1129  -0.0088   0.0480  
     anxiety |  -0.0018  -0.2060   0.2686   0.0126  -0.0272  -0.1434   0.0266  
      sleep1 |   0.0162  -0.1532   0.2471   0.0228   0.0352  -0.1027   0.0326  
      sleep2 |   0.0110  -0.1648   0.2151   0.0735   0.0713  -0.0598   0.0371  
      sleep3 |   0.0003  -0.1675   0.2480   0.0230   0.0142  -0.0818   0.0269  
      sleep4 |  -0.0020  -0.1813   0.3014   0.0247  -0.0337  -0.0705   0.0200  
         out |  -0.0022  -0.1554   0.2502   0.2320   0.3669  -0.1078   0.1013  
      partic |   0.0189  -0.1608   0.2308   0.1396   0.1966  -0.0606   0.0759  
     obesity |  -0.0101  -0.0988   0.1349  -0.0401  -0.1006  -0.0384   0.0088  
   physfunct |  -0.0160   0.3525  -0.4878  -0.2653  -0.3937   0.1320  -0.1142  
     painint |   0.0145  -0.4996   0.5589   0.1571   0.1977  -0.0374   0.0939  
   cognitive |   0.0109  -0.1985   0.2688   0.1076   0.1484  -0.0455   0.0247  
        slp3 |        .        .        .        .        .        .        .  
        bmi3 |        .        .        .        .        .        .        .  
         pf3 |        .        .        .        .        .        .        .  
        anx3 |        .        .        .        .        .        .        .  
        dep3 |        .        .        .        .        .        .        .  
        cog3 |        .        .        .        .        .        .        .  
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         gh3 |        .        .        .        .        .        .        .  
       part3 |        .        .        .        .        .        .        .  
 
             |   income  alcohol    smoke  control   health depres~n  anxiety 
-------------+--------------------------------------------------------------- 
      income |   1.0000  
     alcohol |   0.1104   1.0000  
       smoke |  -0.0153   0.1158   1.0000  
     control |  -0.0183   0.0002  -0.1999   1.0000  
      health |   0.2131   0.1598  -0.0613  -0.0208   1.0000  
  depression |   0.1843   0.1205  -0.0228  -0.0093   0.4413   1.0000  
     anxiety |   0.1966   0.0856   0.0093  -0.0463   0.3234   0.4194   1.0000  
      sleep1 |   0.1366   0.0943   0.0159  -0.0210   0.2494   0.2458   0.2644  
      sleep2 |   0.1028   0.0764   0.0773  -0.2186   0.2480   0.2141   0.2287  
      sleep3 |   0.1277   0.0701   0.0020  -0.0150   0.2533   0.2595   0.2775  
      sleep4 |   0.1580   0.0853  -0.0090  -0.0167   0.3126   0.3434   0.3157  
         out |   0.1423   0.1925  -0.0011  -0.0112   0.4615   0.3932   0.2236  
      partic |   0.1802   0.1316  -0.0131   0.0373   0.3890   0.3266   0.2428  
     obesity |   0.0809   0.0709  -0.0148  -0.0148   0.1423   0.0809   0.0592  
   physfunct |  -0.2186  -0.2143   0.0236   0.0378  -0.6629  -0.4536  -0.3021  
     painint |   0.2139   0.1430  -0.0337  -0.0276   0.5991   0.4082   0.3212  
   cognitive |   0.1619   0.0893  -0.0113  -0.0263   0.3374   0.3500   0.3471  
        slp3 |        .        .        .        .        .        .        .  
        bmi3 |        .        .        .        .        .        .        .  
         pf3 |        .        .        .        .        .        .        .  
        anx3 |        .        .        .        .        .        .        .  
        dep3 |        .        .        .        .        .        .        .  
        cog3 |        .        .        .        .        .        .        .  
         gh3 |        .        .        .        .        .        .        .  
       part3 |        .        .        .        .        .        .        .  
 
             |   sleep1   sleep2   sleep3   sleep4      out   partic  obesity 
-------------+--------------------------------------------------------------- 
      sleep1 |   1.0000  
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      sleep2 |   0.4145   1.0000  
      sleep3 |   0.5954   0.5615   1.0000  
      sleep4 |   0.4645   0.3710   0.5106   1.0000  
         out |   0.1898   0.1781   0.1792   0.2070   1.0000  
      partic |   0.1729   0.1439   0.1654   0.2007   0.3858   1.0000  
     obesity |   0.0710   0.0755   0.0821   0.0925   0.0588   0.0663   1.0000  
   physfunct |  -0.2685  -0.2789  -0.2762  -0.3075  -0.5691  -0.4574  -0.1629  
     painint |   0.2669   0.2630   0.2840   0.3106   0.4388   0.4100   0.1405  
   cognitive |   0.2026   0.2101   0.2179   0.2623   0.2751   0.2715   0.0497  
        slp3 |        .        .        .        .        .        .        .  
        bmi3 |        .        .        .        .        .        .        .  
         pf3 |        .        .        .        .        .        .        .  
        anx3 |        .        .        .        .        .        .        .  
        dep3 |        .        .        .        .        .        .        .  
        cog3 |        .        .        .        .        .        .        .  
         gh3 |        .        .        .        .        .        .        .  
       part3 |        .        .        .        .        .        .        .  
 
             | physfu~t  painint cognit~e     slp3     bmi3      pf3     anx3 
-------------+--------------------------------------------------------------- 
   physfunct |   1.0000  
     painint |  -0.7328   1.0000  
   cognitive |  -0.3703   0.3374   1.0000  
        slp3 |        .        .        .        .  
        bmi3 |        .        .        .        .        .  
         pf3 |        .        .        .        .        .        .  
        anx3 |        .        .        .        .        .        .        .  
        dep3 |        .        .        .        .        .        .        .  
        cog3 |        .        .        .        .        .        .        .  
         gh3 |        .        .        .        .        .        .        .  
       part3 |        .        .        .        .        .        .        .  
 
             |     dep3     cog3      gh3    part3 
-------------+------------------------------------ 
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        dep3 |        .  
        cog3 |        .        .  
         gh3 |        .        .        .  
       part3 |        .        .        .        .  
 
             | m_depr~n     pain  numpain   censor      age      sex educat~n 
-------------+--------------------------------------------------------------- 
m_depression |   1.0000  
        pain |  -0.0031   1.0000  
     numpain |  -0.0036  -0.5166   1.0000  
      censor |   0.0258  -0.0124   0.0262   1.0000  
         age |   0.0533   0.0064  -0.0068   0.3915   1.0000  
         sex |   0.0022   0.0328  -0.0747   0.0518  -0.0690   1.0000  
   education |   0.0064  -0.0491   0.0448   0.0574   0.1316   0.0546   1.0000  
      income |   0.0095  -0.1015   0.1639   0.0205   0.0011  -0.0089   0.0854  
     alcohol |   0.0161  -0.0345   0.1042   0.0612   0.1774  -0.2396   0.0480  
       smoke |   0.0002   0.0179  -0.0282  -0.0447   0.0234  -0.2045  -0.0207  
     control |   0.0075   0.0340  -0.0253  -0.0355   0.0079   0.0004  -0.0231  
      health |   0.0332  -0.2913   0.4020   0.2056   0.2392  -0.0032   0.1192  
        walk |   0.0163  -0.1561   0.2255   0.1543   0.1947  -0.0922   0.0467  
     anxiety |  -0.0004  -0.2060   0.2686   0.0126  -0.0272  -0.1434   0.0266  
      sleep1 |   0.0174  -0.1532   0.2471   0.0228   0.0352  -0.1027   0.0326  
      sleep2 |   0.0134  -0.1648   0.2151   0.0735   0.0713  -0.0598   0.0371  
      sleep3 |   0.0210  -0.1675   0.2480   0.0230   0.0142  -0.0818   0.0269  
      sleep4 |   0.0043  -0.1813   0.3014   0.0247  -0.0337  -0.0705   0.0200  
         out |   0.0308  -0.1554   0.2502   0.2320   0.3669  -0.1078   0.1013  
      partic |   0.0350  -0.1608   0.2308   0.1396   0.1966  -0.0606   0.0759  
     obesity |  -0.0128  -0.0988   0.1349  -0.0401  -0.1006  -0.0384   0.0088  
   physfunct |  -0.0353   0.3525  -0.4878  -0.2653  -0.3937   0.1320  -0.1142  
     painint |   0.0309  -0.4996   0.5589   0.1571   0.1977  -0.0374   0.0939  
   cognitive |   0.0302  -0.1985   0.2688   0.1076   0.1484  -0.0455   0.0247  
        slp3 |        .        .        .        .        .        .        .  
        bmi3 |        .        .        .        .        .        .        .  
         pf3 |        .        .        .        .        .        .        .  
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        anx3 |        .        .        .        .        .        .        .  
        dep3 |        .        .        .        .        .        .        .  
        cog3 |        .        .        .        .        .        .        .  
         gh3 |        .        .        .        .        .        .        .  
       part3 |        .        .        .        .        .        .        .  
 
             |   income  alcohol    smoke  control   health     walk  anxiety 
-------------+--------------------------------------------------------------- 
      income |   1.0000  
     alcohol |   0.1104   1.0000  
       smoke |  -0.0153   0.1158   1.0000  
     control |  -0.0183   0.0002  -0.1999   1.0000  
      health |   0.2131   0.1598  -0.0613  -0.0208   1.0000  
        walk |   0.0898   0.1398  -0.0122  -0.0217   0.3826   1.0000  
     anxiety |   0.1966   0.0856   0.0093  -0.0463   0.3234   0.1692   1.0000  
      sleep1 |   0.1366   0.0943   0.0159  -0.0210   0.2494   0.1541   0.2644  
      sleep2 |   0.1028   0.0764   0.0773  -0.2186   0.2480   0.1485   0.2287  
      sleep3 |   0.1277   0.0701   0.0020  -0.0150   0.2533   0.1502   0.2775  
      sleep4 |   0.1580   0.0853  -0.0090  -0.0167   0.3126   0.1934   0.3157  
         out |   0.1423   0.1925  -0.0011  -0.0112   0.4615   0.5116   0.2236  
      partic |   0.1802   0.1316  -0.0131   0.0373   0.3890   0.2798   0.2428  
     obesity |   0.0809   0.0709  -0.0148  -0.0148   0.1423   0.1125   0.0592  
   physfunct |  -0.2186  -0.2143   0.0236   0.0378  -0.6629  -0.5167  -0.3021  
     painint |   0.2139   0.1430  -0.0337  -0.0276   0.5991   0.3743   0.3212  
   cognitive |   0.1619   0.0893  -0.0113  -0.0263   0.3374   0.1898   0.3471  
        slp3 |        .        .        .        .        .        .        .  
        bmi3 |        .        .        .        .        .        .        .  
         pf3 |        .        .        .        .        .        .        .  
        anx3 |        .        .        .        .        .        .        .  
        dep3 |        .        .        .        .        .        .        .  
        cog3 |        .        .        .        .        .        .        .  
         gh3 |        .        .        .        .        .        .        .  
       part3 |        .        .        .        .        .        .        .  
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             |   sleep1   sleep2   sleep3   sleep4      out   partic  obesity 
-------------+--------------------------------------------------------------- 
      sleep1 |   1.0000  
      sleep2 |   0.4145   1.0000  
      sleep3 |   0.5954   0.5615   1.0000  
      sleep4 |   0.4645   0.3710   0.5106   1.0000  
         out |   0.1898   0.1781   0.1792   0.2070   1.0000  
      partic |   0.1729   0.1439   0.1654   0.2007   0.3858   1.0000  
     obesity |   0.0710   0.0755   0.0821   0.0925   0.0588   0.0663   1.0000  
   physfunct |  -0.2685  -0.2789  -0.2762  -0.3075  -0.5691  -0.4574  -0.1629  
     painint |   0.2669   0.2630   0.2840   0.3106   0.4388   0.4100   0.1405  
   cognitive |   0.2026   0.2101   0.2179   0.2623   0.2751   0.2715   0.0497  
        slp3 |        .        .        .        .        .        .        .  
        bmi3 |        .        .        .        .        .        .        .  
         pf3 |        .        .        .        .        .        .        .  
        anx3 |        .        .        .        .        .        .        .  
        dep3 |        .        .        .        .        .        .        .  
        cog3 |        .        .        .        .        .        .        .  
         gh3 |        .        .        .        .        .        .        .  
       part3 |        .        .        .        .        .        .        .  
 
             | physfu~t  painint cognit~e     slp3     bmi3      pf3     anx3 
-------------+--------------------------------------------------------------- 
   physfunct |   1.0000  
     painint |  -0.7328   1.0000  
   cognitive |  -0.3703   0.3374   1.0000  
        slp3 |        .        .        .        .  
        bmi3 |        .        .        .        .        .  
         pf3 |        .        .        .        .        .        .  
        anx3 |        .        .        .        .        .        .        .  
        dep3 |        .        .        .        .        .        .        .  
        cog3 |        .        .        .        .        .        .        .  
         gh3 |        .        .        .        .        .        .        .  
       part3 |        .        .        .        .        .        .        .  
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             |     dep3     cog3      gh3    part3 
-------------+------------------------------------ 
        dep3 |        .  
        cog3 |        .        .  
         gh3 |        .        .        .  
       part3 |        .        .        .        .  
 
             | m_anxi~y     pain  numpain   censor      age      sex educat~n 
-------------+--------------------------------------------------------------- 
   m_anxiety |   1.0000  
        pain |  -0.0056   1.0000  
     numpain |  -0.0010  -0.5166   1.0000  
      censor |   0.0267  -0.0124   0.0262   1.0000  
         age |   0.0612   0.0064  -0.0068   0.3915   1.0000  
         sex |  -0.0003   0.0328  -0.0747   0.0518  -0.0690   1.0000  
   education |   0.0062  -0.0491   0.0448   0.0574   0.1316   0.0546   1.0000  
      income |   0.0098  -0.1015   0.1639   0.0205   0.0011  -0.0089   0.0854  
     alcohol |   0.0195  -0.0345   0.1042   0.0612   0.1774  -0.2396   0.0480  
       smoke |   0.0017   0.0179  -0.0282  -0.0447   0.0234  -0.2045  -0.0207  
     control |   0.0048   0.0340  -0.0253  -0.0355   0.0079   0.0004  -0.0231  
      health |   0.0362  -0.2913   0.4020   0.2056   0.2392  -0.0032   0.1192  
        walk |   0.0160  -0.1561   0.2255   0.1543   0.1947  -0.0922   0.0467  
  depression |   0.0317  -0.1664   0.2844   0.1168   0.1129  -0.0088   0.0480  
      sleep1 |   0.0171  -0.1532   0.2471   0.0228   0.0352  -0.1027   0.0326  
      sleep2 |   0.0150  -0.1648   0.2151   0.0735   0.0713  -0.0598   0.0371  
      sleep3 |   0.0192  -0.1675   0.2480   0.0230   0.0142  -0.0818   0.0269  
      sleep4 |   0.0041  -0.1813   0.3014   0.0247  -0.0337  -0.0705   0.0200  
         out |   0.0346  -0.1554   0.2502   0.2320   0.3669  -0.1078   0.1013  
      partic |   0.0374  -0.1608   0.2308   0.1396   0.1966  -0.0606   0.0759  
     obesity |  -0.0091  -0.0988   0.1349  -0.0401  -0.1006  -0.0384   0.0088  
   physfunct |  -0.0416   0.3525  -0.4878  -0.2653  -0.3937   0.1320  -0.1142  
     painint |   0.0333  -0.4996   0.5589   0.1571   0.1977  -0.0374   0.0939  
   cognitive |   0.0294  -0.1985   0.2688   0.1076   0.1484  -0.0455   0.0247  
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        slp3 |        .        .        .        .        .        .        .  
        bmi3 |        .        .        .        .        .        .        .  
         pf3 |        .        .        .        .        .        .        .  
        anx3 |        .        .        .        .        .        .        .  
        dep3 |        .        .        .        .        .        .        .  
        cog3 |        .        .        .        .        .        .        .  
         gh3 |        .        .        .        .        .        .        .  
       part3 |        .        .        .        .        .        .        .  
 
             |   income  alcohol    smoke  control   health     walk depres~n 
-------------+--------------------------------------------------------------- 
      income |   1.0000  
     alcohol |   0.1104   1.0000  
       smoke |  -0.0153   0.1158   1.0000  
     control |  -0.0183   0.0002  -0.1999   1.0000  
      health |   0.2131   0.1598  -0.0613  -0.0208   1.0000  
        walk |   0.0898   0.1398  -0.0122  -0.0217   0.3826   1.0000  
  depression |   0.1843   0.1205  -0.0228  -0.0093   0.4413   0.2985   1.0000  
      sleep1 |   0.1366   0.0943   0.0159  -0.0210   0.2494   0.1541   0.2458  
      sleep2 |   0.1028   0.0764   0.0773  -0.2186   0.2480   0.1485   0.2141  
      sleep3 |   0.1277   0.0701   0.0020  -0.0150   0.2533   0.1502   0.2595  
      sleep4 |   0.1580   0.0853  -0.0090  -0.0167   0.3126   0.1934   0.3434  
         out |   0.1423   0.1925  -0.0011  -0.0112   0.4615   0.5116   0.3932  
      partic |   0.1802   0.1316  -0.0131   0.0373   0.3890   0.2798   0.3266  
     obesity |   0.0809   0.0709  -0.0148  -0.0148   0.1423   0.1125   0.0809  
   physfunct |  -0.2186  -0.2143   0.0236   0.0378  -0.6629  -0.5167  -0.4536  
     painint |   0.2139   0.1430  -0.0337  -0.0276   0.5991   0.3743   0.4082  
   cognitive |   0.1619   0.0893  -0.0113  -0.0263   0.3374   0.1898   0.3500  
        slp3 |        .        .        .        .        .        .        .  
        bmi3 |        .        .        .        .        .        .        .  
         pf3 |        .        .        .        .        .        .        .  
        anx3 |        .        .        .        .        .        .        .  
        dep3 |        .        .        .        .        .        .        .  
        cog3 |        .        .        .        .        .        .        .  
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         gh3 |        .        .        .        .        .        .        .  
       part3 |        .        .        .        .        .        .        .  
 
             |   sleep1   sleep2   sleep3   sleep4      out   partic  obesity 
-------------+--------------------------------------------------------------- 
      sleep1 |   1.0000  
      sleep2 |   0.4145   1.0000  
      sleep3 |   0.5954   0.5615   1.0000  
      sleep4 |   0.4645   0.3710   0.5106   1.0000  
         out |   0.1898   0.1781   0.1792   0.2070   1.0000  
      partic |   0.1729   0.1439   0.1654   0.2007   0.3858   1.0000  
     obesity |   0.0710   0.0755   0.0821   0.0925   0.0588   0.0663   1.0000  
   physfunct |  -0.2685  -0.2789  -0.2762  -0.3075  -0.5691  -0.4574  -0.1629  
     painint |   0.2669   0.2630   0.2840   0.3106   0.4388   0.4100   0.1405  
   cognitive |   0.2026   0.2101   0.2179   0.2623   0.2751   0.2715   0.0497  
        slp3 |        .        .        .        .        .        .        .  
        bmi3 |        .        .        .        .        .        .        .  
         pf3 |        .        .        .        .        .        .        .  
        anx3 |        .        .        .        .        .        .        .  
        dep3 |        .        .        .        .        .        .        .  
        cog3 |        .        .        .        .        .        .        .  
         gh3 |        .        .        .        .        .        .        .  
       part3 |        .        .        .        .        .        .        .  
 
             | physfu~t  painint cognit~e     slp3     bmi3      pf3     anx3 
-------------+--------------------------------------------------------------- 
   physfunct |   1.0000  
     painint |  -0.7328   1.0000  
   cognitive |  -0.3703   0.3374   1.0000  
        slp3 |        .        .        .        .  
        bmi3 |        .        .        .        .        .  
         pf3 |        .        .        .        .        .        .  
        anx3 |        .        .        .        .        .        .        .  
        dep3 |        .        .        .        .        .        .        .  
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        cog3 |        .        .        .        .        .        .        .  
         gh3 |        .        .        .        .        .        .        .  
       part3 |        .        .        .        .        .        .        .  
 
             |     dep3     cog3      gh3    part3 
-------------+------------------------------------ 
        dep3 |        .  
        cog3 |        .        .  
         gh3 |        .        .        .  
       part3 |        .        .        .        .  
 
             | m_sleep1     pain  numpain   censor      age      sex educat~n 
-------------+--------------------------------------------------------------- 
    m_sleep1 |   1.0000  
        pain |  -0.0076   1.0000  
     numpain |  -0.0245  -0.5166   1.0000  
      censor |   0.0234  -0.0124   0.0262   1.0000  
         age |   0.0677   0.0064  -0.0068   0.3915   1.0000  
         sex |  -0.0240   0.0328  -0.0747   0.0518  -0.0690   1.0000  
   education |   0.0101  -0.0491   0.0448   0.0574   0.1316   0.0546   1.0000  
      income |   0.0186  -0.1015   0.1639   0.0205   0.0011  -0.0089   0.0854  
     alcohol |   0.0423  -0.0345   0.1042   0.0612   0.1774  -0.2396   0.0480  
       smoke |   0.0056   0.0179  -0.0282  -0.0447   0.0234  -0.2045  -0.0207  
     control |   0.0103   0.0340  -0.0253  -0.0355   0.0079   0.0004  -0.0231  
      health |   0.0242  -0.2913   0.4020   0.2056   0.2392  -0.0032   0.1192  
        walk |   0.0137  -0.1561   0.2255   0.1543   0.1947  -0.0922   0.0467  
  depression |   0.0120  -0.1664   0.2844   0.1168   0.1129  -0.0088   0.0480  
     anxiety |   0.0065  -0.2060   0.2686   0.0126  -0.0272  -0.1434   0.0266  
      sleep2 |   0.0268  -0.1648   0.2151   0.0735   0.0713  -0.0598   0.0371  
      sleep3 |   0.0271  -0.1675   0.2480   0.0230   0.0142  -0.0818   0.0269  
      sleep4 |   0.0075  -0.1813   0.3014   0.0247  -0.0337  -0.0705   0.0200  
         out |   0.0298  -0.1554   0.2502   0.2320   0.3669  -0.1078   0.1013  
      partic |   0.0530  -0.1608   0.2308   0.1396   0.1966  -0.0606   0.0759  
     obesity |   0.0002  -0.0988   0.1349  -0.0401  -0.1006  -0.0384   0.0088  
454 
 
   physfunct |  -0.0238   0.3525  -0.4878  -0.2653  -0.3937   0.1320  -0.1142  
     painint |   0.0174  -0.4996   0.5589   0.1571   0.1977  -0.0374   0.0939  
   cognitive |  -0.0114  -0.1985   0.2688   0.1076   0.1484  -0.0455   0.0247  
        slp3 |        .        .        .        .        .        .        .  
        bmi3 |        .        .        .        .        .        .        .  
         pf3 |        .        .        .        .        .        .        .  
        anx3 |        .        .        .        .        .        .        .  
        dep3 |        .        .        .        .        .        .        .  
        cog3 |        .        .        .        .        .        .        .  
         gh3 |        .        .        .        .        .        .        .  
       part3 |        .        .        .        .        .        .        .  
 
             |   income  alcohol    smoke  control   health     walk depres~n 
-------------+--------------------------------------------------------------- 
      income |   1.0000  
     alcohol |   0.1104   1.0000  
       smoke |  -0.0153   0.1158   1.0000  
     control |  -0.0183   0.0002  -0.1999   1.0000  
      health |   0.2131   0.1598  -0.0613  -0.0208   1.0000  
        walk |   0.0898   0.1398  -0.0122  -0.0217   0.3826   1.0000  
  depression |   0.1843   0.1205  -0.0228  -0.0093   0.4413   0.2985   1.0000  
     anxiety |   0.1966   0.0856   0.0093  -0.0463   0.3234   0.1692   0.4194  
      sleep2 |   0.1028   0.0764   0.0773  -0.2186   0.2480   0.1485   0.2141  
      sleep3 |   0.1277   0.0701   0.0020  -0.0150   0.2533   0.1502   0.2595  
      sleep4 |   0.1580   0.0853  -0.0090  -0.0167   0.3126   0.1934   0.3434  
         out |   0.1423   0.1925  -0.0011  -0.0112   0.4615   0.5116   0.3932  
      partic |   0.1802   0.1316  -0.0131   0.0373   0.3890   0.2798   0.3266  
     obesity |   0.0809   0.0709  -0.0148  -0.0148   0.1423   0.1125   0.0809  
   physfunct |  -0.2186  -0.2143   0.0236   0.0378  -0.6629  -0.5167  -0.4536  
     painint |   0.2139   0.1430  -0.0337  -0.0276   0.5991   0.3743   0.4082  
   cognitive |   0.1619   0.0893  -0.0113  -0.0263   0.3374   0.1898   0.3500  
        slp3 |        .        .        .        .        .        .        .  
        bmi3 |        .        .        .        .        .        .        .  
         pf3 |        .        .        .        .        .        .        .  
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        anx3 |        .        .        .        .        .        .        .  
        dep3 |        .        .        .        .        .        .        .  
        cog3 |        .        .        .        .        .        .        .  
         gh3 |        .        .        .        .        .        .        .  
       part3 |        .        .        .        .        .        .        .  
 
             |  anxiety   sleep2   sleep3   sleep4      out   partic  obesity 
-------------+--------------------------------------------------------------- 
     anxiety |   1.0000  
      sleep2 |   0.2287   1.0000  
      sleep3 |   0.2775   0.5615   1.0000  
      sleep4 |   0.3157   0.3710   0.5106   1.0000  
         out |   0.2236   0.1781   0.1792   0.2070   1.0000  
      partic |   0.2428   0.1439   0.1654   0.2007   0.3858   1.0000  
     obesity |   0.0592   0.0755   0.0821   0.0925   0.0588   0.0663   1.0000  
   physfunct |  -0.3021  -0.2789  -0.2762  -0.3075  -0.5691  -0.4574  -0.1629  
     painint |   0.3212   0.2630   0.2840   0.3106   0.4388   0.4100   0.1405  
   cognitive |   0.3471   0.2101   0.2179   0.2623   0.2751   0.2715   0.0497  
        slp3 |        .        .        .        .        .        .        .  
        bmi3 |        .        .        .        .        .        .        .  
         pf3 |        .        .        .        .        .        .        .  
        anx3 |        .        .        .        .        .        .        .  
        dep3 |        .        .        .        .        .        .        .  
        cog3 |        .        .        .        .        .        .        .  
         gh3 |        .        .        .        .        .        .        .  
       part3 |        .        .        .        .        .        .        .  
 
             | physfu~t  painint cognit~e     slp3     bmi3      pf3     anx3 
-------------+--------------------------------------------------------------- 
   physfunct |   1.0000  
     painint |  -0.7328   1.0000  
   cognitive |  -0.3703   0.3374   1.0000  
        slp3 |        .        .        .        .  
        bmi3 |        .        .        .        .        .  
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         pf3 |        .        .        .        .        .        .  
        anx3 |        .        .        .        .        .        .        .  
        dep3 |        .        .        .        .        .        .        .  
        cog3 |        .        .        .        .        .        .        .  
         gh3 |        .        .        .        .        .        .        .  
       part3 |        .        .        .        .        .        .        .  
 
             |     dep3     cog3      gh3    part3 
-------------+------------------------------------ 
        dep3 |        .  
        cog3 |        .        .  
         gh3 |        .        .        .  
       part3 |        .        .        .        .  
 
             | m_sleep2     pain  numpain   censor      age      sex educat~n 
-------------+--------------------------------------------------------------- 
    m_sleep2 |   1.0000  
        pain |   0.0150   1.0000  
     numpain |  -0.0337  -0.5166   1.0000  
      censor |   0.0269  -0.0124   0.0262   1.0000  
         age |   0.0657   0.0064  -0.0068   0.3915   1.0000  
         sex |  -0.0066   0.0328  -0.0747   0.0518  -0.0690   1.0000  
   education |  -0.0011  -0.0491   0.0448   0.0574   0.1316   0.0546   1.0000  
      income |   0.0016  -0.1015   0.1639   0.0205   0.0011  -0.0089   0.0854  
     alcohol |   0.0196  -0.0345   0.1042   0.0612   0.1774  -0.2396   0.0480  
       smoke |   0.0087   0.0179  -0.0282  -0.0447   0.0234  -0.2045  -0.0207  
     control |   0.0084   0.0340  -0.0253  -0.0355   0.0079   0.0004  -0.0231  
      health |   0.0020  -0.2913   0.4020   0.2056   0.2392  -0.0032   0.1192  
        walk |  -0.0004  -0.1561   0.2255   0.1543   0.1947  -0.0922   0.0467  
  depression |  -0.0089  -0.1664   0.2844   0.1168   0.1129  -0.0088   0.0480  
     anxiety |  -0.0198  -0.2060   0.2686   0.0126  -0.0272  -0.1434   0.0266  
      sleep1 |  -0.0001  -0.1532   0.2471   0.0228   0.0352  -0.1027   0.0326  
      sleep3 |   0.0032  -0.1675   0.2480   0.0230   0.0142  -0.0818   0.0269  
      sleep4 |  -0.0040  -0.1813   0.3014   0.0247  -0.0337  -0.0705   0.0200  
457 
 
         out |   0.0146  -0.1554   0.2502   0.2320   0.3669  -0.1078   0.1013  
      partic |   0.0314  -0.1608   0.2308   0.1396   0.1966  -0.0606   0.0759  
     obesity |  -0.0095  -0.0988   0.1349  -0.0401  -0.1006  -0.0384   0.0088  
   physfunct |  -0.0004   0.3525  -0.4878  -0.2653  -0.3937   0.1320  -0.1142  
     painint |  -0.0008  -0.4996   0.5589   0.1571   0.1977  -0.0374   0.0939  
   cognitive |  -0.0173  -0.1985   0.2688   0.1076   0.1484  -0.0455   0.0247  
        slp3 |        .        .        .        .        .        .        .  
        bmi3 |        .        .        .        .        .        .        .  
         pf3 |        .        .        .        .        .        .        .  
        anx3 |        .        .        .        .        .        .        .  
        dep3 |        .        .        .        .        .        .        .  
        cog3 |        .        .        .        .        .        .        .  
         gh3 |        .        .        .        .        .        .        .  
       part3 |        .        .        .        .        .        .        .  
 
             |   income  alcohol    smoke  control   health     walk depres~n 
-------------+--------------------------------------------------------------- 
      income |   1.0000  
     alcohol |   0.1104   1.0000  
       smoke |  -0.0153   0.1158   1.0000  
     control |  -0.0183   0.0002  -0.1999   1.0000  
      health |   0.2131   0.1598  -0.0613  -0.0208   1.0000  
        walk |   0.0898   0.1398  -0.0122  -0.0217   0.3826   1.0000  
  depression |   0.1843   0.1205  -0.0228  -0.0093   0.4413   0.2985   1.0000  
     anxiety |   0.1966   0.0856   0.0093  -0.0463   0.3234   0.1692   0.4194  
      sleep1 |   0.1366   0.0943   0.0159  -0.0210   0.2494   0.1541   0.2458  
      sleep3 |   0.1277   0.0701   0.0020  -0.0150   0.2533   0.1502   0.2595  
      sleep4 |   0.1580   0.0853  -0.0090  -0.0167   0.3126   0.1934   0.3434  
         out |   0.1423   0.1925  -0.0011  -0.0112   0.4615   0.5116   0.3932  
      partic |   0.1802   0.1316  -0.0131   0.0373   0.3890   0.2798   0.3266  
     obesity |   0.0809   0.0709  -0.0148  -0.0148   0.1423   0.1125   0.0809  
   physfunct |  -0.2186  -0.2143   0.0236   0.0378  -0.6629  -0.5167  -0.4536  
     painint |   0.2139   0.1430  -0.0337  -0.0276   0.5991   0.3743   0.4082  
   cognitive |   0.1619   0.0893  -0.0113  -0.0263   0.3374   0.1898   0.3500  
458 
 
        slp3 |        .        .        .        .        .        .        .  
        bmi3 |        .        .        .        .        .        .        .  
         pf3 |        .        .        .        .        .        .        .  
        anx3 |        .        .        .        .        .        .        .  
        dep3 |        .        .        .        .        .        .        .  
        cog3 |        .        .        .        .        .        .        .  
         gh3 |        .        .        .        .        .        .        .  
       part3 |        .        .        .        .        .        .        .  
 
             |  anxiety   sleep1   sleep3   sleep4      out   partic  obesity 
-------------+--------------------------------------------------------------- 
     anxiety |   1.0000  
      sleep1 |   0.2644   1.0000  
      sleep3 |   0.2775   0.5954   1.0000  
      sleep4 |   0.3157   0.4645   0.5106   1.0000  
         out |   0.2236   0.1898   0.1792   0.2070   1.0000  
      partic |   0.2428   0.1729   0.1654   0.2007   0.3858   1.0000  
     obesity |   0.0592   0.0710   0.0821   0.0925   0.0588   0.0663   1.0000  
   physfunct |  -0.3021  -0.2685  -0.2762  -0.3075  -0.5691  -0.4574  -0.1629  
     painint |   0.3212   0.2669   0.2840   0.3106   0.4388   0.4100   0.1405  
   cognitive |   0.3471   0.2026   0.2179   0.2623   0.2751   0.2715   0.0497  
        slp3 |        .        .        .        .        .        .        .  
        bmi3 |        .        .        .        .        .        .        .  
         pf3 |        .        .        .        .        .        .        .  
        anx3 |        .        .        .        .        .        .        .  
        dep3 |        .        .        .        .        .        .        .  
        cog3 |        .        .        .        .        .        .        .  
         gh3 |        .        .        .        .        .        .        .  
       part3 |        .        .        .        .        .        .        .  
 
             | physfu~t  painint cognit~e     slp3     bmi3      pf3     anx3 
-------------+--------------------------------------------------------------- 
   physfunct |   1.0000  
     painint |  -0.7328   1.0000  
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   cognitive |  -0.3703   0.3374   1.0000  
        slp3 |        .        .        .        .  
        bmi3 |        .        .        .        .        .  
         pf3 |        .        .        .        .        .        .  
        anx3 |        .        .        .        .        .        .        .  
        dep3 |        .        .        .        .        .        .        .  
        cog3 |        .        .        .        .        .        .        .  
         gh3 |        .        .        .        .        .        .        .  
       part3 |        .        .        .        .        .        .        .  
 
             |     dep3     cog3      gh3    part3 
-------------+------------------------------------ 
        dep3 |        .  
        cog3 |        .        .  
         gh3 |        .        .        .  
       part3 |        .        .        .        .  
 
             | m_sleep3     pain  numpain   censor      age      sex educat~n 
-------------+--------------------------------------------------------------- 
    m_sleep3 |   1.0000  
        pain |   0.0043   1.0000  
     numpain |  -0.0317  -0.5166   1.0000  
      censor |   0.0330  -0.0124   0.0262   1.0000  
         age |   0.0882   0.0064  -0.0068   0.3915   1.0000  
         sex |  -0.0357   0.0328  -0.0747   0.0518  -0.0690   1.0000  
   education |   0.0036  -0.0491   0.0448   0.0574   0.1316   0.0546   1.0000  
      income |   0.0101  -0.1015   0.1639   0.0205   0.0011  -0.0089   0.0854  
     alcohol |   0.0365  -0.0345   0.1042   0.0612   0.1774  -0.2396   0.0480  
       smoke |   0.0162   0.0179  -0.0282  -0.0447   0.0234  -0.2045  -0.0207  
     control |   0.0054   0.0340  -0.0253  -0.0355   0.0079   0.0004  -0.0231  
      health |   0.0135  -0.2913   0.4020   0.2056   0.2392  -0.0032   0.1192  
        walk |   0.0079  -0.1561   0.2255   0.1543   0.1947  -0.0922   0.0467  
  depression |   0.0001  -0.1664   0.2844   0.1168   0.1129  -0.0088   0.0480  
     anxiety |  -0.0236  -0.2060   0.2686   0.0126  -0.0272  -0.1434   0.0266  
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      sleep1 |  -0.0090  -0.1532   0.2471   0.0228   0.0352  -0.1027   0.0326  
      sleep2 |  -0.0016  -0.1648   0.2151   0.0735   0.0713  -0.0598   0.0371  
      sleep4 |   0.0010  -0.1813   0.3014   0.0247  -0.0337  -0.0705   0.0200  
         out |   0.0274  -0.1554   0.2502   0.2320   0.3669  -0.1078   0.1013  
      partic |   0.0513  -0.1608   0.2308   0.1396   0.1966  -0.0606   0.0759  
     obesity |  -0.0001  -0.0988   0.1349  -0.0401  -0.1006  -0.0384   0.0088  
   physfunct |  -0.0170   0.3525  -0.4878  -0.2653  -0.3937   0.1320  -0.1142  
     painint |   0.0031  -0.4996   0.5589   0.1571   0.1977  -0.0374   0.0939  
   cognitive |  -0.0280  -0.1985   0.2688   0.1076   0.1484  -0.0455   0.0247  
        slp3 |        .        .        .        .        .        .        .  
        bmi3 |        .        .        .        .        .        .        .  
         pf3 |        .        .        .        .        .        .        .  
        anx3 |        .        .        .        .        .        .        .  
        dep3 |        .        .        .        .        .        .        .  
        cog3 |        .        .        .        .        .        .        .  
         gh3 |        .        .        .        .        .        .        .  
       part3 |        .        .        .        .        .        .        .  
 
             |   income  alcohol    smoke  control   health     walk depres~n 
-------------+--------------------------------------------------------------- 
      income |   1.0000  
     alcohol |   0.1104   1.0000  
       smoke |  -0.0153   0.1158   1.0000  
     control |  -0.0183   0.0002  -0.1999   1.0000  
      health |   0.2131   0.1598  -0.0613  -0.0208   1.0000  
        walk |   0.0898   0.1398  -0.0122  -0.0217   0.3826   1.0000  
  depression |   0.1843   0.1205  -0.0228  -0.0093   0.4413   0.2985   1.0000  
     anxiety |   0.1966   0.0856   0.0093  -0.0463   0.3234   0.1692   0.4194  
      sleep1 |   0.1366   0.0943   0.0159  -0.0210   0.2494   0.1541   0.2458  
      sleep2 |   0.1028   0.0764   0.0773  -0.2186   0.2480   0.1485   0.2141  
      sleep4 |   0.1580   0.0853  -0.0090  -0.0167   0.3126   0.1934   0.3434  
         out |   0.1423   0.1925  -0.0011  -0.0112   0.4615   0.5116   0.3932  
      partic |   0.1802   0.1316  -0.0131   0.0373   0.3890   0.2798   0.3266  
     obesity |   0.0809   0.0709  -0.0148  -0.0148   0.1423   0.1125   0.0809  
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   physfunct |  -0.2186  -0.2143   0.0236   0.0378  -0.6629  -0.5167  -0.4536  
     painint |   0.2139   0.1430  -0.0337  -0.0276   0.5991   0.3743   0.4082  
   cognitive |   0.1619   0.0893  -0.0113  -0.0263   0.3374   0.1898   0.3500  
        slp3 |        .        .        .        .        .        .        .  
        bmi3 |        .        .        .        .        .        .        .  
         pf3 |        .        .        .        .        .        .        .  
        anx3 |        .        .        .        .        .        .        .  
        dep3 |        .        .        .        .        .        .        .  
        cog3 |        .        .        .        .        .        .        .  
         gh3 |        .        .        .        .        .        .        .  
       part3 |        .        .        .        .        .        .        .  
 
             |  anxiety   sleep1   sleep2   sleep4      out   partic  obesity 
-------------+--------------------------------------------------------------- 
     anxiety |   1.0000  
      sleep1 |   0.2644   1.0000  
      sleep2 |   0.2287   0.4145   1.0000  
      sleep4 |   0.3157   0.4645   0.3710   1.0000  
         out |   0.2236   0.1898   0.1781   0.2070   1.0000  
      partic |   0.2428   0.1729   0.1439   0.2007   0.3858   1.0000  
     obesity |   0.0592   0.0710   0.0755   0.0925   0.0588   0.0663   1.0000  
   physfunct |  -0.3021  -0.2685  -0.2789  -0.3075  -0.5691  -0.4574  -0.1629  
     painint |   0.3212   0.2669   0.2630   0.3106   0.4388   0.4100   0.1405  
   cognitive |   0.3471   0.2026   0.2101   0.2623   0.2751   0.2715   0.0497  
        slp3 |        .        .        .        .        .        .        .  
        bmi3 |        .        .        .        .        .        .        .  
         pf3 |        .        .        .        .        .        .        .  
        anx3 |        .        .        .        .        .        .        .  
        dep3 |        .        .        .        .        .        .        .  
        cog3 |        .        .        .        .        .        .        .  
         gh3 |        .        .        .        .        .        .        .  
       part3 |        .        .        .        .        .        .        .  
 
             | physfu~t  painint cognit~e     slp3     bmi3      pf3     anx3 
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-------------+--------------------------------------------------------------- 
   physfunct |   1.0000  
     painint |  -0.7328   1.0000  
   cognitive |  -0.3703   0.3374   1.0000  
        slp3 |        .        .        .        .  
        bmi3 |        .        .        .        .        .  
         pf3 |        .        .        .        .        .        .  
        anx3 |        .        .        .        .        .        .        .  
        dep3 |        .        .        .        .        .        .        .  
        cog3 |        .        .        .        .        .        .        .  
         gh3 |        .        .        .        .        .        .        .  
       part3 |        .        .        .        .        .        .        .  
 
             |     dep3     cog3      gh3    part3 
-------------+------------------------------------ 
        dep3 |        .  
        cog3 |        .        .  
         gh3 |        .        .        .  
       part3 |        .        .        .        .  
 
             | m_sleep4     pain  numpain   censor      age      sex educat~n 
-------------+--------------------------------------------------------------- 
    m_sleep4 |   1.0000  
        pain |   0.0132   1.0000  
     numpain |  -0.0387  -0.5166   1.0000  
      censor |   0.0357  -0.0124   0.0262   1.0000  
         age |   0.0825   0.0064  -0.0068   0.3915   1.0000  
         sex |  -0.0209   0.0328  -0.0747   0.0518  -0.0690   1.0000  
   education |   0.0040  -0.0491   0.0448   0.0574   0.1316   0.0546   1.0000  
      income |  -0.0009  -0.1015   0.1639   0.0205   0.0011  -0.0089   0.0854  
     alcohol |   0.0316  -0.0345   0.1042   0.0612   0.1774  -0.2396   0.0480  
       smoke |   0.0152   0.0179  -0.0282  -0.0447   0.0234  -0.2045  -0.0207  
     control |   0.0132   0.0340  -0.0253  -0.0355   0.0079   0.0004  -0.0231  
      health |   0.0066  -0.2913   0.4020   0.2056   0.2392  -0.0032   0.1192  
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        walk |   0.0005  -0.1561   0.2255   0.1543   0.1947  -0.0922   0.0467  
  depression |  -0.0011  -0.1664   0.2844   0.1168   0.1129  -0.0088   0.0480  
     anxiety |  -0.0283  -0.2060   0.2686   0.0126  -0.0272  -0.1434   0.0266  
      sleep1 |   0.0029  -0.1532   0.2471   0.0228   0.0352  -0.1027   0.0326  
      sleep2 |   0.0013  -0.1648   0.2151   0.0735   0.0713  -0.0598   0.0371  
      sleep3 |   0.0163  -0.1675   0.2480   0.0230   0.0142  -0.0818   0.0269  
         out |   0.0194  -0.1554   0.2502   0.2320   0.3669  -0.1078   0.1013  
      partic |   0.0451  -0.1608   0.2308   0.1396   0.1966  -0.0606   0.0759  
     obesity |  -0.0075  -0.0988   0.1349  -0.0401  -0.1006  -0.0384   0.0088  
   physfunct |  -0.0034   0.3525  -0.4878  -0.2653  -0.3937   0.1320  -0.1142  
     painint |  -0.0018  -0.4996   0.5589   0.1571   0.1977  -0.0374   0.0939  
   cognitive |  -0.0337  -0.1985   0.2688   0.1076   0.1484  -0.0455   0.0247  
        slp3 |        .        .        .        .        .        .        .  
        bmi3 |        .        .        .        .        .        .        .  
         pf3 |        .        .        .        .        .        .        .  
        anx3 |        .        .        .        .        .        .        .  
        dep3 |        .        .        .        .        .        .        .  
        cog3 |        .        .        .        .        .        .        .  
         gh3 |        .        .        .        .        .        .        .  
       part3 |        .        .        .        .        .        .        .  
 
             |   income  alcohol    smoke  control   health     walk depres~n 
-------------+--------------------------------------------------------------- 
      income |   1.0000  
     alcohol |   0.1104   1.0000  
       smoke |  -0.0153   0.1158   1.0000  
     control |  -0.0183   0.0002  -0.1999   1.0000  
      health |   0.2131   0.1598  -0.0613  -0.0208   1.0000  
        walk |   0.0898   0.1398  -0.0122  -0.0217   0.3826   1.0000  
  depression |   0.1843   0.1205  -0.0228  -0.0093   0.4413   0.2985   1.0000  
     anxiety |   0.1966   0.0856   0.0093  -0.0463   0.3234   0.1692   0.4194  
      sleep1 |   0.1366   0.0943   0.0159  -0.0210   0.2494   0.1541   0.2458  
      sleep2 |   0.1028   0.0764   0.0773  -0.2186   0.2480   0.1485   0.2141  
      sleep3 |   0.1277   0.0701   0.0020  -0.0150   0.2533   0.1502   0.2595  
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         out |   0.1423   0.1925  -0.0011  -0.0112   0.4615   0.5116   0.3932  
      partic |   0.1802   0.1316  -0.0131   0.0373   0.3890   0.2798   0.3266  
     obesity |   0.0809   0.0709  -0.0148  -0.0148   0.1423   0.1125   0.0809  
   physfunct |  -0.2186  -0.2143   0.0236   0.0378  -0.6629  -0.5167  -0.4536  
     painint |   0.2139   0.1430  -0.0337  -0.0276   0.5991   0.3743   0.4082  
   cognitive |   0.1619   0.0893  -0.0113  -0.0263   0.3374   0.1898   0.3500  
        slp3 |        .        .        .        .        .        .        .  
        bmi3 |        .        .        .        .        .        .        .  
         pf3 |        .        .        .        .        .        .        .  
        anx3 |        .        .        .        .        .        .        .  
        dep3 |        .        .        .        .        .        .        .  
        cog3 |        .        .        .        .        .        .        .  
         gh3 |        .        .        .        .        .        .        .  
       part3 |        .        .        .        .        .        .        .  
 
             |  anxiety   sleep1   sleep2   sleep3      out   partic  obesity 
-------------+--------------------------------------------------------------- 
     anxiety |   1.0000  
      sleep1 |   0.2644   1.0000  
      sleep2 |   0.2287   0.4145   1.0000  
      sleep3 |   0.2775   0.5954   0.5615   1.0000  
         out |   0.2236   0.1898   0.1781   0.1792   1.0000  
      partic |   0.2428   0.1729   0.1439   0.1654   0.3858   1.0000  
     obesity |   0.0592   0.0710   0.0755   0.0821   0.0588   0.0663   1.0000  
   physfunct |  -0.3021  -0.2685  -0.2789  -0.2762  -0.5691  -0.4574  -0.1629  
     painint |   0.3212   0.2669   0.2630   0.2840   0.4388   0.4100   0.1405  
   cognitive |   0.3471   0.2026   0.2101   0.2179   0.2751   0.2715   0.0497  
        slp3 |        .        .        .        .        .        .        .  
        bmi3 |        .        .        .        .        .        .        .  
         pf3 |        .        .        .        .        .        .        .  
        anx3 |        .        .        .        .        .        .        .  
        dep3 |        .        .        .        .        .        .        .  
        cog3 |        .        .        .        .        .        .        .  
         gh3 |        .        .        .        .        .        .        .  
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       part3 |        .        .        .        .        .        .        .  
 
             | physfu~t  painint cognit~e     slp3     bmi3      pf3     anx3 
-------------+--------------------------------------------------------------- 
   physfunct |   1.0000  
     painint |  -0.7328   1.0000  
   cognitive |  -0.3703   0.3374   1.0000  
        slp3 |        .        .        .        .  
        bmi3 |        .        .        .        .        .  
         pf3 |        .        .        .        .        .        .  
        anx3 |        .        .        .        .        .        .        .  
        dep3 |        .        .        .        .        .        .        .  
        cog3 |        .        .        .        .        .        .        .  
         gh3 |        .        .        .        .        .        .        .  
       part3 |        .        .        .        .        .        .        .  
 
             |     dep3     cog3      gh3    part3 
-------------+------------------------------------ 
        dep3 |        .  
        cog3 |        .        .  
         gh3 |        .        .        .  
       part3 |        .        .        .        .  
 
             |    m_out     pain  numpain   censor      age      sex educat~n 
-------------+--------------------------------------------------------------- 
       m_out |   1.0000  
        pain |   0.0035   1.0000  
     numpain |  -0.0025  -0.5166   1.0000  
      censor |   0.0395  -0.0124   0.0262   1.0000  
         age |   0.0696   0.0064  -0.0068   0.3915   1.0000  
         sex |  -0.0183   0.0328  -0.0747   0.0518  -0.0690   1.0000  
   education |   0.0158  -0.0491   0.0448   0.0574   0.1316   0.0546   1.0000  
      income |   0.0179  -0.1015   0.1639   0.0205   0.0011  -0.0089   0.0854  
     alcohol |   0.0271  -0.0345   0.1042   0.0612   0.1774  -0.2396   0.0480  
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       smoke |   0.0074   0.0179  -0.0282  -0.0447   0.0234  -0.2045  -0.0207  
     control |  -0.0035   0.0340  -0.0253  -0.0355   0.0079   0.0004  -0.0231  
      health |   0.0389  -0.2913   0.4020   0.2056   0.2392  -0.0032   0.1192  
        walk |   0.0285  -0.1561   0.2255   0.1543   0.1947  -0.0922   0.0467  
  depression |   0.0319  -0.1664   0.2844   0.1168   0.1129  -0.0088   0.0480  
     anxiety |   0.0088  -0.2060   0.2686   0.0126  -0.0272  -0.1434   0.0266  
      sleep1 |   0.0111  -0.1532   0.2471   0.0228   0.0352  -0.1027   0.0326  
      sleep2 |   0.0112  -0.1648   0.2151   0.0735   0.0713  -0.0598   0.0371  
      sleep3 |   0.0045  -0.1675   0.2480   0.0230   0.0142  -0.0818   0.0269  
      sleep4 |   0.0040  -0.1813   0.3014   0.0247  -0.0337  -0.0705   0.0200  
      partic |   0.0386  -0.1608   0.2308   0.1396   0.1966  -0.0606   0.0759  
     obesity |  -0.0089  -0.0988   0.1349  -0.0401  -0.1006  -0.0384   0.0088  
   physfunct |  -0.0385   0.3525  -0.4878  -0.2653  -0.3937   0.1320  -0.1142  
     painint |   0.0401  -0.4996   0.5589   0.1571   0.1977  -0.0374   0.0939  
   cognitive |   0.0161  -0.1985   0.2688   0.1076   0.1484  -0.0455   0.0247  
        slp3 |        .        .        .        .        .        .        .  
        bmi3 |        .        .        .        .        .        .        .  
         pf3 |        .        .        .        .        .        .        .  
        anx3 |        .        .        .        .        .        .        .  
        dep3 |        .        .        .        .        .        .        .  
        cog3 |        .        .        .        .        .        .        .  
         gh3 |        .        .        .        .        .        .        .  
       part3 |        .        .        .        .        .        .        .  
 
             |   income  alcohol    smoke  control   health     walk depres~n 
-------------+--------------------------------------------------------------- 
      income |   1.0000  
     alcohol |   0.1104   1.0000  
       smoke |  -0.0153   0.1158   1.0000  
     control |  -0.0183   0.0002  -0.1999   1.0000  
      health |   0.2131   0.1598  -0.0613  -0.0208   1.0000  
        walk |   0.0898   0.1398  -0.0122  -0.0217   0.3826   1.0000  
  depression |   0.1843   0.1205  -0.0228  -0.0093   0.4413   0.2985   1.0000  
     anxiety |   0.1966   0.0856   0.0093  -0.0463   0.3234   0.1692   0.4194  
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      sleep1 |   0.1366   0.0943   0.0159  -0.0210   0.2494   0.1541   0.2458  
      sleep2 |   0.1028   0.0764   0.0773  -0.2186   0.2480   0.1485   0.2141  
      sleep3 |   0.1277   0.0701   0.0020  -0.0150   0.2533   0.1502   0.2595  
      sleep4 |   0.1580   0.0853  -0.0090  -0.0167   0.3126   0.1934   0.3434  
      partic |   0.1802   0.1316  -0.0131   0.0373   0.3890   0.2798   0.3266  
     obesity |   0.0809   0.0709  -0.0148  -0.0148   0.1423   0.1125   0.0809  
   physfunct |  -0.2186  -0.2143   0.0236   0.0378  -0.6629  -0.5167  -0.4536  
     painint |   0.2139   0.1430  -0.0337  -0.0276   0.5991   0.3743   0.4082  
   cognitive |   0.1619   0.0893  -0.0113  -0.0263   0.3374   0.1898   0.3500  
        slp3 |        .        .        .        .        .        .        .  
        bmi3 |        .        .        .        .        .        .        .  
         pf3 |        .        .        .        .        .        .        .  
        anx3 |        .        .        .        .        .        .        .  
        dep3 |        .        .        .        .        .        .        .  
        cog3 |        .        .        .        .        .        .        .  
         gh3 |        .        .        .        .        .        .        .  
       part3 |        .        .        .        .        .        .        .  
 
             |  anxiety   sleep1   sleep2   sleep3   sleep4   partic  obesity 
-------------+--------------------------------------------------------------- 
     anxiety |   1.0000  
      sleep1 |   0.2644   1.0000  
      sleep2 |   0.2287   0.4145   1.0000  
      sleep3 |   0.2775   0.5954   0.5615   1.0000  
      sleep4 |   0.3157   0.4645   0.3710   0.5106   1.0000  
      partic |   0.2428   0.1729   0.1439   0.1654   0.2007   1.0000  
     obesity |   0.0592   0.0710   0.0755   0.0821   0.0925   0.0663   1.0000  
   physfunct |  -0.3021  -0.2685  -0.2789  -0.2762  -0.3075  -0.4574  -0.1629  
     painint |   0.3212   0.2669   0.2630   0.2840   0.3106   0.4100   0.1405  
   cognitive |   0.3471   0.2026   0.2101   0.2179   0.2623   0.2715   0.0497  
        slp3 |        .        .        .        .        .        .        .  
        bmi3 |        .        .        .        .        .        .        .  
         pf3 |        .        .        .        .        .        .        .  
        anx3 |        .        .        .        .        .        .        .  
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        dep3 |        .        .        .        .        .        .        .  
        cog3 |        .        .        .        .        .        .        .  
         gh3 |        .        .        .        .        .        .        .  
       part3 |        .        .        .        .        .        .        .  
 
             | physfu~t  painint cognit~e     slp3     bmi3      pf3     anx3 
-------------+--------------------------------------------------------------- 
   physfunct |   1.0000  
     painint |  -0.7328   1.0000  
   cognitive |  -0.3703   0.3374   1.0000  
        slp3 |        .        .        .        .  
        bmi3 |        .        .        .        .        .  
         pf3 |        .        .        .        .        .        .  
        anx3 |        .        .        .        .        .        .        .  
        dep3 |        .        .        .        .        .        .        .  
        cog3 |        .        .        .        .        .        .        .  
         gh3 |        .        .        .        .        .        .        .  
       part3 |        .        .        .        .        .        .        .  
 
             |     dep3     cog3      gh3    part3 
-------------+------------------------------------ 
        dep3 |        .  
        cog3 |        .        .  
         gh3 |        .        .        .  
       part3 |        .        .        .        .  
 
             | m_partic     pain  numpain   censor      age      sex educat~n 
-------------+--------------------------------------------------------------- 
    m_partic |   1.0000  
        pain |   0.0248   1.0000  
     numpain |  -0.0456  -0.5166   1.0000  
      censor |  -0.0420  -0.0124   0.0262   1.0000  
         age |  -0.0153   0.0064  -0.0068   0.3915   1.0000  
         sex |   0.0380   0.0328  -0.0747   0.0518  -0.0690   1.0000  
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   education |   0.0181  -0.0491   0.0448   0.0574   0.1316   0.0546   1.0000  
      income |  -0.0149  -0.1015   0.1639   0.0205   0.0011  -0.0089   0.0854  
     alcohol |  -0.0101  -0.0345   0.1042   0.0612   0.1774  -0.2396   0.0480  
       smoke |  -0.0784   0.0179  -0.0282  -0.0447   0.0234  -0.2045  -0.0207  
     control |   0.2141   0.0340  -0.0253  -0.0355   0.0079   0.0004  -0.0231  
      health |  -0.0534  -0.2913   0.4020   0.2056   0.2392  -0.0032   0.1192  
        walk |  -0.0392  -0.1561   0.2255   0.1543   0.1947  -0.0922   0.0467  
  depression |  -0.0306  -0.1664   0.2844   0.1168   0.1129  -0.0088   0.0480  
     anxiety |  -0.0385  -0.2060   0.2686   0.0126  -0.0272  -0.1434   0.0266  
      sleep1 |  -0.0381  -0.1532   0.2471   0.0228   0.0352  -0.1027   0.0326  
      sleep2 |  -0.0976  -0.1648   0.2151   0.0735   0.0713  -0.0598   0.0371  
      sleep3 |  -0.0375  -0.1675   0.2480   0.0230   0.0142  -0.0818   0.0269  
      sleep4 |  -0.0337  -0.1813   0.3014   0.0247  -0.0337  -0.0705   0.0200  
         out |  -0.0374  -0.1554   0.2502   0.2320   0.3669  -0.1078   0.1013  
     obesity |  -0.0237  -0.0988   0.1349  -0.0401  -0.1006  -0.0384   0.0088  
   physfunct |   0.0769   0.3525  -0.4878  -0.2653  -0.3937   0.1320  -0.1142  
     painint |  -0.0762  -0.4996   0.5589   0.1571   0.1977  -0.0374   0.0939  
   cognitive |  -0.0504  -0.1985   0.2688   0.1076   0.1484  -0.0455   0.0247  
        slp3 |        .        .        .        .        .        .        .  
        bmi3 |        .        .        .        .        .        .        .  
         pf3 |        .        .        .        .        .        .        .  
        anx3 |        .        .        .        .        .        .        .  
        dep3 |        .        .        .        .        .        .        .  
        cog3 |        .        .        .        .        .        .        .  
         gh3 |        .        .        .        .        .        .        .  
       part3 |        .        .        .        .        .        .        .  
 
             |   income  alcohol    smoke  control   health     walk depres~n 
-------------+--------------------------------------------------------------- 
      income |   1.0000  
     alcohol |   0.1104   1.0000  
       smoke |  -0.0153   0.1158   1.0000  
     control |  -0.0183   0.0002  -0.1999   1.0000  
      health |   0.2131   0.1598  -0.0613  -0.0208   1.0000  
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        walk |   0.0898   0.1398  -0.0122  -0.0217   0.3826   1.0000  
  depression |   0.1843   0.1205  -0.0228  -0.0093   0.4413   0.2985   1.0000  
     anxiety |   0.1966   0.0856   0.0093  -0.0463   0.3234   0.1692   0.4194  
      sleep1 |   0.1366   0.0943   0.0159  -0.0210   0.2494   0.1541   0.2458  
      sleep2 |   0.1028   0.0764   0.0773  -0.2186   0.2480   0.1485   0.2141  
      sleep3 |   0.1277   0.0701   0.0020  -0.0150   0.2533   0.1502   0.2595  
      sleep4 |   0.1580   0.0853  -0.0090  -0.0167   0.3126   0.1934   0.3434  
         out |   0.1423   0.1925  -0.0011  -0.0112   0.4615   0.5116   0.3932  
     obesity |   0.0809   0.0709  -0.0148  -0.0148   0.1423   0.1125   0.0809  
   physfunct |  -0.2186  -0.2143   0.0236   0.0378  -0.6629  -0.5167  -0.4536  
     painint |   0.2139   0.1430  -0.0337  -0.0276   0.5991   0.3743   0.4082  
   cognitive |   0.1619   0.0893  -0.0113  -0.0263   0.3374   0.1898   0.3500  
        slp3 |        .        .        .        .        .        .        .  
        bmi3 |        .        .        .        .        .        .        .  
         pf3 |        .        .        .        .        .        .        .  
        anx3 |        .        .        .        .        .        .        .  
        dep3 |        .        .        .        .        .        .        .  
        cog3 |        .        .        .        .        .        .        .  
         gh3 |        .        .        .        .        .        .        .  
       part3 |        .        .        .        .        .        .        .  
 
             |  anxiety   sleep1   sleep2   sleep3   sleep4      out  obesity 
-------------+--------------------------------------------------------------- 
     anxiety |   1.0000  
      sleep1 |   0.2644   1.0000  
      sleep2 |   0.2287   0.4145   1.0000  
      sleep3 |   0.2775   0.5954   0.5615   1.0000  
      sleep4 |   0.3157   0.4645   0.3710   0.5106   1.0000  
         out |   0.2236   0.1898   0.1781   0.1792   0.2070   1.0000  
     obesity |   0.0592   0.0710   0.0755   0.0821   0.0925   0.0588   1.0000  
   physfunct |  -0.3021  -0.2685  -0.2789  -0.2762  -0.3075  -0.5691  -0.1629  
     painint |   0.3212   0.2669   0.2630   0.2840   0.3106   0.4388   0.1405  
   cognitive |   0.3471   0.2026   0.2101   0.2179   0.2623   0.2751   0.0497  
        slp3 |        .        .        .        .        .        .        .  
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        bmi3 |        .        .        .        .        .        .        .  
         pf3 |        .        .        .        .        .        .        .  
        anx3 |        .        .        .        .        .        .        .  
        dep3 |        .        .        .        .        .        .        .  
        cog3 |        .        .        .        .        .        .        .  
         gh3 |        .        .        .        .        .        .        .  
       part3 |        .        .        .        .        .        .        .  
 
             | physfu~t  painint cognit~e     slp3     bmi3      pf3     anx3 
-------------+--------------------------------------------------------------- 
   physfunct |   1.0000  
     painint |  -0.7328   1.0000  
   cognitive |  -0.3703   0.3374   1.0000  
        slp3 |        .        .        .        .  
        bmi3 |        .        .        .        .        .  
         pf3 |        .        .        .        .        .        .  
        anx3 |        .        .        .        .        .        .        .  
        dep3 |        .        .        .        .        .        .        .  
        cog3 |        .        .        .        .        .        .        .  
         gh3 |        .        .        .        .        .        .        .  
       part3 |        .        .        .        .        .        .        .  
 
             |     dep3     cog3      gh3    part3 
-------------+------------------------------------ 
        dep3 |        .  
        cog3 |        .        .  
         gh3 |        .        .        .  
       part3 |        .        .        .        .  
 
             | m_obes~y     pain  numpain   censor      age      sex educat~n 
-------------+--------------------------------------------------------------- 
   m_obesity |   1.0000  
        pain |   0.0028   1.0000  
     numpain |  -0.0034  -0.5166   1.0000  
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      censor |   0.0462  -0.0124   0.0262   1.0000  
         age |   0.1012   0.0064  -0.0068   0.3915   1.0000  
         sex |  -0.0542   0.0328  -0.0747   0.0518  -0.0690   1.0000  
   education |   0.0104  -0.0491   0.0448   0.0574   0.1316   0.0546   1.0000  
      income |   0.0333  -0.1015   0.1639   0.0205   0.0011  -0.0089   0.0854  
     alcohol |   0.0606  -0.0345   0.1042   0.0612   0.1774  -0.2396   0.0480  
       smoke |   0.0295   0.0179  -0.0282  -0.0447   0.0234  -0.2045  -0.0207  
     control |  -0.0089   0.0340  -0.0253  -0.0355   0.0079   0.0004  -0.0231  
      health |   0.0549  -0.2913   0.4020   0.2056   0.2392  -0.0032   0.1192  
        walk |   0.0470  -0.1561   0.2255   0.1543   0.1947  -0.0922   0.0467  
  depression |   0.0508  -0.1664   0.2844   0.1168   0.1129  -0.0088   0.0480  
     anxiety |   0.0156  -0.2060   0.2686   0.0126  -0.0272  -0.1434   0.0266  
      sleep1 |   0.0197  -0.1532   0.2471   0.0228   0.0352  -0.1027   0.0326  
      sleep2 |   0.0184  -0.1648   0.2151   0.0735   0.0713  -0.0598   0.0371  
      sleep3 |   0.0075  -0.1675   0.2480   0.0230   0.0142  -0.0818   0.0269  
      sleep4 |   0.0110  -0.1813   0.3014   0.0247  -0.0337  -0.0705   0.0200  
         out |   0.0727  -0.1554   0.2502   0.2320   0.3669  -0.1078   0.1013  
      partic |   0.0649  -0.1608   0.2308   0.1396   0.1966  -0.0606   0.0759  
   physfunct |  -0.0636   0.3525  -0.4878  -0.2653  -0.3937   0.1320  -0.1142  
     painint |   0.0242  -0.4996   0.5589   0.1571   0.1977  -0.0374   0.0939  
   cognitive |   0.0422  -0.1985   0.2688   0.1076   0.1484  -0.0455   0.0247  
        slp3 |        .        .        .        .        .        .        .  
        bmi3 |        .        .        .        .        .        .        .  
         pf3 |        .        .        .        .        .        .        .  
        anx3 |        .        .        .        .        .        .        .  
        dep3 |        .        .        .        .        .        .        .  
        cog3 |        .        .        .        .        .        .        .  
         gh3 |        .        .        .        .        .        .        .  
       part3 |        .        .        .        .        .        .        .  
 
             |   income  alcohol    smoke  control   health     walk depres~n 
-------------+--------------------------------------------------------------- 
      income |   1.0000  
     alcohol |   0.1104   1.0000  
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       smoke |  -0.0153   0.1158   1.0000  
     control |  -0.0183   0.0002  -0.1999   1.0000  
      health |   0.2131   0.1598  -0.0613  -0.0208   1.0000  
        walk |   0.0898   0.1398  -0.0122  -0.0217   0.3826   1.0000  
  depression |   0.1843   0.1205  -0.0228  -0.0093   0.4413   0.2985   1.0000  
     anxiety |   0.1966   0.0856   0.0093  -0.0463   0.3234   0.1692   0.4194  
      sleep1 |   0.1366   0.0943   0.0159  -0.0210   0.2494   0.1541   0.2458  
      sleep2 |   0.1028   0.0764   0.0773  -0.2186   0.2480   0.1485   0.2141  
      sleep3 |   0.1277   0.0701   0.0020  -0.0150   0.2533   0.1502   0.2595  
      sleep4 |   0.1580   0.0853  -0.0090  -0.0167   0.3126   0.1934   0.3434  
         out |   0.1423   0.1925  -0.0011  -0.0112   0.4615   0.5116   0.3932  
      partic |   0.1802   0.1316  -0.0131   0.0373   0.3890   0.2798   0.3266  
   physfunct |  -0.2186  -0.2143   0.0236   0.0378  -0.6629  -0.5167  -0.4536  
     painint |   0.2139   0.1430  -0.0337  -0.0276   0.5991   0.3743   0.4082  
   cognitive |   0.1619   0.0893  -0.0113  -0.0263   0.3374   0.1898   0.3500  
        slp3 |        .        .        .        .        .        .        .  
        bmi3 |        .        .        .        .        .        .        .  
         pf3 |        .        .        .        .        .        .        .  
        anx3 |        .        .        .        .        .        .        .  
        dep3 |        .        .        .        .        .        .        .  
        cog3 |        .        .        .        .        .        .        .  
         gh3 |        .        .        .        .        .        .        .  
       part3 |        .        .        .        .        .        .        .  
 
             |  anxiety   sleep1   sleep2   sleep3   sleep4      out   partic 
-------------+--------------------------------------------------------------- 
     anxiety |   1.0000  
      sleep1 |   0.2644   1.0000  
      sleep2 |   0.2287   0.4145   1.0000  
      sleep3 |   0.2775   0.5954   0.5615   1.0000  
      sleep4 |   0.3157   0.4645   0.3710   0.5106   1.0000  
         out |   0.2236   0.1898   0.1781   0.1792   0.2070   1.0000  
      partic |   0.2428   0.1729   0.1439   0.1654   0.2007   0.3858   1.0000  
   physfunct |  -0.3021  -0.2685  -0.2789  -0.2762  -0.3075  -0.5691  -0.4574  
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     painint |   0.3212   0.2669   0.2630   0.2840   0.3106   0.4388   0.4100  
   cognitive |   0.3471   0.2026   0.2101   0.2179   0.2623   0.2751   0.2715  
        slp3 |        .        .        .        .        .        .        .  
        bmi3 |        .        .        .        .        .        .        .  
         pf3 |        .        .        .        .        .        .        .  
        anx3 |        .        .        .        .        .        .        .  
        dep3 |        .        .        .        .        .        .        .  
        cog3 |        .        .        .        .        .        .        .  
         gh3 |        .        .        .        .        .        .        .  
       part3 |        .        .        .        .        .        .        .  
 
             | physfu~t  painint cognit~e     slp3     bmi3      pf3     anx3 
-------------+--------------------------------------------------------------- 
   physfunct |   1.0000  
     painint |  -0.7328   1.0000  
   cognitive |  -0.3703   0.3374   1.0000  
        slp3 |        .        .        .        .  
        bmi3 |        .        .        .        .        .  
         pf3 |        .        .        .        .        .        .  
        anx3 |        .        .        .        .        .        .        .  
        dep3 |        .        .        .        .        .        .        .  
        cog3 |        .        .        .        .        .        .        .  
         gh3 |        .        .        .        .        .        .        .  
       part3 |        .        .        .        .        .        .        .  
 
             |     dep3     cog3      gh3    part3 
-------------+------------------------------------ 
        dep3 |        .  
        cog3 |        .        .  
         gh3 |        .        .        .  
       part3 |        .        .        .        .  
 
             | m_phys~t     pain  numpain   censor      age      sex educat~n 
-------------+--------------------------------------------------------------- 
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 m_physfunct |   1.0000  
        pain |  -0.0038   1.0000  
     numpain |  -0.0203  -0.5166   1.0000  
      censor |   0.0399  -0.0124   0.0262   1.0000  
         age |   0.1272   0.0064  -0.0068   0.3915   1.0000  
         sex |  -0.0570   0.0328  -0.0747   0.0518  -0.0690   1.0000  
   education |   0.0078  -0.0491   0.0448   0.0574   0.1316   0.0546   1.0000  
      income |   0.0372  -0.1015   0.1639   0.0205   0.0011  -0.0089   0.0854  
     alcohol |   0.0595  -0.0345   0.1042   0.0612   0.1774  -0.2396   0.0480  
       smoke |   0.0335   0.0179  -0.0282  -0.0447   0.0234  -0.2045  -0.0207  
     control |   0.0066   0.0340  -0.0253  -0.0355   0.0079   0.0004  -0.0231  
      health |   0.0530  -0.2913   0.4020   0.2056   0.2392  -0.0032   0.1192  
        walk |   0.0307  -0.1561   0.2255   0.1543   0.1947  -0.0922   0.0467  
  depression |   0.0376  -0.1664   0.2844   0.1168   0.1129  -0.0088   0.0480  
     anxiety |   0.0207  -0.2060   0.2686   0.0126  -0.0272  -0.1434   0.0266  
      sleep1 |   0.0433  -0.1532   0.2471   0.0228   0.0352  -0.1027   0.0326  
      sleep2 |   0.0264  -0.1648   0.2151   0.0735   0.0713  -0.0598   0.0371  
      sleep3 |   0.0232  -0.1675   0.2480   0.0230   0.0142  -0.0818   0.0269  
      sleep4 |   0.0196  -0.1813   0.3014   0.0247  -0.0337  -0.0705   0.0200  
         out |   0.0492  -0.1554   0.2502   0.2320   0.3669  -0.1078   0.1013  
      partic |   0.0721  -0.1608   0.2308   0.1396   0.1966  -0.0606   0.0759  
     obesity |  -0.0021  -0.0988   0.1349  -0.0401  -0.1006  -0.0384   0.0088  
     painint |   0.0270  -0.4996   0.5589   0.1571   0.1977  -0.0374   0.0939  
   cognitive |   0.0219  -0.1985   0.2688   0.1076   0.1484  -0.0455   0.0247  
        slp3 |        .        .        .        .        .        .        .  
        bmi3 |        .        .        .        .        .        .        .  
         pf3 |        .        .        .        .        .        .        .  
        anx3 |        .        .        .        .        .        .        .  
        dep3 |        .        .        .        .        .        .        .  
        cog3 |        .        .        .        .        .        .        .  
         gh3 |        .        .        .        .        .        .        .  
       part3 |        .        .        .        .        .        .        .  
 
             |   income  alcohol    smoke  control   health     walk depres~n 
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-------------+--------------------------------------------------------------- 
      income |   1.0000  
     alcohol |   0.1104   1.0000  
       smoke |  -0.0153   0.1158   1.0000  
     control |  -0.0183   0.0002  -0.1999   1.0000  
      health |   0.2131   0.1598  -0.0613  -0.0208   1.0000  
        walk |   0.0898   0.1398  -0.0122  -0.0217   0.3826   1.0000  
  depression |   0.1843   0.1205  -0.0228  -0.0093   0.4413   0.2985   1.0000  
     anxiety |   0.1966   0.0856   0.0093  -0.0463   0.3234   0.1692   0.4194  
      sleep1 |   0.1366   0.0943   0.0159  -0.0210   0.2494   0.1541   0.2458  
      sleep2 |   0.1028   0.0764   0.0773  -0.2186   0.2480   0.1485   0.2141  
      sleep3 |   0.1277   0.0701   0.0020  -0.0150   0.2533   0.1502   0.2595  
      sleep4 |   0.1580   0.0853  -0.0090  -0.0167   0.3126   0.1934   0.3434  
         out |   0.1423   0.1925  -0.0011  -0.0112   0.4615   0.5116   0.3932  
      partic |   0.1802   0.1316  -0.0131   0.0373   0.3890   0.2798   0.3266  
     obesity |   0.0809   0.0709  -0.0148  -0.0148   0.1423   0.1125   0.0809  
     painint |   0.2139   0.1430  -0.0337  -0.0276   0.5991   0.3743   0.4082  
   cognitive |   0.1619   0.0893  -0.0113  -0.0263   0.3374   0.1898   0.3500  
        slp3 |        .        .        .        .        .        .        .  
        bmi3 |        .        .        .        .        .        .        .  
         pf3 |        .        .        .        .        .        .        .  
        anx3 |        .        .        .        .        .        .        .  
        dep3 |        .        .        .        .        .        .        .  
        cog3 |        .        .        .        .        .        .        .  
         gh3 |        .        .        .        .        .        .        .  
       part3 |        .        .        .        .        .        .        .  
 
             |  anxiety   sleep1   sleep2   sleep3   sleep4      out   partic 
-------------+--------------------------------------------------------------- 
     anxiety |   1.0000  
      sleep1 |   0.2644   1.0000  
      sleep2 |   0.2287   0.4145   1.0000  
      sleep3 |   0.2775   0.5954   0.5615   1.0000  
      sleep4 |   0.3157   0.4645   0.3710   0.5106   1.0000  
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         out |   0.2236   0.1898   0.1781   0.1792   0.2070   1.0000  
      partic |   0.2428   0.1729   0.1439   0.1654   0.2007   0.3858   1.0000  
     obesity |   0.0592   0.0710   0.0755   0.0821   0.0925   0.0588   0.0663  
     painint |   0.3212   0.2669   0.2630   0.2840   0.3106   0.4388   0.4100  
   cognitive |   0.3471   0.2026   0.2101   0.2179   0.2623   0.2751   0.2715  
        slp3 |        .        .        .        .        .        .        .  
        bmi3 |        .        .        .        .        .        .        .  
         pf3 |        .        .        .        .        .        .        .  
        anx3 |        .        .        .        .        .        .        .  
        dep3 |        .        .        .        .        .        .        .  
        cog3 |        .        .        .        .        .        .        .  
         gh3 |        .        .        .        .        .        .        .  
       part3 |        .        .        .        .        .        .        .  
 
             |  obesity  painint cognit~e     slp3     bmi3      pf3     anx3 
-------------+--------------------------------------------------------------- 
     obesity |   1.0000  
     painint |   0.1405   1.0000  
   cognitive |   0.0497   0.3374   1.0000  
        slp3 |        .        .        .        .  
        bmi3 |        .        .        .        .        .  
         pf3 |        .        .        .        .        .        .  
        anx3 |        .        .        .        .        .        .        .  
        dep3 |        .        .        .        .        .        .        .  
        cog3 |        .        .        .        .        .        .        .  
         gh3 |        .        .        .        .        .        .        .  
       part3 |        .        .        .        .        .        .        .  
 
             |     dep3     cog3      gh3    part3 
-------------+------------------------------------ 
        dep3 |        .  
        cog3 |        .        .  
         gh3 |        .        .        .  
       part3 |        .        .        .        .  
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             | m_pain~t     pain  numpain   censor      age      sex educat~n 
-------------+--------------------------------------------------------------- 
   m_painint |   1.0000  
        pain |   0.0121   1.0000  
     numpain |  -0.0150  -0.5166   1.0000  
      censor |   0.0320  -0.0124   0.0262   1.0000  
         age |   0.0738   0.0064  -0.0068   0.3915   1.0000  
         sex |   0.0066   0.0328  -0.0747   0.0518  -0.0690   1.0000  
   education |   0.0034  -0.0491   0.0448   0.0574   0.1316   0.0546   1.0000  
      income |   0.0158  -0.1015   0.1639   0.0205   0.0011  -0.0089   0.0854  
     alcohol |   0.0215  -0.0345   0.1042   0.0612   0.1774  -0.2396   0.0480  
       smoke |  -0.0088   0.0179  -0.0282  -0.0447   0.0234  -0.2045  -0.0207  
     control |  -0.0050   0.0340  -0.0253  -0.0355   0.0079   0.0004  -0.0231  
      health |   0.0407  -0.2913   0.4020   0.2056   0.2392  -0.0032   0.1192  
        walk |   0.0143  -0.1561   0.2255   0.1543   0.1947  -0.0922   0.0467  
  depression |   0.0353  -0.1664   0.2844   0.1168   0.1129  -0.0088   0.0480  
     anxiety |   0.0005  -0.2060   0.2686   0.0126  -0.0272  -0.1434   0.0266  
      sleep1 |   0.0127  -0.1532   0.2471   0.0228   0.0352  -0.1027   0.0326  
      sleep2 |   0.0047  -0.1648   0.2151   0.0735   0.0713  -0.0598   0.0371  
      sleep3 |   0.0044  -0.1675   0.2480   0.0230   0.0142  -0.0818   0.0269  
      sleep4 |   0.0054  -0.1813   0.3014   0.0247  -0.0337  -0.0705   0.0200  
         out |   0.0428  -0.1554   0.2502   0.2320   0.3669  -0.1078   0.1013  
      partic |   0.0575  -0.1608   0.2308   0.1396   0.1966  -0.0606   0.0759  
     obesity |  -0.0100  -0.0988   0.1349  -0.0401  -0.1006  -0.0384   0.0088  
   physfunct |  -0.0381   0.3525  -0.4878  -0.2653  -0.3937   0.1320  -0.1142  
   cognitive |   0.0104  -0.1985   0.2688   0.1076   0.1484  -0.0455   0.0247  
        slp3 |        .        .        .        .        .        .        .  
        bmi3 |        .        .        .        .        .        .        .  
         pf3 |        .        .        .        .        .        .        .  
        anx3 |        .        .        .        .        .        .        .  
        dep3 |        .        .        .        .        .        .        .  
        cog3 |        .        .        .        .        .        .        .  
         gh3 |        .        .        .        .        .        .        .  
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       part3 |        .        .        .        .        .        .        .  
 
             |   income  alcohol    smoke  control   health     walk depres~n 
-------------+--------------------------------------------------------------- 
      income |   1.0000  
     alcohol |   0.1104   1.0000  
       smoke |  -0.0153   0.1158   1.0000  
     control |  -0.0183   0.0002  -0.1999   1.0000  
      health |   0.2131   0.1598  -0.0613  -0.0208   1.0000  
        walk |   0.0898   0.1398  -0.0122  -0.0217   0.3826   1.0000  
  depression |   0.1843   0.1205  -0.0228  -0.0093   0.4413   0.2985   1.0000  
     anxiety |   0.1966   0.0856   0.0093  -0.0463   0.3234   0.1692   0.4194  
      sleep1 |   0.1366   0.0943   0.0159  -0.0210   0.2494   0.1541   0.2458  
      sleep2 |   0.1028   0.0764   0.0773  -0.2186   0.2480   0.1485   0.2141  
      sleep3 |   0.1277   0.0701   0.0020  -0.0150   0.2533   0.1502   0.2595  
      sleep4 |   0.1580   0.0853  -0.0090  -0.0167   0.3126   0.1934   0.3434  
         out |   0.1423   0.1925  -0.0011  -0.0112   0.4615   0.5116   0.3932  
      partic |   0.1802   0.1316  -0.0131   0.0373   0.3890   0.2798   0.3266  
     obesity |   0.0809   0.0709  -0.0148  -0.0148   0.1423   0.1125   0.0809  
   physfunct |  -0.2186  -0.2143   0.0236   0.0378  -0.6629  -0.5167  -0.4536  
   cognitive |   0.1619   0.0893  -0.0113  -0.0263   0.3374   0.1898   0.3500  
        slp3 |        .        .        .        .        .        .        .  
        bmi3 |        .        .        .        .        .        .        .  
         pf3 |        .        .        .        .        .        .        .  
        anx3 |        .        .        .        .        .        .        .  
        dep3 |        .        .        .        .        .        .        .  
        cog3 |        .        .        .        .        .        .        .  
         gh3 |        .        .        .        .        .        .        .  
       part3 |        .        .        .        .        .        .        .  
 
             |  anxiety   sleep1   sleep2   sleep3   sleep4      out   partic 
-------------+--------------------------------------------------------------- 
     anxiety |   1.0000  
      sleep1 |   0.2644   1.0000  
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      sleep2 |   0.2287   0.4145   1.0000  
      sleep3 |   0.2775   0.5954   0.5615   1.0000  
      sleep4 |   0.3157   0.4645   0.3710   0.5106   1.0000  
         out |   0.2236   0.1898   0.1781   0.1792   0.2070   1.0000  
      partic |   0.2428   0.1729   0.1439   0.1654   0.2007   0.3858   1.0000  
     obesity |   0.0592   0.0710   0.0755   0.0821   0.0925   0.0588   0.0663  
   physfunct |  -0.3021  -0.2685  -0.2789  -0.2762  -0.3075  -0.5691  -0.4574  
   cognitive |   0.3471   0.2026   0.2101   0.2179   0.2623   0.2751   0.2715  
        slp3 |        .        .        .        .        .        .        .  
        bmi3 |        .        .        .        .        .        .        .  
         pf3 |        .        .        .        .        .        .        .  
        anx3 |        .        .        .        .        .        .        .  
        dep3 |        .        .        .        .        .        .        .  
        cog3 |        .        .        .        .        .        .        .  
         gh3 |        .        .        .        .        .        .        .  
       part3 |        .        .        .        .        .        .        .  
 
             |  obesity physfu~t cognit~e     slp3     bmi3      pf3     anx3 
-------------+--------------------------------------------------------------- 
     obesity |   1.0000  
   physfunct |  -0.1629   1.0000  
   cognitive |   0.0497  -0.3703   1.0000  
        slp3 |        .        .        .        .  
        bmi3 |        .        .        .        .        .  
         pf3 |        .        .        .        .        .        .  
        anx3 |        .        .        .        .        .        .        .  
        dep3 |        .        .        .        .        .        .        .  
        cog3 |        .        .        .        .        .        .        .  
         gh3 |        .        .        .        .        .        .        .  
       part3 |        .        .        .        .        .        .        .  
 
             |     dep3     cog3      gh3    part3 
-------------+------------------------------------ 
        dep3 |        .  
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        cog3 |        .        .  
         gh3 |        .        .        .  
       part3 |        .        .        .        .  
 
             | m_cogn~e     pain  numpain   censor      age      sex educat~n 
-------------+--------------------------------------------------------------- 
 m_cognitive |   1.0000  
        pain |  -0.0314   1.0000  
     numpain |   0.0293  -0.5166   1.0000  
      censor |   0.0568  -0.0124   0.0262   1.0000  
         age |   0.1326   0.0064  -0.0068   0.3915   1.0000  
         sex |  -0.0559   0.0328  -0.0747   0.0518  -0.0690   1.0000  
   education |   0.0090  -0.0491   0.0448   0.0574   0.1316   0.0546   1.0000  
      income |   0.0356  -0.1015   0.1639   0.0205   0.0011  -0.0089   0.0854  
     alcohol |   0.0548  -0.0345   0.1042   0.0612   0.1774  -0.2396   0.0480  
       smoke |   0.0183   0.0179  -0.0282  -0.0447   0.0234  -0.2045  -0.0207  
     control |   0.0052   0.0340  -0.0253  -0.0355   0.0079   0.0004  -0.0231  
      health |   0.0776  -0.2913   0.4020   0.2056   0.2392  -0.0032   0.1192  
        walk |   0.0506  -0.1561   0.2255   0.1543   0.1947  -0.0922   0.0467  
  depression |   0.0681  -0.1664   0.2844   0.1168   0.1129  -0.0088   0.0480  
     anxiety |   0.0657  -0.2060   0.2686   0.0126  -0.0272  -0.1434   0.0266  
      sleep1 |   0.0509  -0.1532   0.2471   0.0228   0.0352  -0.1027   0.0326  
      sleep2 |   0.0311  -0.1648   0.2151   0.0735   0.0713  -0.0598   0.0371  
      sleep3 |   0.0406  -0.1675   0.2480   0.0230   0.0142  -0.0818   0.0269  
      sleep4 |   0.0429  -0.1813   0.3014   0.0247  -0.0337  -0.0705   0.0200  
         out |   0.0919  -0.1554   0.2502   0.2320   0.3669  -0.1078   0.1013  
      partic |   0.0999  -0.1608   0.2308   0.1396   0.1966  -0.0606   0.0759  
     obesity |  -0.0003  -0.0988   0.1349  -0.0401  -0.1006  -0.0384   0.0088  
   physfunct |  -0.0969   0.3525  -0.4878  -0.2653  -0.3937   0.1320  -0.1142  
     painint |   0.0682  -0.4996   0.5589   0.1571   0.1977  -0.0374   0.0939  
        slp3 |        .        .        .        .        .        .        .  
        bmi3 |        .        .        .        .        .        .        .  
         pf3 |        .        .        .        .        .        .        .  
        anx3 |        .        .        .        .        .        .        .  
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        dep3 |        .        .        .        .        .        .        .  
        cog3 |        .        .        .        .        .        .        .  
         gh3 |        .        .        .        .        .        .        .  
       part3 |        .        .        .        .        .        .        .  
 
             |   income  alcohol    smoke  control   health     walk depres~n 
-------------+--------------------------------------------------------------- 
      income |   1.0000  
     alcohol |   0.1104   1.0000  
       smoke |  -0.0153   0.1158   1.0000  
     control |  -0.0183   0.0002  -0.1999   1.0000  
      health |   0.2131   0.1598  -0.0613  -0.0208   1.0000  
        walk |   0.0898   0.1398  -0.0122  -0.0217   0.3826   1.0000  
  depression |   0.1843   0.1205  -0.0228  -0.0093   0.4413   0.2985   1.0000  
     anxiety |   0.1966   0.0856   0.0093  -0.0463   0.3234   0.1692   0.4194  
      sleep1 |   0.1366   0.0943   0.0159  -0.0210   0.2494   0.1541   0.2458  
      sleep2 |   0.1028   0.0764   0.0773  -0.2186   0.2480   0.1485   0.2141  
      sleep3 |   0.1277   0.0701   0.0020  -0.0150   0.2533   0.1502   0.2595  
      sleep4 |   0.1580   0.0853  -0.0090  -0.0167   0.3126   0.1934   0.3434  
         out |   0.1423   0.1925  -0.0011  -0.0112   0.4615   0.5116   0.3932  
      partic |   0.1802   0.1316  -0.0131   0.0373   0.3890   0.2798   0.3266  
     obesity |   0.0809   0.0709  -0.0148  -0.0148   0.1423   0.1125   0.0809  
   physfunct |  -0.2186  -0.2143   0.0236   0.0378  -0.6629  -0.5167  -0.4536  
     painint |   0.2139   0.1430  -0.0337  -0.0276   0.5991   0.3743   0.4082  
        slp3 |        .        .        .        .        .        .        .  
        bmi3 |        .        .        .        .        .        .        .  
         pf3 |        .        .        .        .        .        .        .  
        anx3 |        .        .        .        .        .        .        .  
        dep3 |        .        .        .        .        .        .        .  
        cog3 |        .        .        .        .        .        .        .  
         gh3 |        .        .        .        .        .        .        .  
       part3 |        .        .        .        .        .        .        .  
 
             |  anxiety   sleep1   sleep2   sleep3   sleep4      out   partic 
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-------------+--------------------------------------------------------------- 
     anxiety |   1.0000  
      sleep1 |   0.2644   1.0000  
      sleep2 |   0.2287   0.4145   1.0000  
      sleep3 |   0.2775   0.5954   0.5615   1.0000  
      sleep4 |   0.3157   0.4645   0.3710   0.5106   1.0000  
         out |   0.2236   0.1898   0.1781   0.1792   0.2070   1.0000  
      partic |   0.2428   0.1729   0.1439   0.1654   0.2007   0.3858   1.0000  
     obesity |   0.0592   0.0710   0.0755   0.0821   0.0925   0.0588   0.0663  
   physfunct |  -0.3021  -0.2685  -0.2789  -0.2762  -0.3075  -0.5691  -0.4574  
     painint |   0.3212   0.2669   0.2630   0.2840   0.3106   0.4388   0.4100  
        slp3 |        .        .        .        .        .        .        .  
        bmi3 |        .        .        .        .        .        .        .  
         pf3 |        .        .        .        .        .        .        .  
        anx3 |        .        .        .        .        .        .        .  
        dep3 |        .        .        .        .        .        .        .  
        cog3 |        .        .        .        .        .        .        .  
         gh3 |        .        .        .        .        .        .        .  
       part3 |        .        .        .        .        .        .        .  
 
             |  obesity physfu~t  painint     slp3     bmi3      pf3     anx3 
-------------+--------------------------------------------------------------- 
     obesity |   1.0000  
   physfunct |  -0.1629   1.0000  
     painint |   0.1405  -0.7328   1.0000  
        slp3 |        .        .        .        .  
        bmi3 |        .        .        .        .        .  
         pf3 |        .        .        .        .        .        .  
        anx3 |        .        .        .        .        .        .        .  
        dep3 |        .        .        .        .        .        .        .  
        cog3 |        .        .        .        .        .        .        .  
         gh3 |        .        .        .        .        .        .        .  
       part3 |        .        .        .        .        .        .        .  
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             |     dep3     cog3      gh3    part3 
-------------+------------------------------------ 
        dep3 |        .  
        cog3 |        .        .  
         gh3 |        .        .        .  
       part3 |        .        .        .        .  
 
             |   m_slp3     pain  numpain   censor      age      sex educat~n 
-------------+--------------------------------------------------------------- 
      m_slp3 |   1.0000  
        pain |   0.0197   1.0000  
     numpain |  -0.0275  -0.5166   1.0000  
      censor |   0.1362  -0.0124   0.0262   1.0000  
         age |   0.2224   0.0064  -0.0068   0.3915   1.0000  
         sex |  -0.0279   0.0328  -0.0747   0.0518  -0.0690   1.0000  
   education |   0.0707  -0.0491   0.0448   0.0574   0.1316   0.0546   1.0000  
      income |   0.0611  -0.1015   0.1639   0.0205   0.0011  -0.0089   0.0854  
     alcohol |   0.0842  -0.0345   0.1042   0.0612   0.1774  -0.2396   0.0480  
       smoke |  -0.0092   0.0179  -0.0282  -0.0447   0.0234  -0.2045  -0.0207  
     control |   0.0388   0.0340  -0.0253  -0.0355   0.0079   0.0004  -0.0231  
      health |   0.1479  -0.2913   0.4020   0.2056   0.2392  -0.0032   0.1192  
        walk |   0.0854  -0.1561   0.2255   0.1543   0.1947  -0.0922   0.0467  
  depression |   0.0902  -0.1664   0.2844   0.1168   0.1129  -0.0088   0.0480  
     anxiety |   0.0410  -0.2060   0.2686   0.0126  -0.0272  -0.1434   0.0266  
      sleep1 |   0.0313  -0.1532   0.2471   0.0228   0.0352  -0.1027   0.0326  
      sleep2 |   0.0098  -0.1648   0.2151   0.0735   0.0713  -0.0598   0.0371  
      sleep3 |   0.0172  -0.1675   0.2480   0.0230   0.0142  -0.0818   0.0269  
      sleep4 |   0.0205  -0.1813   0.3014   0.0247  -0.0337  -0.0705   0.0200  
         out |   0.1592  -0.1554   0.2502   0.2320   0.3669  -0.1078   0.1013  
      partic |   0.1482  -0.1608   0.2308   0.1396   0.1966  -0.0606   0.0759  
     obesity |  -0.0167  -0.0988   0.1349  -0.0401  -0.1006  -0.0384   0.0088  
   physfunct |  -0.1356   0.3525  -0.4878  -0.2653  -0.3937   0.1320  -0.1142  
     painint |   0.0749  -0.4996   0.5589   0.1571   0.1977  -0.0374   0.0939  
   cognitive |   0.0624  -0.1985   0.2688   0.1076   0.1484  -0.0455   0.0247  
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        bmi3 |        .        .        .        .        .        .        .  
         pf3 |        .        .        .        .        .        .        .  
        anx3 |        .        .        .        .        .        .        .  
        dep3 |        .        .        .        .        .        .        .  
        cog3 |        .        .        .        .        .        .        .  
         gh3 |        .        .        .        .        .        .        .  
       part3 |        .        .        .        .        .        .        .  
 
             |   income  alcohol    smoke  control   health     walk depres~n 
-------------+--------------------------------------------------------------- 
      income |   1.0000  
     alcohol |   0.1104   1.0000  
       smoke |  -0.0153   0.1158   1.0000  
     control |  -0.0183   0.0002  -0.1999   1.0000  
      health |   0.2131   0.1598  -0.0613  -0.0208   1.0000  
        walk |   0.0898   0.1398  -0.0122  -0.0217   0.3826   1.0000  
  depression |   0.1843   0.1205  -0.0228  -0.0093   0.4413   0.2985   1.0000  
     anxiety |   0.1966   0.0856   0.0093  -0.0463   0.3234   0.1692   0.4194  
      sleep1 |   0.1366   0.0943   0.0159  -0.0210   0.2494   0.1541   0.2458  
      sleep2 |   0.1028   0.0764   0.0773  -0.2186   0.2480   0.1485   0.2141  
      sleep3 |   0.1277   0.0701   0.0020  -0.0150   0.2533   0.1502   0.2595  
      sleep4 |   0.1580   0.0853  -0.0090  -0.0167   0.3126   0.1934   0.3434  
         out |   0.1423   0.1925  -0.0011  -0.0112   0.4615   0.5116   0.3932  
      partic |   0.1802   0.1316  -0.0131   0.0373   0.3890   0.2798   0.3266  
     obesity |   0.0809   0.0709  -0.0148  -0.0148   0.1423   0.1125   0.0809  
   physfunct |  -0.2186  -0.2143   0.0236   0.0378  -0.6629  -0.5167  -0.4536  
     painint |   0.2139   0.1430  -0.0337  -0.0276   0.5991   0.3743   0.4082  
   cognitive |   0.1619   0.0893  -0.0113  -0.0263   0.3374   0.1898   0.3500  
        bmi3 |        .        .        .        .        .        .        .  
         pf3 |        .        .        .        .        .        .        .  
        anx3 |        .        .        .        .        .        .        .  
        dep3 |        .        .        .        .        .        .        .  
        cog3 |        .        .        .        .        .        .        .  
         gh3 |        .        .        .        .        .        .        .  
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       part3 |        .        .        .        .        .        .        .  
 
             |  anxiety   sleep1   sleep2   sleep3   sleep4      out   partic 
-------------+--------------------------------------------------------------- 
     anxiety |   1.0000  
      sleep1 |   0.2644   1.0000  
      sleep2 |   0.2287   0.4145   1.0000  
      sleep3 |   0.2775   0.5954   0.5615   1.0000  
      sleep4 |   0.3157   0.4645   0.3710   0.5106   1.0000  
         out |   0.2236   0.1898   0.1781   0.1792   0.2070   1.0000  
      partic |   0.2428   0.1729   0.1439   0.1654   0.2007   0.3858   1.0000  
     obesity |   0.0592   0.0710   0.0755   0.0821   0.0925   0.0588   0.0663  
   physfunct |  -0.3021  -0.2685  -0.2789  -0.2762  -0.3075  -0.5691  -0.4574  
     painint |   0.3212   0.2669   0.2630   0.2840   0.3106   0.4388   0.4100  
   cognitive |   0.3471   0.2026   0.2101   0.2179   0.2623   0.2751   0.2715  
        bmi3 |        .        .        .        .        .        .        .  
         pf3 |        .        .        .        .        .        .        .  
        anx3 |        .        .        .        .        .        .        .  
        dep3 |        .        .        .        .        .        .        .  
        cog3 |        .        .        .        .        .        .        .  
         gh3 |        .        .        .        .        .        .        .  
       part3 |        .        .        .        .        .        .        .  
 
             |  obesity physfu~t  painint cognit~e     bmi3      pf3     anx3 
-------------+--------------------------------------------------------------- 
     obesity |   1.0000  
   physfunct |  -0.1629   1.0000  
     painint |   0.1405  -0.7328   1.0000  
   cognitive |   0.0497  -0.3703   0.3374   1.0000  
        bmi3 |        .        .        .        .        .  
         pf3 |        .        .        .        .        .        .  
        anx3 |        .        .        .        .        .        .        .  
        dep3 |        .        .        .        .        .        .        .  
        cog3 |        .        .        .        .        .        .        .  
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         gh3 |        .        .        .        .        .        .        .  
       part3 |        .        .        .        .        .        .        .  
 
             |     dep3     cog3      gh3    part3 
-------------+------------------------------------ 
        dep3 |        .  
        cog3 |        .        .  
         gh3 |        .        .        .  
       part3 |        .        .        .        .  
 
             |   m_bmi3     pain  numpain   censor      age      sex educat~n 
-------------+--------------------------------------------------------------- 
      m_bmi3 |   1.0000  
        pain |   0.0252   1.0000  
     numpain |  -0.0321  -0.5166   1.0000  
      censor |   0.0415  -0.0124   0.0262   1.0000  
         age |   0.2136   0.0064  -0.0068   0.3915   1.0000  
         sex |  -0.0365   0.0328  -0.0747   0.0518  -0.0690   1.0000  
   education |   0.0260  -0.0491   0.0448   0.0574   0.1316   0.0546   1.0000  
      income |   0.0225  -0.1015   0.1639   0.0205   0.0011  -0.0089   0.0854  
     alcohol |   0.0655  -0.0345   0.1042   0.0612   0.1774  -0.2396   0.0480  
       smoke |   0.0379   0.0179  -0.0282  -0.0447   0.0234  -0.2045  -0.0207  
     control |  -0.0353   0.0340  -0.0253  -0.0355   0.0079   0.0004  -0.0231  
      health |   0.0613  -0.2913   0.4020   0.2056   0.2392  -0.0032   0.1192  
        walk |   0.0318  -0.1561   0.2255   0.1543   0.1947  -0.0922   0.0467  
  depression |   0.0372  -0.1664   0.2844   0.1168   0.1129  -0.0088   0.0480  
     anxiety |   0.0146  -0.2060   0.2686   0.0126  -0.0272  -0.1434   0.0266  
      sleep1 |   0.0173  -0.1532   0.2471   0.0228   0.0352  -0.1027   0.0326  
      sleep2 |   0.0188  -0.1648   0.2151   0.0735   0.0713  -0.0598   0.0371  
      sleep3 |   0.0104  -0.1675   0.2480   0.0230   0.0142  -0.0818   0.0269  
      sleep4 |  -0.0035  -0.1813   0.3014   0.0247  -0.0337  -0.0705   0.0200  
         out |   0.0936  -0.1554   0.2502   0.2320   0.3669  -0.1078   0.1013  
      partic |   0.0994  -0.1608   0.2308   0.1396   0.1966  -0.0606   0.0759  
     obesity |  -0.1050  -0.0988   0.1349  -0.0401  -0.1006  -0.0384   0.0088  
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   physfunct |  -0.0709   0.3525  -0.4878  -0.2653  -0.3937   0.1320  -0.1142  
     painint |   0.0228  -0.4996   0.5589   0.1571   0.1977  -0.0374   0.0939  
   cognitive |   0.0309  -0.1985   0.2688   0.1076   0.1484  -0.0455   0.0247  
        slp3 |        .        .        .        .        .        .        .  
         pf3 |        .        .        .        .        .        .        .  
        anx3 |        .        .        .        .        .        .        .  
        dep3 |        .        .        .        .        .        .        .  
        cog3 |        .        .        .        .        .        .        .  
         gh3 |        .        .        .        .        .        .        .  
       part3 |        .        .        .        .        .        .        .  
 
             |   income  alcohol    smoke  control   health     walk depres~n 
-------------+--------------------------------------------------------------- 
      income |   1.0000  
     alcohol |   0.1104   1.0000  
       smoke |  -0.0153   0.1158   1.0000  
     control |  -0.0183   0.0002  -0.1999   1.0000  
      health |   0.2131   0.1598  -0.0613  -0.0208   1.0000  
        walk |   0.0898   0.1398  -0.0122  -0.0217   0.3826   1.0000  
  depression |   0.1843   0.1205  -0.0228  -0.0093   0.4413   0.2985   1.0000  
     anxiety |   0.1966   0.0856   0.0093  -0.0463   0.3234   0.1692   0.4194  
      sleep1 |   0.1366   0.0943   0.0159  -0.0210   0.2494   0.1541   0.2458  
      sleep2 |   0.1028   0.0764   0.0773  -0.2186   0.2480   0.1485   0.2141  
      sleep3 |   0.1277   0.0701   0.0020  -0.0150   0.2533   0.1502   0.2595  
      sleep4 |   0.1580   0.0853  -0.0090  -0.0167   0.3126   0.1934   0.3434  
         out |   0.1423   0.1925  -0.0011  -0.0112   0.4615   0.5116   0.3932  
      partic |   0.1802   0.1316  -0.0131   0.0373   0.3890   0.2798   0.3266  
     obesity |   0.0809   0.0709  -0.0148  -0.0148   0.1423   0.1125   0.0809  
   physfunct |  -0.2186  -0.2143   0.0236   0.0378  -0.6629  -0.5167  -0.4536  
     painint |   0.2139   0.1430  -0.0337  -0.0276   0.5991   0.3743   0.4082  
   cognitive |   0.1619   0.0893  -0.0113  -0.0263   0.3374   0.1898   0.3500  
        slp3 |        .        .        .        .        .        .        .  
         pf3 |        .        .        .        .        .        .        .  
        anx3 |        .        .        .        .        .        .        .  
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        dep3 |        .        .        .        .        .        .        .  
        cog3 |        .        .        .        .        .        .        .  
         gh3 |        .        .        .        .        .        .        .  
       part3 |        .        .        .        .        .        .        .  
 
             |  anxiety   sleep1   sleep2   sleep3   sleep4      out   partic 
-------------+--------------------------------------------------------------- 
     anxiety |   1.0000  
      sleep1 |   0.2644   1.0000  
      sleep2 |   0.2287   0.4145   1.0000  
      sleep3 |   0.2775   0.5954   0.5615   1.0000  
      sleep4 |   0.3157   0.4645   0.3710   0.5106   1.0000  
         out |   0.2236   0.1898   0.1781   0.1792   0.2070   1.0000  
      partic |   0.2428   0.1729   0.1439   0.1654   0.2007   0.3858   1.0000  
     obesity |   0.0592   0.0710   0.0755   0.0821   0.0925   0.0588   0.0663  
   physfunct |  -0.3021  -0.2685  -0.2789  -0.2762  -0.3075  -0.5691  -0.4574  
     painint |   0.3212   0.2669   0.2630   0.2840   0.3106   0.4388   0.4100  
   cognitive |   0.3471   0.2026   0.2101   0.2179   0.2623   0.2751   0.2715  
        slp3 |        .        .        .        .        .        .        .  
         pf3 |        .        .        .        .        .        .        .  
        anx3 |        .        .        .        .        .        .        .  
        dep3 |        .        .        .        .        .        .        .  
        cog3 |        .        .        .        .        .        .        .  
         gh3 |        .        .        .        .        .        .        .  
       part3 |        .        .        .        .        .        .        .  
 
             |  obesity physfu~t  painint cognit~e     slp3      pf3     anx3 
-------------+--------------------------------------------------------------- 
     obesity |   1.0000  
   physfunct |  -0.1629   1.0000  
     painint |   0.1405  -0.7328   1.0000  
   cognitive |   0.0497  -0.3703   0.3374   1.0000  
        slp3 |        .        .        .        .        .  
         pf3 |        .        .        .        .        .        .  
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        anx3 |        .        .        .        .        .        .        .  
        dep3 |        .        .        .        .        .        .        .  
        cog3 |        .        .        .        .        .        .        .  
         gh3 |        .        .        .        .        .        .        .  
       part3 |        .        .        .        .        .        .        .  
 
             |     dep3     cog3      gh3    part3 
-------------+------------------------------------ 
        dep3 |        .  
        cog3 |        .        .  
         gh3 |        .        .        .  
       part3 |        .        .        .        .  
 
             |    m_pf3     pain  numpain   censor      age      sex educat~n 
-------------+--------------------------------------------------------------- 
       m_pf3 |   1.0000  
        pain |   0.0187   1.0000  
     numpain |  -0.0204  -0.5166   1.0000  
      censor |   0.1387  -0.0124   0.0262   1.0000  
         age |   0.2230   0.0064  -0.0068   0.3915   1.0000  
         sex |  -0.0251   0.0328  -0.0747   0.0518  -0.0690   1.0000  
   education |   0.0684  -0.0491   0.0448   0.0574   0.1316   0.0546   1.0000  
      income |   0.0664  -0.1015   0.1639   0.0205   0.0011  -0.0089   0.0854  
     alcohol |   0.0859  -0.0345   0.1042   0.0612   0.1774  -0.2396   0.0480  
       smoke |  -0.0131   0.0179  -0.0282  -0.0447   0.0234  -0.2045  -0.0207  
     control |   0.0418   0.0340  -0.0253  -0.0355   0.0079   0.0004  -0.0231  
      health |   0.1587  -0.2913   0.4020   0.2056   0.2392  -0.0032   0.1192  
        walk |   0.0999  -0.1561   0.2255   0.1543   0.1947  -0.0922   0.0467  
  depression |   0.1011  -0.1664   0.2844   0.1168   0.1129  -0.0088   0.0480  
     anxiety |   0.0476  -0.2060   0.2686   0.0126  -0.0272  -0.1434   0.0266  
      sleep1 |   0.0438  -0.1532   0.2471   0.0228   0.0352  -0.1027   0.0326  
      sleep2 |   0.0163  -0.1648   0.2151   0.0735   0.0713  -0.0598   0.0371  
      sleep3 |   0.0262  -0.1675   0.2480   0.0230   0.0142  -0.0818   0.0269  
      sleep4 |   0.0310  -0.1813   0.3014   0.0247  -0.0337  -0.0705   0.0200  
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         out |   0.1685  -0.1554   0.2502   0.2320   0.3669  -0.1078   0.1013  
      partic |   0.1554  -0.1608   0.2308   0.1396   0.1966  -0.0606   0.0759  
     obesity |  -0.0159  -0.0988   0.1349  -0.0401  -0.1006  -0.0384   0.0088  
   physfunct |  -0.1446   0.3525  -0.4878  -0.2653  -0.3937   0.1320  -0.1142  
     painint |   0.0803  -0.4996   0.5589   0.1571   0.1977  -0.0374   0.0939  
   cognitive |   0.0672  -0.1985   0.2688   0.1076   0.1484  -0.0455   0.0247  
        slp3 |        .        .        .        .        .        .        .  
        bmi3 |        .        .        .        .        .        .        .  
        anx3 |        .        .        .        .        .        .        .  
        dep3 |        .        .        .        .        .        .        .  
        cog3 |        .        .        .        .        .        .        .  
         gh3 |        .        .        .        .        .        .        .  
       part3 |        .        .        .        .        .        .        .  
 
             |   income  alcohol    smoke  control   health     walk depres~n 
-------------+--------------------------------------------------------------- 
      income |   1.0000  
     alcohol |   0.1104   1.0000  
       smoke |  -0.0153   0.1158   1.0000  
     control |  -0.0183   0.0002  -0.1999   1.0000  
      health |   0.2131   0.1598  -0.0613  -0.0208   1.0000  
        walk |   0.0898   0.1398  -0.0122  -0.0217   0.3826   1.0000  
  depression |   0.1843   0.1205  -0.0228  -0.0093   0.4413   0.2985   1.0000  
     anxiety |   0.1966   0.0856   0.0093  -0.0463   0.3234   0.1692   0.4194  
      sleep1 |   0.1366   0.0943   0.0159  -0.0210   0.2494   0.1541   0.2458  
      sleep2 |   0.1028   0.0764   0.0773  -0.2186   0.2480   0.1485   0.2141  
      sleep3 |   0.1277   0.0701   0.0020  -0.0150   0.2533   0.1502   0.2595  
      sleep4 |   0.1580   0.0853  -0.0090  -0.0167   0.3126   0.1934   0.3434  
         out |   0.1423   0.1925  -0.0011  -0.0112   0.4615   0.5116   0.3932  
      partic |   0.1802   0.1316  -0.0131   0.0373   0.3890   0.2798   0.3266  
     obesity |   0.0809   0.0709  -0.0148  -0.0148   0.1423   0.1125   0.0809  
   physfunct |  -0.2186  -0.2143   0.0236   0.0378  -0.6629  -0.5167  -0.4536  
     painint |   0.2139   0.1430  -0.0337  -0.0276   0.5991   0.3743   0.4082  
   cognitive |   0.1619   0.0893  -0.0113  -0.0263   0.3374   0.1898   0.3500  
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        slp3 |        .        .        .        .        .        .        .  
        bmi3 |        .        .        .        .        .        .        .  
        anx3 |        .        .        .        .        .        .        .  
        dep3 |        .        .        .        .        .        .        .  
        cog3 |        .        .        .        .        .        .        .  
         gh3 |        .        .        .        .        .        .        .  
       part3 |        .        .        .        .        .        .        .  
 
             |  anxiety   sleep1   sleep2   sleep3   sleep4      out   partic 
-------------+--------------------------------------------------------------- 
     anxiety |   1.0000  
      sleep1 |   0.2644   1.0000  
      sleep2 |   0.2287   0.4145   1.0000  
      sleep3 |   0.2775   0.5954   0.5615   1.0000  
      sleep4 |   0.3157   0.4645   0.3710   0.5106   1.0000  
         out |   0.2236   0.1898   0.1781   0.1792   0.2070   1.0000  
      partic |   0.2428   0.1729   0.1439   0.1654   0.2007   0.3858   1.0000  
     obesity |   0.0592   0.0710   0.0755   0.0821   0.0925   0.0588   0.0663  
   physfunct |  -0.3021  -0.2685  -0.2789  -0.2762  -0.3075  -0.5691  -0.4574  
     painint |   0.3212   0.2669   0.2630   0.2840   0.3106   0.4388   0.4100  
   cognitive |   0.3471   0.2026   0.2101   0.2179   0.2623   0.2751   0.2715  
        slp3 |        .        .        .        .        .        .        .  
        bmi3 |        .        .        .        .        .        .        .  
        anx3 |        .        .        .        .        .        .        .  
        dep3 |        .        .        .        .        .        .        .  
        cog3 |        .        .        .        .        .        .        .  
         gh3 |        .        .        .        .        .        .        .  
       part3 |        .        .        .        .        .        .        .  
 
             |  obesity physfu~t  painint cognit~e     slp3     bmi3     anx3 
-------------+--------------------------------------------------------------- 
     obesity |   1.0000  
   physfunct |  -0.1629   1.0000  
     painint |   0.1405  -0.7328   1.0000  
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   cognitive |   0.0497  -0.3703   0.3374   1.0000  
        slp3 |        .        .        .        .        .  
        bmi3 |        .        .        .        .        .        .  
        anx3 |        .        .        .        .        .        .        .  
        dep3 |        .        .        .        .        .        .        .  
        cog3 |        .        .        .        .        .        .        .  
         gh3 |        .        .        .        .        .        .        .  
       part3 |        .        .        .        .        .        .        .  
 
             |     dep3     cog3      gh3    part3 
-------------+------------------------------------ 
        dep3 |        .  
        cog3 |        .        .  
         gh3 |        .        .        .  
       part3 |        .        .        .        .  
 
             |   m_anx3     pain  numpain   censor      age      sex educat~n 
-------------+--------------------------------------------------------------- 
      m_anx3 |   1.0000  
        pain |   0.0186   1.0000  
     numpain |  -0.0200  -0.5166   1.0000  
      censor |   0.1388  -0.0124   0.0262   1.0000  
         age |   0.2220   0.0064  -0.0068   0.3915   1.0000  
         sex |  -0.0249   0.0328  -0.0747   0.0518  -0.0690   1.0000  
   education |   0.0684  -0.0491   0.0448   0.0574   0.1316   0.0546   1.0000  
      income |   0.0665  -0.1015   0.1639   0.0205   0.0011  -0.0089   0.0854  
     alcohol |   0.0829  -0.0345   0.1042   0.0612   0.1774  -0.2396   0.0480  
       smoke |  -0.0146   0.0179  -0.0282  -0.0447   0.0234  -0.2045  -0.0207  
     control |   0.0491   0.0340  -0.0253  -0.0355   0.0079   0.0004  -0.0231  
      health |   0.1600  -0.2913   0.4020   0.2056   0.2392  -0.0032   0.1192  
        walk |   0.0988  -0.1561   0.2255   0.1543   0.1947  -0.0922   0.0467  
  depression |   0.1015  -0.1664   0.2844   0.1168   0.1129  -0.0088   0.0480  
     anxiety |   0.0475  -0.2060   0.2686   0.0126  -0.0272  -0.1434   0.0266  
      sleep1 |   0.0441  -0.1532   0.2471   0.0228   0.0352  -0.1027   0.0326  
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      sleep2 |   0.0134  -0.1648   0.2151   0.0735   0.0713  -0.0598   0.0371  
      sleep3 |   0.0255  -0.1675   0.2480   0.0230   0.0142  -0.0818   0.0269  
      sleep4 |   0.0306  -0.1813   0.3014   0.0247  -0.0337  -0.0705   0.0200  
         out |   0.1680  -0.1554   0.2502   0.2320   0.3669  -0.1078   0.1013  
      partic |   0.1543  -0.1608   0.2308   0.1396   0.1966  -0.0606   0.0759  
     obesity |  -0.0168  -0.0988   0.1349  -0.0401  -0.1006  -0.0384   0.0088  
   physfunct |  -0.1447   0.3525  -0.4878  -0.2653  -0.3937   0.1320  -0.1142  
     painint |   0.0802  -0.4996   0.5589   0.1571   0.1977  -0.0374   0.0939  
   cognitive |   0.0687  -0.1985   0.2688   0.1076   0.1484  -0.0455   0.0247  
        slp3 |        .        .        .        .        .        .        .  
        bmi3 |        .        .        .        .        .        .        .  
         pf3 |        .        .        .        .        .        .        .  
        dep3 |        .        .        .        .        .        .        .  
        cog3 |        .        .        .        .        .        .        .  
         gh3 |        .        .        .        .        .        .        .  
       part3 |        .        .        .        .        .        .        .  
 
             |   income  alcohol    smoke  control   health     walk depres~n 
-------------+--------------------------------------------------------------- 
      income |   1.0000  
     alcohol |   0.1104   1.0000  
       smoke |  -0.0153   0.1158   1.0000  
     control |  -0.0183   0.0002  -0.1999   1.0000  
      health |   0.2131   0.1598  -0.0613  -0.0208   1.0000  
        walk |   0.0898   0.1398  -0.0122  -0.0217   0.3826   1.0000  
  depression |   0.1843   0.1205  -0.0228  -0.0093   0.4413   0.2985   1.0000  
     anxiety |   0.1966   0.0856   0.0093  -0.0463   0.3234   0.1692   0.4194  
      sleep1 |   0.1366   0.0943   0.0159  -0.0210   0.2494   0.1541   0.2458  
      sleep2 |   0.1028   0.0764   0.0773  -0.2186   0.2480   0.1485   0.2141  
      sleep3 |   0.1277   0.0701   0.0020  -0.0150   0.2533   0.1502   0.2595  
      sleep4 |   0.1580   0.0853  -0.0090  -0.0167   0.3126   0.1934   0.3434  
         out |   0.1423   0.1925  -0.0011  -0.0112   0.4615   0.5116   0.3932  
      partic |   0.1802   0.1316  -0.0131   0.0373   0.3890   0.2798   0.3266  
     obesity |   0.0809   0.0709  -0.0148  -0.0148   0.1423   0.1125   0.0809  
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   physfunct |  -0.2186  -0.2143   0.0236   0.0378  -0.6629  -0.5167  -0.4536  
     painint |   0.2139   0.1430  -0.0337  -0.0276   0.5991   0.3743   0.4082  
   cognitive |   0.1619   0.0893  -0.0113  -0.0263   0.3374   0.1898   0.3500  
        slp3 |        .        .        .        .        .        .        .  
        bmi3 |        .        .        .        .        .        .        .  
         pf3 |        .        .        .        .        .        .        .  
        dep3 |        .        .        .        .        .        .        .  
        cog3 |        .        .        .        .        .        .        .  
         gh3 |        .        .        .        .        .        .        .  
       part3 |        .        .        .        .        .        .        .  
 
             |  anxiety   sleep1   sleep2   sleep3   sleep4      out   partic 
-------------+--------------------------------------------------------------- 
     anxiety |   1.0000  
      sleep1 |   0.2644   1.0000  
      sleep2 |   0.2287   0.4145   1.0000  
      sleep3 |   0.2775   0.5954   0.5615   1.0000  
      sleep4 |   0.3157   0.4645   0.3710   0.5106   1.0000  
         out |   0.2236   0.1898   0.1781   0.1792   0.2070   1.0000  
      partic |   0.2428   0.1729   0.1439   0.1654   0.2007   0.3858   1.0000  
     obesity |   0.0592   0.0710   0.0755   0.0821   0.0925   0.0588   0.0663  
   physfunct |  -0.3021  -0.2685  -0.2789  -0.2762  -0.3075  -0.5691  -0.4574  
     painint |   0.3212   0.2669   0.2630   0.2840   0.3106   0.4388   0.4100  
   cognitive |   0.3471   0.2026   0.2101   0.2179   0.2623   0.2751   0.2715  
        slp3 |        .        .        .        .        .        .        .  
        bmi3 |        .        .        .        .        .        .        .  
         pf3 |        .        .        .        .        .        .        .  
        dep3 |        .        .        .        .        .        .        .  
        cog3 |        .        .        .        .        .        .        .  
         gh3 |        .        .        .        .        .        .        .  
       part3 |        .        .        .        .        .        .        .  
 
             |  obesity physfu~t  painint cognit~e     slp3     bmi3      pf3 
-------------+--------------------------------------------------------------- 
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     obesity |   1.0000  
   physfunct |  -0.1629   1.0000  
     painint |   0.1405  -0.7328   1.0000  
   cognitive |   0.0497  -0.3703   0.3374   1.0000  
        slp3 |        .        .        .        .        .  
        bmi3 |        .        .        .        .        .        .  
         pf3 |        .        .        .        .        .        .        .  
        dep3 |        .        .        .        .        .        .        .  
        cog3 |        .        .        .        .        .        .        .  
         gh3 |        .        .        .        .        .        .        .  
       part3 |        .        .        .        .        .        .        .  
 
             |     dep3     cog3      gh3    part3 
-------------+------------------------------------ 
        dep3 |        .  
        cog3 |        .        .  
         gh3 |        .        .        .  
       part3 |        .        .        .        .  
 
             |   m_dep3     pain  numpain   censor      age      sex educat~n 
-------------+--------------------------------------------------------------- 
      m_dep3 |   1.0000  
        pain |   0.0182   1.0000  
     numpain |  -0.0198  -0.5166   1.0000  
      censor |   0.1385  -0.0124   0.0262   1.0000  
         age |   0.2221   0.0064  -0.0068   0.3915   1.0000  
         sex |  -0.0251   0.0328  -0.0747   0.0518  -0.0690   1.0000  
   education |   0.0683  -0.0491   0.0448   0.0574   0.1316   0.0546   1.0000  
      income |   0.0664  -0.1015   0.1639   0.0205   0.0011  -0.0089   0.0854  
     alcohol |   0.0831  -0.0345   0.1042   0.0612   0.1774  -0.2396   0.0480  
       smoke |  -0.0144   0.0179  -0.0282  -0.0447   0.0234  -0.2045  -0.0207  
     control |   0.0488   0.0340  -0.0253  -0.0355   0.0079   0.0004  -0.0231  
      health |   0.1601  -0.2913   0.4020   0.2056   0.2392  -0.0032   0.1192  
        walk |   0.0988  -0.1561   0.2255   0.1543   0.1947  -0.0922   0.0467  
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  depression |   0.1016  -0.1664   0.2844   0.1168   0.1129  -0.0088   0.0480  
     anxiety |   0.0477  -0.2060   0.2686   0.0126  -0.0272  -0.1434   0.0266  
      sleep1 |   0.0442  -0.1532   0.2471   0.0228   0.0352  -0.1027   0.0326  
      sleep2 |   0.0135  -0.1648   0.2151   0.0735   0.0713  -0.0598   0.0371  
      sleep3 |   0.0257  -0.1675   0.2480   0.0230   0.0142  -0.0818   0.0269  
      sleep4 |   0.0307  -0.1813   0.3014   0.0247  -0.0337  -0.0705   0.0200  
         out |   0.1680  -0.1554   0.2502   0.2320   0.3669  -0.1078   0.1013  
      partic |   0.1543  -0.1608   0.2308   0.1396   0.1966  -0.0606   0.0759  
     obesity |  -0.0167  -0.0988   0.1349  -0.0401  -0.1006  -0.0384   0.0088  
   physfunct |  -0.1450   0.3525  -0.4878  -0.2653  -0.3937   0.1320  -0.1142  
     painint |   0.0804  -0.4996   0.5589   0.1571   0.1977  -0.0374   0.0939  
   cognitive |   0.0689  -0.1985   0.2688   0.1076   0.1484  -0.0455   0.0247  
        slp3 |        .        .        .        .        .        .        .  
        bmi3 |        .        .        .        .        .        .        .  
         pf3 |        .        .        .        .        .        .        .  
        anx3 |        .        .        .        .        .        .        .  
        cog3 |        .        .        .        .        .        .        .  
         gh3 |        .        .        .        .        .        .        .  
       part3 |        .        .        .        .        .        .        .  
 
             |   income  alcohol    smoke  control   health     walk depres~n 
-------------+--------------------------------------------------------------- 
      income |   1.0000  
     alcohol |   0.1104   1.0000  
       smoke |  -0.0153   0.1158   1.0000  
     control |  -0.0183   0.0002  -0.1999   1.0000  
      health |   0.2131   0.1598  -0.0613  -0.0208   1.0000  
        walk |   0.0898   0.1398  -0.0122  -0.0217   0.3826   1.0000  
  depression |   0.1843   0.1205  -0.0228  -0.0093   0.4413   0.2985   1.0000  
     anxiety |   0.1966   0.0856   0.0093  -0.0463   0.3234   0.1692   0.4194  
      sleep1 |   0.1366   0.0943   0.0159  -0.0210   0.2494   0.1541   0.2458  
      sleep2 |   0.1028   0.0764   0.0773  -0.2186   0.2480   0.1485   0.2141  
      sleep3 |   0.1277   0.0701   0.0020  -0.0150   0.2533   0.1502   0.2595  
      sleep4 |   0.1580   0.0853  -0.0090  -0.0167   0.3126   0.1934   0.3434  
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         out |   0.1423   0.1925  -0.0011  -0.0112   0.4615   0.5116   0.3932  
      partic |   0.1802   0.1316  -0.0131   0.0373   0.3890   0.2798   0.3266  
     obesity |   0.0809   0.0709  -0.0148  -0.0148   0.1423   0.1125   0.0809  
   physfunct |  -0.2186  -0.2143   0.0236   0.0378  -0.6629  -0.5167  -0.4536  
     painint |   0.2139   0.1430  -0.0337  -0.0276   0.5991   0.3743   0.4082  
   cognitive |   0.1619   0.0893  -0.0113  -0.0263   0.3374   0.1898   0.3500  
        slp3 |        .        .        .        .        .        .        .  
        bmi3 |        .        .        .        .        .        .        .  
         pf3 |        .        .        .        .        .        .        .  
        anx3 |        .        .        .        .        .        .        .  
        cog3 |        .        .        .        .        .        .        .  
         gh3 |        .        .        .        .        .        .        .  
       part3 |        .        .        .        .        .        .        .  
 
             |  anxiety   sleep1   sleep2   sleep3   sleep4      out   partic 
-------------+--------------------------------------------------------------- 
     anxiety |   1.0000  
      sleep1 |   0.2644   1.0000  
      sleep2 |   0.2287   0.4145   1.0000  
      sleep3 |   0.2775   0.5954   0.5615   1.0000  
      sleep4 |   0.3157   0.4645   0.3710   0.5106   1.0000  
         out |   0.2236   0.1898   0.1781   0.1792   0.2070   1.0000  
      partic |   0.2428   0.1729   0.1439   0.1654   0.2007   0.3858   1.0000  
     obesity |   0.0592   0.0710   0.0755   0.0821   0.0925   0.0588   0.0663  
   physfunct |  -0.3021  -0.2685  -0.2789  -0.2762  -0.3075  -0.5691  -0.4574  
     painint |   0.3212   0.2669   0.2630   0.2840   0.3106   0.4388   0.4100  
   cognitive |   0.3471   0.2026   0.2101   0.2179   0.2623   0.2751   0.2715  
        slp3 |        .        .        .        .        .        .        .  
        bmi3 |        .        .        .        .        .        .        .  
         pf3 |        .        .        .        .        .        .        .  
        anx3 |        .        .        .        .        .        .        .  
        cog3 |        .        .        .        .        .        .        .  
         gh3 |        .        .        .        .        .        .        .  
       part3 |        .        .        .        .        .        .        .  
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             |  obesity physfu~t  painint cognit~e     slp3     bmi3      pf3 
-------------+--------------------------------------------------------------- 
     obesity |   1.0000  
   physfunct |  -0.1629   1.0000  
     painint |   0.1405  -0.7328   1.0000  
   cognitive |   0.0497  -0.3703   0.3374   1.0000  
        slp3 |        .        .        .        .        .  
        bmi3 |        .        .        .        .        .        .  
         pf3 |        .        .        .        .        .        .        .  
        anx3 |        .        .        .        .        .        .        .  
        cog3 |        .        .        .        .        .        .        .  
         gh3 |        .        .        .        .        .        .        .  
       part3 |        .        .        .        .        .        .        .  
 
             |     anx3     cog3      gh3    part3 
-------------+------------------------------------ 
        anx3 |        .  
        cog3 |        .        .  
         gh3 |        .        .        .  
       part3 |        .        .        .        .  
 
             |   m_cog3     pain  numpain   censor      age      sex educat~n 
-------------+--------------------------------------------------------------- 
      m_cog3 |   1.0000  
        pain |   0.0184   1.0000  
     numpain |  -0.0175  -0.5166   1.0000  
      censor |   0.1387  -0.0124   0.0262   1.0000  
         age |   0.2226   0.0064  -0.0068   0.3915   1.0000  
         sex |  -0.0270   0.0328  -0.0747   0.0518  -0.0690   1.0000  
   education |   0.0665  -0.0491   0.0448   0.0574   0.1316   0.0546   1.0000  
      income |   0.0671  -0.1015   0.1639   0.0205   0.0011  -0.0089   0.0854  
     alcohol |   0.0835  -0.0345   0.1042   0.0612   0.1774  -0.2396   0.0480  
       smoke |  -0.0177   0.0179  -0.0282  -0.0447   0.0234  -0.2045  -0.0207  
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     control |   0.0541   0.0340  -0.0253  -0.0355   0.0079   0.0004  -0.0231  
      health |   0.1601  -0.2913   0.4020   0.2056   0.2392  -0.0032   0.1192  
        walk |   0.0985  -0.1561   0.2255   0.1543   0.1947  -0.0922   0.0467  
  depression |   0.1024  -0.1664   0.2844   0.1168   0.1129  -0.0088   0.0480  
     anxiety |   0.0475  -0.2060   0.2686   0.0126  -0.0272  -0.1434   0.0266  
      sleep1 |   0.0434  -0.1532   0.2471   0.0228   0.0352  -0.1027   0.0326  
      sleep2 |   0.0110  -0.1648   0.2151   0.0735   0.0713  -0.0598   0.0371  
      sleep3 |   0.0263  -0.1675   0.2480   0.0230   0.0142  -0.0818   0.0269  
      sleep4 |   0.0334  -0.1813   0.3014   0.0247  -0.0337  -0.0705   0.0200  
         out |   0.1681  -0.1554   0.2502   0.2320   0.3669  -0.1078   0.1013  
      partic |   0.1550  -0.1608   0.2308   0.1396   0.1966  -0.0606   0.0759  
     obesity |  -0.0183  -0.0988   0.1349  -0.0401  -0.1006  -0.0384   0.0088  
   physfunct |  -0.1452   0.3525  -0.4878  -0.2653  -0.3937   0.1320  -0.1142  
     painint |   0.0802  -0.4996   0.5589   0.1571   0.1977  -0.0374   0.0939  
   cognitive |   0.0703  -0.1985   0.2688   0.1076   0.1484  -0.0455   0.0247  
        slp3 |        .        .        .        .        .        .        .  
        bmi3 |        .        .        .        .        .        .        .  
         pf3 |        .        .        .        .        .        .        .  
        anx3 |        .        .        .        .        .        .        .  
        dep3 |        .        .        .        .        .        .        .  
         gh3 |        .        .        .        .        .        .        .  
       part3 |        .        .        .        .        .        .        .  
 
             |   income  alcohol    smoke  control   health     walk depres~n 
-------------+--------------------------------------------------------------- 
      income |   1.0000  
     alcohol |   0.1104   1.0000  
       smoke |  -0.0153   0.1158   1.0000  
     control |  -0.0183   0.0002  -0.1999   1.0000  
      health |   0.2131   0.1598  -0.0613  -0.0208   1.0000  
        walk |   0.0898   0.1398  -0.0122  -0.0217   0.3826   1.0000  
  depression |   0.1843   0.1205  -0.0228  -0.0093   0.4413   0.2985   1.0000  
     anxiety |   0.1966   0.0856   0.0093  -0.0463   0.3234   0.1692   0.4194  
      sleep1 |   0.1366   0.0943   0.0159  -0.0210   0.2494   0.1541   0.2458  
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      sleep2 |   0.1028   0.0764   0.0773  -0.2186   0.2480   0.1485   0.2141  
      sleep3 |   0.1277   0.0701   0.0020  -0.0150   0.2533   0.1502   0.2595  
      sleep4 |   0.1580   0.0853  -0.0090  -0.0167   0.3126   0.1934   0.3434  
         out |   0.1423   0.1925  -0.0011  -0.0112   0.4615   0.5116   0.3932  
      partic |   0.1802   0.1316  -0.0131   0.0373   0.3890   0.2798   0.3266  
     obesity |   0.0809   0.0709  -0.0148  -0.0148   0.1423   0.1125   0.0809  
   physfunct |  -0.2186  -0.2143   0.0236   0.0378  -0.6629  -0.5167  -0.4536  
     painint |   0.2139   0.1430  -0.0337  -0.0276   0.5991   0.3743   0.4082  
   cognitive |   0.1619   0.0893  -0.0113  -0.0263   0.3374   0.1898   0.3500  
        slp3 |        .        .        .        .        .        .        .  
        bmi3 |        .        .        .        .        .        .        .  
         pf3 |        .        .        .        .        .        .        .  
        anx3 |        .        .        .        .        .        .        .  
        dep3 |        .        .        .        .        .        .        .  
         gh3 |        .        .        .        .        .        .        .  
       part3 |        .        .        .        .        .        .        .  
 
             |  anxiety   sleep1   sleep2   sleep3   sleep4      out   partic 
-------------+--------------------------------------------------------------- 
     anxiety |   1.0000  
      sleep1 |   0.2644   1.0000  
      sleep2 |   0.2287   0.4145   1.0000  
      sleep3 |   0.2775   0.5954   0.5615   1.0000  
      sleep4 |   0.3157   0.4645   0.3710   0.5106   1.0000  
         out |   0.2236   0.1898   0.1781   0.1792   0.2070   1.0000  
      partic |   0.2428   0.1729   0.1439   0.1654   0.2007   0.3858   1.0000  
     obesity |   0.0592   0.0710   0.0755   0.0821   0.0925   0.0588   0.0663  
   physfunct |  -0.3021  -0.2685  -0.2789  -0.2762  -0.3075  -0.5691  -0.4574  
     painint |   0.3212   0.2669   0.2630   0.2840   0.3106   0.4388   0.4100  
   cognitive |   0.3471   0.2026   0.2101   0.2179   0.2623   0.2751   0.2715  
        slp3 |        .        .        .        .        .        .        .  
        bmi3 |        .        .        .        .        .        .        .  
         pf3 |        .        .        .        .        .        .        .  
        anx3 |        .        .        .        .        .        .        .  
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        dep3 |        .        .        .        .        .        .        .  
         gh3 |        .        .        .        .        .        .        .  
       part3 |        .        .        .        .        .        .        .  
 
             |  obesity physfu~t  painint cognit~e     slp3     bmi3      pf3 
-------------+--------------------------------------------------------------- 
     obesity |   1.0000  
   physfunct |  -0.1629   1.0000  
     painint |   0.1405  -0.7328   1.0000  
   cognitive |   0.0497  -0.3703   0.3374   1.0000  
        slp3 |        .        .        .        .        .  
        bmi3 |        .        .        .        .        .        .  
         pf3 |        .        .        .        .        .        .        .  
        anx3 |        .        .        .        .        .        .        .  
        dep3 |        .        .        .        .        .        .        .  
         gh3 |        .        .        .        .        .        .        .  
       part3 |        .        .        .        .        .        .        .  
 
             |     anx3     dep3      gh3    part3 
-------------+------------------------------------ 
        anx3 |        .  
        dep3 |        .        .  
         gh3 |        .        .        .  
       part3 |        .        .        .        .  
 
             |    m_gh3     pain  numpain   censor      age      sex educat~n 
-------------+--------------------------------------------------------------- 
       m_gh3 |   1.0000  
        pain |   0.0197   1.0000  
     numpain |  -0.0203  -0.5166   1.0000  
      censor |   0.1402  -0.0124   0.0262   1.0000  
         age |   0.2220   0.0064  -0.0068   0.3915   1.0000  
         sex |  -0.0266   0.0328  -0.0747   0.0518  -0.0690   1.0000  
   education |   0.0682  -0.0491   0.0448   0.0574   0.1316   0.0546   1.0000  
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      income |   0.0665  -0.1015   0.1639   0.0205   0.0011  -0.0089   0.0854  
     alcohol |   0.0843  -0.0345   0.1042   0.0612   0.1774  -0.2396   0.0480  
       smoke |  -0.0138   0.0179  -0.0282  -0.0447   0.0234  -0.2045  -0.0207  
     control |   0.0424   0.0340  -0.0253  -0.0355   0.0079   0.0004  -0.0231  
      health |   0.1592  -0.2913   0.4020   0.2056   0.2392  -0.0032   0.1192  
        walk |   0.0973  -0.1561   0.2255   0.1543   0.1947  -0.0922   0.0467  
  depression |   0.1016  -0.1664   0.2844   0.1168   0.1129  -0.0088   0.0480  
     anxiety |   0.0487  -0.2060   0.2686   0.0126  -0.0272  -0.1434   0.0266  
      sleep1 |   0.0425  -0.1532   0.2471   0.0228   0.0352  -0.1027   0.0326  
      sleep2 |   0.0166  -0.1648   0.2151   0.0735   0.0713  -0.0598   0.0371  
      sleep3 |   0.0242  -0.1675   0.2480   0.0230   0.0142  -0.0818   0.0269  
      sleep4 |   0.0296  -0.1813   0.3014   0.0247  -0.0337  -0.0705   0.0200  
         out |   0.1674  -0.1554   0.2502   0.2320   0.3669  -0.1078   0.1013  
      partic |   0.1555  -0.1608   0.2308   0.1396   0.1966  -0.0606   0.0759  
     obesity |  -0.0163  -0.0988   0.1349  -0.0401  -0.1006  -0.0384   0.0088  
   physfunct |  -0.1436   0.3525  -0.4878  -0.2653  -0.3937   0.1320  -0.1142  
     painint |   0.0793  -0.4996   0.5589   0.1571   0.1977  -0.0374   0.0939  
   cognitive |   0.0664  -0.1985   0.2688   0.1076   0.1484  -0.0455   0.0247  
        slp3 |        .        .        .        .        .        .        .  
        bmi3 |        .        .        .        .        .        .        .  
         pf3 |        .        .        .        .        .        .        .  
        anx3 |        .        .        .        .        .        .        .  
        dep3 |        .        .        .        .        .        .        .  
        cog3 |        .        .        .        .        .        .        .  
       part3 |        .        .        .        .        .        .        .  
 
             |   income  alcohol    smoke  control   health     walk depres~n 
-------------+--------------------------------------------------------------- 
      income |   1.0000  
     alcohol |   0.1104   1.0000  
       smoke |  -0.0153   0.1158   1.0000  
     control |  -0.0183   0.0002  -0.1999   1.0000  
      health |   0.2131   0.1598  -0.0613  -0.0208   1.0000  
        walk |   0.0898   0.1398  -0.0122  -0.0217   0.3826   1.0000  
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  depression |   0.1843   0.1205  -0.0228  -0.0093   0.4413   0.2985   1.0000  
     anxiety |   0.1966   0.0856   0.0093  -0.0463   0.3234   0.1692   0.4194  
      sleep1 |   0.1366   0.0943   0.0159  -0.0210   0.2494   0.1541   0.2458  
      sleep2 |   0.1028   0.0764   0.0773  -0.2186   0.2480   0.1485   0.2141  
      sleep3 |   0.1277   0.0701   0.0020  -0.0150   0.2533   0.1502   0.2595  
      sleep4 |   0.1580   0.0853  -0.0090  -0.0167   0.3126   0.1934   0.3434  
         out |   0.1423   0.1925  -0.0011  -0.0112   0.4615   0.5116   0.3932  
      partic |   0.1802   0.1316  -0.0131   0.0373   0.3890   0.2798   0.3266  
     obesity |   0.0809   0.0709  -0.0148  -0.0148   0.1423   0.1125   0.0809  
   physfunct |  -0.2186  -0.2143   0.0236   0.0378  -0.6629  -0.5167  -0.4536  
     painint |   0.2139   0.1430  -0.0337  -0.0276   0.5991   0.3743   0.4082  
   cognitive |   0.1619   0.0893  -0.0113  -0.0263   0.3374   0.1898   0.3500  
        slp3 |        .        .        .        .        .        .        .  
        bmi3 |        .        .        .        .        .        .        .  
         pf3 |        .        .        .        .        .        .        .  
        anx3 |        .        .        .        .        .        .        .  
        dep3 |        .        .        .        .        .        .        .  
        cog3 |        .        .        .        .        .        .        .  
       part3 |        .        .        .        .        .        .        .  
 
             |  anxiety   sleep1   sleep2   sleep3   sleep4      out   partic 
-------------+--------------------------------------------------------------- 
     anxiety |   1.0000  
      sleep1 |   0.2644   1.0000  
      sleep2 |   0.2287   0.4145   1.0000  
      sleep3 |   0.2775   0.5954   0.5615   1.0000  
      sleep4 |   0.3157   0.4645   0.3710   0.5106   1.0000  
         out |   0.2236   0.1898   0.1781   0.1792   0.2070   1.0000  
      partic |   0.2428   0.1729   0.1439   0.1654   0.2007   0.3858   1.0000  
     obesity |   0.0592   0.0710   0.0755   0.0821   0.0925   0.0588   0.0663  
   physfunct |  -0.3021  -0.2685  -0.2789  -0.2762  -0.3075  -0.5691  -0.4574  
     painint |   0.3212   0.2669   0.2630   0.2840   0.3106   0.4388   0.4100  
   cognitive |   0.3471   0.2026   0.2101   0.2179   0.2623   0.2751   0.2715  
        slp3 |        .        .        .        .        .        .        .  
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        bmi3 |        .        .        .        .        .        .        .  
         pf3 |        .        .        .        .        .        .        .  
        anx3 |        .        .        .        .        .        .        .  
        dep3 |        .        .        .        .        .        .        .  
        cog3 |        .        .        .        .        .        .        .  
       part3 |        .        .        .        .        .        .        .  
 
             |  obesity physfu~t  painint cognit~e     slp3     bmi3      pf3 
-------------+--------------------------------------------------------------- 
     obesity |   1.0000  
   physfunct |  -0.1629   1.0000  
     painint |   0.1405  -0.7328   1.0000  
   cognitive |   0.0497  -0.3703   0.3374   1.0000  
        slp3 |        .        .        .        .        .  
        bmi3 |        .        .        .        .        .        .  
         pf3 |        .        .        .        .        .        .        .  
        anx3 |        .        .        .        .        .        .        .  
        dep3 |        .        .        .        .        .        .        .  
        cog3 |        .        .        .        .        .        .        .  
       part3 |        .        .        .        .        .        .        .  
 
             |     anx3     dep3     cog3    part3 
-------------+------------------------------------ 
        anx3 |        .  
        dep3 |        .        .  
        cog3 |        .        .        .  
       part3 |        .        .        .        .  
 
             |  m_part3     pain  numpain   censor      age      sex educat~n 
-------------+--------------------------------------------------------------- 
     m_part3 |   1.0000  
        pain |   0.0187   1.0000  
     numpain |  -0.0196  -0.5166   1.0000  
      censor |   0.1375  -0.0124   0.0262   1.0000  
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         age |   0.2220   0.0064  -0.0068   0.3915   1.0000  
         sex |  -0.0256   0.0328  -0.0747   0.0518  -0.0690   1.0000  
   education |   0.0661  -0.0491   0.0448   0.0574   0.1316   0.0546   1.0000  
      income |   0.0668  -0.1015   0.1639   0.0205   0.0011  -0.0089   0.0854  
     alcohol |   0.0844  -0.0345   0.1042   0.0612   0.1774  -0.2396   0.0480  
       smoke |  -0.0193   0.0179  -0.0282  -0.0447   0.0234  -0.2045  -0.0207  
     control |   0.0564   0.0340  -0.0253  -0.0355   0.0079   0.0004  -0.0231  
      health |   0.1598  -0.2913   0.4020   0.2056   0.2392  -0.0032   0.1192  
        walk |   0.0991  -0.1561   0.2255   0.1543   0.1947  -0.0922   0.0467  
  depression |   0.1028  -0.1664   0.2844   0.1168   0.1129  -0.0088   0.0480  
     anxiety |   0.0470  -0.2060   0.2686   0.0126  -0.0272  -0.1434   0.0266  
      sleep1 |   0.0440  -0.1532   0.2471   0.0228   0.0352  -0.1027   0.0326  
      sleep2 |   0.0095  -0.1648   0.2151   0.0735   0.0713  -0.0598   0.0371  
      sleep3 |   0.0261  -0.1675   0.2480   0.0230   0.0142  -0.0818   0.0269  
      sleep4 |   0.0315  -0.1813   0.3014   0.0247  -0.0337  -0.0705   0.0200  
         out |   0.1675  -0.1554   0.2502   0.2320   0.3669  -0.1078   0.1013  
      partic |   0.1559  -0.1608   0.2308   0.1396   0.1966  -0.0606   0.0759  
     obesity |  -0.0163  -0.0988   0.1349  -0.0401  -0.1006  -0.0384   0.0088  
   physfunct |  -0.1453   0.3525  -0.4878  -0.2653  -0.3937   0.1320  -0.1142  
     painint |   0.0810  -0.4996   0.5589   0.1571   0.1977  -0.0374   0.0939  
   cognitive |   0.0686  -0.1985   0.2688   0.1076   0.1484  -0.0455   0.0247  
        slp3 |        .        .        .        .        .        .        .  
        bmi3 |        .        .        .        .        .        .        .  
         pf3 |        .        .        .        .        .        .        .  
        anx3 |        .        .        .        .        .        .        .  
        dep3 |        .        .        .        .        .        .        .  
        cog3 |        .        .        .        .        .        .        .  
         gh3 |        .        .        .        .        .        .        .  
 
             |   income  alcohol    smoke  control   health     walk depres~n 
-------------+--------------------------------------------------------------- 
      income |   1.0000  
     alcohol |   0.1104   1.0000  
       smoke |  -0.0153   0.1158   1.0000  
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     control |  -0.0183   0.0002  -0.1999   1.0000  
      health |   0.2131   0.1598  -0.0613  -0.0208   1.0000  
        walk |   0.0898   0.1398  -0.0122  -0.0217   0.3826   1.0000  
  depression |   0.1843   0.1205  -0.0228  -0.0093   0.4413   0.2985   1.0000  
     anxiety |   0.1966   0.0856   0.0093  -0.0463   0.3234   0.1692   0.4194  
      sleep1 |   0.1366   0.0943   0.0159  -0.0210   0.2494   0.1541   0.2458  
      sleep2 |   0.1028   0.0764   0.0773  -0.2186   0.2480   0.1485   0.2141  
      sleep3 |   0.1277   0.0701   0.0020  -0.0150   0.2533   0.1502   0.2595  
      sleep4 |   0.1580   0.0853  -0.0090  -0.0167   0.3126   0.1934   0.3434  
         out |   0.1423   0.1925  -0.0011  -0.0112   0.4615   0.5116   0.3932  
      partic |   0.1802   0.1316  -0.0131   0.0373   0.3890   0.2798   0.3266  
     obesity |   0.0809   0.0709  -0.0148  -0.0148   0.1423   0.1125   0.0809  
   physfunct |  -0.2186  -0.2143   0.0236   0.0378  -0.6629  -0.5167  -0.4536  
     painint |   0.2139   0.1430  -0.0337  -0.0276   0.5991   0.3743   0.4082  
   cognitive |   0.1619   0.0893  -0.0113  -0.0263   0.3374   0.1898   0.3500  
        slp3 |        .        .        .        .        .        .        .  
        bmi3 |        .        .        .        .        .        .        .  
         pf3 |        .        .        .        .        .        .        .  
        anx3 |        .        .        .        .        .        .        .  
        dep3 |        .        .        .        .        .        .        .  
        cog3 |        .        .        .        .        .        .        .  
         gh3 |        .        .        .        .        .        .        .  
 
             |  anxiety   sleep1   sleep2   sleep3   sleep4      out   partic 
-------------+--------------------------------------------------------------- 
     anxiety |   1.0000  
      sleep1 |   0.2644   1.0000  
      sleep2 |   0.2287   0.4145   1.0000  
      sleep3 |   0.2775   0.5954   0.5615   1.0000  
      sleep4 |   0.3157   0.4645   0.3710   0.5106   1.0000  
         out |   0.2236   0.1898   0.1781   0.1792   0.2070   1.0000  
      partic |   0.2428   0.1729   0.1439   0.1654   0.2007   0.3858   1.0000  
     obesity |   0.0592   0.0710   0.0755   0.0821   0.0925   0.0588   0.0663  
   physfunct |  -0.3021  -0.2685  -0.2789  -0.2762  -0.3075  -0.5691  -0.4574  
508 
 
     painint |   0.3212   0.2669   0.2630   0.2840   0.3106   0.4388   0.4100  
   cognitive |   0.3471   0.2026   0.2101   0.2179   0.2623   0.2751   0.2715  
        slp3 |        .        .        .        .        .        .        .  
        bmi3 |        .        .        .        .        .        .        .  
         pf3 |        .        .        .        .        .        .        .  
        anx3 |        .        .        .        .        .        .        .  
        dep3 |        .        .        .        .        .        .        .  
        cog3 |        .        .        .        .        .        .        .  
         gh3 |        .        .        .        .        .        .        .  
 
             |  obesity physfu~t  painint cognit~e     slp3     bmi3      pf3 
-------------+--------------------------------------------------------------- 
     obesity |   1.0000  
   physfunct |  -0.1629   1.0000  
     painint |   0.1405  -0.7328   1.0000  
   cognitive |   0.0497  -0.3703   0.3374   1.0000  
        slp3 |        .        .        .        .        .  
        bmi3 |        .        .        .        .        .        .  
         pf3 |        .        .        .        .        .        .        .  
        anx3 |        .        .        .        .        .        .        .  
        dep3 |        .        .        .        .        .        .        .  
        cog3 |        .        .        .        .        .        .        .  
         gh3 |        .        .        .        .        .        .        .  
 
             |     anx3     dep3     cog3      gh3 
-------------+------------------------------------ 
        anx3 |        .  
        dep3 |        .        .  
        cog3 |        .        .        .  
         gh3 |        .        .        .        .  
 
. log close 
      name:  <unnamed> 
       log:  S:\Data\NORSTOP\NorStOPmissingdata.log 
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  log type:  text 
 closed on:  22 Dec 2014, 10:48:14 
-------------------------------------------------------------------------------------------
--- 
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Appendix IV - Weighted survival analyses 
 
Table AIV.1. Risk of all-cause mortality in the ELSA complete case sample according to pain phenotype (n=6324) and weighted results 
Pain phenotype N Person 
years of 
follow up 
Number of 
deaths 
Mortality 
rate*  
Model 1 
MRR (95% 
CI) 
Model 2 
MRR (95% 
CI) 
Model 3 
MRR (95% 
CI) 
Weighted 
Model 1 
MRR (95% 
CI) 
Weighted 
Model 2 
MRR (95% 
CI) 
Weighted 
Model 3 
MRR (95% 
CI) 
Not often troubled 4052 28048 428 15.26 Reference Reference Reference Reference Reference Reference 
Often troubled  2272 15414 336 21.80 1.43 (1.24, 
1.65) 
1.36 (1.18, 
1.58) 
1.29 (1.12, 
1.49) 
1.43 (1.24, 
1.65) 
1.37 (1.18, 
1.58) 
1.29 (1.11, 
1.50) 
Not often troubled 4052 28048 428 15.26 Reference Reference Reference Reference Reference Reference 
Mild  680 4737 60 12.67 0.83 (0.63, 
1.09) 
0.87 (0.66, 
1.14) 
0.89 (0.68, 
1.16) 
0.82 (0.63, 
1.08) 
0.85 (0.65, 
1.12) 
0.87 (0.67, 
1.14) 
Moderate  1183 7943 201 25.31 1.65 (1.40, 
1.95) 
1.52 (1.28, 
1.80) 
1.42 (1.20, 
1.68) 
1.68 (1.42, 
1.98) 
1.54 (1.30, 
1.84) 
1.43 (1.20, 
1.72) 
Severe  409 2734 75 27.43 1.81 (1.41, 
2.31) 
1.70 (1.33, 
2.18) 
1.54 (1.20, 
1.97) 
1.80 (1.41, 
2.31) 
1.70 (1.31, 
2.19) 
1.53 (1.19, 
1.98) 
MRR=Mortality Rate Ratio, 95% CI = 95% confidence interval 
Model 1: Crude 
Model 2: Adjusted for age, sex  
Model 3: Adjusted for age, sex, education and wealth 
*per 1000 person-years 
MRRs in bold indicate significant associations 
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Table AIV.2. Risk of all-cause mortality in the NorStOP complete case sample according to pain phenotype (n=10985) and weighted results 
Pain phenotype N 
 
Person years 
of follow up 
Number of 
deaths 
Mortality 
rate*  
Model 1 
MRR (95% 
CI) 
Model 2 
MRR (95% 
CI) 
Model 3 
MRR (95% 
CI) 
Weighted 
Model 1 
MRR (95% 
CI) 
Weighted 
Model 2 
MRR (95% 
CI) 
Weighted 
Model 3 
MRR (95% 
CI) 
No pain  3166 28813 412 14.30 Reference Reference Reference Reference Reference Reference 
Any pain  7819 71116 1072 15.07 1.05 (0.94, 
1.18) 
1.08 (0.96, 
1.21) 
1.06 (0.95, 
1.19) 
1.00 (0.89, 
1.12) 
1.08 (0.96, 
1.20) 
1.06 (0.95, 
1.19) 
No pain 3166 28813 412 14.30 Reference Reference Reference Reference Reference Reference 
Pain but not ACR WP 5038 45709 714 15.62 1.09 (0.97, 
1.23) 
1.06 (0.94, 
1.20) 
1.05 (0.93, 
1.19) 
1.06 (0.94, 
1.19) 
1.07 (0.95, 
1.20) 
1.06 (0.94, 
1.19) 
ACR WP 2749 25158 352 13.99 0.97 (0.85, 
1.12) 
1.10 (0.95, 
1.26) 
1.07 (0.92, 
1.23) 
0.90 (0.78, 
1.04) 
1.09 (0.95, 
1.26) 
1.07 (0.92, 
1.23) 
No pain 3166 28813 412 14.30 Reference Reference Reference Reference Reference Reference 
Pain but not 
Manchester WP 
6062 55194 827 14.98 1.05 (0.93, 
1.18) 
1.05 (0.93, 
1.18) 
1.03 (0.92, 
1.16) 
1.02 (0.90, 
1.14) 
1.05 (0.93, 
1.18) 
1.04 (0.92, 
1.17) 
Manchester WP 1725 15673 239 15.25 1.06 (0.91, 
1.25) 
1.19 (1.02, 
1.40) 
1.16 (0.99, 
1.36) 
0.94 (0.80, 
1.11) 
1.19 (1.01, 
1.39) 
1.16 (0.99, 
1.36) 
No sites 3166 28813 412 14.30 Reference Reference Reference Reference Reference Reference 
1-3 sites 1952 17843 245 13.73 0.96 (0.82, 
1.12) 
0.95 (0.81, 
1.11) 
0.95 (0.81, 
1.11) 
0.95 (0.81, 
1.11) 
0.94 (0.81, 
1.10) 
0.94 (0.80, 
1.10) 
4-6 sites 1942 17559 276 15.72 1.10 (0.94, 
1.28) 
1.09 (0.94, 
1.27) 
1.08 (0.93, 
1.26) 
1.07 (0.92, 
1.24) 
1.09 (0.93, 
1.26) 
1.07 (0.92, 
1.25) 
7-11 sites 1833 16836 241 14.31 1.00 (0.85, 
1.17) 
1.07 (0.92, 
1.26) 
1.05 (0.90, 
1.24) 
0.94 (0.80, 
1.10) 
1.06 (0.91, 
1.25) 
1.05 (0.89, 
1.23) 
12+ sites 2060 18630 304 16.32 1.14 (0.98, 
1.32) 
1.18 (1.02, 
1.37) 
1.15 (0.99, 
1.34) 
1.01 (0.87, 
1.17) 
1.17 (1.01, 
1.36) 
1.14 (0.99, 
1.33) 
MRR= Mortality Rate Ratio, 95% CI = 95% confidence interval, ACR = American College of Rheumatology,  WP = Widespread pain 
Model 1: Crude, Model 2: Adjusted for age, sex, Model 3: Adjusted for age, sex, education, adequacy of income 
*per 1000 person-years,  MRRs in bold indicate significant associations 
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Table AIV.3.  Risk of all-cause mortality in the ELSA sample with predictor, outcome and confounder information according to pain phenotype 
(n=8572) 
Pain phenotype N (total 
=8572) 
Person 
years of 
follow up 
Number of 
deaths 
Mortality 
rate*  
Model 1 MRR 
(95% CI) 
Model 2 MRR 
(95% CI) 
Model 3 MRR 
(95% CI) 
Not often troubled 5322 36145 775 21.44 Reference Reference Reference 
Often troubled  3250 21624 615 28.44 1.33 (1.19, 1.47) 1.25 (1.13, 1.39) 1.18 (1.06, 1.31) 
Not often troubled 5322 36145 775 21.44 Reference Reference Reference 
Mild  882 5997 118 19.68 0.92 (0.76, 1.11) 0.95 (0.78, 1.16) 0.96 (0.79, 1.17) 
Moderate  1698 11271 340 30.17 1.40 (1.23, 1.59) 1.31 (1.16, 1.50) 1.23 (1.08, 1.40) 
Severe  670 4356 157 36.04 1.69 (1.42, 2.01) 1.46 (1.23, 1.73) 1.30 (1.09, 1.55) 
MRR=Mortality Rate Ratio, 95% CI = 95% confidence interval 
Model 1 Crude 
Model 2 Age, sex  
Model 3 Age, sex, education, wealth 
*per 1000 person-years 
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Table AIV.4 Risk of all-cause mortality in the NorStOP baseline sample (with predictor, outcome and confounder information)  according to pain 
phenotype (n=14023) 
Pain phenotype N 
(14023) 
Person 
years of 
follow up 
Number of 
deaths 
Mortality 
rate*  
Model 1 MRR 
(95% CI) 
Model 2 MRR 
(95% CI) 
Model 3 MRR 
(95% CI) 
No pain  4016 36272 556 15.33 Reference Reference Reference 
Any pain  10007 90394 1434 15.86 1.03 (0.94, 1.14) 1.07 (0.97, 1.18) 1.06 (0.96, 1.17) 
No pain 4016 36272 556 15.33 Reference Reference Reference 
Pain but not ACR 6483 58302 953 16.35 1.06 (0.96, 1.18) 1.06 (0.95, 1.17) 1.05 (0.94, 1.16) 
ACR 3524 32092 481 14.99 0.97 (0.86, 1.10) 1.10 (0.98, 1.25) 1.08 (0.96, 1.22) 
No pain 4016 36272 556 15.33 Reference Reference Reference 
Pain but not 
Manchester definition 
7812 70473 1121 15.91 1.04 (0.94, 1.15) 1.04 (0.94, 1.16) 1.04 (0.93, 1.15) 
Manchester definition 2195 19921 313 15.71 1.02 (0.89, 1.17) 1.18 (1.03, 1.36) 1.16 (1.01, 1.33) 
No sites 4062 36615 566 15.46 Reference Reference Reference 
1-3 sites 2562 23235 335 14.42 0.93 (0.81, 1.06) 0.94 (0.82, 1.08) 0.94 (0.82, 1.07) 
4-6 sites 2459 22112 360 16.28 1.05 (0.92, 1.20) 1.07 (0.93, 1.22) 1.06 (0.93, 1.21) 
7-11 sites 2330 21220 320 15.08 0.97 (0.85, 1.11) 1.04 (0.91, 1.19) 1.03 (0.89, 1.18) 
12+ sites 2610 23484 409 17.42 1.12 (0.99, 1.27) 1.21 (1.06, 1.37) 1.19 (1.04, 1.35) 
MRR= Mortality Rate Ratio, 95% CI = 95% confidence interval 
Model 1 Crude 
Model 2 Age, sex  
Model 3 Age, sex, education, adequacy of income 
*per 1000 person-years 
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Table AIV.5 Risk of all-cause mortality in the NorStOP baseline sample (with predictor, outcome and confounder information)  according to pain 
interference (n=14023) 
Pain interference N  
(14023) 
Person 
years of 
follow up 
Number of 
deaths 
(1990) 
Mortality 
rate*  
Model 1 MRR 
(95% CI) 
Model 2 MRR 
(95% CI) 
Model 3 MRR 
(95% CI) 
No interference 4648 42740 419 9.80 Reference Reference Reference 
A little 3622 33177 414 12.48 1.27 (1.11, 1.46) 1.14 (1.00, 1.31) 1.14 (1.00, 1.31) 
Moderately 2246 20148 398 19.75 2.02 (1.76, 2.31) 1.49 (1.30, 1.71) 1.48 (1.29, 1.71) 
Quite a bit 2719 24053 534 22.20 2.27 (2.00, 2.58) 1.67 (1.46, 1.90) 1.67 (1.46, 1.90) 
Extremely 788 6549 225 34.36 3.53 (3.00, 4.15) 2.62 (2.22, 3.08) 2.63 (2.22, 3.10) 
MRR= Mortality Rate Ratio, 95% CI = 95% confidence interval 
Model 1 Crude 
Model 2 Age, sex  
Model 3 Age, sex, education, adequacy of income 
*per 1000 person-years 
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Appendix V - Schoenfeld tests and residual plots 
 
Results from the English Longitudinal Study of Ageing (ELSA) 
Instructions on how to perform the tests can be found at: 
http://www.ats.ucla.edu/stat/examples/asa/test_proportionality.htm 
 
Table AV.1. Results of Schoenfeld tests for baseline sample for those often troubled with pain (n=6324) 
 chi2 df p 
Often troubled with pain 2.87 1 0.0904 
Age 1.50 1 0.2205 
Sex 1.26 1 0.2610 
Education 1.28 1 0.2585 
Wealth 0.01 1 0.9188 
Global test 8.13 5 0.1492 
df=degrees of freedom 
 
Figure AV.1. Plot of Schoenfeld residuals for baseline sample (n=6324) comparing those 
often troubled with pain to those not often troubled 
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Table AV.2. Results of Schoenfeld tests for baseline sample according to severity of pain (n=6324) 
 Chi2 df p 
Mild pain 0.04 1 0.8514 
Moderate pain 3.33 1 0.0682 
Severe pain 1.82 1 0.1772 
Age 1.39 1 0.2378 
Sex 1.39 1 0.2390 
Education 1.54 1 0.2143 
Wealth 0.00 1 0.9853 
Global test 9.82 7 0.1992 
df=degrees of freedom 
          
 
Figures AV.2 a-c. Plots of Schoenfeld residuals for baseline sample (n=6324) according 
to severity of pain 
 
a) Mild pain 
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b) Moderate pain 
 
 
 
c) Severe pain 
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Results from the North Staffordshire Osteoarthritis Project (NorStOP) 
Table AV.3. Results of Schoenfeld tests for baseline complete case sample for those reporting any pain 
(n=10985) 
 Chi2 df p 
Any Pain 3.09 1 0.0786 
Age 2.50 1 0.1140 
Sex 1.42 1 0.2326 
Education 1.86 1 0.1723 
Adequacy of income 0.34 1 0.5585 
Global test 9.63 5 0.0863 
df=degrees of freedom 
 
 
Figure AV.3. Plot of Schoenfeld residuals for baseline complete case sample (n=10953) 
according to pain report 
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Table AV.4. Results of Schoenfeld tests for baseline complete case sample  according to pain phenotype 
(ACR criteria) (n=10953) 
 Chi2 df p 
Pain but not ACR WP 2.64 1 0.1039 
ACR WP 2.10 1 0.1471 
Age 2.62 1 0.1056 
Sex 1.29 1 0.2570 
Education 1.87 1 0.1716 
Adequacy of income 0.35 1 0.5557 
Global test 9.66 6 0.1399 
df=degrees of freedom 
 
Figure AV.4 a-b. Plot of Schoenfeld residuals for baseline complete case sample 
(n=10953) according pain phenotype (ACR criteria) 
 
a) Pain but not ACR WP 
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b) ACR WP 
 
 
 
 
 
 
Table AV.5. Results of Schoenfeld tests for baseline complete case sample  according to pain phenotype 
(Manchester criteria) (n=10953) 
 Chi2 df p 
Pain but not Manchester WP 1.60 1 0.2056 
Manchester WP 5.95 1 0.0147 
Age 2.38 1 0.1231 
Sex 1.63 1 0.2021 
Education 1.91 1 0.1675 
Adequacy of income 0.53 1 0.4650 
Global test 12.44 6 0.0528 
df=degrees of freedom 
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Figure  AV.5 a-b. Plot of Schoenfeld residuals for baseline complete case sample 
(n=10953) according to pain phenotype (Manchester criteria) 
 
a) Pain but not Manchester WP 
 
 
 
 
b) Manchester WP 
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Table AV.6. Results of Schoenfeld tests for baseline complete case sample according to number of pain 
sites (n=10953) 
 Chi2 df p 
1-3 sites 0.49  1 0.4843 
4-6 sites 3.30 1 0.0694 
7-11 sites 0.11 1 0.7407 
12+ sites 4.88 1 0.0271 
Age 2.68 1 0.1014 
Sex 1.37 1 0.2417 
Education 1.78 1 0.1826 
Adequacy of income 0.50 1 0.4777 
Global test 13.29 8 0.1022 
df=degrees of freedom 
       
           
Figure AV.6 a-d. Plot of Schoenfeld residuals for baseline complete case sample 
(n=10953) according number of pain sites 
 
a) 1-3 sites 
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b) 4-6 sites 
 
 
 
 
c) 7-11 sites 
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d) 12+ sites 
 
 
 
 
 
 
 
Table AV.7. Results of Schoenfeld tests for baseline complete case sample according to pain interference 
(n=10985) 
 Chi2 df p 
A little 0.15 1 0.7001 
Moderately 1.07 1 0.3001 
Quite a bit 2.74 1 0.0977 
Extremely 11.22 1 0.0008 
Age 4.75 1 0.0292 
Sex 2.32 1 0.1273 
Education 1.96 1 0.1617 
Adequacy of income 1.41 1 0.2353 
Global test 21.43 8 0.0061 
df=degrees of freedom 
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Figure AV.7 a-d. Plot of Schoenfeld residuals for baseline complete case sample 
(n=10985) according to pain interference 
 
a) A little 
 
 
 
 
 
b) Moderately    
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c) Quite a bit 
 
 
 
d) Extremely 
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PAIN INTERFERENCE - TIMEBANDS 
  
Table AV. 8. Results of Schoenfeld tests for the complete case sample according to pain interference 0-
365 days (n=10985)   
 Chi2 df p 
A little 0.18 1 0.6672 
Moderately 1.37 1 0.2424 
Quite a bit 0.01 1 0.9373 
Extremely 1.24 1 0.2659 
Age 3.64 1 0.0566 
Sex 0.01 1 0.9085 
Education 2.31 1 0.1286 
Adequacy of income 0.00 1 0.9520 
Global test 10.88 8 0.2088 
df=degrees of freedom 
 
TIMEBAND 1 
Figure AV.8 a-d. Plot of Schoenfeld residuals for baseline complete case sample 
(n=10985) according to pain interference (0-365 days) 
 
a) A little 
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b) Moderately 
 
 
c) Quite a bit 
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d) Extremely 
 
 
 
TIMEBAND 2 
Table AV.9. Results of Schoenfeld tests for the complete case sample according to pain interference  365+ 
days (n=10888) 
 Chi2 df p 
A little 0.01 1 0.9413 
Moderately 1.16 1 0.2813 
Quite a bit 2.85 1 0.0914 
Extremely 3.98 1 0.0460 
Age 1.46 1 0.2273 
Sex 0.88 1 0.3484 
Education 2.57 1 0.1090 
Adequacy of income 6.59 1 0.0102 
Global test 14.87 8 0.0617 
df=degrees of freedom 
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Figure AV.9 a-d. Plot of Schoenfeld residuals for baseline complete case sample 
(n=10888) according to pain interference (365days+) 
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c) Quite a bit 
 
 
 
d) Extremely 
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Cause specific mortality (ELSA only) 
Table AV.10 Results of Schoenfeld tests for complete case sample for cancer deaths for those often 
troubled with pain (n=6324) 
 Chi2 df p 
Often troubled with pain 2.73 1 0.0982 
Age 0.04 1 0.8409 
Sex 0.28 1 0.5971 
Education 0.03 1 0.8517 
Wealth 1.12 1 0.2899 
Global test 4.18 5 0.5232 
df=degrees of freedom 
 
Figure AV.10. Plot of Schoenfeld residuals for cancer mortality for the complete case 
sample (n=6324) comparing those often troubled with pain to those not often troubled 
 
 
 
Table AV.11. Results of Schoenfeld tests for baseline sample for cancer deaths according to severity of 
pain (n=6324) 
 Chi2 df p 
Mild pain 0.31 1 0.5794 
Moderate pain 4.06 1 0.0440 
Severe pain 1.63 1 0.2016 
Age 0.04 1 0.8346 
Sex 0.34 1 0.5584 
Education 0.09 1 0.7631 
Wealth 1.49 1 0.2225 
Global test 7.22 7 0.4062 
df=degrees of freedom 
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Figures AV.11.a-c. Plots of Schoenfeld residuals for cancer mortality for the complete 
case sample (n=6324) according to severity of pain 
 
a) Mild pain 
 
 
 
b) Moderate pain  
 
 
 
-5
 
0
 
5
 
1
0
 
1
5
 
S
c
a
le
d
 S
c
h
o
e
n
fe
ld
 -
 M
ild
 p
a
in
 
0 20 40 60 80 100 
Time (months) 
-2
 
0
 
2
 
4
 
6
 
S
c
a
le
d
 S
c
h
o
e
n
fe
ld
 -
 M
o
d
e
ra
te
 p
a
in
 
0 20 40 60 80 100 
Time (months) 
534 
 
c) Severe pain 
 
 
Table AV.12. Results of Schoenfeld tests for complete case sample for cardiovascular disease deaths for 
those often troubled with pain (n=6324) 
 Chi2 df P 
Often troubled with pain 0.33 1 0.5662 
Age 0.08 1 0.7840 
Sex 0.04 1 0.8461 
Education 2.22 1 0.1366 
Wealth 1.36 1 0.2431 
Global test 3.32 5 0.6507 
df=degrees of freedom 
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Figure AV.12. Plot of Schoenfeld residuals for cardiovascular disease mortality for the 
complete case sample (n=6324) comparing those often troubled with pain to those not 
often troubled 
 
 
 
 
Table AV.13. Results of Schoenfeld tests for baseline sample for cardiovascular disease deaths according 
to severity of pain (n=6324) 
 Chi2 df p 
Mild pain 0.00 1 0.9829 
Moderate pain 0.40 1 0.5285 
Severe pain 0.16 1 0.6935 
Age 0.06 1 0.8071 
Sex 0.05 1 0.8306 
Education 2.30 1 0.1291 
Wealth 1.28 1 0.2586 
Global test 3.48 7 0.8368 
df=degrees of freedom 
 
  
-2
 
-1
 
0
 
1
 
2
 
3
 
S
c
a
le
d
 S
c
h
o
e
n
fe
ld
 -
 O
ft
e
n
 t
ro
u
b
le
d
 w
it
h
 p
a
in
 
0 20 40 60 80 100 
Time (months) 
536 
 
Figures AV.13 a-c. Plots of Schoenfeld residuals for cardiovascular disease mortality for 
the complete case sample (n=6324) according to severity of pain 
 
 
a) Mild pain 
 
 
 
b) Moderate pain 
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Severe pain 
 
 
Table AV.14. Results of Schoenfeld tests for complete case sample for respiratory disease deaths for 
those often troubled with pain (n=6324) 
 Chi2 df p 
Often troubled with pain 5.51 1 0.0189 
Age 2.57 1 0.1086 
Sex 0.23 1 0.6293 
Education 0.10 1 0.7558 
Wealth 0.15 1 0.6952 
Global test 9.07 5 0.1063 
df=degrees of freedom 
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Figure AV.14. Plot of Schoenfeld residuals for respiratory disease mortality for the 
complete case sample (n=6324) comparing those often troubled with pain to those not 
often troubled 
 
 
 
 
Table AV.15. Results of Schoenfeld tests for baseline sample for respiratory disease  deaths according to 
severity of pain (n=6324) 
 Chi2 df p 
Mild pain 1.43 1 0.2321 
Moderate pain 4.25 1 0.0391 
Severe pain 2.09 1 0.1480 
Age 2.50 1 0.1141 
Sex 0.24 1 0.6277 
Education 0.12 1 0.7299 
Wealth 0.13 1 0.7178 
Global test 9.02 7 0.2512 
df=degrees of freedom 
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Figures AV.15 a-c. Plots of Schoenfeld residuals for respiratory disease mortality for the 
complete case sample (n=6324) according to severity of pain 
 
a) Mild pain 
 
 
 
b) Moderate pain 
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c) Severe pain 
 
 
Table AV.16. Results of Schoenfeld tests for complete case sample for other (known) deaths for those 
often troubled with pain (n=6324) 
 Chi2 df p 
Often troubled with pain 2.09 1 0.1486 
Age 1.35 1 0.2458 
Sex 2.71 1 0.1000 
Education 0.24 1 0.6208 
Wealth 0.47 1 0.4942 
Global test 6.76 5 0.2392 
df=degrees of freedom 
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Figure AV.16. Plot of Schoenfeld residuals for other (known) mortality for the complete 
case sample (n=6324) comparing those often troubled with pain to those not often 
troubled 
 
 
 
 
Table AV.17. Results of Schoenfeld tests for baseline sample for other deaths according to severity of pain 
(n=6324) 
 Chi2 df p 
Mild pain 2.82 1 0.0933 
Moderate pain 0.89 1 0.3448 
Severe pain 0.25 1 0.6145 
Age 1.45 1 0.2287 
Sex 2.48 1 0.1154 
Education 0.32 1 0.5687 
Wealth 0.62 1 0.4297 
Global test 7.96 7 0.3359 
df=degrees of freedom 
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Figures AV.17 a-c. Plots of Schoenfeld residuals for other (known) mortality for the 
complete case sample (n=6324) according to severity of pain 
 
a) Mild pain 
 
 
 
b) Moderate pain 
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c) Severe pain 
 
 
 
Table AV.18. Results of Schoenfeld tests for complete case sample for other (known) deaths for those 
often troubled with pain (n=6324) 
 Chi2 df p 
Often troubled with pain 0.02 1 0.8828 
Age 1.67 1 0.1958 
Sex 1.10 1 0.2953 
Education 0.05 1 0.8154 
Wealth 0.42 1 0.5174 
Global test 4.76 5 0.4455 
df=degrees of freedom 
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Figure AV.18. Plot of Schoenfeld residuals for unknown mortality for the complete case 
sample (n=6324) comparing those often troubled with pain to those not often troubled 
 
 
 
 
Table AV.19. Results of Schoenfeld tests for baseline sample for other deaths according to severity of pain 
(n=6324) 
 Chi2 df p 
Mild pain 1.24 1 0.2654 
Moderate pain 0.67 1 0.4126 
Severe pain 0.02 1 0.8998 
Age 1.64 1 0.2004 
Sex 1.24 1 0.2654 
Education 0.10 1 0.7531 
Wealth 0.60 1 0.4385 
Global test 7.17 7 0.4109 
df=degrees of freedom 
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Figures AV.19 a-c. Plots of Schoenfeld residuals for unknown mortality for the complete 
case sample (n=6324) according to severity of pain 
 
a) Mild pain 
 
 
 
 
b) Moderate pain 
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c) Severe pain 
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Appendix VI - Survival models with interaction terms 
 
Table AVI.1 Interactions between pain phenotype and sex and pain phenotype and comorbidity in the 
ELSA complete case sample (n=6324) 
Pain phenotype Model 1 MRR (95% 
CI) 
Model 2 MRR (95% 
CI) 
Model 3 MRR (95% 
CI) 
Not often troubled  Reference Reference Reference 
Often troubled x sex 0.94 (0.71, 1.26) 0.89 (0.67, 1.19) 0.90 (0.67, 1.20) 
Not often troubled Reference Reference Reference 
Mild x sex 1.11 (0.65, 1.90) 1.32 (0.77, 2.26) 1.31 (0.76, 2.26) 
Moderate x sex 0.80 (0.57, 1.12) 0.72 (0.51, 1.00) 0.73 (0.52, 1.03) 
Severe x sex 1.16 (0.71, 1.89) 0.92 (0.56, 1.50) 0.94 (0.58, 1.55)  
Not often troubled  Reference Reference Reference 
Often troubled x comorbidity 1.50 (1.03, 2.19) 1.12 (0.77, 1.64) 1.10 (0.76, 1.61) 
Not often troubled Reference Reference Reference 
Mild x comorbidity 1.53 (0.79, 2.96) 0.96 (0.49, 1.86) 0.97 (0.50, 1.89) 
Moderate x comorbidity 1.23 (0.77, 1.98) 1.05 (0.65, 1.69) 1.02 (0.64, 1.64) 
Severe x comorbidity 1.41 (0.63, 3.13) 1.21 (0.54, 2.69) 1.21 (0.54, 2.70) 
MRR=Mortality Rate Ratio, 95% CI = 95% confidence interval 
Model 1: Crude 
Model 2:Adjusted for age, sex 
Model 3: Adjusted for age, sex, education, wealth 
 
 
Table AVI.2 Interactions between pain phenotype and sex in the NorStOP complete case sample 
(n=10985) 
Pain phenotype Model 1 MRR (95% 
CI) 
Model 2 MRR (95% 
CI) 
Model 3 MRR (95% 
CI) 
No pain  Reference Reference Reference 
Any pain x sex 0.98 (0.78, 1.23) 0.92 (0.74, 1.16) 0.93 (0.74, 1.17) 
No pain Reference Reference Reference 
Pain but not ACR x sex 1.03 (0.81, 1.31) 0.97 (0.76, 1.24) 0.98 (0.77, 1.25) 
ACR WP x sex 0.91 (0.68, 1.21) 0.83 (0.63, 1.11) 0.84 (0.63, 1.11) 
No pain Reference Reference Reference 
Pain but not Manchester WP x 
sex  
1.02 (0.81, 1.30) 0.98 (0.77, 1.24) 0.98 (0.77, 1.25) 
Manchester WP x sex  0.84 (0.61, 1.15) 0.74 (0.54, 1.02) 0.75 (0.54, 1.03) 
No sites Reference Reference Reference 
1-3 sites x sex 1.10 (0.80, 1.51) 0.96 (0.70, 1.32)  0.96 (0.70, 1.33) 
4-6 sites x sex 1.01 (0.74, 1.37) 0.97 (0.71, 1.32) 0.98 (0.72, 1.33) 
7-11 sites x sex 0.99 (0.72, 1.37) 0.99 (0.72, 1.36) 0.99 (0.72, 1.36) 
12+ sites x sex 0.84 (0.62, 1.13) 0.80 (0.59, 1.08) 0.81 (0.60, 1.09) 
MRR=Mortality Rate Ratio, 95% CI = 95% confidence interval 
Model 1: Crude 
Model 2: Adjusted for age, sex 
Model 3: Adjusted for age, sex, education, wealth 
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Table AVI.3 Interactions between pain phenotype and comorbidity in the NorStOP complete case sample 
(n=10985) 
Pain phenotype Model 1 MRR (95% 
CI) 
Model 2 MRR (95% 
CI) 
Model 3 MRR (95% 
CI) 
No pain  Reference Reference Reference 
Any pain x comorbidity 0.74 (0.49, 1.10) 0.73 (0.49, 1.09) 0.73 (0.49, 1.08) 
No pain Reference Reference Reference 
Pain but not ACR x comorbidity 0.72 (0.48, 1.10) 0.68 (0.45, 1.04) 0.68 (0.45, 1.03) 
ACR WP x comorbidity 0.86 (0.43, 1.72) 0.91 (0.46, 1.83) 0.90 (0.45, 1.81) 
No pain Reference Reference Reference 
Pain but not Manchester WP x 
comorbidity 
0.72 (0.48, 1.08) 0.69 (0.46, 1.03) 0.68 (0.46, 1.03) 
Manchester WP x comorbidity 1.03 (0.32, 3.34) 1.14 (0.35, 3.71) 1.14 (0.35, 3.70) 
No sites Reference Reference Reference 
1-3 sites x comorbidity 0.59 (0.36, 0.97) 0.51 (0.31, 0.83) 0.51 (0.31, 0.83) 
4-6 sites x comorbidity 0.77 (0.44, 1.35) 0.76 (0.43, 1.33) 0.75 (0.43, 1.32) 
7-11 sites x comorbidity 1.07 (0.48, 2.40) 1.16 (0.52, 2.59) 1.15 (0.51, 2.57) 
12+ sites x comorbidity 0.82 (0.32, 2.07) 0.92 (0.36, 2.34) 0.91 (0.36, 2.31) 
MRR=Mortality Rate Ratio, 95% CI = 95% confidence interval 
Model 1: Crude 
Model 2: Adjusted for age, sex 
Model 3: Adjusted for age, sex, education, wealth 
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Appendix VII - Measurement of the proposed mediators in the ELSA and 
NorStOP datasets 
 
Lifestyle factors 
Physical activity 
In ELSA, participants were asked to indicate whether they took part in vigorous, moderate 
or mild physical activities more than once a week, once a week, one to three times a 
month or hardly ever. Similar to previous research, (Hamer, Molloy, de Oliveira, & 
Demakakos, 2009) four physical activity categories were derived (none, mild activity, 
moderate and vigorous activity at least once a week). Three dichotomous variables were 
created for vigorous, moderate and mild activities scored as 1 if a participant indicated 
they took part in that level of activity once a week or more and 0 if not. A summary 
variable was then created whereby if participants scored 1 for vigorous activity more than 
once a week they were allocated to this category, if they indicated moderate activity and 
did not separately indicate vigorous activity they were allocated to the ‘moderate’ 
category. It they indicated mild activity at least once a week and did not also indicate 
moderate or vigorous activity they were allocated to the ‘mild’ activity category. If they 
did not indicate activity at any of the above levels at least once a week they were 
allocated to the ‘no activity’ category. This variable was then dichotomised for use in the 
mediation analysis to compare no/mild activity to moderate/vigorous activity at least 
once a week. No/mild activity has previously been used to form a category of low activity 
in ELSA (Hamer et al., 2009) and this formed the reference group for the analysis.  
In NorStOP, two single items were used to measure the frequency of physical activity; 
frequency of going to activities outside the home and frequency of going for a walk for at 
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least ten to fifteen minutes.  Participants were asked to indicate if they went out on all 
days, most days, some days, few days or no days. This was dichotomised into few/no days 
compared to all/most/some days. Frequency of going for a walk was categorised as daily, 
every other day, twice per week, less than twice per week, or not at all. This was 
dichotomised into less than weekly versus weekly or more. These dichotomies were 
chosen to be comparable to the physical activity variable from ELSA.  
Smoking 
In ELSA, smoking status was determined by asking participants to indicate whether they 
never smoked, used to be an occasional, regular or frequent smoker, or were a current 
smoker. The dichotomous variable used in the mediation analysis compared non-smokers 
(never and past) (reference) to current smokers. 
In the NorStOP participants were asked to indicate their current smoking status and 
specify if they “never smoked”, “previously smoked” or were “currently smoking”. This 
variable was dichotomised into never/previous smokers (reference) versus current 
smokers. 
The dichotomy of non-smoker/current smoker is a routinely used method of capturing 
smoker status, however the category of non-smoker will include ex-smokers and those 
who quit recently are at greater risk of disease than non-smokers (Marston et al., 2014). 
The earlier an individual stops smoking the greater the reduction mortality risk; in a study 
of 34,439 British doctors Doll et al. found stopping smoking at age 60, 50, 40 or 30 years 
of age meant a gain of 3,6,9 or 10 years of life expectancy respectively (Doll et al., 2004).  
Alcohol consumption 
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In ELSA, participants were asked about the frequency of their alcohol consumption over 
the last 12 months. Responses options were ‘not at all’, ‘ once or twice a year’, ‘once 
every couple of months’, ‘once or twice a month’, ‘once or twice a week’, three or four 
times a week’, ‘five or six days a week’, and ’almost every day’. These options were 
categorised to alcohol consumption less than weekly (reference) and weekly or more 
often. 
In the NorStOP sample, alcohol consumption was assessed using a single question where 
participants were asked on average how often they drank and to select a response from 
“daily or most days”, once or twice a week”, “once or twice a month”, “once or twice a 
year,” or “never”. Responses were then dichotomised to weekly or more often versus less 
than weekly consumption (reference). 
The dichotomies were selected to provide low/high alcohol consumption variables 
comparable across the two datasets. 
Obesity 
In NorStOP measures of self-reported body weight relative to self-reported height were 
used to calculate BMI by dividing weight in kilograms (kg) by the square of height in 
metres (m) (BMI = weight (kg)/[height(m)]2). The collection of self-reported height and 
weight data has been found to be a valid and accurate method of measuring 
anthropometric characteristics in population studies (Spencer, Appleby, Davey, & Key, 
2002) although the level of accuracy decreases in older populations (Kuczmarski, 
Kuczmarski, & Najjar, 2001). Responders were categorised into standard BMI groups. 
These are (i) underweight (BMI<18.5 kg/m2), (ii) normal weight (BMI 18.5 – 24.9 kg/m2), 
552 
 
(iii) overweight (BMI 25 –29.9 kg/m2) and (iv) obese (BMI ≥30 kg/m2) (World Health 
Organization, 2006). For the analysis undertaken in this study this variable was 
dichotomised into obese versus not obese (reference) as those meeting the criteria for 
obese are at greatest risk of health problems.   
Sleep problems  
Sleep problems were measured using the Jenkins Sleep Questionnaire (JSQ) (Jenkins et 
al., 1988). The questionnaire asks about recent problems with sleep and contains items 
on the most commonly occurring symptoms of poor sleep quality: sleep onset (‘during 
the past four weeks did you have trouble falling asleep?’); sleep maintenance (‘during the 
past four weeks did you wake up several times per night?’); early wakening (‘during the 
past four weeks did you have trouble staying asleep, including waking up far too early?’); 
and non-restorative sleep (‘during the past four weeks did you wake up after your usual 
amount of sleep feeling tired and worn out?’). Participants indicated the number of days 
in the past month that they have experienced difficulties in each of the four sleep 
components on a 3-point scale ranging; not at all/on some nights/on most nights. Sleep 
problems for each item were defined as problems experienced on most nights (Hayward, 
Jordan, & Croft, 2012); items were dichotomised into none/some versus most nights. 
Items were individually analysed because they represented different constructs of 
“difficulty with sleep initiation, duration, consolidation or quality” (American Academy of 
Sleep Medicine, 2005).  
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Health factors 
Self-rated health 
In ELSA participants were asked to indicate how they rated their health; ‘excellent’, ‘very 
good’, ‘good’, ‘fair’ or ‘poor’. This variable was dichotomised to compare poor/fair ratings 
as the reference group to good, very good and excellent. 
In the NorStOP dataset a measure of general health was used. General health was 
measured using a single item from the Medical Outcomes Study Short Form-12 (MOS-
SF12) (Ware et al., 1995). In response to the need to produce a shorter instrument that 
could be completed more rapidly, the developers of the SF-36 produced the 12-item SF-
12 using regression analysis. The selected 12 items reproduced 90% of the variance in the 
overall Physical and Mental Health components of the SF-36. The general health item 
required participants to rate their health as ‘excellent’, ‘very good’, ‘good’, ‘fair’ or ‘poor’.  
This was dichotomised into poor/fair (reference) versus good/ very good/ excellent. 
As before the dichotomies for the ELSA and NorStOP variables were determined to 
provide comparable variables across datasets comparing better to poorer self-rated 
health. 
Functional limitation 
In ELSA functional limitation was assessed using measurements of activities of daily living 
(ADL) (dressing, walking across a room, bathing or showering, eating, getting in or out of 
bed and using the toilet) and instrumental ADLs (IADLs) (map reading, preparing a hot 
meal, shopping for groceries, making telephone calls, taking medications, doing work 
around the house and garden and managing money). Participants scored 1 if they 
indicated difficulties with any of these activities and items were summed to form a scale 
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ranging from 0-13. An expanded scale measuring both ADL and IADL is unidimensional, 
has greater content validity for measuring the need for help and shows greater sensitivity 
to age (i.e. more accurately captures changes in functional health with age) than ADL 
measures alone (LaPlante, 2010). The combined scale also results in increased 
measurement equivalence between ELSA and a comparative national database, the 
Health and Retirement Survey (HRS) (Chan et al., 2012). Functional limitations were 
dichotomised around the median score (0) to produce categories of high and low 
limitation. This resulted in a comparison between no difficulties (reference) and any 
difficulties (24.57% of the study sample).  
 
In NorStOP functional limitation was measured using the Medical Outcomes Study Short 
Form-36 which has been recommended for use in primary care research due to its brevity 
and extensive psychometric testing (Bohannon & DePasquale, 2010). The Physical 
Functioning Scale of the SF-36 has been used previously in other studies using NorStOP 
data as a measure of physical function/limitation (Jordan et al., 2012). This is a 10-item 
sub-scale, proposed as a measure of general physical activity (Ware & Sherbourne, 1992). 
The scores for the 10 items are summed and normalized so that total score ranges from 
0-100, with higher scores indicating better physical functioning. Responders were 
empirically dichotomised according to whether or not their score lay below the median 
(reference) representing low physical function or above the median, representing high 
physical function. 
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Symptoms preventing walking 
Participants were asked to specify what symptoms made it difficult for them to walk 
quarter of a mile. Options were chest pain, fatigue/too tired, shortness of breath, tremor, 
pain in leg or foot, swelling in leg or foot, incontinence, seeing difficulty, hearing difficulty, 
confusion, difficulty concentrating, memory problems, unsteady on feet or balance 
problems, lightheaded or dizziness, fear of falling, anxiety or fear or other problem or 
symptom. Variables were recoded and a single symptom count variable was created. This 
was again dichotomised around the median score to produce a category of high symptom 
count compared to a category of low symptom count. Using the median again resulted in 
a comparison between no difficulties (reference) and any difficulties.  
Frailty 
Using ELSA data, frailty was identified according to Fried’s criteria (Fried et al., 2001). 
Physical measures taken as part of the nurse visit were used for weight loss, grip strength, 
and walking speed. Frailty was identified by the presence of three or more of the 
following characteristics: Weight loss (loss of ≥10% body weight since Wave 0 survey or 
BMI<18.5), low grip strength (in the lowest 20% of the distribution of scores, adjusted for 
age and sex, for maximum grip strength tested using a dynamometer), low walking speed 
(in the lowest 20% of the distribution for time taken to walk 8 feet at “usual” pace), low 
physical activity levels, (in the lowest sex specific 20% distribution for activity level 
(derived from the 3 questions about activity levels) and exhaustion (positive response to 2 
CES-D questions (‘felt everything was an effort’ and ‘could not get going’ in the last week). 
Participants with less than three of these characteristics were categorised as the not frail 
group and formed the reference group in the mediation analysis. This approach to 
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identifying frailty has been used previously in the ELSA dataset (Gale, Baylis, Cooper, & 
Sayer, 2013) and is comparable to other studies using the clinical phenotype definition of 
frailty (Blyth et al., 2008; Gruenewald et al., 2009; Szanton et al., 2009).  
Allostatic load 
Determining allostatic load involves measurements of the activity of stress-regulatory 
systems (e.g., immune, cardiovascular, neuroendocrine, and metabolic) (Karlamangla, 
Singer, McEwen, Rowe, & Seeman, 2002). An estimate of allostatic load was derived in 
ELSA only using objective data collected by nurses including the information obtained 
from blood samples. The following measurements were used to create an allostatic load 
index (range 0-10): systolic blood pressure, diastolic blood pressure, mean arterial 
pressure, resting pulse rate, fibrinogen, high density lipid cholesterol (HDL), low density 
lipid cholesterol (LDL), C-reactive protein (CRP), glycosylated haemoglobin (HBA1C), and 
waist/hip ratio (Gruenewald et al., 2009; McEwen, 1998). Participants were allocated a 
score of 1 when their score was above the highest 25th percentile for nine of the 
measures and below the 75th percentile for HDL. Alternative criteria for calculating 
allostatic load have been examined such as summing the number of parameters for which 
an individual scored in the top (or bottom, according to highest risk) 10% of the 
distribution or averaging z-scores for each of the indicators however but the results were 
equivalent to using the quartile criteria (McEwen & Seeman, 1999). The allostatic load 
score was dichotomised around the median score for use in the mediation analyses. 
Scores ranged from 0-9 out of a possible 10, the median was 2 (IQR 1-4).  Those scoring 
above the median (high allostatic load) were compared to those scoring below the 
median (low allostatic load) which formed the reference group.  
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Social factors 
Social group membership 
Group membership has been used as a measure of social participation in older adults in 
ELSA and was found to be an independent predictor of cardiovascular risk factors (Kamiya 
et al., 2010). Group membership was measured using eight items. Each participant 
reported current membership of or participation in (1) political party, trade union or 
environmental groups, (2) tenants groups, resident groups or neighbourhood watch, (3) 
church or other religious groups, (4) charitable associations, (5) education, art or music 
groups or evening classes, (6) social club, (7) sports club, gym or exercise classes or (8) 
any other organisations club or societies (Kamiya et al., 2010). The total score (0-8) was 
dichotomised at the median with membership of 0 or 1 group (reference) being 
compared to membership of 2 or more groups allowing low and high social group 
membership to be compared. 
Volunteer work 
In ELSA, participants were asked to indicate whether they undertook any voluntary work. 
This was dichotomised into ‘yes’ if they indicated any frequency of volunteer work and 
‘no’ if they indicated they never did (Banks et al., 2014). This dichotomy of volunteer work 
has been used previously in ELSA and undertaking volunteer work was shown to be 
associated with increased quality of life in older adults (Netuveli, Wiggins, Hildon, 
Montgomery, & Blane, 2006), reduced depression and greater life satisfaction (McMunn 
Nazroo, Wahrendorf, Breeze, & Zaninotto, 2009).    
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Social participation 
In NorStOP, social participation was measured using the Keele Assessment of 
Participation (KAP) (Wilkie et al., 2005) which measures taking part in 11 activities in 
accordance with the World Health Organization International Classification of Function 
(ICF) framework (World Health Organization, 2002) and include domains of mobility, 
domestic and major life (Wilkie et al., 2005) (Table AVII.1). Participants were considered 
to have reduced social participation if they reported that they were not taking part during 
the previous 4 weeks “as and when [they] wanted” for “some of the time” or less. The 
resulting 11 binary items were then summed to give a total score ranging from 0 to 11 
and categorized to 0 (no restriction) and >=1 (any restriction) (Wilkie et al., 2005). The 
KAP has demonstrated adequate levels of reliability and validity for use in population 
studies (Wilkie et al., 2005). 
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Table AVII.1 Items from the Keele Assessment of Participation (KAP) (reproduced from Wilkie et al., 
2005).   
1. During the past 4 weeks, I have moved around in my home, as and when I have wanted. 
 
2. During the past 4 weeks, I have moved around outside my home, as and when I have wanted. 
 
3. During the past 4 weeks, my self-care needs (examples are washing, toileting, dressing, feeding, 
maintaining health) have been met, as and when I have wanted. 
 
4. During the past 4 weeks, my home has been looked after, as and when I have wanted. 
 
5. During the past 4 weeks, my things (belongings) have been looked after, as and when I have wanted. 
 
6. Do you have any relatives, or other people, who depend on you? (Yes/No) 
If yes, during the past 4 weeks, were these people looked after, as and when you wanted? 
 
7. During the past 4 weeks, I have met and spoken to other people as and when I have wanted. 
 
8. During the past 4 weeks, I, or someone else on my behalf, have managed my money, as I have 
wanted. 
 
9. Do you choose to take part in paid or voluntary work? (Yes/No) 
If yes, during the past 4 weeks, have you taken part in paid or voluntary work, as and when you have 
wanted? 
 
10. Do you choose to take part in education or training courses? (Yes/No) 
If yes, during the past 4 weeks, have you taken part in education or training, as and when you have 
wanted? 
 
11. Do you choose to take part in social activities? (Yes/No) 
If yes, during the past 4 weeks, have you taken part in social activities, as and when you have wanted 
 
Psychological factors  
Quality of life 
In ELSA, quality of life was measured using the CASP-19 (Control, Autonomy, Self-
realisiation and Pleasure) scale which was designed in a population of adults in early old 
age (65-75 years) (Hyde et al., 2003). CASP-19 has 19 items which map to four domains; 
control (4 items) for example ‘I feel free to plan for the future’, autonomy (5 items) for 
example ‘I feel that I can please myself what I do’, self-realisation (5 items) for example ‘I 
feel that life is full of opportunities’ and pleasure for example ‘I enjoy the things that I do’ 
(5 items). Responses options are ‘often’, ‘sometimes’, ‘not often’ and ‘never’ and are 
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scored 3-0 unless negatively worded where this is reversed. The psychometric properties 
(factor structure, content validity) of CASP-19 support its application in population studies 
and a test comparing the total model, a domain only model and a total and domain model 
demonstrated little difference between the latter two models indicating it is better to 
present the individual domain scores alongside the total quality of life score to give the 
scale greater utility (Sim, Bartlam, & Bernard, 2011). The enjoyment of life domain has 
previously been shown to be associated with longer survival in the ELSA dataset (Steptoe 
& Wardle, 2012).  All quality of life domains were dichotomised at the median score for 
use in the mediation analysis to represent high (above the median) and low (below the 
median) quality of life specific to each domain (median scores were: Control = 9 (IQR 7-
10), autonomy = 11 (IQR 9-13), self-realisation = 11 (IQR 8-13), pleasure = 14 (IQR 13-15), 
total = 44 (IQR 38-50)). 
Anxiety and depression 
In ELSA depression was measured using the eight item version of the 20 item Centre for 
Epidemiological Studies Depression (CES-D) scale. The CES-D is a short, structured self-
report measure developed to assess depressive symptoms in epidemiological studies 
(Radloff, 1977).  The reliability and factor structure of the 8 item scale has been tested 
and deemed to have internal consistency and be unidimensional (Gallo & Bradley, 2006; 
Steffick, 2000). Participants respond yes or no to eight questions regarding depressive 
symptoms (Table AVII.2). Responses were summed to give a score between 0 and 8 (two 
items worded in the positive direction were reverse scored) (Banks et al., 2014). The 
score was then dichotomised to no depression (score of 0 to 3) (reference) and possible 
case (score of 4 or more) (Steffick, 2000). 
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Table AVII.2 Items of the 8 item version of the CES-D 
(reproduced from Van de Velde, Levecque, & Bracke, 2009) 
Much of the time during the past week… 
…did you feel depressed? 
…did you feel everything you did was an effort? 
…was your sleep restless? 
…were you happy? 
…did you feel lonely? 
…did you enjoy life? 
…did you feel sad? 
…were you unable to get going? 
 
In NorStOP anxiety and depression were measured using the Hospital Anxiety and 
Depression scale (HADs) which was designed to detect the presence and severity of 
relatively mild mood disorders likely to be found in non-psychiatric hospital out-patients 
(Zigmond & Snaith, 1983). It was intended for use both as a screening device and to chart 
progress over time. It has been validated for use as a self-complete questionnaire. From a 
review of 747 studies which had used the HADs, overall the instrument performed well in 
identifying cases and assessing symptom severity of anxiety disorders and depression in 
somatic, psychiatric and primary care patients and in the general population (Bjelland et 
al., 2002). The scale comprises 14 items each with four response options (scored 0-3) 
which form two sub-scales (7 for anxiety and 7 for depression). Scores for each sub-scale 
are totalled across the 7 items with higher scores indicating greater anxiety or depression. 
The scores were calculated separately and categorised as non-cases (scores of 0-7), 
possible cases (8-10) and probable cases (11-21) (Zigmond & Snaith, 1983). For use in this 
study these items were dichotomised into non-cases versus possible/ probable cases.  
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Cognitive impairment 
In ELSA cognitive impairment was measured using a memory test consisting of 10 words 
respondents were asked to recall immediately and five minutes later. The words were 
common nouns and were presented aurally by a computer. One word was presented 
every two seconds. Four different word lists were used interchangeably to ensure 
different versions of the test were administered to members of the same household 
(Llewellyn et al., 2008). The total number of words recalled (range 0-20) was used as an 
indication of memory (Banks et al., 2014). This was dichotomised around the median 
comparing a score of 0-10 (low cognitive ability) (reference) with 11-20 (high cognitive 
ability). 
In NorStOP the 10-item Cognitive and Alertness Behaviour subscale from the Functional 
Limitations Profile (FLP) (the British version of the Sickness Impact Profile (SIP) was used 
to measure cognitive impairment (Table AVII.3). The SIP was designed to measure 
sickness related changes in normal life (Bergner et al., 1981), has previously been 
administered as a postal questionnaire (Trigg & Wood, 2003) and used as a measure of 
cognitive impairment in this dataset (Wilkie et al., 2007). Each item of the subscale has a 
simple yes/no response option, with responses being allocated a weight, and the 
summation of the 10 weights is then converted to a percentage value, with higher scores 
indicating poorer function. Scores of 0 formed the “no cognitive impairment” category 
(reference) and scores greater than 0 formed the impairment category where any 
cognitive impairment was indicated. 
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Table AVII.3 Items from the Cognitive and Alertness subscale 
(reproduced from McCracken & Iverson, 2001)  
Forgetting a lot, recent things, appointments 
Minor incidents 
Not finishing things started 
Not keeping attention on activity 
Difficulty with concentration and thinking 
Making mistakes 
Difficulty reasoning and problem solving  
Confusion 
Reacting slowly 
Behaving confused or disoriented 
 
Perceived control over health 
The Illness Perception Questionnaire (IPQ ) (Weinman, Petrie, Moss-Morris, & Horne, 
1996) was revised by Moss-Morris and colleagues in 2002 to enable a more accurate 
embodiment of the parallel-processing aspect of the SRM (described in Chapter One) and 
provides a tool to enable researchers to quantify people’s illness perceptions and 
behaviours. The original questionnaire was improved and the scope of the existing 
subscales was extended for the cure/control and timeline components by creating 
separate subscales (Moss-Morris et al., 2002). The cure/control component was 
separated into personal control items and treatment control items. The timeline 
component was separated into acute/chronic items and cyclical items. Two further 
subscales were also added to incorporate emotional representations and to assess illness 
coherence.  
In NorStOP a single item taken from the Revised Illness Perception Questionnaire at 
baseline (Moss-Morris et al., 2002) was used to measure personal control.  Participants 
were asked to confirm ’yes’ or ‘no’ to indicate their agreement to the statement ‘there is 
a lot I can do to control my health’ ‘yes’/’no’ (reference). There is a high correlation 
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between personal and treatment control items when the IPQ-R is used for 
musculoskeletal pain conditions as often patients are unlikely to have received much 
treatment so their representations of treatment effectiveness are indistinguishable from 
those of personal control (Nicholls, Hill, & Foster, 2013).   
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 Appendix VIII - R code for mediation in survival analysis 
 
library(foreign) 
d<-read.dta("S:/Data/datasetname.dta") 
d<-data.frame(d) 
attach(d) 
library(splines) 
library(survival) 
 
TE= coxph(Surv(time, censor) ~ pain + age + sex + education + income, data=d) 
# view results 
summary(TE) 
mmediator=glm(mediator ~ pain + age + sex + education + income, family=binomial(), data=d) 
# view results 
summary(mmediator) 
#for exponentiated estimates (ie ORs)  and 95%CI 
exp(coef(mmediator)) 
exp(confint(mmediator)) 
doEffectDecomp=function(d) 
{ 
# step1: replicate exposure variable, predict mediators  
# ie logistic regression is used to get effect estimates for the influence of exposure on mediator 
d$painTemp=d$pain 
mmediator=glm(mediator ~painTemp + age + sex + education + income, family=binomial(), 
data=d) 
 
# step 2: replicate data with different exposures for mediator variable 
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# ie dataframe is replicated with difference (counterfactual) values of exposure for mediator 
categories 
d1=d2=d 
d1$medmediator=d1$pain 
d2$medmediator=!d2$pain 
newd=rbind(d1, d2) 
# step 3: compute weights for mediator 
newd$painTemp=newd$pain 
w = predict(mmediator, newdata=newd, type='response') 
direct = ifelse(newd$mediator, w, 1-w) 
newd$painTemp=newd$medmediator 
w=predict(mmediator, newdata=newd, type='response') 
indirect=ifelse(newd$mediator, w, 1-w) 
newd$Wmediator=indirect/direct 
# step 4: weighted Cox model 
newd$W = newd$Wmediator 
cox=coxph(Surv(time, censor) ~ pain + medmediator + age + sex + education + income, 
weight=W, data=newd) 
# return value: estimates of total, direct and indirect effects 
TE=exp(sum(coef(cox)[c('pain', 'medmediator')])) 
DE=exp(unname(coef(cox)['pain'])) 
IE=exp(sum(coef(cox)[c('medmediator')])) 
#calculate proportion mediated 
PM=log(IE)/log(TE) 
return(c(exp(coef(cox)), TE=TE, DE=DE, IE=IE, PM=PM)) 
} 
doEffectDecomp(d) 
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Step 5: get 95% confidence intervals for estimates obtained in step 4:  step 4 doesn’t produce 
confidence intervals so need to do bootstrap resampling 
csamp=function(d) 
{ 
s=sample(unique(d$surveyid),  replace=TRUE) 
return(do.call('rbind', lapply(s, function(x) d[d$surveyid == x, ]))) 
} 
HRs = replicate(100, doEffectDecomp(csamp(d))) 
apply(HRs, 1, quantile, c(0.025, 0.975)) 
 
  
568 
 
Appendix IX – Systematic review paper 
 
 
 
